dacarbazine has been researched along with temozolomide in 3904 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (0.31) | 18.7374 |
| 1990's | 99 (2.54) | 18.2507 |
| 2000's | 1134 (29.05) | 29.6817 |
| 2010's | 2547 (65.24) | 24.3611 |
| 2020's | 112 (2.87) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, AS; Deans, B; Denny, BJ; Hartley, JA; Stevens, MF; Tisdale, MJ; Wheelhouse, RT | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Alfio, A; Almerico, AM; Barone, G; Bonsignore, R; Gennaro, G; Gentile, C; Lauria, A; Martorana, A; Terenzi, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonfanti, M; Catapano, CV; Citti, L; D'Incalci, M; Taverna, P | 1 |
| Clark, AS; Lowe, PR; Sansom, CE; Schwalbe, CH; Stevens, MF | 1 |
| Deans, B; Tisdale, MJ | 1 |
| Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS | 1 |
| Hepburn, PA; Tisdale, MJ | 1 |
| Gescher, A; Quarterman, CP; Slack, JA; Tsang, LL | 1 |
| Farmer, PB; Gescher, A; Slack, JA; Tsang, LL | 1 |
| Clark, AS; Sansom, CE; Schwalbe, CH; Stevens, MF | 1 |
| Bull, VL; Tisdale, MJ | 1 |
| Dive, C; Watson, JV; Workman, P | 1 |
| Catapano, CV; D'Incalci, M; Erba, E; Filippeschi, S; Zucchetti, M | 1 |
| Tisdale, MJ | 5 |
| Wilman, DE | 1 |
| Hooper, NI; Thornalley, PJ; Tisdale, MJ | 1 |
| Broggini, M; Catapano, CV; Citti, L; D'Incalci, M; Erba, E; Mariani, L; Ponti, M | 1 |
| Baig, G; Chubb, D; Gibson, NW; Goddard, C; Hickman, JA; Langdon, SP; Slack, JA; Stevens, MF; Stone, R; Vickers, L | 1 |
| Bonmassar, E; D'Atri, S; Gilberti, S; Graziani, G; Lacal, PM; Tentori, L | 1 |
| Artemov, D; Bhujwalla, ZM; Glickson, JD; Griffiths, JR; Judson, IR; Leach, MO; Maxwell, RJ | 1 |
| Boulton, S; Curtin, NJ; Durkacz, BW; Golding, BT; Griffin, RJ; Pemberton, LC; Porteous, JK | 1 |
| Bonmassar, E; Caravita, T; D'Atri, S; Franchi, A; Graziani, G; Papa, G; Piccioni, D | 1 |
| Brampton, MH; Crowther, D; Harper, PG; Harris, M; Johnson, PW; Newlands, ES; Soukop, M; Woll, PJ | 1 |
| Castellano, A; Christiansen, N; D'Atri, S; Franchi, A; Frankel, S; Lu, K; Papa, G; Piccioni, D; Rustum, YM; Tuorto, V | 1 |
| Aquino, A; Leonetti, C; Tentori, L | 1 |
| Biollax, J; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Shen, F | 1 |
| Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N | 1 |
| Köberle, B; Masters, JR; Pera, MF | 1 |
| Berger, NA | 1 |
| Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC | 1 |
| Elder, RH; Fairbairn, LJ; Margison, GP; Rafferty, JA; Watson, AJ | 1 |
| Lowe, PR; Schwalbe, CH | 1 |
| Grever, MR; Koutsoukos, AD; Moore, TD; Plowman, J; Rubinstein, LV; Waud, WR | 1 |
| Denny, BJ; Slack, JA; Stevens, MF; Tsang, LL; Wheelhouse, RT | 1 |
| Crowther, D; Lee, SM; Margison, GP; Thatcher, N | 1 |
| Dolan, ME; Mitchell, RB | 1 |
| Newlands, ES; Stevens, MF | 1 |
| McVie, JG | 1 |
| Brampton, M; Colquhoun, IR; Glaser, MG; Illingworth, RD; Kennard, C; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG | 1 |
| Baer, JC; Freeman, AA; Margison, GP; Newlands, ES; Rafferty, JA; Watson, AJ | 1 |
| Bianchi, R; Binaglia, L; Bonmassar, E; D'Atri, S; Faraoni, I; Graziani, G; Grohmann, U; Margison, GP; Orlando, L; Watson, AJ | 1 |
| May, BL; Newlands, ES; Porteus, JK; Wedge, SR | 1 |
| Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB | 1 |
| Devineni, D; Gallo, JM; Klein-Szanto, A | 1 |
| Newlands, ES; Wedge, SR | 1 |
| Anderson, CM; Buzaid, AC; Legha, SS | 1 |
| Newlands, ES; Porteous, JK; Wedge, SR | 2 |
| Bonmassar, E; D'Atri, S; Graziani, G; Lacal, PM; Orlando, L | 1 |
| Gerson, SL; Liu, L; Markowitz, S | 1 |
| Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG | 1 |
| Ashby, J; Chinnasamy, N; Dexter, TM; Fairbairn, LJ; Hickson, I; Margison, GP; Rafferty, JA; Tinwell, H | 1 |
| Glaser, MG; Marcus, K; Newlands, ES; Porteous, JK; Wedge, SR | 1 |
| Brock, C; Newlands, ES; Stevens, MF; Wedge, SR; Wheelhouse, RT | 1 |
| Armand, JP | 1 |
| Benincasa, E; Bonmassar, E; D'Atri, S; Faraoni, I; Graziani, G; Lacal, PM; Orlando, L; Tentori, L | 1 |
| Boulton, S; Durkacz, BW; Kyle, S | 2 |
| Begent, RJ; Bleehen, NM; Bower, M; Brada, M; Brampton, MH; Calvert, H; Colquhoun, I; Lewis, P; Newlands, ES | 1 |
| Kim, HK; Likhari, P; Lim, J; Lin, CC; Marco, A; Nomeir, AA; Parker, D; Statkevich, P; Veals, J | 1 |
| Burris, HA; Eckhardt, SG; Rodriguez, GI; Sharma, S; Valley, A; Weiss, GR | 1 |
| Benincasa, E; Bonmassar, E; Faraoni, I; Franco, D; Graziani, G; Lacal, PM; Tentori, L | 1 |
| Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P | 1 |
| Chan, AT; Johnson, PJ; Kwan, WH; Lai, M; Leung, TW; Mok, TS; Yeo, W | 1 |
| Benincasa, E; Bonmassar, E; D'Atri, S; Graziani, G; Jiricny, J; Lacal, PM; Pagani, E; Tentori, L; Zambruno, G | 1 |
| Ames, MM; Ettinger, AG; Krailo, M; Liu-Mares, W; Nicholson, HS; Reaman, GH; Reid, JM; Seibel, NL; Vezina, LG | 1 |
| Feld, R; Hedley, D; Moore, MJ; Oza, A; Siu, LL | 1 |
| Bailey, JA; Cooper, DP; Deans, B; Elder, RH; Heeran, MC; Jansen, JG; Margison, GP; Mynett, KJ; Rafferty, JA; van Zeeland, AA; Watson, AJ; Weeks, RJ; Wijnhoven, SW; Willington, MA | 1 |
| Ablett, S; Batra, V; Dicks-Mireaux, C; Dugan, M; Estlin, EJ; Gholkar, A; Gowing, R; Kohler, J; Lashford, L; Lewis, IJ; Marco, A; McDowell, H; Morland, B; Mott, M; Newell, DR; Pearson, AD; Pinkerton, CR; Price, L; Reidenberg, P; Statkevich, P; Stevens, MC; Stevens, R; Walker, D | 1 |
| Chinnasamy, N; Dexter, TM; Fairbairn, LJ; Hickson, I; Lashford, LS; Margison, GP; Rafferty, JA; Thatcher, N | 1 |
| Chinnasamy, N; Dexter, TM; Fairbairn, LJ; Hickson, I; Lashford, LS; Longhurst, SJ; Margison, GP; Rafferty, JA; Thatcher, N | 1 |
| Bower, M; Brampton, MH; Brock, CS; Colquhoun, I; Evans, H; Glaser, M; Newlands, ES; Roddie, M; Rustin, GJ; Wedge, SR | 1 |
| Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F | 1 |
| Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD | 1 |
| Ames, MM; Reid, JM; Rubin, J; Stevens, DC | 1 |
| Bonmassar, E; De Vecchis, L; Faraoni, I; Graziani, G; Masci, G; Shay, JW; Turriziani, M | 1 |
| Ames, MM; Buckner, JC; Burch, PA; Dhodapkar, M; Pitot, HC; Reid, JM; Rubin, J; Suman, VJ | 1 |
| Berger, MS; Blank, A; Bobola, MS; Silber, JR; Tseng, SH | 1 |
| Bleehen, NM; Brampton, MH; Calvert, AH; Lee, SM; Lind, MJ; Lunn, JM; Margison, GP; Middleton, MR; Morris, C; Newell, DR; Newlands, ES; Rustin, G; Thatcher, N; Wedge, SR | 1 |
| Ashley, DM; Bigner, DD; Bigner, SH; Cokgor, I; Colvin, OM; Dugan, M; Friedman, AH; Friedman, HS; Haglund, MM; Henry, AJ; Kerby, T; Krischer, J; Lovell, S; Marchev, F; McLendon, RE; Modrich, PL; Provenzale, JM; Rasheed, K; Rich, J; Seman, AJ; Stewart, E | 1 |
| Fei, ZL; Gallo, JM; Klein-Szanto, A; Ma, J | 1 |
| Davis, BM; Gerson, SL; Liu, L; Reese, JS | 1 |
| Alton, K; Baker, SD; Batra, V; Cutler, D; Donehower, RC; Dugan, M; Grochow, LB; Reidenberg, P; Rowinsky, EK; Sartorius, SE; Statkevich, P; Wirth, M | 1 |
| Chan, TH; Damian, Z; De Marte, J; Jean-Claude, BJ; Leyland-Jones, B; Mustafa, A; Vasilescu, DE; Yen, R | 1 |
| Arends, MJ; Clarke, AR; Dekker, M; Howard, LA; Kelly, J; Margison, GP; te Riele, H; Toft, NJ; Winton, DJ; Wyllie, AH | 1 |
| Darling, JL; Sankar, A; Thomas, DG | 1 |
| Ek, O; Messinger, Y; Reaman, GH; Uckun, FM | 1 |
| Burton, E; Prados, M | 1 |
| Archer, GE; Bigner, DD; Bishop, WR; Friedman, AH; Friedman, HS; McLendon, RE; Sampson, JH; Villavicencio, AT | 1 |
| Bonmassar, E; Franco, D; Graziani, G; Levati, L; Roy, R; Serafino, A; Tentori, L; Turriziani, M | 1 |
| Allan, JM; Broekhof, JL; Carls, NH; Donker, I; Engelward, BP; Glassner, BJ; Hampson, RJ; Hersmus, R; Hickman, MJ; Hoeijmakers, JH; Roth, RB; Samson, LD; Warren, HB; Weeda, G; Wu, MM | 1 |
| Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M | 1 |
| Agarwala, SS; Baker, SD; Barrington, R; Britten, CD; Diab, SG; Eckardt, JR; Eckhardt, SG; Fraass, U; Hammond, LA; Johnson, T; Rowinsky, EK; Statkevich, P; Villalona-Calero, M; Von Hoff, DD | 1 |
| Buesa, JM; Hermans, C; Judson, I; Lee, SM; Leyvraz, S; Lorigan, PC; Nielsen, OS; Rodenhuis, S; van Glabbeke, M; Verweij, J; Woll, PJ | 1 |
| Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D | 1 |
| Arrowsmith, J; Missailidis, S; Stevens, MF | 1 |
| Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Chatterjee, S; Gerson, SL; Liu, L; Taverna, P; Whitacre, CM | 1 |
| Miller, JL | 1 |
| Baker, SD; Dugan, M; Eckardt, JR; Eckhardt, SG; Forral, K; Hammond, LA; Reidenberg, P; Rinaldi, DA; Rowinsky, EK; Statkevich, P; Von Hoff, DD; Weiss, GR | 1 |
| Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S | 1 |
| Alvino, E; Bonmassar, E; D'Atri, S; Lacal, PM; Nunziata, C; Pagani, E; Pepponi, R | 1 |
| Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P | 1 |
| Donnelly, DJ; Kelly, J; Margison, GP; McCormick, JE; McElhinney, RS; McMurry, TB; Middleton, MR; Thatcher, N | 1 |
| Goodger, S; Kelly, J; Margison, GP; Middleton, MR; Thatcher, N | 1 |
| Brock, CS; Evans, H; Matthews, J; Newlands, ES; O'Reilly, SM; Osman, S; Price, PM; Young, H | 1 |
| Alton, KB; Blumenkrantz, N; Chowdhury, SK; Laudicina, D; Wirth, M | 1 |
| Glickson, JD; Griffiths, JR | 1 |
| Agarwala, S; Hillner, BE; Middleton, MR | 1 |
| Brada, M; Osoba, D; Prados, M; Yung, WK | 1 |
| Chang, J; Clemons, M; Dexter, TM; Heyworth, C; Howell, A; Lord, B; Margison, G; Testa, N; Watson, A | 1 |
| Brent, TP; Friedman, HS; Houghton, PJ; Kirstein, MN; Middlemas, DS; Poquette, C; Stewart, CF | 1 |
| Ferreri, AJ; Landoni, C; Reni, M; Villa, E | 1 |
| Cairncross, JG | 1 |
| Arends, MJ; Brookes, RA; Clarke, AR; Margison, GP; Sansom, OJ; Toft, NJ; Winton, DJ; Wood, M | 1 |
| MacConnachie, AM | 1 |
| Batchelor, T | 1 |
| Gerson, SL; Koç, ON; Reese, JS | 1 |
| Agarwala, SS; Kirkwood, JM | 2 |
| Cohen, MH; Johnson, JR; Middleton, MR | 1 |
| Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J | 1 |
| Busstra, MB; Catsburg, T; Lang, MS; Mickisch, GH; Schröder, FH; van Brussel, JP | 1 |
| Yung, WK | 3 |
| Friedman, HS | 1 |
| Prados, MD | 1 |
| Aravantinos, G; Christodoulou, C; Efstathiou, E; Janinis, J; Panopoulos, C; Samantas, E; Skarlos, D | 1 |
| Bonmassar, E; D'Atri, S; Faraoni, I; Gilberti, S; Graziani, G; Lacal, PM; Margison, GP; Nisticò, V; Watson, AJ | 1 |
| Calvert, H; Friedman, HS; Kerby, T | 1 |
| Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
| Almerico, AM; Barraja, P; Cirrincione, G; Dattolo, G; Diana, P; Lauria, A | 1 |
| Cher, L | 1 |
| Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S | 1 |
| Brada, M; Osoba, D; Prados, MD; Yung, WK | 1 |
| Cai, Y; Dolan, ME; Ludeman, SM; Pegg, AE; Wu, MH; Xu-Welliver, M | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Heimberger, AB; Hulette, C; McLendon, RE; Sampson, JH | 1 |
| Bigner, DD; Dolan, ME; Elion, GB; Friedman, HS; Houghton, PJ; Johnson, SP; Keir, S; Patel, VJ; Pegg, AE | 1 |
| Brandes, AA; Monfardini, S; Pasetto, LM; Vastola, F | 1 |
| Arance, A; Lee, SM; Margison, GP; Middleton, MR; Thatcher, N; Wood, M | 1 |
| Arris, CE; Bleasdale, C; Boyle, FT; Calvert, AH; Curtin, NJ; Dalby, C; Golding, BT; Griffin, RJ; Kanugula, S; Lembicz, NK; Newell, DR; Pegg, AE | 1 |
| Almassy, R; Calvert, AH; Curtin, NJ; Golding, BT; Griffin, RJ; Hostomsky, Z; Maegley, K; Newell, DR; Srinivasan, S; White, AW | 1 |
| Osoba, D | 1 |
| Brown, R; Kaye, SB; Plumb, JA; Sludden, J; Strathdee, G | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Gerson, SL; Hanson, AJ; Liu, L; Monks, A; Taverna, P | 1 |
| Affrime, MB; Batra, VK; Cutler, DL; Hajian, G; Heft, S; Jen, JF; Pai, SM; Zambas, DN | 1 |
| Brent, TP; Houghton, P; Sawai, N; Sorrentino, BP; Vanin, EF; Zhou, S | 1 |
| Jean-Claude, BJ; Matheson, SL; McNamee, J | 1 |
| Kim, H; Likhari, P; Lin, CC; Marco, A; Nomeir, AA; Parker, D; Statkevich, P | 1 |
| Hwu, WJ | 1 |
| Bocangel, DB; Kokkinakis, DM; Moschel, RC; Pegg, AE; Schold, SC | 1 |
| Hall, CN; Harrison, KL; Lees, NP; Margison, GP; Povey, AC; Wood, M | 1 |
| Berger, MS; Hirose, Y; Pieper, RO | 2 |
| Bacoyiannis, C; Bafaloukos, D; Bamias, A; Christodoulou, C; Karabelis, A; Kosmidis, P; Papakostas, P; Samantas, E; Skarlos, DV | 1 |
| Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R | 1 |
| Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA | 1 |
| Bosik, ME; Chang, SM; Fink, KL; Fulton, D; Kuhn, JG; Mehta, MP; Prados, MD; Robins, HI; Schold, SC; Spence, AM | 1 |
| Burg, G; Dummer, R | 1 |
| Si, YK | 1 |
| Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X | 1 |
| Balduzzi, A; Bonmassar, E; De Fabritiis, P; Graziani, G; Madaio, R; Portarena, I; Roy, R; Tentori, L; Vernole, P | 1 |
| Frenkel, EP; Han, Q; Hoffman, RM; Kokkinakis, DM; Schold, SC; Tan, Y; Wick, JB; Xu, M | 1 |
| Cave, C; Dinnes, J; Huang, S; Major, K; Milne, R | 1 |
| Bartosova, Z; Bonmassar, L; Cattaruzza, MS; Corti, C; D'Atri, S; Heinimann, K; Jiricny, J; Marra, G; Nyström-Lahti, M; Schweizer, P | 1 |
| Bonmassar, E; Graziani, G; Portarena, I; Tentori, L | 1 |
| Ashley, DL; Cher, L; Harris, MT; Rosenthal, MA | 1 |
| Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW | 1 |
| Frommhold, H; Koch, D; Liegibel, J; Lutterbach, J; Madlinger, A; Pagenstecher, A | 1 |
| Chu, J; Gallo, JM; Li, S; Ma, J; Pulfer, S; Reed, K | 1 |
| Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ | 1 |
| Gerson, SL; Haaga, J; Liu, L; Majka, S; Spiro, TP; Willson, JK | 1 |
| Biasco, G; Casadei, S; Pantaleo, MA | 1 |
| Macdonald, DR | 1 |
| Chinot, O | 2 |
| Newlands, E; Stupp, R | 1 |
| Prados, M | 1 |
| Abrey, LE; Christodoulou, C | 1 |
| Bardenheuer, W; Flasshove, M; Jansen, M; Moritz, T; Seeber, S; Sorg, UR | 1 |
| Mehta, MP; Rao, RD; Robins, HI | 1 |
| Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S | 1 |
| Gerson, SL; Hanson, AJ; Hwang, HS; Kinsella, TJ; Liu, L; Taverna, P | 1 |
| Chou, TC; Droege, JW; Fels, C; Kramm, CM; Rainov, NG; Schäfer, C | 1 |
| Abrey, LE; Boutros, DY; Mack, M; Malkin, MG; Olson, JD; Raizer, JJ; Rodavitch, A | 1 |
| Benjelloun, A; Delavelle, J; Dietrich, PY; Lazeyras, F | 1 |
| Dolan, ME; Long, L | 1 |
| Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Newton, HB; Santi, M; Stevens, C | 1 |
| de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R | 1 |
| Groves, MD; Hess, KR; Jaeckle, KA; Levin, VA; Peterson, P; Puduvalli, VK; Yung, WK | 1 |
| Brada, M | 1 |
| Cave, C; Dinnes, J; Huang, S; Milne, R | 1 |
| Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G | 1 |
| Hwu, WJ; Lis, E; Panageas, KS; Raizer, J | 1 |
| Gander, M; Leyvraz, S; Newlands, E; Stupp, R | 1 |
| Dichgans, J; Rodemann, HP; Schulz, JB; Weller, M; Wick, A; Wick, W | 1 |
| Lichtman, SM; Skirvin, JA | 1 |
| Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N | 1 |
| Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G | 1 |
| Baas, P; Debruyne, C; Galdermans, D; Giaccone, G; Lentz, MA; Manegold, C; Smit, EF; van Klaveren, RJ; van Meerbeeck, JP | 1 |
| Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K | 1 |
| Lambert, P; Wang, D; Wang, Y; Zhao, L | 1 |
| Dichgans, J; Herrlinger, U; Küker, W; Platten, M; Weller, M | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ | 1 |
| Graziani, G; Tentori, L | 3 |
| Croteau, D; Mikkelsen, T | 1 |
| Afra, D; Sipos, L; Vitanovics, D | 2 |
| Pavelka, Z; Slampa, P; Sterba, J | 1 |
| Ashley, DL; Cher, L; Rosenthal, MA | 2 |
| Danson, SJ; Middleton, MR | 1 |
| Nieder, C | 2 |
| Beauchesne, P | 1 |
| Donnelly, DJ; Margison, GP; McElhinney, RS; McMurry, TB; Middleton, MR; Thatcher, N | 1 |
| Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S | 1 |
| Ahmed, T; Baskind, P; Liu, D; Loughran, T; Seiter, K; Siddiqui, A | 1 |
| Bhakat, KK; Bocangel, DB; Finkelstein, S; Kokkinakis, DM; Mitra, S; Schold, SC | 1 |
| Dolan, ME; Park, DK; Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S | 1 |
| Antonadou, D; Coliarakis, N; Economou, I; Karageorgis, P; Paraskevaidis, M; Sarris, G; Throuvalas, N | 1 |
| Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F | 1 |
| Cappugi, P; Coronnello, M; Giannotti, B; Mini, E; Pimpinelli, N; Prignano, F | 1 |
| Fang, HB; Houghton, PJ; Tan, M; Tian, GL | 3 |
| Gerson, SL; Liu, L; Nakatsuru, Y | 1 |
| Blank, A; Bobola, MS; Haroldson, PD; Huynh, MB; Kolstoe, DD; Schoeler, KD; Silber, JR | 1 |
| Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F | 1 |
| Lacy, J; Lerro, KA | 1 |
| Gaya, A; Greenstein, A; Rees, J; Stebbing, J | 1 |
| Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F | 1 |
| Friedman, HS; Gilbert, MR; Kuttesch, JF; Olson, JJ; Prados, MD; Reaman, GH; Zaknoen, SL | 1 |
| Chiamchanya, S; Dhanachai, M; Hongeng, S; Laothamatus, J; Visudtibhan, A | 1 |
| Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L | 1 |
| Newton, HB | 1 |
| Isaacson, BJ; Islam, R; Ratanawong, C; Tipping, SJ; Zickerman, PM | 1 |
| Albano, J; Cernuda, M; Garcia, I; Lima, L; Oliveira, C; Portela, I; Teixeira, MM | 1 |
| Li, Y; McClay, EF | 1 |
| Almassy, RJ; Boritzki, TJ; Calabrese, CR; Calvert, AH; Canan Koch, SS; Curtin, NJ; Ekker, A; Golding, BT; Griffin, RJ; Hostomsky, Z; Kumpf, RA; Kyle, S; Li, J; Maegley, KA; Mansour, RN; Newell, DR; Thomas, HD; Thoresen, LH; Tikhe, JG; Wang, LZ; Webber, SE; Yu, XH; Zhang, C; Zhang, KE; Zook, SE | 1 |
| Belogurova, MB; Borodina, ID; Gorbatykh, SV; Kumirova, EV; Melikian, AG; Prityko, AG; Shcherbenko, OI; Tarasova, IS; Zheludkova, OG | 1 |
| Patel, SR | 1 |
| Brady, F; Brock, CS; Brown, GD; Luthra, SK; Price, PM; Stevens, MF | 1 |
| Arrowsmith, J; Clark, AS; Jennings, SA; Stevens, MF | 1 |
| Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE | 1 |
| Castel, T; Conill, C; Puig, S; Toscas, I | 1 |
| Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G | 1 |
| Baker, SD; Donehower, RC; Grochow, LB; Rowinsky, EK; Schellens, JH; Sparreboom, A; Verweij, J | 1 |
| Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M | 1 |
| Almassy, R; Calvert, AH; Curtin, NJ; Eastman, BW; Ekker, A; Golding, BT; Griffin, RJ; Hostomsky, Z; Li, J; Maegley, KA; Marakovits, JT; Newell, DR; Skalitzky, DJ; Webber, SE; Yu, XH | 1 |
| Boiardi, A; Eoli, M; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Bonmassar, E; D'Atri, S; Falcinelli, S; Fuggetta, MP; Jiricny, J; Marra, G; Pagani, E; Pepponi, R | 1 |
| Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R; Vastola, F | 1 |
| Arnold, H; Damasceno, R; Günther, W; Pawlak, E; Terzis, AJ | 1 |
| Affronti, ML; Avgeropoulos, N; Bigner, DD; Evans, B; Finlay, J; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S | 1 |
| Ebert, BL; Niemierko, E; Salgia, R; Shaffer, K | 1 |
| Dréno, B; Wallon-Dumont, G | 1 |
| Batchelor, D; Boogerd, W; de Gast, GC; de Waal, MA; Kersten, MJ; Nieweg, OE; Nooijen, WJ; Sein, J; van de Kasteele, WF; Vyth-Dreese, FA | 1 |
| Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K | 1 |
| Baayen, HC; Barkhof, F; Boogerd, W; Castelijns, JA; Elkhuizen, PH; Heimans, JJ; Postma, TJ; Uitdehaag, BM; Vos, MJ | 1 |
| Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ | 1 |
| Berger, MS; Erickson, LC; Hirose, Y; Kreklau, EL; Pieper, RO | 1 |
| Allay, ER; Brent, TP; Hanawa, H; Hargrove, PW; Nienhuis, AW; Persons, DA; Sawai, N; Sorrentino, BP | 1 |
| Cutler, DL; Denis, L; Edwards, T; Gerson, SL; Geyer, C; Goetz, AD; Hammond, LA; Patnaik, A; Reyderman, L; Rowinsky, EK; Schwartz, G; Statkevich, P; Tolcher, AW | 1 |
| Cairncross, JG; Chinot, OL; van den Bent, M | 1 |
| Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA | 1 |
| Balis, FM; Godwin, K; McCully, C; Patel, M | 1 |
| Barnett, G; Chahlavi, A; Elson, P; Kanner, A; Peereboom, D; Staugaitis, SM | 1 |
| Aboagye, EO; Barthel, H; Collingridge, DR; Hutchinson, OC; Price, PM | 1 |
| Ariza, A; Balaña, C; Ballester, R; Mendez, P; Ramirez, JL; Rosell, R; Roussos, Y; Sanchez, JJ; Sarries, C; Taron, M | 1 |
| Chou, TC; Dong, HJ; Figul, M; Rainov, NG; Söling, A | 1 |
| Ator, M; Bihovsky, R; Chatterjee, S; Dionne, C; Hudkins, R; Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Miknyoczki, SJ; Pritchard, S; Ruggeri, B; Wan, W; Zhao, H | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Chamberlain, M; Glantz, M; Litofsky, NS; Liu, Q; Recht, LD | 1 |
| Gerson, SL; Liu, L; Reese, JS | 1 |
| Aboagye, EO; Brady, F; Brock, CS; Brown, GD; Jones, T; Luthra, SK; Newlands, E; Osman, S; Price, P; Ranicar, AS; Saleem, A; Stevens, MF | 1 |
| Finlay, JL; Knopp, EA; Kuo, DJ; Miller, DC; Weiner, HL; Wisoff, J | 1 |
| Ardizzoni, A; Debruyne, C; Dziadziuszko, R; Giaccone, G; Legrand, C; Postmus, PE; Price, A; Smit, EF | 1 |
| Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S | 1 |
| Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Miranda, FT; Shipley, DL; Thompson, DS; Toomey, MA; Willcutt, NT | 1 |
| Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK | 1 |
| Berger, MS; Bodell, WJ; Gaikwad, NW; Miller, D | 1 |
| Allgeier, A; Brandes, AA; Chinot, O; Frenay, M; Gorlia, T; Kros, JM; Menten, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, ChJ | 1 |
| Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N | 1 |
| Batey, MA; Boritzki, T; Calabrese, CR; Calvert, AH; Curtin, NJ; Durkacz, BW; Hostomsky, Z; Kyle, S; Li, J; Maegley, K; Newell, DR; Skalitzky, D; Thomas, HD; Wang, LZ; Zhang, C | 1 |
| Foster, T; Newlands, ES; Zaknoen, S | 1 |
| Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S | 1 |
| Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD | 1 |
| Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M | 1 |
| Kurzen, H; Möhler, T; Näher, H; Schmitt, S | 1 |
| Bishop, SM; Clarke, AR; Court, H; Dudley, S; Liskay, RM; Sansom, OJ | 1 |
| Fouladi, M; Gajjar, A; Heideman, RL; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF; Wilkinson, M | 1 |
| Barone, C; Caldarelli, M; Cefalo, G; Garrè, ML; Lazzareschi, I; Madon, E; Maira, G; Massimino, M; Mastrangelo, S; Mazzarella, G; Riccardi, A; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A | 1 |
| Ahmed, MM; Chendil, D; Kokkinakis, DM; Moschel, RC; Pegg, AE | 1 |
| Brown, P; Buckner, J | 1 |
| van den Bent, MJ | 3 |
| Fouladi, M; Gajjar, AJ; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF | 1 |
| Calvet, D; Delattre, JY; Janoray, P; Rojas-Marcos, I | 1 |
| Bird, A; Bishop, SM; Clarke, AR; Guy, J; Sansom, OJ; Zabkiewicz, J | 1 |
| Engelhard, HH; Mundt, A; Stelea, A | 1 |
| Artizzu, S; Brogna, C; Caroli, E; Frati, A; Piccirilli, M; Salvati, M | 1 |
| Bagiella, E; Hesdorffer, M; Keohan, ML; Orrico, R; Talbot, SM; Taub, RN; Troxel, AB | 1 |
| Berger, MS; Haas-Kogan, DA; Hirose, Y; Katayama, M; Pieper, RO; Stokoe, D | 1 |
| Aoki, T; Hashimoto, N; Ishikawa, M; Mizutani, T; Sugiyama, K | 1 |
| Baruchel, S; Becker, L; Bouffet, E; Gammon, J; Hargrave, D; Rutka, J | 1 |
| Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ | 1 |
| D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G | 1 |
| Dolan, ME; Nagasubramanian, R | 1 |
| Baumert, BG; Stupp, R | 2 |
| Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P | 1 |
| Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A | 1 |
| Bamberg, M; Belka, C; Jendrossek, V | 1 |
| Hartmann, P; Herholz, K; Petereit, HF; Salzberger, B | 1 |
| Beach, J; Benjamin, RS; Burgess, MA; Chen, LL; Papadopolous, N; Patel, SR; Trent, JC | 1 |
| Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K | 1 |
| Ambrosetto, P; Barbiroli, B; Cortelli, P; Crinò, L; Franceschi, E; Lodi, R; Setola, E; Tonon, C | 1 |
| Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y | 1 |
| Almassy, R; Barton, S; Batey, MA; Calabrese, CR; Calvert, AH; Canan-Koch, S; Curtin, NJ; Durkacz, BW; Hostomsky, Z; Kumpf, RA; Kyle, S; Li, J; Maegley, K; Newell, DR; Notarianni, E; Skalitzky, D; Stratford, IJ; Thomas, HD; Wang, LZ; Webber, SE; Williams, KJ | 1 |
| Germano, IM; Ito, H; Kanzawa, T; Komata, T; Kondo, S; Kondo, Y | 1 |
| Baumgartner, M; Kaina, B; Roos, W | 1 |
| Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD | 1 |
| Gajewski, TF | 1 |
| Jonas, DL; Kiebert, GM; Middleton, MR | 1 |
| Oubre, DN | 1 |
| Bacik, J; Bajorin, D; Bosl, GJ; Marion, S; Mazumdar, M; Motzer, RJ; Schwartz, L; Sheinfeld, J; Varuni Kondagunta, G; Vuky, J | 1 |
| Baker, SD; Batra, VK; Cutler, DL; Donehower, RC; Rudek, MA; Statkevich, P | 1 |
| Berger, MS; Chang, SM; Keles, GE; Lamborn, KR; Prados, MD | 1 |
| Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P | 1 |
| Buster, WP; Gruber, ML | 1 |
| DeAngelis, LM | 3 |
| Chinot, OL | 2 |
| Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK | 1 |
| Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM | 1 |
| Albritton, K; Crews, KR; Fuller, CE; Goldsby, RE; Houghton, PJ; Iacono, LC; McCarville, MB; Santana, VM; Stewart, CF; Wagner, LM | 1 |
| Arris, CA; Calvert, HA; Canan-Koch, S; Curtin, NJ; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; Webber, SE; Yiakouvaki, A | 1 |
| Abson, C; Brada, M; Dzik-Jurasz, AS; Leach, MO; Murphy, PS; Rowland, IJ; Viviers, L | 1 |
| Carducci, MA; Denmeade, S; Eisenberger, M; Huff, CA; Pili, R; Rogers, T; Sinibaldi, V; Summerson, L; Sunkara, U; Walczak, JR | 1 |
| Barvaux, VA; Brown, R; Margison, GP; McElhinney, RS; McMurry, TB; Ranson, M | 1 |
| Harkness, KA; Manford, MR | 1 |
| Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR | 1 |
| Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A | 1 |
| Dello Russo, C; Graziani, G; Navarra, P; Tentori, L; Tringali, G; Vairano, M | 1 |
| Chamberlain, MC; Tsao-Wei, DD | 1 |
| Bilbao, JM; Morrison, T; Perry, JR; Yang, G | 1 |
| de Tribolet, N; Dietrich, PY; Diserens, AC; Godard, S; Hegi, ME; Ostermann, S; Otten, P; Regli, L; Stupp, R; Van Melle, G | 1 |
| Eigentler, TK; Garbe, C | 1 |
| Liang, H; Sha, N | 1 |
| Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M | 1 |
| Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK | 1 |
| Agarwala, SS; Tarhini, AA | 1 |
| Chamberlain, MC; Groshen, S; Tsao-Wei, DD | 2 |
| Castel, T; Conill, C; González-Cao, M; Jorcano, S; Malvehy, J; Martí, R; Puig, S | 1 |
| Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R | 1 |
| Curtin, NJ; Eastman, BW; Golding, BT; Griffin, RJ; Hostomsky, Z; Kyle, S; Li, J; Maegley, KA; Skalitzky, DJ; Webber, SE; White, AW; Yu, XH | 1 |
| Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F | 1 |
| Lobrinus, JA; Matzinger, O; Michielin, O; Périard, D; Stupp, R; Udry, E | 1 |
| Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J | 1 |
| Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Frauger, E; Grisoli, F; Hoang-Xuan, K; Martin, PM; Moktari, K; Palmari, J; Peragut, JC | 1 |
| Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F | 1 |
| Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P | 1 |
| Awada, A; de Valeriola, D; Dubuisson, M; Gil, T; Klastersky, J; Moerman, C; Piccart, MJ; Sales, F; Vereecken, P | 1 |
| Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N | 1 |
| Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R | 1 |
| Castellano, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Ilari, I; Inserra, A; Jenkner, A; Milano, GM | 1 |
| Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G | 1 |
| Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W | 1 |
| Argenta, PA; Blair Harkness, C; Boente, MP; Carson, LF; Downs, LS; Judson, PL | 1 |
| Berger, MS; Hirose, Y; Katayama, M; Pieper, RO | 1 |
| Barron, L; Tishler, R; Wong, ET; Wu, JK | 1 |
| Aguirre-Cruz, L; Crinière, E; Delattre, JY; Duprez, A; Golmard, JL; Kujas, M; Leuraud, P; Marie, Y; Medioni, J; Poupon, MF; Sanson, M; Taillandier, L | 1 |
| Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L | 1 |
| Abbadessa, A; Bernardi, D; Bordonaro, R; Candela, M; Dell'Oro, S; Ferreri, AJ; Franceschi, E; Latte, G; Mason, W; Pace, A; Perry, J; Reni, M; Stelitano, C; Villa, E; Zaja, F | 1 |
| Ataman, F; Fisher, B; Mirimanoff, RO; Poortmans, P; Stupp, R | 1 |
| Christmann, M; Garcia Boy, R; Kaina, B; Mühlhausen, U; Piee-Staffa, A; Rösch, F; Schirrmacher, R | 1 |
| Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA | 1 |
| Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC | 1 |
| Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B | 1 |
| Chamberlain, MC | 10 |
| Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S | 1 |
| Gomori, JM; Levin, N; Siegal, T | 1 |
| Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ | 1 |
| Broët, P; Capelle, L; Carpentier, AF; Cornu, P; Crinière, E; Delattre, JY; Duffau, H; Hoang-Xuan, K; Kujas, M; Laigle, F; Lejeune, J; Marie, Y; Mokhtari, K; Polivka, M; Sanson, M; Simon, JM; Taillibert, S | 1 |
| Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R | 1 |
| Caldwell, D; Kelley, MR; Rinne, M | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A | 1 |
| de Bruin, HG; de Wit, MC; Eijkenboom, W; Sillevis Smitt, PA; van den Bent, MJ | 1 |
| Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D | 1 |
| Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC | 1 |
| Chinnasamy, D; Chinnasamy, N; Fairbairn, LJ; Hanson, JP; Margison, GP; Neuenfeldt, J; Treisman, JS | 1 |
| Bonmassar, E; Caporali, S; D'Atri, S; Falcinelli, S; Jiricny, J; Russo, MT; Starace, G | 1 |
| Ahmed, T; Lerner, R; Liu, D; Nelson, J; Seiter, K; Siddiqui, AD | 1 |
| Abrey, LE; DeAngelis, LM; Demopoulos, A; Enting, RH | 1 |
| Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I | 1 |
| Aaltonen, K; Mäenpää, HO; Mäntylä, R; Minn, H | 1 |
| Batra, VK; Patrick, J; Reyderman, L; Statkevich, P; Thonoor, CM; Wirth, M | 1 |
| Gillespie, GY; Kufe, DW; Weichselbaum, RR; Yamini, B; Yu, X | 1 |
| Aryan, HE; Bruce, DA; Levy, ML; Lu, DC; Meltzer, HS; Ozgur, BM | 1 |
| Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W | 1 |
| Leyvraz, S; Mirimanoff, RO; Ostermann, S; Pica, A; Stupp, R; Villemure, JG; Wasserfallen, JB | 1 |
| Bafaloukos, D; Bedikian, AY; Gogas, H | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Panner, A; Pieper, RO; Saito, R; Tamas, M | 1 |
| Barvaux, VA; Gillum, AM; Lorigan, P; Margison, GP; McElhinney, RS; McMurry, TB; Ranson, M | 1 |
| Anandakumar, P; Beard, BC; Kiem, HP; Neff, T; Peterson, LJ; Thompson, J | 1 |
| Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G | 1 |
| Fairbairn, LJ; Humphries, RK; Margison, GP; Milsom, MD; Woolford, LB | 1 |
| Alliot, C | 1 |
| Branle, F; Everaert, E; Joosens, E; Menten, J; Neyns, B; Strauven, T | 1 |
| Dichgans, J; Küker, W; Weller, M; Wick, A; Wick, W | 1 |
| Peterson, RA; Rostomily, RC; Scharnhorst, JD; Silbergeld, DL; Spence, AM | 1 |
| Arrigo, C; Pitini, V; Righi, M | 1 |
| Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T | 1 |
| Cereda, E; Gariboldi, MB; Monti, E; Ravizza, R | 1 |
| Erber, R; Grobholz, R; Korn, T; Tuettenberg, J; Vajkoczy, P; Wenz, F | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Koch, M; Koomen, GJ; Rodenko, B; Wanner, MJ | 1 |
| Harting, MS; Kim, KB | 1 |
| Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F | 1 |
| Fang, HB; Tan, M; Tian, GL | 1 |
| Bowman, FD; Helms, RW; Sen, PK; Stewart, PW | 1 |
| Banik, NL; Das, A; Patel, SJ; Ray, SK | 1 |
| Bailey, A; Bennani, YL; Bom, D; Boozer, S; Brunden, K; Dent, T; Gleason, E; Harrington, J; Huck, B; Leventhal, C; Murphy, S; Rundlett, S; Sherf, B; Silver, D; Tumey, LN; Wang, J | 1 |
| Buzaid, AC | 1 |
| Koch, M; Koomen, GJ; Wanner, MJ | 1 |
| Carpentier, AF | 1 |
| Gil, M; Graus, F; Pujol, T; Quintó, L; Verger, E; Villà, S; Viñolas, N; Yaya, R | 1 |
| Roitberg, B | 2 |
| Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J | 1 |
| Byrne, TN | 1 |
| Balaña, C; Balart, J; Ballester, R; Benavides, M; Berrocal, A; Capellades, J; Cerdá-Nicolás, M; García, JL; Herrero, A; López-Pousa, A; Martín-Broto, J; Yaya-Tur, R | 1 |
| Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
| Liccardo, G; Lunardi, P; Menniti, A; Moschettoni, L | 1 |
| Banik, NL; Patel, SJ; Ray, SK; Sribnick, EA; Sur, P | 1 |
| Batchelor, TT; Cosgrove, GR; Louis, DN; Voloschin, AD | 1 |
| Middleton, MR; Payne, MJ; Pratap, SE | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D | 1 |
| Golubnitschaja, O; Haertel, N; Moenkemann, H; Schüller, H; Trog, D | 1 |
| Chang, MC; Chiang, MF; Hsieh, RK; Su, YW | 1 |
| Abali, H; Aksoy, S; Güler, N; Kiliçkap, S | 1 |
| Wong, ET | 2 |
| Azzabi, A; Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Hughes, AN; Kelly, C; Lind, MJ; Maraveyas, A; Plummer, ER; Todd, R | 1 |
| Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R | 1 |
| Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M | 1 |
| Bromberg, JE; Cairncross, JG; de Tribolet, N; Diserens, AC; Gorlia, T; Hainfellner, JA; Hamou, MF; Hau, P; Hegi, ME; Janzer, RC; Kros, JM; Mariani, L; Mason, W; Mirimanoff, RO; Stupp, R; Weller, M | 1 |
| Antonadou, D; Athanassiou, H; Beroukas, K; Karageorgis, P; Maragoudakis, E; Misailidou, D; Paraskevaidis, M; Saris, G; Synodinou, M; Verigos, C | 1 |
| Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA | 1 |
| Cairncross, JG; Mymryk, JS; Xu, GW | 2 |
| Langer, CJ; Somer, RA | 1 |
| Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A | 1 |
| Blank, A; Bobola, MS; Ellenbogen, RG; Geyer, JR; Goff, RD; Silber, JR | 1 |
| Butowski, N; Chang, SM; Lamborn, KR; Larson, DA; Malec, M; Page, M; Prados, MD; Rabbitt, J; Sneed, PK; Wara, WM | 1 |
| Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF | 1 |
| Bafaloukos, D; Briassoulis, E; Chalkidou, S; Christodoulou, C; Efstathiou, E; Fountzilas, G; Gogas, H; Iconomou, T; Kalofonos, H; Kouroussis, C; Linardou, E; Panagiotou, P; Polyzos, A; Tsoutsos, D | 1 |
| Leyvraz, S; Ostermann, S; Stupp, R; Wasserfallen, JB | 1 |
| Cai, S; Cooper, RJ; Ferkowicz, MJ; Hartwell, JR; Kelley, MR; Pollok, KE; Xu, Y | 1 |
| Curtin, NJ | 1 |
| Brandes, AA; Lonardi, S; Tosoni, A | 1 |
| Shirato, H | 1 |
| Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC | 1 |
| Legha, SS | 1 |
| Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD | 1 |
| Brahimi, F; Jean-Claude, BJ; Katsoulas, A; McNamee, J; Rachid, Z | 1 |
| Abrey, LE | 1 |
| Hegi, ME; Stupp, R; van den Bent, MJ | 2 |
| Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ | 1 |
| Ashley, S; Brada, M; Dowe, A; Gonsalves, A; Huchet, A; Pesce, G; Reni, M; Saran, F; Wharram, B; Wilkins, M; Wilkins, P | 1 |
| Brotchi, J; Camby, I; Darro, F; Gabius, J; Gaussin, JF; James, S; Kiss, R; Lefranc, F | 1 |
| Geddis, A; Kadota, R; Kerlin, B; Kung, F; Levy, M; Loh, KC; Martin, L; Meltzer, H; Roberts, W; Schiff, D; Spear, MA; White, G; Willert, J; Yu, A | 1 |
| Dichgans, J; Hebart, H; Herrlinger, U; Kanz, L; Weller, M | 1 |
| Akasaki, Y; Black, KL; Das, A; Khong, HT; Liu, G; Wheeler, CJ; Yu, JS | 1 |
| Aghajanian, C; Anderson, S | 1 |
| Combs, SE; Debus, J; Edler, L; Gutwein, S; Schulz-Ertner, D; Thilmann, C; van Kampen, M; Wannenmacher, MM | 1 |
| Berger, MS; Hirose, Y; Katayama, M; Mirzoeva, OK; Pieper, RO | 1 |
| Seiter, K | 1 |
| Ashby, L; LaRocca, R; Ryken, T | 1 |
| Altundag, K; Altundag, MB; Altundag, O; Boruban, C; Turen, S | 1 |
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
| Cao, Y; Chenevert, TL; Kessler, ML; Lawrence, TS; Shen, Z; Tatro, DS; Ten Haken, R; Tsien, CI | 1 |
| Weller, M; Wick, W | 1 |
| Beardsley, NJ; Glickson, JD; Mancuso, A; Pickup, S; Wehrli, S; Zhu, A | 1 |
| Cavallo, G; Crinò, L; Esposti, RD; Foschini, MP; Franceschi, E; Marliani, AF; Paioli, A; Paioli, G; Palmerini, E; Scopece, L | 1 |
| Brock, C; Newlands, ES; Palmieri, C | 1 |
| Bromberg, JE; Postma, TJ | 1 |
| Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I | 1 |
| Forini, O; Graziani, G; Lacal, PM; Levati, L; Muzi, A; Ruffini, F; Tentori, L; Vergati, M; Vernole, P | 1 |
| Abbruzzese, A; Addeo, R; Budillon, A; Caraglia, M; Costanzo, R; Del Prete, S; Faiola, V; Grillone, F; Marra, M; Montella, L; Palmieri, G; Tagliaferri, P; Venuta, S | 1 |
| Almeida, KH; Fornsaglio, JL; Schamus, S; Sobol, RW; Trivedi, RN | 1 |
| Benedetti, G; Biasco, G; Pantaleo, MA; Poggi, R | 1 |
| Blanco, G; Bordonaro, R; Castorina, S; Failla, G; Giorgio, CG; Giuffrida, D; Pappalardo, A; Russo, A; Salice, P; Santini, D | 1 |
| Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Passagne, I; Vian, L | 1 |
| Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Reddiconto, G; Sica, S | 1 |
| Bouffet, E; Foreman, N; Korones, DN; Smith, A | 1 |
| Castellano, A; De Sio, L; Dominici, C; Donfrancesco, A; Fidani, P; Jenkner, A; Milano, GM | 1 |
| Liang, H | 1 |
| Fairbairn, LJ; Margison, GP; Milsom, MD; Southgate, TD; Woolford, LB | 1 |
| Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J | 1 |
| Lang, P; Mazeron, JJ; Simon, JM; Taillibert, S; Toubiana, T | 1 |
| Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P | 1 |
| Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C | 1 |
| Holland, EC; Momota, H; Nerio, E | 1 |
| Birner, A | 1 |
| Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R | 1 |
| Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A | 1 |
| Beschorner, AF; Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Kennerly, G; Miranda, FT; Raefsky, EL; Willcutt, NT | 1 |
| Chastagner, P; Couanet, D; Djafari, L; Doz, F; Frappaz, D; Gentet, JC; Geoerger, B; Geoffray, A; Margison, GP; O'Quigley, J; Pein, F; Raquin, MA; Rubie, H; Vassal, G; Wartelle, M; Watson, AJ | 1 |
| Hatano, H; Ishii, D; Mizuno, M; Natsume, A; Tsuno, T; Wakabayashi, T; Yoshida, J | 1 |
| Comella, P; Formato, R; Iaffaioli, RV; Muto, P; Pisano, A; Quattrin, S; Tafuto, S; Tortoriello, A | 1 |
| Alinari, L; Baccarani, M; Fina, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Bogdahn, U; Koch, HJ; Kuchelmeister, K; Roeber, S; Schachenmayr, W; Schäfer, C; Steinbrecher, A; Villarrubia, V; Zimmermann, UW | 1 |
| Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA | 1 |
| Kokkinakis, DM; Liu, X; Neuner, RD | 1 |
| Ali-Osman, F; Bigner, DD; Cheng, CL; Dolan, ME; Friedman, HS; Johnson, SP; Keir, ST; Li, H; Modrich, P; Quinn, JA; Salzman, AL; Szabo, C | 1 |
| Bigner, DD; Birch, R; Brem, H; Dancey, JE; Delaney, SM; Desjardins, A; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Maxwell, J; McLendon, RE; Moschel, RC; Pegg, AE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, J; Sampson, JH; Tourt-Uhlig, S; Vredenburgh, J; Weingart, J | 1 |
| Aronson, F; Kennedy, T; Ready, N; Wanebo, H | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Houghton, PJ; Iacono, LC; Kocak, M; Krasin, MJ; Kun, LE; Ledet, D; Merchant, TE; Stewart, CF | 1 |
| Nakada, M | 1 |
| Sawamura, Y | 1 |
| Takahashi, H; Tanaka, R; Uzuka, T | 1 |
| Narita, Y | 2 |
| Cohen, MH; Johnson, JR; Pazdur, R | 1 |
| Antipas, VP; Stamatakos, GS; Uzunoglu, NK | 2 |
| Weller, M | 4 |
| Abrey, LE; Mehta, MP | 1 |
| Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ | 1 |
| Aikin, AA; Balis, FM; Fox, E; Libucha, M; Packer, RJ; Warren, KE; Widemann, BC | 1 |
| Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD | 1 |
| Denny, SR; Harvey, WB; Kashani-Sabet, M; Madland, MT; Minor, DR | 1 |
| Chaskis, C; De Ridder, M; Keyaerts, M; Michotte, A; Neyns, B; Sadones, J; Veld, PI | 1 |
| Bernays, RL; Gutteck-Amsler, U; Hofer, S; Meier, UR; Meier-Abt, PJ; Peghini, PE; Rentsch, K; Rutz, HP | 1 |
| Allen, R; Ames, P; Cook, M; Cruickshank, S; Deck, R; Gonzalez, R; Good, J; Meyer, J; O'Day, S; Rose, M; Spitler, LE; Timmerman, M; Trautvetter, S; Weber, RW | 1 |
| Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P | 1 |
| Erridge, SC; Gregor, A | 1 |
| Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM | 1 |
| Therasse, P | 1 |
| Clemons, M; Howell, A; Kelly, J; Margison, GP; McElhinney, RS; McMurry, TB; Watson, AJ | 1 |
| Gilbert, MR; Gonzalez, J | 1 |
| Bissola, L; Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Finocchiaro, G; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Pruitt, AA; Rosenfeld, MR | 1 |
| Duncan, T; Lindahl, T; Paik, J; Sedgwick, B | 1 |
| Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J | 1 |
| Koch, D; Wick, W | 1 |
| Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A | 1 |
| Fabian, K; Kaina, B; Thacker, J; Tsaryk, R | 1 |
| Danielpour, M; Das, A; Simmons, C | 1 |
| Argon, A; Camlica, H; Tas, F; Topuz, E | 1 |
| Albritton, K; Goldsby, RE; McAllister, N; McCarville, MB; McNall-Knapp, RY; Rausen, AR; Wagner, LM | 1 |
| Baumert, BG; Bottomley, A; Coens, C; Eisenhauer, E; Forsyth, P; Kortmann, R; Mason, W; Mirimanoff, RO; Osoba, D; Stupp, R; Taphoorn, MJ; van den Bent, MJ | 1 |
| Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS | 1 |
| Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K | 1 |
| Chan, DT; Chan, YL; Ng, HK; Poon, WS | 1 |
| Ashley, D; Cher, L; Dowling, A; Jennens, R; Rosenthal, MA; Wong, S; Woods, AM | 1 |
| Hoon, DS; Kitago, M; Koyanagi, K; Kuo, C; Martinez, SR; Milford, R; Mori, T; Nguyen, SL; O'Day, SJ; Takeshima, TL; Umetani, N; Vu, VD; Wang, HJ | 1 |
| Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX | 1 |
| Barbarisi, M; Moraci, A; Moraci, M; Parlato, C | 1 |
| Hamilton, D | 1 |
| Crausaz, S; McNee, W; Metcalfe, S; Moodie, P | 1 |
| Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF | 1 |
| Aghi, M; Martuza, RL; Rabkin, S | 2 |
| Benouaich-Amiel, A; Delattre, JY; Simon, JM | 1 |
| Abdel-Wahab, OI; Abdel-Wahab, Z; Chu, E; Dewhirst, MW; Friedman, HS; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoo, JS; Yoshimoto, Y | 1 |
| Lai, TL; Shih, MC; Wong, SP | 1 |
| Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J | 1 |
| Conway, BR; Suppasansatorn, P; Wang, G; Wang, W; Wang, Y | 1 |
| Amadori, S; Bonmassar, E; Bonmassar, L; Buccisano, F; Cantonetti, M; Caporaso, P; D'Atri, S; Turriziani, M; Venditti, A | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M | 1 |
| Covas, DT; Davis, BM; Encell, LP; Fontes, AM; Gerson, SL; Lingas, K; Loeb, LA; Pegg, AE; Zago, MA | 1 |
| Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M | 1 |
| Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S | 1 |
| Bex, A; De Gast, GC; Horenblas, S; Kerst, J; Mallo, H; Van Tinteren, H | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Burghaus, L; Galldiks, N; Heiss, WD; Herholz, K; Jacobs, AH; Kracht, LW; Thomas, A | 1 |
| Benouaich-Amiel, A; Delattre, JY | 1 |
| Brock, C; Newlands, ES; Rehman, S | 1 |
| Reardon, DA | 2 |
| Gilbert, MR | 1 |
| Mirimanoff, RO | 1 |
| Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A | 1 |
| Artemov, D; Kato, Y; Okollie, B | 1 |
| Chan, V; Chaudhry, AA; Clark, CT; Daw, HA; Kundranda, MN | 1 |
| Bigner, DD; Friedman, HS; Reardon, DA; Rich, JN | 1 |
| Rasiah, D | 1 |
| Bridgewater, J; Dawson, M; Donnelly, D; Gumbrell, L; Halbert, G; Jowle, D; Lee, SM; Margison, GP; McElhinney, RS; McGrath, H; McMurry, TB; Middleton, MR; Ranson, M; Waller, S | 1 |
| Kerr, C | 1 |
| Bokstein, F; Fellig, Y; Fuchs, D; Lavon, I; Levin, N; Siegal, T; Zelikovitsh, B | 1 |
| Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y | 1 |
| Dannenmann, SR; Davies, SM; Geiger, H; Nattamai, KJ; Schleimer, D; Weiss, BD | 1 |
| Steinbach, JP; Weller, M; Wick, W | 1 |
| Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L | 1 |
| Barone, G; Maurizi, P; Riccardi, R; Tamburrini, G | 1 |
| Audra, P; Cartalat-Carel, S; Colin, P; Ducray, F; Gaucherand, P; Honnorat, J; Mahla, K; Pelissou-Guyotat, I; Trouillas, P | 1 |
| Itasaka, S; Kim, JT; Lee, JI; Nam, DH | 1 |
| Fountoulakis, M; Friedlein, A; Golubnitschaja, O; Trog, D | 1 |
| Addo-Yobo, SO; Donson, AM; Foreman, NK; Gore, L; Handler, MH | 1 |
| Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ | 1 |
| Avis, T; Barthorpe, S; Batchelor, TT; Bignell, G; Brackenbury, L; Buck, G; Butler, A; Cahill, DP; Clements, J; Cole, J; Davies, H; Dicks, E; Easton, DF; Edkins, S; Forbes, S; Futreal, PA; Gorton, M; Gray, K; Greenman, C; Halliday, K; Harrison, R; Hills, K; Hinton, J; Hunter, C; Jenkinson, A; Jones, D; Kosmidou, V; Laman, R; Levine, KK; Louis, DN; Lugg, R; Menzies, A; Mueller, W; O'Meara, S; Parker, A; Perry, J; Petty, R; Raine, K; Richardson, D; Riggins, G; Roy, JE; Shepherd, R; Small, A; Smith, R; Solomon, H; Stephens, P; Stevens, C; Stratton, MR; Teague, J; Tofts, C; Varian, J; West, S; Widaa, S; Wooster, R; Yates, A | 1 |
| Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK | 1 |
| Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD | 1 |
| Capelle, L; Duffau, H; Taillandier, L | 1 |
| Kiem, HP; Partap, S; Peterson, RA; Schuetze, S; Silber, JR; Spence, AM | 1 |
| den Dunnen, W; Enting, RH; Heesters, M; Kros, JM; Metzemaekers, J; van der Graaf, WT | 1 |
| Collins, CA; Manasanch, EE; Ramaprasad, C; van Besien, K; Villano, JL | 1 |
| Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R | 1 |
| Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W | 1 |
| Dehdashti, AR; Hegi, ME; Pica, A; Regli, L; Stupp, R | 1 |
| Kiss, R; Lefranc, F | 1 |
| Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D | 1 |
| Brandes, AA; Ermani, M; Gardiman, M; Ghimenton, C; Iuzzolino, P; Nicolardi, L; Reni, M; Rotilio, A; Sotti, G; Tosoni, A | 1 |
| Baehring, J; Ballen, KK; Berliner, N; Henson, JW; Kracher, J; Lacy, J; Noronha, V | 1 |
| Marx, J | 1 |
| Hamilton, DA | 1 |
| Blümcke, I; Buslei, R; Eyüpoglu, IY; Fahlbusch, R; Hahnen, E; Lemke, D; Savaskan, NE; Siebzehnrübl, FA; Tränkle, C; Wick, W | 1 |
| Allgeier, A; Brandes, AA; Cairncross, G; Curschmann, J; Fisher, B; Gorlia, T; Kortmann, RD; Lacombe, D; Mason, W; Mirimanoff, RO; Reni, M; Stupp, R; Van den Bent, MJ; Villa, S | 1 |
| Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E | 1 |
| Fortin, D; Mathieu, D | 1 |
| Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS | 1 |
| Heaney, AP; Lim, S; Maya, MM; Shahinian, H; Yong, W | 1 |
| Bally, F; Christen, G; de Ribaupierre, S; Ganière, V; Guillou, L; Pica, A; Stupp, R | 1 |
| Aragoncillo, P; Casado Herraez, A; Díaz-Rubio García, E; Gómez Díaz, R; Moreno Antón, F; Puente Vázquez, J | 1 |
| Barbaud, A; Schmutz, JL; Trechot, P | 1 |
| Bartolomei, M; Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Amato, R; Doh, LS; Paulino, AC; Teh, BS | 1 |
| Middleton, MR; Sabharwal, A | 1 |
| Gagua, RO; Ninua, NG; Papuashvili, GSh | 1 |
| Eoh, W; Kang, CM; Kim, JS; Kim, JT; Kim, MH; Ko, KW; Kong, DS; Lee, DS; Nam, DH; Shin, HJ; Son, MJ; Song, HS | 1 |
| Berard, H; Bombaron, P; Breton, JL; Chavaillon, JM; Corre, R; Cortot, AB; Falchero, L; Gerinière, L; Gimenez, C; Mercier, C; Perol, M; Robinet, G; Souquet, PJ | 1 |
| Abuja, B; Deinsberger, R; Hassler, M; Marosi, C; Micksche, M; Payer, F; Pichler, J; Stockhammer, G | 1 |
| Breipohl, W; Fountoulakis, M; Friedlein, A; Golubnitschaja, O; Haertel, N; Leppert, D; Moenkemann, H; Schild, H; Schueller, H; Trog, D; Yeghiazaryan, K | 1 |
| Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J | 1 |
| Batista, LF; Kaina, B; Menck, CF; Naumann, SC; Roos, WP; Weller, M; Wick, W | 1 |
| Frank, B; Möhle, R; Tabatabai, G; Weller, M; Wick, W | 1 |
| Baum, C; Fujita, J; Itoh, K; Itoh, Y; Masuda, T; Okanoue, T; Umemura, A; Yamaguchi, K | 1 |
| Natsume, A; Wakabayashi, T; Yoshida, J | 1 |
| Barnett, CM; Brock, C; Bydder, GM; Charnley, N; Glaser, M; Matthews, J; Newlands, ES; Price, P; Swindell, R; West, CM | 1 |
| Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G | 1 |
| Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M | 1 |
| Eickmeyer, F; Fiedler, VU; Niehoff, H; Schwarzmaier, HJ; Ulrich, F; Ulrich, SD; von Tempelhoff, W; Yang, Q | 1 |
| Bokstein, F; Lavon, I; Siegal, T; Taliansky-Aronov, A | 1 |
| Bajciova, V; Kadlecova, V; Kepak, T; Mazanek, P; Mudry, P; Pavelka, Z; Sterba, J; Valik, D; Zitterbart, K | 1 |
| Glass, J; Nei, M; Ngo, L | 1 |
| Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H | 1 |
| Hong, YK; Jeun, SS; Kang, JK; Kim, MC; Kim, MK; Lee, KS; Lee, TK; Park, CK; Yang, SH | 1 |
| Baruchel, S; Bouffet, E; Coppes, MJ; Diezi, M; Fernandez, CV; Gammon, J; Hargrave, D; Moghrabi, A; Stempak, D | 1 |
| Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R | 1 |
| Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR | 1 |
| Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G | 1 |
| Biemond-ter Stege, EM; Brandes, AA; French, PJ; Graveland, WJ; Kouwenhoven, MC; Kros, JM; Taphoorn, MJ; van den Bent, MJ | 1 |
| Landi, A; Piccirilli, M; Salvati, M | 1 |
| Mutter, N; Stupp, R | 1 |
| Cairncross, JG; Mason, WP | 1 |
| Alfó, M; Banelli, E; De Sanctis, V; Enrici, RM; Mazzarella, G; Osti, MF; Salvati, M; Tombolini, V; Valeriani, M | 1 |
| Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A | 1 |
| Marosi, C | 1 |
| Berger, MS; Katayama, M; Kawaguchi, T; Pieper, RO | 1 |
| Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A | 1 |
| Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G | 1 |
| Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T | 1 |
| Leenstra, S; Majoie, CB; Richel, DJ; Terheggen, F; Troost, D | 1 |
| Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G | 1 |
| Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W | 1 |
| Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Penagos, LC; Syro, LV; Uribe, H | 2 |
| Mabasa, VH; Taylor, SC | 1 |
| Auger, N; Dutrillaux, B; Idbaih, A; Legrier, ME; Poupon, MF; Sanson, M; Thillet, J; Wanherdrick, K | 1 |
| Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Gao, S; Zhang, H | 1 |
| Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T | 1 |
| Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ | 1 |
| Chalmers, L; Chamberlain, MC | 1 |
| Bertorelle, R; Biscuola, M; Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Ermani, M; Franceschi, E; Gioia, V; Tosoni, A | 1 |
| Beijnen, JH; Boogerd, W; Buckle, T; Heerschap, A; Kemper, EM; Küsters, B; Leenders, W; Lyons, S; van Tellingen, O | 1 |
| Chakravarti, A; Mehta, MP; Siker, ML | 1 |
| Boor, S; Hundsberger, T; Kaina, B; Koch, D | 1 |
| Aimar, E; Banna, GL; Bettio, D; Colombo, P; Gaetani, P; Navarria, P; Rodriguez Baena, R; Rognone, F; Santoro, A; Scorsetti, M; Simonelli, M | 1 |
| Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK | 1 |
| Dickerman, RD; Howes, G; Lee, JM; Nardone, EM; Stevens, QE | 1 |
| Azcoaga Blasco, JM; Contreras Martínez, J; Delgado Rico, R; Herruzo Cabrera, I; Rivas Sánchez, D; Villanueva Alvarez, A; Wals Zurita, A | 1 |
| Breipohl, W; Golubnitschaja, O; Moenkemann, H; Schild, H; Schueller, H; Trog, D | 1 |
| Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH | 1 |
| Hong, YK; Joe, YA; Kim, TG; Park, JA | 1 |
| Gerber, DE; Grossman, SA; Kleinberg, L; Parisi, MA; Zeltzman, M | 1 |
| Auvrignon, A; Baunin, C; Bergeron, C; Biassoni, L; Brisse, H; Chisholm, J; Coze, C; Defachelles, AS; Dickinson, F; Djafari, L; Giammarile, F; Hobson, R; McHugh, K; Morland, B; Mosseri, V; Munzer, C; Rubie, H; Valteau-Couanet, D; Vassal, G; Weston, C | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 2 |
| Delaney, SM; Dolan, ME; Hansen, RJ; Nagasubramanian, R; Samson, LD | 1 |
| Kawaguchi, T; Mirzoeva, OK; Pieper, RO | 1 |
| Norden, AD; Wen, PY | 1 |
| Cambar, J; L'Azou, B; Liguoro, D; Pédeboscq, S; Pometan, JP | 1 |
| Alonso, MM; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y | 1 |
| Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K | 1 |
| Boogerd, W; Dalesio, O; de Gast, GC | 1 |
| Amini, A; Chin, SS; Schmidt, MH | 1 |
| Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y | 1 |
| Chen, ZP; Mu, YG; Sai, K; Shi, HL; Yue, WY; Zhang, JP; Zhang, XH | 1 |
| Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J | 1 |
| Nishikawa, R | 2 |
| Fishel, ML; He, Y; Kelley, MR; Smith, ML | 1 |
| Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M | 1 |
| Cipak, L; Jantova, S; Letasiova, S; Repicky, A | 1 |
| Briegert, M; Kaina, B | 1 |
| Chen, CC; D'Andrea, A; Taniguchi, T | 1 |
| Altavilla, G; Arrigo, C; Baldari, S; Naro, C; Perniciaro, F; Pitini, V | 1 |
| Alibhai, SM; Brandwein, JM; Gupta, V; Minden, MD; Schimmer, AD; Schuh, AC; Wells, RA; Xu, W; Yang, L | 1 |
| Addeo, R; Capasso, E; Caraglia, M; Caserta, L; Del Prete, S; Faiola, V; Guarrasi, R; Montella, L; Vincenzi, B | 1 |
| Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B | 1 |
| Gallo, JM; Guo, P; Nuthalapati, S; Wang, X; Zhou, Q | 1 |
| Baroncini, M; Blond, S; Bordron, A; Dam-Hieu, P; Maurage, CA; Mineo, JF; Ramirez, C | 1 |
| Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JA; Park, SD; Sohn, HJ | 1 |
| Cole, A; Hedges, TR; Lawrence, D; Lechan, RM; Neff, LM; Shucart, W; Tischler, AS; Weil, M; Zhu, JJ | 1 |
| Tear, S | 1 |
| Hirose, Y; Sano, H | 1 |
| Delattre, JY; Sanson, M | 1 |
| Laigle-Donadey, F; Sanson, M | 1 |
| Gijtenbeek, JM; Kappelle, AC; Soetekouw, PM; van der Maazen, RW; van Herpen, CM | 1 |
| Jones, B; Sanghera, P | 1 |
| Bauer, B; Bogdahn, U; Brenner, A; Hau, P; Hundsberger, T; Jauch, T; Koch, D; Koch, H; Marg, E; Rauch, M; Rieckmann, P; Rudolph, R; Schuth, J | 1 |
| Abbadessa, A; Bordonaro, R; Candela, M; Corazzelli, G; Faedi, M; Ferreri, AJ; Franceschi, E; Ilariucci, F; Latte, G; Manno, P; Mason, W; Mazza, E; Pace, A; Perry, J; Reni, M; Spina, M; Stelitano, C; Zaja, F | 1 |
| Bulgar, A; Donze, JR; Gerson, SL; Liu, L; Mahajan, V; Miao, Y; Yan, L | 1 |
| Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G | 1 |
| Bigner, DD; Friedman, HS; Johnson, SP; Kamen, BA | 1 |
| Barcia, JA; Barcia-Mariño, C; Gallego, JM | 1 |
| Berger, W; Buchroithner, J; Fischer, J; Marosi, C; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S | 1 |
| Fehlauer, F; Muench, M; Rades, D; Richter, E | 1 |
| Allen, JC; Desjardins, A; Fisher, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Krauser, JM; Phillips, PC; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Watral, MA | 1 |
| Ducray, F; Honnorat, J | 1 |
| Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A | 1 |
| Batey, MA; Calabrese, CR; Canan, S; Curtin, NJ; Hostomsky, Z; Kyle, S; Maegley, KA; Newell, DR; Skalitzky, D; Thomas, HD; Wang, LZ; Webber, SE | 1 |
| Dalmau, J; de la Fuente, BP; Rosenfeld, M | 1 |
| Chheda, MG; Doherty, LM; Drappatz, J; Gigas, DC; Greenberger, NJ; Kesari, S; Weiss, SE; Wen, PY | 1 |
| Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR | 1 |
| Goldman, B | 1 |
| Choong, NW; Hoffman, PC; Kozloff, M; Mauer, AM; Rudin, CM; Sciortino, DF; Szeto, L; Villano, JL; Vokes, EE; Wade, JL; Winegarden, JD | 1 |
| Mehta, M; Robins, HI; Traynor, AM | 1 |
| Dellinger, CA; Grewal, J; Yung, WK | 1 |
| Germano, IM; Keller, G; Uzzaman, M | 1 |
| Gerrard, GE; Khanduri, S; O'Toole, L | 1 |
| Dambatta, S; Grundy, PL; Vajramani, GV; Walker, M | 1 |
| Hegi, ME; Stupp, R | 2 |
| Barrié, M; Braguer, D; Chinot, OL; Dufour, H; Eudes, N; Figarella-Branger, D; Fuentes, S; Lancelot, S; Martin, PM; Metellus, P; Muracciole, X; Ouafik, L | 1 |
| Amiel-Benouaich, A; Capelle, L; Carpentier, AF; Cornu, P; Delattre, JY; Duffau, H; Guillevin, R; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Laigle-Donadey, F; Lejeune, J; Mandonnet, E; Marie, Y; Mokhtari, K; Omuro, A; Ricard, D; Sanson, M; Taillibert, S | 1 |
| Ilson, DH; Krol, G; Ku, GY | 1 |
| Gatta, G; Mazza, E; Reni, M; Stupp, R; Vecht, C | 1 |
| Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Nagane, M | 3 |
| Brandes, AA; Franceschi, E; Tosoni, A | 2 |
| De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S | 1 |
| Alvino, E; Amadori, S; Bonmassar, E; Buccisano, F; Caporaso, P; D'Atri, S; Garbin, A; Marchesi, F; Tirindelli, MC; Toppo, L; Tortorelli, G; Turriziani, M; Venditti, A | 1 |
| Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ | 1 |
| Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S | 1 |
| Kohandel, M; Milosevic, M; Oza, A; Powathil, G; Sivaloganathan, S | 1 |
| Gujral, S; Jalali, R; Menon, H; Singh, P | 1 |
| Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S | 1 |
| DeAngulo, G; Heimberger, AB; Hussain, SF; Jordan, JT; Prabhu, SS; Sun, W | 1 |
| Kudo, M; Kuratsu, J; Makino, K; Nakamura, H; Takeshima, H | 1 |
| Brown, MP; Selva-Nayagam, S; Singhal, N | 1 |
| Rovin, RA; Winn, R | 1 |
| Combs, SE; Debus, J; Herold-Mende, C; Roth, W; Schulz-Ertner, D; Weber, KJ | 1 |
| Akagi, T; Aoyanagi, E; Kaneko, S; Sasai, K; Tabu, K; Tanaka, S | 1 |
| Ang, EL; Back, MF; Chan, SP; Lim, CC; Ng, WH; See, SJ; Yeo, TT | 1 |
| See, SJ; Ty, A; Wong, MC | 1 |
| Aubrey, MC; Lim, KG; Limper, AH; Maldonado, F | 1 |
| Alemany, R; Alonso, MM; Bekele, NB; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y; Yung, WK | 1 |
| Fujii, M; Ishii, D; Ito, M; Maruta, H; Natsume, A; Shimato, S; Wakabayashi, T; Yoshida, J | 1 |
| Fujita, M; Inagaki, M; Katsumata, S; Mizuno, M; Nakahara, N; Natsume, A; Osawa, H; Satoh, Y; Tsuno, T; Wakabayashi, T; Yoshida, J | 1 |
| Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A | 1 |
| Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ | 1 |
| Artemov, D; Baker, SD; Bhujwalla, ZM; Kato, Y; Okollie, B; Raman, V; Vesuna, F; Zhao, M | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Ashley, DM; Coleman, LT; Downie, PA; Heath, JA; Khaw, SL | 1 |
| Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ | 1 |
| Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M | 1 |
| Gerrard, G; Khanduri, S | 1 |
| Boucher, KM; Jensen, RL; Leachman, SA; Majer, M; Samlowski, WE; Shrieve, DC; Wang, M; Watson, GA | 1 |
| Ardito, R; Romano, C; Tartarone, A | 1 |
| Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q | 1 |
| Conway, BR; Du, L; Nimmannit, U; Suppasansatorn, P; Wang, Y | 1 |
| Darga, TE; Dolan, ME; Kufe, DW; Weichselbaum, RR; Wu, MH; Yamini, B; Yu, X | 1 |
| Chalmers, AJ; Yu, SK | 1 |
| Hong, YK; Kim, CH; Kim, HS; Kim, TG; Park, JS; Park, MY; Park, SD; Woo, SJ | 1 |
| Aristu, J; De la Cruz, S; Fernández Hidalgo, O; Nieto, Y; Santisteban, M; Zubieta, JL | 1 |
| Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W | 1 |
| Friedman, HS; Maxwell, J | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Crott, R | 1 |
| Cadile, CD; Dervisis, NG; Dominguez, PA; Kitchell, BE; Newman, RG; Sarbu, L; Swanson, CN | 1 |
| Ator, M; Chang, H; Deibold, J; Grobelny, J; Hudkins, R; Husten, J; McGann, N; Miknyoczki, S; Parchment, R; Pritchard, S; Ruggeri, B; Worrell, C; Zulli, A | 1 |
| Boots-Sprenger, SH; Cornelissen, SJ; Dekkers, MM; Errami, A; Jeuken, JW; Sijben, A; Vriezen, M; Wesseling, P | 1 |
| Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N | 1 |
| Anderson, P; Curley, S; Green, HL; Hayes-Jordan, A; Herzog, C; Hunt, K; Lally, KP; Mansfield, P | 1 |
| Fan, XJ; Fu, YJ; Liang, AH; Liu, ZL; Xu, CG; Xu, QL; Yang, J; Yin, LT | 1 |
| Bernsen, HJ; Poelen, J; Prick, MJ | 1 |
| Abe, T; Fukushima, S; Miyagi, N; Ogo, E; Sakata, K; Shigemori, M; Terasaki, M | 1 |
| Asano, Y; Fujii, M; Hatano, H; Ishii, D; Ito, M; Natsume, A; Shimato, S; Takeuchi, H; Wakabayashi, T; Yoshida, J | 1 |
| Hesse, A; Mainka, A; Nettelbeck, DM; Quirin, C | 1 |
| Cloud, GA; Fiveash, JB; Guthrie, BL; Markert, JM; Meredith, RF; Nordal, RA; Sawrie, SM; Spencer, SA | 1 |
| Greenman, J; Hetherington, JW; Lam, T; Little, S; Maraveyas, A | 1 |
| Billups, CA; Danks, MK; McLendon, RE; Wagner, LM; Weiss, BD; Yoon, KJ | 1 |
| Bay, JO; Durando, X; Gilliot, O; Irthum, B; Thivat, E; Verrelle, P; Vincent, C | 1 |
| Berger, MS; Carlson, BL; Dinca, EB; Gupta, N; James, CD; Sarkaria, JN; Schroeder, MA; Voicu, R | 1 |
| Earl, S; Gounaris, I; Lyons, B; Rahamim, J; Shivasankar, S; Yiannakis, D | 1 |
| Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L | 1 |
| Avvisati, G; De Vecchis, L; Marchesi, F; Torino, F; Tortorelli, G; Turriziani, M | 1 |
| Brandsma, D; van den Bent, MJ | 2 |
| Camlica, H; Tas, F; Topuz, E | 1 |
| Daido, S; Iwado, E; Kondo, S; Kondo, Y | 1 |
| Bak, K; Charette, M; Petrella, T; Quirt, I; Verma, S | 1 |
| Kovacs, K; Lombardero, M; McLendon, RE; Ortiz, LD; Penagos, LC; Scheithauer, BW; Syro, LV; Uribe, H | 1 |
| Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K | 1 |
| Adema, AD; Bhakat, KK; Boven, E; Fontijn, D; Peters, GJ; Pinedo, HM | 1 |
| Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
| Sinkovics, J | 1 |
| Bickenbach, K; Galanopoulos, N; Pytel, P; Rawlani, V; Veerapong, J; Weichselbaum, RR; Yamini, B; Yu, X | 1 |
| Taylor, RE | 1 |
| Schiff, D | 2 |
| Reardon, DA; Rich, JN; Sathornsumetee, S | 1 |
| Hulsebos, TJ; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; van den Berg, J; van Nifterik, KA | 1 |
| Bischof, M; Combs, SE; Debus, J; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T | 1 |
| Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD | 1 |
| Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF | 1 |
| Abrey, LE; Gavrilovic, IT; Hormigo, A; Iwamoto, FM; Lassman, AB; Nolan, CP; Omuro, AM; Raizer, JJ | 1 |
| Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Price, A; Rogers, G; Somerville, M; Stein, K | 1 |
| Biggs, MT; Clarkson, A; Cook, RJ; Little, NS; McDonald, KL; McKenzie, CA; Messina, M; Parkinson, JF; Robinson, BG; Wheeler, HR | 1 |
| Boyett, JM; Broniscer, A; Danks, MK; Friedman, HS; Gajjar, A; Goldman, S; Gururangan, S; Kun, LE; MacDonald, TJ; Packer, RJ; Poussaint, TY; Stewart, CF; Wallace, D | 1 |
| Burgess, TL; Coxon, A; Jun, HT; Kendall, R; Radinsky, R; Rex, K; Sun, J | 1 |
| Aoki, T; Hashimoto, N; Matsutani, M | 1 |
| Asadpour, B; Eble, MJ; Gagel, B; Pinkawa, M; Piroth, MD; Stanzel, S | 1 |
| Bouffet, E; Fukushima, S; Katsuki, H; Shigemori, M; Terasaki, M | 1 |
| Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK | 1 |
| Enting, RH; Heesters, MA; Irwan, R; Meiners, LC; Oudkerk, M; Potze, JH; Sijens, PE; van der Graaf, WT | 1 |
| Bhawan, J; Demierre, MF; Karakis, I; McGeeney, B; Thiele, JJ; Wolpowitz, D | 1 |
| Basu, A; Goel, A; Gupta, T; Jalali, R; Menon, H; Munshi, A; Sarin, R | 1 |
| Aldape, K; Archer, GE; Bigner, DD; Crutcher, L; Dey, M; Gilbert, M; Hassenbusch, SJ; Heimberger, AB; Hussain, SF; Mitchell, DA; Sampson, JH; Sawaya, R; Schmittling, B; Sun, W | 1 |
| Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Gorlia, T; Hegi, ME; Lacombe, D; Mirimanoff, RO; Stupp, R; van den Bent, MJ; Weller, M | 1 |
| Alonso, MM; Bekele, BN; Fueyo, J; Gomez-Manzano, C; Yung, WK | 1 |
| Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA | 1 |
| Baia, GS; Dinca, EB; James, CD; Kimura, ET; Lal, A; McDermott, MW; Ozawa, T; VandenBerg, SR | 1 |
| Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y | 1 |
| Facchini, V; Kiss, R; Lefranc, F | 1 |
| Kyritsis, AP; Puduvalli, VK; Rao, JS; Tachmazoglou, F | 1 |
| Bredel, M | 1 |
| Becker, JC; Beyeler, M; Bröcker, EB; Dummer, R; Garbe, C; Gille, J; Hauschild, A; Kaehler, KC; Kaufmann, R; Leiter, U; Pföhler, C; Schadendorf, D; Spieth, K; Tilgen, W; Ugurel, S | 1 |
| Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P | 1 |
| Al, MJ; Crott, R; Gorlia, T; Jin Seung, S; Lamers, LM; Mittmann, N; Stupp, R; Uyl-de Groot, CA; van den Bent, MJ; Wasserfallen, JB | 1 |
| Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Avutu, B; Barker, FG; Batchelor, TT; Chakravarti, A; Henson, JW; Hochberg, FH; Loeffler, JS; Martuza, RL; Sher, DJ | 1 |
| Wakabayashi, T | 2 |
| Mizoguchi, M; Shono, T | 1 |
| Chakravarti, A; Palanichamy, K | 1 |
| Beam, K; Burgan, WE; Camphausen, K; Carter, D; Cerna, D; Kil, WJ; Steeg, PS; Tofilon, PJ | 1 |
| Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M | 1 |
| Bozzao, A; De Paula, U; De Sanctis, V; Filippone, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Tombolini, V; Valeriani, M | 1 |
| Bi, X; Dou, M; Huang, G; Zhang, N | 1 |
| Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A | 1 |
| Aldape, K; Aoki, H; Bogler, O; Conrad, C; Hess, K; Hollingsworth, EF; Iwado, E; Kobayashi, R; Kondo, S; Kondo, Y; Mills, G; Sawaya, R; Shingu, T; Shinojima, N; Tamada, Y; Yamamoto, A; Yokoyama, T; Zhang, L | 1 |
| Katayama, Y; Yoshino, A | 1 |
| El-Koussy, M; Fathi, AR; Kappeler, A; Mariani, L; Novoa, E; Vajtai, I | 1 |
| Camacho, L; Gupta, R; Hoos, A; Kirkwood, JM; Lutzky, J; Mann, GB; Parmiani, G; Richards, J; Srivastava, PK; Testori, A; Tosti, G; Whitman, E; Yuh, L | 1 |
| Boiardi, A; Botturi, A; Broggi, G; Di Meco, F; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Solari, A | 1 |
| Delattre, JY; Ducray, F; Everhard, S; Hoang-Xuan, K; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Marie, Y; Mokhtari, K; Navarro, S; Sanson, M; Thillet, J | 1 |
| Neff, WJ; Nystrom, KK; Pick, AM | 1 |
| da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G | 1 |
| Bontempi, G; Debeir, O; Decaestecker, C; Haibe-Kains, B; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Mijatovic, T | 1 |
| Gallo, JM; Guo, P; Zhou, Q | 1 |
| Banerjee, D; Garbow, JR; Gutmann, DH; Hegedus, B; Perry, A; Rothermich, S; Rubin, JB; Yeh, TH | 1 |
| Benouaich-Amiel, A; Delattre, JY; Ducray, F; Idbaih, A; Laigle-Donadey, F; Rousseau, A; Sanson, M | 1 |
| Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E | 1 |
| Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC | 1 |
| Bael, TE; Gollob, JA; Peterson, BL | 1 |
| Nakamura, O; Saito, K; Shinoura, N; Tabei, Y; Takahashi, M; Yamada, R | 1 |
| Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH | 1 |
| Dorio, AS; Graziani, G; Lacal, PM; Muzi, A; Navarra, P; Ruffini, F; Tentori, L | 1 |
| Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD | 1 |
| Kleinberg, LR; Lin, SH | 1 |
| Ng, W; Steckley, JL; Watling, CJ | 1 |
| Mitchell, SB; Pan, E; Tsai, JS | 1 |
| Kiss, R; Lefranc, F; Mijatovic, T | 1 |
| Adam, M; Grosu, AL; Nieder, C | 1 |
| Bischof, M; Combs, SE; Debus, J; Edler, L; Nagy, M; Rausch, R; Schulz-Ertner, D; Welzel, T | 1 |
| Groves, MD; Katz, RL | 1 |
| Choi, JD; Friedman, AH; Powers, CJ; Sampson, JH; Vredenburgh, JJ | 1 |
| Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY | 1 |
| Lefranc, F | 2 |
| Kirkwood, JM; Lotze, MT; Mandic, M; Moschos, SJ; Storkus, WJ | 1 |
| Fang, SH; Huang, XJ; Li, CT; Lu, YB; Wei, EQ; Zhang, WP | 1 |
| Benveniste, RJ; Manzano, G; Petito, CK | 1 |
| Kawase, T; Sasaki, H; Yoshida, K | 1 |
| Alvino, E; Bonmassar, E; Caporali, S; D'Atri, S; Levati, L; Ragone, G; Starace, G | 1 |
| Coppola, JM; Rehemtulla, A; Ross, BD | 1 |
| Brell, J; Dehart, WK; Gilliam, AC; Lu, KQ | 1 |
| Ogawa, M; Ueda, T; Yamauchi, T | 1 |
| Bontempi, G; Decaestecker, C; Haibe-Kains, B; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Mijatovic, T | 1 |
| Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A | 1 |
| Banik, NL; Das, A; Ray, SK | 1 |
| Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A | 1 |
| Fu, W; Geiger, GA; Kao, GD | 1 |
| Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC | 1 |
| Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ | 1 |
| Apel, MA; Battastini, AM; Braganhol, E; Canedo, AD; da Frota, ML; Henriques, AT; Klamt, F; Lerner, C; Moreira, JC; Mothes, B | 1 |
| Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T | 1 |
| Busam, K; Chapman, PB; Gerst, S; Jungbluth, AA; Krown, S; Orlow, I; Panageas, K; Rietschel, P; Smith, K; Wolchok, JD | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Belenky, ML; Buchsbaum, DJ; Fiveash, JB; Gillespie, GY; Oliver, PG; Zhou, T | 1 |
| Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ | 1 |
| Goellner, EM; Jelezcova, E; Sobol, RW; Tang, JB; Trivedi, RN; Wang, XH | 1 |
| Chamberlain, MC; Glantz, MJ | 1 |
| Augustine, CK; Febbo, P; Gupta, M; Pendergast, AM; Peters, WP; Selim, MA; Tyler, DS; Yoshimoto, Y; Zipfel, PA | 1 |
| Jean-Claude, BJ; Katsoulas, A; McNamee, JP; Rachid, Z; Williams, C | 1 |
| Brandsma, D; Bromberg, JE; de Bruin, HG; Smitt, PA; Swaak-Kragten, AT; Taal, W; van den Bent, MJ; van Es, CA | 1 |
| Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T | 1 |
| Aitipamula, S; Babu, NJ; Nangia, A; Reddy, LS | 1 |
| Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S | 1 |
| Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Grandel, R; Johnson, EF; Klinghofer, V; Liu, X; Lubisch, W; Luo, Y; Marsh, KC; Olson, AM; Park, CH; Penning, TD; Rosenberg, SH; Shi, Y; Thomas, S; Wernet, W; Zhu, GD | 1 |
| Chamberlain, MC; Mrugala, MM | 1 |
| Hottinger, AF; Stupp, R | 1 |
| Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Gunel, N; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Del Maestro, R; Guiot, MC; Kavan, P; Lambert, C; Leblanc, R; Muanza, T; Panet-Raymond, V; Roberge, D; Shakibnia, L; Shenouda, G; Souhami, L | 1 |
| Navalitloha, Y; Siangprasertkij, C | 1 |
| Chiamchanya, S; Dhanachai, M; Hongeng, S; Laothamatas, J; Pakakasama, S; Sirachainan, N; Tuntiyatorn, L; Visudithbhan, A | 1 |
| Cairncross, JG; de Tribolet, N; Delorenzi, M; Dietrich, PY; Domany, E; Gorlia, T; Hainfellner, JA; Hamou, MF; Hegi, ME; Heppner, FL; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Migliavacca, E; Murat, A; Regli, L; Shay, T; Stupp, R; Wick, W; Zimmer, Y | 1 |
| Jenkinson, MD | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S | 1 |
| Hidaka, M; Sanada, M; Sekiguchi, M; Takagi, Y; Yoshida, H | 1 |
| Guiot, MC; Huang, F; Kavan, P; Markovic, Y; Roberge, D | 1 |
| Akimoto, J; Kobayashi, I; Oka, H; Tanaka, S; Ujiie, H | 1 |
| Aoki, H; Fujiwara, T; Georgescu, MM; Hashimoto, Y; Hayashi, Y; Hess, KR; Iwado, E; Kawamura, H; Kondo, S; Kondo, Y; Mills, GB; Sawaya, R; Urata, Y; Yokoyama, T | 1 |
| Ashley, DM; Dobrovic, A; Drummond, KJ; Friedman, HS; Gan, HK; Hawkins, CJ; Johns, TG; Kaye, AH; Lovric, MM; Maxwell, JA; Mikeska, T; Riffkin, CD | 1 |
| Albani, F; Baruzzi, A; Contin, M; Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Pace, A; Zarabla, A | 1 |
| Anile, C; Balducci, M; de Bonis, P; Lama, G; Lauriola, L; Maira, G; Mangiola, A; Sica, G | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I | 1 |
| Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Giebel, B; Hau, P; Kunz-Schughart, LA; Leukel, P; Pillai, DR; Proescholdt, M; Reifenberger, G; Röhrl, S; Schwarz, S; Trampe-Kieslich, A; Wischhusen, J | 1 |
| Bräuer-Krisch, E; Bravin, A; Keyriläinen, J; Le Duc, G; Régnard, P; Troprès, I | 1 |
| Jiang, T; Li, G; Li, S; Wang, Z | 1 |
| Kikuchi, T; Kumabe, T; Sonoda, Y; Sugiyama, S; Tominaga, T; Yamashita, Y | 1 |
| Colon-Lopez, M; Donawho, C; Ellis, PA; Frost, DJ; Giranda, VL; Kinders, R; LeBlond, D; Lin, CT; Liu, X; Luo, Y; Palma, J; Rodriguez, LE; Saltarelli, M; Shi, Y | 1 |
| Beule, AC; Bromberg, J; Ernemann, U; Karnath, HO; Marosi, C; Mason, WP; Platten, M; Rorden, C; Stupp, R; van den Bent, M; Weller, M; Wick, A; Wick, W | 1 |
| Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A | 1 |
| Barnes, J; Dellagatta, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, NR; Sauvageot, CM; Stiles, CD; Weatherbee, JL; Wen, PY; Winters, SE | 1 |
| Dill, C; Ehninger, G; Illmer, T; Kestel, L; Kramer, M; Krex, D; Pfirrmann, M; Robel, K; Schackert, G; Schaich, M | 1 |
| D'Amico, A; Dall'oglio, S; Gabbani, M; Maluta, S; Pasini, F; Passarin, MG; Pioli, F; Talacchi, A; Turazzi, S | 1 |
| Dario, A; Tomei, G | 1 |
| Butowski, N; Chang, SM; Fedoroff, A; Lamborn, KR; Liu, R; Page, M; Polley, MY; Prados, M; Rabbitt, J; Solheim, K | 1 |
| Adachi, J; Georgescu, G; Isola, IM; Rolston, K; Youssef, S | 1 |
| Agarwala, SS; Gooding, WE; Kirkwood, JM; Moschos, S; Tarhini, AA | 1 |
| Deluca, NA; Fellows-Mayle, W; Hadjipanayis, CG | 1 |
| Cashman, R; Morrison, M; Morrison, T; Perry, JR; Rizek, P | 1 |
| Bozzao, A; Cantore, GP; De Sanctis, V; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Rasio, D; Salvati, M; Valeriani, M | 1 |
| Geisert, EE; Kang, GS; Kirichenko, OV; Miller, DD; Mohler, ML; Orr, WE; Patil, R; Wang, XD | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Platten, M; Weller, M; Wick, W | 1 |
| Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA | 1 |
| Black, PM; Bracht, LK; Drappatz, J; Hornick, JL; Kesari, S; Kulke, MH; LaFrankie, DC; Meyerhardt, JA; Norden, A; Redston, M; Wen, P | 1 |
| Fichtner, I; Hess-Stumpp, H; Hoffmann, J; Hofmann, B; Klar, U; Lemm, M; Lienau, P; Rotgeri, A | 1 |
| Brandes, AA; Dietrich, PY; Hottinger, AF; Stupp, R; van den Bent, MJ | 1 |
| Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G | 1 |
| Eagan, P; Fischer, I; Golfinos, JG; Gruber, ML; Kelly, P; Knopp, EA; Medabalmi, P; Narayana, A; Parker, E; Raza, S; Zagzag, D | 1 |
| Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
| Braun, K; Debus, J; Didinger, B; Ehemann, V; Langowski, J; Mueller, G; Pipkorn, R; Spring, H; Waldeck, W; Wiessler, M | 1 |
| Addeo, R; Caraglia, M; Cennamo, G; De Rosa, C; Del Prete, S; Faiola, V; Guarrasi, R; Leo, L; Montella, L; Vincenzi, B | 1 |
| Cordera, S; Joosens, E; Nader, P; Neyns, B; Pouratian, N | 1 |
| Ancheta, K; Chtchetinin, J; Cloughesy, T; Lai, A; Nghiemphu, PL; Remington, M | 1 |
| Adumala, RR; Altaha, R; Crowell, EB; Hobbs, GR; Vinjamuri, M | 1 |
| Ang, KK; Chakravarti, A; Chinnaiyan, P; Curran, W; Hammond, E; Mehta, MP; Rojiani, AM; Tofilon, PJ; Wang, M; Zhang, HZ | 1 |
| Broniscer, A; Ellison, D; Kasow, K; Morris, EB; Reiss, U | 1 |
| Jones, C; Plummer, ER | 1 |
| Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
| Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C | 1 |
| Boiangiu, I; Gore, A; Machin, D; Sridhar, T; Symonds, RP | 1 |
| Kaina, B; Kiedron, O; Naumann, SC; Nikolova, T; Quiros, S; Roos, WP; Zdzienicka, MZ | 1 |
| Garside, R; Grant, R; Hart, MG; Rogers, G; Somerville, M; Stein, K | 1 |
| Aoki, T; Hashimoto, N; Kayama, T; Kurisu, K; Natsume, A; Nishikawa, R; Ogura, M; Takahashi, H; Wakabayashi, T; Yoshida, J; Yoshimine, T | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Gathinji, M; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, AR; Than, K; Weingart, JD | 1 |
| Colon-Lopez, M; Cox, BF; Donawho, C; Frost, D; Ghoreishi-Haack, N; Giranda, VL; Guan, R; Hradil, VP; Jarvis, K; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Palma, J; Penning, T; Rodriguez, LE; Rosenberg, SH; Shi, Y; Zhu, GD | 1 |
| Patel, R; Shervington, A | 1 |
| Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE | 1 |
| Bierau, K; Califice, SF; Chaskis, C; D'Hondt, LA; De Grève, J; Joossens, EJ; Menten, J; Michotte, A; Neyns, B; Sadones, J; Sartenaer, D; Sciot, R; Strauven, T; Svensson, C; Veld, P | 1 |
| Autret-Leca, E; Beau Salinas, F; Carré, P; de Luca, K; Diot, P; Guilleminault, L; Narciso, B | 1 |
| Carlson, BL; Decker, PA; Grogan, PT; James, CD; Kitange, GJ; Lamont, JD; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Speer, TW | 1 |
| Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH | 1 |
| Hollingshead, MG | 1 |
| Gallo, JM; Zhou, Q | 1 |
| Aldrich, W; Dombos, C; Triozzi, PL | 1 |
| de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA | 1 |
| Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N | 1 |
| Alusi, G; Berney, DM; Drake, WM; Evanson, J; Kovacs, K; Monson, JP; Moyes, VJ; Plowman, PN; Sabin, HI | 1 |
| Eisele, G; Happold, C; Linnebank, M; Roth, P; Steinbach, JP; Weller, M; Wick, W | 1 |
| Auger, N; Bhangoo, R; Da Costa, L; Dufour, C; Grill, J; Jullien, M | 1 |
| Cairncross, G; de Robles, P; Easaw, J; Forsyth, P; Hamilton, M; Kalra, S; Magliocco, T; McIntyre, J; Roldán, G | 1 |
| Classon, M; Hingtgen, S; Ren, X; Shah, K; Terwilliger, E; Weissleder, R | 1 |
| Kalia, VK; Prabhakara, S | 1 |
| Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE | 1 |
| Buchfelder, M | 1 |
| Ballman, KV; Buckner, JC; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Anderson, J; Avedissian, R; Croteau, D; Doyle, T; Gutierrez, J; Hasselbach, L; Margolis, J; Mikkelsen, T; Paleologos, N; Schultz, L | 1 |
| Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S | 1 |
| Becker, G; Borberg, SK; Fischedick, AR; Frommolt, P; Grauthoff, H; Herfarth, K; Kocher, M; Müller, RP; Niewald, M; Rühl, U; Staar, S; Steingräber, M; Stuschke, M | 1 |
| Dou, M; Huang, G; Xi, Y; Zhang, N | 1 |
| Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, T | 1 |
| Jalali, R | 1 |
| Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD | 1 |
| Goldhoff, P; Hope, A; Jackson, E; Limbrick, DD; Perry, A; Piwnica-Worms, D; Rubin, JB; Warrington, NM; Woerner, BM | 1 |
| Boddy, A; Calvert, H; Curtin, N; Dewji, R; Evans, J; Harris, A; Johnson, P; Jones, C; McHugh, P; Middleton, M; Newell, D; Olsen, A; Plummer, R; Robson, L; Steinfeldt, H; Wang, D; Wilson, R | 1 |
| De Nève, N; Dehoux, M; Dewelle, J; Gaussin, JF; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V | 1 |
| Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M | 1 |
| Davidoff, AM; Fan, M; McGee, MC; Nathwani, AC; Ng, CY; Nunnally, LC; Pfeffer, LM; Rosati, SF; Sims, TL; Stewart, CF; Tracey, L; Williams, RF; Zhou, J | 1 |
| Davies, SM; Geiger, H; Weiss, B | 1 |
| Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM | 1 |
| Braund, WJ; Burt, MG; Campbell, KA; Clark, SJ; Clifton-Bligh, RJ; Cook, RJ; Gill, AJ; Grossman, AB; Little, NS; McCormack, AI; McDonald, KL; Robinson, BG | 1 |
| Cayli, SR; Guzel, A; Guzel, E; Sav, A; Senturk, S; Tatli, M | 1 |
| Berger, MS; Dinca, EB; Haas-Kogan, DA; James, CD; Lu, KV; Pieper, RO; Prados, MD; Sarkaria, JN; Vandenberg, SR | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Campos, M; Flaherty, KT; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Niessner, H; Schittek, B; Sinnberg, T | 1 |
| Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M | 1 |
| Heymann, S; Karamanoukian, D; Noël, G; Quetin, P; Schott, R | 1 |
| Chamberlain, MC; Raizer, J | 1 |
| Chang, KP; Hsu, TR; Wang, CH; Wong, TT | 1 |
| Bokemeyer, C; Celik, I; Fiedler, W; Hauschild, J; Nippgen, J; Oliveira-Ferrer, L; Schuch, G | 1 |
| Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D | 1 |
| Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P | 1 |
| Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE | 1 |
| Black, PM; Bradshaw, J; Ciampa, A; Doherty, L; Drappatz, J; Kesari, S; LaFrankie, D; Levy, B; Ligon, KL; Macklin, EA; Muzikansky, A; Norden, AD; Radakovic, G; Ramakrishna, N; Santagata, S; Schiff, D; Wen, PY | 1 |
| Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K | 1 |
| Beumer, JH; Egorin, MJ; Park, DM; Shah, DD | 1 |
| Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW | 1 |
| Battastini, AM; Braganhol, E; Brunetto, AL; Cechim, G; de Castro, CG; de Oliveira, MS; Lenz, G; Meurer, L; Roesler, R; Santos, DG; Schwarstmann, G; Schwartsmann, G | 1 |
| Georgoulias, V; Giassas, S; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Kouroussis, C; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Garrett-Mayer, E; Giglio, P; Herrin, AE; Jenrette, JM; Marshall, DT; Patel, S; Watkins, JM | 1 |
| Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Penning, TD; Shi, Y; Zhu, GD | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Beam, K; Burgan, WE; Camphausen, K; Carter, D; Chakravarti, A; Kwon, HC; Russo, AL; Slusher, BS; Tofilon, PJ; Weizheng, X; Zhang, J | 1 |
| Chaskis, C; De Ridder, M; Everaert, H; Michotte, A; Neyns, B | 1 |
| Aikawa, E; Chen, JW; Figueiredo, JL; McCann, CM; Waterman, P; Weissleder, R | 1 |
| Czech, T; Knosp, E; Kotter, MR; Marosi, C; Preusser, M; Widhalm, G; Woehrer, A; Wolfsberger, S | 1 |
| Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A | 1 |
| Crews, KR; Daldrup-Link, HE; Groshen, S; Hawkins, RA; Jackson, HA; Maris, JM; Matthay, KK; Park, JR; Reynolds, CP; Stewart, CF; Villablanca, JG; Wagner, LM | 1 |
| Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA | 2 |
| Carlson, BL; Clarke, MJ; Curtin, NJ; Decker, PA; Grogan, PT; Lou, Z; Mladek, AC; Mulligan, EA; Plummer, ER; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Braun, K; Didinger, B; Koch, M; Mueller, G; Pipkorn, R; Waldeck, W; Wiessler, M | 1 |
| Armstrong, TS; Bondy, M; Cao, Y; Gilbert, MR; Manning, R; Okcu, MF; Scheurer, ME; Vera-Bolaños, E; Zhou, R | 1 |
| Dohmen-Scheufler, H; Guzel, A; Maciaczyk, J; Nikkhah, G; Ostertag, CB; Senturk, S; Volk, B | 1 |
| Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A | 1 |
| Bähr, O; Glas, M; Happold, C; Herrlinger, U; Kortmann, RD; Reifenberger, G; Rieger, J; Steinbach, JP; Weller, M; Wick, W; Wiewrodt, D | 1 |
| de Groot, J; LaFortune, T; Milano, V; Piao, Y | 1 |
| Amoroso, R; Bartoli, B; Benvenuti, L; Gagliardi, R; Gremigni, V; Lena, A; Rechichi, M; Rossi, L; Salvetti, A; Scarcelli, V; Vecchio, D | 1 |
| Binello, E; Germano, IM | 1 |
| Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Boeckmann, L; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Struever, D; Thoms, KM | 1 |
| Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A | 2 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W | 1 |
| Banissi, C; Carpentier, AF; Chen, L; Ghiringhelli, F | 1 |
| Gerstner, ER; Lafrankie, D; McNamara, MB; Norden, AD; Wen, PY | 1 |
| Hoorens, A; Neyns, B; Stupp, R | 1 |
| Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W | 1 |
| Baloglu, A; Bezircioglu, I; Cetinkaya, B; Yavuzcan, A | 1 |
| Berger, W; Dehoux, M; DeNeve, N; Gaussin, JF; Kiss, R; Lefranc, F; Martin de Lassalle, E; Mathieu, V; Mijatovic, T; Pirker, C; Vernier, M | 1 |
| Eccles, S; Gaspar, N; Jones, C; Pacey, S; Pearson, A; Sharp, SY; Vassal, G; Walton, M; Workman, P | 1 |
| Batchelor, TT; Cahill, DP; Codd, PJ; Curry, WT; Louis, DN | 1 |
| Hashida, T; Inui, K; Katsura, T; Kodawara, T; Mizuno, T; Taue, H; Yano, I | 1 |
| Fujii, M; Ito, M; Natsume, A; Ohno, M; Wakabayashi, T | 1 |
| Persson, AI; Weiss, WA | 1 |
| Bleau, AM; Brennan, CW; Fomchenko, EI; Hambardzumyan, D; Holland, EC; Huse, JT; Ozawa, T | 1 |
| Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P | 1 |
| Hop, WC; Jeurissen, FJ; Roon, K; Taphoorn, MJ; Vecht, CJ; Zwinkels, H | 1 |
| Heppner, FL; Ingold, B; Moch, H; Schraml, P | 1 |
| Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
| Chen, L; Dinca, EB; James, CD; Kadoch, C; Karrim, J; Lowell, CA; Nguyen, D; Parikh, S; Rubenstein, JL; Shuman, MA; Treseler, PA; Voicu, R | 1 |
| Han, Y; Khramtsov, A; Lesniak, MS; Nandi, S; Sonabend, AM; Ulasov, IV | 1 |
| Bohl, J; Combs, SE; Debus, J; Elsasser, T; Schulz-Ertner, D; Weber, KJ; Weyrather, WK | 1 |
| Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR | 1 |
| Bell, D; Khasraw, M; Wheeler, H | 1 |
| Darzynkiewicz, Z; Kurose, A; Ogasawara, K; Ogawa, A; Sato, Y; Sawai, T; Traganos, F | 1 |
| Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F | 1 |
| Dehais, C; Laigle-Donadey, F; Mazeron, JJ; Sanson, M | 1 |
| Favaudon, V; Hennequin, C; Quero, L | 1 |
| Méhes, G; Molnár, P | 1 |
| Annibali, O; Avvisati, G; Cellini, F; Greco, R; Nobile, C; Petrucci, MT; Quattrocchi, CC; Tirindelli, MC | 1 |
| Fisseler-Eckhoff, A; Handzhiev, S; Höffken, G; Holotiuk, O; Koschel, D; Leucht, V | 1 |
| Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J | 1 |
| Burton, TR; Eisenstat, DD; Gibson, SB | 1 |
| Cusimano, MD; Kovacs, K; Mason, W; Mohammed, S; Smyth, H | 1 |
| De Jesus, A; Grossman, SA; Paun, O | 1 |
| Buchsbaum, DJ; Gillespie, GY; Grizzle, WE; Harmon, DK; Kaliberov, SA; Kaliberova, LN; Krendelchtchikova, V; Markert, JM; Petersen, AS; Stockard, CR | 1 |
| Barraja, P; Basso, G; Brun, P; Cecconet, L; Cirrincione, G; Dall'Acqua, F; Diana, P; Leszl, A; Salvador, A; Viola, G | 1 |
| Ducray, F | 1 |
| Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ | 1 |
| Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ | 1 |
| Bärtschi, E; Bruehlmeier, M; Buettner, UW; Hefti, M; Hofer, S; Roelcke, U; Uhlmann, C; Wyss, M | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W | 1 |
| Lesser, GJ; Ruiz, J | 1 |
| Beli, I; Chaldeopoulos, D; Fotineas, A; Koukourakis, GV; Kouloulias, V; Kouvaris, J; Maravelis, G; Pantelakos, P; Papadimitriou, C; Zacharias, G | 1 |
| Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IH; Lee, SH; Paek, SH; Park, CK | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Aksamit, AJ; Clarke, MJ; Giannini, C; Glantz, J; Jicha, GA; Kumar, N; Lehwald, LM; Russo, DP; Uhm, J; Wald, JT; Wetmore, CJ | 1 |
| Chang, S; Heimberger, A; McCoy, L; Patil, C; Patoka, J; Prados, M; Rice, T; Sampson, JH; Schwartzbaum, J; Wiemels, JL; Wiencke, JK; Wilson, D; Wrensch, M | 1 |
| Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K | 1 |
| Fukushima, T; Inoue, T; Komatsu, F; Ohmura, T; Ohta, M; Oshiro, S; Sakamoto, S; Tsugu, H | 1 |
| Behr, J; Garthe, A; Kempermann, G | 1 |
| Lesniak, MS; Tyler, MA; Ulasov, IV | 1 |
| Aikin, AA; Balis, FM; Cole, DE; Fox, E; Meany, HJ; Warren, KE | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| Hwu, WJ; Patel, SP; Trinh, VA | 1 |
| Chen, M; Orlow, SJ; Osman, I | 1 |
| Bachoo, RM; Boothman, DA; Burma, S; Camacho, CV; Cavenee, WK; Furnari, F; Hatanpaa, KJ; Madden, C; Maher, E; McEllin, B; Mickey, B; Mukherjee, B; Nannepaga, S; Sirasanagandala, S; Tomimatsu, N | 1 |
| Bedikian, AY; Cain, S; Glass, MR; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Rudewicz, P; Vernillet, L | 1 |
| Campion, L; Cartron, PF; Charbord, J; Debien, E; Hervouet, E; Menanteau, J; Vallette, FM | 1 |
| Chansakul, P; Ito, M; Kato, T; Kim, SU; Kondo, Y; Natsume, A; Ohno, M; Wakabayashi, T; Yokoyama, H; Yuki, K | 1 |
| Ahmed, N; Katragadda, S; Ponce, D; Rasul, M; Seiter, K | 1 |
| Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P | 1 |
| Sarma, N | 1 |
| Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J | 1 |
| Choi, U; Clevenger, JR; Donahue, RE; Dunbar, CE; Kang, E; Krouse, A; Larochelle, A; Loktionova, NA; Malech, HL; Metzger, M; Naumann, N; Persons, D; Shou, Y; Sorrentino, BP; Stewart, C | 1 |
| Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Watanabe, T; Yachi, K; Yoshino, A | 1 |
| Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ | 1 |
| Agati, R; Bacci, A; Benevento, F; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Mazzocchi, V; Scopece, L; Tosoni, A | 1 |
| Hirose, Y; Kawase, T; Ohba, S; Sano, H | 1 |
| Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M | 1 |
| Stupp, R; Uyl-de Groot, CA; van der Bent, M | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Das, P; Dwary, A; Goyal, S; Gupta, D; Mohanti, BK; Muzumder, S; Sharma, A; Thulkar, S | 1 |
| Alam, F; Baborie, A; Brodbelt, A; Crooks, D; Dunn, J; Haylock, B; Husband, D; Joyce, K; Liloglou, T; Moxham, M; Shenoy, A; Sibson, R; Walker, C; Wong, H | 1 |
| Bravo, EL; Gill, I; Kalmadi, SR | 1 |
| Dubey, A; Erasmus, A; Gauden, AJ; Gauden, SJ; Hunn, A; Waites, P | 1 |
| Bressler, LR; Seery, TE; Villano, JL | 1 |
| Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F | 1 |
| Cevenini, G; Marsili, S; Miracco, C; Mourmouras, V; Oliveri, G; Pirtoli, L; Rubino, G; Tini, P; Vannini, M | 1 |
| Clamp, A; Danson, S; Lorigan, P; Margison, GP; Middleton, MR; Sabharwal, A; Thatcher, N; Waters, R | 1 |
| Chiang, J; Hodes, R; Johnson, F; Kovach, JS; Lonser, R; Lu, J; Zhuang, Z | 1 |
| Chen, FR; Chen, ZP; Fu, J; Liu, XM; Liu, ZG; Ng, HK; Pangjesse, CS; Shi, HL | 1 |
| Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Chamberlain, MC; Johnston, SK | 1 |
| Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA | 1 |
| Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S | 1 |
| Banerjee, A; Dinca, EB; Gupta, N; Hashizume, R; James, CD; Ozawa, T; Prados, MD | 1 |
| Hall, JR; Short, SC | 1 |
| Fukuhara, N; Inoshita, N; Ohashi, K; Okuda, C; Oyama, K; Sano, T; Taguchi, M; Takeshita, A; Takeuchi, Y; Yamada, S | 1 |
| Christmann, M; Kaina, B; Nikolova, T | 1 |
| Cognetti, F; Di Giovanni, S; Fabi, A; Metro, G; Russillo, M; Vidiri, A | 1 |
| Bektas, M; Bigner, DD; Friedman, HS; Johnson, SP; Poe, WE | 1 |
| Kondo, N; McKinnon, PJ; Mori, E; Nakase, H; Ohnishi, K; Ohnishi, T; Sakaki, T; Takahashi, A | 1 |
| Anderson, SK; Brown, PD; Cerhan, JH; Lageman, SK; Locke, DE; Wu, W | 1 |
| Konishi, N; Nakamura, M; Nakase, H; Shimada, K | 1 |
| Larocca, LM; Montano, N; Pallini, R | 1 |
| Gong, F; Ji, SP; Li, AM; Tai, JL; Zhang, YP; Zheng, CQ | 1 |
| Batchelor, T; Chamberlain, M; Desideri, S; Fine, HA; Fisher, J; Grossman, SA; Mikkelsen, T; Piantadosi, S; Ye, X | 1 |
| Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH | 1 |
| Jeon, HJ; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Park, KB | 1 |
| de Wind, N; Güvercin, F; Kaina, B; Roos, WP; Tsaalbi-Shtylik, A; Tsaryk, R | 1 |
| Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y | 1 |
| Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R | 1 |
| Walker, JG | 1 |
| Carré, P; Diot, P; Guilleminault, L | 1 |
| Cionini, L; De Franco, L; Fabrini, MG; Grespi, S; Pasqualetti, F; Perrone, F; Vannozzi, R | 1 |
| Andersen, M; Hagen, C; Hansen, S; Schroeder, HD | 1 |
| Estlin, EJ; McGown, A; Najim, N; Podmore, ID | 1 |
| Brockmann, MA; Hermes, P; Kohlhof, P; Neumaier-Probst, E; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P; VON Deimling, A | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Eichinger, JB; George, BJ; Richard, TJ | 1 |
| Balaña, C; Berrocal, A; Gallego, O; Garcia Lopez, J; Gil, M; Iglesias, L; Perez Segura, P; Reynes, G; Rodríguez, J; Yaya, R | 1 |
| Berg, SL; Bertuch, AA; Blaney, SM; Delaney, SL; Dolan, ME; Hegde, M; Horton, TM; Jenkins, G; Pati, D; Ribes-Zamora, A; Zhang, L | 1 |
| Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK | 1 |
| Khuntia, D; Mehta, MP; Platta, CS; Suh, JH | 1 |
| Balducci, M; Calista, F; Cantore, GP; Cellini, N; Cilla, S; Deodato, F; Digesù, C; Esposito, V; Ferro, M; Ianiri, M; Macchia, G; Morganti, AG; Piermattei, A; Romanelli, P; Salvati, M; Valentini, V | 1 |
| Dresemann, G; Engel, E; Fluge, O; Heinrich, B; Hosius, C; Karup-Hansen, A; Krex, D; Mayer-Steinacker, R; Mehdorn, M; Nikolova, Z; Nowak, A; Olver, IN; Parker, R; Rosenthal, MA; Schleyer, E; Sieder, C; Sorenson, G; Steinbach, JP; Wagner, W; Wedding, U; Weller, M | 1 |
| Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Matsuno, A | 1 |
| Chen, B; Jiang, T; Li, S; Wang, Z; Zhang, W | 1 |
| Anile, C; Apicella, G; Balducci, M; Cellini, N; Colicchio, G; D'Agostino, GR; De Bari, B; De Renzi, F; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Pompucci, A; Valentini, V | 1 |
| Iwata, H; Shibamoto, Y; Sugie, C | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Pappo, A; Paulino, AC | 1 |
| Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Park, KB; Rhee, DJ; Song, SY; Suh, YL | 1 |
| Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ | 1 |
| Subbiah, V; Wolff, JE | 1 |
| Aricò, M; Buccoliero, AM; Cetica, V; Genitori, L; Giunti, L; Massimino, M; Sardi, I | 1 |
| Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G | 1 |
| Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, TS | 1 |
| Cheng, AL; Kuo, KT; Kuo, LT; Lee, WC; Lin, CH; Lin, YT; Lu, YS; Tasi, JC; Tseng, HM; Tseng, SH; Tu, YK; Wu, PF; Wu, RM; Yang, CH | 1 |
| Boeckmann, L; Brockmoeller, J; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Rosenberger, A; Schirmer, M; Schoen, MP; Struever, D; Thoms, KM | 1 |
| Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI | 1 |
| Murawski, N; Pfreundschuh, M | 1 |
| Beijnen, JH; de Vries, NA; van Tellingen, O | 1 |
| Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M | 1 |
| Coffey, M; Hollywood, D; Lawler, M; Marignol, L; Marples, B; Martin, L | 1 |
| Inamasu, J; Kuramae, T; Nakatsukasa, M | 1 |
| Ali, M; Curtin, NJ; Hirst, DG; Kamjoo, M; Kyle, S; McCrudden, C; O'Rourke, M; Robson, T; Shaw, C; Telfer, BA; Thomas, HD; Williams, KJ | 1 |
| Kovach, JS; Lonser, R; Lu, J; Zhuang, Z | 1 |
| Aghi, MK; Yang, I | 1 |
| Ahn, BJ; Berger, MS; Chang, SM; Han, SJ; McDermott, MW; Otero, JJ; Parsa, AT; Tihan, T; Yang, I | 1 |
| Byrne, S; Karapetis, C; Vrodos, N | 1 |
| Collichio, F; Ewend, MG; Grabowski, S; Kimple, RJ; Morris, DE; Papez, M | 1 |
| Chen, B; Jiang, T; Lin, Y; Song, SW; Zhang, W | 1 |
| Anderson, M; Giranda, VL; Han, EK; Johnson, EF; Lasko, L; Leverson, J; Liu, X; Luo, Y; McGonigal, T; Palma, J; Penning, T; Roberts, L; Rosenberg, S; Semizarov, D; Shi, Y; Shoemaker, AR; Wang, G; Zhu, GD | 1 |
| Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES | 1 |
| Bilbao, JM; Del Maestro, RF; Fazl, M; Guiot, MC; Oh, J; Perry, JR; Tsao, MN | 1 |
| Arbaje, YM; Lozier, AP; Scheithauer, BW | 1 |
| Cao, VT; Chae, HJ; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Lee, KH; Moon, KS; Park, CS | 1 |
| Bähr, O; Bamberg, M; Gorlia, T; Hartmann, C; Herrlinger, U; Meyermann, R; Tatagiba, M; von Deimling, A; Weiler, M; Weller, M; Wick, W; Wiewrodt, D | 1 |
| Barazzuol, L; Burnet, NG; Jefferies, SJ; Jena, R; Jones, B; Kirkby, NF | 1 |
| Glas, M; Herrlinger, U; Kurzwelly, D; Lohner, H; Reifenberger, G; Roth, P; Schabet, M; Waha, A; Weimann, E; Weller, M | 1 |
| Bhakat, KK; Bocangel, D; Mitra, S; Sengupta, S | 1 |
| Della Puppa, A; Lombardi, G; Pastorelli, D; Rotilio, A; Scienza, R; Zustovich, F | 1 |
| Baron, MH; Bauchet, L; Bernier, V; Capelle, L; Duffau, H; Fontaine, D; Guyotat, J; Mandonnet, E; Pallud, J; Peruzzi, P; Taillandier, L | 1 |
| Badie, B; Blanchard, S; Chen, M; Liu, A; Portnow, J; Synold, TW | 1 |
| Fruehauf, S; Laufs, S; Maier, P; Spier, I; Veldwijk, MR; Wenz, F; Zeller, WJ | 1 |
| Buffone, E; Ghimenton, C; Iuzzolino, P; Masotto, B; Moretto, G; Musso, AM; Ottaviani, S; Passarin, MG; Pedersini, R; Rudà, R; Soffietti, R; Vattemi, E | 1 |
| Choi, JR; Jang, SJ; Kim, SH; Kim, SJ; Lee, CH; Lee, ST; Park, TS; Song, J; Suh, B | 1 |
| Liu, R; Ma, B; Tian, J; Wang, X; Yang, K; Zhang, Q | 1 |
| Yamanaka, R | 1 |
| Bouska, JJ; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Johnson, EF; Leverson, J; Liu, X; Luo, Y; Marcotte, PA; Olson, AM; Osterling, DJ; Penning, TD; Przytulinska, M; Rodriguez, LE; Shi, Y; Soni, N; Stavropoulos, J; Thomas, S; Tong, Y | 1 |
| Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD | 1 |
| Jeremic, B; Kortmann, R; Miriamanoff, R; Okunieff, P; Roa, W; Shibamoto, Y; Small, C; Xing, JZ | 1 |
| Baltas, D; Chatzisotiriou, A; Fountzilas, G; Fragkoulidi, A; Iliadis, G; Kalogera-Fountzila, A; Misailidou, D; Selviaridis, P; Tselis, N; Zamboglou, N | 1 |
| Hu, D; Kong, B; Li, Y; Sun, Y | 1 |
| Bamberg, M; Engel, C; Ernemann, U; Felsberg, J; Hartmann, C; Ketter, R; Koeppen, S; Kortmann, RD; Meisner, C; Meyermann, R; Pietsch, T; Rapp, M; Reifenberger, G; Sabel, MC; Stockhammer, F; Stoffels, M; von Deimling, A; Weller, M; Wick, W; Wiestler, OD | 1 |
| Bernsen, HJ; Jeuken, JW; Poelen, J; Prick, MJ; Wesseling, P | 1 |
| Dasgupta, A; McCarty, D; Spencer, HT | 1 |
| Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA | 1 |
| Chalmers, AJ; Lovegrove, N; Martindale, C; Ruff, EM; Short, SC | 1 |
| Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kros, JM; Postma, TJ; Smitt, PA; Taal, W; van den Bent, MJ; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB | 1 |
| Chen, M; Doudican, N; Orlow, SJ; Osman, I; Rose, AE | 1 |
| Bukofzer, G; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Lasko, L; Liu, X; Montgomery, D; Niquette, A; Palma, JP; Penning, TD; Rodriguez, LE; Rosenberg, SH; Shi, Y; Wang, YC; Zhu, GD | 1 |
| Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ | 1 |
| Braun, K; Didinger, B; Ehemann, V; Mueller, G; Pipkorn, R; Waldeck, W; Wiessler, M | 1 |
| Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Bruce, JN; Fine, RL; Freda, PU; Isaacson, SR; Lee, Y; Thearle, MS | 1 |
| Cote, G; Dunn, SE; Faury, D; Fotovati, A; Gao, Y; Guns, E; Jabado, N; Lee, C; Toyota, B; Wang, M | 1 |
| Banerjee, S; Bulkin, CD; Izumi, T; Jaiswal, AS; Narayan, S; Ostrov, DA; Panda, H; Sarkar, FH | 1 |
| Cifarelli, CP; Dassoulas, K; Han, S; Olson, C; Rainey, J; Sheehan, J | 1 |
| Chang, Y; Fu, Z; Liu, XM; Liu, XY; Qian, ZZ; Wang, HQ; Yang, SY; Yu, H | 1 |
| Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA | 1 |
| Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G | 1 |
| Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y | 1 |
| Campisi Hegan, D; Dalal, S; Donigan, KA; Glazer, PM; Stachelek, GC; Sweasy, JB | 1 |
| Fukushima, T; Kataoka, H; Takeshima, H | 1 |
| Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE | 1 |
| Buhk, JH; Hoffmann, AL; Strik, H | 1 |
| Braun, K; Kliem, C; Pipkorn, R; Waldeck, W; Wiessler, M | 1 |
| Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM | 1 |
| Ahn, BJ; Berger, MS; Han, SJ; McDermott, MW; Otero, JJ; Parsa, AT; Prados, MD; Tihan, T; Yang, I | 1 |
| Benito, M; Mintzer, DM; Nagamine, M; Newman, J; Zheng, S | 1 |
| Cartalat-Carel, S; Chinot, O; Delattre, JY; Figarella-Branger, D; Honnorat, J; Kaloshi, G; Laigle-Donadey, F; Sanson, M; Taillandier, L | 1 |
| Lavini, C; Majoie, CBLM; Reijneveld, JC; Richel, DJ; Stalpers, LJA; van Furth, WR; van Linde, ME; Verhoeff, JJC | 1 |
| Bontempi, G; Bruyère, C; Decaestecker, C; Dubois, J; Haibe-Kains, B; Kiss, R; Lamoral-Theys, D; Le Calvé, B; Le Mercier, M; Lefranc, F; Rynkowski, MA | 1 |
| Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E | 1 |
| Athanasios, K; Gousias, K; Konstantinos, G; Kyritsis, A | 1 |
| Brady, MS; Carvajal, RD; Chapman, PB; Coit, DG; Gold, JS; Panageas, KS; Shah, GD; Socci, ND; Viale, A; Wolchok, JD | 1 |
| Cho, KH; Kim, JY; Kim, TH; Lee, DH; Lee, SH; Moon, SH; Pyo, HR; Shin, KH; Shin, SH; Yoo, H; Yoon, M | 1 |
| Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM | 1 |
| Adanja, I; Amighi, K; Debeir, O; Decaestecker, C; Deleuze, P; Hecq, J; Kiss, R; Mathieu, V; Roland, I; Saussez, S; Wauthoz, N | 1 |
| Park, DM; Rich, JN; Sathornsumetee, S | 1 |
| Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT | 1 |
| Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC | 1 |
| Batchelor, TT; Ciampa, A; Doherty, LM; Drappatz, J; Gerard, M; Kesari, S; Lafrankie, DC; Ligon, KL; Muzikansky, A; Norden, AD; Phan, P; Sceppa, C; Schiff, D; Weiss, SE; Wen, PY; Wong, ET; Young, G | 1 |
| Berger, W; Buchroithner, J; Filipits, M; Fischer, J; Lötsch, D; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S; Weis, S | 1 |
| Artemov, D; Holm, DA; Kato, Y; Okollie, B | 1 |
| Linz, U | 1 |
| Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE | 1 |
| Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A | 1 |
| Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M | 2 |
| Dong, SM; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Nam, DH; Suh, YL | 1 |
| Aviv, R; Davey, P; Lam, K; Morrison, M; Perry, J; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN | 1 |
| Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A | 1 |
| Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F | 1 |
| Abdulkarim, B; Aghi, M; Chahal, M; Christensen, JG; Famulski, K; Graham, K; Jacques, A; Lesniak, D; Murray, D; Sabri, S; Xu, Y | 1 |
| Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H | 1 |
| Ali-Osman, F; Angelica Selim, M; Augustine, CK; Friedman, HS; Padussis, JC; Pruitt, SK; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y | 1 |
| Harrison, C | 1 |
| Hendzel, MJ; Kaufmann, SH; Patel, A; Poirier, GG; Rouleau, M | 1 |
| Cadosch, D; Collen, TD; Fournier, JY; Gautschi, OP; Hildebrandt, G; Hoederath, P; Hundsberger, T; Land, M | 1 |
| Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA | 1 |
| Cruickshanks, N; Munje, C; Patel, R; Shervington, A; Shervington, L; Thakkar, D | 1 |
| Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB | 1 |
| Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M | 1 |
| Chang, FC; Chang, KP; Chen, YW; Chiang, KL; Hsu, TR; Huang, PI; Lee, YY; Wong, TT | 1 |
| Alameda Hernando, C; Lahera Vargas, M; Varela Da Costa, C | 1 |
| Bernhard, EJ; Helleday, T; Hickson, ID; Higgins, GS; Lee, YF; McKenna, WG; Muschel, RJ; Prevo, R; Taylor, S; Yoshimura, M | 1 |
| Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P | 1 |
| Ayers-Ringler, J; Banerjee, A; Berger, MS; Gupta, N; Hashizume, R; James, CD; Prados, MD; VandenBerg, SR | 1 |
| Wen, PY | 1 |
| Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B | 1 |
| Cho, BK; Jung, HL; Kim, CY; Kim, IA; Kim, IH; Kim, SK; Lee, MJ; Lee, MM; Phi, JH; Wang, KC | 1 |
| Aldrich, W; Triozzi, PL | 1 |
| Agha, CA; Elias, DA; Fathallah-Shaykh, HM; Hassan, A; Ibrahim, S | 1 |
| Bontcheva-Diaz, V; Bouska, JJ; Buchanan, FG; Bukofzer, GT; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Park, CH; Penning, TD; Rodriguez, LE; Shi, Y; Thomas, S; Zhu, GD | 1 |
| Black, P; Brady, LW; Cohen, SC; Emrich, JG; Gracely, EJ; Jenrette, JM; Kim, JH; Li, L; Quang, TS; Yaeger, TE | 1 |
| Dolezalova, H; Fadrus, P; Hrstka, R; Kren, L; Lakomy, R; Lzicarova, E; Michalek, J; Novakova, J; Slaby, O; Smrcka, M; Svoboda, M; Valik, D; Vyzula, R | 1 |
| Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Chiba, Y; Hashimoto, N; Hosen, N; Kagawa, N; Kinoshita, M; Murao, A; Nishida, S; Oji, Y; Oka, Y; Sugiyama, H; Tsuboi, A; Yoshimine, T | 1 |
| Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X | 1 |
| Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S | 1 |
| Ali-Osman, F; Augustine, CK; Friedman, HS; Jung, SH; Olson, JA; Sohn, I; Tyler, DS; Yoo, JS; Yoshimoto, Y | 1 |
| Jung, S; Jung, TY; Kang, SS; Kim, IY; Kim, YH; Lee, KH; Moon, KS; Park, CS | 1 |
| Aird, E; Bar-Deroma, R; Baumert, BG; Bernard Davis, J; Collette, L; Fenton, P; Gulyban, A; Musat, E; Roelofs, E; Stupp, R; Weber, DC | 1 |
| Bendinelli, S; Casalini, F; Costa, B; Da Pozzo, E; Da Settimo, F; Gabelloni, P; Martini, C; Nuti, E; Orlandini, E; Rossello, A | 1 |
| Black, KL; Ding, H; Holler, E; Hu, J; Inoue, S; Konda, B; Ljubimova, JY; Patil, R; Portilla-Arias, J; Shin, PK; Wawrowsky, KA | 1 |
| Beauchamp, D; Blough, MD; Cairncross, JG; Kelly, JJ; Ramirez, AL; Stechishin, O; Weiss, S; Westgate, MR | 1 |
| Hattermann, K; Held-Feindt, J; Lucius, R; Mentlein, R; Müerköster, SS; Penfold, ME; Schall, TJ | 1 |
| Liu, JM; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK | 1 |
| Heideman, RL; McNall-Knapp, RY; Meyer, WH; Reeves, EN; Williams, CN | 1 |
| Algar, E; Benson, A; Cher, L; Dowling, A; Gan, HK; Kalnins, R; Rosenthal, MA; Wong, N; Woods, AM | 1 |
| Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M | 1 |
| Berthelet, F; Bidlingmaier, M; Morin, E; Serri, O; Weisnagel, J | 1 |
| Brem, H; McGirt, MJ | 1 |
| Kawamoto, K; Li, Y; Numa, Y; Oishi, T; Oshige, H; Yamahara, T; Zhen, Y | 1 |
| Celkan, T; Ozdemir, N | 1 |
| Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A | 1 |
| Alegria, C; Almeida, R; Amorim, J; Augusto, I; Braga, F; Caeiro, C; Carvalho, E; Castro, L; Costa, BM; Costa, P; Damasceno, M; Guimarães, I; Honavar, M; Jaraquemada, T; Linhares, P; Lopes, JM; Martinho, O; Nabiço, R; Osório, L; Pardal, F; Pinheiro, C; Pires, M; Reis, RM; Resende, M; Silva, A | 1 |
| Anderson, J; Avedissian, R; Croteau, D; Doyle, TJ; Mikkelsen, T; Ryu, S; Schultz, L | 1 |
| Brathwaite, CD; Sandberg, DI; Zoeller, GK | 1 |
| Anderson, WS; Dunn, I; Norden, A; Sure, D | 1 |
| Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH | 1 |
| Birol Sarica, F; Cekinmez, M; Cem Onal, H; Erdogan, B; Mertsoylu, H; Nur Altinors, M; Pehlivan, B; Sen, O; Topkan, E; Tufan, K | 1 |
| Chouaid, C; Chua, D; Curran, W; Gottfried, M; Krzakowski, M; Martinez, JI; Pallotta, MG; Throuvalas, N | 1 |
| Amies, K; Anderson, S; Browett, P; Dare, T; Findlay, M | 1 |
| Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M | 1 |
| Grisdale, K; Groves, MD; Hunter, K; Ritterhouse, M; Williams, MD | 1 |
| Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Ballman, KV; Carlson, BL; Decker, PA; Giannini, C; Kitange, GJ; Morlan, BW; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E | 1 |
| Hayashi, K; Kamada, K; Matsuo, T; Matsuse, M; Mitsutake, N; Nagata, I; Saenko, V; Suzuki, K; Takakura, S; Ujifuku, K; Yamashita, S | 1 |
| Blechschmidt, C; Czabanka, M; Koch, A; Misch, M; Plotkin, M; Stockhammer, F; Tuettenberg, J; Vajkoczy, P | 1 |
| Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V | 1 |
| Blank, A; Bobola, MS; Kolstoe, DD; Silber, JR | 1 |
| Dehais, C; Delattre, JY; Ducray, F; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Omuro, A; Psimaras, D; Sanson, M; Sierra del Rio, M; Taillibert, S | 1 |
| Camaioni, E; Dantzer, F; Dorio, AS; Gold, B; Graziani, G; Leonetti, C; Muzi, A; Pellicciari, R; Scarsella, M; Shah, GM; Tentori, L; Xu, W; Zhang, J | 1 |
| Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A | 1 |
| Jean-Claude, BJ; Rachid, Z; Watt, HL | 1 |
| Grimsdale, R; Han, S; Nguyen, J; Rainey, J; Sheehan, J | 1 |
| Eriksson, B | 1 |
| Kim, SY; Niswander, LM | 1 |
| Cortes, U; Dkhissi, F; Dusanter-Fourt, I; Karayan-Tapon, L; Le Corf, A; Martin-Lannerée, S; Tourani, JM; Turhan, AG; Villalva, C; Wager, M | 1 |
| Erickson, D; Fealey, ME; Horvath, E; Kovacs, K; Lloyd, RV; McLendon, R; Scheithauer, BW | 1 |
| Back, W; Bode, H; Brockmann, MA; Hammes, HP; Lammert, A; Seiz, M; Thomé, C | 1 |
| Butowski, NA; Cha, S; Chang, SM; Elkhaled, A; Jalbert, L; Khayal, IS; Nelson, SJ; Polley, MY | 1 |
| Boos, J; Brauckmann, C; Heshe, D; Hoogestraat, S; Karst, U; Lanvers-Kaminsky, C | 1 |
| Barletta, L; Garbossa, D; Prevost, C; Spena, G; Versari, P | 1 |
| Advani, A; Cahill, A; Gerson, SL; Karsten, V; Khan, K; LoRusso, S; Moore, J; Rizzieri, D; Tse, W | 1 |
| Ameziane, N; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; Steenbergen, RD; van den Berg, J; van der Meide, WF; van Nifterik, KA; Wedekind, LE | 1 |
| Bankiewicz, K; Hachisu, R; Iwamizu, H; Kato, T; Motomura, K; Natsume, A; Sugita, T; Toda, H; Wakabayashi, T; Watanabe, R; Yuki, K | 1 |
| Emmerich, J; Giménez-Pando, J; Gómez-González, E; Márquez-Rivas, J; Ollero-Ortiz, A; Quiroga-Cantero, E; Ramirez, G; Rivas, E | 1 |
| Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M | 1 |
| Brem, H; Chaichana, KL; Halthore, AN; Olivi, A; Parker, SL; Quinones-Hinojosa, A; Weingart, JD | 1 |
| Avgeropoulos, NG; Baker, CH; Bobustuc, GC; Jenkins, WD; Konduri, SD; Limaye, A; Pearl, G | 1 |
| Choe, G; Kim, CY; Kim, HJ; Kim, IA; Kim, JH; Kim, KJ; Kim, WH; Kim, YJ; Lee, MM; Yoon, SH | 1 |
| Ekholm, SE; Korones, DN; Mangla, R; Milano, MT; Singh, G; Zhong, J; Ziegelitz, D | 1 |
| Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N | 1 |
| Biggs, MT; Cook, RJ; Hegi, ME; Henson, JD; Little, NS; McDonald, KL; McDonnell, J; Muntoni, A; Reddel, RR; Robinson, BG; Royds, JA; von Deimling, A; Wheeler, HR | 1 |
| Attinà, G; Bertolini, P; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Migliorati, R; Pastore, M; Riccardi, R; Rizzo, D; Ruggiero, A | 1 |
| Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A | 1 |
| Mukherji, SK; Rajdev, P; Wesolowski, JR | 1 |
| Burd, R; Limesand, KH; Mendoza, EE; Mitchell, GC; Radhakrishnan, VM; Sittadjody, S; Thangasamy, T | 1 |
| Brada, M; Pentheroudakis, G; Stupp, R; Tonn, JC | 1 |
| Carpentier, C; Dehais, C; del Rio, MS; Delattre, JY; Ducray, F; Hoang-Xuan, K; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Mokhtari, K; Omuro, A; Psimaras, D; Sanson, M; Taillibert, S | 1 |
| Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G | 1 |
| Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V | 1 |
| Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A | 1 |
| Del Porto, L; Dobson, M; Maartens, NF | 1 |
| Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Gupta, A; Gupta, DK; Jain, A; Jha, P; Mallick, S; Puri, T; Sarkar, C; Sharma, MC; Srivastava, A; Suri, V | 1 |
| Kögel, D; Lang, V; Ronellenfitsch, MW; Seifert, V; Senft, C; Steinbach, JP; Voss, V | 1 |
| Brat, DJ; Burger, PC; Cohen, KJ; Finlay, JL; Gilles, FH; Hamilton, RL; Jakacki, RI; LaFramboise, WA; Lyons-Weiler, MA; Nikiforov, YE; Nikiforova, MN; Pollack, IF; Rosenblum, MK; Sobol, RW; Yates, AJ; Zhou, T | 1 |
| Brasme, JF; Daudigeos-Dubus, E; Debussche, L; Geoerger, B; Opolon, P; Vassal, G; Venot, C; Vrignaud, P | 1 |
| Beauchamp, DC; Blough, MD; Cairncross, JG; Kelly, JJ; Westgate, MR | 1 |
| Bei, R; Marzocchella, L; Turriziani, M | 1 |
| Giusti, V; Gorlia, T; H-Stenstam, B; Hopewell, JW; Pellettieri, L; Sköld, K | 1 |
| Dinapoli, L; Maschio, M; Muti, P; Vidiri, A | 1 |
| Batchelor, TT; Chamberlain, MC; Desideri, S; Grossman, SA; Lesser, GJ; Peereboom, DM; Rosenfeld, MR; Salazar, AM; Ye, X | 1 |
| Kumabe, T; Nishihara, M; Saito, R; Satoh, T; Sonoda, Y; Sugiyama, S; Tominaga, T; Yamashita, Y; Yokosawa, M; Yokoyama, M | 1 |
| Blasel, S; Franz, K; Gasser, T; Oszvald, A; Rathert, J; Seifert, V; Senft, C | 1 |
| Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R | 1 |
| Andrasi, M; Bustos, R; Gaspar, A; Gomez, FA; Klekner, A | 1 |
| Donze, J; Liu, L; McGraw, M; Palomo, JM; Rahmathulla, G; Robinson, CG; Vogelbaum, MA | 1 |
| Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH | 1 |
| Chen, J; Pan, T; Shi, L; Wang, Z; Yang, J; Zhang, S | 1 |
| Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T | 1 |
| Banerjee, P; Shen, J; Wu, W; Zhou, S | 1 |
| Berti, F; Bertoni, F; Biti, G; Buglione, M; Cipressi, S; De Renzis, C; Detti, B; Fariselli, L; Fatigante, L; Fusco, V; Krengli, M; Lioce, M; Lupattelli, M; Magrini, SM; Maluta, S; Mantovani, C; Muto, P; Parisi, S; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S; Sotti, G; Tombolini, V | 1 |
| Coenen, HH; Eble, MJ; Holy, R; Kaiser, HJ; Klotz, J; Langen, KJ; Nussen, S; Pinkawa, M; Piroth, MD; Stoffels, G | 1 |
| Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK | 1 |
| Baumann, RP; Ishiguro, K; Penketh, PG; Sartorelli, AC; Shyam, K; Zhu, YL | 1 |
| Jakubowicz-Gil, J; Langner, E; Piersiak, T; Rzeski, W; Wertel, I | 1 |
| Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U | 1 |
| Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S | 1 |
| Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J | 1 |
| Adams, E; Ansorge, O; Barber, TM; Byrne, JV; Karavitaki, N; Wass, JA | 1 |
| Bush, ZM; Cunningham, T; Jane, JA; Laws, ER; Longtine, JA; Lopes, MB; Schiff, D; Thorner, MO; Vance, ML | 1 |
| Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC | 1 |
| Grommes, C; Papanicolaou, G; Redelman-Sidi, G | 1 |
| Molczyk, A; Łata, S | 1 |
| Arcella, A; Buttarelli, F; D'Elia, A; Esposito, V; Giangaspero, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Salvati, M; Scarpino, S | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B | 1 |
| Kim, JH; Kim, ST; Kim, WS; Kong, DS; Kwon, KH; Lee, JI; Lim, DH; Nam, DH; Park, K; Suh, YL | 1 |
| Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M | 1 |
| Bracci, PM; McCoy, LS; Patoka, JS; Rice, T; Sison, JD; Wiemels, JL; Wiencke, JK; Wrensch, MR; Zhou, M | 1 |
| Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK | 1 |
| Dianov, GL; Digweed, M; Eich, M; Kaina, B; Roos, WP | 1 |
| Goldbecker, A; Herrmann, J; Raab, P; Tryc, AB; Weissenborn, K; Worthmann, H | 1 |
| Chen, C; Damek, DM; Franklin, W; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Olsen, C; Rusthoven, KE; Waziri, A | 1 |
| Daou, MC; Gilbert, CA; Moser, RP; Ross, AH | 1 |
| Dummer, R; Edler, L; Hassel, JC; Kurzen, H; Mauch, C; Moll, I; Rass, K; Schadendorf, D; Spieth, K; Stresemann, C; Sucker, A | 1 |
| Bello, L; Bertani, G; Mårlind, J; Neri, D; Pedretti, M; Sala, C; Verpelli, C | 1 |
| Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Scheithauer, B; Syro, LV | 1 |
| Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L | 1 |
| Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H | 1 |
| Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P | 1 |
| Beery, E; Fenig, E; Gil-Ad, I; Israeli, M; Lahav, M; Nordenberg, J; Tzadok, S; Uziel, O; Weizman, A | 1 |
| Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A | 1 |
| Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Combs, SE; Debus, J; Haberer, T; Habermehl, D; Haselmann, R; Jäkel, O; Kieser, M; Nikoghosyan, A; Rieken, S; Unterberg, A; Wick, W | 1 |
| Arnold, L; Faoro, D; Gerber, NU; Grotzer, MA; Haybaeck, J; Hegi, M; Hürlimann, ML; Mittelbronn, M; Rutkowski, S; Sciuscio, D; Shalaby, T; von Bueren, AO | 1 |
| Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L | 1 |
| Bontempi, G; Bruyère, C; Decaestecker, C; Gras, T; Haibe-Kains, B; Kiss, R; Le Calvé, B; Le Mercier, M; Lefranc, F; Lonez, C; Ruysschaert, JM; Rynkowski, M | 1 |
| Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR | 1 |
| Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM | 1 |
| Cusimano, M; Gonzalez, R; Horvath, E; Kovacs, K; Lau, Q; Lloyd, R; Ortiz, LD; Scheithauer, BW; Syro, LV; Uribe, H | 1 |
| Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM | 1 |
| Franz, K; Fraunholz, I; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, R; Peters, K; Reardon, DA; Rich, JN; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Augustine, CK; Osmond, GW; Padussis, J; Tyler, DS; Zipfel, PA | 1 |
| Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S | 1 |
| Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC | 1 |
| Mariani, L; Ochsenbein, AF; Schubert, AD; Vassella, E | 1 |
| Ellsworth, R; Hsieh, A; Hsieh, D | 1 |
| Belka, C; Eigenbrod, S; Grasbon-Frodl, EM; Kreth, FW; Kreth, S; Kretzschmar, HA; Lutz, J; Popperl, G; Thon, N; Tonn, JC | 1 |
| Bae, SH; Cha, SH; Cho, WH; Choe, G; Jung, HW; Kim, CY; Kim, DG; Kim, IA; Kim, IH; Kim, YH; Lee, MM; Moon, S; Park, CK; Park, SH | 1 |
| Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W | 1 |
| Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C | 1 |
| Cangi, MG; Gill, AJ; Losa, M; Mazza, E; McCormack, A; Mortini, P; Motta, M; Reni, M; Talarico, A; Terreni, MR | 1 |
| Bailey, SM; Darley-Usmar, VM; Diers, A; Gillespie, GY; Griguer, CE; Landar, A; Markert, JM; McClugage, SG; Nozell, SE; Oliva, CR; Sarkaria, JN | 1 |
| Krug, LM; O'Rourke, D; Pietanza, MC; Zauderer, M | 1 |
| Abacioglu, U; Akgun, Z; Atasoy, BM; Caglar, HB; Sengoz, M; Yumuk, PF | 1 |
| Jin, YH; Liu, HY; Shu, F; Wang, QJ; Wang, Z; Yang, Y; Zhang, WB | 1 |
| Davis, MD; Harlan, E; Pittelkow, MR | 1 |
| Hegi, ME; Stupp, R; Tabatabai, G; Weller, M; Wick, W | 1 |
| Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S | 1 |
| Aldape, KD; Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Gilbert, MR; Heimberger, AB; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sawaya, R; Schmittling, RJ; Shi, W; Vredenburgh, JJ | 1 |
| Bäuerle, T; Braun, K; Ehemann, V; Fleischhacker, H; Lorenz, P; Müller, G; Pipkorn, R; Waldeck, W; Wiessler, M | 1 |
| Kern, BC; Krex, D; Mehdorn, HM; Nestler, U; Pichlmeier, U; Stockhammer, F; Stummer, W; Vince, GH | 1 |
| Cai, W; Cui, W; Harutyunyan, N; Ji, L; Keshelava, N; Maldonado, NV; Reynolds, CP; Sposto, R | 1 |
| Drabick, JJ; Fateh, S; Gingrich, R; Neves, RI; Schell, TD | 1 |
| Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A | 1 |
| Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY | 1 |
| Bax, DA; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Reis, RM; Sharp, SY; Vassal, G; Viana-Pereira, M; Workman, P | 1 |
| Albanese, A; Anile, C; Apicella, G; Azario, L; Balducci, M; Cellini, N; Chiesa, S; D'Agostino, GR; de Bonis, P; Dinapoli, N; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Valentini, V | 1 |
| Berg, A; Kolesar, J; Mehta, M; Petrich, RJ; Steen, P; Sylvester, RK; Tate, JM | 1 |
| Davis, ME; Hsueh, T; Koya, RC; Ribas, A; Zuckerman, JE | 1 |
| Chen, Z; Mao, Y; Wang, Y; Wu, J; Yao, Y; Zhang, C; Zhou, L | 1 |
| Dawirs, S; Dörner, L; Hedderich, J; Mehdorn, HM; Nabavi, A; Schwartz, F | 1 |
| Delashaw, JB; Dillard, TH; Fleseriu, M; Gultekin, SH; Neuwelt, EA; Yedinak, CG | 1 |
| Boisselier, B; Delattre, JY; Guillevin, R; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laffaire, J; Laigle-Donadey, F; Mokhtari, K; Paris, S; Sanson, M; Wang, X | 1 |
| Ahmed, MM; Gupta, S; Sathishkumar, S | 1 |
| Belka, C; Ertl, L; Ganswindt, U; Geisler, J; Kreth, FW; la Fougère, C; Linn, J; Niyazi, M; Schwarz, SB; Siefert, A; Tonn, JC | 1 |
| Lefebvre, G; Poirot, C; Prades, M; Sanson, M; Schubert, B; Sitbon Sitruk, L | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Butowski, NA; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Nelson, SJ; Polley, MY | 1 |
| Jiang, G; Liu, YQ; Zheng, JN | 1 |
| Bodoky, G; Pregun, I; Rácz, K; Tulassay, Z | 1 |
| D'Avella, D; Fassan, M; Gardiman, MP; Onisto, M; Perilongo, G; Tassone, E | 1 |
| Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M | 1 |
| Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH | 1 |
| Abo Hamar, AH; El-Shorbagy, D; Galal, S; Shawky, H; Zakaria, F | 1 |
| Altavilla, G; Cannavò, S; Curtò, L; Ferraù, F; Granata, F; Hofland, LJ; Longo, M; Pitini, V; Torre, ML; Trimarchi, F | 1 |
| Ang, C; Guiot, MC; Kavan, P; Ramanakumar, AV; Roberge, D | 1 |
| Drake, WM; Horvath, E; Kovacs, K; Manoranjan, B; Moyes, VJ; Salehi, F; Scheithauer, BW; Sharma, S; Syro, LV | 1 |
| Slotman, BJ; Van Den Berg, J; van Nifterik, KA; Van Rijn, J | 1 |
| Colucci, G; Cramarossa, A; Fistola, E; Giudice, G; Guida, M; Lubello, K; Porcelli, M | 1 |
| Aguilera, DG; Fangusaro, J; Goldman, S | 1 |
| Di Giacomo, AM; Maio, M; Margolin, KA | 1 |
| Choi, SH; Han, JH; Jung, HW; Kim, CY; Kim, DG; Kim, J; Kim, SK; Kim, TM; Lee, AR; Lee, SH; Park, CK; Park, SH; Yim, SY | 1 |
| Hegi, M; Stupp, R; Weller, M | 1 |
| Cappella, P; Pesenti, E; Rizzitano, S; Scabini, M; Stellari, F; Texido, G | 1 |
| Chattopadhyay, P; Chosdol, K; Gupta, D; Jain, A; Jha, P; Pathak, P; Sarkar, C; Sharma, MC; Srivastava, A; Suri, A; Suri, V | 1 |
| D'Atri, S; Graziani, G; Lacal, PM; Levati, L; Muzi, A; Ruffini, F; Umezawa, K | 1 |
| Ahn, JM; Jin, J; Jin, Y; Jo, MY; Joo, KM; Kim, JK; Kim, Y; Lee, SJ; Lim, J; Nam, DH; Yoon, MJ | 1 |
| Mehta, MP; Nieder, C | 1 |
| Bagatell, R; Cohn, SL; Kretschmar, C; London, WB; Maris, JM; Stewart, CF; Voss, SD; Wagner, LM | 1 |
| Amighi, K; Deleuze, P; Duret, C; Kiss, R; Saumet, A; Wauthoz, N | 1 |
| Fujita, M; Okada, H; Snyder, LA; Zhu, X | 1 |
| Cloughesy, T | 1 |
| Brem, S; Wong, ET | 1 |
| Black, K; Cloughesy, T; Elashoff, R; Fehrenbacher, L; Filka, E; Green, RM; Kolevska, T; Lai, A; Liau, LM; Mischel, PS; Nghiemphu, PL; Peak, S; Phuphanich, S; Polikoff, J; Pope, WB; Selch, M; Solis, OE; Spier, CE; Tran, A; Yong, WH | 1 |
| Banerjee, R; Belinsky, G; Huang, Y; Jean-Claude, BJ; McNamee, JP; Qiu, Q | 1 |
| Berti, F; Borgato, L; Cecchin, D; Della Puppa, A; Farina, P; Gardiman, MP; Lombardi, G; Manara, R; Orvieto, E; Scienza, R; Zagonel, V; Zustovich, F | 1 |
| Aldape, KD; Archer, GE; Bigner, DD; Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gilbert, MR; Heimberger, AB; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sawaya, R; Schmittling, R; Shi, W; Vredenburgh, JJ | 1 |
| Aoki, T; Fujimaki, T; Itoh, K; Kajiwara, K; Kurisu, K; Mineta, T; Narita, Y; Sawamura, Y; Shibui, S; Terasaki, M; Yamada, A | 1 |
| Fan, X; Liu, Y; Ni, S; Qi, H; Wang, C; Wang, X | 1 |
| Auvergne, R; Ayers-Ringler, J; Berger, MS; Bergers, G; Goldenberg, DD; Goldman, SA; Itsara, M; McKnight, TR; Nguyen, KN; Nishiyama, A; Persson, AI; Petritsch, C; Sim, FJ; Stallcup, WB; Swartling, FJ; Vandenberg, SR; Weiss, WA; Yakovenko, S | 1 |
| Elandt, K; Heinzl, H; Marosi, C; Preusser, M; Schwarzinger, I | 1 |
| Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF | 1 |
| Chasoo, G; Jain, A; Jain, SK; Saxena, AK; Singh, SK | 1 |
| Balsamo, T; Barbano, R; Carella, M; Catapano, D; Coco, M; Copetti, M; D'Angelo, V; Fazio, VM; Icolaro, N; la Torre, A; Merla, G; Muscarella, LA; Notarangelo, A; Parisi, S; Parrella, P; Pellegrini, F; Troiano, M; Valori, VM | 1 |
| Cheng, J; Liu, D; Yang, JG; Zhao, LX | 1 |
| Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB | 1 |
| Chen, YF; Flickinger, JC; Heron, DE; Huq, MS; Landsittel, D; Mintz, A; Paravati, AJ | 1 |
| Marosi, C; Pichler, J | 1 |
| Ikeda, J; Kanno, H; Katoh, M; Kimura, T; Mahabir, R; Nagashima, K; Nishihara, H; Sawamura, Y; Takahashi, K; Tanaka, S; Tanino, M; Yoshinaga, T | 1 |
| Lou, X; Qiao, G; Wang, F | 1 |
| Connor, JR; Hong, YS; Lee, SY; Liu, S; Mitchell, RM; Sheehan, JM; Slagle-Webb, B | 1 |
| Eriksson, B; Granberg, D; Lindholm, DP | 1 |
| Aghi, MK; Oh, MC | 1 |
| Basaldella, L; Brem, H; Cima, MJ; Grossman, R; Langer, RS; Masi, BC; Patta, YR; Scott, AW; Tyler, BM; Upadhyay, UM | 1 |
| Barcia, J; García-Taboada, E; Guzmán, M; Hernández-Tiedra, S; Lorente, M; Rodríguez-Fornés, F; Salazar, M; Torres, S; Velasco, G | 1 |
| Aderka, D; Beny, A; Blachar, A; Figer, A; Geva, R; Shacham-Shmueli, E | 1 |
| Hackel, RE; He, SX; Heckenlively, JR; Johnson, MW; Khan, NW; Koreen, L | 1 |
| Frame, JN; Ghareeb, ER; John, K; Peters, KB; Schmidt, JH; Snelling, BM; Vargo, JA | 1 |
| Adair, J; Kiem, HP; Mrugala, MM | 1 |
| Anson, J; Gollard, RP; Khoury, J; Mason, J; Rosen, L | 1 |
| Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK | 1 |
| Agnihotri, S; Cairns, R; Guha, A; Hawkins, C; Micallef, J; Mukherjee, J; Sabha, N; Wolf, A | 1 |
| Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W | 1 |
| Huang, Y; Jean-Claude, BJ; Rachid, Z | 1 |
| Aoki, H; Fujii, Y; Kakita, A; Miyahara, H; Natsumeda, M; Takahashi, H; Toyoshima, Y; Uzuka, T; Yajima, N | 1 |
| Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P | 1 |
| Chansriwong, P; Sirisinha, T | 1 |
| Boyer, P; Dufour, P; Fischer-Lokou, D; Froelich, S; Gaub, MP; Kehrli, P; Maitrot, D; Noël, G; Schott, R | 1 |
| Inoue, T; Kanamori, M; Kumabe, T; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Cornes, P; Greenslade, M; Herbert, C; Hopkins, K; Sawyer, H; Williams, M | 1 |
| Aneja, R; Banerjee, S; Jaiswal, AS; Narayan, S; Ostrov, DA; Sarkar, FH | 1 |
| Erickson, D; Fealey, M; Horvath, E; Kovacs, K; Kros, JM; Lau, Q; Lloyd, RV; Salehi, F; Scheithauer, BW | 1 |
| Payer, F | 1 |
| Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X | 1 |
| Altuntaş, Y; Aydın, Y; Karaman, O; Müslüman, AM; Ozderya, A; Ozkayalar, H; Oztürk, FY; Tanık, C; Zuhur, SS | 1 |
| Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
| Aoki, T; Hashimoto, N; Kayama, T; Natsume, A; Nishikawa, R; Ogura, M; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T; Yoshida, J | 1 |
| Gao, L; Huang, F; Li, Q; Liu, Y; Luan, S; Mao, Y; Zhang, H; Zhuang, D | 1 |
| Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN | 1 |
| Chen, TC | 1 |
| Ito, I; Mitsuya, K; Nakajima, T; Nakasu, S; Nakasu, Y; Tashiro, H; Watanabe, R | 1 |
| Bölke, E; Budach, W; Gerber, PA; Hoffmann, TK; Lammering, G; Matuschek, C; Nawatny, J; Orth, K; Peiper, M; Rusnak, E | 1 |
| Abbasova, EV; Govorina, EV; Parkhomenko, RA; Rodionov, MV; Shcherbenko, OI; Zelinskaia, NI | 1 |
| Côté, AL; Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH | 1 |
| Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Hamilton, RL; Heideman, RL; Holmes, EJ; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T | 1 |
| Bernardo, M; Chiang, J; Lonser, R; Lu, J; Martiniova, L; Pacak, K; Zhuang, Z | 1 |
| Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT | 1 |
| Achawal, S; Dixit, S; Hingorani, M; Scott, I | 1 |
| Bouffet, E; Cohen, KJ; Heideman, RL; Holmes, EJ; Lavey, RS; Pollack, IF; Zhou, T | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S | 1 |
| Belinsky, SA; Bernauer, AM; Burki, EA; Costello, JF; Crowell, RE; Do, KC; Flores, KG; Gilliland, FD; Hong, C; Leng, S; Picchi, MA; Prados, MD; Stidley, CA; Tellez, CS; Tessema, M; Willink, RP; Yingling, CM | 1 |
| Alcaide-German, M; Bourne, S; Giampieri, S; Lio, KI; Martindale, C; Shaked-Rabi, M; Short, SC; Sioftanos, G; Worku, M | 1 |
| Egensperger, R; Eigenbrod, S; Hinske, LC; Kreth, FW; Kreth, S; Kretzschmar, HA; Ledderose, C; Lutz, J; Thon, N; Tonn, JC | 1 |
| Bogdahn, U; Brawanski, A; Grauer, O; Hartmann, C; Hau, P; Pascher, C; Pietsch, T; Proescholdt, M; Weller, M; Wick, W; Zeman, F | 1 |
| Banze, LA; Brown, AR; Goellner, EM; Hamilton, RL; Moore, B; Sobol, RW; Svilar, D; Tang, JB; Trivedi, RN; Wang, XH | 1 |
| Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA | 1 |
| Blasberg, RG; de Stanchina, E; Gamez, I; Huang, R; Kochetkov, T; Moroz, MA; Ryan, RP; Shi, W; Thaler, H | 1 |
| Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K | 1 |
| Aiyama, H; Endo, K; Ishikawa, E; Kumada, H; Matsumura, A; Mizumoto, M; Nakai, K; Nariai, T; Okumura, T; Shibata, Y; Takada, T; Tsuboi, K; Yamamoto, T; Yoshida, F; Zaboronok, A | 1 |
| Oymak, E; Parlak, C; Pehlivan, B; Topkan, E; Topuk, S | 1 |
| Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S | 1 |
| Brunetti, E; Bucci, B; D'agnano, I; De Paula, U; De Salvo, M; Gagliassi, R; Marchese, R; Maresca, G; Raza, GH; Stigliano, A | 1 |
| Brown, AR; Goellner, EM; Grimme, B; Lin, YC; Mitchell, L; Sobol, RW; Sugrue, KF; Tang, JB; Trivedi, RN; Wang, XH | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE | 2 |
| Hou, X; Sun, JH; Wang, JJ; Wu, ZC; Zhao, Y; Zheng, YR | 1 |
| Eigenbrod, S; Felsberg, J; Hentschel, B; Kreth, FW; Löffler, M; Pietsch, T; Reifenberger, G; Sabel, MC; Schackert, G; Thon, N; Tonn, JC; Weller, M; Westphal, M | 1 |
| Chinot, OL; Cloughesy, T; Das, A; de La Motte Rouge, T; Modrusan, Z; Moore, N; Phillips, H; Zeaiter, A | 1 |
| Furuya, K; Goto, T; Kikuchi, Y; Kita, T; Kouta, H; Kudoh, K; Susumu, N; Takano, M | 1 |
| Fukushima, T; Inoue, T; Kawaguchi, H; Komatsu, F; Komatsu, M; Nabeshima, K; Oshiro, S; Tsugu, H | 1 |
| Hamada, J; Hayashi, Y; Misaki, K; Mohri, M; Nakada, M | 1 |
| Kyritsis, AP; Levin, VA | 1 |
| Diao, Y; Feng, W; Huang, ZC; Lin, XN; Ren, L; Tian, XH; Wang, P; Wei, F | 1 |
| Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J | 2 |
| Lin, F; Lin, J; Rao, J; Sheng, H; Yang, L; Yin, B; Zhang, N; Zhou, H | 1 |
| Baumer, B; Keefer, LK; Koentges, C; Kogias, E; Osterberg, N; Papazoglou, A; Psarras, N; Saavedra, JE; Weyerbrock, A | 1 |
| Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S | 1 |
| Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y | 1 |
| Etcheverry, A; Hamlat, A; Lesimple, T; Mosser, J; Quillien, V; Saikali, S; Vauléon, E | 1 |
| Boeckmann, L; Emmert, S; Kuschal, C; Nickel, AC; Schaefer, A; Schön, MP; Thomale, J; Thoms, KM | 1 |
| Gevertz, JL | 1 |
| Agnihotri, S; Aldape, K; Clarke, ID; Dirks, PB; Fuller, GN; Gajadhar, A; Guha, A; Hawkins, C; Kesari, S; McGlade, CJ; Mischel, PS; Munoz, DM; Restrepo, A; Smith, CJ; Stanford, WL; Wolf, A | 1 |
| Abe, T; Higashi, H; Kishida, Y; Kondo, Y; Motomura, K; Nakasu, Y; Namba, H; Natsume, A; Wakabayashi, T; Wakai, K | 1 |
| Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T | 1 |
| Stummer, W; van den Bent, MJ; Westphal, M | 1 |
| Barrie, M; Chinot, O; Colin, C; Coulibaly, B; Delfino, C; Figarella-Branger, D; Fina, F; Loundou, A; Metellus, P; Nanni-Metellus, I; Ouafik, L; Tchogandjian, A | 1 |
| Araujo, DM; Benjamin, RS; Boonsirikamchai, P; Choi, H; Conrad, CA; Lazar, AJ; Ludwig, JA; Park, MS; Patel, SR; Trent, JC; Wang, WL; Wang, X | 1 |
| Bailey, B; Baluyut, AR; Cai, S; Chan, RJ; Ernstberger, A; Goebel, WS; Jones, DR; Juliar, BE; Mayo, LD; Pollok, KE; Sinn, AL; Wang, H | 1 |
| Andrews, D; Curran, WJ; Dicker, AP; Lawrence, YR; Mehta, M; Michalski, JM; Souhami, L; Wang, M; Yung, WK | 1 |
| Cuneo, KC; Desjardins, A; Friedman, HS; Kirkpatrick, JP; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Willett, CG | 1 |
| Belohlavek, C; Fritz, G; Jöst, E; Kaina, B; Nagel, G; Roos, WP | 1 |
| Grossman, AB; McCormack, AI; Wass, JA | 1 |
| Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G | 1 |
| Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J | 1 |
| Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH; Lallana, EC; Lewis, LD; Li, Z; Rhodes, CH; Szczepiorkowski, ZM; Tosteson, TD; Wishart, HA | 1 |
| García, S; Garzás, C; Izquierdo, L; López-Laso, E; Mateos, ME; Pérez-Navero, JL | 1 |
| Bruyère, C; Cludts, S; Duray, A; Kiss, R; Lonez, C; Mijatovic, T; Ruysschaert, JM; Saussez, S; Yeaton, P | 1 |
| Hueng, DY; Liu, MY; Ma, HI; Sytwu, HK | 1 |
| Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X | 1 |
| Ichikawa, M; Kurokawa, M; Nakamura, F; Nannya, Y; Ogura, M; Tanaka, M; Todo, T | 1 |
| Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R | 1 |
| Addeo, R; Caraglia, M | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Hu, A; Kesari, S; Kim, RY; Lee, JW; Nguyen, A; Xu, Z | 1 |
| Guha, M | 1 |
| Bangert, A; Cristofanon, S; Debatin, KM; Fulda, S; Häcker, S | 1 |
| Hasegawa, M; Helleday, T; Kinashi, Y; Kondo, N; Masunaga, S; Mori, E; Noda, T; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Thompson, LH; Zdzienicka, MZ | 1 |
| Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH | 1 |
| Algazi, AP; Cha, EN; Daud, AI; Soon, CW; Webb, EM | 1 |
| Camci, C; Dirier, A; Kalender, ME; Pehlivan, Y; Sevinc, A; Turkbeyler, IH | 1 |
| Aamdal, S; Dueland, S; Gaudernack, G; Julsrud, L; Kyte, JA; Trachsel, S | 1 |
| Cejna, M; DeVries, A; Eiter, H; Maier, R; Muxel, B; Muxel, M; Roessler, K; Zachenhofer, I | 1 |
| Bok, R; James, CD; Nelson, SJ; Ozawa, T; Park, I; Phillips, JJ; Ronen, SM; Vigneron, DB | 1 |
| Biswas, A; Gupta, K; Kumar, N; Kumar, P; Mathuriya, SN; Patel, F; Sharma, SC; Vasishta, RK | 1 |
| Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U | 1 |
| Jakubowicz-Gil, J; Langner, E; Rzeski, W | 1 |
| Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK | 1 |
| Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN | 1 |
| Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A | 1 |
| Abdur, S; Bressler, LR; Letarte, N; Villano, JL; Yu, JM | 1 |
| Akiyoshi, K; Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Kimura, M; Manome, Y; Nomura, M; Saito, H; Saito, Y; Somura, H | 1 |
| Bao, X; Cai, F; Dai, C; Feng, M; Li, G; Liu, X; Ma, S; Ma, W; Wang, R; Wei, J; Yao, Y; Zhang, B | 1 |
| de la Barrera, EH; De Las Heras Gozalo, M; Dominguez, JS; Mónica, RG | 1 |
| Davis, ME; Stoiber, AM | 1 |
| Demopoulos, A; Nandipati, S | 1 |
| Abrey, LE; Aldape, KD; Ashby, LS; Cairncross, JG; Chamberlain, MC; Cloughesy, TF; DeAngelis, LM; Eichler, AF; Fisher, BJ; Green, RM; Iwamoto, FM; Jhanwar, SC; Kamar, FG; Lassman, AB; Ligon, KL; Louis, DN; Mason, WP; Paleologos, NA; Panageas, KS; Rivera, AL; Robins, HI; Rocque, BG; Roldán, GB; Rosenblum, MK; Schiff, D; Weaver, SA; Wen, PY | 1 |
| Bommer, M; Haenle, MM; Klaus, B; Mayer-Steinacker, R; Scheuerle, A; Schmid, M; Schönsteiner, SS | 1 |
| Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN | 1 |
| Han, N; Hauser, K; Herion, TW; Huber, PE; Lahn, M; Peschke, P; Timke, C; Weber, KJ; Wirkner, U; Zhang, M | 1 |
| Handler, MZ; Mruthyunjaya, P; Nelson, K | 1 |
| Boulinguez, S | 1 |
| Lesniak, MS | 1 |
| Barrie, M; Beauchesne, P; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, O; Delattre, JY; Ducray, F; Gállego Pérez-Larraya, J; Guillamo, JS; Honnorat, J; Huchet, A; Matta, M; Mokhtari, K; Monjour, A; Taillandier, L; Tanguy, ML | 1 |
| Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W | 1 |
| Bradshaw, TD; Hummersone, M; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Hide, T; Kuratsu, J; Makino, K; Nakamura, H | 1 |
| Barnes, J; Fast, EM; Keating, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, N; Veldhuijzen van Zanten, SE; Zawel, L; Ziegler, DS | 1 |
| Jing, Z; Qiu, B; Wang, Y; Wu, A; Zhang, D | 1 |
| Motomura, K; Natsume, A; Wakabayashi, T | 1 |
| Andrási, M; Gáspár, A; Klekner, Á; Törzsök, B | 1 |
| Aparicio, J; Garcia del Muro, X; Germa-Lluch, JR; Horwich, A; Huddart, R; Maroto, P; Paz Ares, L | 1 |
| Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ | 1 |
| Blasius, E; Glas, M; Herrlinger, U; Moehlenbruch, M; Rasch, K; Schaefer, N; Scheffler, B; Stuplich, M; Urbach, H | 1 |
| Salameire, D | 1 |
| Carraway, H; Desideri, S; Grossman, SA; Lesser, G; Piantadosi, S; Sloan, A; Ye, X | 1 |
| Baron, J; Dolan, ME; Foss, F; Guitart, J; Kuzel, TM; Pezen, DS; Querfeld, C; Rademaker, A; Rosen, ST; Yarosh, DB | 1 |
| Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S | 1 |
| Hirose, Y | 1 |
| Berkhof, J; Bosma, I; Buter, J; Heimans, JJ; Hoekstra, OS; Lagerwaard, FJ; Noske, DP; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Vos, MJ | 1 |
| Archer, GE; Bigner, DD; Congdon, KL; Cui, X; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sanchez-Perez, L; Schmittling, RJ; Snyder, DJ; Vredenburgh, JJ | 1 |
| Bauchet, L; Beauchesne, P; Blonski, M; Campello, C; Duffau, H; Fabbro, M; Gozé, C; Herbet, G; Kerr, C; Maldonado, IL; Moritz-Gasser, S; Rigau, V; Rudà, R; Soffietti, R; Taillandier, L | 1 |
| Cho, BK; Kim, SK; Lee, JY; Park, CK; Park, SH; Wang, KC | 1 |
| Boström, J; Glas, M; Herrlinger, U; Kim, Y; Mack, F; Rieger, J; Schäfer, N; Scheffler, B; Simon, M; Steinbach, JP; Stuplich, M; Thanendrarajan, S; Tichy, J | 1 |
| Altuntaş, Y; Çil, E; Karaman, Ö; Müslüman, AM; Özkayalar, H; Öztürk, FY; Tanik, C; Velet, S; Zuhur, SS | 1 |
| Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| de Ilarduya, AM; García-Alvarez, M; Holler, E; Lanz-Landázuri, A; Ljubimova, JY; Muñoz-Guerra, S; Patil, R; Portilla-Arias, J | 1 |
| Fukushima, T; Katayama, Y; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tashiro, S; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A | 1 |
| Bernasconi, S; Caccuri, AM; Capozzi, O; Chiorino, G; Clivio, L; D'Incalci, M; Damia, G; Di Giandomenico, S; Erba, E; Fossati, A; Fuso Nerini, I; Ganzinelli, M; Grosso, F; Mantovani, R; Marangon, E; Marchini, S; Margison, GP; Pastore, A; Rocchi, M; Romano, M; Sala, F; Tercero, JC; Uboldi, S; Watson, AJ | 1 |
| Fujimoto, Y; Hashimoto, N; Kagawa, N; Kinoshita, M; Miyazaki, Y; Takehara, T; Tanaka, S; Yakushijin, T; Yoshimine, T | 1 |
| Abysheva, SN; Bakholdin, DV; Ievleva, AG; Imianitov, EN; Luchin, EI; Matsko, DE; Matsko, MV; Potapova, ON; Ulitin, AIu; Zavgorodniaia, EV | 1 |
| Ananda, S; Brown, C; Cher, L; Dowling, A; Nowak, AK; Rosenthal, MA; Simes, J | 1 |
| Berberat, J; Bodis, S; Merlo, A; Rogers, S | 1 |
| Liu, B; Qu, L; Tao, H; Wu, Y | 1 |
| Fukuhara, N; Nishioka, H; Yamada, S | 1 |
| Demir, H; Joshi, K; Miyazaki, T; Nakano, I; Ray-Chaudhury, A; Yamada, R | 1 |
| Aguilar, LK; Aguilar-Cordova, E; Baskin, DS; Bell, SD; Cavaliere, R; Chakravarti, A; Chiocca, EA; Grecula, J; Grossman, RG; Hardcastle, J; Harris, KS; Kaur, B; Lo, S; Manzanera, AG; McGregor, J; Monterroso, C; New, PZ; Newton, H; Ray-Chaudhuri, A; Trask, TW | 1 |
| Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P | 1 |
| Buttmann, M; Flentje, M; Guckenberger, M; Mayer, M; Sweeney, RA; Vince, GH | 1 |
| Canale, S; Chassot, A; Dhermain, F; Dufour, C; Grill, J; Negretti, L; Puget, S; Raquin, MA; Rialland, X; Roujeau, T; Varlet, P | 1 |
| Borson-Chazot, F; Ducray, F; Favrel, V; Honnorat, J; Jouanneau, E; Raverot, G; Trouillas, J; Wierinckx, A | 1 |
| Akyüz, C; Büyükpamukçu, M; Demir, HA; Kutluk, T; Varan, A; Yalçin, B | 1 |
| Feng, K; Fu, Z; Shi, L; Wan, Y; Wang, Y; Wang, Z; Wu, F; Yan, W; You, Y; Zhang, J; Zhang, S | 1 |
| Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M | 1 |
| Brower, V | 1 |
| Darefsky, AS; Dubrow, R; King, JT | 1 |
| Bao, Z; Chen, L; Han, L; Jiang, T; Kang, C; Li, S; Liu, Y; Shi, Z; Wang, Y; Yan, W; Yang, P; You, G; Zhang, W | 1 |
| Delattre, JY | 1 |
| Dong, XT; Li, JM; Li, Y; Pan, Q; Wang, HM; Wang, W; Yang, XJ | 1 |
| Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S | 1 |
| Cooper, DA; Fujita, M; Goldstein, NB; Norris, DA; Partyka, KA; Reuland, SN; Shellman, YG | 1 |
| Desjardins, A; Friedman, HS; Lou, E; Peters, KB; Reardon, DA; Sampson, JH; Sumrall, A; Turner, S; Vredenburgh, JJ | 1 |
| Bianchi, F; D'Alessandris, QG; Doglietto, F; Fernandez, E; Lauretti, L; Maira, G; Montano, N; Pallini, R | 1 |
| Abdollahi, A; Combs, SE; Debus, J; Hartmann, C; Rieken, S; von Deimling, A; Wick, W | 1 |
| Ersen, A; Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H | 1 |
| Brem, H; Grossman, R; Hwang, L; Javaherian, K; Lal, B; Tyler, B; Zadnik, P | 1 |
| Chen, TC; Cho, H; Hofman, FM; Jhaveri, N; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Wang, W | 1 |
| Gillespie, GY; Griguer, CE; Moellering, DR; Oliva, CR | 1 |
| Ara, J; Chadarévian, JP; Faerber, EN; Grant, ML; Halligan, GE; Katsetos, CD; Legido, A; Morrissette, JD; Piatt, JH | 1 |
| Abastado, JP; Avril, MF; Hong, M; Huang, C; Kato, M; Loumagne, L; Mackay, C; Nardin, A; Prévost-Blondel, A; Puaux, AL; Tow, C | 1 |
| Kayama, T; Kitanaka, C; Matsuda, K; Sato, A; Seino, S; Sunayama, J; Suzuki, K; Tachibana, K; Tomiyama, A; Watanabe, E | 1 |
| Das, UN; Faragó, N; Fehér, LZ; Kitajka, K; Puskás, LG | 1 |
| Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Ishizawa, S; Kimura, M; Manome, Y; Saito, H | 1 |
| Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE | 1 |
| Adachi, J; Fukuoka, K; Matsutani, M; Mishima, K; Nishikawa, R; Sasaki, A; Suzuki, T; Wakiya, K; Yanagisawa, T | 1 |
| Day, PJ; Lee, NP; Leung, GK; Lui, WM; Ng, GK; Pu, JK; Sun, S; Wong, TS; Zhang, XQ | 1 |
| Craig, EA; Spiegelman, VS | 1 |
| Addas, A; Al-Hussaini, M; Al-Rashdan, A; Almousa, A; Alsharbaji, A; Elyan, M; Ezam, N; Hashem, SA; Mohamad, I; Nour, A; Salem, A; Sughayer, M | 1 |
| Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A | 1 |
| Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F | 1 |
| Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G | 1 |
| Beier, CP; Beier, D; Schulz, JB | 1 |
| Albanese, A; Anile, C; Balducci, M; Chiesa, S; D'Agostino, GR; De Bari, B; De Rose, F; Diletto, B; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Micciche', F; Morganti, AG; Valentini, V | 1 |
| Cheung, T; Fraser, JA; Proulx, A | 1 |
| Ahluwalia, MS | 1 |
| Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J | 1 |
| Berdel, C; Fleckenstein, J; Ketter, R; Licht, N; Niewald, M; Rübe, C | 1 |
| Gizewski, ER; Hansen, N; Hense, J; Kastrup, O; Van de Nes, JA; Wittig, A | 1 |
| Kayama, T; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Ueno, H | 1 |
| Asano, S; Fujimaki, T; Hoya, K; Ishida, Y; Matsuno, A; Murakami, M; Nakaguchi, H; Yamada, SM; Yamazaki, K | 1 |
| Fei, Y; HuiXia, H; LanXiao, W; Lei, Y; Si, G; SongTao, Q; XueLin, Z; YanQing, D | 1 |
| Desjardins, A; Sampson, JH | 1 |
| Eagan, P; Golfinos, JG; Gruber, D; Gruber, ML; Kunnakkat, S; Narayana, A; Parker, E; Raza, S; Zagzag, D | 1 |
| Franz, K; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C | 1 |
| Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA | 1 |
| Andre, N; Chinot, O; Cowen, D; Figarella Branger, D; Gentet, JC; Muracciole, X; Padovani, L; Scavarda, D; Verschuur, A | 1 |
| Johnson, DR; O'Neill, BP | 1 |
| Bastholt, L; Cantarini, M; Dummer, R; Hersey, P; Kemsley, K; Kirkwood, JM; Larkin, J; Middleton, M; Robert, C; Sosman, J; Zazulina, V | 1 |
| Arber, DA; Coutre, SE; Gotlib, J; Kohrt, HE; Medeiros, BC; Zehnder, JL; Zhang, B | 1 |
| Brown, D; Cao, Y; Chenevert, T; Gomez-Hassan, D; Heth, J; Junck, L; Lawrence, T; Normolle, D; Piert, M; Schipper, M; Ten Haken, RK; Tsien, CI | 1 |
| Chambers, CR; Lam, N | 1 |
| Bakker, A; Benedetti, G; De Rosa, A; Ferruzzi, P; Giordano, C; Magnoni, L; Magrini, R; Mennillo, F; Miragliotta, V; Mori, E; Pericot Mohr, Gl; Rossi, M; Thomas, R; Tunici, P | 1 |
| Chen, L; Han, L; Jiang, C; Jiang, T; Kang, C; Pu, P; Zhang, A; Zhang, C; Zhang, J; Zheng, Y | 1 |
| Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL | 1 |
| Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C | 1 |
| Chen, L; Han, L; Jiang, C; Jiang, T; Kang, C; Liu, Y; Pu, P; Shi, Z; Zhang, K; Zheng, Y | 1 |
| Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A | 1 |
| Lee, CC; Lin, CJ; Lin, TY; Lin, YF; Shih, CM; Shih, YL; Wang, SH | 1 |
| Chang, YL; Chen, MT; Chen, YW; Cherng, JY; Chien, Y; Chiou, GY; Chiou, SH; Huang, PI; Lo, WL; Shih, YH; Wang, ML; Yang, YP | 1 |
| Arivazhagan, A; Chandramouli, BA; Hegde, AS; Kondaiah, P; Kumar, DM; Mondal, N; Patric, IR; Prasanna, K; Rao, MR; Sagar, V; Santosh, V; Somasundaram, K; Sridevi, S; Srividya, MR; Thennarasu, K; Thota, B | 1 |
| Anderson, P; Bilton, SD; Chang, EL; Fontanilla, HP; Green, HL; Grosshans, DR; Hayes-Jordan, A; Mahajan, A; McAleer, MF; Pinnix, CC; Subbiah, V; Sulman, EP; Woo, SY | 1 |
| Bauman, GS; Cao, JQ; Fisher, BJ; Macdonald, DR; Megyesi, JF; Watling, CJ | 1 |
| Alksne, J; Cornell, M; Kesari, S; Lawson, JD; Mundt, AJ; Murphy, KT; Pan, H | 1 |
| Corbella, F; Di Liberto, R; Facoetti, A; Mazzini, G; Nano, R; Paolini, A; Pasi, F | 1 |
| Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F | 1 |
| Madhusudan, S | 1 |
| Bradshaw, TD; Stevens, MF; Zhang, J | 1 |
| Augurio, A; Buonaguidi, R; Céfaro, GA; Di Nicola, M; Galzio, RJ; Genovesi, D; Taraborrelli, M; Trignani, M; Vinciguerra, A | 1 |
| Donawho, CK; Ellis, PA; Harlan, JE; Iyer, R; Johnson, EF; Ladror, US; Liu, X; Maag, DX; Palma, JP; Patterson, MJ; Penning, TD; Ready, DB; Shi, Y; Shoemaker, AR; Solomon, LR; Soni, NB; Surber, BW; Xu, AJ | 1 |
| Casalegno-Garduno, R; Classen, CF; Enders, A; Freund, M; Linnebacher, M; Mani, J; Schmitt, A; Schmitt, M; Stockhammer, F; Xu, X | 1 |
| Afzal, P; Campbell, AP; Dixit, S; Hingorani, M | 1 |
| Gunjur, A; Lau, E; Ryan, G; Taouk, Y | 1 |
| Hirose, Y; Iwama, T; Nakayama, N; Ohe, N; Shinoda, J; Yano, H; Yoshimura, S | 1 |
| Bressler, LR; Letarte, N; Villano, JL | 1 |
| Agnihotri, S; Aldape, K; Carlson, BL; Diefes, KL; Gajadhar, AS; Gorlia, T; Guha, A; Hawkins, C; Hegi, M; Kelly, J; Margison, GP; McGown, G; Mischel, PS; Sarkaria, JN; Ternamian, C; Thorncroft, M | 1 |
| Bageritz, J; Barbus, S; Becker, N; Danner, A; Dittmann, LM; Felsberg, J; Goidts, V; Gronych, J; Grzendowski, M; Lichter, P; Reifenberger, G; Sabel, MC; Stühler, K; Tews, B; Toedt, G; Wolter, M | 1 |
| Borges, KS; Brassesco, MS; Carlotti, CG; Castro-Gamero, AM; da Silva Silveira, V; de Oliveira, HF; de Paula Queiroz, RG; Moreno, DA; Scrideli, CA; Tone, LG | 1 |
| Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S | 1 |
| Tu, Q; Wang, L; Zhou, R; Zhou, W | 1 |
| Czyż, M; Koprowska, K | 1 |
| Hirose, Y; Kanai, R; Louis, DN; Martuza, RL; Rabkin, SD; Sgubin, D; Wakimoto, H; Yip, S; Zaupa, CM | 1 |
| Deméocq, F; Halle, P; Isfan, F; Kanold, J; Kelly, A; Lang, P; Marabelle, A; Merlin, E; Paillard, C; Rochette, E; Tchirkov, A | 1 |
| Enger, PØ; Leiss, L; Li, X; Skaftnesmo, KO; Sleire, L; Wang, J; Yan, T | 1 |
| Black, J; Shen, H; Webb, S; Wheeler, H | 1 |
| Aoude, LG; Bonazzi, VF; Brooks, BR; Brown, KM; Chow, D; Dutton-Regester, K; Ellis, JJ; Gartside, MG; Gibbs, R; Hayward, NK; Kobe, B; Lanagan, C; MacKeigan, JP; Muzny, D; Newsham, I; Niemi, NM; Palmer, JM; Pollak, T; Reid, J; Schmidt, CW; Sereduk, C; Stark, MS; Tang, N; Trent, J; Tyagi, S; Woods, SL; Wu, Y; Yin, H; Youngkin, D; Zismann, V | 1 |
| Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S | 1 |
| Chen, R; Devito, N; Pan, E; Yu, M | 1 |
| Kilickap, S; Oztoprak, I; Yucel, B | 1 |
| Aaberg-Jessen, C; Christensen, KG; Jensen, PH; Jensen, SS; Kolenda, J; Kristensen, BW; Nørregaard, A; Schrøder, HD | 1 |
| Bennett, DC; Chang, PJ; Chinen, M; Cleaver, JE; Demetriou, S; Huang, ZM; Millhauser, GL; Oh, DH; Patel, MP; Scherzer, R; Sviderskaya, EV; Wei, ML; Xie, T; Zhong, L | 1 |
| Chatzisotiriou, A; Eleftheraki, AG; Fountzilas, G; Iliadis, G; Kotoula, V; Lambaki, S; Misailidou, D; Selviaridis, P; Televantou, D | 1 |
| Dunne, M; Faul, C; Fitzpatrick, D; Forde, P; McArdle, O; O'Neill, B; Rock, K | 1 |
| Bouffet, E; Maeda, M; Morioka, M; Sawamura, Y; Sugita, Y; Terasaki, M | 1 |
| Azzoli, CG; Chan, TA; Fiore, JJ; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Rizvi, NA; Sima, CS; Sumner, DK; Travis, WD | 1 |
| Behler, CM; Cha, S; Damon, LE; Hwang, J; Issa, S; McDermott, M; O'Brien, J; Rubenstein, JL; Shuman, MA; Treseler, P; Valles, F; Wieduwilt, MJ | 1 |
| Belka, C; Niyazi, M; Schwarz, SB; Suchorska, B | 1 |
| Aoki, Y; Banerjee, A; Gupta, N; Hashizume, R; James, CD; Ozawa, T; Prados, M | 1 |
| Antoniou, S; Dimitriadis, G; Economopoulos, N; Kaltsas, G; Kanakis, G; Koumarianou, A; Ntavatzikos, A; Pectasides, D; Rontogianni, D; Tsavaris, N | 1 |
| Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P | 1 |
| Ivanov, VG; Korytova, LI; Masliukova, EA; Meshechkin, AV; Zhabuna, RM | 1 |
| Abrams, J; Harlan, L; Mann, B; Yabroff, KR; Zeruto, C | 1 |
| Cenci, T; D'Alessandris, QG; De Maria, R; Larocca, LM; Maira, G; Martini, M; Montano, N; Pallini, R; Pelacchi, F; Ricci-Vitiani, L | 1 |
| Packer, RJ | 1 |
| Bady, P; Besuchet Schmutz, N; Diserens, AC; Gorlia, T; Hamou, MF; Hartmann, C; Hegi, ME; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Martinet, D; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; van den Bent, MJ; von Deimling, A; Weller, M; Wesseling, P | 1 |
| Li, Y; Qiu, R; Shi, L; Wu, W; Zhou, S; Zhu, H | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Arrieta, Ó; Ferrari-Carballo, T; Gamboa-Vignolle, C; Mohar, A | 1 |
| Alexiou, GA; Argyropoulou, MI; Fotakopoulos, G; Fotopoulos, AD; Goussia, A; Kyritsis, AP; Ntoulia, A; Tsekeris, P; Voulgaris, S; Zikou, A | 1 |
| Decker, R; Gharib, M; Gorlia, T; Lacombe, D; Lai, C; Rampling, R; Sanson, M; Stoffregen, C; Taal, W; van den Bent, MJ | 1 |
| Ewelt, C; Felsberg, J; Jakobs, O; Martus, P; Meinel, T; Reifenberger, G; Stummer, W | 1 |
| Qiu, B; Tian, A; Wang, M; Wu, A; Xue, X; Zhang, D | 1 |
| Hattermann, K; Held-Feindt, J; Mentlein, R | 1 |
| Hofstra, DE; Koo, S; Marty, FM; Shearer, JF; Sigler, L; Sutton, DA; Thompson, EH; Wickes, BL; Yeh, WW | 1 |
| Li, HQ; Liu, ZF; Tao, RJ | 1 |
| Gu, F; Li, WL; Sun, ZF | 1 |
| Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q | 1 |
| Adamson, DC; Lark, AL; Mattox, AK | 1 |
| Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW | 1 |
| Calderaro, F; Cevenini, G; Comincini, S; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M | 1 |
| Estrada-Bernal, A; Palanichamy, K; Ray Chaudhury, A; Van Brocklyn, JR | 1 |
| Bernaudin, M; Chapon, F; Colin, P; Diebold, MD; Dugué, AE; Emery, E; Guillamo, JS; Lechapt-Zalcman, E; Levallet, G; Menei, P; Peruzzy, P; Vital, A | 1 |
| Comet, B; Le Rhun, E; Ramirez, C; Reich, M | 1 |
| Adams, BR; Beckta, JM; Golding, SE; O'Connor, MJ; Rosenberg, E; Valerie, K; Wignarajah, S | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Aylwin, SJ; Barazi, S; Buchanan, CR; Dworakowska, D; Gilbert, JA; Hampton, T; King, AP; Landau, DB; Lipscomb, D; Riordan-Eva, P; Thomas, NW; Whitelaw, BC | 1 |
| Hedderich, J; Mehdorn, HM; Nabavi, A; Stark, AM; van de Bergh, J | 1 |
| Gu, K; Wang, J; Zhai, X; Zhang, J | 1 |
| Easaw, JC; Roldán Urgoiti, GB; Singh, AD | 1 |
| Brandal, P; Dahlback, HS; Håvik, AB; Heim, S; Hektoen, M; Helseth, E; Honne, H; Lind, GE; Lothe, RA; Meling, TR; Scheie, D | 1 |
| Jallo, GI; Siu, IM; Thomale, UW; Yoshimura, J | 1 |
| Berkutzki, T; Cooper, I; Mohar, B; Ruban, A; Teichberg, VI | 1 |
| Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M | 1 |
| Bromberg, JE; Kros, JM; Segers-van Rijn, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CC; van Heuvel, I | 1 |
| Dasgupta, A; Shields, JE; Spencer, HT | 1 |
| Ho, JT; Hsieh, MS; Huang, AP; Lin, LW; Perry, A; Tu, PH | 1 |
| Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M | 1 |
| Brue, T; Castinetti, F; Dufour, H; Figarella-Branger, D; Jouanneau, E; Morange, I; Raverot, G; Trouillas, J | 1 |
| Blasco, J; Bruna, J; Gil, M; Graus, F; Pineda, E; Simó, M; Velasco, R; Verger, E | 1 |
| Chang, JH; Cho, J; Kim, DS; Kim, JW; Kim, SH; Kim, YS; Lee, KS; Suh, CO | 1 |
| Bertholle, V; Billard, M; Borget, I; Brignone, M; Cartalat, S; Charlety, D; Chinot, O; Exinger, D; Gensollen, S; Hassani, Y; Labrande, C; Lahille, B; Pedeboscq, S; Pinguet, F; Prebay, D; Taillibert, S; Tilleul, P | 1 |
| Huang, H; Li, J; Lin, H; Zhang, X | 1 |
| Benner, A; Christians, A; Hartmann, C; Meyer, J; von Deimling, A; Weiler, M; Weller, M; Wick, W | 1 |
| Barker, J; Foltz, G; Honkakoski, P; Küblbeck, J; Li, W; Lin, B; Ma, L; Zhang, J; Zhou, C | 1 |
| Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T | 1 |
| Jensen, SA; Kouri, FM; Stegh, AH | 1 |
| Reidy-Lagunes, D; Thornton, R | 1 |
| Combs, SE; Debus, J; Haberer, T; Habermehl, D; Jaekel, O; Rieken, S | 1 |
| Kaina, B; Marosi, C; Neyns, B; Strik, HM | 1 |
| Chow, F; Cremer, N; Kim, W; Nagasawa, DT; Yang, I; Yew, A | 1 |
| Boockvar, JA; Burkhardt, JK; Riina, HA; Shin, BJ | 1 |
| Bedford, T; Kelly, S; McGrane, J | 1 |
| Dorjsuren, D; Jadhav, A; Maloney, DJ; Rai, G; Simeonov, A; Vyjayanti, VN; Wilson, DM | 1 |
| Itoh, T; Kanno, H; Kato, M; Kimura, T; Kubota, K; Murata, J; Nagashima, K; Nishihara, H; Oikawa, M; Ozaki, Y; Sawamura, Y; Tanaka, S; Tanino, M | 1 |
| Bouchekoua, M; Hieu, PD; Malhaire, JP; Miglierini, P; Pradier, O; Rousseau, B | 1 |
| Breneman, JC; Gerena-Lewis, M; McPherson, CM; Warnick, RE | 1 |
| Ban, HJ; Chi, SY; Kang, HW; Kim, KS; Kim, TO; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Oh, IJ | 1 |
| Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Merchant, MJ | 1 |
| Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Karl, S; Marschall, V; Vucic, D; Wagner, L; Zobel, K | 1 |
| Berger, MS; Brem, S; Browning, JE; Buckner, JC; Chang, SM; Decker, PA; Egan, KM; Fridley, BL; Hansen, HM; Jenkins, RB; Kosel, ML; Lachance, DH; Madden, MH; McCoy, LS; Nabors, LB; O'Neill, BP; Olson, JJ; Patoka, JS; Prados, MD; Rice, T; Smirnov, I; Thompson, RC; Tihan, T; Wiemels, JL; Wiencke, JK; Wrensch, MR; Xiao, Y | 1 |
| Bortoluzzi, S; Cieply, K; Fardo, DW; Hamilton, RL; Hobbs, J; Horbinski, C; Nikiforova, MN | 1 |
| Schmitt, M; Stockhammer, F; Xu, X | 1 |
| Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Rudnick, J; Yu, JS | 1 |
| Brodie, C; Brown, SL; Golembieski, WA; King, DA; Rempel, SA; Schultz, CR | 1 |
| Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A | 1 |
| Ling, Y; Wei, K; Zhong, S; Zou, F | 1 |
| Dervisis, NG; Gagnon, J; Kitchell, BE | 1 |
| Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y | 1 |
| Addasi, A; Al-Hussaini, M; Al-Rashdan, A; Almousa, A; Alsharbaji, A; Elyan, M; Ezam, N; Hashem, SA; Mohamad, I; Nour, A; Rejeeth, C; Salem, A; Sughayer, M | 1 |
| Jo, MY; Joo, KM; Kim, HH; Kim, MH; Kim, Y; Kim, YG; Lee, SJ; Nam, DH | 1 |
| Beagley, L; Crough, T; Jones, L; Khanna, R; Smith, C; Walker, DG | 1 |
| Kloet, A; Schipper, MH; Taphoorn, MJ; van Duinen, SG; Vecht, CJ; Walchenbach, R; Wiggenraad, RG | 1 |
| Bai, Y; Chen, H; Miao, Y; Qiu, Y; Shen, J; Wu, B; Xu, Y; Ye, M | 1 |
| Falchi, L; Ferranti, L; Gunnellini, M; Liberati, AM | 1 |
| Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X | 1 |
| Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D | 1 |
| Abe, S; Azuma, A; Fujita, K; Gemma, A; Hayashi, H; Kobayashi, K; Kokuho, N; Morimoto, T; Saito, Y; Tanaka, T | 1 |
| Gu, X; Pan, T; Qian, C; Shi, L; Sun, G; Sun, L; Wan, Y; Wang, Z; Xiang, Y; Zhang, S | 1 |
| Guo, RB; Hu, G; Sun, XL; Xue, X; Yuan, Y | 1 |
| Itoh, T; Kimura, T; Kohsaka, S; Mahabir, R; Narita, T; Nishihara, H; Tanaka, S; Tanino, M; Wang, L; Yachi, K | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Johnson, TD; Lawrence, TS; Lemasson, B; Leopold, JS; Li, F; Mikkelsen, T; Rehemtulla, A; Ross, BD; Williams, TM | 1 |
| André, N; Bajciova, V; Deak, L; Demlova, R; Doubek, M; Dubska, L; Husek, K; Kepak, T; Kutnikova, L; Kyr, M; Martincekova, A; Mazanek, P; Mudry, P; Pavelka, Z; Skotakova, J; Sterba, J; Valik, D; Zapletalova, D; Zitterbart, K | 1 |
| Bertoni, F; Biti, G; Buglione, M; Cipressi, S; Dall'oglio, S; de Renzis, C; Detti, B; Fariselli, L; Fusco, V; Krengli, M; Lioce, M; Magrini, SM; Mantovani, C; Masini, L; Muto, P; Parisi, S; Pirtoli, L; Ricardi, U; Rubino, G; Saieva, C; Santoni, R; Scoccianti, S; Sotti, G; Tombolini, V | 1 |
| Hara, K; Kageji, T; Kitazato, KT; Kuwayama, K; Matsuzaki, K; Mizobuchi, Y; Morigaki, R; Mure, H; Nagahiro, S; Okazaki, T | 1 |
| Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J | 1 |
| Mohammad Alizadeh, A; Zamani, N | 1 |
| Bar-Deroma, R; Baumert, BG; Fairchild, A; Fenton, PA; Gulyban, A; Stupp, R; Weber, DC | 1 |
| Florea, AM; Happold, C; Reifenberger, G; Roth, P; Schmidt, N; Silginer, M; Weller, M; Wick, W | 1 |
| Chen, CC; Hoadley, K; Jiang, C; Jiang, T; Kang, C; Kushwaha, D; Li, S; Ramakrishnan, V; Song, SW; You, Y; Zhang, J; Zhang, W | 1 |
| Baek, HJ; Choi, HS; Jung, TY; Kim, CY; Kim, DS; Kim, IA; Kim, SH; Ra, YS | 1 |
| Braun, C; Combs, SE; Felsberg, J; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Nikkhah, G; Papsdorf, K; Platten, M; Reifenberger, G; Sabel, M; Simon, M; Steinbach, JP; Tabatabai, G; Vesper, J; Weller, M; Wick, W | 1 |
| Caivano, R; Chiumento, C; Clemente, S; Cozzolino, M; Fiorentino, A; Fusco, V; Pedicini, P | 1 |
| Bonizzoni, E; Detti, B; Fabrini, MG; Lolli, I; Paccapelo, A; Perrone, F; Perrone, T; Santoni, M; Savio, G; Scoccianti, S; Silvano, G | 1 |
| Fadul, CE; Horvath, E; Kovacs, K; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H | 1 |
| Barceló-Coblijn, G; Busquets, X; Escribá, PV; García-Verdugo, JM; Gómez-Pinedo, U; Higuera, M; Lladó, V; Marcilla-Etxenike, A; Martin, ML; Noguera-Salvà, MA; Saus, C; Soriano-Navarro, M; Terés, S | 1 |
| Bow, H; Brem, H; Cima, MJ; Langer, R; Masi, BC; Tyler, BM; Wicks, RT; Xue, Y | 1 |
| Bossert, C; Chastagner, P; Dontenwill, M; Entz-Werle, N; Godet, J; Guenot, D; Guerin, E; Janouskova, H; Leger, DY; Lehmann-Che, J; Maglott, A; Martin, S; Noulet, F; Pinel, S; Plenat, F; Teisinger, J | 1 |
| Bjerkvig, R; Johannessen, TC | 1 |
| Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP | 1 |
| Dummer, R; Michielin, O; Mihic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schraml, P; Seifert, B; Simcock, M; von Moos, R; von Teichman, A | 1 |
| Babu, NJ; Nangia, A; Sanphui, P | 1 |
| Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M | 1 |
| Brodeur, GM; Brown, JL; Evans, AE; Ho, R; Iyer, R; Light, JE; Minturn, JE; Simpson, AM; Thress, K; Varela, CR; Zhao, H | 1 |
| Beard, BC; Gori, JL; Ironside, C; Karponi, G; Kiem, HP | 1 |
| Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G | 1 |
| Chang, SM; Johnson, DR | 1 |
| Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P | 1 |
| Hargreaves, S; Kooner, I; Liu, ZW; Menashy, R; Michalarea, V; Williams, M; Wilson, E; Woolf, D | 1 |
| Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY | 1 |
| Atlani, D; Aumont, M; Bernier, V; Bondiau, PY; Clavier, JB; Collin, P; D'Hombres, A; de Crevoisier, R; Durando, X; Feuvret, L; Henzen, C; Huchet, A; Kerr, C; Lagrange, JL; Le Rhun, E; Maire, JP; Missohou, F; Noel, G; Sunyach, MP; Taillandier, L; Thillays, F; Truc, G; Verrelle, P; Vinchon-Petit, S | 1 |
| Franz, K; Güresir, E; Oszvald, Á; Quick, J; Seifert, V; Szelényi, A; Vatter, H | 1 |
| Abrey, LE; Aldape, KD; Ashby, LS; Cairncross, JG; Chamberlain, MC; Cloughesy, TF; Deangelis, LM; Eichler, AF; Fisher, BJ; Green, RM; Iwamoto, FM; Jhanwar, SC; Kamar, FG; Lassman, AB; Ligon, KL; Louis, DN; Mason, WP; Paleologos, NA; Panageas, KS; Rivera, AL; Robins, HI; Rocque, BG; Roldán Urgoiti, GB; Rosenblum, MK; Schiff, D; Weaver, SA; Wen, PY | 1 |
| Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K | 1 |
| Anile, C; Balducci, M; Chiesa, S; Colicchio, G; D'Agostino, GR; De Bari, B; De Bonis, P; Fiorentino, A; Frascino, V; Gambacorta, MA; Manfrida, S; Mangiola, A; Mantini, G; Mattiucci, GC; Miccichè, F; Morganti, AG; Valentini, V | 1 |
| Carlson, BL; Cen, L; Decker, PA; Gupta, SK; Kitange, GJ; Lomberk, GA; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Urrutia, RA; Wu, W | 1 |
| Gavrilovic, IT; Kaley, TJ; Mondesire-Crump, I | 1 |
| Chen, C; Chen, J; Lu, Y; Wu, S; Xu, T | 1 |
| Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M | 1 |
| Barker, CA; Beal, K; Chang, M; Chou, JF; Gutin, PH; Iwamoto, FM; Zhang, Z | 1 |
| Filss, C; Glas, M; Hadizadeh, DR; Herrlinger, U; Kuchelmeister, K; Langen, KJ; Mack, F; Pietsch, T; Schäfer, N; Schüller, H; Scorzin, J; Simon, M; Stuplich, M; Urbach, H | 1 |
| Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS | 1 |
| Fernández de Mattos, S; Ramis, G; Rodríguez, J; Thomàs-Moyà, E; Villalonga, P | 1 |
| Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW | 1 |
| Barr, JG; Grundy, PL | 1 |
| Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A | 1 |
| Goldenberg, F; Lukas, RV; Nicholas, MK | 1 |
| Brandes, AA; Laperriere, N; Perry, JR; Stupp, R; van den Bent, MJ; Weller, M; Wick, W | 1 |
| Ak, S; Bilir, A; Cecener, G; Egeli, U; Malyer, H; Tezcan, G; Tumen, G; Tunca, B | 1 |
| Eckrich, MJ; Engel, ME; Lowas, S; Mixon, BA | 1 |
| Chen, JX; Ding, XH; Dong, Y; He, H; Hu, GH; Li, B; Lu, YC; Luo, C; Sheng, P; Tao, BB; Zhang, L; Zhao, ZY | 1 |
| Gerson, SL; Liu, L; Savvides, P; Xu, Y; Yang, S | 1 |
| Chammas, R; da Silva, R; Gimenez, M; Izumi, C; Laure, HJ; Marie, SK; Oba-Shinjo, SM; Otake, A; Rosa, JC; Uno, M | 1 |
| Chen, TH; Lee, CC; Lin, CH; Lin, CJ; Shih, CM; Shih, YL; Wang, SH | 1 |
| Harasaki, Y; Waziri, A | 1 |
| Kirova, Y; Tallet, A | 1 |
| Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S | 1 |
| Chan, HL; Leung, GK; Li, CH; Wong, ST; Zhang, XQ; Zhuang, JT | 1 |
| Algharabil, J; Begum, G; Clark, PA; Kahle, KT; Kintner, DB; Kuo, JS; Lin, SH; Sun, D; Wang, Q; Yang, SS | 1 |
| Doñate, F; Fruehauf, JP; Lee, K; Mazar, AP; Trapp, V | 1 |
| Fung, CF; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Wong, ST | 1 |
| Li, S; Liu, Y; Sun, P; Ying, H | 1 |
| Bauer, M; Goldstein, M; Heylmann, D; Kaina, B | 1 |
| Bhargava, P; Blaszkowsky, L; Chan, JA; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Miksad, R; Stuart, K; Zheng, H | 1 |
| Jiang, G; Li, LT; Liu, YQ; Xin, Y; Zhang, L; Zheng, JN | 1 |
| Engh, JA; Faraji, AH; Horowitz, M; Lunsford, LD; Park, DM | 1 |
| Clifton-Bligh, R; Cook, R; Gill, AJ; Kaplan, W; Little, N; McCormack, A; Robinson, B | 1 |
| He, F; Song, S; Tian, C; Wang, J; Wang, S; Xing, G; Yin, Y; Yuan, L; Zhang, L | 1 |
| Boxerman, J; Jeyapalan, S; Raghavan, D; Rogg, J | 1 |
| Groves, MD; Plummer, AB | 1 |
| Li, S; Xie, Q; Zhang, W; Zheng, X | 1 |
| Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E | 1 |
| Chen, Y; Cui, B; Dai, X; Dong, J; Huang, Q; Lan, Q; Tang, D; Zhang, J; Zhou, G | 1 |
| Akers, KG; Frankland, PW; Josselyn, SA; Martinez-Canabal, A | 1 |
| Montaldi, AP; Sakamoto-Hojo, ET | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Cortes, U; Karayan-Tapon, L; Marquant, C; Martin, S; Rivet, P; Tourani, JM; Turhan, AG; Villalva, C; Wager, M | 1 |
| Baker, L; Dixit, S; Hingorani, M; Walmsley, V | 1 |
| Kang, C; Long, L; Pu, P; Qian, X; Ren, Y; Sheng, J; Shi, Z; Yuan, X | 1 |
| Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS | 1 |
| Groll, MJ; Kapp, KS; Langsenlehner, T; Mokry, M; Payer, F; Quehenberger, F | 1 |
| Cipak, L | 1 |
| Helseth, E; Johannesen, TB; Meling, TR; Rønning, PA | 1 |
| Akers, J; Carter, BS; Carvajal, I; Chakravarti, A; Chen, CC; Furfine, E; Futalan, D; Gonda, DD; Marsh, N; Morse, B; Palanichamy, K; Sahin, A; Sanchez, C; Scheer, JK; Waterman, P; Waters, JD; Weissleder, R | 1 |
| Buckner, JC; Meyer, FB; Parney, IF; Tanaka, S; Uhm, JH; Yan, ES | 1 |
| Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ | 1 |
| Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B | 1 |
| Cloughesy, T; Nghiemphu, PL | 1 |
| Paci, A; Vassal, G | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS | 1 |
| Chen, Y; Dallaglio, K; Fujita, M; Gonzalez, R; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Thompson, DC; Vasiliou, V; Wang, J | 1 |
| Matsko, MV | 1 |
| Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E | 1 |
| Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; Iodice, P; Lombardi, A; Montella, L; Parlato, C; Prete, SD; Russo, P; Salzano, A; Sperlongano, P; Sperlongano, R; Vincenzi, B | 1 |
| Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V | 1 |
| Easaw, JC; Gui, X; Miller, RJ; Tsang, RY | 1 |
| Otty, Z; Sabesan, S | 1 |
| Chang, NS; Chen, YJ; Chiang, MF; Liao, HF; Yeh, ST | 1 |
| Aguilar, LK; Aguilar-Cordova, E; Arvizu, M; Chiocca, EA | 1 |
| Cao, K; Li, QY; Lu, PS; Lu, XY; Yuan, ZC | 1 |
| Fortin, MA; Pouliot, JF; Roberge, D; Souhami, L | 1 |
| Faivre, S; Hammel, P; Hentic, O; Neuzillet, C; Raymond, E; Ruszniewski, P | 1 |
| Annibali, D; Bianchi, F; Cenci, T; D'Alessandris, QG; Falchetti, ML; Larocca, LM; Martini, M; Montano, N; Nasi, S; Pallini, R; Pierconti, F; Savino, M | 1 |
| Ducray, F; Lekoubou, A; Viaccoz, A | 1 |
| Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Gilbertson, RJ; Graham, TA | 1 |
| Bannykh, SI; Black, KL; Elramsisy, A; Hu, J; Irvin, DK; Mukherjee, D; Nuño, M; Patil, CG; Yi, A; Yu, JS | 1 |
| Chedid, K; Hong, X; Kalkanis, SN | 1 |
| Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK | 1 |
| Bleeker-Rovers, CP; De Vos, FY; Gijtenbeek, JM; van Herpen, CM | 1 |
| Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K | 1 |
| Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T | 1 |
| Appel, EA; Heywood, RM; Loh, XJ; Rowland, MJ; Scherman, OA; Watts, C | 1 |
| Bagriacik, EU; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Ozet, A; Uslu, K; Yaman, M | 1 |
| Escalon, E; Melnick, SJ; Nair, SM; Ramachandran, C | 1 |
| Degenhardt, YY; Diskin, SJ; Haglund, E; Maris, JM; Mayes, PA; Moy, C; Toporovskya, Y; Wood, A; Wooster, R | 1 |
| Federspiel, B; Hansen, CP; Kjaer, A; Knigge, U; Langer, SW; Olsen, IH; Sørensen, JB | 1 |
| Baumert, BG; Fedrigo, CA; Narayan, RS; Sminia, P; Stalpers, LJ | 1 |
| Brewer, J; Hitchins, MP; Kuroiwa-Trzmielina, J; Lu, D; McDonald, KL; Nozue, K; Olivier, J; Rapkins, RW; Tiwari, S; Wheeler, HR; Zhao, L | 1 |
| Bacolod, MD; Fedier, A; Friedman, HS; Grotzer, MA; Hagel, C; Heinimann, K; Kool, M; Kordes, U; Koster, J; Marra, G; Pietsch, T; Rutkowski, S; von Bueren, AO | 1 |
| Huang, S; Huang, Z; Wu, X; Xiao, F; Yang, L; Zhang, H; Zhang, N; Zhou, A | 1 |
| Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R | 1 |
| Masood, N; Osmani, AH | 1 |
| Geng, J; Luo, H; Pu, Y; Wu, X; Xu, W; Yang, Z; Zhou, Z | 1 |
| Beal, K; Chan, TA; Gutin, PH; Lassman, AB; Reyngold, M; Yamada, Y | 1 |
| Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M | 1 |
| Homicsko, K; Hottinger, AF; Lhermitte, B; Negretti, L; Stupp, R | 1 |
| Bao, Z; Chen, CC; Jiang, C; Jiang, T; Kang, C; Li, S; Song, SW; Yan, W; You, G; You, Y; Zhang, J; Zhang, W; Zhang, Y | 1 |
| Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F | 1 |
| Cher, L; Gan, HK; Wong, SF | 1 |
| Hoshimaru, M; Kawanabe, Y; Kihara, S; Koizumi, T; Sasaki, N; Sawada, M; Ueda, S; Yukawa, H | 1 |
| Koekkoek, JA; Oosterkamp, HM; Oosterkamp, RM; Taphoorn, MJ; Wiggenraad, RG; Zwinkels, H | 1 |
| Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R | 1 |
| Burbach, GJ; Vajkoczy, P; Zuberbier, T | 1 |
| Allgayer, H; Fruehauf, S; Heckmann, D; Laufs, S; Maier, P; Spier, I; Wenz, F; Zeller, WJ; Zucknick, M | 1 |
| Begley, TJ; Braganza, A; Brown, AR; Dyavaiah, M; Lazo, JS; Li, J; Maniar, S; McDonald, PR; Pollack, IF; Shun, TY; Sobol, RW; St Croix, CM; Svilar, D; Tang, JB; Wang, XH | 1 |
| Anderson, ML; Nokia, MS; Shors, TJ | 1 |
| Stupp, R; Weller, M | 1 |
| Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K | 1 |
| Bressel, M; Gunjur, A; Ryan, G | 1 |
| Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S | 1 |
| Auman, JT; Brown, CC; Havener, TM; Krauss, RM; Mangravite, LM; McLeod, HL; Medina, MW; Motsinger-Reif, AA | 1 |
| Chen, J; Grogan, PT; Mladek, AC; Nadkarni, A; Sarkaria, JN; Schwingler, PM; Shrivastav, M | 1 |
| Guiot, MC; Panet-Raymond, V; Petrecca, K; Souhami, L | 1 |
| Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM | 1 |
| Caporello, P; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| Miyakita, Y; Nagai, S; Narita, Y; Ohno, M; Okita, Y; Shibui, S | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Ersen, A; Horvath, E; Kovacs, K; Ortiz, LD; Penagos, L; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H | 1 |
| Abbadi, S; Basso, G; Della Puppa, A; Frasson, C; Indraccolo, S; Persano, L; Pistollato, F; Rampazzo, E; Scienza, R; Volpin, F | 1 |
| Claringbold, PG; Price, RA; Turner, JH | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Bigner, DD; Friedman, HS; Gray, LA; Keir, ST; Reardon, DA | 1 |
| Matsuo, H; Nagatani, K; Nakanishi, K; Nawashiro, H; Osada, H; Otani, N; Shimazaki, H; Shinomiya, N; Takeuchi, S; Toyooka, T; Uozumi, Y; Wada, K | 1 |
| Alonso-Llamazares, A; Beitia-Mazuecos, JM; Cardenas-Contreras, R; Mateo-Borrega, B; Vega-Castro, A | 1 |
| Kawai, N; Miyake, K; Okada, M; Shinomiya, A; Tamiya, T | 1 |
| Hewer, E; Kappeler, A; Reinert, MM; Vajtai, I; Vassella, E | 1 |
| Fujii, T; Saito, N; Takahashi, K; Tanaka, M; Todo, T; Tsuno, NH | 1 |
| Ahmed, AS; Dellinger, RW; Duong, PH; Matundan, HH; Meyskens, FL | 1 |
| Chen, R; Chen, W; Chou, AP; Cloughesy, T; Deng, Y; Everson, RG; Faull, KF; Lai, A; Li, S; Liau, LM; Lou, JJ; Phillips, HS; Selfridge, J; Wu, KC; Zurayk, M | 1 |
| Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Fan, X; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Yu, JS | 1 |
| Barré, L; Bernaudin, M; Corroyer-Dulmont, A; Delamare, J; Divoux, D; Guillamo, JS; Ibazizène, M; Jacobs, AH; Lecocq, M; MacKenzie, ET; Pérès, EA; Petit, E; Roussel, S; Toutain, J; Valable, S; Varoqueaux, N | 1 |
| Cuellar, S; Popa, AM; Radhakrishnan, L; Valla, K; Villano, JL | 1 |
| Payne, CA; Safdar, S; Taite, LJ; Tu, NH | 1 |
| Cong, ZX; Ji, XJ; Li, N; Li, WC; Pan, H; Wang, HD; Wang, JW; Zhou, Y; Zhu, L | 1 |
| De Sanctis, V; Di Stefano, D; Enrici, RM; Esposito, V; Falco, T; Lanzetta, G; Minniti, G; Scaringi, C | 1 |
| Beier, CP; Bettstetter, M; Gempt, J; Hoepner, I; Koeritzer, J; Meyer, B; Rasper, M; Ringel, F; Schäfer, A; Schlegel, J; Schmidt-Graf, F; Teufel, J | 1 |
| Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H | 1 |
| Frishman, C; Marrinan, J; Sampath, P; Sengupta, S | 1 |
| Bartolotti, M; Brandes, AA | 1 |
| Lopes, IC; Oliveira, SC; Oliveira-Brett, AM | 1 |
| Ding, W; Jiang, H; Li, WP; Qian, C; Wu, BJ; Zhou, ZW | 1 |
| Carlin, SM; Hooker, JM; Moseley, CK; Neelamegam, R | 1 |
| Goto, Y; Hashimoto, N; Kagawa, N; Khoo, HM; Kinoshita, M; Kishima, H; Maruno, M; Yoshimine, T | 1 |
| Anderluh, G; Assunção, Fdos S; Biasoli, D; de Souza, JM; Frauches, AC; Garcia, C; Geraldo, LH; Kahn, SA; Lima, FR; Moura-Neto, V; Pontes, B; Romão, L; Sobrinho, M; Soletti, RC; Tovar-Moll, F | 1 |
| Consales, A; Garrè, ML; Morana, G; Nozza, P; Piccardo, A; Rossi, A | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Arcella, A; Battaglia, G; Bonelli, M; Ciceroni, C; De Maria, R; Larocca, LM; Laurenza, M; Mastrantoni, E; Melchiorri, D; Niccolini, C; Nicoletti, F; Pallini, R; Ricci-Vitiani, L; Spinsanti, P; Traficante, A | 1 |
| Hatanaka, Y; Kanno, H; Kato, Y; Kimura, T; Mohri, H; Nishihara, H; Tanaka, S; Tanino, M; Yuzawa, S | 1 |
| Caivano, R; Chiumento, C; Cozzolino, M; Fiorentino, A; Fusco, V; Pedicini, P | 1 |
| Aydincak, O; Baykaner, K; Emmez, H; Kurt, G; Memis, L; Sepici, A; Yilmaz, MB | 1 |
| Chan, MD; Debinski, W; Ellis, TL; Hinson, WH; Johnson, AJ; Kearns, WT; Lesser, GJ; McMullen, KP; Paulsson, AK; Peiffer, AM; Shaw, EG; Tatter, SB | 1 |
| Akers, KG; Epp, JR; Frankland, PW; Josselyn, SA; Niibori, Y; Yu, TS | 1 |
| Conjeevaram, HS; Grant, LM; Kleiner, DE; Lee, WM; Vuppalanchi, R | 1 |
| Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E | 1 |
| Chen, JX; Liu, YH; Mao, Q; Wang, X; You, C | 1 |
| Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y | 1 |
| Bauer, R; Freyschlag, CF; Kerschbaumer, J; Obwegeser, AA; Schubert, GA; Seiz, M; Thomé, C | 1 |
| Bharwani, L; Vellayappan, BA | 1 |
| Chen, LY; Han, L; Kang, CS; Liu, CY; Pu, PY; Qian, XM; Shi, ZD; Yuan, XB; Zhang, JX; Zhang, KL | 1 |
| Fine, RL; Gulati, AP; Krantz, B; Moss, RA; Mowatt, KB; Moyal, WN; Schreibman, S; Tsushima, DA | 1 |
| Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA | 1 |
| Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C | 1 |
| Cance, WG; Eliceiri, BP; Golubovskaya, VM; Ho, B; Huang, G; Lee, J; Morrison, CD; Yemma, M | 1 |
| Alvarez, PJ; Aránega, A; Concha, A; González, B; López, R; Madeddu, R; Melguizo, C; Oliver, JA; Ortiz, R; Perazzoli, G; Prados, J; Rodríguez-Serrano, F | 1 |
| Kimura, T; Kohsaka, S; Nishihara, H; Takahashi, K; Tanaka, S; Tanino, M; Wang, L | 1 |
| Aguilera, DG; Esiashivilli, N; Hayes, L; Janns, A; Jordan, C; Macdonald, TJ; Mazewski, C | 1 |
| Fountzilas, G; Hytiroglou, P; Iliadis, G; Karkavelas, G; Kotoula, V; Lampaki, S; Polyzoidis, KS; Selviaridis, P; Televantou, D | 1 |
| Chen, FR; Chen, ZP; Li, C; Shao, CJ; Wu, MW; Xia, YF | 1 |
| Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G | 1 |
| Bjerkvig, R; Grudic, A; Hegi, ME; Johannessen, TC; Prestegarden, L; Tysnes, BB | 1 |
| Ascierto, PA; Atzori, MG; Bonmassar, E; Caporali, S; D'Atri, S; Graziani, G; Levati, L; Muzi, A; Palmieri, G | 1 |
| Brown, PD; Gilbert, MR; McAleer, MF; Prabhu, SS; Walker, GV | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hoffman, RM; Momiyama, M; Suetsugu, A | 1 |
| Cloughesy, TF; Ellingson, BM; Lai, A; Liau, LM; Nghiemphu, PL; Pope, WB | 1 |
| Chen, J; Xu, T | 1 |
| Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J | 1 |
| Berry, I; Cassol, E; Celsis, P; Cohen-Jonathan, EM; Delannes, M; Filleron, T; Franceries, X; Ken, S; Laprie, A; Lotterie, JA; Lubrano, V; Simon, L; Supper, C; Vieillevigne, L | 1 |
| Chang-Chien, YC; Chen, MH; Guo, WY; Ho, DM; Ho, HL; Hsu, CY; Hsu, SP; Lin, SC; Yen, YS | 1 |
| Björklund, P; Crona, J; Granberg, D; Kozlovacki, G; Oberg, K; Welin, S | 1 |
| Jiang, Y; Sun, Y; Yuan, Y | 1 |
| Enk, AH; Gronau, M; Hassel, JC; Jäger, D | 1 |
| Chen, J; Hu, G; Lu, Y; Luo, C; Qian, J; Wang, J; Wang, Q | 1 |
| Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D | 1 |
| Blackwood, R; Brown, M; Harmon, M; Lesser, G; Lovato, J; Strowd, RE; Yalcinkaya, T | 1 |
| Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY | 1 |
| Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J | 1 |
| Borges, KS; Carlotti, CG; Castro-Gamero, AM; de Oliveira, HF; de Paula Gomes Queiroz, R; Fujinami, MM; Moreno, DA; Scrideli, CA; Suazo, VK; Tone, LG | 1 |
| Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M | 1 |
| Jang, WY; Jeong, EH; Jung, S; Jung, TY; Kim, IY; Lee, JH; Moon, KS | 1 |
| Fraefel, C; Fricke, IB; Jacobs, AH; Kuhlmann, MT; Monfared, P; Schelhaas, S; Viel, T | 1 |
| Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR | 1 |
| Bowersock, J; Dasgupta, A; Gillespie, GY; Johnson, A; Lamb, LS; Spencer, HT; Su, Y | 1 |
| Bi, ZF; He, Y; Liao, K; Liu, YM | 1 |
| Ancheta, K; Buchanan, C; Carrillo, JA; Chen, W; Chou, AP; Chowdhury, R; Cloughesy, TF; Elashoff, RM; Ellingson, BM; Green, R; Hanna, R; Khanlou, N; Lai, A; Lalezari, J; Lalezari, S; Li, S; Liau, LM; Lou, JJ; Miller, P; Mischel, PS; Nghiemphu, PL; Ormiston, L; Piccioni, D; Pope, WB; Sanchez, DE; Selfridge, J; Solis, OE; Tran, A; Wang, HJ; Wilson, RW; Yong, WH; Zurayk, M | 1 |
| Arce Abaitua, B; Blumenfeld Olivares, JA; Cormenzana Carpio, M; Hernández-Marqués, C; Lassaletta-Atienza, A; Madero Lopez, L; Ruiz Hernández, A | 1 |
| Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wu, J | 1 |
| Jiang, R; Li, X; Sun, J; Wang, Z; Yang, S; Yang, W; Yang, X; Yue, S; Zhang, J; Zhu, T | 1 |
| Egensperger, R; Hinske, LC; Hoefig, K; Kreth, FW; Kreth, S; Limbeck, E; Schütz, SV; Thon, N | 1 |
| Albanese, C; Alzani, R; Amboldi, N; Brasca, M; Ciomei, M; Degrassi, A; Festuccia, C; Fiorentini, F; Galvani, A; Gravina, G; Mercurio, C; Pastori, W; Pesenti, E | 1 |
| Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL | 1 |
| Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K | 1 |
| Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M | 1 |
| Alagu, J; Araki, A; Inoue, M; Itami, M; Iuchi, T; Kageyama, H; Nakagawara, A; Ohira, M; Saeki, N; Suenaga, Y; Takatori, A; Yamaki, T; Yokoi, S | 1 |
| Amano, K; Arita, K; Asano, K; Fujio, S; Fukuhara, N; Hirohata, T; Hizuka, N; Ikeda, H; Ishii, Y; Isozaki, O; Iwai, Y; Kawamata, T; Matsuno, A; Nishioka, H; Ogawa, Y; Osamura, RY; Sakata, K; Shimatsu, A; Tahara, S; Takano, K; Takano, S; Teramoto, A; Tominaga, A; Yamada, S | 1 |
| Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA | 1 |
| Choi, SH; Heo, DS; Jung, HW; Kim, IH; Kim, TM; Lee, SH; Park, CK; Park, SH | 1 |
| Aguilar, HN; Hung, RW; Kotylak, T; Mehta, V | 1 |
| Christmann, M; Kaina, B; Knizhnik, AV; Nikolova, T; Quiros, S; Roos, WP; Tomaszowski, KH | 1 |
| Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H | 1 |
| Brookes, C; Cruickshank, G; Jones, B; Sanghera, P; Senthil, L; Sherriff, J; Spooner, D; Tamangani, J | 1 |
| Conroy, J; Golubovskaya, V; Ho, B; Huang, G; Liu, S; Qiang, H | 1 |
| Boxerman, J; Cielo, D; Constantinou, M; Dipetrillo, T; Donahue, J; Elinzano, H; Evans, D; Goldman, M; Isdale, D; Jeyapalan, S; Kinsella, T; Mantripragada, K; Oyelese, A; Puthawala, Y; Rosati, K; Safran, H; Santaniello, A; Stopa, E | 1 |
| Anile, C; Autorino, R; Balducci, M; Chiesa, S; Ciurlia, E; De Bonis, P; De Filippo, L; De Rose, F; Diletto, B; Fersino, S; Fiorentino, A; Fusco, V; Mangiola, A; Matteucci, P; Rinaldi, C; Valentini, V | 1 |
| Alacacioglu, A; Canpolat, S; Coskun, A; Karatas, A; Oztekin, O; Postaci, H; Sop, G; Unal, S; Yurt, A | 1 |
| André, N; Barbolosi, D; Faivre, C; Pasquier, E | 1 |
| Dixit, S; Hingorani, M; Rajaraman, C; Rowland-Hill, C; Salvage, D | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ | 1 |
| Banasavadi-Siddegowda, Y; Beullens, M; Chow, LM; Joshi, K; Kig, C; Kim, SH; Kornblum, HI; Mao, P; Mo, X; Nakano, I; Nardini, D; Sobol, RW; Waclaw, R | 1 |
| Bigner, DD; Choudhury, GR; Ghorpade, A; Keir, ST; Li, W; Liu, R; Poteet, E; Ryou, MG; Simpkins, JW; Tang, L; Wen, Y; Winters, A; Yan, H; Yang, SH; Yuan, F | 1 |
| Nelson, B | 1 |
| Agarwal, A; Jain, R; Kumar, S; Mikkelsen, T; Narang, J; Poptani, H; Schultz, L; Siddiqui, S; Wang, S | 1 |
| Felsberg, J; Goeppert, M; Rapp, M; Sabel, M; Steiger, HJ | 1 |
| Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH | 1 |
| Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W | 1 |
| Fiveash, JB; Friedman, GK; Harrison, DK; Reddy, AT; Spiller, SE | 1 |
| Braca, J; Kovanda, T; Prabhu, V | 1 |
| Carlson, GW; Crocker, IR; Delman, KA; Khan, MK; Lawson, DH; Lowe, M; Marcus, DM; Maynard, N; Melton, A; Rizzo, M; Shelton, JW | 1 |
| Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Tian, H; Zheng, JN | 1 |
| Farinotti, R; Fernandez, C; Goldwirt, L; Zahr, N | 1 |
| Doyle, TJ; Glynne-Jones, R; Grávalos, C; Hochhauser, D; Pathiraja, K; Potter, V; Sausville, EA; Zhang, L; Zhang, Q | 1 |
| Day, PJ; Fung, CF; Ho, AS; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Zhang, XQ | 1 |
| Borawska, MH; Car, H; Fiedorowicz, A; Markiewicz-Żukowska, R; Naliwajko, SK; Sawicka, D | 1 |
| Botti, A; Cagni, E; Ciammella, P; D'Abbiero, N; Galeandro, M; Iori, M; Iotti, C; Pisanello, A; Podgornii, A | 1 |
| Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X | 1 |
| Asano, K; Katayama, K; Kurose, A; Naraoka, M; Ogasawara, Y; Ohkuma, H; Shimamura, N | 1 |
| Aguas, J; Barceló, I; Belenguer, A; Brell, M; Bruna, J; Crespo, JA; de Andrés, P; Erro, E; Escudero, D; Estela, J; Fuentes, R; García-Castaño, A; García-Romero, JC; Gelabert, M; Gil, M; Graus, F; Henríquez, I; Lema, M; Manzano, A; Martino, J; Mas, G; Mata, E; Muñoz-Carmona, D; Murcia, M; Navas, I; Pardo, J; Pascual, C; Pérez, P; Rojas-Marcos, I; Simón, A; Verger, E; Vilas, D; Vivanco, R | 1 |
| Deangelis, LM; Deutsch, MB; Lassman, AB; Panageas, KS | 1 |
| Biris, AS; Bratu, I; Casciano, D; Florea, A; Florian, S; Olenic, L; Orza, A; Pall, E; Pana, O; Soriţău, O; Tomuleasa, C | 1 |
| Batisse, M; Chazal, J; Durando, X; Kemeny, JL; Maqdasy, S; Montoriol, PF; Raverot, G; Sturm, N; Tauveron, I; Trouillas, J | 1 |
| Baron, MH; Bauchet, L; Beauchesne, P; Blonski, M; Darlix, A; Duffau, H; Fabbro, M; Fontaine, D; Gozé, C; Mandonnet, E; Pallud, J; Peruzzi, P; Rigau, V; Taillandier, L | 1 |
| Anderson, SK; Ballman, KV; Carlson, BL; Cen, L; Decker, PA; Giannini, C; Grogan, PT; Kitange, GJ; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Cliby, WA; Janco, JM; Markovic, SN; Weaver, AL | 1 |
| Grah, JJ; Juretic, A; Katalinic, D; Paladino, J; Plestina, S; Santek, F; Stern-Padovan, R; Supe, M; Zarkovic, K | 1 |
| Auf, G; Bayerl, SH; Broggini, T; Bruenner, J; Czabanka, M; Harms, C; Harms, U; Heppner, FL; Jabouille, A; Koch, A; Kremenetskaia, I; Mueller, S; Nieminen, M; Parmaksiz, G; Topalovic, M; Vajkoczy, P | 1 |
| Furuta, T; Hamada, J; Hayashi, Y; Misaki, K; Nakada, M; Nakanuma, Y; Sato, Y | 1 |
| Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB | 1 |
| Kanno, H; Kohsaka, S; Tanaka, S | 1 |
| Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB | 1 |
| Miyakita, Y; Momota, H; Narita, Y; Shibui, S | 1 |
| Canpinar, H; Castresana, JS; Ilgaz, S; Ozdemir, M; Ozkan, T; Oztuna, D; Rey, JA; Sunguroğlu, A; Taspinar, M; Ugur, HC | 1 |
| Aquino, A; Bernardini, S; Bianchi, A; Bonmassar, E; Bonmassar, L; D'Atri, S; Franzese, O; Lattuada, D; Marchesi, F; Margison, GP; Pascale, E | 1 |
| Bueno e Silva, MM; Filippi-Chiela, EC; Garicochea, B; Ledur, PF; Lenz, G; Pelegrini, AL; Thomé, MP; Zamin, LL | 1 |
| Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M | 1 |
| Cahill, D; Gilbert, MR; Lei, X; Shonka, NA; Smith, L; Theeler, B; Yung, A | 1 |
| Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC | 1 |
| Archer, GE; Bigner, DD; Choi, BD; Cui, X; Flores, C; Herndon, JE; Johnson, LA; Mitchell, DA; Sampson, JH; Sanchez-Perez, LA; Schmittling, RJ; Snyder, D | 1 |
| Amano, T; Fujioka, Y; Hata, N; Iwaki, T; Mizoguchi, M; Murata, H; Nakamizo, A; Sasaki, T; Suzuki, SO; Yoshimoto, K | 1 |
| Braunsdorf, WE; Giese, A; Gutenberg, A; Lumenta, CB; Mehdorn, HM; Sabel, M; Westphal, M | 1 |
| Bailey, BJ; Baluyut, AR; Cai, S; Cai, W; Crean, C; Czader, MB; Ernstberger, A; Goebel, WS; Mayo, LD; Pollok, KE; Shokolenkoc, I; Suvannasankha, A; Wang, H; Wang, MZ; Wilson, GL | 1 |
| Chaichana, K; Chen, L; Ford, E; Guerrero-Cazares, H; Kleinberg, L; Lim, M; McNutt, T; Quinones-Hinojosa, A; Redmond, K; Ye, X | 1 |
| Keating, RF; Puscasiu, E; Rood, BR; Yeo, KK | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Morelli, MB; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Kruser, TJ; Mehta, MP; Robins, HI | 1 |
| Ahtiainen, L; Bramante, S; Cerullo, V; Diaconu, I; Hemminki, A; Hemminki, O; Hirvinen, ML; Joensuu, T; Kanerva, A; Kangasniemi, L; Koski, A; Laasonen, L; Liikanen, I; Nokisalmi, P; Oksanen, M; Partanen, K; Pesonen, S; Pesonen, SK; Zhao, F | 1 |
| Adams, S; Ahrendt, T; Bode, HB; Guillemin, GJ; Oezen, I; Opitz, CA; Platten, M; Radlwimmer, B; Sahm, F; von Deimling, A; Wick, W | 1 |
| Li, X; Liu, J; Wang, T; Yang, S; You, C | 1 |
| Chen, LC; Du, WZ; Feng, Y; Jiang, CL; Jiang, T; Li, RY; Li, XF; Li, YL; Liu, X; Sun, Y; Wang, HB; Wen, JQ; Yang, DB; Zhang, HY | 1 |
| Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ | 1 |
| Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B | 1 |
| Hatzidaki, E; Papandreou, CN; Vlachostergios, PJ | 1 |
| Bao, X; Cai, F; Dai, C; Deng, K; Feng, M; Guo, K; Jiao, Y; Junji, W; Lian, W; Liu, X; Ma, S; Wang, R; Wei, Z; Xing, B; Yang, Y; Yao, Y; Zhang, B | 1 |
| Sun, J; Yang, SY; Yang, XJ | 1 |
| Bauer, M; Bechmann, I; Dehghani, F; Durante, M; Gaunitz, F; Giese, A; Gutenberg, A; Hellwig, C; Meixensberger, J; Merz, F; Renner, C; Schäfer, M; Schopow, K; Stöcker, H; Taucher-Scholz, G | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Harrabi, S; Weber, KJ | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I | 2 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Dhamija, R; Nelson, A; Nickels, K | 1 |
| Hernández, V; Martínez-Aranda, A; Modolell, I; Picón, C; Sierra, A | 1 |
| Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ | 1 |
| Boockvar, JA; Brüning, A; Cappello, F; Chang, WW; Cvek, B; Dou, QP; Duenas-Gonzalez, A; Efferth, T; Focosi, D; Ghaffari, SH; Halatsch, ME; Karpel-Massler, G; Kast, RE; Keizman, D; Ketola, K; Khoshnevisan, A; Magné, N; Marosi, C; McDonald, K; Muñoz, M; Paranjpe, A; Pourgholami, MH; Sardi, I; Sella, A; Srivenugopal, KS; Tuccori, M; Wang, W; Wirtz, CR | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Dharmalingam, K; Kumar, DM; Nila, MV; Patil, V; Ramachandran, B; Somasundaram, K | 1 |
| Gonzales, DM; Jasmin, JF; Lisanti, MP; Mercier, I; Pestell, RG; Quann, K; Sotgia, F; Wang, C | 1 |
| Camaioni, E; Ekblad, T; Macchiarulo, A; Schüler, H | 1 |
| Alexander, BM; Ligon, KL; Wen, PY | 1 |
| Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW | 1 |
| Cripe, T; Geller, J; Nagarajan, R; Turpin, B; Wagner, L; Weiss, B | 1 |
| Bar, EE; Chu, Q; Eberhart, CG; Orr, BA; Semenkow, S | 1 |
| Garside, R; Grant, R; Hart, MG; Rogers, G; Stein, K | 1 |
| Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S | 1 |
| Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ | 1 |
| Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C | 1 |
| Chen, FR; Chen, ZP; Sai, K; Wang, J | 1 |
| Befani, CD; Hatzidaki, E; Liakos, P; Papandreou, CN; Vlachostergios, PJ | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Bischoff, P; Burckel, H; Josset, E; Noël, G | 1 |
| Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P | 1 |
| Bashamboo, A; Berthaut, I; Deluen, F; Dessolle, L; McElreavey, K; Montjean, D; Morcel, K; Poirot, C; Ravel, C | 1 |
| Albanese, C; Avantaggiati, ML; Machado, FS; Tanowitz, HB | 1 |
| Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M | 1 |
| Attinà, G; Bertolini, P; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Migliorati, R; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A | 1 |
| Gaensler, K; Ito, M; Mukherjee, J; Ohba, S; Pieper, RO; Ronen, SM | 1 |
| Becker, KA; Gramatzki, D; Gulbins, E; Happold, C; Herrmann, C; Tabatabai, G; Weller, M | 1 |
| Brokinkel, B; Ewelt, C; Hargus, G; Heindel, W; Holling, M; Schober, O; Stummer, W; Wölfer, J | 1 |
| Alksne, JF; Carter, BS; Chen, CC; Gonda, DD; Lawson, J; Murphy, K; Rose, B; Russell, M; Scanderbeg, DJ; Waters, JD | 1 |
| Chen, SE; Choi, SS; De Groot, JF; Lei, X; Rogers, JE | 1 |
| Bechter, OE; Clement, PM; De Vleeschouwer, S; Demaerel, P; Geussens, Y; Menten, J; Sciot, R; Van Calenbergh, F; Van Gool, S; Van Mieghem, E; Wilms, G; Wozniak, A | 1 |
| Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H | 1 |
| Dunst, M; Huber, HJ; Kilbride, SM; Kögel, D; Mittelbronn, M; Murphy, ÁC; Murphy, BM; Prehn, JH; Rehm, M; Schmid, J; Seifert, V; Senft, C; Weissenberger, J; Weyhenmeyer, B | 1 |
| Abramson, JS; Batchelor, TT; Clark, SW; Taylor, J; Wang, DL | 1 |
| Austin, AD; Desjardins, A; Friedman, HS; Herndon, JE; Jiang, X; McLendon, RE; Quinn, JA; Reardon, DA; Vredenburgh, JJ | 1 |
| Aftab, Q; Chen, VC; Gielen, PR; Hong, X; Lozinsky, S; Ma, N; Naus, CC; Sin, WC | 1 |
| Agarwal, S; Al-Keilani, MS; Alqudah, MA; Assem, M; Ryken, TC; Sibenaller, ZA | 1 |
| Cao, B; Dhruv, H; Eschbacher, JM; Kloss, J; Loftus, JC; Ross, JT; Schumacher, CA; Tran, NL; Tuncali, S; Williams, BO; Yang, Z | 1 |
| Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, T; Sasajima, T; Shimada, N | 1 |
| Jedynak, Ł; Puchalska, M; Zagrodzka, J; Zezula, M; Łaszcz, M; Łuniewski, W | 1 |
| Araki, N; Hide, T; Hirayama, M; Kobayashi, D; Komohara, Y; Kuratsu, J; Makino, K; Midorikawa, U; Mizuguchi, S; Nagai, M; Nagayama, M; Nakamura, H; Niibori-Nambu, A; Takeya, M; Takezaki, T; Tsubota, N | 1 |
| Boxhammer, V; Klämpfl, TG; Köritzer, J; Li, YF; Morfill, GE; Schäfer, A; Schlegel, J; Schwenk-Zieger, S; Shimizu, T; Welz, C; Zimmermann, JL | 1 |
| Fedulau, AS; Furuyama, N; Hamada, J; Hayashi, Y; Kawakami, K; Minamoto, T; Nakada, M; Pyko, IV; Sabit, H; Teng, L | 1 |
| Chhabra, L; Sareen, P; Trivedi, N | 1 |
| Ancarani, V; Ascierto, PA; Baravelli, S; de Rosa, F; Fiammenghi, L; Gentilcore, G; Granato, AM; Guidoboni, M; Nicoletti, SV; Pancisi, E; Petrini, M; Riccobon, A; Ridolfi, L; Ridolfi, R; Scarpi, E; Simeone, E; Valmorri, L | 1 |
| Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M | 1 |
| Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, KO; Ney, D; Reddy, K; Waziri, A | 1 |
| Colao, A; Grasso, LF; Pivonello, R | 1 |
| Cuperlovic-Culf, M; Morin, P; St-Coeur, PD; Touaibia, M | 1 |
| Allen, J; Blaszkowsky, L; Chan, JA; Gonzalez, M; Kulke, MH; Meyerhardt, J; Regan, E; Ryan, DP; Stuart, K; Wadlow, R; Zheng, H; Zhu, AX | 1 |
| Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L | 1 |
| Bright, JJ; Kanakasabai, S; Rafi, MM; Reyes, MD | 1 |
| Classen, CF; Linnebacher, M; Mullins, CS; Schneider, B; Schubert, J | 1 |
| Christiansen, H; Kortmann, RD; Kramm, CM; Müller, K; Schlamann, A; Seidel, C; von Bueren, AO; Vordermark, D; Warmuth-Metz, M | 1 |
| Gupta, T; Jalali, R; Mohanty, S; Moiyadi, A | 1 |
| Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Couraud, PO; Ghigo, D; Kopecka, J; Mellai, M; Pinzòn-Daza, ML; Riganti, C; Salaroglio, IC; Schiffer, D | 1 |
| Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ | 1 |
| Darabi, A; Eberstål, S; Fritzell, S; Sandén, E; Siesjö, P; Visse, E | 1 |
| Bilska, K; Chaber, R; Drabko, K; Pogorzala, M; Polczyńska, K; Raciborska, A; Rodriguez-Galindo, C; Rogowska, E; Wozniak, W; Wyrobek, E | 1 |
| Anderson, MD; Gilbert, MR | 1 |
| Ejaz, S; Habra, MA; Henderson, SA; Shawa, H | 1 |
| Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Allavena, G; Angeletti, F; Comincini, S; Durando, F; Miracco, C; Morini, M; Palumbo, S; Pirtoli, L | 1 |
| Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA | 1 |
| Campanella, G; Cimmino, A; De Marco, L; Fiano, V; Gillio Tos, A; Lolli, I; Morra, I; Piombino, M; Rudà, R; Soffietti, R; Trevisan, E; Trevisan, M | 1 |
| Antonietti, P; Balss, J; Capper, D; Frank, J; Kögel, D; Mohrenz, IV; Mukrowsky, A; Pusch, S; Seifert, V; Senft, C; Voigt, S; von Deimling, A; Weissert, S | 1 |
| Ayad, NG; Bregy, A; Clarke, J; Komotar, RJ; Pastori, C; Penas, C; Shah, AH; Wahlestedt, C | 1 |
| Brabletz, S; Brabletz, T; Deleyrolle, LP; Devers, KG; Kladde, MP; Kupper, MD; Nabilsi, NH; Neal, D; Reynolds, BA; Sarkisian, MR; Siebzehnrubl, D; Siebzehnrubl, FA; Silver, DJ; Steindler, DA; Suslov, O; Tugertimur, B; Yachnis, AT | 1 |
| Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P | 1 |
| Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B | 1 |
| Shi, L; Sun, G; Wan, Y; Wang, Z; Zhang, S | 1 |
| Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD | 1 |
| Qi, XC; Qian, C; Wang, YR; Xie, DJ; Yan, QF; Yang, SX; Zhu, YX | 1 |
| Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S | 1 |
| Aerts, I; Bailey, S; Breazna, A; Cañete, A; Cisar, L; de Toledo Codina, JS; Dorman, A; Estlin, E; Geoerger, B; Gesner, L; Grill, J; Grundy, RG; Hargrave, D; Leblond, P; Madero, L; Nicolin, G; Perek, D; Verlooy, J | 1 |
| Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S | 1 |
| Arza, C; Díez Valle, R; Galván, J; Romariz, C; Slof, J; Vidal, C | 1 |
| Li, C; Li, X; Liu, X; Yan, B; Zhang, Q; Zhou, H | 1 |
| Abdollahi, M; Nikfar, S; Teimouri, F | 1 |
| Blume, C; Boström, J; Greschus, S; van Landeghem, F; von Lehe, M | 1 |
| Brassesco, MS; Carlotti, CG; de Oliveira, JC; de Paula Queiroz, RG; Machado, HR; Morales, AG; Neder, L; Pezuk, JA; Scrideli, CA; Tone, LG | 1 |
| Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N | 1 |
| Dilnawaz, F; Sahoo, SK | 1 |
| Bernal, GM; Cahill, KE; Kang, S; LaRiviere, MJ; Larsen, GF; Mansour, N; Noriega, SE; Nunez, L; Pytel, P; Spretz, R; Voce, DJ; Weichselbaum, RR; Welp, U; Yamini, B | 1 |
| Davidson, TB; Malogolowkin, M; Mascarenhas, L; May, W; Sposto, R; Venkatramani, R | 1 |
| Lukas, RV; Nicholas, MK | 1 |
| Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Ghigo, D; Kopecka, J; Mellai, M; Riganti, C; Salaroglio, IC; Schiffer, D | 1 |
| Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P | 1 |
| Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S | 1 |
| Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F | 1 |
| Altorjai, G; Dieckmann, K; Geissler, K; Hassler, MR; Knocke-Abulesz, TH; Marosi, C; Pfeifer, W | 1 |
| Boothman, DA; Burma, S; Chakraborty, S; Cochran, B; Habib, AA; Li, L; Puliyappadamba, VT; Raisanen, J; Tang, H; Wu, J; Xie, Y | 1 |
| Chen, B; Chen, L; Chen, X; Jiang, T; Li, S; Wang, J; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhang, Z | 1 |
| De Sanctis, V; Enrici, RM; Minniti, G; Scaringi, C | 1 |
| Aboody, KS; Ahmed, AU; Auffinger, B; Balyasnikova, IV; Han, Y; Kim, CK; Lesniak, MS; Rincón, E; Thaci, B; Tobias, AL; Zhang, L | 1 |
| Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D | 1 |
| Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H | 1 |
| Hay, JW; Messali, A; Villacorta, R | 2 |
| Camphausen, K; Fine, HA; Ho, J; Iwamoto, F; Kim, L; Krauze, A; Kreisl, T; McNeil, K; Ning, H; Ondos, J; Shankavaram, U; Smith, S; Sul, J | 1 |
| Adachi, K; Hayashi, T; Hirose, Y; Ohba, S | 1 |
| Carter, AF; DeTroye, AT; Harmon, MS; Lesser, GJ; Morrell, RM; Tooze, JA | 1 |
| Classen, CF; Krohn, M; Linnebacher, M; Mullins, CS; Schneider, B; Stockhammer, F | 1 |
| Hirohata, T; Hoya, K; Ide, F; Ishii, Y; Matsuno, A; Miyamoto, S; Mizutani, A; Murakami, M; Nagashima, H; Nishido, H; Okinaga, H; Osamura, RY; Son, JH; Sugaya, M; Tahara, S; Teramoto, A; Yamada, S; Yamada, SM | 1 |
| Fenton, E; Khalil, A; Molnar, P; Sattar, MT; Zakaria, Z | 1 |
| Chen, YS; Chen, ZP; Feng, BH; Guo, CC; Qiu, ZK; Shen, D; Yang, QY | 1 |
| Bachour, M; Hussein, T; Kenj, M; Salamoon, M | 1 |
| Eich, M; Kaina, B; Nikolova, T; Roos, WP | 1 |
| Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M | 1 |
| Antonodimitrakis, P; Crona, J; Eriksson, B; Fanola, I; Granberg, D; Lindholm, DP; Öberg, K | 1 |
| Chen, W; Du, G; Huang, L; Xiao, Z; Zhao, Y | 1 |
| Alitto, AR; Anile, C; Balducci, M; Chiesa, S; Colosimo, C; D'Agostino, GR; De Bonis, P; Fiorentino, A; Frascino, V; Mangiola, A; Mantini, G; Mattiucci, GC; Valentini, V | 1 |
| Kuo, LT; Lin, LW; Tsai, SY; Yang, CY | 1 |
| Al-Zahrani, A; Atenafu, E; Laperriere, N; Lwin, Z; MacFadden, D; Mason, WP; Menard, C; Miller, BA; Sahgal, A | 1 |
| Chen, H; Cheung, F; Chow, JP; Li Lung, M; Man, WY; Mao, M; Nicholls, J; Poon, RY; Tsao, SW | 1 |
| Behm, T; Bock, HC; Horowski, A; Mielke, D; Rohde, V; Schneider, S; Stockhammer, F | 1 |
| Asano, K; Ito, E; Katayama, K; Komori, T; Ohkuma, H; Sasaki, S; Sato, T; Terui, K | 1 |
| Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS | 1 |
| Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Michaelsen, SR; Poulsen, HS; Stockhausen, MT | 1 |
| Aboukais, R; Assaker, R; Maurage, CA; Zairi, F | 1 |
| Bailey, S; Boota, N; Connolly, DJ; Fisher, D; Gibson, M; Glaser, A; Hargrave, D; Howman, A; Kearns, P; Picton, S; Pizer, B; Saran, F; Wheatley, K; Wherton, D | 1 |
| Awada, A; Buttice, A; Cardoso, F; D'Hondt, V; de Azambuja, E; Devriendt, D; Gil, T; Lalami, Y; Lebrun, F; Lemort, M; Moulin, C; Paesmans, M; Piccart-Gebhart, M; Rossari, J; Sotiriou, C; Zardavas, D | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
| Fan, X; Li, X; Ni, S; Qi, H; Wang, J | 1 |
| Gupte, M; Sharma, VP; Tuck, AN; Williams, KJ | 1 |
| Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM | 1 |
| Decrey, G; Eisele, G; Weller, M; Wolpert, F | 1 |
| Bellyei, S; Boronkai, A; Cseh, A; Hocsak, E; Pozsgai, E; Racz, B; Sumegi, B; Szabo, A | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Bigner, DD; Dechkovskaia, AM; Dodd, RD; Dusto, NL; Epple, LM; Graner, MW; Herring, M; Lencioni, AM; Madsen, H; Merz, AL; Nega, M; Nicchitta, CV; Russell, RL; Serkova, NJ; White, J; Winston, BA | 1 |
| Beier, D; Girbinger, V; Holm, PS; Lage, H; Mantwill, K; Mittelbronn, M; Naumann, U; Schlegel, J; Seznec, J; Surowiak, P | 1 |
| Jin, Z; Xu, S; Yang, B; Yu, H; Zhao, G; Zhao, H | 1 |
| Darefsky, AS; Dubrow, R; Jacobs, DI; King, JT; Laurans, MS; Park, LS; Rose, MG | 1 |
| Blüml, S; Brown, RJ; Dhall, G; Finlay, JL; Wellner, M; Zaky, W | 1 |
| Cheng, WY; Chiang, IP; Chiang, SF; Chiou, SH; Chow, KC; Huang, CY; Lin, JC; Lin, TY; Shen, CC; Shieh, SH; Sudhakar, JN; Yang, CL; You, WC | 1 |
| Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL | 1 |
| Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F | 1 |
| Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J | 1 |
| Airenne, K; Alasaarela, L; Määttä, AM; Pikkarainen, J; Samaranayake, H; Stedt, H; Ylä-Herttuala, S | 1 |
| Cong, ZX; Pan, H; Wang, HD; Wang, JW; Zhang, DD; Zhang, L; Zhou, Y; Zhu, L | 1 |
| Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X | 1 |
| Beelen, AP; Coker, SA; Crosby, NA; Dandamudi, UB; Ernstoff, MS; Fisher, JL; Lewis, LD; Obrocea, M | 1 |
| Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J | 1 |
| Aldape, KD; Armstrong, TS; Baumert, B; Blumenthal, DT; Brown, PD; Chakravarti, A; Curran, WJ; Erridge, S; Gilbert, MR; Hegi, ME; Hopkins, KI; Jaeckle, KA; Mahajan, A; Mehta, MP; Schultz, CJ; Stupp, R; Tzuk-Shina, T; Wang, M; Wefel, JS; Won, M | 1 |
| Armstrong, TS; Bottomley, A; Brachman, DG; Choucair, AK; Coens, C; Gilbert, MR; Mehta, M; Mendoza, TR; Wang, M; Wefel, JS; Werner-Wasik, M; Won, M | 1 |
| Kaoru, K; Kazuhiko, S; Koji, I; Takeshi, N; Toshikazu, H | 1 |
| Clark, B; Mackinnon, M; Martin, S; Nowicki, S; Owusu-Agyemang, K; Paul, J; St George, J; Stewart, W; Teo, M | 1 |
| Kim, SS; Kim, SY; Lim, SH; Seong, S | 1 |
| Malogolowkin, MH; Mascarenhas, L; Venkatramani, R | 1 |
| Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Fusco, V | 1 |
| Bazan, F; Gayete, A; Vollmer, I | 1 |
| Barzo, P; Cserhati, A; Fodor, E; Hideghety, K; Mozes, P; Szanto, E; Tiszlavicz, L | 1 |
| Han, G; Hu, X; Li, Y; Liu, J; Wang, L; Yue, Z; Zhao, R; Zhao, W; Zhou, X | 1 |
| Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC | 1 |
| Chonan, M; Jokura, H; Kanamori, M; Katakura, R; Kato, H; Kawagishi, J; Kawaguchi, T; Kayama, T; Kumabe, T; Mano, Y; Saito, R; Shibahara, I; Sonoda, Y; Tominaga, T; Watanabe, M; Yamashita, Y | 1 |
| Al-Nuaimi, SK; Alnaami, IM; Gourishankar, S; Mehta, V; Murtha, AD; Senthilselvan, A; Walling, S | 1 |
| Condorelli, G; De Marinis, P; Diaz-Lagares, A; Donnarumma, E; Esteller, M; Fiore, D; Iaboni, M; Mangani, D; Quintavalle, C; Romano, G; Roscigno, G; Soini, Y | 1 |
| Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L | 1 |
| Cao, H; Chen, L; Fan, CH; Jiang, G; Liu, WL; Wen, C | 1 |
| An, SS; Gwak, SJ; Ha, Y; Joe, E; Kim, DH; Kim, KN; Yang, MS; Yoon, DH | 1 |
| Allgeier, A; Bottomley, A; de Gans, J; Delgadillo, D; Enting, RH; Gijtenbeek, AM; Habets, EJ; Hoang-Xuan, K; Klein, M; Nederend, S; Reijneveld, JC; Seute, T; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ | 1 |
| Jia, HY; Jiang, G; Lei, TC; Li, RH; Liu, YQ; Sun, C | 1 |
| Cai, S; Cheng, JX; Dong, Y; Liu, BL; Yin, AA; Zhang, LH; Zhang, X | 1 |
| Jiang, Z; Kuo, PY; Leshchenko, VV; Parekh, S; Thirukonda, VK | 1 |
| Allgar, V; Dixit, S; Hingorani, M | 1 |
| Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P | 1 |
| Beal, K; Chan, TA; Folkert, M; Gutin, PH; Pentsova, E; Spratt, DE; Yamada, Y; Zumsteg, ZS | 1 |
| Ancukiewicz, M; Batchelor, TT; Chi, AS; Dietrich, J; Duda, DG; Eichler, AF; Emblem, KE; Gerstner, ER; Hochberg, FH; Iafrate, AJ; Ivy, SP; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Loeffler, JS; Lu-Emerson, C; Pinho, MC; Plotkin, SR; Polaskova, P; Rosen, BR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Bellu, L; Della Puppa, A; Gardiman, MP; Lombardi, G; Pambuku, A; Pomerri, F; Rumanò, L; Zagonel, V | 1 |
| Alonso-Basanta, M; Dorsey, JF; Fang, P; Hahn, SM; Lustig, RA; Maity, A | 1 |
| Bacher, J; Brinster, L; McCully, CM; Murphy, RF; Pastakia, D; Saleem, K; Steffen-Smith, EA; Thomas, ML; Walbridge, S; Warren, KE; Widemann, BC | 1 |
| Back, M; Guo, L; Gzell, C; Kastelan, M; Wheeler, H | 2 |
| Bruce, JN; Carminucci, AS; Fine, RL; Gulati, AP; Lignelli, A; Remotti, H; Siegelin, M; Wardlaw, SL; Zacharia, BE | 1 |
| Chen, JX; Liu, JP; Liu, YH; Mao, Q; Wang, X; You, C | 1 |
| Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
| Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y | 1 |
| Arita, K; Furukawa, T; Hirano, H; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Shinsato, Y; Tokimura, H; Yamamoto, M; Yonezawa, H; Yunoue, S | 1 |
| Cloughesy, TF; Liau, LM; Liu, Y; McBride, W; Menjivar, JC; Mischel, PS; Nelson, SF; Schaue, D; Tian, JY; Tso, CL; Tso, JL; Yamada, K; Ye, F; Yong, WH; Zhang, Y | 1 |
| Bosma, I; Buter, J; de Groot, M; Douw, L; Froklage, FE; Heimans, JJ; Klein, M; Lagerwaard, FJ; Oosterbaan, LJ; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Uitdehaag, BM | 1 |
| Nagaishi, M; Nakano, T; Nakazato, Y; Noda, SE; Oike, T; Shirai, K; Sugawara, K; Suzuki, Y; Tamaki, T; Yokoo, H | 1 |
| Chen, P; Hu, Y; Hyytiäinen, M; Keski-Oja, J; Li, H; Li, L; Ylivinkka, I | 1 |
| Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R | 1 |
| Armstrong, AE; Cohn, RA; Dargart, J; Gosiengfiao, Y; Matossian, D; Reichek, J; Walterhouse, DO | 1 |
| Guérard, M; Tang, L; Zeller, A | 1 |
| Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M | 1 |
| Chang, PY; Chou, KN; Lin, YC; Liu, MY | 1 |
| Chen, B; Liu, XY; Ming, ZJ; Ren, YJ; Wang, J; Wu, J; Yang, JM; Yang, WQ; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Cloughesy, TF; Ellingson, BM; Harris, RJ; Lai, A; Li, S; Nghiemphu, PL; Pope, WB; Teixeira, S; Tran, AN; Woodworth, DC | 1 |
| Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Chang, S; Costello, JF; Fouse, SD; James, CD; Nakamura, JL | 1 |
| Kayama, T; Kitanaka, C; Narita, Y; Okada, M; Sato, A; Seino, M; Seino, S; Shibui, S; Shibuya, K; Suzuki, S; Watanabe, E | 1 |
| Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G | 1 |
| Chung, H; Jo, S; Kim, IC; Kim, S; Kim, TU; Lee, H; Yim, JH | 1 |
| Balañà, C; Comas, S; Villà, S | 1 |
| Hu, JA; Shen, W; Zheng, JS | 1 |
| Lin, ZX; Yang, LJ; Zhou, CF | 1 |
| Gabarski, K; Jedynak, L; Kaczmarek, Ł; Kaczmarska, M; Kubiszewski, M; Kuziak, K; Malińska, M; Witkowska, A; Łaszcz, M; Łuniewski, W | 1 |
| Abrey, L; Das, A; Han, K; Jin, J; Reardon, DA; Ren, M; Wick, W | 1 |
| Aburatani, H; Aihara, K; Asthana, S; Barnes, M; Berger, MS; Bollen, AW; Cha, S; Chang, SM; Charron, E; Costello, JF; Fouse, SD; Gustafson, WC; Hirst, M; Hong, C; Jalbert, LE; Johnson, BE; Jones, SJM; Marra, MA; Mazor, T; McLean, CY; Moore, RA; Mukasa, A; Mungall, AJ; Nelson, SJ; Olshen, AB; Saito, N; Smirnov, IV; Song, JS; Tatsuno, K; Taylor, BS; Ueda, H; Weiss, WA; Yamamoto, S; Zhao, Y | 1 |
| Hernández-Pedro, NY; Magaña-Maldonado, R; Manoutcharian, K; Pérez-De la Cruz, V; Pineda, B; Rangel-López, E; Rodríguez-Balderas, C; Sotelo, J | 1 |
| Chinot, O; Crétel, E; Retornaz, F; Rousseau, F; Tabouret, E; Tassy, L | 1 |
| Bagó, A; Bajcsay, A; Fedorcsák, I; Kásler, M; Lövey, J; Mangel, L; Sipos, L | 1 |
| Bazsó, P; Fekete, Z; Kiss, E; Lahm, E; Nagy, P; Pápai, Z; Takácsi-Nagy, Z; Vachaja, J | 1 |
| Iversen, TZ | 1 |
| Doroshow, JH; Huang, SY; Ji, J; Morris, J; Murai, J; Pommier, Y; Renaud, A; Takeda, S; Teicher, B; Zhang, Y | 1 |
| Bow, H; Brem, H; Hwang, LS; Murray, L; Salditch, Q; Schildhaus, N; Tyler, B; Weingart, J; Xing, J; Ye, X; Zhang, Y | 1 |
| Boothman, DA; Burma, S; Chakraborty, S; Habib, AA; Hatanpaa, KJ; Koduru, P; Li, L; Puliyappadamba, VT; Rehman, A; Saha, D; Souza, RF; Vemireddy, V | 1 |
| Bachoo, R; Burma, S; Gao, X; Gil del Alcazar, CR; Habib, AA; Hardebeck, MC; Li, L; Mukherjee, B; Tomimatsu, N; Xie, XJ; Yan, J | 1 |
| Canpinar, H; Castresana, JS; Ilgaz, S; Rey, JA; Sert, F; Sunguroglu, A; Taspinar, M; Ugur, HC | 1 |
| Kapoor, S; Padhi, R; Rallabandi, VP; Roy, PK; Sakode, C | 1 |
| Chen, HJ; Hsu, CT; Huang, PH; Huang, SH; Lu, K; Sha, SJ; Wu, HP | 1 |
| Gabel, D; Sander, A; Wosniok, W | 1 |
| Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P | 1 |
| Biondani, P; Bossi, I; Busico, A; Castano, A; de Braud, F; Di Bartolomeo, M; Festinese, F; Gariboldi, M; Gevorgyan, A; Maggi, C; Pacifici, M; Perrone, F; Pietrantonio, F; Tamborini, E | 1 |
| Ammirati, M; Chotai, S; Grecula, J; Lamki, T; Newton, H; Wei, L | 1 |
| Dhermain, F | 1 |
| Casaubon, LK; Mason, WP; Petrescu, N; Tsai, JP | 1 |
| Balañà, C; Capdevila, L; Carrato, C; Cros, S; Cuadra, JL; Etxaniz, O; Hostalot, C; Massuet, A; Ramirez, JL; Romeo, M; Sanz, C; Villà, S | 1 |
| Balzarini, L; Mancini, C; Marvisi, M | 1 |
| Ali, AN; Crocker, IR; Curran, WJ; Hardy, CW; Ogunleye, T; Shu, HK | 1 |
| Ho, YK; Low, SY; Ng, WH; Too, HP; Yap, CT | 1 |
| Cho, BJ; Choi, EJ; Chun, SH; Hwang, YH; Kim, HH; Kim, IA; Lee, DJ | 1 |
| Basso, ME; Bertin, D; Fagioli, F; Mussano, A; Pittana, LS; Vallero, SG | 1 |
| Dubus, P; Figarella-Branger, D; Ichimura, K; Karayan-Tapon, L; Lavenu, A; Legrain, M; Mosser, J; Quillien, V; Sanson, M | 1 |
| Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS | 2 |
| Jouanneau, E; Raverot, G; Trouillas, J | 1 |
| Jang, JD; Jeong, CH; Jeun, SS; Kim, SM; Ryu, CH; Woo, JS | 1 |
| Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W | 1 |
| Boros, S; Cato, K; Donovan, P; Hall, B; Harding, A; Jayalath, R; Legaie, R; Olson, S; Olsson, G; Reynolds, BA | 1 |
| Becker, F; Fietkau, R; Hecht, M; Schmidtner, J; Semrau, S | 1 |
| Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C | 1 |
| Bardin, AL; Carson-Walter, E; Cui, W; Folts, CJ; Noble, M; Stevens, BM; Vescovi, A; Walter, K | 1 |
| Howard, S; Ian Robins, H; Magnuson, W; Mohindra, P | 1 |
| Bernstein, M; Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Templeton, AJ; Zadeh, G | 1 |
| Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A | 1 |
| Ohta, H; Sato, Y; Takeshima, H; Uehara, H; Yamasaki, K; Yamashita, S; Yokogami, K | 1 |
| Adamson, DC; Di, C; Fee, BE; Kang, C; Lin, J; Rivas, M; Zeng, L | 1 |
| Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F | 1 |
| Bodell, MA; Kraus, ES; Lipson, EJ; Sharfman, WH | 1 |
| Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S | 1 |
| Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T | 1 |
| Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K | 1 |
| Ahlzadeh, GE; Candolfi, M; Castro, MG; Ghiasi, H; Kamran, N; Lowenstein, PR; Paran, C; Puntel, M; Wibowo, M; Yagiz, K | 1 |
| Cloughesy, TF; Kornblum, HI; Laks, DR; Lasky, JL; Lee, WN; Lin, HJ; Moore, TB; Pak, Y; Panosyan, EH; Wang, Y; Xia, P | 1 |
| Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR | 1 |
| Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L | 1 |
| Bynevelt, M; Lau, PK; Lee, G; Nowak, AK | 1 |
| Cassoni, P; Castiglione, A; De Marco, L; Fiano, V; Gillio-Tos, A; Grasso, C; Magistrello, M; Merletti, F; Rudà, R; Sacerdote, C; Senetta, R; Soffietti, R; Tondat, F; Trevisan, E; Trevisan, M | 1 |
| Deenen, R; Florea, AM; Frei, K; Happold, C; Lamszus, K; Reifenberger, G; Roth, P; Silginer, M; Weller, M | 1 |
| Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T | 1 |
| Dong, DF; Gao, K; Wang, JB; Wang, MD | 1 |
| Aldape, KD; Armstrong, TS; Blumenthal, DT; Brachman, DG; Brown, PD; Chakravarti, A; Colman, H; Curran, WJ; Dignam, JJ; Gilbert, MR; Jaeckle, KA; Jeraj, R; Mehta, MP; Pugh, S; Schiff, D; Stieber, VW; Sulman, EP; Tremont-Lukats, IW; Vogelbaum, MA; Wefel, JS; Werner-Wasik, M; Won, M | 1 |
| Abrey, L; Brandes, AA; Carpentier, AF; Cernea, D; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Hoang-Xuan, K; Kavan, P; Mason, W; Nishikawa, R; Saran, F; Wick, W | 1 |
| Fine, HA | 1 |
| Jee, TK; Kong, DS; Lee, JI; Nam, DH; Oh, SW; Seol, HJ | 1 |
| Bakó, G; Barzó, P; Bognár, L; Daróczi, B; Hideghéty, K; Mózes, P; Szántó, E; Szántó, J; Tóth, J | 1 |
| Allen, JE; Berg, A; Cheng, Y; Connor, J; El-Deiry, WS; Huang, SY; Liu, CG; Liu, X; Lu, Z; Ren, X; Webb, BS; Yang, JM; Yang, W; Yuan, Y; Zhang, L; Zhang, Y | 1 |
| Alavi, A; Goncalves, MD; Torigian, DA | 1 |
| Dolan, ME; Godley, LA; Moen, EL; Stark, AL; Zhang, W | 1 |
| Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y | 1 |
| Cui, Y; Lei, Q; Li, G; Luo, Z; She, X; Wang, Z; Wu, M; Xu, G; Yu, Z | 1 |
| Archinet, A; Badaoui, N; Bauchet, L; Cartalat-Carel, S; d'Hombres, A; Ducray, F; Frappaz, D; Guyotat, J; Honnorat, J; Jouanneau, E; Jouvet, A; Louis-Tisserand, G; Meyronet, D; Sunyach, MP | 1 |
| Bauer, J; Büttner, P; Eigentler, TK; Garbe, C; Keim, U; Leiter, U; Meckbach, D; Pflugfelder, A; Richter, S; Weide, B | 1 |
| Ito, M; Kato, K; Kato, Y; Motomura, A; Motomura, K; Natsume, A; Ohka, F; Ranjit, M; Saito, K; Senga, T; Soga, T; Wakabayashi, T | 1 |
| Arvold, ND; Reardon, DA | 1 |
| Caiafa, P; Calabrese, R; Ciccarone, F; Graziani, G; Muzi, A; Pallini, R; Pelacchi, F; Ricci-Vitiani, L; Runci, D; Tentori, L | 1 |
| Borawska, MH; Markiewicz-Zukowska, R; Moskwa, J; Naliwajko, SK; Puscion-Jakubik, A; Socha, K; Soroczynska, J | 1 |
| Case, D; Dietrich, AM; Duncan, SE; Harmon, M; Lesser, G; Mirlohi, S | 1 |
| Koon, HB; Megahed, AI | 1 |
| Kerr, J; Reyes, C; Satram-Hoang, S; Stepanski, EJ; Walker, MS | 1 |
| Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Jiang, WQ; Wang, XX; Xia, YF; Xia, ZJ | 1 |
| Ahmed, AU; Auffinger, B; Dey, M; Guo, D; Han, Y; Lee, G; Lesniak, MS; Tobias, AL | 1 |
| Wachtel, MS; Yang, S | 1 |
| Davis, T; Felsberg, J; Gramatzki, D; Hentschel, B; Kaulich, K; Loeffler, M; Pietsch, T; Reifenberger, G; Schackert, G; Simon, M; Tonn, JC; von Deimling, A; Weiss, WA; Weller, M; Westphal, M | 1 |
| Bachoo, RM; Hatanpaa, KJ; Maher, EA; Mashimo, T; Mickey, BE; Pan, E; Sagiyama, K; Sherry, AD; Takahashi, M; Togao, O; Vemireddy, V | 1 |
| Saif, MW; Tejani, MA | 1 |
| Barath, M; Chen, TC; Cho, HY; Hofman, FM; Schönthal, AH; Sharma, N; Wang, W | 1 |
| Akbari, MR; Aldape, KD; Denton-Schneider, BR; Hicks, D; Lee, J; McMullin, RP; Moulis, S; Narod, SA; Ramaswamy, S; Sgroi, DC; Singavarapu, R; Steeg, PS; Wittner, BS; Yang, C | 1 |
| Barnett, KD; Brown, SL; deCarvalho, AC; Ecsedy, JA; Hong, X; Lehman, NL; Mikkelsen, T; O'Donnell, JP; Pearl, DK; Salazar, CR; Van Brocklyn, JR | 1 |
| Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Glück, A; Guckenberger, M; Kortmann, RD; Kramm, C; Müller, K; Pietschmann, S; Schlamann, A; von Bueren, AO; Warmuth-Metz, M; Wawer, A | 1 |
| Hu, J; Huang, A; Liu, J; Liu, Y; Liu, Z; Shuai, X; Wen, X | 1 |
| Chen, J; Fu, X; Jiang, D; Shi, L; Wan, Y; Wang, Z | 1 |
| Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS | 1 |
| Beijnen, JH; Beumer, JH; Buil, LC; Christner, SM; de Gooijer, MC; Lin, F; Roig, EM; van Tellingen, O; Würdinger, T | 1 |
| Aandahl, G; Dalhaug, A; Haukland, E; Marienhagen, K; Nieder, C; Pawinski, A | 1 |
| Doroshow, JH; Ji, J; Morris, J; Murai, J; Pommier, Y; Takeda, S; Zhang, Y | 1 |
| Elicin, O; Inac, E; Karacam, S; Uzel, EK; Uzel, OE | 1 |
| Berger, MS; Butowski, NA; Chang, SM; Clarke, JL; DeSilva, A; Han, SJ; Molinaro, AM; Prados, MD; Rolston, JD | 1 |
| Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S | 1 |
| Greco, SJ; Ligon, KL; Munoz, JL; Rameshwar, P; Ramkissoon, SH; Rodriguez-Cruz, V | 2 |
| Buslei, R; Derer, A; Fietkau, R; Frey, B; Gaipl, US; Muth, C; Rubner, Y; Sieber, R; Strnad, A | 1 |
| Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L | 1 |
| Drappatz, J; Hamilton, RL; Laymon, CM; Lieberman, FS; Mountz, JM; Oborski, MJ | 1 |
| Balyasnikova, IV; Chang, AL; Cheng, Y; Dey, M; Han, Y; Kim, CK; Kim, JW; Lesniak, MS; Qiao, J; Tobias, A; Wainwright, DA; Zhang, L | 1 |
| Agoulnik, IU; Beaver, JM; Lai, Y; Liu, Y; Lorente, K; Melo, J; Ramjagsingh, S; Zhang, Z | 1 |
| Bekar, A; Berghoff, AS; Budak, F; Cecener, G; Egeli, U; Kocaeli, H; Preusser, M; Ricken, G; Taskapılıoglu, MO; Tezcan, G; Tolunay, S; Tunca, B | 1 |
| Allavena, G; Angeletti, F; Comincini, S; Manai, F; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M | 1 |
| Ghosh, S; Ifediba, MA; Medarova, Z; Moore, A; Yoo, B | 1 |
| Deng, D; Fang, HB; Tan, M; Zhang, T | 1 |
| Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH | 1 |
| Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY | 1 |
| Benoit, JP; Boesen, K; Lagarce, F; Messaoudi, K; Saulnier, P | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Clark, PA; Cong, D; Hu, S; Kuo, JS; Pointer, KB; Shen, H; Shi, Y; Sun, D; Zhu, W | 1 |
| Perry, JR | 1 |
| Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A | 1 |
| Bozzao, A; De Sanctis, V; Enrici, RM; Lanzetta, G; Minniti, G; Osti, M; Romano, A; Scaringi, C; Valeriani, M | 1 |
| Cohen, MS; Grogan, PT; Sarkaria, JN; Timmermann, BN | 1 |
| Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M | 1 |
| Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I | 1 |
| Cao, KI; Kirova, YM | 1 |
| Altonok, D; Konski, A; Poulik, J; Sood, S; Wang, ZJ | 1 |
| Brügge, D; Hottinger, A; Hundsberger, T; Putora, PM; Roelcke, U; Stupp, R; Tonder, M; Weller, M | 1 |
| Li, B; Wang, Q; Wang, W; Xie, B; Zou, Y | 1 |
| Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY | 1 |
| Alrwas, A; Bassett, R; Bedikian, AY; Cain, S; Davies, MA; Deburr, TL; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Woodman, SE | 1 |
| Bähr, O; Fischer, S; Fulda, S; Harter, PN; Kögel, D; Mittelbronn, M; Paschke, R; Reichert, S; Ronellenfitsch, MW; Steinbach, JP; Thiepold, AL; Weller, M | 1 |
| Arcella, A; Bozzao, A; Di Stefano, D; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Salvati, M; Scaringi, C; Scarpino, S; Villani, V | 1 |
| Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J | 1 |
| Al Aswy, H; Berthois, Y; Boudouresque, F; Delfino, C; Fina, F; Metellus, P; Nanni-Metellus, I; Ouafik, L; Pirisi, V | 1 |
| Alumkal, JJ; Carducci, MA; Cetnar, J; Chyla, B; Giranda, VL; Hussain, M; McKeegan, EM; Qian, J; Refici-Buhr, M; Shepherd, SP; Slovin, S | 1 |
| Borisova, LM; Ermakova, KV; Kiselyova, MP; Kubasova, IY; Luk'yanets, EA; Meerovich, GA; Oborotova, NA; Smirnova, ZS | 1 |
| Lebrun-Frenay, C | 1 |
| Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC | 1 |
| Bandey, I; Chiou, SH; Huang, AP; Tsai, JC; Tu, PH | 1 |
| Fuentes-Raspall, R; Guerra-Prio, S; Marcos-Gragera, R; Perez-Bueno, F; Puig-Vives, M | 1 |
| Biffoni, M; De Majo, M; De Maria, R; di Martino, S; Giannetti, S; Larocca, LM; Morgante, L; Pallini, R; Pelacchi, F; Petricoin, EF; Ricci-Vitiani, L; Runci, D; Signore, M; Stancato, L | 1 |
| Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM | 2 |
| Chang, EH; Dagata, JA; Farkas, N; Kim, E; Kim, SS; Nishida, M; Pirollo, KF; Rait, A | 1 |
| Anderson, JC; Bonner, JA; Bredel, M; Choradia, NV; Duarte, CW; Rohrbach, TD; Thottassery, JV; Welaya, K; Willey, CD; Yancey Gillespie, G; Yang, ES | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Sugino, T; Yamaguchi, K | 1 |
| Cusimano, MD; Di Ieva, A; Kovacs, K; Rotondo, F; Syro, LV | 1 |
| Barrientos, A; Carazo, Á; Delgado, Á; López Viota, J; Muñoz-de-Rueda, P; Muñoz-Gámez, JA; Quiles-Perez, R; Ruiz-Extremera, Á; Salmerón, J; Sanjuán-Nuñez, L | 1 |
| Ambrosi, B; Corbetta, S; Mendola, M; Passeri, E | 1 |
| Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA | 1 |
| Gao, X; Li, XM; Li, ZQ; Liang, GB; Luo, LH; Song, ZQ; Su, JY; Zhu, TZ | 1 |
| Akiyama, Y; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Oshita, C; Sugino, T; Yamaguchi, K | 1 |
| Burgess, RJ; Johnson, JE; Mich, JK; Morrison, SJ; Nakada, D; Pineda, A; Signer, RA; Vue, TY | 1 |
| Gao, Y; Li, Y; Liu, G; Ma, L; Wang, Y; Zhou, X | 1 |
| Chen, Q; Jiang, BH; Jiang, C; Jiang, T; Kang, C; Li, C; Li, H; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, Z; Wang, L; Wang, X; You, Y | 1 |
| Cui, XL; Li, HL; Lin, S; Zhang, JN | 1 |
| Cao, P; Li, XM; Liang, GB; Liu, Y; Luo, LH; Xu, YH; Zhu, TZ | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L | 1 |
| Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P | 1 |
| Gergel, T; Lacroix, M; Toms, SA; Turner, SG; Wu, H | 1 |
| Bradshaw, TD; Coyle, B; Grundy, RG; Kerr, ID; Kimishi, I; Korshunov, A; Othman, RT; Pfister, SM; Storer, LC | 1 |
| Jiang, Z; Leng, C; Liang, S; Liu, H; Lu, F; Lu, S; Qi, X; Shi, J; Wang, Q; Wang, S | 1 |
| Baumgartner, U; Glück, A; Haemmig, S; Kappeler, A; Mariani, L; Tschan, MP; Vajtai, I; Vassella, E; Zbinden, S | 1 |
| García-Alvarez, M; Holler, E; Lanz-Landázuri, A; Ljubimova, J; Martínez de Ilarduya, A; Muñoz-Guerra, S; Portilla-Arias, J | 1 |
| Lan, Q; Li, RJ; Sang, DP | 1 |
| Albert, A; Bottomley, A; Coens, C; Donneau, AF; Mauer, M | 1 |
| Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM | 1 |
| Adesina, A; Blaney, SM; Boyett, J; Chen, A; Chyla, B; Fouladi, M; Giranda, V; Goldman, S; Kilburn, L; Kocak, M; Kun, L; Li, XN; McKeegan, E; Onar-Thomas, A; Pollack, IF; Su, JM; Thompson, P; Warren, KE | 1 |
| Bai, Y; Flavahan, W; Lathia, JD; Mattson, MP; Rich, JN; Zhang, P | 1 |
| Chalmers, AJ; Morley, SJ; Smalley, S | 1 |
| Clementi, E; Corti, M; Guari, Y; Larionova, J; Lascialfari, A; Nano, R; Orlando, T; Paolini, A; Pasi, F; Pineider, F; Sacchi, L | 1 |
| Rovere, RK | 1 |
| Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Raktoe, RS; Vandertop, WP; Wesseling, P; Wurdinger, T | 1 |
| Ho, AS; Kiang, KM; Lee, D; Leung, GK; Sun, S; Xu, FF; Zhang, XQ | 1 |
| Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X | 1 |
| Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD | 1 |
| Arozarena, I; Erice, O; Ferguson, J; Goicoechea, I; Margison, GP; Wellbrock, C | 1 |
| Pittman, T; Villano, JL | 1 |
| Linn, J | 1 |
| Ladizinski, B; Sankey, C | 1 |
| Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC | 1 |
| Cesano, A; Conroy, A; Cordeiro, JA; Fields, SZ; Hawtin, RE; Leung, LY; Louie, B; Rosen, DB; Shapira, I | 1 |
| Sands, MJ; Wunderle, KA | 1 |
| Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K | 1 |
| Chen, QD; Ge, X; Jiang, BH; Jiang, CF; Li, DM; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, ZM; Wang, L; Wang, XF; You, YP | 1 |
| Arrighetti, N; Carenini, N; Ciniselli, CM; Ciusani, E; Cominetti, D; Corna, E; De Cesare, M; Gatti, L; Manenti, G; Perego, P; Rivoltini, L; Rodolfo, M; Sevko, A; Umansky, V; Verderio, P; Zaffaroni, N | 1 |
| Fang, W; Hu, Z; Li, Z; Liu, Z; Long, H; Peng, Y; Qi, S; Que, T; Song, Y; Wang, G; Yi, L; Zhang, X; Zheng, S | 1 |
| Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC | 1 |
| Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Xin, Y; Zheng, JN | 1 |
| Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Gallagher, M; Heitjan, DF; Kaiser, J; Kramer, A; Leone, R; Nathanson, KL; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rangwala, R; Rodgers, G; Schuchter, LM; Tan, KS; Troxel, AB | 1 |
| Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X | 1 |
| Buckner, JC; Decker, PA; Giannini, C; Hardie, J; Jenkins, RB; Kizilbash, SH; Laack, NN; Parney, IF; Uhm, JH; Voss, JS | 1 |
| Abe, T; Hashimoto, K; Ikuta, S; Ishihara, T; Ishikawa, E; Karasawa, K; Maruyama, T; Matsuda, M; Matsumura, A; Matsutani, M; Muragaki, Y; Nakazato, Y; Ohno, T; Tsuboi, K; Uemae, Y; Yamamoto, T | 1 |
| Fields, B; Macomson, S; Mansour, J; Rixe, O | 1 |
| Blank, A; Dawson, H; Komminoth, P; Pavel, M; Perren, A; Rudolph, T; Schmitt, AM; Vassella, E | 1 |
| Avdieiev, S; Gera, L; Havrylyuk, D; Hodges, RS; Kavsan, V; Lesyk, R; Ribrag, V; Vassetzky, Y | 1 |
| Cui, Y; Lei, Q; Li, G; She, X; Wang, Z; Wu, M; Xiang, J; Xu, G; Yu, Z | 1 |
| Athawale, R; Bajaj, A; Goel, PN; Gude, R; Jain, D; Nikam, Y; Patil, S; Prashant Raut, P; Shrikhande, S | 1 |
| Bressler, LR; Gabay, MP; Letarte, N; Long, KE; Stachnik, JM; Villano, JL | 1 |
| Hu, Y; Li, J; Li, W; Lu, Z; Ma, C; Tohti, M; Wang, S; Wang, Y | 1 |
| Ang, AL; See, SJ; Tan, CW; Tham, CK | 1 |
| Canal, F; Cavallin, S; Dei Tos, AP; Gherlinzoni, F; Scarpa, M; Scquizzato, E; Stefani, PM; Toffolatti, L | 1 |
| Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W | 1 |
| Mukherjee, J; Ohba, S; Pieper, RO; See, WL | 1 |
| Abbasi, S; Albaba, H; Kashashna, A | 1 |
| Bloch, O; Oh, T; Parsa, AT; Rutkowski, MJ; Safaee, M; Sayegh, ET; Sun, MZ; Tihan, T | 1 |
| Desai, A; Gerson, S | 1 |
| Jo, J; Lopes, MB; Schiff, D; Shaffrey, ME; Smolkin, M; Williams, B; Wintermark, M | 1 |
| Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ | 1 |
| Ge, N; Gong, A; Liang, H; Lu, L; Yao, W | 1 |
| Hu, X; Shao, J; Wang, L; Wen, C; Yin, H; You, C; Zhang, W; Zhou, C; Zhou, Y | 1 |
| Greco, SJ; Munoz, JL; Nagula, V; Rameshwar, P; Rodriguez-Cruz, V; Scotto, KW | 1 |
| Azadi, J; Bow, H; Brem, H; Hutt-Cabezas, M; Hwang, L; Joshi, A; Mangraviti, A; Martin, KL; Rudek, MA; Tyler, BM; Wicks, RT; Zhang, I; Zhao, M | 1 |
| Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ | 2 |
| Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C | 1 |
| Ferolla, P | 1 |
| Berkowitz, MJ; Boggs, DH; Langer, CJ; Mehta, MP; Robins, HI; Traynor, AM | 1 |
| Beveridge, RD; Carroll, TA; Collis, SJ; Cox, A; Depondt, ML; Fernando, M; Jellinek, D; Kriplani, DH; Myers, KN; Patil, AA; Roylance, A; Sayal, P | 1 |
| Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR | 1 |
| Karagiannis, D; Kirches, E; Mawrin, C; Rupa, R; Schneider, T; Tapia-Perez, JH; Voellger, B | 1 |
| Cocuzza, P; Fabbrini, MG; Fatigante, L; Ferrazza, P; Monzani, F; Pasqualetti, F; Pasqualetti, G | 1 |
| Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S | 1 |
| Chen, H; Fang, J; Han, C; Lan, J; Lou, M; Wu, Z; Xue, Y; Zhao, S | 1 |
| Cantelli, E; De Vries, S; Dekker, M; Delzenne-Goette, E; Plug, M; Song, JY; Te Riele, H; Van Der Wal, A; Van Gerwen, B; Wojciechowicz, K | 1 |
| Han, S; Li, Z; Master, LM; Master, ZW; Wu, A | 1 |
| Cheung, P; Harrison, SD; McMurry, AS; Meshaw, KR; Rainbolt, EA; Roix, JJ; Saha, S | 1 |
| Chinot, O; Delattre, JY; Hoang-Xuan, K; Idbaih, A; Loundou, A; Sanson, M; Tabouret, E | 1 |
| Capelli, E; Di Liberto, R; Nano, R; Paolini, A; Pasi, F | 1 |
| Agnihotri, S; Barszczyk, MS; Buczkowicz, P; Burrell, K; Chornenkyy, Y; Clarke, ID; Dirks, PB; Fernandez, NA; Gajadhar, A; Golbourn, B; Hawkins, C; Head, R; Jones, C; Pajovic, S; Remke, M; Rutka, JT; Sabha, N; Sobol, RW; Taylor, MD; Ternamian, C; Zadeh, G | 1 |
| Jiang, G; Li, RH; Liu, YQ; Sun, C; Wei, ZP; Zheng, JN | 1 |
| Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR | 1 |
| Akimoto, J; Narita, Y; Oka, H; Tanaka, S; Tashiro, T | 1 |
| Abrey, LE; Barradas-Panchal, R; Baser, RE; Beal, K; Brennan, CW; Chan, TA; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, C; Gutin, P; Hormigo, A; Huse, JT; Kaley, TJ; Karimi, S; Lassman, AB; Mellinghoff, I; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Reiner, AS; Sanchez, J; Tabar, V; Zhang, J | 1 |
| Baklaushev, VP; Chekhonin, VP; Golanov, AV; Gorlachev, GE; Goryainov, SA; Gubskii, IL; Gurina, OI; Kobyakov, GL; Konovalov, AN; Potapov, AA; Yusubalieva, GM; Zorkina, YA | 1 |
| Fukai, J; Koizumi, F; Nakao, N | 1 |
| Bonnet, P; Cartron, PF; Cheray, M; Nadaradjane, A; Routier, S; Vallette, FM | 1 |
| Abernethy, AP; Jiang, BS; Mosca, PJ; Speicher, PJ; Thomas, S; Tyler, DS | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Di Martino, A; Sedlarik, V | 1 |
| Akers, J; Bao, ZS; Carter, B; Chen, CC; Chen, HM; Fan, XL; Hu, BQ; Hu, HM; Jiang, T; Kang, CS; Li, J; Li, MY; Li, RQ; Liu, YW; Qiu, XG; Ramakrishnan, V; Song, WS; Su, XD; Wang, Z; Yan, W; Yang, MY; Yao, K; Ye, WL; You, YP; Yu, K; Zhang, CB; Zhang, W | 1 |
| Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G | 1 |
| Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S | 1 |
| Augustine, CK; Beasley, GM; Dolber, PC; Mosca, PJ; Peterson, BL; Ross, M; Royal, R; Sharma, K; Speicher, P; Tyler, DS; Zager, JS | 1 |
| Hyodo, A; Nagaishi, M; Sugiura, Y; Suzuki, K; Takano, I; Tanaka, Y; Yokoo, H | 1 |
| Galldiks, N; Goldbrunner, R; Hamisch, C; Kickingereder, P; Kocher, M; Ruge, MI; Suchorska, B; Treuer, H; Visser-Vandewalle, V; Voges, J | 1 |
| Castro, GN; Cayado-Gutiérrez, N; Ciocca, DR; Cuello-Carrión, FD; Fanelli, MA; Nadin, SB; Sottile, M; Zoppino, FC | 1 |
| Brandwein, JM; Galarneau, A; Hogge, D; Howson-Jan, K; Kassis, J; Leber, B; Minden, MD; Pouliot, JF | 1 |
| Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T | 1 |
| Armoiry, X; Aulagner, G; Breant, V; Cartalat-Carel, S; Diebold, G; Ducray, F; Fouquet, A; Frappaz, D; Guyotat, J; Henaine, AM; Honnorat, J | 1 |
| Aiken, RD; Byrne, RW | 1 |
| Aiken, R | 1 |
| Ajlan, A; Recht, L | 1 |
| Du, B; Li, HY; Ma, JW; Wang, SX; Xie, SM; Ye, JC; Zhang, Y; Zhong, XY | 1 |
| Rees, J | 1 |
| Bertero, L; Cassoni, P; Rudà, R | 1 |
| Ashary, A; Cabrera-Aldana, EE; Chaichana, KL; Gokaslan, A; Jusue-Torres, I; Lemos, AM; Olivi, A; Quinones-Hinojosa, A | 1 |
| Bergagnini, I; Drilon, A; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Sima, CS; Sumner, DK; Travis, WD; Zauderer, MG | 1 |
| Chourasia, MK; Ojha, P; Singh, Y; Srivastava, M | 1 |
| Chapet, S; Lévy, S; Mazeron, JJ | 1 |
| Andersen, MH; Iversen, TZ; Svane, IM | 1 |
| Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M | 1 |
| Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y | 1 |
| Chakravarti, A; Chu, Z; Denton, N; Dmitrieva, N; Hardcastle, J; Jacob, NK; Kaur, B; Kwon, CH; Marsh, R; Meisen, WH; Qi, X; Thorne, AH; Van Meir, EG; Wojton, J | 1 |
| Bekar, A; Bilir, A; Budak, F; Cecener, G; Demir, C; Egeli, U; Erkan, LG; Evrensel, T; Guvenc, G; Malyer, H; Sahin, S; Taskapilioglu, MO; Tezcan, G; Tunca, B; Yalcin, M; Yilmaz, G | 1 |
| Bauman, G; Cao, J; Ferguson, M; Rodrigues, G | 1 |
| Adeberg, S; Bostel, T; Combs, SE; Debus, J; Harrabi, S; König, L; Welzel, T | 1 |
| Chmura, SJ; Gabikian, P; Garza, M; Lukas, RV | 1 |
| Aubry, M; Boniface, R; de Tayrac, M; Delattre, JY; Etcheverry, A; Figarella-Branger, D; Idbaih, A; Karayan-Tapon, L; Marie, Y; Menei, P; Mosser, J; Quillien, V; Sanson, M; Vauleon, E | 1 |
| Egger, ME; Gomez-Gutierrez, JG; McMasters, KM; McNally, LR; Nitz, J | 1 |
| Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK | 1 |
| Chang, EH; Kim, E; Kim, SS; Pirollo, KF; Rait, A | 1 |
| Athawale, R; Bajaj, A; Jain, D; Shrikhande, S | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Brennan, CW; DeAngelis, LM; Omuro, AM; Thomas, AA | 1 |
| Cheng, Z; Gao, Z; Guo, H; Shen, X; Wu, L; Xiong, Y; Yang, L; Zhang, Y; Zhu, X | 1 |
| Ilhan, IE; Kurucu, N; Sari, N | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Huber, KM; Jain, AK; Kavitha, CV; Keating, A; Pierce, A; Serkova, NJ; Wempe, MF | 1 |
| Connor, JR; Lee, SY; Miller, PA; Patel, A; Rizk, E; Slagle-Webb, B; Sung, SS | 1 |
| Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K | 1 |
| Chen, D; Mohamad, O; Song, M; Yu, SP | 1 |
| Bartosiuk, E; Borawska, MH; Kochanowicz, J; Mariak, Z; Markiewicz-Żukowska, R; Moskwa, J; Naliwajko, SK; Socha, K; Surażyński, A | 1 |
| Badiyan, SN; Chicoine, MR; Dacey, R; DeWees, T; Dowling, JL; Huang, J; Jalalizadeh, R; Kim, AH; Leuthardt, EC; Linette, G; Markovina, S; Rich, KM; Robinson, CG; Simpson, JR; Tran, DD; Zipfel, GJ | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Akimoto, J; Beppu, M; Fujiwara, Y; Hiranuma, M; Hironaka, C; Miki, Y; Moritake, K; Omata, H | 1 |
| Cai, T; Chen, YD; Liao, F; Liu, Q; Wang, ZF; Wu, H | 1 |
| Chun, W; Kim, SS; Lee, HJ; Lee, JW; Lim, SY; Vo, VA | 1 |
| Bradshaw, TD; Hummersone, M; Matthews, CS; Stevens, MF; Zhang, J | 1 |
| Costea, DE; Enger, PØ; Huang, B; Leiss, L; Li, X; Liang, X; Sakariassen, PØ; Skaftnesmo, KO; Wang, J; Yan, T; Yang, N; Zhu, H | 1 |
| Asklund, T; Birgander, R; Brynolfsson, P; Garpebring, A; Hauksson, J; Henriksson, R; Karlsson, M; Nilsson, D; Nyholm, T; Trygg, J | 1 |
| Chen, J; Cui, D; Ni, L; Shi, J; Shi, W; Sun, B; Zuo, H | 1 |
| Brown, BD; Brown, T; Juarez, T; Kesari, S; Piccioni, DE; Saria, MG; van Vugt, VA | 1 |
| Barnes, PD; Bubalo, J; Fu, R; Gahramanov, S; Lacy, C; Nasseri, M; Neuwelt, AJ; Neuwelt, EA; Nguyen, TM; Tyson, RM | 1 |
| Chang, YZ; Chen, CM; Hsieh, TY; Hung, HC; Liao, CL; Lin, CL; Liu, GY | 1 |
| Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H | 1 |
| Arita, K; Bakhtiar, Y; Fujio, S; Habu, M; Hanaya, R; Hiraki, Y; Hirano, H; Kawano, H; Ogita, M; Oyoshi, T; Sugata, S; Tokimura, H; Uchida, H; Yamahata, H; Yatsushiro, K; Yonezawa, H; Yunoue, S | 1 |
| Nam, DH; Park, C; Yeom, SY | 1 |
| Fei, Z; He, X; Liu, W; Wang, Y | 1 |
| Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Stechishin, OD; Weiss, S | 1 |
| Chaumeil, MM; Gaensler, K; Ito, M; Jalbert, LE; Mukherjee, J; Nelson, SJ; Park, I; Pieper, RO; Ronen, SM | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ | 1 |
| Chai, KM; Fang, KM; Liaw, HJ; Tzeng, SF; Wang, CY; Yang, CS | 1 |
| Liang, H; Xing, BZ; Yang, WB | 1 |
| Brem, H; Cima, M; Grossman, R; Hwang, L; Langer, R; Masi, B; Patta, Y; Scott, A; Spencer, K; Tyler, B; Upadhyay, UM; Wicks, R | 1 |
| Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT | 1 |
| Du, J; Gao, Y; Gong, H; Shi, H; Tang, Y; Wang, L; Wu, Y; Yu, R; Zheng, B | 1 |
| Bourgier, C; Cao, KI; Gerber, S; Gobillion, A; Kirova, YM; Le Scodan, R; Lebas, N; Levy, C; Pierga, JY; Savignoni, A | 1 |
| Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB | 1 |
| Barnholtz-Sloan, JS; Bauchet, L; Woehrer, A | 1 |
| Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE | 1 |
| Hsieh, CH; Lee, HT; Lin, YJ; Shyu, WC; Wang, CC; Wu, CP | 1 |
| Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J | 1 |
| Cai, J; Chang, L; Chen, L; Cui, Y; Dou, Z; Du, W; Jiang, C; Liu, X; Liu, Y; Wang, G; Wang, H; Wang, X; Yi, L; Zhang, P | 1 |
| Berger, MS; Bollen, AW; Breshears, JD; Cotter, JA; Ivan, ME; Theodosopoulos, PV | 1 |
| Aresu, L; Cancedda, S; Dacasto, M; Gracis, M; Leone, VF; Marconato, L; Pizzoni, S; Rohrer Bley, C | 1 |
| Guo, H; Guo, M; Wang, Y; Yang, L | 1 |
| Archer, G; DeLeon, G; Desjardins, A; Friedman, AH; Friedman, HS; Mitchell, DA; Norberg, P; Reap, E; Sampson, JH; Sayour, EJ; Schmittling, R | 1 |
| Brodeur, GM; Croucher, JL; Gordon, WP; Iyer, R; Li, N; Liu, B; Loren, J; Molteni, V; Tuntland, T | 1 |
| Schiff, D; Taylor, JW | 1 |
| Cobbs, C; Schroeder, B; Shah, N | 1 |
| Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P | 1 |
| Fan, TY; Lei, BX; Li, HZ; Liu, YW; Qi, ST; Wang, H; Xiang, P; Yu, M | 1 |
| Li, P; Liu, H; Qian, C; Shi, L; Wang, Y; Yan, W; You, Y; Zhang, J | 1 |
| Dempsey, RJ; Kuo, JS; Pointer, KB; Zhang, RR | 1 |
| Braun, SM; Jessberger, S; Knobloch, M; Vidmar, M; von Schoultz, C; Zurkirchen, L | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Ryoo, I; Sohn, CH; Yun, TJ | 1 |
| Daniele, S; Martini, C; Natali, L; Trincavelli, ML; Zappelli, E | 1 |
| Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S | 1 |
| Adeyi, O; Fung, S; Mason, M; Millar, BA | 1 |
| Bu, G; Li, M; Li, W; Zhao, Y; Zhou, B; Zhou, Y | 1 |
| Chen, TC; Cho, HY; Golden, EB; Hofman, FM; Jahanian, A; Louie, SG; Schönthal, AH | 1 |
| Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G | 1 |
| Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J | 1 |
| Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I | 1 |
| Hirohata, T; Ishii, Y; Matsuno, A | 1 |
| Jiang, S; Yin, S; Zhong, C; Zhou, P | 1 |
| Guo, M; Hu, S; Shen, L; Zhang, X | 1 |
| Cai, Q; Chen, Q; Ding, J; Dong, H; He, Y; Ji, B; Liu, B; Tian, D; Wang, J; Wang, L; Wu, L; Yuan, X; Zhang, S; Zhu, X | 1 |
| Canello, T; Lavon, I; Ovadia, H; Refael, M; Siegal, T; Zrihan, D | 1 |
| Asslaber, M; Bruckmann, L; Hoffermann, M; Kariem Mahdy, A; Payer, F; von Campe, G | 1 |
| Bennett, CL; DeBoer, R; Deeb, M; Fisher, MJ; Fitzner, KA; Grimm, SA; Haleem, MS; Jacobs, DI; Liebling, DB; Luu, TH; McKoy, JM; Raizer, JJ; Ray, PS; Trifilio, SM; Tulas, KM | 1 |
| Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M | 1 |
| Bersvendsen, H; Eriksson, M; Erlanson, M; Fagerli, UM; Fiirgaard, B; Fluge, Ø; Fosså, A; Hagberg, H; Kuittinen, O; Leppä, S; Nordstrøm, M; Pulczynski, EJ; Østenstad, B | 1 |
| Chen, JY; Chen, PY; Huang, CY; Liu, HL; Wang, HY; Wei, KC | 1 |
| Alder, JE; Boissinot, M; Droop, A; Hayes, J; Hughes, TA; Lawler, SE; Shaw, L; Short, SC; Thygesen, H; Tumilson, C; Westhead, D | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Lyalin, D; Maris, JM; Reynolds, CP; Smith, MA | 1 |
| Anton, M; Holm, PS; Kostova, Y; Mantwill, K | 1 |
| Huo, L; Tang, G; Wu, J; Xiao, G | 1 |
| Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W | 1 |
| Debatin, KM; Dwucet, A; Halatsch, ME; Hlavac, M; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Siegelin, MD; Welscher, N; Westhoff, MA; Wirtz, CR | 1 |
| Carlson, JA; Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, KO; Ney, DE; Reddy, K; Waziri, AE | 1 |
| Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH | 1 |
| Akiyama, Y; Hori, YS; Horio, Y; Hosoda, R; Kuno, A; Maruyama, M; Mikami, T; Mikuni, N; Sebori, R; Sugino, T; Suzuki, K; Tsukamoto, M; Wanibuchi, M | 1 |
| Rashidi, A; Sorscher, SM | 1 |
| Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM | 1 |
| Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H | 1 |
| Begini, P; Delle Fave, G; Gallina, S; Marignani, M; Minniti, G; Purchiaroni, F | 1 |
| Agaimy, A; Kloska, S; Linker, RA; Olmes, DG | 1 |
| Cai, T; Fang, J; Gong, C; Liu, Q; Tan, C; Wang, Z; Zhou, R; Zou, R | 1 |
| He, W; Liu, R; Yang, SH; Yuan, F | 1 |
| Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A | 1 |
| Escalon, E; Lollett, IV; Melnick, SJ; Quirin, KW; Ramachandran, C | 1 |
| Bernaudin, M; Divoux, D; Gérault, AN; Guillamo, JS; Pérès, EA; Petit, E; Roussel, S; Sanson, M; Toutain, J; Valable, S | 1 |
| Bochenek-Cibor, J; Krupa, M; Moskała, M; Trojanowski, T | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Pacaud, R; Vallette, FM | 1 |
| Balça-Silva, J; do Carmo, A; Girão, H; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB | 1 |
| Bertorelle, R; Boscaro, M; Ceccato, F; D'Avella, D; Denaro, L; Emanuelli, E; Gardiman, MP; Lombardi, G; Manara, R; Milanese, L; Occhi, G; Scanarini, M; Scaroni, C; Zagonel, V | 1 |
| Christmann, M; Kaina, B; Krumm, A; Loquai, C; Merz, S; Quiros, S; Roos, WP; Switzeny, OJ | 1 |
| Bader, GD; Bayani, J; Bernstein, M; Clarke, ID; Cusimano, M; Dirks, PB; Head, R; Kushida, M; Lan, X; Lionel, AC; Meyer, M; Pressey, JC; Reimand, J; Scherer, SW; Squire, JA; Woodin, MA; Zhu, X | 1 |
| Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ | 1 |
| Chen, L; Li, X; Liu, L; Liu, Y; Xue, Y; Yu, B | 1 |
| Cheng, JT; Chou, AK; Chou, CH; Hong, YR; Howng, SL; Huang, WS; Li, YY; Lieu, AS; Loh, JK; Wang, YT; Yang, MC | 1 |
| Chen, S; Cheng, Y; Deng, J; Liang, P; Wang, F; Xie, Z; Xu, Z; Zhai, X; Zhang, Q; Zhao, H | 1 |
| Archer, GE; Baehring, JM; Bigner, DD; Cruickshank, S; Davis, TA; Green, JA; Groves, MD; Heimberger, AB; Jensen, R; Keler, T; Lai, RK; Mrugala, MM; Paleologos, NA; Reardon, DA; Recht, LD; Sampson, JH; Schuster, J; Sloan, A | 1 |
| Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z | 1 |
| Kim, HR; Kim, KH; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Seol, HJ | 1 |
| Basu, A; Basu, P; Basu, SK; Bhattacharya, RN; Biswas, NK; Chandra, V; Chatterjee, A; Chattopadhyay, A; Das, S; Das, T; Dhara, S; Kumar, S; Maitra, A; Mukherjee, A; Sarkar-Roy, N; Tripathy, LN | 1 |
| Lei, Q; Li, G; Liu, C; Ma, J; Wang, W; Wang, Z; Wu, M; Xiang, J; Xiao, L; Xiong, J; Xu, G; Yang, H; Yang, J; Yu, Z; Zeng, L | 1 |
| Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD | 1 |
| Eigenbrod, S; Jansen, NL; Janssen, H; Kreth, FW; Kretzschmar, H; la Fougere, C; Linn, J; Pöpperl, G; Simon, M; Suchorska, B; Tonn, JC; Weller, M | 1 |
| Bruno, OD; Christiansen, SB; Danilowicz, K; Juárez-Allen, L | 1 |
| Laterra, JJ; Salvatori, R; Strowd, RE | 1 |
| Lok, E; Swanson, KD; Wong, ET | 2 |
| Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X | 1 |
| Alexandru-Abrams, D; Bota, DA; Hsu, FP; Paff, M | 1 |
| Chen, A; Chen, S; Chen, W; Du, X; He, Y; Huang, B; Li, X; Ma, C; Qu, X; Shao, Q; Wang, D; Zhao, P | 1 |
| Giatromanolaki, A; Kalamida, D; Kalamida, S; Karagounis, IV; Koukourakis, MI; Mitrakas, A | 1 |
| Chicoine, MR; Dacey, RG; DeWees, TA; Dowling, JL; Huang, J; Kim, AH; Leuthardt, EC; Linette, G; Rich, KM; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD; Zipfel, GJ | 1 |
| Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K | 1 |
| Barboriak, DP; Boxerman, JL; Gilbert, MR; Prah, M; Schmainda, KM; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Baudin, E; Caplin, ME; Ferolla, P; Filosso, P; Garcia-Yuste, M; Lim, E; Oberg, K; Pelosi, G; Perren, A; Rossi, RE; Travis, WD | 1 |
| Wang, Q; Wang, W; Zou, Y | 1 |
| Andersen, M; Bengtsson, D; Berinder, K; Burman, P; Feldt Rasmussen, U; Hoybye, C; Johannsson, G; Maiter, D; Petersson, M; Ragnarsson, O; Rasmussen, ÅK; Schrøder, HD; van der Lely, AJ | 1 |
| Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B | 1 |
| Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG | 1 |
| Bhardwaj, RD; Nakaji, P; Ponce, FA; Rosenfeld, A; Xu, DS | 1 |
| Chang-Halpenny, CN; Lien, WW; Yeh, J | 1 |
| Bafaloukos, D; Fountzilas, G; Gogas, H; Linardou, H; Makatsoris, T; Pectasides, D; Pentheroudakis, G; Varthalitis, I | 1 |
| Armstrong, JL; Babatunde, F; Corazzari, M; Eleni Anagnostou, M; Hernandez-Tiedra, S; Hill, DS; Lopez-Valero, I; Lorente, M; Lovat, PE; McKee, CS; Redfern, CPF; Velasco, G | 1 |
| Bian, LG; Cai, S; Liu, W; Pan, SJ; Pan, YX; Sun, B; Sun, QF; Wu, YB | 1 |
| Bahary, JP; Brachman, DG; Chakravarti, A; Coons, SW; Fisher, BJ; Hu, C; Lesser, GJ; Liu, J; Macdonald, DR; Mehta, M; Ryu, S; Werner-Wasik, M | 1 |
| Hong, SH; Hong, YK; Joe, YA; Kim, HK; Kim, HS; Lee, NH; Lee, SW; Yi, HY | 1 |
| Bendszus, M; Blaes, J; Heiland, S; Hertenstein, A; Jestaedt, L; Kessler, T; Milford, D; Osswald, M; Pfenning, PN; Platten, M; Rübmann, P; Ruiz de Almodóvar, C; Sahm, F; Urban, S; von Deimling, A; Weiler, M; Wick, A; Wick, W; Winkler, F | 1 |
| Curran, W; Dignam, JJ; Gilbert, MR; Mehta, M; Wang, M; Won, M | 1 |
| Gu, Y; Liu, J; Ma, L; Qi, J; Yu, W; Zhang, X | 1 |
| Eriksson, J; Froklage, FE; Hendrikse, NH; Reijneveld, JC; Schuit, RC; Van Kooij, R; Windhorst, AD | 1 |
| Bueno e Silva, MM; Filippi-Chiela, EC; Lenz, G; Thomé, MP | 1 |
| Amirbaigloo, A; Cusimano, MD; Di Ieva, A; Fathalla, H; Ghazi, AA; Kovacs, K; Rotondo, F; Syro, LV | 1 |
| Chen, Y; Gao, H; Hu, X; Huang, H; Jiang, Z; Lei, T; Li, P; Liu, P; Mu, Q; Sayari, AJ; Shen, J; Wang, L; Yu, F; Zheng, X | 1 |
| Cerasti, D; Crafa, P; D'Abbiero, N; Froio, E; Ghadirpour, R; Iaccarino, C; Maggi, M; Michiara, M; Nicoli, D; Orlandi, E; Pedrazzi, G; Pisanello, A; Ruggeri, F; Servadei, F; Torricelli, F | 1 |
| Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B | 1 |
| Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
| Biau, J; Chautard, E; Dalloz, P; Durando, X; Hager, MO; Khalil, T; Lemaire, JJ; Ouédraogo, ZG; Verrelle, P | 1 |
| Liu, L; Zhang, M | 1 |
| Bernard, B; Cogdell, DE; Fuller, GN; Granberg, KJ; Hu, L; Ji, P; Nykter, M; Shmulevich, I; Sun, Y; Turner, KM; Yli-Harja, O; Yung, WK; Zhang, W; Zhou, X | 1 |
| Bonetti, MF; Branca, C; Buglione, M; Buttolo, L; Cominelli, M; Dalerba, P; Facchetti, F; Finocchiaro, G; Furlan, D; Galli, R; Grisanti, S; Liserre, B; Liserre, R; Mazzoleni, S; Medicina, D; Pellegatta, S; Pellegrini, V; Pizzi, M; Poliani, PL | 1 |
| Clavreul, A; Lagarce, F; Messaoudi, K | 2 |
| Brown, DV; D'Abaco, GM; Daniel, PM; Gogos, A; Mantamadiotis, T; Morokoff, AP; Ng, W | 1 |
| Chang, FC; Chang, KP; Chen, HH; Chen, YW; Guo, WY; Ho, DM; Hu, YW; Lai, IC; Lee, YY; Liang, ML; Shiau, CY; Wong, TT; Yen, SH | 1 |
| Elhag, R; Mazzio, EA; Soliman, KF | 1 |
| Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH | 1 |
| Chiu, DT; Fang, C; Kievit, FM; Mu, Q; Press, OW; Stephen, ZR; Wang, K; Zhang, M | 1 |
| Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V | 1 |
| Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A | 1 |
| Chuang, SE; Hu, TS; Lai, GM; Lai, IC; Lai, TY; Lui, TN; Shih, PH; Wang-Peng, J; Yao, CJ; Yeh, CT | 1 |
| Ampie, L; Kusne, Y; Sanai, N | 1 |
| Andreieva, S; Huleyuk, N; Kavsan, V; Korets, K; Mykytenko, D; Stepanenko, A; Vassetzky, Y | 1 |
| Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T | 1 |
| Eloy, JA; Liu, JK; Patel, J | 1 |
| Dong, Y; He, H; Lu, Y; Luo, C; Tao, B; Wang, C; Wang, L; Xiang, J; Yu, X; Zhao, Z; Zhou, H | 1 |
| Borghetti, P; Buglione, M; Fontanella, MM; Gipponi, S; Grisanti, S; Liserre, R; Magrini, SM; Pedretti, S; Poliani, LP; Spena, G; Spiazzi, L; Triggiani, L | 1 |
| Ding, WX; Gu, L; Guo, XW; Huang, XE; Liu, YC; Yin, XX; Zhou, SB | 1 |
| Acosta, JC; Arozarena, I; Barriuso, J; Erice, O; Goicoechea, I; Jones, C; Margison, GP; Smith, MP; Wellbrock, C; White, R | 1 |
| Bilke, S; Cao, L; Helman, LJ; Khan, J; Meltzer, PS; Murai, J; Pommier, Y; Rajapakse, V; Sousa, FG; Tang, SW; Varma, S; Yamade, M | 1 |
| Deibert, CP; Engh, JA; Zussman, BM | 1 |
| McDonald, H; Olmez, I; Ozpolat, B; Shen, W | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C | 1 |
| Cai, Q; Chen, Q; Daofeng, T; Dong, H; Guo, Z; Ji, B; Liu, B; Liu, Y; Wang, J; Wang, L; Wu, L; Zhang, S; Zhu, X | 1 |
| Balyasnikova, IV; Bernal, GM; Cahill, KE; Crawley, CD; Larsen, GF; Mansour, NM; Nunez, L; Spretz, R; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W | 1 |
| Belloli, S; Bosari, S; Diceglie, C; Gianelli, U; Lo Dico, A; Lucignani, G; Martelli, C; Moresco, RM; Ottobrini, L; Politi, LS; Raccagni, I; Vaira, V; Valtorta, S | 1 |
| Clemente, MA; Corsa, P; Cossa, S; Donno, E; Munafò, T; Parisi, F; Parisi, S; Perrone, A; Piombino, M; Raguso, A; Sanpaolo, G; Valle, G | 1 |
| Balducci, N; Biolato, M; Di Napoli, N; Diletto, B; Grieco, A; Miele, L; Tafuri, MA; Vecchio, FM | 1 |
| Chai, H; Chen, H; Chen, X; Duan, C; Li, Y; Qin, T; Tang, T; Wang, C; Yang, J; Yue, J; Zhang, J; Zhang, X | 1 |
| Berger, MS; Chang, S; Das, S; Gosio, J; Perry, J; Sahgal, A; Zarnett, OJ | 1 |
| Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H | 1 |
| Sonoda, Y | 1 |
| Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V | 1 |
| Jancalek, R; Kazda, T; Laack, NN; Pospisil, P; Prochazka, T; Sevela, O; Slampa, P; Vrzal, M | 1 |
| Avcı, ÇB; Çıtışlı, V; Dodurga, Y; Eroğlu, C; Şatıroğlu-Tufan, NL; Seçme, M | 1 |
| Aizer, AA; Alexander, BM; Arvold, ND; Chiocca, EA; Christianson, LW; Claus, EB; Dunn, IF; Golby, AJ; Horvath, MC; Johnson, MD; Lee, EQ; Ligon, KL; Nayak, L; Reardon, DA; Tanguturi, SK; Wen, PY | 1 |
| Hattermann, K; Held-Feindt, J; Kubelt, C; Mehdorn, HM; Sebens, S | 1 |
| Krishnamurthy, N; Liu, L; Montano, MM; Xiong, X; Zhang, J | 1 |
| Adesina, A; Chintagumpala, M; Eckel, SP; Gajjar, A; Krailo, M; Lau, C; Morris, M; Packer, R | 1 |
| Berger, MS; Butowski, NA; Chang, SM; Clarke, JL; Han, SJ; Molinaro, AM; Prados, MD; Rutledge, WC; Taylor, JW | 1 |
| Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Metellus, P; Nanni, I; Ouafik, L; Padovani, L; Tabouret, E; Tchoghandjian, A | 1 |
| Cui, L; Gu, X; Li, K; Li, Y; Liang, W; Ma, G; Wang, X; Xiao, H; Zhao, B; Zhou, H | 1 |
| Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM | 1 |
| Jiang, T; Liu, Y; Wang, Z; Yan, W; Yang, P; You, Y | 1 |
| Blanco, E; Castilla-Ortega, E; Estivill-Torrús, G; Ladrón de Guevara-Miranda, D; Pavón, FJ; Pedraz, M; Rodríguez de Fonseca, F; Santín, LJ; Serrano, A | 1 |
| Fei, X; Shi, L; Wang, Z | 1 |
| Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM | 1 |
| Balvers, RK; Berghauser Pont, LM; Dirven, CM; Kleijn, A; Kloezeman, JJ; Lamfers, ML; Leenstra, S | 1 |
| Chong, DQ; Dinesh, N; Ho, IA; Ho, MM; Lai, SH; Lam, PY; Newman, JP; Ng, WH; Sia, KC; Tham, CK; Toh, XY; Yulyana, Y | 1 |
| Gao, Z; Hao, S; Liu, Y; Yu, L | 1 |
| Chen, H; Li, W; Li, X; Zheng, H | 1 |
| Annovazzi, L; Battaglia, L; Caldera, V; Chirio, D; Melcarne, A; Mellai, M; Riganti, C; Schiffer, D | 1 |
| Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H | 1 |
| Beier, CP; Beier, D; Fosmark, S; Hellwege, S; Kristensen, BW; Sørensen, MD | 1 |
| Brown, PD; McAleer, MF | 1 |
| Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F | 1 |
| Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET | 1 |
| Budach, W; Rapp, M; Sabel, M; Sadat, H; Slotty, PJ; Steiger, HJ | 1 |
| Hupert, M; Linz, U; Santiago-Schübel, B; Stab, J; Wagner, S; Wien, S | 1 |
| Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS | 1 |
| Carlson, JA; Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K | 1 |
| Barberis, M; Berruti, A; Fazio, N; Fumagalli, C; Galdy, S; Kaltsas, G; Koumarianou, A; Kulke, MH; Oberg, K; Spada, F; Strosberg, JR | 1 |
| Abdulkarim, B; Azoulay, M; Guiot, MC; Owen, S; Panet-Raymond, V; Patyka, M; Petrecca, K; Sabri, S; Santos, F; Shenouda, G; Souhami, L | 1 |
| Hromas, R; Jaiswal, AS; Jani, J; Law, BK; Narayan, S; Panda, H; Sharma, J | 1 |
| Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Brenke, C; Capper, D; Ening, G; Osterheld, F; Schmieder, K | 1 |
| Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF | 1 |
| Annovazzi, L; Biunno, I; Cassoni, P; Cattaneo, M; De Blasio, P; Melcarne, A; Mellai, M; Schiffer, D; Storaci, AM | 1 |
| Levin, VA | 1 |
| Rinne, ML; Wen, PY | 1 |
| Bryukhovetskiy, I; Bryukhovetsky, A; Khotimchenko, R; Khotimchenko, Y; Mischenko, P; Tolok, E | 1 |
| Balaj, L; Breakefield, XO; Carter, BS; Chung, J; Hochberg, FH; Lee, H; Lee, K; Min, C; Shao, H; Weissleder, R | 1 |
| Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhan, Q; Zhou, D | 1 |
| Kast, RE | 1 |
| Adjabi, A; Almokhles, H; Chargari, C; Falk, AT; Forest, F; Fournel, P; Garin, C; Guy, JB; Hoarau, D; Kawaye, S; Magné, N; Mery, B; Nuti, C; Peoc'h, M; Rivoirard, R | 1 |
| Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH | 1 |
| Caciagli, F; Ciccarelli, R; D'Alimonte, I; Di Iorio, P; Giuliani, P; Lanuti, P; Nargi, E; Pallini, R; Ricci-Vitiani, L; Zuccarini, M | 1 |
| Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K | 1 |
| Ashcraft, KA; Boss, MK; Choudhury, KR; Dewhirst, MW; Keir, ST | 1 |
| Lan, F; Pan, Q; Yu, H; Yue, X | 1 |
| Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW | 1 |
| Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Kraus, A; Nagel, G; Seiwert, N | 1 |
| Fujiwara, H; Hirose, Y; Katayama, M; Kimura, T; Kitamura, Y; Ohira, T; Sasaki, H; Toda, M; Yazaki, T; Yoshida, K | 1 |
| Buckner, JC; Gangat, N; Kourelis, TV; Patnaik, MM | 1 |
| Kovic, B; Xie, F | 1 |
| Bottomley, A; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Mason, WP; Nishikawa, R; Ravelo, A; Saran, F; Taphoorn, MJ; Theodore-Oklota, C; Wick, W | 1 |
| Chung, C; Kiehl, TR; Laperriere, N; Lovblom, LE; Mason, W; McNamara, MG; Ménard, C; Millar, BA; Perkins, BA; Tieu, MT | 1 |
| Chen, Z; Lai, X; Song, S; Zhu, J; Zhu, X | 1 |
| Fietkau, R; Knippen, S; Lahmer, G; Putz, F; Semrau, S | 1 |
| Benecke, R; Grossmann, A; Hildebrandt, G; Kirschstein, T; Piek, J; Rösche, J | 1 |
| Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY | 1 |
| Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P | 1 |
| Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM | 1 |
| Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD | 1 |
| Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; McSherry, F; Miller, E; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| Banković, J; Dinić, J; Hadžić, S; Isaković, A; Paunović, V; Pešić, M; Podolski-Renić, A; Stanković, T; Stojković, S; Tanić, N | 1 |
| Arfuso, F; Bhuvanalakshmi, G; Dharmarajan, A; Millward, M; Warrier, S | 1 |
| Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM | 1 |
| Aquino, A; Bonmassar, E; Bonmassar, L; Caporali, S; Cioccoloni, G; D'Atri, S; Fuggetta, MP; Pagani, E | 1 |
| Cabrini, G; Dechecchi, MC; Fabbri, E; Gambari, R; Lo Nigro, C | 1 |
| Fritsch, J; Hattermann, K; Held-Feindt, J; Krossa, S; Mehdorn, HM; Scheidig, AJ; Schmitt, AD | 1 |
| Agarwal, A; Churi, S; Epari, S; Goda, JS; Gupta, T; Jalali, R; Lewis, S; Moiyadi, A; Padmavati, A; Shetty, P | 1 |
| Butz, L; Dittmann, K; Huber, SM; Klumpp, L; Ruth, P; Stegen, B; Zips, D | 1 |
| Cao, Y; Guo, A; Jiao, Y; Li, H; Li, Y; Liu, Y; Qu, X; Wang, S; Xu, X; Zhao, J | 2 |
| Li, A; Li, Z; Lu, H; Luo, R; Tian, T; Zhang, M | 1 |
| Chie, EK; Cho, BJ; Choi, EJ; Eom, KY; Kim, IA; Kim, IH; Kim, JH; Kim, JS; Paek, SH; Wu, HG | 1 |
| Appelt, JU; Brehmer, S; Gehweiler, J; Giordano, FA; Schmiedek, P; Seiz-Rosenhagen, M; von Deimling, A; Welzel, G; Wenz, F | 1 |
| Alkhafaji, A; Belin, C; Carpentier, AF; Doridam, J; Januel, E; Levy-Piedbois, C; Marantidou, A; Ursu, R | 1 |
| Becher, OJ; Carter, BS; Cavenee, WK; Chen, CC; Chen, HZ; Desai, A; Esashi, F; Furnari, FB; Futalan, D; Kennedy, R; Li, J; Nitta, M; Sarkaria, JN; Shen, Y; Steed, T; Stevens, D; Taich, Z; Treiber, JM; Wykosky, J | 1 |
| Liu, S; Yuan, Y; Zhao, Y; Zhou, L | 1 |
| Claringbold, PG; Turner, JH | 1 |
| Bentayeb, H; Dayen, C; Delentaigne Delogivieres, X; Douadi, Y; Drouard, M; Le Meunier, F; Lecuyer, E; Rault, I; Solomalalarivelo, F; Suguenot, R; Trouve, C | 1 |
| Azinovic, I; Brugarolas, A; Cañón, R; Cases, FG; Rebollo, J; Sapena, NS; Sureda, M; Vanaclocha, V | 1 |
| Brachman, DG; Giannini, C; Hu, C; Jenkins, RB; Laack, NN; Macdonald, DR; Mehta, MP; Peereboom, DM; Shrieve, DC; Souhami, L; Suh, JH; Vogelbaum, MA | 1 |
| Altin, D; Bardal, T; Berg, K; Ellingsen, PG; Gederaas, OA; Hauge, A; Høgset, A; Lindgren, M | 1 |
| Chen, K; Gao, J; Guan, J; He, H; Kong, X; Li, Y; Liu, S; Ma, W; Wang, R; Wang, Y; Xing, B; Yan, C; Yang, Y; Zhou, Q | 1 |
| Cao, Y; Junck, LR; Kim, MM; Lawrence, TS; Mammoser, AG; Parmar, HA; Pramanik, PP; Tsien, CI | 1 |
| Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK | 1 |
| Atif, F; Patel, NR; Stein, DG; Yousuf, S | 1 |
| Amatu, A; Barault, L; Bardelli, A; Bleeker, FE; Cassingena, A; Cassoni, P; De Braud, F; de Witt Hamer, P; Di Nicolantonio, F; Esteller, M; Falcomatà, C; Fiano, V; Milione, M; Moutinho, C; Pietrantonio, F; Rudà, R; Sartore-Bianchi, A; Siena, S; Siravegna, G; Soffietti, R; Venesio, T; Wesseling, P | 1 |
| Cher, L; Dally, M; Drummond, K; Gan, HK; Murphy, M; Rosenthal, MA; Thursfield, V | 1 |
| Debatin, KM; Halatsch, ME; Karpel-Massle, G; Karpel-Massler, G; Nonnenmacher, L; Schneele, L; Schneider, M; Siegelin, MD; Ströbele, S; Westhoff, MA; Zhou, S | 1 |
| Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Garcia, J; Hegde, P; Henriksson, R; Kharbanda, S; Lai, A; Li, C; Mason, W; Moore, N; Nishikawa, R; Peale, F; Phillips, HS; Sandmann, T; Saran, F; Wick, W | 1 |
| Choi, YR; Kim, HR; Kong, DS; Lee, JI; Nam, DH; Seol, HJ | 1 |
| Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J | 1 |
| Cassou-Mounat, T; Cayssials, E; Delwail, V; Puyade, M; Terroir, M | 1 |
| Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN | 1 |
| Boldorini, R; Buosi, R; Gaudino, E; Mancuso, G; Mercalli, F; Mezzapelle, R; Miglio, U; Paganotti, A; Rena, O; Veggiani, C | 1 |
| Furukawa, G; Marco Antonio, DS; Moreira, JC; Okamoto, OK; Rodini, CO; Santos, MC; Silva, PB; Zanotto-Filho, A | 1 |
| Barbeau, LM; Granton, PV; Paesmans, K; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S | 1 |
| Bai, QL; Hu, CW; Li, WL; Lv, YM; Ren, BW; Wang, XR; Yin, GF; Zhang, WG; Zhao, WQ | 1 |
| Fei, X; Shi, L; Wang, Z; You, Y | 1 |
| Moukhlissi, M; Naciri, F | 1 |
| Bastian, A; Gangjee, A; Ihnat, M; Pavana, RK; Saunders, D; Smith, N; Towner, RA | 1 |
| Aalberti, S; Arcella, A; Bartolo, M; Cantore, G; Frati, A; Giangaspero, F; Grillea, G; Madonna, M; Oliva, MA; Pavone, L; Staffieri, S | 1 |
| Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G | 1 |
| Dong, Y; He, H; Hu, G; Li, S; Li, Y; Liu, F; Lu, Y; Luo, C; Meng, Y; Tao, B; Yao, M; Zhang, C; Zhang, W; Zong, H | 1 |
| Gao, J; Huang, G; Liu, H; Wang, L; Wang, Z | 1 |
| Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ | 1 |
| Amighi, K; Gelbcke, M; Mathieu, V; Rosière, R; Van Antwerpen, P; Wauthoz, N | 1 |
| Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M | 1 |
| Du, J; Mao, G; Song, S; Zhu, X | 1 |
| Fan, Y; Lv, S; Wu, M; Xiao, B; Ye, M; Zhu, X | 1 |
| Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND | 1 |
| Batchelor, TT; Dietrich, J; Gerstner, ER; Jafari-Khouzani, K; Kalpathy-Cramer, J; Polaskova, P; Prust, MJ | 1 |
| Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F | 1 |
| Adeberg, S; Bernhardt, D; Bostel, T; Combs, SE; Debus, J; Harrabi, S; Welzel, T; Wick, W | 1 |
| Alvarez, P; Bandiera, P; Farace, C; Madeddu, R; Malaguarnera, G; Melguizo, C; Oliver, JA; Ortiz, R; Prados, J; Rama, AR | 1 |
| Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV | 1 |
| Cai, T; Chen, YD; Liu, Q; Wang, ZF; Wu, H | 1 |
| Giridhar, P; Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK | 1 |
| Brem, H; Burger, P; Chaichana, KL; Gallia, GL; Grossman, R; Olivi, A; Quiñones-Hinojosa, A; Sidransky, D; Soudry, E; Tyler, B; Weingart, J; Ye, X | 1 |
| Hu, M; Lan, F; Xia, T; Yu, H; Yue, X | 1 |
| Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J | 1 |
| Dmitrenko, VV; Stepanenko, AA | 1 |
| Arevalo-Perez, J; Kaley, T; Lyo, J; Peck, KK; Shi, W; Thomas, AA; Young, RJ; Zhang, Z | 1 |
| Bird, TG; Child, F; Morris, SL; Wain, EM; Whittaker, S | 1 |
| Chen, TC; Cho, HY; Hofman, FM; Nguyen, J; Schönthal, AH; Singh, A; Wang, W; Wetzel, SJ | 1 |
| Awaji, M; Boman, BM; Endo, S; Fields, JZ; Hayakawa, Y; Kozano, H; Kurimoto, M; Kuroda, S; Ogata, T; Sugimori, M; Tamura, R; Yamada, M; Yamamoto, S | 1 |
| Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ | 1 |
| Fujihara, I; Fukuoka, K; Ichimura, K; Komori, K; Miyairi, Y; Morita, D; Nakamura, T; Ogiso, Y; Sakashita, K; Sano, K; Shigeta, H; Shiohara, M; Shirahata, M; Yanagisawa, R | 1 |
| Barciszewska, AM; Gurda, D; Głodowicz, P; Naskręt-Barciszewska, MZ; Nowak, S | 1 |
| Dubey, A; Koul, R; Salim, M; Tai, P; Vu, K | 1 |
| Bai, CF; Cai, MQ; Dai, WZ; Jia, SZ; Lin, L; Liu, BX; Wang, LM; Wang, WH; Xu, XY; Zhang, XF; Zhou, RJ | 1 |
| Cuperlovic-Culf, M; Morin, P; Poitras, JJ; St-Coeur, PD; Touaibia, M | 1 |
| Gao, D; He, J; Li, N; Liu, C; Wang, B; Zuo, G | 1 |
| Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M | 1 |
| Chang, EH; DeMarco, J; Kim, E; Kim, SS; Pirollo, KF; Rait, A | 1 |
| Chen, CM; Huang, LJ; Kuo, SC; Lin, CL; Lin, CT; Syu, JP; Way, TD | 1 |
| Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S | 1 |
| Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY | 1 |
| Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W | 1 |
| Narayan, S; Sharma, R | 1 |
| Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L | 1 |
| Lu, P; Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhou, D | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T | 1 |
| Cachia, D; Cykowski, MD; Jalali, A; Langford, LA; Li, J; Penas-Prado, M; Shah, K; Strickland, BA; Weinberg, JS | 1 |
| Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
| Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y | 1 |
| Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS | 1 |
| Kaina, B; Schirrmacher, R; Tomaszowski, KH | 1 |
| Fulda, S; Marschall, V | 1 |
| Bertucci, A; Brognara, E; Corradini, R; De Cola, L; Gambari, R; Manicardi, A; Prasetyanto, EA; Septiadi, D | 1 |
| Scorsone, K; Woodfield, SE; Zage, PE; Zhang, L | 1 |
| Fan, L; He, J; Qiao, Y; Tan, J; Wang, Q; Wu, H; Yang, Q; Zhang, Y | 1 |
| Du Four, S; Duerinck, J; Everaert, H; Hau, P; Michotte, A; Neyns, B; Sander, W; Van Binst, AM | 1 |
| Aasland, D; Berte, N; Christmann, M; Kaina, B; Kitzinger, R; Krämer, OH; Meise, R; Tomicic, MT | 1 |
| Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F | 1 |
| Anghileri, E; Bazzoli, E; Bellu, L; Berti, F; D'Avella, D; Dall'Agata, M; Della Puppa, A; Eoli, M; Fabi, A; Faedi, M; Ferrazza, P; Gurrieri, L; Lombardi, G; Nicolotto, E; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Villani, V; Zagonel, V | 1 |
| An, JB; Bai, GR; Chu, Y; Griffin, AN; Gu, N; Li, SM; Li, W; Liu, CX; Lü, FR; Sun, BY; Sun, H; Wang, GC; Wang, XY; Yan, KJ; Zhou, SP | 1 |
| Chen, X; Gao, J; Li, B; Lu, L; Lu, W; Qian, J; Tai, L; Xie, C; Zhang, M | 1 |
| Chen, Y; Li, C; Li, Y; Xie, G; Yu, H; Yu, Z; Zhang, Z; Zhao, G; Zhao, L | 1 |
| Agar, NY; Boddy, AV; Calligaris, D; Carlson, BL; Cen, L; Curtin, NJ; Elmquist, WF; Kizilbash, S; Mittapalli, RK; Murray, J; Parrish, KE; Sarkaria, JN; Schroeder, MA; Sludden, J | 1 |
| Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM | 1 |
| Gandhi, AK; Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK; Sharma, DN | 1 |
| Bruce, JN; Cheng, SK; Chow, DS; Estrada, JP; Gartrell, R; Isaacson, SR; Jani, A; Lassman, AB; McKhann, GM; Qureshi, YH; Saad, S; Sisti, MB; Soun, JE; Ung, TH; Wang, TJ | 1 |
| Berdasco, M; Caba, O; Cabeza, L; Gónzalez, B; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J | 1 |
| Bulik, M; Jancalek, R; Kazda, T; Slampa, P | 1 |
| Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H | 1 |
| Chen, D; Chen, W; Chen, Y; Chen, Z; Cheng, G; Jiang, T; Liu, N; Lu, D; Luo, H; Peng, C; Qiu, W; Wang, H; Wang, HW; Wang, S; Wu, W; Xu, R; Yang, J; You, Y; Zhang, R; Zhang, S; Zhang, X; Zhao, C; Zhao, L | 1 |
| Ahmed, KA; Caudell, JJ; Chinnaiyan, P; Eschrich, S; Fulp, WJ; Torres-Roca, JF | 1 |
| Adamson, C; Agarwal, VJ; Babu, R; Britt, D; Friedman, AH; Grossi, PM; Iyer, A; Karikari, IO; Komisarow, JM; Rahimpour, S; Thomas, S | 1 |
| Altay, C; Congur, G; Eksin, E; Erdem, A | 1 |
| Neagu, MR; Reardon, DA | 1 |
| Shi, L; Sun, G | 1 |
| Chen, HM; Guan, DG; Liao, SF; Zhao, TZ | 1 |
| Bauer, I; Braun, S; Pannen, B; Werdehausen, R | 1 |
| Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK | 1 |
| Chen, JX; Chen, ZP; Li, ZY; Lu, YC; Ma, WB; Mao, Y; Qi, ST; Shen, H; Wang, JS; Wang, RZ; Wang, X; Yang, QY; Yang, SY; Yang, XJ; Yao, Y; You, C; Zhang, JM; Zhang, LW; Zhang, X; Zhen, HN; Zhou, LF | 1 |
| Ellsworth, S; Grossman, SA; Ye, X | 1 |
| Aleksic, T; Asher, R; Bridges, E; Gao, S; Kamdoum, WP; Li, JL; Macaulay, VM; Margison, GP; Middleton, MR; Pfister, SX; Ramcharan, R; Repapi, E; Tanner, J; Watson, AJ; Woodcock, M | 1 |
| Beauchesne, P; Bernier, V; Carnin, C; Faure, G; Gorlia, T; Noel, G; Pedeux, R; Quetin, P; Quillien, V | 1 |
| Chen, B; Chen, CC; Jiang, T; Li, G; Li, J; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yan, W; Yang, P; Yao, K; You, Y; Zhang, W | 1 |
| Andresen, C; Falchook, GS; George, GC; Hong, DS; Kim, KB; Kurzrock, R; Kwak, J; Nemunaitis, J; Nguyen, LM; O'Brien, JP; Ren, M; Xu, L | 1 |
| Barthorpe, S; Benes, CH; Garnett, MJ; Gill, SJ; Jackson, SP; Kogera, FA; McDermott, U; Mironenko, T; Pshenichnaya, I; Richardson, L; Stratton, MR; Travers, J | 1 |
| Kouri, FM; Ritner, C; Stegh, AH | 1 |
| An, Z; Wang, C; Wang, L; Zhu, N | 1 |
| Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P | 1 |
| Ackermann, K; Chang, P; Chen, Z; Huang, KC; Kolber-Simonds, D; McGonigle, S; Miu, JT; Moniz, GA; Nomoto, K; Shie, JL; Twine, NC; Wu, J | 1 |
| Broes, K; Claes, J; Cox, T; Deben, K; Joosens, E; Maes, A; Mebis, J; Schepers, S; Theunissen, K; Van Ginderachter, L | 1 |
| Gruden, K; Koren, A; Lah, TT; Motaln, H; Ramšak, Ž; Schichor, C | 1 |
| Dullea, A; Marignol, L | 1 |
| Godoy, PR; Montaldi, AP; Sakamoto-Hojo, ET | 1 |
| Bourne, TD; Chen, L; LaRocca, R; Parsons, S; Shearer, AJ; Shelton, BJ; Shields, LB; Spalding, AC; Sun, DA | 1 |
| Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT | 1 |
| Kanamori, M; Saito, R; Shibahara, I; Sonoda, Y; Sugiyama, S; Tominaga, T; Zhang, R | 1 |
| Berenato, R; Bossi, I; Caporale, M; de Braud, F; Di Bartolomeo, M; Dotti, KF; Federici, S; Festinese, F; Iacovelli, R; Leone, G; Maggi, C; Milione, M; Pellegrinelli, A; Perrone, F; Pietrantonio, F; Tamborini, E | 1 |
| Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH | 1 |
| Antonosante, A; Astarita, C; Benedetti, E; Cifone, MG; Cimini, A; Cinque, B; Courty, J; Cristiano, L; d'Angelo, M; Destouches, D; Dhez, AC; Fidoamore, A; Florio, TM; Galzio, R; Giordano, A; Ippoliti, R; Rosati, F | 1 |
| Gourdie, RG; Guo, S; Jourdan, J; Kanabur, P; Lamouille, S; Murphy, SF; Osimani, AM; Pridham, KJ; Rodgers, CM; Sharma, S; Sheng, Z; Simonds, GR; Varghese, RT | 1 |
| Lassman, AB | 1 |
| Bui, Y; Cloughesy, TF; Hong, I; Lai, A; Liau, LM; McBride, WH; Menjivar, JC; Nelson, SF; Stream, A; Tso, CL; Tso, JL; Yamada, K; Yang, S; Yong, WH; Zhang, Y | 1 |
| Brassesco, MS; Delsin, LE; Pezuk, JA; Scrideli, CA; Tone, LG; Valera, ET | 1 |
| Huang, A; Lei, B; Li, H; Liu, Y; Lu, Y; Pan, J; Qi, S; Wang, H; Xiao, L; Zhou, Q | 1 |
| Ananta, JS; Massoud, TF; Paulmurugan, R | 3 |
| Gomez-Gutierrez, JG; Martinez-Jaramillo, E; McMasters, KM; Nitz, J; Riedinger, E; Sam Zhou, H; Sharma, R; Wechman, SL | 1 |
| Beccaria, K; Canney, M; Carpentier, A; Chapelon, JY; Fernandez, C; Goldwirt, L; Lafon, C; Perier, MC; Piquet, J | 1 |
| Allemanni, G; Banelli, B; Barbieri, F; Carosio, R; Carra, E; Daga, A; Florio, T; Forlani, A; Marubbi, D; Parodi, F; Pattarozzi, A; Romani, M; Würth, R | 1 |
| Collier, AB; Gresh, RC; Kamara, DF; Kolb, EA; Sampson, VB; Vetter, NS | 1 |
| Chakrabarti, M; Ray, SK | 1 |
| Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V | 1 |
| Crippa, F; Galldiks, N; Hofer, S; Nowosielski, M; Roelcke, U; Roth, P; Rudà, R; Soffietti, R; Weller, M; Wyss, MT | 1 |
| Azevedo, H; Moreira-Filho, CA | 1 |
| Aller, J; Campderá, M; Estrada, J; Lilienfeld, H; Magallón, R; Martín, P; Palacios, N; Saucedo, G | 1 |
| Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY | 1 |
| Bregy, A; Hanft, S; Hernández-Durán, S; Komotar, RJ; Manzano, GR; Shah, AH | 1 |
| Field, KM; Khasraw, M; Nowak, AK; Rosenthal, MA; Sawkins, K | 1 |
| Schuchter, LM; Wilson, MA | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Coveñas, R; Kast, RE; Lladó, S; Muñoz, M; Ramiro, S; Toro, S | 1 |
| Arita, H; Fukushima, S; Ichimura, K; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Takami, H; Yonezawa, M; Yoshida, A | 1 |
| Pellerino, A; Rudà, R; Soffietti, R | 2 |
| Bogazzi, F; Cannavo, S; Ceccato, F; Curtò, L; De Marinis, L; Iacovazzo, D; Lombardi, G; Losa, M; Mantovani, G; Mazza, E; Minniti, G; Nizzoli, M; Reni, M; Scaroni, C | 1 |
| Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG | 1 |
| Chen, TC; Guo, W; Li, Y; Lv, L; Song, X; Wang, W; Wang, X; Wei, L; Xie, L | 1 |
| Anders, NM; Brem, H; Grossman, SA; Jackson, S; Liu, A; Mangraviti, A; Rudek, MA; Sankey, EW; Tyler, B; Wanjiku, TM | 1 |
| Backus, L; Chow, LM; DeWire, M; Doughman, R; Drissi, R; Fouladi, M; Goldman, S; Grimme, L; Hummel, TR; Kumar, S; Lane, A; Leach, J; Miles, L; Pai, A; Pruitt, D; Salloum, R; Sobo, M; Stevenson, C; Sutton, M | 1 |
| Ji, X; Kang, J; Liu, F; Liu, K; Liu, X; Luo, Y; Wen, S; Zeng, X; Zhao, S | 1 |
| Hanihara, M; Kawataki, T; Kinouchi, H; Mitsuka, K; Nakao, A; Oh-Oka, K | 1 |
| Leung, GK; Poon, MW; Sun, S; Wong, ST; Zhang, XQ; Zhuang, JT | 1 |
| Liang, P; Tang, H; Zhang, L; Zhao, J; Zhuang, Y | 1 |
| Bin, X; Bingbing, X; Dongchun, W; Kun, Z; Xiaoli, L; Yuling, Y | 1 |
| Han, J; Lan, F; Wu, Q; Yang, Y; Yu, H; Yue, X | 1 |
| Boyd, AW; Byrne, AT; Day, BW; Flanagan, L; Kögel, D; Murray, DW; O'Brien, DF; Prehn, JH; Rehm, M; Salvucci, M; Stringer, BW; Tivnan, A; Zakaria, Z | 1 |
| An, P; Chi, XY; Long, B; Tian, Y; Tong, DY; Wu, XY; Zhang, LM; Zhao, XC | 1 |
| Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ | 1 |
| Black, KL; Ly, D; Mukherjee, D; Nuño, M; Ortega, A; Patil, CG; Sarmiento, JM | 1 |
| Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hock, S; Savaskan, NE; Sehm, T; Yakubov, E | 1 |
| Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F | 1 |
| Duan, Y; Gao, P; Shen, M; Sun, Y; Xu, Y | 1 |
| El-Shorbagy, SH; Khedr, RA; Younis, SG | 1 |
| Agasse, F; Armstrong, D; Chen, L; Chen, TC; Commins, D; Hofman, FM; Jhaveri, N; Peng, L; Rosenstein-Sisson, R; Santiago, SV; Santos, T; Schönthal, AH; Vaikari, VP; Wang, W | 1 |
| Benderitter, M; Bernier, MO; Brochet, B; Delattre, JY; Douzane, H; Durand, T; Feuvret, L; Hoang-Xuan, K; Jacob, S; Lebouil, L; Leclercq, D; Lestaevel, P; Milliat, F; Noël, G; Psimaras, D; Rahimian, A; Ricard, D; Tamarat, R; Vayatis, N | 1 |
| Barrié, M; Benouaich-Amiel, A; Chinot, O; Choquet, S; del Rio, MS; Delgadillo, D; Delwail, V; Ghesquieres, H; Gonzalez-Aguilar, A; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Huchet, A; Lacomblez, L; Lamy, T; Lebouvier-Sadot, S; Omuro, A; Soubeyran, P; Soussain, C; Taillandier, L; Tanguy, ML; Touitou, V | 1 |
| Muldoon, LL; Netto, JP; Neuwelt, EA; Pagel, MA | 1 |
| Bianchi, N; Borgatti, M; Breveglieri, G; Brognara, E; Cabrini, G; Corradini, R; Dechecchi, MC; Fabbri, E; Finotti, A; Gambari, R; Gasparello, J; Lampronti, I; Manicardi, A; Milani, R; Montagner, G | 1 |
| Cao, Y; Sun, J; Yang, X; Zhang, W | 1 |
| Choi, KH; Park, M; Song, C; Yoon, H | 1 |
| Bi, Y; Chen, X; Cho, K; Dong, X; Han, D; Hou, X; Liu, H; Liu, Y; Peng, F; Shen, C; Teng, L; Wu, J; Zhao, S | 1 |
| Gao, S; Hao, B; Hong, B; Jiang, C; Li, J | 1 |
| Bihari, F; Hebb, MO; Schmid, S; Whitehead, S; Wong, E; Xu, HU | 1 |
| Chen, Q; Han, J | 1 |
| Mohile, NA | 1 |
| Campian, JL; Gao, F; Govindan, A; Huang, J; Leong, J; Mendez, JS | 1 |
| Belasco, JB; Cervone, KA; Egan, G; Finlay, JL; Gardner, SL; Philips, PC | 1 |
| Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X | 1 |
| Armoiry, X; Aulagner, G; Cartalat-Carel, S; Diebold, G; Ducray, F; Frappaz, D; Guyotat, J; Hartmann, D; Henaine, AM; Honnorat, J; Paubel, N | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E; Tosoni, A | 1 |
| Archer, GE; Choi, BD; Congdon, KL; Healy, P; Herndon, JE; Norberg, PK; Reap, EA; Sampson, JH; Sanchez-Perez, L; Saraswathula, A; Sayour, EJ; Schmittling, RJ | 1 |
| Bégué, RE; Deputy, S; Toler, J; Zakris, E | 1 |
| Berens, ME; Dhruv, HD; Ensign, SP; Loftus, JC; Mathews, IT; Roos, A; Sarkaria, JN; Symons, MH; Tran, NL; Tuncali, S | 1 |
| Battiste, JD; Bonney, PA; Maurer, AJ; McNall-Knapp, RY; Santucci, JA; Sughrue, ME | 1 |
| Nagane, M; Nitta, Y; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K | 1 |
| Dang, X; Hu, J; Wang, G; Wang, J; Yao, Z | 1 |
| Cho, YJ; Hwang, YI; Joo, KM; Kang, W; Kim, M; Kim, N; Kim, SH; Nam, DH; Paddison, PJ; Sa, JK | 1 |
| Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W | 1 |
| Brodeur, GM; Cam, N; Croucher, JL; Golden, RL; Guan, P; Hornby, Z; Iyer, R; Kolla, V; Li, G; MacFarland, SP; Naraparaju, K; Wehrmann, L; Wei, G | 1 |
| Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W | 1 |
| Bash, RE; Ewend, MG; Huey, L; McNeill, RS; Miller, CR; Schmid, RS; Simon, JM; Vitucci, M; Werneke, AM; White, KK; Wu, J | 1 |
| Álvarez de Eulate-Beramendi, S; Álvarez-Vega, MA; Balbin, M; Martino-González, J; Sanchez-Pitiot, A; Vallina-Alvarez, A | 1 |
| Alizadeh, D; Badie, B; Berlin, JM; Chen, X; Da Fonseca, A; Gao, H; Guo, Q; Manuel, ER; Ouyang, M; Ren, H; Shah, S; Vonderfecht, SL; Weng, Y; White, EE; Yanyan, S; Zhang, I; Zhang, L | 1 |
| Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP | 1 |
| Dai, S; Gong, Z; Qian, L; Sun, L; Xu, Z; Yan, Y | 1 |
| Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S | 1 |
| Balakrishnan, A; Jaglal, M; Ledford, R | 1 |
| Balana, C; Berrocal, A; Capellades, J; Carrato, C; De la Cruz, JJ; De Las Penas, R; Fernandez, I; Gallego, O; Garcia, A; Gil-Gil, MJ; Giner, P; Henriquez, I; Herrero, A; Luque, R; Martinez-Garcia, M; Peralta, S; Pérez-Segura, P; Ramirez, JL; Reynes, G; Sanz, C; Sepúlveda, JM; Vazquez-Estevez, S; Vieitez, JM; Villà, S | 1 |
| Backen, A; Barriuso, J; Elliott, E; Hubner, R; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Ai, L; Akgoz, A; Cheng, S; Dai, J; Jiang, T; Leung, K; Li, H; Li, S; Li, X; Qin, L; Qu, J; Rahman, R; Seethamraju, R; Wang, Q; Young, GS | 1 |
| Chen, K; Chen, TC; Groshen, SL; Hofman, FM; Jhaveri, N; Kota, R; Kushal, S; Olenyuk, BZ; Shih, JC; Vaikari, VP; Wang, W; Yeh, TS | 1 |
| Feng, F; Ling, Z; Sun, C; Wang, L; Wang, S; Wu, B; Xia, L; Yu, Y | 1 |
| Aldaz, P; Arrizabalaga, O; Barrena, C; Carrasco-Garcia, E; Garcia, I; Garros-Regulez, L; Lovell-Badge, R; Manterola, L; Matheu, A; Moncho-Amor, V; Moreno-Cugnon, L; Pollard, S; Ruiz, I; Sampron, N; Villanua, J | 1 |
| Jiang, T; Li, MY; Li, WB; Liu, YW; Peng, XX; Qiu, XG; Wang, KY; Wang, YY; Wang, YZ; Yang, P; Yao, K; Zhang, CB; Zhang, W | 1 |
| Casey, A; Conway, GE; Cullen, PJ; Curtin, JF; Howe, O; Liu, Y; Milosavljevic, V | 1 |
| Aslan, D; Broholm, H; Christensen, IJ; Dyrbye, H; Grunnet, K; Grønbæk, K; Kristensen, LS; Michaelsen, SR; Poulsen, HS | 1 |
| Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS | 1 |
| Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L | 1 |
| Berglund, A; Etame, AB; Forsyth, PA; Kenchappa, RS; Mulé, JJ; Wang, D | 1 |
| Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG | 1 |
| Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R | 1 |
| Borkowska, P; Fila-Daniłow, A; Kowalczyk, M; Kowalski, J; Paul-Samojedny, M; Pudełko, A; Suchanek-Raif, R | 1 |
| Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V | 1 |
| Amatu, A; Barault, L; Bardelli, A; Bencardino, K; Bonazzina, E; Cassingena, A; Chirico, G; Cipani, T; Crivori, P; Di Nicolantonio, F; Esteller, M; Gatto, R; Ghezzi, S; Marrapese, G; Moutinho, C; Palmeri, L; Ricotta, R; Sartore-Bianchi, A; Siena, S; Tosi, F; Truini, M | 1 |
| Chen, J; Chen, X; Ji, M; Jin, J; Xu, B; Xue, N; Zhou, J; Zhou, Q | 1 |
| Beattie, CW; Das Gupta, TK; Yamada, T | 1 |
| Chen, Y; Cheng, Y; Gao, H; Gao, J; Huang, H; Lei, T; Li, G; Li, P; Liu, P; Mu, Q; Sayari, AJ; Sun, Y; Yu, F; Zhai, X | 1 |
| Han, D; Li, B; Qin, Q; Sun, J; Teng, J; Wang, Z; Zhao, Q | 1 |
| Chao, ME; Chen, W; Chu, SS; Ho, DM; Hsieh, TH; Liang, ML; Lin, SC; Liu, DJ; Liu, RS; Liu, YR; Ng, KH; Tsai, CF; Tsai, YN; Wang, HW; Wong, TT; Yang, MH | 1 |
| Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H | 1 |
| Gatto, F; Nielsen, J | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y | 1 |
| Chen, J; Cheng, ZJ; Dwight, T; Howell, VM; Hudson, AL; Ikin, RJ; Khong, P; Parker, NR; Parkinson, JF; Vafaee, F; Wheeler, HR; Zhu, Y | 1 |
| Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M | 1 |
| Baruzzi, A; Bertolini, F; Biasini, C; Brandes, AA; Cavallo, MA; Crisi, G; Dazzi, C; Depenni, R; Ermani, M; Faedi, M; Franceschi, E; Michiara, M; Mucciarini, C; Paccapelo, A; Pasini, G; Pavesi, G; Pisanello, A; Servadei, F; Sturiale, C; Urbini, B | 1 |
| Bromberg, JE; Buckner, J; Van Den Bent, MJ | 1 |
| Chen, TC; Song, X; Wang, W; Wang, X; Xie, L; Zeng, Q | 1 |
| Acanda, AM; Alonso, MM; Aragón, T; Fueyo, J; Garzón, AG; Gomez-Manzano, C; Gonzalez-Huarriz, M; Idoate, MA; Jones, C; Lang, FF; Martínez-Irujo, JJ; Martínez-Velez, N; Vera, B; Xipell, E | 1 |
| Choi, C; Choi, K; Kim, E; Lee, J; Ryu, SW | 1 |
| Duan, Y; Li, Y; Shen, M; Sun, Y; Teng, Y; Wang, Y; Xu, Y | 1 |
| Chen, D; Chen, Y; Chen, Z; Liu, N; Luo, H; Peng, C; Qiu, W; Wang, H; Wang, HW; Wang, S; Xu, R; You, Y; Zhao, L | 1 |
| Cicchelero, L; Daminet, S; de Rooster, H; Denies, S; Polis, I; Sanders, NN; Van de Maele, I | 1 |
| Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI | 1 |
| Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W | 1 |
| Carlson, BL; Decker, PA; Kitange, GJ; Lee, JH; Mladek, AC; Nair, AA; Pokorny, JC; Sarkaria, JN; Schroeder, MA; Yan, H; Zhang, Y; Zhang, Z | 1 |
| Ferguson, SD; Ghali, MG; Heimberger, AB; Srinivasan, VM | 1 |
| Cabrera, I; De Cola, L; Maggini, L; Prasetyanto, EA; Robinet, E; Ruiz-Carretero, A | 1 |
| Belka, C; Brehmer, S; Dunkl, E; Fietkau, R; Friedrich, F; Gerlach, R; Glas, M; Goldbrunner, R; Grau, S; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Kohnen, R; Kortmann, RD; Krex, D; Leutgeb, B; Maciaczyk, J; Mack, F; Mayer-Steinacker, R; Mehdorn, M; Pietsch, T; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Stuplich, M; Tüttenberg, J; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A | 1 |
| Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L | 1 |
| Jiang, P; Li, W; Ma, X; Sun, X; Xu, S; Zhan, R | 1 |
| Knisely, JP; Zhang, I | 1 |
| Baronchelli, S; Bentivegna, A; Butta, V; Cilibrasi, C; Dalprà, L; Lavitrano, M; Redaelli, S; Riva, G | 1 |
| Bredlau, AL; Broome, AM; Dixit, S; McKinnon, E; Miller, K; Moore, A | 1 |
| Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T | 1 |
| An, X; Ba, Y; Chen, C; Huang, P; Li, C; Li, Y; Wang, D; Wang, F; Xu, R; Zeng, J; Zeng, Z; Zhang, L | 1 |
| Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL | 1 |
| Gorospe Sarasúa, L; Muñoz Del Toro, JR; Ureña-Vacas, A | 1 |
| Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M | 1 |
| Cai, J; Chen, B; Feng, Y; Han, B; Jiang, C; Li, J; Li, Q; Li, R; Li, Y; Sun, Y; Tian, Y; Wang, G; Yi, L | 1 |
| Adeberg, S; Bernhardt, D; Debus, J; Diehl, C; Harrabi, SB; Koelsche, C; Rieken, S; Unterberg, A; von Deimling, A | 1 |
| Amornkitbamrung, V; Ruangpornvisuti, V; Sang-Aroon, W | 1 |
| Cai, P; Dahmane, N; Fan, Y; Gong, Y; Huang, M; Kim, HJ; Koumenis, C; Li, C; Liu, T; Ma, P; Mitteer, RA; O'Rourke, DM; Roccograndi, L; Yeo, E; Zhang, D; Zhang, L; Zhang, Z; Zhao, B | 1 |
| Kishor, K; Pandit, PN; Raj, S | 1 |
| Gramatzki, D; Roth, P; Seystahl, K; Weller, M | 1 |
| Arús, C; Candiota, AP; Ciezka, M; Delgado-Goñi, T; Fernández, F; Julià-Sapé, M; Lisboa, PJ; Olier, I; Ortega-Martorell, S; Pumarola, M | 1 |
| An, Y; Bo, C; Li, N; Ma, W; Zhang, G; Zhou, C | 1 |
| Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T | 1 |
| Brem, S; Chawla, S; Mohan, S; Peters, KB; Poptani, H; Skolnik, A; Verma, G; Wang, S | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Limpastan, K; Nanegrungsunk, D; Sripetchwandee, J; Vaniyapong, T; Watcharasaksilp, W; Yarana, C | 1 |
| Wang, E; Wu, F; Yu, G | 1 |
| Huang, GH; Li, N; Lv, SQ; Ma, ZX; Sidlauskas, K; Tang, JH; Xiang, Y; Xu, QF; Zhang, EE | 1 |
| Aoki, H; Echizenya, S; Fujii, Y; Ichikawa, S; Isogawa, M; Kondo, T; Maenaka, K; Matsuda, A; Natsumeda, M; Ogura, R; Ohtsu, N; Otsuguro, S; Sakaitani, M; Tsukamoto, Y | 1 |
| Cher, L; Gan, HK; Hamid, A; Parakh, S | 1 |
| Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H | 1 |
| Bao, L; Chen, Y; Feng, J; Han, S; Lv, L; Wang, X; Zhao, H | 1 |
| Chan, MD; Debinski, W; Li, KC; Liu, K; Paulsson, A; Qian, X; Tan, H; Wang, G; Wang, M; Yang, T; Yu, H; Zhang, J; Zhou, X | 1 |
| Brown, PD; Cachia, D; Crane, CH; Kamiya-Matsuoka, C; Mahajan, A; McCutcheon, IE; Nam, JY; Penas-Prado, M; Waguespack, SG | 1 |
| DeAngelis, LM; Lin, AL; Sum, MW | 1 |
| Akasov, R; Burov, S; Chiper, M; Dontenwill, M; Leko, M; Markvicheva, E; Vandamme, T; Zaytseva-Zotova, D | 1 |
| Felsberg, J; Gramatzki, D; Hentschel, B; Hofer, S; Krex, D; Reifenberger, G; Roth, P; Rushing, EJ; Schnell, O; Simon, M; Weller, M; Westphal, M; Wick, W | 1 |
| Bernier, V; Blanchard, N; Bonnetain, F; Dalban, C; Lagneau, É; Maingon, P; Mazoyer, F; Mirjolet, C; Noël, G; Truc, G | 1 |
| Chen, S; Cirovic, B; Drachsler, M; Gieffers, C; Kleber, S; Martin-Villalba, A; Mateos, A; Mohr, N; Mueller, W; Sykora, J; Synowitz, M; Tüttenberg, J; Volk, K; Wirtz, CR | 1 |
| Brenner, A; Cavazos, D; Garcia, L; Garcia, M; Gruslova, A; Gustafsson, JA; Li, X; Liu, J; Sareddy, GR; Strom, AM; Tekmal, RR; Vadlamudi, RK; Viswanadhapalli, S | 1 |
| Brandal, P; Johannesen, TB; Tjønnfjord, GE; Vandraas, K | 1 |
| Bodaghi, B; Cassoux, N; Choquet, S; Costopoulos, M; Hoang-Xuan, K; Houillier, C; Le Cossec, C; Legarf-Tavernier, M; LeHoang, P; Nguyen, DT; Omuro, A; Soussain, C; Touitou, V | 1 |
| Arcella, A; Ascierto, PA; Cicala, D; De Divitiis, C; Grimaldi, AM; Iaffaioli, RV; Romano, GM; Simeone, E; Tafuto, S; Tatangelo, F; von Arx, C | 1 |
| Barnholtz-Sloan, JS; Dazard, JE; Stetson, LC | 1 |
| Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W | 1 |
| Khoshnevisan, A; Safari, M | 1 |
| Budriene, S; Di Martino, A; Maciulyte, S; Pavelkova, A; Sedlarik, V | 1 |
| Hsieh, YJ; Hsu, CW; Huang, CW; Huang, YM; Hung, TY; Sze, CI; Wu, SJ; Wu, SN; Yeh, PS | 1 |
| Bellu, L; D'Avella, D; Della Puppa, A; Farina, M; Fiduccia, P; Lombardi, G; Pambuku, A; Zagonel, V | 1 |
| Antoni, D; Berger, A; Biau, J; Castelli, J; Crehange, G; de Crevoisier, R; Feuvret, L; Gutierrez, FL; Haoming, QC; Jouglar, E; Le Reste, PJ; Loussouarn, D; Morandi, X; Noel, G; Nouhaud, E; Thillays, F; Truc, G; Vauleon, E | 1 |
| Al-Sarraj, S; Bridges, LR; Burford, A; Carceller, F; Fowkes, LA; Hovestadt, V; Jerome, N; Jones, C; Jones, DT; Khabra, K; Koh, DM; Laxton, R; Leach, MO; Mackay, A; Mandeville, H; Marshall, LV; Moreno, L; Pearson, AD; Pfister, SM; Saran, F; Vaidya, S; Zacharoulis, S | 1 |
| Chen, Z; Gao, Z; Lai, X; Mao, G; Qu, J; Zhang, L; Zhu, J; Zhu, X | 1 |
| Fenstermaker, RA; Mechtler, LL; Morr, S; Prasad, D; Qiu, J | 1 |
| Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S | 1 |
| Du, J; Liu, J; Wang, J; Wang, Q; Wang, X; Xu, B; Xu, L | 1 |
| Badakhshi, H; Budach, V; Exner, S; Florange, J; Ghadjar, P; Grün, A; Kaul, D | 1 |
| Amini, A; Gaspar, LE; Jones, BL; Karam, SD; Kavanagh, BD; Koshy, M; Ney, DE; Ormond, DR; Rusthoven, CG; Sher, DJ; Youssef, AS | 1 |
| Ashcraft, KA; Batinic-Haberle, I; Birer, SR; Boico, A; Dewhirst, MW; Herndon, J; Peters, KB; Rodriguiz, RM; Roy Choudhury, K; Spasojevic, I; Tovmasyan, A; Weitzel, DH; Wetsel, WC | 1 |
| Beyer, DT; Boudreaux, JP; Chauhan, A; Ramirez, RA; Wang, YZ; Woltering, EA | 1 |
| Lasolle, H; Raverot, G | 1 |
| Cai, Y; Liu, P; Zhao, W; Zhu, J | 1 |
| Cantero, D; Hernandez-Lain, A; Hilario, A; Perez-Nuñez, A; Ramos, A; Sepulveda, JM | 1 |
| Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D | 1 |
| Rybalkina, EY; Shushanov, SS; Stavrovskaya, AA | 1 |
| Chen, X; He, X; Hu, P; Lian, H; Liu, W; Tang, F; Wang, Z; Xie, C; Zhang, Y | 1 |
| Abate, F; Blumberg, AJ; Cazzato, E; Elliott, O; Eoli, M; Finocchiaro, G; Frattini, V; Iavarone, A; Ladewig, E; Lasorella, A; Lee, IH; Lee, JK; Liu, Z; Nam, DH; Park, WY; Rabadan, R; Rosenbloom, DI; Shin, YJ; Wang, J; Zairis, S | 1 |
| Guo, H; He, Z; Huang, Y; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H | 1 |
| Botelho, RV; de Oliveira, MF; Reis, RC; Rotta, JM | 1 |
| Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S | 1 |
| Dollé, F; Gee, AD; Hooker, JM; Liang, SH; Placzek, MS; Rotstein, BH; Vasdev, N; Wilson, AA | 1 |
| Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR | 1 |
| Kraus, JL; Ross, AH; Weatherbee, JL | 1 |
| Behe, M; Frank, S; Grzmil, M; Hemmings, BA; Hess, D; Moncayo, G; Schibli, R; Seebacher, J | 1 |
| Fujimoto, N; Horiguchi, H; Miyamoto, T; Nakata, S; Nobusawa, S; Ueta, H; Uyama, S; Yokoo, H | 1 |
| Bredel, M; Chandler, JP; Ferrarese, R; Grimm, SA; Helenowski, I; Levy, RM; Muro, K; Paton, M; Rademaker, A; Raizer, JJ; Rosenow, J | 1 |
| Mitrofanov, AA; Moiseeva, NI; Panteleev, DY; Pavlova, GV; Pustogarov, NA; Rybalkina, EY; Stavrovskaya, AA; Susova, OY | 1 |
| Ikota, H; Kagoshima, K; Matsumura, N; Nagano, T; Nakajima, N; Nobusawa, S; Yamazaki, T; Yokoo, H | 1 |
| Chosdol, K; Das, BC; Jalota, A; Kumar, M; Sinha, S; Yadav, AK | 1 |
| Bracci, S; Chevalier, A; Delattre, JY; Duran-Peña, A; Feuvret, L; Hitchcock, K; Hoang-Xuan, K; Jacob, J; Laigle-Donadey, F; Mazeron, JJ; Navarro, S; Troussier, I | 1 |
| Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R | 1 |
| Braun, CJ; Bruno, PM; Gilbert, LA; Hemann, MT; Horlbeck, MA; Weissman, JS | 1 |
| Castilho, RF; De Melo, DR; Facchini, G; Ignarro, RS; Lopes-Cendes, I; Rogerio, F; Vieira, AS | 1 |
| Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR | 1 |
| Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M | 1 |
| Kondo, T; Miyamoto, M; Ohta, T; Watanabe, T; Yamamoto, Y; Yamasaki, H | 1 |
| Ji, D; Li, H; Li, Y; Wang, J; Wang, X; Xu, Y; Zhu, Q | 1 |
| Gallo, JM; Pickard, AJ; Wang, T | 1 |
| Burma, S; Gil Del Alcazar, CR; Habib, AA; Mukherjee, B; Todorova, PK | 1 |
| Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F | 1 |
| Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A | 1 |
| Chen, Z; Feng, W; He, M; Lei, B; Li, H; Liu, Y; Lu, Y; Qi, S; Sun, X; Wang, H; Xiang, W; Zhao, L | 1 |
| Ahn, KJ; Chang, JH; Cho, SJ; Cho, YH; Chung, DS; Gwak, HS; Hong, CK; Hong, YK; Hwang, SC; Jung, TY; Kang, MK; Kang, SG; Kang, SH; Kim, BS; Kim, CY; Kim, EH; Kim, EY; Kim, IA; Kim, IH; Kim, JH; Kim, SH; Kim, TM; Lee, KH; Lee, SH; Lee, SI; Lee, YS; Lim, DH; Nam, DH; Park, CK; Seol, HJ; Song, JH; Suh, CO; Yoo, H; Yoon, SM | 1 |
| Liao, Y; Liu, J; Liu, Q; Lv, R; Qiu, X; Wu, M; Xiao, S; Yang, Z | 1 |
| Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME | 1 |
| Billimek, J; Bota, DA; Lee, B; Nolen, SC; Shantharam, S; Su, L; Yu, HJ | 1 |
| Blankenstein, MA; Buter, J; de Groot, M; Heimans, JJ; Holla, FK; Klein, M; Postma, TJ; Reijneveld, JC; Sizoo, EM; Uitdehaag, BMJ; van Mierlo, TJM; Vos, MJ | 1 |
| Choi, E; Han, J; Lee, D; Lee, M; Oh, J; Rhim, T; Tan, X | 1 |
| Kesavan, M; Turner, JH | 1 |
| Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F | 1 |
| Chen, ZY; Liu, YW; Qi, ST; Wang, H; Xiang, W; Xie, SD; Yi, GZ | 1 |
| Choi, CG; Kim, C; Kim, HS; Kim, JH; Kim, SJ; Shim, WH | 1 |
| de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
| Blaes, J; Dong, Z; Green, E; Hertenstein, A; Jugold, M; Lemke, D; Löw, S; Ott, M; Platten, M; Pledl, HW; Sahm, F; Steffen, AC; Weiler, M; Wick, W; Winkler, F; Zorn, M | 1 |
| Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y | 1 |
| Belmonte, G; Miracco, C; Pirtoli, L; Tini, P; Toscano, M | 1 |
| Chatziioannou, A; Kolisis, F; Koryllou, A; Moulos, P; Papadodima, O; Piroti, G; Pletsa, V | 1 |
| Hu, Q; Li, S; Liu, Y; Yan, W; You, Y; Zeng, A | 1 |
| Kamamoto, D; Mizutani, K; Ohara, K; Sasaki, H; Yoshida, K | 1 |
| Cai, Z; Hu, G; Hu, L; Liang, Q; Lu, Y; Wang, Q; Zhang, C | 1 |
| Hong, YS; Jeong, JH; Kim, J; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Park, JH; Park, Y; Yu, CS | 1 |
| Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W | 1 |
| Choi, SH; Heo, DS; Jung, HW; Kim, DG; Kim, IH; Kim, SK; Kim, TM; Lee, SH; Lee, ST; Park, CK | 1 |
| Brock, J; Chalmers, AJ; Lorimer, CF; Saran, F | 1 |
| Bielecka, AM; Obuchowicz, E | 1 |
| Gao, Z; Hao, S; Ji, N; Li, Y; Song, G; Su, Z; Wang, J; Wang, X; Xie, J; Yu, L; Zhang, C; Zhang, P | 1 |
| Battista, S; Colamaio, M; Del Vecchio, L; Federico, A; Fusco, A; Gattordo, R; Gemei, M; Hirata, H; Kuzay, Y; Mari, A; Mimori, K; Pepe, A; Puca, F; Ragozzino, E; Raia, M; Sarnataro, D; Tosti, N | 1 |
| Fan, X; Lan, T; Qu, Y; Song, Y; Wang, H; Yu, C; Zhan, Q; Zhang, M; Zhang, Z; Zhao, Z; Zhou, W | 1 |
| Ambriović-Ristov, A; Berte, N; Christmann, M; Diesler, K; Freund, H; Kaina, B; Majhen, D; Osmak, M; Steigerwald, C; Stojanović, N; Tomicic, MT | 1 |
| Hiddinga, BI; Janssens, A; Pauwels, P; van Meerbeeck, JP | 1 |
| Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML | 1 |
| Arita, H; Fujita, K; Fukai, J; Hashimoto, N; Hatae, R; Higuchi, F; Ichimura, K; Ishibashi, K; Kagawa, N; Kanemura, Y; Kawahara, N; Kinoshita, M; Kobayashi, K; Kodama, Y; Komori, T; Maehara, T; Matsushita, Y; Miyakita, Y; Miyaoka, E; Mori, K; Moriuchi, S; Mukasa, A; Nagane, M; Nakamura, H; Nakamura, T; Narita, Y; Nishikawa, R; Nonaka, M; Ohno, M; Okita, Y; Otani, R; Saito, K; Saito, N; Shibuya, M; Shimizu, S; Shimokawa, A; Shinojima, N; Shirahata, M; Shofuda, T; Sumita, K; Suzuki, H; Suzuki, K; Takami, H; Tamura, K; Tanaka, S; Terakawa, Y; Tomogane, Y; Tsuyuguchi, N; Ueki, K; Uzuka, T; Yamasaki, K; Yoshimine, T; Yoshimoto, K | 1 |
| Cho, BJ; Choi, EJ; Han, TJ; Kim, DH; Kim, IA; Paek, SH; Song, SH | 1 |
| Kasende, OE; Nziko, Vde P; Scheiner, S | 1 |
| Bendszus, M; Chinot, OL; Cloughesy, T; Henriksson, R; Kerloeguen, Y; Mason, W; Nishikawa, R; Revil, C; Saran, F; Wick, W | 1 |
| Efferth, T; Giordano, FA; Krishna, S; Schmiedek, P; Schöttler, U; Wenz, F | 2 |
| Bian, LG; Jiang, H; Liu, W; Pan, SJ; Pan, YX; Sun, B; Sun, QF; Zhan, SK | 1 |
| Butowski, N; Cha, S; Chang, SM; Clarke, J; Crane, JC; Li, Y; Lupo, JM; Molinaro, A; Nelson, SJ; Olson, M; Prados, M; Roy, R | 1 |
| Ishikawa, E; Ishikawa, H; Matsuda, M; Matsumura, A; Mizumoto, M; Okumura, T; Sakurai, H; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP | 1 |
| Carpentier, C; Chiforeanu, D; Chinot, O; Ducray, F; Entz-Werle, N; Escande, F; Figarella-Branger, D; Fina, F; Joly, MO; Karayan-Tapon, L; Lavenu, A; Legrain, M; Levallet, G; Quillien, V; Ramirez, C; Rivet, P; Sanson, M; Vauleon, E; Zalcman, EL | 1 |
| Gu, S; Huang, D; Lin, C; Wen, X; Zhao, P | 1 |
| Bradbury, RH; Brown, H; Caldecott, KW; Cranston, AN; Evers, B; Jaspers, JE; Jones, L; Jonkers, J; Knights, C; Lau, A; Martin, NM; O'Connor, MJ; Odedra, R; Oplustil O'Connor, L; Pajic, M; Rottenberg, S; Rudge, D; Rulten, SL; Ting, A | 1 |
| Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J | 1 |
| Amoroso, L; Bautista, F; Chevance, A; Gambart, M; Garaventa, A; Geoerger, B; Le Deley, MC; Moreno, L; Paoletti, X; Pearson, AD; Rubie, H; Valteau-Couanet, D; Varo, A; Vassal, G | 1 |
| Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M | 1 |
| Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M | 1 |
| Ashby, LS; Smith, KA; Stea, B | 1 |
| Castro, MG; Doherty, R; Lowenstein, PR; Wilson, TJ; Zamler, DB | 1 |
| Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Nanni, I; Padovani, L; Tabouret, E | 1 |
| Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M | 1 |
| Butowski, N; Cha, S; Chang, S; Crane, J; Kadambi, AK; Li, Y; Molinaro, A; Nelson, SJ; Olson, M; Park, I; Roy, R | 1 |
| Halevy, C; Whitelaw, BC | 1 |
| Chang, JH; Cheong, JH; Choi, J; Huh, YM; Jeon, JY; Kang, SG; Kim, EH; Kim, P; Kim, SH; Koh, I; Lee, JH; Lee, SJ; Park, J; Pollak, M; Shim, JK; Yook, JI; Yun, M | 1 |
| Agnihotri, S; Alamsahebpour, A; Aldape, KD; Burrell, KE; Golbourn, B; Jalali, S; Mansouri, S; Taccone, MS; Tonge, PD; Vartanian, A; Wilson, MR; Zadeh, G | 1 |
| Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W | 1 |
| Chen, XB; Gao, YT; Liu, HL | 1 |
| Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W | 1 |
| Engel, D; Flüh, C; Hattermann, K; Held-Feindt, J; Mehdorn, HM; Mentlein, R; Synowitz, M | 1 |
| Creemers, SG; de Herder, WW; Feelders, RA; Franssen, GJ; Hofland, LJ; Korpershoek, E; van den Dungen, ES; van Kemenade, FJ; van Koetsveld, PM | 1 |
| Buchfelder, M; Eyüpoglu, IY; Rauh, M; Savaskan, NE; Sehm, T; Wiendieck, K | 1 |
| Banerjee, M; Bernales, S; Chakravarty, S; Dixit, V; Guerrero, J; Gupta, A; Hung, DT; Jangir, R; McCullagh, E; Melkani, P; Middya, S; Olivares, F; Patil, U; Pham, SM; Protter, AA; Rai, R; Raja, M; Riquelme, E; Shrivastava, R; Surya, A; Tripathi, S; Wong, DH; Yadav, S | 1 |
| Arnal, AV; Donovan, LE; Odia, Y; Wang, SH | 1 |
| Berte, N; Eich, M; Kaina, B; Kim, E; Lokan, S | 1 |
| Battiste, J; Bota, DA; Connelly, J; Damek, D; Dunbar, E; Iwamoto, F; Mohile, N; Trusheim, J | 1 |
| Bista, A; Shah, BK; Sharma, S | 1 |
| Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Wang, B; Zhang, XJ | 1 |
| Hou, CX; Wang, P; Ye, JA; Zhan, SQ; Zhou, D | 1 |
| Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M | 1 |
| Hertenstein, A; Platten, M; Wick, W | 1 |
| Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF | 1 |
| Braga, C; Brites, D; Bronze, MR; Falcão, AS; Moreira, R; Perry, MJ; Pinheiro, R; Santos, G | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T | 1 |
| Dalsin, E; Filippi-Chiela, EC; Lenz, G; Onzi, GR; Silva, AO | 1 |
| Baumert, BG; Hegi, ME; Hottinger, AF | 1 |
| Bao, S; Dong, L; Wang, M; Wu, Y; Yun, Y; Zhu, R | 1 |
| Back, M; Baumert, BG; Borchers, C; Bottomley, A; Brandes, AA; Bromberg, JEC; Chinot, O; Coens, C; Enting, RH; Golfinopoulos, V; Gorlia, T; Hassel, MB; Hau, P; Hoang-Xuan, K; Kantor, G; Klein, M; Mason, WP; Reijneveld, JC; Reni, M; Ryan, G; Smits, A; Stupp, R; Taphoorn, MJB; Thiessen, B; Verger, E; Wick, A | 1 |
| Balana, C; Baumert, BG; Brandes, AA; Bravo-Marques, J; Bromberg, JE; Capper, D; Chinot, O; Clement, PM; Dhermain, F; Dif, N; Enting, R; Feuvret, L; Gijtenbeek, JMM; Gorlia, T; Hartmann, C; Hassel, MB; Hegi, ME; Hoang-Xuan, K; Kantor, G; Kros, JM; Kurscheid, S; Lacombe, D; Marosi, C; Mason, WP; Nordal, RA; Rees, J; Reijneveld, JC; Reni, M; Rossiter, JP; Ryan, G; Stupp, R; Taphoorn, MJB; Thiessen, B; Tzuk-Shina, T; van den Bent, MJ; von Deimling, A; Wick, W | 1 |
| Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T | 1 |
| Chang, JH; Chung, YG; Kang, SH; Kim, CH; Kim, JH; Kim, JM; Koh, YC; Kong, DS; Lee, JW; Lim, YJ; Nam, DH | 1 |
| Ikawa, F; Ishifuro, M; Kawamata, T; Kurisu, K; Muragaki, Y; Nishibuchi, I; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Oliver, L; Pacaud, R; Vallette, FM | 1 |
| Amiri, A; Gillard, JW; Le, PU; Machkalyan, G; Maysinger, D; Moquin, A; Petrecca, K; Yoganathan, N | 1 |
| Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G | 1 |
| Hartmann, R; Kahlert, UD; Koch, K; Krüger, AC; Maciaczyk, D; Maciaczyk, J; Schröter, F; Suwala, AK; Willbold, D | 1 |
| Boop, FA; Cai, C; Cheng, J; He, P; Pfeffer, LM; Pfeffer, SR; Sims, M; Wang, Y; Yang, CH; Yue, J | 1 |
| Abbritti, RV; Angileri, FF; Baldari, S; Barresi, V; Cannavò, S; Conti, A; Esposito, F; Ferraù, F; Germanò, A; Priola, SM; Tomasello, F | 1 |
| Amaral, R; da Fonseca, AC; Garcia, C; Geraldo, LH; Lima, FR; Matias, D | 1 |
| Carapella, CM; Carosi, M; Fabi, A; Giannarelli, D; Marucci, L; Maschio, M; Merola, R; Pace, A; Vidiri, A; Villani, V | 1 |
| Dai, X; Lan, Q; Ma, C; Xu, T | 1 |
| Cisneros Castillo, LR; Oancea, AD; Régnier-Vigouroux, A; Stüllein, C | 1 |
| Li, L; Song, C; Wang, S; Zha, Y; Zhao, H | 1 |
| Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Giranda, VL; Han, HS; Isakoff, SJ; Johnson, EF; Kaufman, B; Maag, D; Puhalla, S; Qin, Q; Robson, M; Shepherd, SP; Telli, ML | 1 |
| Hirose, Y; Ohba, S | 1 |
| Cheng, G; Li, H; Li, J; Li, X; Zhang, J | 1 |
| Alexiou, GA; Gerogianni, P; Kyritsis, AP; Vartholomatos, E | 1 |
| Arvold, ND; Cefalu, M; Dominici, F; Schrag, D; Wang, Y; Zigler, C | 1 |
| Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B | 1 |
| Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ | 1 |
| Mingyi, M; Qiu, X; Qiu, Y; Tian, T | 1 |
| Chaim, IA; Gupta, SK; Joughin, BA; Kitange, GJ; Lauffenburger, DA; Mazzucato, P; Nagel, ZD; Samson, LD; Sarkaria, JN | 1 |
| Capelli, E; Corbella, F; Fassina, L; Lupo, G; Mognaschi, ME; Nano, R; Pasi, F | 1 |
| Gao, YF; Li, L; Liu, ZQ; Liu, ZX; Mao, CX; Mao, XY; Wang, ZB; Yin, JY; Zhou, HH; Zhu, T | 1 |
| Aller, J; Alonso, V; Alonso-Gordoa, T; Barriuso, J; Capdevila, J; Carmona-Bayonas, A; Crespo, G; Custodio, A; Gajate, P; Grande, E; Jiménez-Fonseca, P; López, C; Matos, I; Navarro, M; Nieto, B; Sevilla, I | 1 |
| Kobos, R; LaQuaglia, MP; Modak, S; Pandit-Taskar, N; Sait, S | 1 |
| Blondin, N; Chaudhry, A; Connelly, J; Hormigo, A; Hu, J; Mohilie, N | 1 |
| Felker, J; Janss, A; Patterson, B; Wrubel, D | 1 |
| Dronca, RS; Ivanov, LV; Kottschade, LA; Leontovich, AA; Markovic, SN; Nevala, WK; Thompson, MA | 1 |
| Denew, P; Kurowska, M; Maksymowicz, M; Malicka, J; Tarach, JS; Zieliński, G | 1 |
| Chen, J; Li, C; Tan, Q; Wang, M; Wang, Y; Xie, C; Zhan, W; Zhang, Z | 1 |
| Choi, SH; Kim, BR; Kim, IH; Kim, JH; Kim, TM; Lee, ST; Park, CK; Park, SH; Park, SW; Sohn, CH; Yun, TJ | 1 |
| Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M | 1 |
| Fan, B; Jiao, BH; Jing, SY; Sun, GZ; Tong, J; Wang, F; Yang, JK; Yang, JP | 1 |
| Bian, H; Huang, Y; Li, XM; Lin, W; Wang, J; Yao, L; Yin, AA; Zhang, J; Zhang, W; Zhang, X | 1 |
| Ling, B; Michel, D; Sakharkar, MK; Yang, J | 1 |
| Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D | 1 |
| Clark, PA; Deming, DA; Gaal, JT; Kuo, JS; Pasch, CA; Robins, HI; Strebe, JK | 1 |
| Alla, P; Dagain, A; Faivre, A; Fouet, B; Joubert, C; Nguyen, AT; Sahuc, P; Wybrecht, D | 1 |
| Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET | 1 |
| Gao, S; Liang, J; Wang, W; Wang, Y | 1 |
| Baer, C; Blaes, J; Claus, R; Felsberg, J; Galldiks, N; Grimm, C; Hartmann, C; Hau, P; Hertenstein, A; Hielscher, T; Meisner, C; Pietsch, T; Plass, C; Platten, M; Reifenberger, G; Roth, P; Sabel, MC; Sahm, F; Schackert, G; Schliesser, MG; Schmidt-Graf, F; Schramm, J; Vajkoczy, P; von Deimling, A; Weichenhan, D; Weiler, M; Weiß, EK; Weller, M; Westphal, M; Wick, W; Wiestler, B; Winkler, F | 1 |
| Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H | 1 |
| Araki, H; Kuwabara, Y; Ohue, S; Suehiro, S; Tanaka, A; Tanaka, M; Watanabe, S; Yamashita, D | 1 |
| Armstrong, TS; Batchelor, TT; Chang, SM; Cloughesy, T; Galanis, E; Gilbert, M; Gondi, V; Ismaila, N; Lovely, M; Mehta, M; Mumber, MP; Sloan, A; Sulman, EP; Tsien, C | 1 |
| Chen, H; Gong, Z; Gui, Q; Guo, X; Liang, P; Meng, J; Shi, H; Xu, Y; Zhu, W | 1 |
| Chang, CK; Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shih, CM | 1 |
| Cai, J; Chen, L; Jiang, C; Li, J; Li, R; Li, Y; Sun, Y; Yao, K; Zhai, X; Zhang, J; Zhao, S | 1 |
| Belka, C; Eigenbrod, S; Kreth, FW; Kreth, S; Lutz, J; Niyazi, M; Schüller, U; Thon, N; Thorsteinsdottir, J; Tonn, JC | 1 |
| Di, H; Du, J; Sun, S; Wang, J; Wang, Q; Wang, X; Xu, B; Xu, X | 1 |
| Chen, CH; Chen, XY; Chen, Y; Ding, J; Gao, ZW; He, JX; He, Q; Huan, XJ; Li, XH; Liao, XM; Lu, XL; Miao, ZH; Shen, YY; Song, SS; Su, Y; Sun, YM; Tan, C; Tong, LJ; Wang, M; Wang, YQ; Wang, YT; Xiong, B; Yang, CH; Yang, XY | 1 |
| Ando, M; Inoue, Y; Iwase, Y; Kato, T; Muto, S; Uno, Y; Yamada, K | 1 |
| Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A | 1 |
| Blair, AA; Ellenbogen, RG; Gebhart, RN; Jeon, M; Silber, JR; Stephen, ZR; Zhang, M | 1 |
| Egorova, AV; Emelyanova, MA; Inshakov, AN; Khochenkov, DA; Nasedkina, TV; Ryabaya, OO; Stepanova, EV; Zasedatelev, AS | 1 |
| Brem, H; Casaos, J; Choi, J; Eisinger-Mathason, TSK; Felder, R; Frikeche, J; Gorelick, N; Lott, T; Mangraviti, A; Scotland, SJ; Sesen, J; Skuli, N; Tyler, B; Volpin, F | 1 |
| Christensen, BC; Davis, MC; Ernstoff, MS; Fadul, CE; Fisher, JL; Gaur, AB; Hampton, TH; Lewis, LD; Rahme, GJ; Steel, SE; Thomas, AA; Tsongalis, GJ; Whipple, CA | 1 |
| Afghani, N; Mehta, T; Quick, QA; Skalli, O; Tang, N; Wang, J | 1 |
| Augustin, HG; Bae, J; Han, S; He, Y; Kim, C; Kim, I; Kim, IK; Kim, JH; Koh, GY; Lee, D; Lee, S; Oh, SJ; Park, I; Park, JS; Woo, DC | 1 |
| Cahill, DP; Chi, AS; Larvie, M; Louis, DN | 1 |
| Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shen, WL; Shih, CM | 1 |
| Aldape, KD; Bahary, JP; Barger, GR; Belanger, K; Bell, EH; Brachman, D; Brown, PD; Cairncross, JG; Chakravarti, A; Chang, S; Dolinskas, CA; Gilbert, MR; Hunter, G; Jaeckle, K; Mehta, M; Penas-Prado, M; Robins, HI; Schiff, D; Schultz, C; Shih, H; Werner-Wasik, M; Zhang, P | 1 |
| Amatu, A; Barault, L; Bardelli, A; Berenato, R; Caporale, M; Cassingena, A; De Braud, F; Di Nicolantonio, F; Falcomatà, C; Ghezzi, S; Milione, M; Nichelatti, M; Pellegrinelli, A; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F | 1 |
| Baretti, M; Di Tommaso, L; Santoro, A; Simonelli, M | 1 |
| Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhi, T; Zhou, X | 1 |
| Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F | 1 |
| Abdulkarim, B; Corredor, AG; Guiot, MC; Owen, S; Panet-Raymond, V; Petrecca, K; Shenouda, G; Souhami, L | 1 |
| Ajit, NE; Burton, GV; El-Osta, H; Peddi, P | 1 |
| de Ceballos, ML; Gil, C; Gradari, S; Martínez, A; Palomo, V; Pérez-Domper, P; Trejo, JL | 1 |
| Connelly, KE; Dykhuizen, EC; Martin, EC | 1 |
| Borchers, C; Eckert, F; Paulsen, F; Schittenhelm, J; Skardelly, M; Zips, D; Zwirner, K | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K | 1 |
| Lee, TY; Lu, H; Sheng, R; Zhang, C | 1 |
| Abu Rmeileh, A; Benson, AA; Chen, S; Cohen, J; Daher, S; Khoury, T; Mizrahi, M; Yaari, S | 1 |
| Cao, H; Chen, R; Chen, Z; Cheng, Q; Huang, J; Jiang, B; Ma, X; Peng, R; Wan, X | 1 |
| Guo, W; Hou, X; Jiang, G; Li, R; Liu, Y; Ma, Y; Tang, J; Xin, Y; Yang, C | 1 |
| Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H | 1 |
| Cai, L; Su, Z; Tu, M; Yu, Z; Zeng, B; Zheng, W; Zhu, D | 1 |
| Chen, H; Deng, X; Fei, S; Fei, Z; Jin, X; Lin, B; Su, H; Xie, CY; Zhao, L; Zheng, Z | 1 |
| Berger, A; Duchesne, M; Godet, J; Karayan-Tapon, L; Milin, S; Pinel, B; Wager, M | 1 |
| Banasavadi-Siddegowda, Y; Bolyard, C; Dmitrieva, N; Jaime-Ramirez, AC; Kaur, B; Relation, T; Wojton, J; Yoo, JY; Zhang, J | 1 |
| Feng, J; Feng, M; Yan, PF; Zhang, FC; Zhao, HY; Zhao, WH | 1 |
| Aldape, K; Barnholtz-Sloan, JS; Becker, AP; Bell, EH; Blumenthal, DT; Brachman, D; Bredel, M; Brown, PD; Chakravarti, A; Curran, W; Flickinger, J; Gilbert, MR; Glass, J; Grosu, AL; Klimowicz, AC; Lee, RJ; Magliocco, A; McElroy, JP; Mehta, M; Pugh, SL; Robe, P; Salavaggione, AL; Souhami, L; Stupp, R; Won, M | 1 |
| Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z | 1 |
| Berens, ME; Chow, D; Dhruv, HD; Hartman, LK; Inge, LJ; Kloss, J; Loftus, JC; Mathews, IT; Millard, N; Roos, A; Tran, NL; Tuncali, S; Winkles, JA; Yin, HH | 1 |
| Haririan, I; Irani, M; Mir Mohamad Sadeghi, G | 2 |
| Aldape, KD; Batchelor, TT; Chang, SM; Chen, A; Cloughesy, TF; de Groot, J; DeAngelis, LM; Drappatz, J; Fisher, J; Gilbert, MR; Grossman, S; Lieberman, F; Nayak, L; Omuro, A; Prados, M; Wefel, JS; Wen, PY; Ye, X; Yung, AW | 1 |
| Chibbaro, S; Clavier, JB; Goichot, B; Lhermitte, B; Proust, F; Todeschi, J | 1 |
| Cheng, L; Fu, J; Guo, Y; Liao, Y; Liu, Q; Peng, R; Shen, L; Zhao, H | 1 |
| Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Zhang, C; Zhang, XJ; Zhang, Y | 1 |
| Bao, L; Liang, F; Wang, B; Zhang, SM; Zhang, SQ; Zhao, YS | 1 |
| Absalyamova, OV; Inozemtseva, MV; Kobyakov, GL; Lodygina, KS; Poddubskiy, AA; Ryzhova, MV | 1 |
| Guo, H; Liu, H; Liu, J; Liu, T; Shi, F; Wu, L; Wu, Q; Zhang, Q; Zhang, R | 1 |
| Pommier, Y; Rajapakse, VN; Reinhold, WC; Tanaka, M; Thomas, A; Trepel, J | 1 |
| Chang, JH; Chang, JS; Cho, JH; Choi, SH; Kim, JW; Kim, SH; Suh, CO | 1 |
| Luedtke, NW; Marsoner, T; Schmidt, OP; Triemer, T | 1 |
| Bahassi, EM; Chan, TA; Chu, Z; Koncar, RF; Qi, X; Romick-Rosendale, LE; Wells, SI | 1 |
| Du, FY; Ge, L; Gong, AH; Han, X; Jin, J; Peng, WX; Zhang, CL | 1 |
| Chen, C; Chen, W; Ge, XS; He, J; Kong, KK; Li, FC; Li, H; Li, JL; Li, P; Wang, F; Xu, XK | 1 |
| Achari, R; Arun, B; Arunsingh, M; Badgami, RK; Chatterjee, S; Mallick, I; Saha, A; Shrimali, RK | 1 |
| Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM | 1 |
| Feng, E; Sui, C; Sun, G; Wang, T | 1 |
| Ballhausen, H; Belka, C; Nachbichler, SB; Niyazi, M; Schupp, G | 1 |
| Bautista, W; Ewend, MG; Frady, LN; Gilbert, MR; Kwintkiewicz, J; Liu, Y; Lu, Y; MacDonald, J; Moon, SI; Su, YT; Tech, K; Wu, J; Yang, C | 1 |
| Biffoni, M; Buccarelli, M; Cenci, T; D'Alessandris, QG; De Maria, R; Larocca, LM; Martini, M; Olivi, A; Pallini, R; Ricci-Vitiani, L; Runci, D; Signore, M; Stancato, L | 1 |
| Chamberlain, MC; Colman, H; Kim, BT; Raizer, J | 1 |
| Beck, J; Belmonte-Beitia, J; Bodnar, M; Bogdańska, MU; Murek, M; Pérez-García, VM; Schucht, P | 1 |
| Abo-Youssef, AM; Hamzawy, MA; Mohammed, SA; Salem, HF | 1 |
| Chen, BD; Chen, L; Li, QZ; Li, WP; Li, ZY; Zhang, C; Zhang, XJ | 1 |
| Im, CN; Lee, JH; Yun, HH | 1 |
| Chen, Y; Dong, B; Guo, B; Liang, Y; Qiao, W; Xu, W; Zhou, H | 1 |
| Mehta, M; Nishikawa, R; Peters, K; Reardon, D; Wen, P | 1 |
| Li, L; Pei, H; Wang, H; Xia, Q; Xu, K; Zhang, Z | 1 |
| Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK | 1 |
| Ben Abdallah, M; Blonski, M; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S | 1 |
| Hu, Z; Ma, W; Wang, Y; Yan, Y; Zhang, K; Zhao, P | 1 |
| Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y | 1 |
| Bartolini, S; Brandes, AA; Danieli, D; De Biase, D; Ermani, M; Fioravanti, A; Franceschi, E; Ghimenton, C; Lanza, G; Paccapelo, A; Pession, A; Pia Foschini, M; Servadei, F; Silini, EM; Sturiale, C; Talacchi, A; Tallini, G; Volpin, L; Zunarelli, E | 1 |
| An, C; He, X; Hua, X; Kong, X; Liu, X; Matkar, S; Wang, L; Xie, G | 1 |
| Asad, AS; Candolfi, M; Castro, MG; Chandran, M; Koschmann, C; Lowenstein, PR; Mineharu, Y; Shah, D; Yadav, VN | 1 |
| Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H | 1 |
| Cruz, R; Figg, WD; League-Pascual, JC; Lester-McCully, CM; Peer, CJ; Rodgers, L; Ronner, L; Shandilya, S; Warren, KE | 1 |
| Hoostal, S; Lou, E; Peterson, RA; SantaCruz, KS; Touma, W; Wiernik, A | 1 |
| Cheng, YS; Ho, ASW; Kiang, KMY; Lee, D; Leung, GKK; Li, N; Poon, MW; Pu, JKS; Sun, S; Zhang, P; Zhang, X | 1 |
| Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C | 1 |
| Bendszus, M; Felsberg, J; Gramatzki, D; Hentschel, B; Herrlinger, U; Kickingereder, P; Loeffler, M; Pietsch, T; Reifenberger, G; Sabel, M; Schackert, G; Schlegel, U; Tonn, JC; Weller, M; Westphal, M; Wick, W | 1 |
| Chang, JH; Choe, G; Choi, SH; Kim, CY; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, JW; Kim, N; Kim, SH; Kim, TM; Kim, YJ; Lee, ST; Park, CK; Park, SH; Suh, CO; Wee, CW | 1 |
| Azzalin, A; Buffo, A; Garello, F; Magrassi, L; Nato, G; Parmigiani, E | 1 |
| Baumert, BG; Brands, E; Dik, R; Fedrigo, CA; Narayan, RS; Peters, GJ; Slotman, BJ; Sminia, P; Stalpers, LJ; Westerman, BA | 1 |
| Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y | 1 |
| Han, Y; Huang, BS; Huang, D; Luo, QZ; Tang, QP; Wu, LX | 1 |
| Chang, CW; Chen, HH; Chiang, CS; Chiang, WH; Chiu, HC; Huang, WC; Lin, YW; Lu, IL; Tsai, YC | 1 |
| Cao, R; Chen, X; Ji, M; Xu, B; Zhou, J; Zhu, Z | 1 |
| Khazaei, M; Pazhouhi, M | 1 |
| Cheng, W; Han, S; Jiang, Y; Meng, L; Tie, X; Wu, A; Xia, J | 1 |
| Brozka, H; Grzyb, AN; Pistikova, A; Radostova, D; Stuchlik, A; Svoboda, J; Vales, K | 1 |
| Behling, F; Bisdas, S; Borchers, C; Dangel, E; Gohde, J; Koch, M; Lepski, G; Naumann, A; Noell, S; Paulsen, F; Ritz, R; Schittenhelm, J; Skardelly, M; Tabatabai, G; Tatagiba, MS; von Hehn, U; Zips, D | 1 |
| Alattar, AA; Ali, MA; Brandel, MG; Carroll, KT; Carter, B; Chen, CC; Hirshman, B; Lanman, T; Lochte, B | 1 |
| Costa, B; Da Settimo, F; Daniele, S; Giacomelli, C; Giustiniano, M; La Pietra, V; La Regina, G; Marinelli, L; Martini, C; Novellino, E; Pietrobono, D; Silvestri, R; Taliani, S; Trincavelli, ML | 1 |
| Armand, P; Batchelor, TT; Chen, YB; DeFilipp, Z; El-Jawahri, A; Li, S; Nayak, L; Wang, N | 1 |
| Corbetta, C; Finocchiaro, G; Langella, T; Pellegatta, S | 1 |
| Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X | 1 |
| Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P | 1 |
| Barnaby, SN; Cayton, TC; Chalastanis, A; Cole, LE; Ghelfi, ST; Hurley, LA; James, CD; Kouri, FM; Lee, A; May, JL; Merkel, TJ; Mirkin, CA; Savalia, N; Sita, TL; Sprangers, AJ; Stegh, AH | 1 |
| Chen, H; Cheng, X; Huang, S; Liu, J; Lou, S | 1 |
| Jin, X; Lv, M; Sun, P; Tong, G; Wang, N; Zhu, X | 1 |
| Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q | 2 |
| Algara, M; Foro Arnalot, P; Granados, R; Membrive, I; Ortiz, A; Pera, O; Reig, A; Rodriguez, N; Sanz, X | 1 |
| Kesari, S; Ram, Z | 1 |
| Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB | 1 |
| Guan, Y; Qiu, B; Wang, Y; Wu, A; Zhang, D; Zhang, L | 1 |
| Fujioka, K; Ikeda, K; Manome, Y; Murayama, Y; Suzuki, Y | 1 |
| Finiuk, N; Grytsyna, II; Klyuchivska, OY; Lehka, L; Lesyk, RB; Panchuk, RR; Starykovych, MO; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI | 1 |
| Liu, YG; Song, Y; Wang, HW; Xu, ZK | 1 |
| Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK | 1 |
| Kang, CS; Lv, SG; Wang, QX; Wu, MJ; Xiao, B; Xu, B; Ye, MH; Zhu, XG | 1 |
| Haririan, I; Irani, M; Sadeghi, GMM | 1 |
| Bian, XW; Chen, X; Huang, N; Li, C; Li, H; Liu, S; Shen, HY; Wang, Y; Wu, N; Xiao, L; Yu, S | 1 |
| Grosch, J; Hänggi, D; Jung, E; Lemke, D; Osswald, M; Ratliff, M; Solecki, G; Weil, S; Wick, W; Winkler, F | 1 |
| Beck, D; Bonin, M; Garbe, C; Kosnopfel, C; Krieg, K; Lasithiotakis, K; Meier, F; Niessner, H; Sinnberg, T; Wanke, I | 1 |
| Dong, Y; Furuta, T; Hayashi, Y; Kinoshita, M; Minamoto, T; Miyashita, K; Nakada, M; Sabit, H; Uchiyama, N | 1 |
| Cerione, RA; Nakano, I; Rojas, K; Sullivan, KE; Wilson, KF | 1 |
| Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X | 1 |
| Roth, P; Silginer, M; Stupp, R; Weller, M | 1 |
| Barbaro, B; Barone, C; Basso, M; Calegari, MA; Camarda, F; Cassano, A; Cenci, T; de Pascalis, I; Gori, S; Inno, A; Larocca, LM; Martini, M; Monterisi, S; Orlandi, A; Santini, D; Tonini, G | 1 |
| Cai, W; He, M; Li, K; Liu, A; Luo, M; Ouyang, L; Pi, R; Tu, Y | 1 |
| Ohara, K; Sasaki, H; Tamura, R; Tokuda, Y; Yoshida, K | 1 |
| Assié, G; Batisse-Lignier, M; Bonnet, F; Borot, S; Bourcigaux, N; Bresson, D; Caron, P; Castinetti, F; Chabre, O; Chanson, P; Cloix, L; Cortet, C; Delemer, B; Desailloud, R; Gaillard, S; Garcia, C; Haissaguerre, M; Jouanneau, E; Jublanc, C; Lasolle, H; Lebrun-Frenay, C; Raverot, G; Reznik, Y; Sadoul, JL; Taillandier, L; Vasiljevic, A; Villa, C | 1 |
| Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M | 1 |
| Battelli, C; Blaszyk, H; Chow, KH; Emery, IF; Florman, J; George, J; Gopalan, A; Wood, S; Yun, K | 1 |
| Baernreuther, J; Kamp, MA; Rapp, M; Sabel, M; Steiger, HJ; Turowski, B | 1 |
| Altinoz, MA; Bolukbasi, FH; Ekmekci, CG; Elmaci, I; Sari, R; Sav, A; Yenmis, G | 1 |
| Liu, L; Liu, Y; Wang, P; Xue, Y; Yao, Y; Yu, Q | 1 |
| Du Preez, A; Egeland, M; Fernandes, C; Guinaudie, C; Musaelyan, K; Pariante, CM; Thuret, S; Zunszain, PA | 1 |
| Fan, X; Lan, T; Qu, Y; Song, Y; Wang, H; Yu, C; Zhan, Q; Zhang, M; Zhang, Z; Zhao, Z | 1 |
| Cai, J; Han, B; Jiang, C; Li, J; Li, Z; Lin, L; Meng, X; Ming, J; Sun, B; Wang, R; Wu, P | 1 |
| Griguer, CE; Langford, C; Oliva, CR; Suto, MJ; Zhang, W | 1 |
| Du, XL; Lu, G; Zhu, JJ; Zhu, P | 1 |
| Binz, A; Herzog, ED; Kfoury, N; Kim, A; Marpegan, L; Rubin, JB; Simon, T; Slat, EA; Sponagel, J | 1 |
| Abrey, LE; Brennan, CW; Briggs, S; Cairncross, JG; Chakravarty, D; DeAngelis, LM; Faivre, G; Forsyth, P; Gao, J; Grimm, S; Huse, JT; Jonsson, P; Kaley, T; Louis, DN; Martinez, NL; Matasar, M; Mehta, J; Mohile, NA; Moskowitz, C; Nimer, SD; Omuro, A; Paleologos, N; Panageas, KS; Raizer, J; Sauter, CS; Schultz, N; Terziev, R; Thomas, AA | 1 |
| Alter, RA; Boockvar, JA; Chakraborty, S; Fanous, AA; Filippi, CG; Pisapia, DJ; Tsiouris, AJ; White, TG | 1 |
| Aghi, MK; Berger, MS; Choi, S; Chou, A; Flanigan, PM; Jahangiri, A; Kuang, R; McDermott, MW; Molinaro, AM; Truong, A | 1 |
| Liang, DS; Liu, YJ; Ma, YC; Qi, XR; Wu, ZF; Yang, ZZ; Zhang, WJ | 1 |
| Trogrlić, D; Trogrlić, I; Trogrlić, Z | 1 |
| Abdollahi, A; Dokic, I; Klein, C; Oancea-Castillo, LR; Régnier-Vigouroux, A; Weber, KJ | 1 |
| Bielecka-Wajdman, AM; Lesiak, M; Ludyga, T; Obuchowicz, E; Sieroń, A | 1 |
| Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J | 1 |
| Glumac, M; Jakimov, D; Kojic, V; Pejin, B; Tommonaro, G | 1 |
| Hu, Q; Jiang, T; Li, R; Liu, YW; Nie, E; Wang, XF; Wang, Z; Yan, W; You, YP; Zeng, AL; Zhou, X | 1 |
| Chandler, J; Fountas, L; Grimm, S; Helenowski, I; Kumthekar, P; Levy, R; Marymont, M; McCarthy, K; Mehta, M; Muro, K; Raizer, J | 1 |
| Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J | 1 |
| Asai, A; Ito, T; Iwata, R; Kanemura, Y; Koike, T; Maruyama, M; Nakano, Y; Nomura, S; Nonaka, M; Oe, S; Sugimoto, T; Yamada, H; Yoshimura, K | 1 |
| Dai, J; Ma, K; Niu, L; Pan, Y; Wang, X; Yin, H; Yuan, G; Zhang, Y; Zhou, W | 1 |
| Bomal, E; Choi, J; Kakkar, A; Maysinger, D; Moquin, A; Na, L | 1 |
| Cappabianca, P; Cavallo, LM; Frio, F; Grujicic, D; Illic, R; Lavrnic, S; Milicevic, M; Milosevic, S; Nikitovic, M; Raicevic, S; Savic, D; Solari, D; Somma, T | 1 |
| An, M; Beattie, CE; Jaros, BD; Welker, AM | 1 |
| Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI | 1 |
| Choi, SH; Kim, E; Kim, IH; Kim, JW; Kim, TM; Lee, ST; Park, CK; Wee, CW; Yoo, RE | 1 |
| Abadi, MFS; Ahmadi, M; Akbarnejad, Z; Dini, L; Eskandary, H; Farsinejad, A; Nematollahi-Mahani, SN; Vergallo, C | 1 |
| Rushworth, SA; Steverding, D | 1 |
| Li, J; Long, C; Peng, P; Wei, W | 1 |
| Jahan, N; Lee, JM; Shah, K; Wakimoto, H | 1 |
| Chen, Y; Gao, F; Hou, J; Jiang, R; Kang, L; Li, Y; Liu, H; Liu, X; Yang, M; Yi, Y | 1 |
| Herrera-Rios, D; Hoerbelt, T; Jiang, T; Kahlert, UD; Koch, K; Li, G; Maciaczyk, D; Maciaczyk, J; Marquardt, V; Ouwens, DM; Pauck, D; Picard, D; Remke, M; Steiger, HJ; Zhang, W; Zhao, L | 1 |
| Chen, CH; Chen, CY; Chen, LY; Feng, LY; Hood, LE; Hsu, PW; Huang, WT; Wang, K; Wei, KC | 1 |
| Beilken, A; Corbacioglu, S; Dilloo, D; Driever, PH; Dürken, M; Gielen, GH; Hoffmann, M; Karremann, M; Krämer, N; Kramm, CM; Kulozik, A; Scheurlen, W; von Bueren, AO; Wiese, M | 1 |
| Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A | 1 |
| Chen, J; Ding, L; Duan, Y; Huang, C; Li, R; Shen, M; Sun, Y; Wang, Q; Zhang, X | 1 |
| Chang, X; Lian, S; Zhang, H; Zhu, W | 1 |
| Back, M; Brazier, D; Cook, R; Gzell, C; Harris, G; Jayamanne, D; Kastelan, M; Khasraw, M; Louw, S; Parkinson, J; Schembri, G; Wheeler, H | 1 |
| Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Onishi, S; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Allen, PJ; Basturk, O; Capanu, M; Chou, JF; Do, RKG; Horvat, N; Klimstra, DS; Raj, N; Reidy-Lagunes, D; Zhang, L | 1 |
| Bassett, RL; Bedikian, AY; Cain, S; Homsi, J; Hwu, P; Hwu, WJ; Kim, DW; Kim, KB; Papadopoulos, NE; Patel, SP; Washington, E | 1 |
| Lin, Z; Liu, H; Lu, J; Lue, S; Xu, Y; Yu, M; Zhang, H; Zhao, H | 1 |
| Fu, Z; Guo, H; Lian, C; Liu, B; Xu, N; Yang, Z; Zeng, H | 1 |
| Snyder, J; Walbert, T | 1 |
| Allison, SJ; Baronou, E; Cooper, PA; Dunnill, C; Georgopoulos, NT; Latif, A; Phillips, RM; Sadiq, M; Shepherd, S; Shnyder, SD; Stratford, IJ; Wheelhouse, RT; Willans, CE | 1 |
| Batchelor, TT; Cahill, DP; Chi, AS; Fisher, DE; Higuchi, F; Iafrate, AJ; Koerner, MVA; Lelic, N; Miller, JJ; Shankar, GM; Tanaka, S; Tateishi, K; Wakimoto, H | 1 |
| Chitkara, D; Italiya, K; Mittal, A; Sharma, S | 1 |
| Carilli, A; Pellini Ferreira, B; Vasquez, J | 1 |
| Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G | 1 |
| Chang, E; Chen, Z; Cheshier, S; Chin, FT; Daldrup-Link, HE; Falconer, RA; Gambhir, SS; Klockow, J; Li, K; Loadman, PM; Mitra, S; Mohanty, S; Morais, GR; Pisani, L; Rao, J; Yerneni, K | 1 |
| Golomb, G; Grad, E; Guez, D; Last, D; Levi-Kalisman, Y; Mardor, Y; Meirow, H; Nordling-David, MM; Salomon, S; Sharabi, S; Yaffe, R | 1 |
| Glickson, JD; Lee, SC; Leeper, DB; Nath, K; Nelson, DS; Putt, ME; Roman, J | 1 |
| Fukusumi, H; Goto, S; Handa, Y; Inazawa, Y; Kamigaki, T; Kanematsu, D; Kanemura, Y; Mori, K; Moriuchi, S; Nakajima, S; Nonaka, M; Okita, Y; Shofuda, T; Sumida, M; Takada, AI; Yamamoto, A; Yamasaki, M; Yoshioka, E | 1 |
| Dong, Y; Guan, F; Li, D; Li, H; Liu, X; Wang, H; Yan, D; Yang, B; Yuan, X | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Abas, FS; Beattie, CE; Canella, A; Gumin, J; Gurcan, MN; Kaur, B; Kesanakurti, D; Lang, FF; Liu, J; Nagarajan, P; Puduvalli, VK; Sampath, D; Sulman, EP; Welker, AM; Xu, J; Yoo, JY | 1 |
| Ahn, SS; Chang, JH; Cho, J; Choi, HJ; Hong, CK; Kang, SG; Kim, DS; Kim, EH; Kim, SH; Lee, KS; Lee, SK; Moon, JH; Park, HH; Roh, TH; Suh, CO | 1 |
| Basso, G; Boso, D; Calvanese, L; D'Auria, G; Della Puppa, A; Dettin, M; Falcigno, L; Maule, F; Persano, L; Porcù, E; Rampazzo, E; Scabello, A; Zamuner, A | 1 |
| Friedman, GK; Li, R; Perry, A; Reddy, AT; Singh, S; Solomon, DA; Sorge, C | 1 |
| Ishikawa, E; Matsuda, M; Matsumura, A; Nakao, J; Takano, S; Yamamoto, T | 1 |
| Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P | 1 |
| Cuppini, L; DiMeco, F; Fariselli, L; Gaviani, P; Marchetti, M; Milanesi, I; Pinzi, V; Salmaggi, A; Silvani, A; Simonetti, G; Tramacere, I | 1 |
| Azambuja, JH; Beira, FT; Braganhol, E; da Silveira, EF; de Carvalho, TR; do Couto, CT; Oliveira, PS; Pacheco, S; Spanevello, RM; Stefanello, FM | 1 |
| Balça-Silva, J; Canedo, NHS; Correia, AH; De Souza, JM; Do Carmo, A; Dubois, LG; Girão, H; Gonçalves, AC; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB | 1 |
| Fu, Z; Guo, H; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Ito, M; Kiyohara, Y; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Yamaguchi, K | 1 |
| Deitz, AC; Desai, VCA; He, J; Holick, CN; Lanes, S; Quinlan, SC | 1 |
| Luo, Y; Tang, J; Tian, J; Xiang, J | 1 |
| Boichuk, SV; Khusnutdinov, RR | 1 |
| Chen, J; Liu, Y; Ma, D; Mao, D | 1 |
| Chaudhari, P; Goda, JS; Mohanty, BS; Mutalik, S; Prabhu, S; Rai, S; Rao, BSS; Udupa, N | 1 |
| Choi, CG; Jung, SC; Kim, HS; Kim, HW; Kim, JH; Kim, SJ; Park, JE; Ryu, KH; Shim, WH | 1 |
| Chen, L; Cong, D; Hu, S; Li, Q; Li, Y; Wang, D | 1 |
| Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS | 1 |
| Brezzell, AL; Hervey-Jumper, SL; Kim, MM; Leung, D; Nathan, JK; Wilkinson, DA | 1 |
| Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL | 1 |
| Bagatell, R; Gupta, AA; Lysecki, D; Mascarenhas, L; Miller, A; Nicholls, L; Okcu, F; Setty, BA; Stanek, JR | 1 |
| Ananiadou, D; Giatromanolaki, A; Ilemosoglou, M; Kostoglou, G; Koukourakis, M; Lamprou, I; Papadopoulou, M; Pouliliou, S; Sivridis, E; Tsolou, A | 1 |
| Kim, Y; Magrath, JW | 1 |
| Baines, SJ; Blackwood, L; Elliott, JW; Treggiari, E | 1 |
| Cui, C; Li, Y; Liu, B; Lu, C; Song, H; Tian, H; Zhao, J; Zou, S | 1 |
| Howard, TA; Villano, JL; Zhou, Z | 1 |
| Bergin, P; Blackley, E; Gill, S; Haydon, A; McLean, C; Moore, M; Tay, RY | 1 |
| Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK | 1 |
| Goodfellow, E; Jean-Claude, B; Senhaji Mouhri, Z | 1 |
| Bilguvar, K; Chen, S; Chow, RD; Dong, MB; Errami, Y; Gunel, M; Guzman, CD; Martinez, MA; Platt, RJ; Renauer, P; Schmidt, F; Sharp, PA; Wang, G; Ye, L; Youngblood, MW; Zhang, F; Zhang, S | 1 |
| Jbeli, AH; Yu, J | 1 |
| Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T | 1 |
| Chang, KY; Chang, WC; Chen, KY; Chou, SW; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Hung, JJ; Kao, TJ; Ko, CY; Liou, JP; Liu, JJ; Liu, MS; Tsai, SY | 1 |
| Buslei, R; Distel, L; Fietkau, R; Putz, F; Stritzelberger, J | 1 |
| Kamimura, S; Kinoshita, M; Miyachi, M; Moritake, H; Sawa, D; Yamada, A | 1 |
| Brennan, C; Chen, Z; Cimino, PJ; Hambardzumyan, D; Herting, CJ; Kaffes, I; Kaluzova, M; Park, JC; Pitter, KL; Szulzewsky, F; Wang, B | 1 |
| de Moraes, FY; Laperriere, N | 1 |
| Zhu, JJ; Zhu, P | 1 |
| Guo, Z; Li, L; Li, P; Song, L; Sun, G; Tan, Q; Yan, X; Yi, H; Yu, D; Zeng, Z | 1 |
| Ashby, L; Butowski, N; Davis, TA; Drappatz, J; Finocchiaro, G; Goldlust, SA; Green, J; Hamilton, MG; He, Y; Hirte, H; Iwamoto, F; Keler, T; Lim, M; Mechtler, L; O'Rourke, DM; Perry, J; Recht, LD; Sampson, JH; Stupp, R; Tran, DD; Turner, CD; Weller, M; Wick, W; Wong, M; Yellin, MJ | 1 |
| Avgeropoulos, N; Benouaich-Amiel, A; David, C; Demireva, P; Goldlust, S; Kanner, AA; Mehdorn, M; Pannullo, S; Salmaggi, A; Silvani, A; Zhu, JJ | 1 |
| Grossman, SA; Kleinberg, L | 1 |
| Komori, T; Mukasa, A; Sota, T; Takai, K; Tanaka, S; Taniguchi, M | 1 |
| Bilodeau, D; Moroney, C; Mueller, C; Myrehaug, S; Perry, JR; Sahgal, A; Soliman, H; Tsang, DS; Tsao, MN; Tseng, CL | 1 |
| Abraham Koshy, A; Kumar A, A | 1 |
| Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J | 1 |
| Amankulor, NM; Kim, WJ; Newman, WC | 1 |
| Chai, JN; Chheda, MG; Diamond, MS; Fernandez, E; Gorman, MJ; Hubert, CG; McKenzie, LD; Prager, BC; Rich, JN; Richner, JM; Shan, C; Shi, PY; Tycksen, E; Wang, X; Zhang, R; Zhu, Z | 1 |
| Buglione, M; Detti, B; Doino, D; Fiorentino, A; Fusco, V; Greto, D; Krengli, M; Livi, L; Lonardi, F; Magrini, SM; Marrazzo, L; Marzano, S; Masini, L; Migliaccio, F; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S | 1 |
| Liu, Y | 1 |
| Chaskis, E; De Witte, O; Devriendt, D; Goldman, S; Lefranc, F; Luce, S; Minichini, V; Sadeghi, N | 1 |
| Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F | 1 |
| Aoki, K; Asai, N; Enomoto, A; Han, YP; Kato, A; Kato, T; Mii, S; Momota, H; Murakumo, Y; Natsume, A; Ogawa, S; Ohka, F; Shiraki, Y; Suzuki, H; Takahashi, M; Todo, T; Ushida, K; Wakabayashi, T | 1 |
| Hou, Y; Su, J; Wang, L; Wang, Z; Xia, J; Yan, J; Yin, X; Zhao, Z; Zheng, N; Zhou, X | 1 |
| Höftberger, R; Knosp, E; Marosi, C; Micko, ASG; Vila, G; Wöhrer, A; Wolfsberger, S | 1 |
| Cheng, ZX; Wang, ZY; Yin, WB | 1 |
| Jing, D; Shen, L; Yu, H; Zhang, Q; Zhao, Y | 1 |
| Hao, X; He, W; Huang, D; Jiang, B; Lun, X; Wang, Y; Wang, Z; Yin, X | 1 |
| Chang, KY; Chang, WC; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Huang, CT; Hung, JJ; Liu, JJ; Tsai, KK | 1 |
| Anjo, SI; Baltazar, F; Costa, BM; Gomes, ED; Granja, S; Manadas, B; Salgado, AJ; Vieira de Castro, J | 1 |
| Bautista, F; Carceller, F; de Rojas, T; Fioravantti, V; Lassaletta, A; Madero, L; Moreno, L | 1 |
| Hawkins, CJ; Miles, MA | 1 |
| Jin, J; Mao, L; Wang, H; Wang, L; Wang, M; Wei, J | 1 |
| de Groot, JF; Nam, JY | 1 |
| Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M | 1 |
| Balcer, M; Belmans, J; Bouleti, C; De Vleeschouwer, S; Dejaegher, J; Georgieva, PB; Gerhardt, H; Mathivet, T; Matsumoto, K; Mazzone, M; Phng, LK; Sciot, R; Stanchi, F; Stockmann, C; Van Woensel, M; Verschuere, T | 1 |
| An, TT; Chen, YD; Dong, TX; Liu, PF; Xu, YT; Yang, XH; Zhang, W; Zhang, Y | 1 |
| Chen, H; Chen, Q; Han, C; Lan, J; Liu, Q; Lou, M; Que, S; Wang, L; Xue, Y; Zhang, X | 1 |
| Lan, J; Lin, Y; Qian, Z; Qiu, Y; Que, S; Yang, X; Zhou, S; Zhou, Z | 1 |
| Adeberg, S; Bernhardt, D; Bougatf, N; Combs, SE; Debus, J; Haberer, T; Harrabi, SB; Herfarth, K; Paul, A; Rieken, S; Uhl, M; Unterberg, A; Verma, V; Wick, W | 1 |
| Battaglia, G; Carbone, SF; Cerase, A; Miracco, C; Nardone, V; Pastina, P; Pirtoli, L; Rubino, G; Sebaste, L; Tini, P | 1 |
| Akao, N; Hayashi, S; Nakazato, Y; Okamoto, K | 1 |
| Kumar, V; Leonardi, D; Radin, D | 1 |
| Chen, CH; Chen, KT; Cheng, YC; Chung, CY; Lee, IN; Lee, MH; Lu, FJ; Yang, JT | 1 |
| Choi, SH; Kang, KM; Kim, JH; Lim, WH; Nam, JG; Sohn, CH; Yoo, RE; Yun, TJ | 1 |
| Ahluwalia, MS; Braun, K | 1 |
| Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S | 1 |
| Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF | 1 |
| Roussakow, SV | 1 |
| Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA | 1 |
| Chen, L; Hu, Z; Li, Z; Liu, C; Liu, L; Lu, D; Teng, L; Wang, L; Zhao, L | 1 |
| Du, S; Du, Y; Ren, J; Yan, Z; Ying, G; Zhu, Z | 1 |
| Huang, H; Ma, L; Peng, J; Peng, Y; Shao, M; Wang, L; Xia, Z; Zhong, G; Zhu, Z | 1 |
| Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A | 1 |
| Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M | 1 |
| Chammas, R; Cirilo, PDR; Corrêa, BRS; de Sousa Andrade, LN; Furuya, TK; Penalva, LOF; Qiao, M | 1 |
| Wang, H; Zhang, L | 1 |
| Du, J; Fang, X; Huang, X; Jiang, C; Li, X; Liu, Z; Shen, F; Su, J; Wang, X | 1 |
| Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
| Bupathi, M; Chen, JL; Hays, JL | 1 |
| Battaglia, G; Cerase, A; Miracco, C; Nardone, V; Pastina, P; Pirtoli, L; Rubino, G; Sebaste, L; Tini, P | 1 |
| Azab, AK; Fettig, N; Goddu, SM; Jin, A; Kapoor, V; Luderer, MJ; Muz, B; Puente, P; Rogers, B; Salama, NN; Shah, S; Shoghi, K; Thotala, D; Tsien, C | 1 |
| Ichimura, K; Kumagai, K; Mori, K; Nakashima, K; Namba, H; Narita, Y; Otani, N; Sakai, R; Sasaki, N; Shirakihara, T; Takeuchi, S; Tomiyama, A; Toyooka, T; Wada, K; Yamaguchi, H; Yamamoto, Y | 1 |
| Gangoso, E; Marques-Torrejon, MA; Pollard, SM | 1 |
| Deng, Y; Liu, Z; Wang, S; Xie, L; Zheng, M | 1 |
| Biau, J; Chautard, E; Dalloz, P; De Schlichting, E; Dillies, AF; Dupic, G; Durando, X; Fogli, A; Godfraind, C; Khalil, T; Müller-Barthélémy, M; Pereira, B; Verrelle, P | 1 |
| Han, L; Kamdar, MR | 1 |
| Liu, HP; Wang, JW; Zheng, KB | 1 |
| Gorlia, T; Le Rhun, E | 1 |
| Berger, G; Chiocca, EA; Grauwet, K; Hussey, AM; Lawler, SE; Lippard, SJ; Nowicki, MO; Wang, DI; Zhang, H | 1 |
| Baghi Yazdi, M; Mortaz, M; Sefidrokh Sharahjin, N; Shabani, M; Taghipour Zahir, S | 1 |
| Day, PJ; Ghanate, AD; Immanuel, SRC; Marriage, F; Panchagnula, V; Parmar, DS; Raghunathan, A | 1 |
| Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S | 1 |
| De Vos, FYFL; Snijders, TJ; Spliet, WGM; Stades, AME; van der Vlist, A | 1 |
| Ahluwalia, MS; Brem, S; Bruna, J; Di Meco, F; Fink, K; Hegi, ME; Hirte, H; Hottinger, A; Idbaih, A; Kanner, A; Kim, CY; Kirson, ED; Lavy-Shahaf, G; Lhermitte, B; Lieberman, F; Nicholas, G; Paek, SH; Palti, Y; Ram, Z; Read, W; Steinberg, D; Stragliotto, G; Stupp, R; Taillibert, S; Toms, S; Tran, D; Weinberg, U; Weller, M; Zhu, JJ | 1 |
| Carideo, L; Cicone, F; Mamede, M; Minniti, G; Russo, I; Scaringi, C; Scopinaro, F | 1 |
| Jani, P; Pandya, N; Tandel, H; Vanza, J | 1 |
| Gupta, L; Gupta, U; Nakhate, KT; Qayum, A; Sahu, H; Sharma, AK; Singh, SK | 1 |
| Lenders, N; McCormack, A | 1 |
| Chen, CC; Huang, BR; Lai, SW; Lin, C; Lin, HY; Liu, YS; Lu, DY; Tsai, CF | 1 |
| Schecker, J; Schlegel, J; Schneider, F; Schönfelder, M; Wu, W; Würstle, S | 1 |
| Antonova, OM; Chekhonin, VP; Cherepanov, SA; Grinenko, NF; Kurapov, PB; Shepeleva, II | 1 |
| Gilis-Januszewska, A; Hubalewska-Dydejczyk, A; Kluczyński, Ł; Pach, D; Pantofliński, J; Sokołowski, G; Sowa-Staszczak, A; Turek-Jabrocka, R; Wilusz, M; Zieliński, G | 1 |
| Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J | 1 |
| Anders, NM; Figg, WD; George, RT; Gilbert, M; Grossman, SA; Harfi, TT; Jackson, S; McAreavey, D; Nduom, EK; Peer, C; Rudek, MA; Weingart, J; Ye, X | 1 |
| Even-Zohar, N; Greenman, Y | 1 |
| Classen, CF; Linnebacher, M; Schneider, B; Walther, M; William, D | 1 |
| Adamski, V; Chitadze, G; Flüh, C; Hattermann, K; Held-Feindt, J; Kabelitz, D; Synowitz, M | 1 |
| Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D | 1 |
| Dong, T; Dong, Y; Gao, Y; Gong, Y; Li, Q; Pei, C; Ren, H; Su, J; Sun, Q; Xiao, Y; Xing, W; Zhen, Z; Zhou, P | 1 |
| Asllani, I; Baumann, M; Beuthien-Baumann, B; Gommlich, A; Hofheinz, F; Jentsch, C; Krause, M; Krukowski, P; Maus, J; Mutsaerts, HJMM; Petr, J; Platzek, I; Seidlitz, A; Troost, EGC; van den Hoff, J; van Osch, MJP | 1 |
| Huang, J; Ke, CS; Qin, Y; Wan, C; Wu, B; Yang, CS; Yang, KY; Zhang, HB | 1 |
| Chen, C; Hu, Y; Jiang, S; Wang, M; Yin, S; Zhang, S; Zhou, P | 1 |
| Ghia, AJ | 1 |
| Cohen, RJ; Mehta, MP | 1 |
| Hoang, N; Puduvalli, VK | 1 |
| Drappatz, J; Lieberman, F | 1 |
| Chang, HH; Chen, Y; Cheng, YC; Sung, YC; Tsai, WC | 1 |
| Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y | 1 |
| Chen, Z; Dong, Y; He, X; Tong, D | 1 |
| Choi, C; Kim, HM; Kim, HT; Kim, NK; Kim, OJ; Oh, SH; Park, J; Shon, J | 1 |
| Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M | 1 |
| Ahmed, EM; Bandopadhyay, G; Coyle, B; Grabowska, A | 1 |
| Bu, XY; Kong, LF; Luo, JC; Ma, CX; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW; Zhou, ZL | 1 |
| Aprile, G; De Carlo, E; De Maglio, G; Fasola, G; Follador, A; Gerratana, L; Gurrieri, L; Macerelli, M; Masiero, E; Pisa, FE; Pizzolitto, S; Puglisi, F; Rizzato, S | 1 |
| Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC | 1 |
| Blasiak, J; Pawlowska, E; Szatkowska, M; Szczepanska, J | 1 |
| Cui, Y; Feng, H; He, H; Li, J; Li, S; Lin, J; Qiu, G; Song, C; Wei, W; Wu, X; Xu, Q; Zuo, J | 1 |
| Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN | 1 |
| Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC | 1 |
| Ahmed, AK; Jiang, Y; Li, Y; Lv, S; Wang, K; Xu, Q; Zhu, Y | 1 |
| Gru, AA; Hamann, D; Kaffenberger, BH; Lee, DE | 1 |
| Chumakova, A; Lathia, JD | 1 |
| Balasubramanian, K; Brown, BS; Celia, C; Evangelopoulos, M; Parodi, A; Tasciotti, E; Yazdi, IK | 1 |
| Chan, D; Chan, KY; Ho, J; Lam, S; Lee, M; Ma, E; Mak, C; Poon, WS; Wong, ST; Wong, WK; Woo, P | 1 |
| Chen, ZY; Deng, SZ; Feng, WY; Guo, ML; He, MY; Li, YM; Liu, YW; Qi, ST; Sun, XG; Xiang, W; Yi, GZ; Zhao, L | 1 |
| Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M | 1 |
| Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N | 1 |
| Coelho, MAN; Gosselet, F; Lima, J; Loureiro, JA; Pereira, MC; Ramalho, MJ; Sevin, E | 1 |
| Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M | 1 |
| Li, D; Li, X; Liu, ZQ; Pang, FM; Tan, D; Wu, J; Yan, H; Zhang, L | 1 |
| Franco, DG; Marie, SKN; Moretti, IF | 1 |
| Cheng, Y; Jin, W; Liu, H; Liu, N; Tu, Y; Wang, X; Wang, Z; Xu, X; Yang, H; Zhang, P; Zhang, Y | 1 |
| Chiou, SJ; Chou, CH; Chu, CW; Hong, YR; Hsiao, BX; Huang, WS; Loh, JK; Wang, YT; Yang, MC | 1 |
| Abramov, I; Khochenkov, D; Prokofieva, A; Ryabaya, O; Stepanova, E; Zasedatelev, A | 1 |
| Abeysekera, IR; Hai, L; Huang, Y; Li, J; Li, T; Liu, P; Ma, H; Tao, Z; Tong, L; Xie, Y; Yang, X; Yi, L; Yu, S; Yuan, F | 1 |
| Kleiner, DE | 1 |
| Dai, B; Li, J; Qi, N; Zhang, G | 1 |
| Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H | 1 |
| Ahad, A; Ali, A; Aqil, M; Imam, SS; Khan, A; Khan, K; Sultana, Y | 1 |
| Alcaín, FJ; Ariza, J; Arjona-Gutiérrez, J; De la Mata, M; Durán-Prado, M; Ferrín, G; Frontiñán-Rubio, J; Gil-Agudo, A; Gómez, MV; Lozano, E; Martínez-González, A; Moreno, M; Nieva-Velasco, CM; Peinado, JR; Pérez-García, VM; Pérez-Romasanta, L; Pesic, M; Santiago-Mora, RM; Villalba, JM | 1 |
| Alter, RA; Boockvar, JA; Chakraborty, S; Demopoulos, A; Filippi, CG; Fralin, S; Kulason, KO; Langer, DJ; Ortiz, R; Pramanik, B; Ray, A; Schneider, JR; Tan, K; Wong, T | 1 |
| Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y | 1 |
| Carvajal, S; Galvis, A; Giraldo, D; Loaiza, S; Ortiz, L | 1 |
| Jin, S; Li, W; Liang, J; Liang, T; Qian, Z; Qiu, X; Sun, L; Yang, F; Zhang, M | 1 |
| Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A | 1 |
| Adamski, V; Adelung, R; Ceynowa, F; Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M | 1 |
| Gao, Z; Lai, X; Mao, G; Xiao, X; Zhang, J; Zhu, J; Zhu, X | 1 |
| Bruhn, H; Hallbeck, M; Lind, J; Milos, P; Strandéus, M; Vrethem, M | 1 |
| Chen, XG; Ji, M; Lai, FF; Lü, YH; Wang, LY | 1 |
| Hegazy, AM; Hirao, A; Ino, Y; Ito, C; Kasahara, A; Kobayashi, M; Nakada, M; Nomura, N; Peng, H; Tadokoro, Y; Takase, Y; Todo, T; Ueno, M; Vu, HT | 1 |
| Fu, C; Liu, X; Yang, X; Zhang, C | 1 |
| Huang, J; Peng, Y; Shuai, X; Wu, T; Xiao, H | 1 |
| Liu, F; Wang, C; Zheng, J | 1 |
| Bernal, G; Larsen, GF; Mansour, N; Nunez, L; Podell, M; Polster, SP; Yamini, B; Young, JS | 1 |
| Brancati, CIFO; Calastri, MCJ; Ferraz Filho, JRL; Godoy, MF; Gregório, ML; Hatori, G; Lancelloti, CLP; Neiva, CM; Rodrigues Junior, ACP; Rodrigues, NLTO; Souza, DRS; Tognola, WA; Zanovelo, EM | 1 |
| Buonerba, C; Cerbone, L; Cordua, N; De Placido, S; Di Lorenzo, G; Lamberti, G; Marinelli, A; Peluso, G | 1 |
| Hanif, F; Jawed, H; Malhi, SM; Perveen, K; Simjee, SU | 1 |
| Koike, H | 1 |
| Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P | 1 |
| Barkhoudarian, G; Eisenberg, A; Kelly, DF; Ogunbameru, R; Palejwala, SK; Wei, H | 1 |
| de Groot, JF; Harrison, RA | 1 |
| Cheng, YS; Kiang, KMY; Leung, GKK; Li, N; Zhang, P | 1 |
| Fortunato, JT; Pan, E; Reys, B; Singh, P | 1 |
| Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA | 1 |
| Chang, HH; Chen, Y; Cheng, YC; Tsai, WC; Tsao, MJ | 1 |
| Bai, YH; Bao, JJ; Chen, RK; Duan, WC; Liu, J; Liu, XZ; Wang, L; Wang, WW; Wang, YM; Yu, B; Zhan, YB; Zhang, FJ; Zhang, ZY; Zhao, XW; Zhou, JQ | 1 |
| Goze, C; Pujol, CN; Pujol, JL; Roch, B | 1 |
| Hou, S; Sha, LG; Xu, P; Zhang, G | 1 |
| Beberok, A; Buszman, E; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Chen, MF; Cheng, CY; Wang, TC; Yang, WH | 1 |
| Almeida, T; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E | 1 |
| Chen, RM; Chio, CC; Liu, SH; Mohanraj, M; Tai, YT; Yang, ST | 1 |
| Chang, KF; Tsai, NM; Wang, JC | 1 |
| Fu, W; Li, W; Lu, L; Lu, Y; Lv, W; Wang, J; Zhao, Z | 1 |
| Bhattacharya, D; Chakarvarty, S; Kondapi, AK; Kumari, S; Rangaraj, N; Rao, NM | 1 |
| Andreucci, E; Bianchini, F; Calorini, L; Carta, F; Laurenzana, A; Peppicelli, S; Ruzzolini, J; Supuran, CT | 1 |
| Bai, CM; Cheng, YJ; Gao, X; Meng, CT; Yan, XY; Ying, HY; Zhou, JF; Zhou, N | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
| Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ | 1 |
| Specenier, P | 1 |
| Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Guonan, C; Naijie, L; Xin, Z; Xingyi, J | 1 |
| Kortmann, RD; Seidel, C | 1 |
| Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A | 1 |
| Alexandraki, KI; Angelousi, A; Chatzellis, E; Daskalakis, K; Gross, D; Grozinsky-Glasberg, S; Kaltsas, G; Kos-Kudła, B; Koumarianou, A; Maimon, O; Meirovitz, A; Tsoli, M; Wachula, E | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Raj, N; Reidy-Lagunes, D; Wu, YL | 1 |
| Handelman, SK; Jain, HV; Sorribes, IC | 1 |
| Khasraw, M; Lwin, Z; Nowak, AK; Sim, HW | 1 |
| Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y | 1 |
| Li, D; Ma, JP; Wang, L; Weng, JC; Wu, Z; Zhang, JT; Zhang, Y | 1 |
| Haggiagi, A; Lassman, AB | 1 |
| Han, Y; Jia, J; Liu, H; Lu, Y; Shen, J; Wang, L; Xu, H; Yu, R; Zhang, L; Zhao, Z | 1 |
| Chatterjee, A; Gupta, T; Patil, V | 1 |
| Chen, TC; Cho, HY; Duc, TC; Hartman, H; Hofman, FM; Huang, M; Minea, RO; Schönthal, AH; Swenson, SD | 1 |
| Balana, C; Carrato, C; Vaz, MA | 1 |
| Liu, Y; Milano, MT; Mohile, NA; Richardson, M; Serventi, JN; Strawderman, MS; Walter, KA; Warren, KT | 1 |
| Grossman, SA | 1 |
| Aldape, K; Armstrong, TS; Gerstner, ER; Gilbert, MR; Lieberman, F; Mendoza, T; Mikkelsen, T; Omuro, A; Robins, HI; Vera, E; Wen, PY; Wu, J; Yuan, Y | 1 |
| Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C | 1 |
| Akimoto, J; Narita, Y; Tanaka, S | 1 |
| Bardhi, R; Daveluy, S; Farshchian, M | 1 |
| de Groot, JF; Gao, F; Koul, D; Li, X; Wu, S; Yung, WKA | 1 |
| Cloughesy, TF; Lassman, AB | 1 |
| Carrillo, JA; Gill, JM; Kesari, S; Nguyen, M; Sharma, A; Truong, J; Wagle, N; Yalamanchi, M | 1 |
| Alghamdi, B; Alkhayyat, S; Baeesa, S; Bardeesi, A; Bari, MO; Butt, NS; Dallol, A; Kurdi, M; Lary, AI; Maghrabi, Y; Mohamed, F; Saeedi, R; Samkari, A | 1 |
| Dong, L; Jiang, X; Meng, L; Qu, C; Wang, B; Wang, H; Wei, J; Xin, Y; Zhao, Q | 1 |
| Chang, EL; Lo, SS | 1 |
| Greenberger, BA; Werner-Wasik, M | 1 |
| Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y | 1 |
| Narayan Saha, R; Singhvi, G; Waghule, T | 1 |
| Da-Costa-Rocha, I; Prieto, JM | 1 |
| Greenspoon, JN; Mir, T; Pond, G | 1 |
| Ma, W; Zhao, B | 1 |
| Adegboyega, G; Bandyopadhyay, S; Kanmounye, US; Ozair, A; Vaqas, B | 1 |
| Winkler, F | 1 |
| Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S | 1 |
| Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Tresch, NS | 1 |
| Huang, B; Liang, R; Yu, Z | 1 |
| Bender, S; Brada, M; Cseh, A; Gattamaneni, R; Harris, F; James, A; Jefferies, S; McBain, C; Pemberton, K; Saran, F; Schaible, J; Welsh, L | 1 |
| Sun, X; Xu, X; Xu, Y; Zhan, W; Zhao, L; Zhu, Y | 1 |
| Bitar, M; Makalowski, J; Schirrmacher, V; Stuecker, W; Van de Vliet, P; Van Gool, SW | 1 |
| Germano, IM; Olson, JJ; Ormond, DR; Wen, P; Ziu, M | 1 |
| Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W | 1 |
| Arunsingh, MA; Basu Achari, R; Bhattacharyya, T; Biswas, B; Chakraborty, S; Chandra, A; Chatterjee, S; Das, A; Goyal, L; Mallick, I; Mishra, D; Parihar, M; Roy, P; Saha, S; Zameer, L | 1 |
| Lin, GH; Wang, BC; Xiao, BY | 1 |
| Chamallamudi, MR; Kumar, G; Kumar, N; Nandakumar, K; Rao, V; Thorat, ND; Vibhavari, RJA | 1 |
| In Yoon, H; Lee, SW; Lim, DH; Wee, CW | 1 |
| Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY | 1 |
| Amatu, A; Barault, L; Bardelli, A; Bartolini, A; Battuello, P; Bonoldi, E; Cassingena, A; Crisafulli, G; Di Nicolantonio, F; Germano, G; Idotta, L; Lazzari, L; Luraghi, P; Macagno, M; Marsoni, S; Mauri, G; Morano, F; Personeni, N; Pessei, V; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F; Valtorta, E; Vitiello, PP; Zampino, MG | 1 |
| Baro, V; Busato, F; Causin, F; Cerretti, G; Chioffi, F; d'Avella, D; Della Puppa, A; Denaro, L; Fiduccia, P; Landi, A; Lombardi, G; Todoverto, M; Volpin, F; Zagonel, V | 1 |
| Bao, L; Kumar, A; Luo, W; Wang, C; Wang, Y; Xing, C; Yang, M; Zhou, M | 1 |
| Altinoz, MA; Elmaci, İ; Er, O; Gokhan Ekmekci, C; Hacker, E; Kahraman Ozlu, EB; Ozpinar, A; Sari, R; Turkgenc, B | 1 |
| Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F | 1 |
| Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B | 1 |
| Du, J; Li, S; Peng, C; Peng, F; Xie, X | 1 |
| Chen, Z; Lei, J; Sheng, C; Song, S; Zhu, G; Zhu, J | 1 |
| Celis-López, MÁ; Cid-Sánchez, DR; Contreras-Palafox, GA; Flores-Vázquez, JG; Gutiérrez-Aceves, GA; Heredia-Gutiérrez, JC; Hernández-Sánchez, LC; Macías-González, MDS; Moreno-Jiménez, S; Moscardini-Martelli, J; Olmos-Guzmán, A; Ortiz-Arce, CS; Pérez, SR; Rodríguez-Camacho, A; Suárez-Campos, JJE; Torres-Ríos, JA | 1 |
| Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S | 1 |
| Ahmed, MA; Basaran, M; Dogan, I; Iribas, A | 1 |
| Bindra, RS; Gueble, SE; Herzon, SB; Huseman, ED; Lin, K; Sundaram, RK | 1 |
| Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN | 1 |
| Fu, C; Shang, J; Wu, D; Yan, L; Yao, W; Zhai, Y | 1 |
| Ligon, KL; Lim-Fat, MJ; Nassar, AH; Rahman, R; Shi, DD; Wen, PY; Youssef, GC | 1 |
| Garzio, K; Grossman, S; Holdhoff, M; McElroy, K; Ozer, B; Yankulina, O | 1 |
| Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S | 1 |
| Becker, H; Blobner, J; Egensperger, R; Katzendobler, S; Niyazi, M; Quach, S; Suchorska, B; Thiele, F; Thon, N; Tonn, JC; Weller, J; Weller, M | 1 |
| Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA | 1 |
| Gao, J; Kang, ZF; Mai, A; Ting, WJ; Tu, JY; Yao, QM; Ye, SW | 1 |
| Gong, X; Liu, C; She, L; Su, L | 1 |
| Meyers, PA; Slotkin, EK | 1 |
| McCormack, A | 1 |
| Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F | 1 |
| Baek, JY; Beom, SH; Cha, Y; Choi, J; Choi, MK; Hong, YS; Kim, J; Kim, JE; Kim, JH; Kim, SY; Kim, TW; Lee, JS; Lim, SB; Oh, CR; Park, IJ; Park, JH | 1 |
| Chung, S; Huang, J; Sugimoto, Y; Zhang, M | 1 |
| Chen, ZS; Claret, FX; Elkabets, M; Kong, D; Liang, H; Lin, HW; Peng, X; Sun, F; Wang, F; Wang, R; Wang, Y; Yu, Z; Zhang, L; Zhang, S; Zhong, Z; Zhou, Z | 1 |
| Amoroso, B; Aronchik, I; Chang, H; Filvaroff, E; González León, P; Hanna, B; Manuel Sepúlveda, J; Mendez, C; Moreno, V; Nikolova, Z; Pérez-Núñez, Á; Reardon, DA; Sanchez-Perez, T; Stephens, D; Vogelbaum, MA; Zuraek, M | 1 |
| Bady, P; Buri, MC; Chiesi, D; Gusyatiner, O; Hegi, ME; Lomazzi, R; Messerer, M; Tancredi, A | 1 |
| Li, L; Liu, H; Ma, H; Qian, F; Quan, A; Ren, Y; Wang, L; Xu, H; Yu, R; Zhang, Y | 1 |
| Brehmer, S; Bullinger, L; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Hau, P; Herrlinger, U; Kowalski, T; Krex, D; Potthoff, AL; Ringel, F; Sabel, M; Schäfer, N; Schaub, C; Schmidt-Graf, F; Schneider, M; Schnell, O; Seidel, C; Steinbach, JP; Tabatabai, G; Tonn, JC; Tzaridis, T; Vajkoczy, P; Vatter, H; Weller, J; Zeiner, PS; Zeyen, T | 1 |
| Cai, Z; Guo, W; Liang, X; Liu, K; Sun, X; Tang, X; Xie, L; Xu, J | 1 |
| Bromberg, JEC; Doorduijn, JK | 1 |
| Cai, L; Cao, X; Chen, Y; Chen, Z; Deng, M; Du, X; Guo, C; Hu, W; Hu, X; Jiang, T; Jiang, X; Ke, C; Li, C; Li, D; Li, G; Li, J; Li, X; Li, Z; Lin, F; Liu, J; Liu, M; Lv, X; Lv, Y; Mou, Y; Ni, X; Ouyang, H; Qin, Z; Sai, K; Su, J; Wang, H; Wang, J; Wang, Y; Wu, S; Xi, S; Xu, P; Xue, X; Yang, H; Yang, Q; Zeng, J; Zhang, J; Zhang, X; Zhong, S; Zhou, T | 1 |
| Elsaid, AA; Elsaka, R; Kitagwa, JM; Mahmoud, AA; Meheissen, MAM; Refaat, T; Shaikh, H | 1 |
| Aldegheri, V; Bosio, A; Caccese, M; Cerretti, G; Chioffi, F; Della Puppa, A; Denaro, L; Guarneri, V; Lombardi, G; Padovan, M; Zagonel, V | 1 |
| Huang, Q; Yang, L; Ye, Z | 1 |
| Barbot, M; Bergo, E; Caccese, M; Ceccato, F; Cerretti, G; Lombardi, G; Occhi, G; Padovan, M; Scaroni, C | 1 |
| Burman, P; Dekkers, OM; Losa, M; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Theodoropoulou, M; Trouillas, J | 1 |
| Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C | 1 |
| Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F | 1 |
| Alalami, H; Bannykh, S; Fan, X; Hu, J | 1 |
| Baghbanzadeh, A; Baradaran, B; Barpour, N; Doustvandi, MA; Javadrashid, D; Mohammadpour, ZJ; Mohammadzadeh, R | 1 |
| Geer, EB | 1 |
| Chen, CC; Li, M; Ma, J; Wang, Z | 1 |
| Bonsanto, MM; Leppert, J; Rades, D; Trillenberg, P; Yu, NY; Zemskova, O | 1 |
| Bradshaw, TD; Lewis, W; Moody, CJ; Stevens, MFG; Summers, HS; Williams, HEL | 1 |
| Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS | 1 |
| Chen, F; Deng, J; Jiang, J; Kang, X; Kang, Z; Li, S; Li, W; Yang, H; Zhang, J | 1 |
| Afzal, M; Castresana, JS; Hasan, H; Shahi, MH | 1 |
| Badalamenti, G; Barretta, ML; Buonaiuto, M; Cannella, L; Chiariotti, L; Clemente, O; De Chiara, AR; Della Monica, R; Di Marzo, M; Di Mauro, A; Guida, M; Iervolino, D; Marretta, AL; Tafuto, S; Vincenzi, B | 1 |
| Barberis, A; Bocci, G; Buffa, FM; Caffo, M; De Salvo, GL; Harris, AL; Ius, T; Lombardi, G; Mazzanti, CM; Montemurro, N; Paiar, F; Pasqualetti, F; Soffietti, R; Zanotti, S | 1 |
| Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M | 1 |
| Ali, A; Alnahhas, I; Cappelli, L; Kayne, A; Khan, MM; Miller, R; Niazi, M; Poiset, S; Shi, W | 1 |
| Ji, N; Wang, J; Wang, N; Wang, P; Yue, S | 1 |
| Grzywna, E; Krajcer, A; Lewandowska-Łańcucka, J | 1 |
| Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X | 1 |
| Fionda, C; Fontanella, RA; Gaetano, C; Illi, B; Malatesta, S; Salvatori, L; Somma, MP; Stabile, H | 1 |
| Arijs, I; Balvers, RK; Beerepoot, LV; Biswas, A; Byrne, AT; Chi Yen, RT; Connor, K; Dilcan, G; Dirven, CMF; Fabro, F; Idbaih, A; Jimenez-Cowell, K; Ju, J; Kers, TV; Kleijn, A; Klein, M; Kremer, A; Kros, JM; Lambrechts, D; Lamfers, MLM; Lawler, SE; Leenstra, S; Li, Y; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Stubbs, AP; van den Bent, MJ; Verreault, M | 1 |
| Antonelli, M; Arcella, A; Bozzao, A; Capone, L; De Pietro, R; Esposito, V; Gianno, F; Giraffa, M; Lanzetta, G; Minniti, G; Paolini, S; Romano, A; Tini, P | 1 |
| Andreassen, M; Clausen, MM; Kjær, A; Knigge, U; Langer, SW; Petersen, RH; Soldath, P; Ørting, AM | 1 |
| Duffy, C; Galldiks, N; Glas, M; Goldbrunner, R; Grauer, O; Hattingen, E; Hau, P; Herrlinger, U; Krex, D; Nitsch, L; Paech, D; Potthoff, AL; Radbruch, A; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Weller, J; Zeiner, PS; Zeyen, T | 1 |
| Berglund, AE; Etame, AB; Macaulay, RJ; Wu, Q | 1 |
| Alcaniz, J; Benesch, M; Birkl-Toeglhofer, AM; Golob-Schwarzl, N; Haybaeck, J; Hoffmann, J; Huber, HJ; Krassnig, S; Leber, SL; Leoni, M; Mahdy-Ali, K; Naumann, M; Orthmann, A; Pennauer, M; Raicht, A; Skofler, C; von Campe, G; Wälchli, T; Weis, S; Wohlrab, C | 1 |
| Arijs, I; Beerens, C; Biswas, A; Byrne, AT; Chien, MP; Connor, K; Dilcan, G; Fabro, F; Feller, KJ; Idbaih, A; Kers, TV; Kremer, A; Lambrechts, D; Lamfers, MLM; Leenstra, S; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Tching Chi Yen, R; Verreault, M | 1 |
| Ayala-Hernández, LE; Bosque, JJ; Chulián, S; Delobel, T; García-Ferrer, M; Murek, M; Pérez-Beteta, J; Pérez-García, VM; Piñero, P; Schucht, P | 1 |
| Frandsen, S; Geissler, UW; Gredal, O; Møller, S; Nørøxe, DS; Pedersen, AJ | 1 |
| Bian, L; Li, D; Li, K; Lin, B; Liu, X; Xi, Z; Yan, J; Yang, Q | 1 |
420 review(s) available for dacarbazine and temozolomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Alkylating agents.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cytokines; Dacarbazine; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 1994 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 1993 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 1995 |
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasms, Experimental; Temozolomide; Tumor Cells, Cultured | 1997 |
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
New anticancer agents.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Humans; Lactones; Macrolides; Neovascularization, Pathologic; Suramin; Temozolomide; Thymidylate Synthase; Tirapazamine; Triazines; Uracil | 1997 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy.
Topics: Antineoplastic Agents; Carbon Isotopes; Dacarbazine; Drug Monitoring; Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Temozolomide | 2000 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2000 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease Progression; Glioblastoma; Humans; Quality of Life; Temozolomide | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Meningitis; Mice; Mice, Nude; Neoplasm Staging; Quality of Life; Temozolomide; Transplantation, Heterologous | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Temozolomide; Topotecan | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Incidence; Melanoma; Temozolomide | 2000 |
'Chemotherapy is useful in treatment of gliomas'.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Glioma; Humans; Temozolomide | 2000 |
Temozolomide in patients with high grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Glioma; Humans; Temozolomide | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Temozolomide; Thalidomide | 2000 |
[Use of nuclear magnetic resonance spectroscopy in drug metabolism studies].
Topics: Ampicillin; Animals; Dacarbazine; Humans; Magnetic Resonance Spectroscopy; Temozolomide | 1997 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Based Medicine; Glioma; Humans; Recurrence; Temozolomide; Treatment Outcome; United Kingdom | 2001 |
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Delivery, Obstetric; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pregnancy; Pregnancy Complications, Neoplastic; Radiosurgery; Radiotherapy; Rhabdoid Tumor; Temozolomide; Teratoma | 2001 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Quality of Life; Temozolomide | 2001 |
Chemotherapy for the treatment of oligodendroglial tumors.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Oligodendroglioma; Procarbazine; Prognosis; Temozolomide; Vincristine | 2001 |
New approaches for temozolomide therapy: use in newly diagnosed glioma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Quality of Life; Temozolomide | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
Temozolomide for treating brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Whole-Body Irradiation | 2001 |
Future directions for temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Forecasting; Humans; Temozolomide | 2001 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Evidence-Based Medicine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2001 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Pharmacological strategies to increase the antitumor activity of methylating agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Repair; Humans; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2002 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Contraindications; Cranial Irradiation; Craniotomy; Dacarbazine; Disease Progression; Epidemiologic Methods; Glioblastoma; Humans; Isotretinoin; Lomustine; Palliative Care; Procarbazine; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Temozolomide; Treatment Outcome; Vincristine | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Melanoma; Temozolomide | 2001 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2002 |
Chemotherapy for the treatment of metastatic brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carboplatin; Clinical Trials as Topic; Dacarbazine; Humans; Neoplasm Metastasis; Temozolomide | 2002 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide | 2002 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors | 2003 |
Recent developments in the molecular characterization and treatment of oligodendroglial tumors.
Topics: Animals; Astrocytoma; Clinical Trials as Topic; Dacarbazine; Humans; Oligodendroglioma; Temozolomide | 2003 |
Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.
Topics: Acridines; Animals; Antineoplastic Agents; Dacarbazine; Fluorouracil; Humans; Molecular Structure; Radioactive Tracers; Radiopharmaceuticals; Temozolomide; Tissue Distribution; Tomography, Emission-Computed | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Inhibition of angiogenesis by non-toxic doses of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cells, Cultured; Dacarbazine; Dose-Response Relationship, Drug; Fibronectins; Humans; Lethal Dose 50; Temozolomide | 2003 |
The role of chemotherapy in brain metastases.
Topics: Anticonvulsants; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Interactions; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2003 |
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Humans; Incidence; Lomustine; Oligodendroglioma; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Temozolomide; Tomography, Emission-Computed; Tomography, X-Ray Computed; Vincristine | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Differentiation; Dacarbazine; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Signal Transduction; Temozolomide | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Nitrosourea Compounds; Patient Selection; Survival Rate; Temozolomide | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Middle Aged; Survival Rate; Temozolomide; Vindesine | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Middle Aged; Radiotherapy; Radiotherapy Dosage; Survival Rate; Temozolomide | 2003 |
Bony metastases of anaplastic oligodendroglioma respond to temozolomide.
Topics: Adult; Bone Neoplasms; Dacarbazine; Humans; Male; Oligodendroglioma; Retrospective Studies; Temozolomide | 2004 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; Dacarbazine; Humans; Immunotherapy; Melanoma; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Computer-Assisted; Survival Rate; Temozolomide | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cohort Studies; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Procarbazine; Temozolomide; Vincristine | 2004 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Eye Neoplasms; Female; Humans; Immunotherapy; Life Tables; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Arachnoid Cysts; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Neurosurgery; Radiotherapy; Temozolomide; Treatment Outcome | 2005 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Tamoxifen; Taxoids; Temozolomide; Treatment Outcome | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Temozolomide; Thionucleotides; Treatment Outcome | 2004 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
Research news and notes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Dendritic Cells; Drug Therapy; Humans; Immunotherapy; Radiotherapy; Temozolomide | 2005 |
Response of low-grade oligodendroglial tumors to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Controlled Clinical Trials as Topic; Dacarbazine; Humans; Loss of Heterozygosity; Oligodendroglioma; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; DNA Repair; Drug Administration Schedule; Humans; Neoplasms; Temozolomide; Treatment Outcome | 2005 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, Human, Pair 11; Dacarbazine; Fatal Outcome; Female; Gene Deletion; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Temozolomide | 2005 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cognition Disorders; Dacarbazine; Disease Progression; Endpoint Determination; Glioblastoma; Health Status; Humans; Neuropsychological Tests; Procarbazine; Quality of Life; Survival Analysis; Temozolomide | 2005 |
PARP inhibitors for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; DNA Repair; DNA, Neoplasm; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Tolerance; Temozolomide | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Delivery Systems; Drug Implants; Glioma; Humans; Patient Selection; Prognosis; Temozolomide | 2005 |
[Highly quality-controlled radiation therapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Maximum Tolerated Dose; Quality Assurance, Health Care; Quality Control; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Temozolomide | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Glioma; Humans; Temozolomide | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Glioblastoma; Humans; Prognosis; Survival Rate; Temozolomide | 2005 |
Chemopotentiation by PARP inhibitors in cancer therapy.
Topics: Animals; Antineoplastic Agents; Dacarbazine; DNA Damage; Drug Synergism; Enzyme Inhibitors; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2005 |
Temozolomide in uterine leiomyosarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Staging; Temozolomide; Uterine Neoplasms | 2005 |
[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Radiotherapy, Adjuvant; Temozolomide | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; Glioma; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Serine Endopeptidases; Temozolomide; Tetracyclines | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infant; Medulloblastoma; Temozolomide | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Glioma; Humans; Neurosurgical Procedures; Prognosis; Radiotherapy, Conformal; Survival Rate; Temozolomide | 2005 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dacarbazine; Dementia, Vascular; Humans; Lung Neoplasms; Melanoma; Metalloporphyrins; Prednisolone; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Temozolomide | 2005 |
[Standards and new developments in the chemotherapy of glioblastomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Cytarabine; Dacarbazine; Decanoic Acids; DNA Modification Methylases; Glioblastoma; Humans; Nimustine; Polyesters; Promoter Regions, Genetic; Temozolomide; Teniposide | 2005 |
Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide.
Topics: Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Radiosurgery; Radiotherapy; Temozolomide | 2003 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Procarbazine; Temozolomide | 2005 |
Treatment of astrocytomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Therapy; Humans; Radiotherapy; Signal Transduction; Temozolomide | 2005 |
[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Radiation Tolerance; Temozolomide | 2005 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temozolomide | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Glioma; Humans; Lymphoma; Radiosurgery; Temozolomide | 2006 |
Advances in the treatment of primary brain tumors: dawn of a new era?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Temozolomide | 2006 |
The evolution of chemoradiation for glioblastoma: a modern success story.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2006 |
Recent advances in the treatment of malignant astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Humans; Temozolomide | 2006 |
Temozolomide: a milestone in the pharmacotherapy of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Temozolomide; Time Factors | 2005 |
Role of temozolomide in pediatric brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Humans; Pediatrics; Temozolomide | 2006 |
Treatment options for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cytotoxins; Dacarbazine; Drug Therapy; Glioblastoma; Growth Inhibitors; Humans; International Agencies; Radiotherapy; Temozolomide | 2006 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Methyltransferases; Neoplasm Recurrence, Local; Patient Selection; Temozolomide; Treatment Outcome | 2006 |
Autophagy, the Trojan horse to combat glioblastomas.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Brain Neoplasms; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Protein Kinases; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2006 |
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oligodendroglioma; Temozolomide | 2006 |
The role of chemotherapy in the treatment of malignant astrocytomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Therapy; Humans; Immunologic Factors; Nitrosourea Compounds; Temozolomide | 2006 |
Radiation therapy in the management of brain metastases from renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Dacarbazine; Humans; Kidney Neoplasms; Metalloporphyrins; Neoplasm Metastasis; Radiation Oncology; Radiation-Sensitizing Agents; Radiosurgery; Temozolomide | 2006 |
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Synergism; Genetic Therapy; Glioma; Humans; Interferon-beta; Nimustine; Radiotherapy; Temozolomide | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Glioma; Humans; Recurrence; Temozolomide | 2006 |
Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; Drug Resistance, Neoplasm; Glioblastoma; Humans; Prognosis; Temozolomide | 2005 |
Chemotherapy for malignant gliomas.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Radiotherapy, Adjuvant; Survival Rate; Temozolomide | 2006 |
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Oligodendroglioma; Salvage Therapy; Temozolomide; Tumor Suppressor Protein p14ARF; Tumor Suppressor Proteins | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgical Procedures; Radiotherapy; Temozolomide | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Glioma; Herpesviridae; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Temozolomide | 2006 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damage; DNA Methylation; DNA Mismatch Repair; DNA Repair; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Protein Kinases; Temozolomide; TOR Serine-Threonine Kinases | 2007 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Epilepsy; Forecasting; Genetic Markers; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Thromboembolism; Time Factors; Tomography, X-Ray Computed | 2006 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; DNA Damage; Drug Administration Schedule; Epilepsy; Forecasting; Glioblastoma; Glioma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Palliative Care; Prognosis; Promoter Regions, Genetic; Temozolomide; Thrombophilia | 2007 |
Anaplastic astrocytoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Risk Factors; Survival Analysis; Temozolomide | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Nitroso Compounds; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2007 |
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Dose-Response Relationship, Drug; Female; Fever; Glioblastoma; Humans; Middle Aged; Neutropenia; Severity of Illness Index; Temozolomide; Treatment Outcome | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Glioma; Humans; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Biological; Molecular Structure; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Temozolomide | 2007 |
Triazene compounds: mechanism of action and related DNA repair systems.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Dacarbazine; DNA Repair; Humans; Temozolomide; Triazenes | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioma; Humans; Medical Oncology; Models, Biological; Neoplasm Metastasis; Oligodendroglioma; Signal Transduction; Temozolomide; Treatment Outcome | 2007 |
Temozolomide for the treatment of metastatic melanoma: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Humans; Melanoma; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2007 |
Diagnosis and treatment of high-grade astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Dacarbazine; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasm Staging; Neurosurgical Procedures; Temozolomide | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioma; Humans; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Quality of Life; Temozolomide | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Genetic Therapy; Glioblastoma; Humans; Immunotherapy; Polyesters; Temozolomide | 2007 |
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasms; Temozolomide | 2007 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genes, Tumor Suppressor; Glioma; Humans; Loss of Heterozygosity; MicroRNAs; Molecular Diagnostic Techniques; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Radiation Tolerance; Radiotherapy; Temozolomide | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-Analysis as Topic; Oligodendroglioma; Randomized Controlled Trials as Topic; Temozolomide | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Delayed-Action Preparations; Glioma; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Temozolomide | 2008 |
Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Prognosis; Temozolomide; Treatment Outcome | 2006 |
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Male; Melanoma; Middle Aged; Temozolomide; Vitiligo | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Gene Deletion; Glioma; Humans; Molecular Diagnostic Techniques; Neurosurgical Procedures; Pharmacogenetics; Reoperation; Temozolomide | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Magnetic Resonance Imaging; Necrosis; Neoplasm Recurrence, Local; Patient Selection; Radiation Injuries; Radiotherapy, Adjuvant; Risk Assessment; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A | 2008 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Substrate Specificity; Survival Analysis; Temozolomide | 2008 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interactions; Glioma; Hematologic Diseases; Humans; Infections; Nausea; Temozolomide; Vomiting | 2006 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2008 |
Management of aggressive pituitary adenomas: current treatment strategies.
Topics: Cabergoline; Dacarbazine; Dopamine Agonists; Ergolines; Female; Humans; Male; Pituitary Neoplasms; Somatostatin; Temozolomide | 2009 |
Recent approaches to improve the antitumor efficacy of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA Repair; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Temozolomide | 2009 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2009 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Irinotecan; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; ErbB Receptors; Gene Amplification; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Signal Transduction; Temozolomide; Up-Regulation | 2009 |
Low-grade gliomas.
Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioma; Humans; Medical Oncology; Middle Aged; Prognosis; Temozolomide; Treatment Outcome | 2009 |
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MEDLINE; Molecular Structure; Randomized Controlled Trials as Topic; Temozolomide | 2009 |
The safety of temozolomide in the treatment of malignancies.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Humans; Lymphopenia; Nausea; Neoplasms; Neutropenia; Radiotherapy; Temozolomide; Thrombocytopenia; Vomiting | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Labeling; Glioblastoma; Glioma; Humans; Temozolomide | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2009 |
Management of glioblastoma multiforme in HIV patients: a case series and review of published studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glioblastoma; HIV Infections; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2009 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genotype; Glioblastoma; Humans; Lomustine; Loss of Heterozygosity; Molecular Diagnostic Techniques; Pharmacogenetics; Procarbazine; Prognosis; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Lomustine; Myelodysplastic Syndromes; Neoplasms, Second Primary; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cognition; Dacarbazine; Humans; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Radiosurgery; Survival Rate; Temozolomide; Time Factors | 2010 |
[Recent trends in the pathophysiology and treatment of pituitary adenomas].
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamic Hormones; Incidental Findings; Neurosurgical Procedures; Octreotide; Pituitary Neoplasms; Prolactinoma; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Temozolomide | 2009 |
Radiotherapy for metastatic brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Humans; Patient Selection; Radiation Injuries; Radiosurgery; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2009 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tumor; Blood-Brain Barrier; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioblastoma; Mice; Phosphorylcholine; Prognosis; Temozolomide; Transplantation, Heterologous | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma; Humans; Radionuclide Imaging; Temozolomide; Treatment Outcome | 2009 |
New advances that enable identification of glioblastoma recurrence.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioblastoma; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiation Injuries; Randomized Controlled Trials as Topic; Temozolomide | 2009 |
Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Humans; Temozolomide; Treatment Outcome | 2010 |
[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Rituximab; Salvage Therapy; Temozolomide; Topotecan | 2009 |
Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Frail Elderly; Glioblastoma; Humans; Quality of Life; Radiotherapy Dosage; Temozolomide | 2009 |
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Oligodendroglioma; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Temozolomide; Tumor Burden; Young Adult | 2010 |
PARP inhibition: PARP1 and beyond.
Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Mice; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Substrate Specificity; Temozolomide | 2010 |
[Glioblastoma multiforme--new hope due to modern therapeutical approaches].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Prognosis; Temozolomide; Time Factors | 2010 |
[Treatment of clinically nonfunctioning pituitary adenomas].
Topics: Adenoma; Adult; Cranial Irradiation; Dacarbazine; Decompression, Surgical; Dopamine Agonists; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hypophysectomy; Male; Neoplasm, Residual; Pituitary Neoplasms; Postoperative Complications; Radiosurgery; Radiotherapy, Intensity-Modulated; Somatostatin; Temozolomide | 2010 |
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infections; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, B-Cell; Male; Middle Aged; Opportunistic Infections; Temozolomide | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Stratifying osteosarcoma: minimizing and maximizing therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dacarbazine; Humans; Integrins; Osteosarcoma; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survivors; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Immunologic Factors; Lymphopenia; Melanoma; Temozolomide; Treatment Outcome | 2010 |
The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Neoplasms; Temozolomide | 2010 |
Nelson's syndrome.
Topics: Adrenocorticotropic Hormone; Alkylating Agents; Dacarbazine; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Temozolomide | 2010 |
MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Immunohistochemistry; Immunosuppression Therapy; Male; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2010 |
Treatment of pituitary neoplasms with temozolomide: a review.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Pituitary Neoplasms; Radiography; Temozolomide; Tumor Suppressor Proteins | 2011 |
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Precision Medicine; Temozolomide; Tumor Suppressor Proteins | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Glioma; Humans; Male; Palliative Care; Recurrence; Temozolomide; Treatment Outcome | 2010 |
[Carcinoid tumors].
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumor; Chromogranin A; Clinical Trials as Topic; Dacarbazine; Early Detection of Cancer; Gastrointestinal Neoplasms; Heterocyclic Compounds; Humans; Hydroxyindoleacetic Acid; Lung Neoplasms; Organometallic Compounds; Prevalence; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Somatostatin; Temozolomide; Thalidomide; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Temozolomide; Treatment Outcome | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; Designer Drugs; DNA Methylation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; India; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Young Adult | 2010 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drugs, Investigational; Evidence-Based Medicine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Palliative Care; Retreatment; Survival Rate; Temozolomide | 2011 |
Dopamine agonist-resistant prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Cell Division; Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Male; Mitotic Index; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Estrogen; Sex Factors; Temozolomide | 2011 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2010 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diagnosis, Differential; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Positron-Emission Tomography; Radiation Injuries; Sensitivity and Specificity; Temozolomide; Tumor Burden | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Silencing; Genetic Therapy; Glioma; Humans; Melanoma; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2011 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Astrocytoma; Bevacizumab; Blood-Brain Barrier; Brain; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Humans; Male; Necrosis; Neoplasm Recurrence, Local; Neurologic Examination; Radiation Injuries; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Temozolomide; Vascular Endothelial Growth Factor A; Young Adult | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Drug Implants; Glioblastoma; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Polyesters; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Temozolomide; Venous Thromboembolism; Young Adult | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Genotype; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Temozolomide; Treatment Failure | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Temozolomide | 2011 |
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2011 |
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Delivery Systems; Humans; Mutant Chimeric Proteins; Temozolomide; Treatment Outcome | 2011 |
Glioblastoma multiforme: enhancing survival and quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Radiotherapy; Seizures; Temozolomide; United States; Venous Thromboembolism | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Neoplasm Grading; Temozolomide | 2011 |
Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dacarbazine; Femur; Humans; Magnetic Resonance Imaging; Male; Oligodendroglioma; Temozolomide | 2011 |
[Pituitary carcinoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged; Pituitary Neoplasms; Temozolomide | 2011 |
[Glioblastoma in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Developed Countries; Glioblastoma; Humans; Temozolomide | 2011 |
Cerebellar gliomatosis in a toddler: case report of a challenging condition and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Cerebellum; Child, Preschool; Dacarbazine; Humans; Intermediate Filament Proteins; Longitudinal Studies; Magnetic Resonance Imaging; Male; Neoplasms, Neuroepithelial; Nerve Tissue Proteins; Nestin; Neurosurgery; Oligodendroglia; Oligodendroglioma; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Tumor Cells, Cultured; Vimentin | 2012 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2011 |
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Temozolomide | 2011 |
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Liver Neoplasms; Male; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide | 2012 |
[Issues around diffuse glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Staging; Temozolomide | 2011 |
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Radiotherapy, Computer-Assisted; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2012 |
Intraventricular glioneuronal tumor with disseminated lesions at diagnosis--a case report.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Chemoradiotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Ganglioglioma; Humans; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome | 2011 |
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Randomized Controlled Trials as Topic; Sulfonamides; Temozolomide; Vemurafenib | 2011 |
Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Neuroepithelial; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
Topics: Adolescent; Adult; Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Humans; Male; Prolactinoma; Temozolomide | 2012 |
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis; Dacarbazine; Glioblastoma; Hepatitis; Humans; Male; Middle Aged; Prognosis; Temozolomide; United States; United States Food and Drug Administration | 2012 |
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2012 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Temozolomide; Time Factors | 2012 |
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2012 |
Cellular-based immunotherapies for patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Cancer Vaccines; Cell Extracts; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Dacarbazine; Dendritic Cells; Glioblastoma; Humans; Immunomodulation; Immunotherapy; Middle Aged; Temozolomide | 2012 |
Cerebral ganglioneuroblastoma of adult onset: two patients and a review of the literature.
Topics: Adult; Age of Onset; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Ganglioneuroblastoma; Humans; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Temozolomide; Tomography, X-Ray Computed | 2012 |
Temozolomide in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2012 |
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioblastoma; Humans; Neoplasm Proteins; Neoplastic Stem Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prodrugs; Radiation-Sensitizing Agents; Temozolomide; Tumor Suppressor Proteins | 2012 |
Recent medical management of glioblastoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Protein Kinase Inhibitors; Temozolomide | 2012 |
The efficacy of temozolomide for recurrent glioblastoma multiforme.
Topics: Administration, Metronomic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Glioblastoma; Humans; Secondary Prevention; Survival Rate; Temozolomide | 2013 |
Optimal management of elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Randomized Controlled Trials as Topic; Temozolomide | 2013 |
Potential usefulness of radiosensitizers in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Radiation-Sensitizing Agents; Radiotherapy; Temozolomide | 2012 |
[Brain metastases from breast cancer: prognostic factors and tailored management].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; Female; Humans; Prognosis; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Temozolomide | 2013 |
Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Oncolytic Viruses; RNA Interference; Temozolomide | 2012 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2013 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Risk Factors; Temozolomide; Young Adult | 2012 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2013 |
The spectrum of vaccine therapies for patients with glioblastoma multiforme.
Topics: Acyclovir; Autoantigens; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Glioblastoma; Humans; Immunotherapy; Immunotherapy, Active; Signal Transduction; Temozolomide; Valacyclovir; Valine | 2012 |
New treatment options with cytotoxic agents in neuroendocrine tumours.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Clinical Trials as Topic; Cytotoxins; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Medical Oncology; Neuroendocrine Tumors; Quality of Life; Streptozocin; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Lomustine; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2012 |
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasm Grading; Pneumocystis carinii; Pneumonia, Pneumocystis; Risk Factors; Temozolomide | 2013 |
Targeting the Akt-pathway to improve radiosensitivity in glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemoradiotherapy; Dacarbazine; DNA Damage; Drug Design; Drug Resistance, Neoplasm; Glioblastoma; Humans; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Survival Rate; Temozolomide | 2013 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide | 2012 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome | 2012 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Integrins; Mice; Rats; Signal Transduction; Snake Venoms; Temozolomide | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Immunologic Factors; Temozolomide | 2012 |
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2013 |
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Dacarbazine; Female; Humans; Liver; Male; Middle Aged; Temozolomide | 2013 |
Cryptococcemia in a patient with glioblastoma: case report and literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Central Nervous System; Cryptococcosis; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy; Temozolomide; Tomography, X-Ray Computed | 2012 |
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2a; Prognosis; Review Literature as Topic; Temozolomide; Tomography, X-Ray Computed | 2013 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dideoxynucleosides; Glioblastoma; Humans; Immunotherapy; Interleukin-13 Receptor alpha2 Subunit; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Temozolomide | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Glioma; Mice; Rats; Survival Analysis; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
[Whole brain radiation therapy plus temozolomide in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnosis, Differential; Ganglioglioma; Ganglioneuroma; Glioma; Humans; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Papilledema; Paresis; Temozolomide; Treatment Outcome; Vision, Low | 2012 |
Triazene compounds in the treatment of acute myeloid leukemia: a short review and a case report.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Triazenes | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2013 |
Essential role of Gli proteins in glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Transcription Factors; Zinc Finger Protein GLI1 | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioma; Humans; Neoplasm Recurrence, Local; Radiation Injuries; Radiotherapy; Temozolomide | 2013 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms; Captopril; Dacarbazine; Disulfiram; Glioblastoma; Gluconates; Humans; Ketoconazole; Morpholines; Nelfinavir; Neoplasm Recurrence, Local; Sertraline; Succinates; Temozolomide | 2013 |
PARP inhibitors: polypharmacology versus selective inhibition.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Catalytic Domain; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Models, Molecular; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2013 |
Enhancing radiation therapy for patients with glioblastoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide | 2013 |
Investigational therapies for acromegaly.
Topics: Acromegaly; Dacarbazine; Drugs, Investigational; Human Growth Hormone; Humans; Octreotide; Pioglitazone; Rosiglitazone; Somatostatin; Temozolomide; Thiazolidinediones | 2013 |
Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Metabolomics; Prognosis; Temozolomide | 2013 |
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Topics: Brain Neoplasms; Dacarbazine; Humans; Isocitrate Dehydrogenase; Mutation; Oligodendroglioma; Temozolomide | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory Networks; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Systems Biology; Temozolomide | 2013 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Melanoma; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome | 2013 |
Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph nodes, vertebrae, cervical muscles and epidural space in a young patient - case report and review of literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Chemoradiotherapy, Adjuvant; Dacarbazine; Epidural Space; Fatal Outcome; Glioblastoma; Humans; Lumbar Vertebrae; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Muscle Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Palliative Care; Patient Compliance; Spinal Neoplasms; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy; Temozolomide | 2013 |
Temozolomide-related hematologic toxicity.
Topics: Antineoplastic Agents, Alkylating; Comorbidity; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Hematologic Diseases; Humans; Incidence; Neoplasms; Risk Factors; Temozolomide; Treatment Outcome | 2013 |
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA-Binding Proteins; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2013 |
Elderly patients with glioblastoma: the treatment challenge.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Prognosis; Temozolomide | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted Therapy; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2013 |
Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome | 2014 |
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, Bibliographic; Glioblastoma; Humans; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Temozolomide | 2014 |
Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Glioblastoma; Humans; Radiosurgery; Temozolomide; Tumor Suppressor Proteins | 2014 |
Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide | 2014 |
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2014 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2013 |
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Epitopes; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inhibitor of Apoptosis Proteins; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphocyte Count; Lymphocytosis; Melanoma; Recombinant Proteins; Survivin; T-Lymphocytes; Temozolomide | 2013 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasm Grading; Particle Accelerators; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Grading; Temozolomide | 2014 |
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Follicle Stimulating Hormone; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Luteinizing Hormone; Pituitary Hormones, Anterior; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Temozolomide; Thyrotropin | 2014 |
Treatment options and outcomes for glioblastoma in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Aged; Prognosis; Temozolomide; Treatment Outcome | 2014 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Evidence-Based Medicine; Glioblastoma; Humans; Temozolomide | 2014 |
Aggressive pituitary adenomas--diagnosis and emerging treatments.
Topics: Adenoma; Biomarkers, Tumor; Dacarbazine; Humans; Ki-67 Antigen; Neoplasm Invasiveness; Neovascularization, Pathologic; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Protein p53 | 2014 |
Straying from the path in neuro-oncology.
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Medical Oncology; Temozolomide | 2014 |
Neuroimaging of therapy-associated brain tissue abnormalities.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Neuroimaging; Temozolomide | 2014 |
Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Research; Temozolomide | 2014 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Death; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Medical treatment of advanced thoracic neuroendocrine tumors.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Sirolimus; Temozolomide; Thoracic Neoplasms | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; Imidazoles; Indoles; Interferon-alpha; Interleukin-2; Ipilimumab; Melanoma; Oximes; Platinum Compounds; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides; Taxoids; Temozolomide; Vemurafenib | 2014 |
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Topics: Antineoplastic Agents; Carmustine; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Glioblastoma; Health Care Costs; Humans; Quality-Adjusted Life Years; Temozolomide | 2014 |
Predictive biomarkers investigated in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; ErbB Receptors; Glioblastoma; Humans; Molecular Targeted Therapy; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2014 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Delivery Systems; Glioblastoma; Humans; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Proto-Oncogene Proteins B-raf; Temozolomide; Tumor Suppressor Proteins | 2014 |
Supratentorial low-grade diffuse astrocytoma: medical management.
Topics: Antineoplastic Agents; Astrocytoma; Dacarbazine; Disease Progression; Humans; Neoplasm Grading; Nitrosourea Compounds; Prognosis; Supratentorial Neoplasms; Temozolomide | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Glioma; Humans; Lomustine; Methylation; Multicenter Studies as Topic; Neoplasm Proteins; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome; Vincristine | 2014 |
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Interleukin-2; Ipilimumab; Lung Neoplasms; Male; Melanoma; Prostatic Neoplasms; Recombinant Proteins; Temozolomide; Tissue Extracts | 2015 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; Glioma; Humans; Temozolomide | 2014 |
Treatment of brain metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Dacarbazine; Humans; Ipilimumab; Neurosurgical Procedures; Prognosis; Radiosurgery; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Temozolomide | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
Emerging therapies for glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell- and Tissue-Based Therapy; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2014 |
Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Humans; Infant; Irinotecan; Male; Retrospective Studies; Sarcoma, Ewing; Survival Rate; Temozolomide | 2015 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2014 |
Glioblastoma survival: has it improved? Evidence from population-based studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Community Health Planning; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2014 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; Combined Modality Therapy; Dacarbazine; Disease Progression; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pituitary Gland; Pituitary Hormones; Pituitary Neoplasms; Temozolomide | 2014 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe; Glioma; Humans; Radiotherapy; Temozolomide; United States | 2015 |
Glioblastoma in the elderly.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Temozolomide; Tumor Suppressor Proteins | 2015 |
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Craniotomy; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Second Primary; Prognosis; Remission Induction; Temozolomide | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cancer Vaccines; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Irinotecan; Mice; Temozolomide; Vaccination; Vaccines, Subunit | 2014 |
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoid Heart Disease; Carcinoid Tumor; Cisplatin; Dacarbazine; Etoposide; Europe; Humans; Lung Neoplasms; Pneumonectomy; Positron-Emission Tomography; Receptors, Somatostatin; Societies, Medical; Temozolomide; Tomography, X-Ray Computed; Ultrasonography | 2015 |
Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Asymptomatic Diseases; Dacarbazine; Growth Hormone-Secreting Pituitary Adenoma; Humans; Male; Neoplasm Invasiveness; Temozolomide | 2015 |
[Elderly patients with glioblastoma: state of the art].
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Prognosis; Radiotherapy, Adjuvant; Temozolomide | 2015 |
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Design; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Glioblastoma; Humans; Molecular Structure; Phenotype; Signal Transduction; Structure-Activity Relationship; Temozolomide | 2015 |
Dose-dense temozolomide: is it still promising?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Glioblastoma; Humans; Recurrence; Temozolomide | 2015 |
The role of temozolomide in the treatment of aggressive pituitary tumors.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Humans; Mutation; Neoplasm Recurrence, Local; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2015 |
Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Cholestasis; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Temozolomide | 2015 |
Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2015 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Octreotide; Temozolomide; Thalidomide | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioma; Humans; Isocitrate Dehydrogenase; Lomustine; Mutation; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Neoplasm Staging; Prognosis; Temozolomide | 2015 |
Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; RNAi Therapeutics; Temozolomide | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic Stem Cells; Temozolomide; Tumor Suppressor Proteins | 2015 |
Therapeutic management of gliosarcoma in the temozolomide era.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Management; Gliosarcoma; Humans; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Streptozocin; Temozolomide | 2015 |
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide; Treatment Outcome | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Canada; Chemoradiotherapy; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Costs; Glioblastoma; Health Resources; Humans; Kaplan-Meier Estimate; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Temozolomide; Time Factors; Treatment Outcome | 2015 |
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Topics: Biomarkers, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Craniotomy; Dacarbazine; Female; Fibrosarcoma; Humans; Infant; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiotherapy, Adjuvant; Rare Diseases; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Carcinogenesis; Colon; Dacarbazine; DNA Polymerase beta; DNA Repair; Flap Endonucleases; Humans; Models, Molecular; Molecular Targeted Therapy; Mutation; Rectum; Temozolomide | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; Quality of Life; Skin Neoplasms; Temozolomide; Treatment Outcome | 2015 |
Comparison of the effectiveness of whole-brain radiotherapy plus temozolomide versus whole-brain radiotherapy in treating brain metastases based on a systematic review of randomized controlled trials.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2016 |
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Tissue Extracts | 2015 |
Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Odds Ratio; Publication Bias; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
MGMT testing allows for personalised therapy in the temozolomide era.
Topics: Aged; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; Gene Silencing; Humans; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Precision Medicine; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Treatment Outcome | 2016 |
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Oligodendroglioma; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Primary spinal cord glioblastoma multiforme treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Spinal Cord Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2015 |
Chemotherapy for Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Melanoma; Neoplasm Staging; Palliative Care; Taxoids; Temozolomide | 2016 |
Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party.
Topics: Adult; Africa, Northern; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Medical Oncology; Mediterranean Region; Neurology; Practice Guidelines as Topic; Quality of Life; Radiotherapy; Societies, Medical; Standard of Care; Temozolomide | 2016 |
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Geriatric Assessment; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methylation; Middle Aged; Prognosis; Promoter Regions, Genetic; Quality of Life; Seizures; Standard of Care; Temozolomide; Tumor Suppressor Proteins | 2016 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Temozolomide; Vincristine | 2016 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chloroquine; Clinical Trials as Topic; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Sirolimus; Temozolomide | 2016 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Neuroendocrine Tumors; Radiopharmaceuticals; Somatostatin; Streptozocin; Temozolomide | 2016 |
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Radiation-Sensitizing Agents; Radiotherapy; Temozolomide | 2016 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Surgical Procedures; Humans; Imidazoles; Indoles; Ipilimumab; Lymph Node Excision; Melanoma; Neoplasm Staging; Nivolumab; Oximes; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Skin Neoplasms; Sulfonamides; Switzerland; Temozolomide; Vemurafenib | 2016 |
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Temozolomide; Treatment Outcome | 2016 |
Low-grade and anaplastic oligodendroglioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Isocitrate Dehydrogenase; Mutation; Oligodendroglioma; Procarbazine; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2016 |
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2016 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Snake Venoms; Temozolomide | 2016 |
Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Databases, Bibliographic; Disease-Free Survival; Humans; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide | 2016 |
Is there a role for early chemotherapy in the management of pituitary adenomas?
Topics: Adenoma; Antineoplastic Agents; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2016 |
Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.
Topics: Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2015 |
Problems of Glioblastoma Multiforme Drug Resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Glioblastoma; Humans; Temozolomide | 2016 |
(11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.
Topics: Carbon Radioisotopes; Dacarbazine; Humans; Molecular Structure; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide | 2016 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Temozolomide | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Disease-Free Survival; Eflornithine; Glioma; Humans; Mitolactol; Network Meta-Analysis; Nimustine; Probability; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide; Treatment Outcome; Vincristine | 2016 |
A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Pineal Gland; Pinealoma; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Temozolomide | 2016 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neuroendocrine Tumors; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Chemical and Drug Induced Liver Injury; Chemoradiotherapy; Dacarbazine; Drugs, Chinese Herbal; Female; Glioblastoma; Humans; Temozolomide | 2017 |
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Europe; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Prognosis; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Vincristine | 2017 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Drug Implants; Glioblastoma; Humans; Middle Aged; Neoplasm Grading; Polyesters; Temozolomide; United States; United States Food and Drug Administration | 2016 |
How effective is temozolomide for treating pituitary tumours and when should it be used?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Prolactinoma; Temozolomide; Treatment Outcome | 2017 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Field Therapy; Magnetic Resonance Imaging; Male; Practice Guidelines as Topic; Temozolomide | 2017 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioma; Humans; Mutation; Prognosis; Temozolomide; Treatment Outcome | 2016 |
Microglia in Cancer: For Good or for Bad?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cytokines; Dacarbazine; ErbB Receptors; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Macrophages; Microglia; Oligodeoxyribonucleotides; Signal Transduction; Temozolomide; Treatment Failure; Tumor Microenvironment | 2016 |
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2016 |
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Mucin-1; Temozolomide | 2017 |
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Consensus; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Evidence-Based Medicine; Glioblastoma; Humans; Patient Selection; Temozolomide; Treatment Outcome | 2017 |
Temozolomide in the Era of Precision Medicine.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Humans; Neoplasms; Precision Medicine; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Temozolomide | 2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Medical Oncology; Middle Aged; Randomized Controlled Trials as Topic; Standard of Care; Temozolomide | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Hypermutations in gliomas: a potential immunotherapy target.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Immunotherapy; Mutation; Temozolomide | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Middle Aged; Pancytopenia; Polymorphism, Single Nucleotide; Prognosis; Temozolomide; Tumor Suppressor Proteins | 2017 |
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome | 2017 |
Managing Glioblastoma in the Elderly Patient: New Opportunities.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Management; Glioblastoma; Humans; Neurosurgical Procedures; Prognosis; Radiotherapy; Temozolomide | 2017 |
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Humans; Isocitrate Dehydrogenase; Male; Oligodendroglioma; Temozolomide | 2017 |
Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dacarbazine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glioma; Humans; Hydroxyurea; Lomustine; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Procarbazine; Randomized Controlled Trials as Topic; Temozolomide; Vincristine | 2017 |
Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).
Topics: Brain; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Pyrans; Temozolomide | 2017 |
Glioblastoma in the elderly: initial management.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Prognosis; Radiation Dose Hypofractionation; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Electric Stimulation Therapy; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Safety; Temozolomide; Treatment Outcome; United States | 2017 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Callosum; Craniotomy; Dacarbazine; Decompression, Surgical; Dexamethasone; Female; Humans; Levetiracetam; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Oligodendroglioma; Piracetam; Remission Induction; Temozolomide; Tomography, X-Ray Computed | 2017 |
Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoradiotherapy, Adjuvant; Dacarbazine; Gastroscopy; Humans; Injections, Spinal; Male; Meningeal Carcinomatosis; Methotrexate; Middle Aged; Pylorus; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2017 |
Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Humans; Medulloblastoma; Molecular Targeted Therapy; Smoothened Receptor; Temozolomide | 2017 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cranial Irradiation; Cytoreduction Surgical Procedures; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Mutation; Neoplasm Recurrence, Local; Neurosurgical Procedures; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Temozolomide; Tumor Suppressor Proteins | 2017 |
Treatment of Glioblastoma in Older Adults.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Prognosis; Temozolomide | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dosage Forms; Glioma; Humans; Neoplasm Recurrence, Local; Neurosurgical Procedures; Quality of Life; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Topics: Adenoma; Animals; Cell Transformation, Neoplastic; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2018 |
Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Humans; Male; Middle Aged; Pituitary ACTH Hypersecretion; Temozolomide | 2018 |
Management of NFAs: medical treatment.
Topics: Adenoma; Dacarbazine; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Temozolomide | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Male; Middle Aged; Radiotherapy Dosage; Temozolomide | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Temozolomide | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescence; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Humans; Mice; Resveratrol; Stilbenes; Temozolomide | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wnt Signaling Pathway | 2018 |
Recent Advances in the Histopathology of Drug-Induced Liver Injury.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Chemical and Drug Induced Liver Injury; Dacarbazine; Diagnosis, Differential; Dietary Supplements; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver; Phytotherapy; Temozolomide | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Electromagnetic Fields; Glioma; Humans; Mitosis; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Temozolomide; Time | 2018 |
Treatment of Glioblastoma in the Elderly.
Topics: Aged; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Quality of Life; Temozolomide | 2018 |
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimumab; Melanoma; Paclitaxel; Sulfonamides; Temozolomide; Vemurafenib | 2018 |
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aurora Kinase A; Benzodiazepinones; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Enhancer of Zeste Homolog 2 Protein; Humans; Immunoconjugates; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Receptors, Notch; Small Cell Lung Carcinoma; Temozolomide; Tumor Suppressor Proteins | 2018 |
Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Phloroglucinol; Seaweed; Temozolomide; Xanthophylls | 2018 |
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Observational Studies as Topic; Survival Analysis; Temozolomide | 2018 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
Efficacy of nab-paclitaxel in treating metastatic melanoma.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Temozolomide | 2019 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; Melanoma; Mutation; Temozolomide | 2021 |
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Quality of Life; Retrospective Studies; Temozolomide | 2021 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Dacarbazine; Humans; Irinotecan; Neoplasms; Temozolomide; Vincristine | 2021 |
Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Topics: Adult; Brain Neoplasms; Brain Stem; Dacarbazine; Glioblastoma; Humans; Male; Pyridines; Temozolomide | 2022 |
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neurosurgeons; Platinum Compounds; Temozolomide | 2022 |
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2023 |
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Retrospective Studies; Temozolomide | 2022 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurrence, Local; Temozolomide | 2022 |
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Humans; RNA, Long Noncoding; Temozolomide | 2022 |
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Topics: Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2022 |
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Sarcoma, Ewing; Temozolomide | 2023 |
Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Systematic Reviews as Topic; Temozolomide | 2022 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Magnetic Iron Oxide Nanoparticles; O(6)-Methylguanine-DNA Methyltransferase; Peptides; RNA, Small Interfering; Temozolomide | 2023 |
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Medical therapy for refractory pituitary adenomas.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Glioblastoma; Humans; MicroRNAs; Temozolomide; Tumor Suppressor Proteins | 2023 |
The impact of survivorship bias in glioblastoma research.
Topics: Aged; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Repair Enzymes; Glioblastoma; Humans; Prognosis; Survivorship; Temozolomide | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
671 trial(s) available for dacarbazine and temozolomide
| Article | Year |
|---|---|
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Stomach Neoplasms; Temozolomide | 1992 |
Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Lymphoma; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Microsomes, Liver; Oxidation-Reduction; Temozolomide; Thymus Neoplasms; Triazines; Tumor Cells, Cultured | 1990 |
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Leukemia; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pilot Projects; Remission Induction; Temozolomide; Treatment Outcome; Triazenes | 1995 |
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Temozolomide | 1995 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Rate; Temozolomide; Thrombocytopenia; United Kingdom | 1995 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leukocytes, Mononuclear; Male; Melanoma; Methyltransferases; Middle Aged; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors | 1994 |
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.
Topics: Administration, Oral; Antineoplastic Agents; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Humans; Temozolomide; Tomography, X-Ray Computed | 1993 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 1996 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Temozolomide | 1997 |
Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Temozolomide; Treatment Outcome | 1998 |
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide | 1998 |
A phase II study of temozolomide in advanced untreated pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Middle Aged; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 1998 |
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Neoplasms; Nitrosourea Compounds; Remission Induction; Temozolomide | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Chromatography, High Pressure Liquid; Dacarbazine; Drug Administration Schedule; England; Female; Glioma; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Temozolomide | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 1998 |
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Topics: Adult; Alkylating Agents; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Dacarbazine; Half-Life; Humans; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Temozolomide | 1997 |
Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Regression Analysis; Temozolomide | 1997 |
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Female; Humans; Leukocytes, Mononuclear; Lymphatic Metastasis; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prospective Studies; Temozolomide | 1998 |
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Topics: Absorption; Administration, Oral; Adult; Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Blood Proteins; Carbon Radioisotopes; Dacarbazine; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Temozolomide | 1999 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Ifosfamide; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 1999 |
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms; Neutropenia; Temozolomide; Treatment Outcome; Vomiting | 1999 |
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Middle Aged; Sarcoma; Survival Analysis; Temozolomide; Treatment Outcome | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 1999 |
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Agents, Alkylating; Biological Availability; Dacarbazine; Female; Gastric Acid; Gastric Acidity Determination; Humans; Male; Middle Aged; Neoplasms; Ranitidine; Temozolomide | 1999 |
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Temozolomide | 1999 |
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quality of Life; Survival Analysis; Temozolomide | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Eating; Female; Glioma; Humans; Male; Melanoma; Middle Aged; Neoplasms; Skin Neoplasms; Temozolomide; Treatment Outcome | 1999 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Radiopharmaceuticals; Temozolomide; Tomography, Emission-Computed | 2000 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Female; Health Care Costs; Humans; Infusions, Intravenous; Male; Melanoma; Quality-Adjusted Life Years; Skin Neoplasms; Temozolomide | 2000 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Health Status; Humans; Male; Middle Aged; Procarbazine; Quality of Life; Temozolomide | 2000 |
A phase II study of temozolomide in hormone-refractory prostate cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Temozolomide | 2000 |
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Recurrence; Temozolomide | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Gliosarcoma; Humans; Male; Middle Aged; Procarbazine; Prognosis; Quality of Life; Recurrence; Temozolomide; Time Factors | 2000 |
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Survival Analysis; Temozolomide; Treatment Failure | 2000 |
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Guanine; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2000 |
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Evaluation; Female; Humans; Male; Middle Aged; Safety; Temozolomide; Treatment Outcome | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Temozolomide | 2001 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Temozolomide | 2001 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Half-Life; Humans; Maximum Tolerated Dose; Temozolomide | 2000 |
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide | 2001 |
Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Implants; Drug Synergism; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Safety; Supratentorial Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2001 |
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease Progression; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tomography, X-Ray Computed | 2001 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pneumocystis Infections; Temozolomide | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Soft Tissue Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Treatment Outcome | 2002 |
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Temozolomide; Thalidomide | 2002 |
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Pilot Projects; Radiotherapy Dosage; Temozolomide | 2002 |
Phase I study of temozolomide in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide; Treatment Outcome | 2002 |
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma, Renal Cell; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Failure | 2002 |
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Procarbazine; Recurrence; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Pilot Projects; Radiotherapy; Survival Rate; Temozolomide | 2002 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Multicenter Studies as Topic; Supratentorial Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Temozolomide; Treatment Outcome; Vinblastine | 2002 |
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioblastoma; Humans; Middle Aged; Portugal; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Male; Temozolomide; Thrombocytopenia | 2002 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Recombinant Proteins; Skin Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2003 |
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome | 2002 |
A prospective study on glioblastoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Male; Neurosurgical Procedures; Procarbazine; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Temozolomide; Vincristine | 2003 |
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Temozolomide | 2003 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Etoposide; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2003 |
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Temozolomide; Treatment Outcome | 2003 |
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome | 2003 |
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Glioma; Humans; Isotretinoin; Male; Middle Aged; Neoplasm Recurrence, Local; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide; Treatment Outcome | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival; Temozolomide; Thalidomide | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Procarbazine; Sleep Stages; Temozolomide; Thrombocytopenia; Treatment Outcome | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Thalidomide; Treatment Outcome | 2003 |
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Body Surface Area; Brain Neoplasms; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dacarbazine; Female; Humans; Infant; Linear Models; Male; Metabolic Clearance Rate; Reproducibility of Results; Temozolomide | 2003 |
Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Temozolomide; Thrombocytopenia | 2003 |
A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Prognosis; Sarcoma; Temozolomide; Treatment Outcome; Uterine Neoplasms | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Survival Rate; Temozolomide | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dacarbazine; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Thrombocytopenia | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Seizures; Temozolomide; Treatment Outcome | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Quality of Life; Radiography; Seizures; Temozolomide; Treatment Outcome | 2003 |
A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Prognosis; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2003 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ondansetron; Temozolomide | 2004 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; Dacarbazine; Emotions; Female; Health Status; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Quality of Life; Skin Neoplasms; Sleep; Survival Analysis; Temozolomide | 2003 |
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
Topics: Adult; Cisplatin; Confidence Intervals; Dacarbazine; Drug Resistance, Neoplasm; Female; Germinoma; Humans; Male; Mediastinal Neoplasms; Temozolomide; Testicular Neoplasms | 2004 |
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Alkylating Agents; Area Under Curve; Bilirubin; Capsules; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Temozolomide; Thrombocytopenia; Tissue Distribution; Treatment Failure | 2004 |
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Supratentorial Neoplasms; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Proportional Hazards Models; Risk Assessment; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence Intervals; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Temozolomide | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2004 |
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Mismatch; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Repair; Female; Humans; Immunohistochemistry; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Time Factors | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Temozolomide; Treatment Outcome; Water | 2004 |
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dacarbazine; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Temozolomide; Treatment Outcome | 2004 |
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neutrophils; Temozolomide | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Promoter Regions, Genetic; Proportional Hazards Models; Survival Analysis; Temozolomide; Time Factors | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide | 2004 |
Temozolomide for treatment-resistant recurrent meningioma.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Interactions; Female; Glioblastoma; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Prognosis; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Stomatitis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; United States | 2004 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Palliative Care; Temozolomide; Topotecan; Treatment Outcome | 2004 |
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Temozolomide | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Female; Humans; Male; Middle Aged; Pilot Projects; Temozolomide | 2004 |
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Diseases; Dacarbazine; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Temozolomide; Treatment Outcome | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Karnofsky Performance Status; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Neuroepithelial; Oligodendroglioma; Procarbazine; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Life Tables; Male; Middle Aged; Neoplasms, Neuroepithelial; Oligodendroglioma; Prospective Studies; Temozolomide; Treatment Outcome | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Temozolomide | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cohort Studies; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Gadolinium; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Procarbazine; Temozolomide; Vincristine | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide; Time Factors | 2004 |
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-alpha; Italy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Evaluation of temozolomide in patients with myelodysplastic syndrome.
Topics: Aged; Anemia; Antineoplastic Agents, Alkylating; Cardiomyopathies; Dacarbazine; Drug Evaluation; Female; Fever; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Temozolomide; Treatment Failure | 2004 |
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cohort Studies; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lomustine; Male; Middle Aged; Oligodendroglioma; Procarbazine; Remission Induction; Retrospective Studies; Salvage Therapy; Sequence Deletion; Temozolomide; Treatment Outcome; Vincristine | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug Costs; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Thalidomide | 2004 |
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Delivery Systems; Female; Glioblastoma; Humans; Italy; Male; Middle Aged; Radioimmunotherapy; Radiopharmaceuticals; Survival Analysis; Temozolomide; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome | 2004 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Temozolomide; Treatment Outcome | 2005 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Temozolomide | 2005 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Female; Humans; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Nausea; Stomach Neoplasms; Temozolomide; Treatment Outcome | 2005 |
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Temozolomide | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Computer-Assisted; Survival Analysis; Temozolomide | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2005 |
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Isotretinoin; Male; Middle Aged; Proportional Hazards Models; Supratentorial Neoplasms; Temozolomide | 2005 |
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Child; Dacarbazine; Humans; Infant; Metabolic Clearance Rate; Monte Carlo Method; Temozolomide | 2005 |
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Temozolomide | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analysis; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2005 |
Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Radiotherapy; Temozolomide; Treatment Outcome | 2005 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Female; Headache; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2005 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Temozolomide | 2005 |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide; Time Factors | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Liposomes; Male; Middle Aged; Prospective Studies; Quality of Life; Temozolomide | 2006 |
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Temozolomide; Treatment Outcome | 2005 |
Temozolomide in resistant or relapsed pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Survival Analysis; Temozolomide | 2006 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Eye Neoplasms; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Melanoma; Middle Aged; Neoplasm Metastasis; Reproducibility of Results; Skin Neoplasms; Survival Analysis; Temozolomide | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Stereotaxic Techniques; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
A Phase I trial of protracted oral fixed-dose temozolomide.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2005 |
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Salvage Therapy; Temozolomide; Treatment Outcome | 2005 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Temozolomide; Time Factors | 2006 |
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
Topics: Aged; Dacarbazine; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Temozolomide | 2005 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Guanine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide | 2005 |
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Temozolomide | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Approval; Female; Glioblastoma; Humans; Male; Middle Aged; Pneumocystis; Pneumocystis Infections; Proportional Hazards Models; Quality of Life; Radiotherapy; Salvage Therapy; Temozolomide; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Temozolomide | 2006 |
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Neoplasms; Prognosis; Temozolomide | 2005 |
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Prognosis; Prospective Studies; Statistics, Nonparametric; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Outcome | 2006 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Emotions; Fatigue; Female; Health Status; Humans; Male; Middle Aged; Quality of Life; Social Behavior; Stress, Psychological; Temozolomide; Treatment Outcome | 2005 |
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adult; Anaplasia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cyclophosphamide; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide | 2006 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Hong Kong; Hospitals, Teaching; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide | 2005 |
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Time Factors; Treatment Outcome | 2006 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Tamoxifen; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine | 2005 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Quality of Life; Radiotherapy; Temozolomide; Time Factors; Treatment Outcome | 2006 |
Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Child; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Spinal Cord; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Islet Cell; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pheochromocytoma; Survival Analysis; Temozolomide; Thalidomide; Treatment Outcome | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Recombinant Proteins; Temozolomide | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionine; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome | 2006 |
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Topics: Adenosine Triphosphatases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Safety; Temozolomide | 2006 |
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Patient Selection; Temozolomide; Treatment Outcome | 2006 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 Enzyme System; Dacarbazine; Disease-Free Survival; Enzyme Inhibitors; Glioma; Humans; Hydroxamic Acids; Joint Diseases; Joints; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neoplasms; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Mouth Neoplasms; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease Progression; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2006 |
Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Glioblastoma; Humans; Quality of Life; Temozolomide | 2006 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Europe; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Infusions, Intravenous; Liver; Lung; Male; Middle Aged; Remission Induction; Sarcoma; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome | 2006 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Polyethylene Glycols; Radioimmunotherapy; Temozolomide | 2003 |
[Temozolomide--a new antitumor preparation in the treatment of central nervous system malignant tumors].
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Temozolomide; Treatment Outcome | 2006 |
Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Temozolomide; Treatment Outcome | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Risk Assessment; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide | 2006 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Feasibility Studies; Female; Glioblastoma; Humans; Laser Coagulation; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Temperature | 2006 |
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Oligodendroglioma; Temozolomide; Treatment Outcome | 2006 |
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Pilot Projects; Pyrazoles; Sulfonamides; Temozolomide; Treatment Outcome; Tretinoin | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Leukopenia; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome; Vomiting | 2006 |
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Neoplasm Recurrence, Local; Temozolomide | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Nausea; Temozolomide; Treatment Outcome; Vomiting | 2006 |
Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide | 2006 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Necrosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Temozolomide; Treatment Outcome | 2007 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA Repair; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Oligodendroglioma; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2006 |
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Temozolomide | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrazoles; Skin Neoplasms; Sulfonamides; Survival Analysis; Temozolomide | 2006 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Failure; Venous Thrombosis; Withholding Treatment | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Temozolomide | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Survival Analysis; Temozolomide | 2007 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Survival Analysis; Temozolomide; Thalidomide | 2007 |
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Child; Child, Preschool; Dacarbazine; Female; France; Humans; Infant; Male; Neuroblastoma; Temozolomide; Thrombocytopenia; Treatment Outcome; United Kingdom | 2006 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lomustine; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Failure | 2007 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Leukopenia; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Temozolomide | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Female; Genetic Markers; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Protein p14ARF; Tumor Suppressor Proteins | 2006 |
A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.
Topics: Acute Disease; Aged; Antineoplastic Agents; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Leukemia, Myeloid; Middle Aged; Predictive Value of Tests; Temozolomide; Tumor Suppressor Proteins | 2007 |
Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life.
Topics: Aged; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Survival Rate; Temozolomide | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Monte Carlo Method; Radiobiology; Relative Biological Effectiveness; Temozolomide; Therapeutic Equivalency | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Feasibility Studies; Female; Glioma; Humans; Longitudinal Studies; Male; Middle Aged; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Survival Analysis; Survivors; Temozolomide; Time Factors; Treatment Outcome | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Temozolomide; Time Factors; Treatment Outcome | 2007 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2006 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Probability; Prospective Studies; Risk Assessment; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Procarbazine; Salvage Therapy; Temozolomide | 2008 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Purines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasms, Unknown Primary; Palliative Care; Rectal Neoplasms; Research Design; Temozolomide; Treatment Outcome | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Prospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Female; Lymphoma; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Ependymoma; Female; Humans; Infant; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Temozolomide; Treatment Outcome | 2007 |
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2007 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2008 |
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia; Male; Microsatellite Instability; Neoplasm Recurrence, Local; Temozolomide; Tumor Suppressor Proteins | 2007 |
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Vinblastine; Vinorelbine | 2008 |
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Enzyme Inhibitors; Female; Guanine; Humans; Infant; Male; Temozolomide; Treatment Outcome | 2007 |
Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Neuroepithelial; Neoplasms, Second Primary; Pilot Projects; Temozolomide; Treatment Outcome | 2008 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2007 |
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Nomograms; Prognosis; Proportional Hazards Models; Survival Analysis; Temozolomide | 2008 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose-Response Relationship, Drug; Drug Delivery Systems; Exotoxins; Female; Glioma; Humans; Infusions, Intralesional; Interleukin-13; Male; Middle Aged; Nervous System Diseases; Radiotherapy, Conformal; Recombinant Fusion Proteins; Temozolomide; Treatment Outcome | 2007 |
Nomograms as clinicobiological predictors of survival in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioblastoma; Humans; Nomograms; Predictive Value of Tests; Prognosis; Temozolomide | 2008 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Glioblastoma; Health Care Costs; Humans; Middle Aged; Quality-Adjusted Life Years; Survival Rate; Temozolomide | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Male; Middle Aged; Prognosis; Temozolomide | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Glioblastoma; Humans; Male; Middle Aged; Prevalence; Radiotherapy; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Humans; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Odds Ratio; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Chromosome Mapping; Chromosomes, Human, Pair 19; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Female; Genetic Markers; Humans; Male; Middle Aged; Neoplasms, Neuroepithelial; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Retrospective Studies; Temozolomide | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Monoterpenes; Neoplasm Recurrence, Local; Oncogene Protein p21(ras); Signal Transduction; Survival Rate; Temozolomide; Transforming Growth Factor beta; Treatment Outcome | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabine; Cyclooxygenase 2 Inhibitors; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Edema; Efferent Pathways; Erythema; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Immunohistochemistry; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pioglitazone; PPAR gamma; Predictive Value of Tests; Quality of Life; Sulfones; Temozolomide; Thiazolidinediones; Treatment Outcome | 2007 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Skin Neoplasms; Temozolomide | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide | 2008 |
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Pilot Projects; Temozolomide | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Mas; Pyrimidines; Temozolomide | 2008 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Dacarbazine; Disease-Free Survival; DNA Methylation; Endostatins; Female; Fibroblast Growth Factor 2; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Pyrazoles; Sulfonamides; Temozolomide; Thalidomide; Thrombospondins; Vascular Endothelial Growth Factor A | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy; Survival Analysis; Temozolomide | 2008 |
Phase II study of extended-dose temozolomide in patients with melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2008 |
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dacarbazine; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Staging; Purines; Temozolomide; Treatment Failure | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Glioma; Humans; Lomustine; Maximum Tolerated Dose; Temozolomide | 2008 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Prospective Studies; Temozolomide | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Pons; Prognosis; Radiotherapy; Temozolomide; Tretinoin | 2008 |
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Topics: Adult; Adult Stem Cells; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Profiling; Genes, Homeobox; Glioblastoma; Humans; Middle Aged; Multigene Family; Radiation Tolerance; Temozolomide | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Procarbazine; Salvage Therapy; Survival Analysis; Temozolomide | 2008 |
Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbamazepine; Dacarbazine; Epilepsy; Female; Follow-Up Studies; Fructose; Humans; Male; Middle Aged; Oxcarbazepine; Temozolomide; Topiramate; Young Adult | 2008 |
Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2008 |
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Survival Rate; Taxoids; Temozolomide | 2008 |
Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results.
Topics: Adult; Antineoplastic Agents, Alkylating; Case-Control Studies; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mutation; Radiotherapy; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide | 2008 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide | 2008 |
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Geriatrics; Glioblastoma; Humans; Karnofsky Performance Status; Male; Prospective Studies; Quality of Life; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2009 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Promoter Regions, Genetic; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2009 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Temozolomide; Thalidomide | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Temozolomide | 2008 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2009 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Magnetic Resonance Imaging; Methionine; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retreatment; Software; Temozolomide; Treatment Failure; Young Adult | 2009 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Glioma; Humans; Interferon-beta; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide; Treatment Outcome | 2008 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Pulmonary Embolism; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2009 |
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Humans; Kaplan-Meier Estimate; Loss of Heterozygosity; Oligodendroglioma; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2009 |
Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Ethics, Medical; Female; Glioblastoma; Humans; Male; Middle Aged; Patient Compliance; Patient Selection; Quality of Life; Radiotherapy Dosage; Salvage Therapy; Survival Analysis; Temozolomide | 2008 |
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comet Assay; Cytochrome P-450 CYP2D6; Dacarbazine; DNA Breaks; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Temozolomide | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2009 |
Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Temozolomide; Time Factors; Treatment Outcome; Triazines | 2009 |
O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Reoperation; Temozolomide; Time Factors | 2009 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Temozolomide | 2009 |
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Recurrence; Temozolomide | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Guanine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Survival Analysis; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioma; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Purines; Skin Neoplasms; Temozolomide; Thrombocytopenia | 2009 |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replication; DNA, Neoplasm; Humans; Kinetics; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Purines; Temozolomide | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotopes; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Temozolomide; Time Factors; Tyrosine; Young Adult | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Guanine; Hematologic Diseases; Humans; Male; Neoplasms; Sex Factors; Tandem Mass Spectrometry; Temozolomide; Young Adult | 2009 |
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dacarbazine; DNA Mismatch Repair; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2009 |
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Temozolomide; Treatment Failure; Young Adult | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2009 |
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome | 2010 |
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Brain Neoplasms; Cranial Irradiation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Excitatory Amino Acid Antagonists; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, AMPA; Risk Assessment; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; United States | 2009 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Colitis; Dacarbazine; Diarrhea; Female; Humans; Irinotecan; Male; Neutropenia; Pneumonia; Recurrence; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Korea; Male; Middle Aged; Radiation Dosage; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Nervous System Neoplasms; Constipation; Cross-Over Studies; Dacarbazine; Drug Administration Schedule; Female; Headache; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Temozolomide; Therapeutic Equivalency; Time Factors; Vomiting | 2010 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Male; Pons; Prospective Studies; Temozolomide | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Delivery Systems; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Temozolomide; Treatment Outcome; Young Adult | 2009 |
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Radiotherapy, Intensity-Modulated; Temozolomide; Tumor Burden | 2010 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Conformal; Temozolomide; Treatment Outcome | 2010 |
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Infant; Male; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2009 |
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glioblastoma; Humans; Male; Middle Aged; Polyethylene Glycols; Temozolomide; Young Adult | 2009 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Community Health Planning; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2009 |
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Follow-Up Studies; Germany; Glioblastoma; Humans; Indomethacin; Karnofsky Performance Status; Male; Middle Aged; Prospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2010 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2009 |
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Female; Humans; Male; Microdialysis; Middle Aged; Pilot Projects; Radiotherapy; Tandem Mass Spectrometry; Temozolomide | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Mutation; Procarbazine; Promoter Regions, Genetic; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Temozolomide; Time Factors; Treatment Failure; Tumor Suppressor Proteins; Vincristine; Young Adult | 2009 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide; Thalidomide | 2010 |
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cohort Studies; Dacarbazine; DNA Mutational Analysis; Female; Humans; Isocitrate Dehydrogenase; Male; Mutation; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2009 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Pyridines; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Double-Blind Method; Female; Glioma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2009 |
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Cross-Linking Reagents; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Lomustine; Male; Melphalan; Middle Aged; Oligodendroglioma; Osmotic Pressure; Procarbazine; Temozolomide; Vincristine; Young Adult | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2010 |
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diverticulitis; Drug Administration Schedule; ErbB Receptors; Female; Gastrointestinal Hemorrhage; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Quinazolines; Temozolomide; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Male; Middle Aged; Temozolomide; Young Adult | 2010 |
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Quality of Life; Temozolomide; Young Adult | 2010 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibroblast Growth Factor 1; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oligopeptides; Receptor, TIE-1; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Treatment Outcome | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome | 2010 |
A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Korea; Male; Pons; Temozolomide; Thalidomide | 2010 |
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Glioblastoma; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Radioimmunotherapy; Radiotherapy, Adjuvant; Temozolomide; Young Adult | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Japan; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Natural Killer T-Cells; Radiotherapy, Conformal; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Temozolomide; WT1 Proteins | 2010 |
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Deletion; Humans; Kaplan-Meier Estimate; Loss of Heterozygosity; Male; Middle Aged; Oligodendroglioma; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Young Adult | 2010 |
Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide | 2010 |
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Temozolomide; Treatment Outcome | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neurosurgical Procedures; Probability; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Risk Assessment; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide | 2011 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioblastoma; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2011 |
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; History, 16th Century; Humans; Hydrazines; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Temozolomide; Young Adult | 2010 |
Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Dacarbazine; Etoposide; Female; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2010 |
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Humans; Infant; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Topotecan; Treatment Outcome; Tumor Protein, Translationally-Controlled 1; Young Adult | 2010 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose Sodium; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Interferon Inducers; Kaplan-Meier Estimate; Male; Middle Aged; Poly I-C; Polylysine; Radiotherapy; Temozolomide; Young Adult | 2010 |
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Canada; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Infant; Male; Maximum Tolerated Dose; Pilot Projects; Temozolomide; Thrombocytopenia; Treatment Outcome | 2010 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Odds Ratio; Organophosphorus Compounds; Temozolomide; Time Factors; Tomography, X-Ray Computed | 2011 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Child; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Lomustine; Male; Middle Aged; Neoplasm Staging; Neoplasms, Neuroepithelial; Neoplasms, Radiation-Induced; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Vincristine; Young Adult | 2010 |
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Pyrazoles; Radiotherapy; Sulfonamides; Supratentorial Neoplasms; Temozolomide; Thalidomide; Young Adult | 2010 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Prognosis; Proton Therapy; Radiotherapy Dosage; Relative Biological Effectiveness; Survival Rate; Temozolomide | 2010 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Membrane Proteins; Middle Aged; Phthalazines; Polymorphism, Single Nucleotide; Pyridines; Radiotherapy; Receptor, TIE-2; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Etoposide; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2011 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Neoplasm Staging; Procarbazine; Proportional Hazards Models; Quality of Life; Recurrence; Risk Assessment; Risk Factors; Temozolomide; Time Factors; Treatment Outcome; United Kingdom; Vincristine | 2010 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Everolimus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sirolimus; Temozolomide | 2011 |
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Injections, Intradermal; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Sample Size; Temozolomide; Time Factors; Tumor Suppressor Proteins; United States | 2010 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Photosensitizing Agents; Radiotherapy; Temozolomide; Treatment Outcome | 2011 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies; Radiotherapy, Intensity-Modulated; Temozolomide; Tumor Burden | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quinolones; Temozolomide | 2011 |
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Radiosurgery; Radiotherapy, Conformal; Survival Rate; Temozolomide | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Craniotomy; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Glucocorticoids; Humans; Injections, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Burden; Young Adult | 2012 |
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2011 |
The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Humans; Infant; Irinotecan; Male; Neuroblastoma; Temozolomide | 2011 |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prospective Studies; Temozolomide | 2011 |
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; DNA Methylation; ErbB Receptors; Female; Glioblastoma; Humans; Hypersensitivity, Delayed; Immunoenzyme Techniques; Lymphopenia; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Survival Rate; T-Lymphocytes; T-Lymphocytes, Regulatory; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2011 |
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioblastoma; HLA-A Antigens; HLA-A24 Antigen; Humans; Japan; Male; Middle Aged; Precision Medicine; Recurrence; Survival Analysis; T-Lymphocytes, Cytotoxic; Temozolomide; Vaccines, Subunit | 2011 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Interferon-beta; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Temozolomide | 2011 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Gliosarcoma; Humans; Immunoenzyme Techniques; Male; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Pons; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Survival Rate; Tamoxifen; Temozolomide; Thrombocytopenia; Venous Thrombosis; Young Adult | 2012 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Diterpenes; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Prospective Studies; Retinaldehyde; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2011 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Temozolomide; Treatment Failure; Treatment Outcome | 2011 |
The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Combined Modality Therapy; Dacarbazine; Humans; Positron-Emission Tomography; Temozolomide | 2011 |
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Europe; Glioblastoma; Humans; Prognosis; Radiotherapy; Recurrence; Standard of Care; Temozolomide; Treatment Outcome | 2011 |
Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2011 |
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Glycoproteins; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Epitopes; Female; Glioblastoma; Humans; Immunity, Cellular; Male; Middle Aged; Radiotherapy; Research Design; Survival Analysis; T-Lymphocytes; Temozolomide; Transplantation, Autologous; Treatment Outcome | 2011 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2012 |
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Cytokines; Dacarbazine; Humans; Immunologic Memory; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; T-Lymphocytes; Telomerase; Temozolomide; Treatment Outcome; Vaccines, Subunit; Young Adult | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Safety; Skin Neoplasms; Temozolomide; Time Factors | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; North America; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Temozolomide; Vascular Endothelial Growth Factor A | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2011 |
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; France; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Polymerase Chain Reaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Topics: Adult; Antineoplastic Agents; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Humans; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Retroperitoneal Neoplasms; Survival Analysis; Temozolomide; Testicular Neoplasms; Treatment Outcome | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazine; Disease-Free Survival; Drug Combinations; Enzyme Inhibitors; Fatty Acids, Unsaturated; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Piperidines; Pyridines; Temozolomide; Vitamin E | 2011 |
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; DNA Mismatch Repair; Female; Humans; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Mycosis Fungoides; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Sezary Syndrome; Temozolomide; Treatment Outcome | 2011 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Netherlands; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Temozolomide; Thallium Radioisotopes; Treatment Outcome; Young Adult | 2012 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Daclizumab; Drug Evaluation, Preclinical; Glioblastoma; Humans; Immunoglobulin G; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Substrate Specificity; T-Lymphocytes, Regulatory; Temozolomide; Young Adult | 2011 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Genetic Vectors; Glioma; Herpesvirus 1, Human; Humans; Immunotherapy; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Thymidine Kinase; Treatment Outcome; Valacyclovir; Valine | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adult; Antineoplastic Agents; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Neoplasm Grading; Pons; Temozolomide | 2012 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Europe; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Valproic Acid; Young Adult | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Case-Control Studies; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Gliosarcoma; Humans; Immunoenzyme Techniques; Indoles; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioma; Guanine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Proportional Hazards Models; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2012 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Survival Rate; Temozolomide; Vomiting | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide | 2012 |
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Recurrence; Temozolomide; Treatment Outcome | 2012 |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Temozolomide; Treatment Outcome; Young Adult | 2012 |
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Marrow; Dacarbazine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
Topics: Adult; Aged; Alberta; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Neutropenia; Temozolomide; Thrombocytopenia | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cognition; Cranial Irradiation; Dacarbazine; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survival Analysis; Temozolomide | 2012 |
Going past the data for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2012 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Combinations; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; PTEN Phosphohydrolase; Sirolimus; Temozolomide; Young Adult | 2012 |
A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Ireland; Male; Middle Aged; Prevalence; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA Methylation; Female; Humans; Lung Neoplasms; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cytarabine; Dacarbazine; Diffusion Magnetic Resonance Imaging; Etoposide; Female; Humans; Immunotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Rituximab; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Double-Blind Method; Humans; Melanoma; Neoplasm Staging; Temozolomide | 2011 |
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Temozolomide | 2012 |
Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide; Young Adult | 2012 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Leukopenia; Male; Middle Aged; Radiation Injuries; Radiotherapy, Conformal; Remission Induction; Survival Rate; Temozolomide; Young Adult | 2011 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Semustine; Temozolomide; Teniposide; Young Adult | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Prospective Studies; Temozolomide | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Reoperation; Temozolomide; Tumor Burden | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Integrins; Male; Middle Aged; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electronic Health Records; Glioma; Humans; Quality Assurance, Health Care; Radiotherapy Dosage; Temozolomide | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Isocitrate Dehydrogenase; Male; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2012 |
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2012 |
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Rituximab; Salvage Therapy; Temozolomide; Treatment Outcome | 2013 |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Comorbidity; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Radiosurgery; Radiotherapy; Temozolomide; Young Adult | 2012 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A | 2013 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Temozolomide; Young Adult | 2012 |
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Radiography; Temozolomide; Treatment Outcome | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxides; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide | 2012 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Evidence-Based Medicine; Female; Glioblastoma; Humans; Male; Middle Aged; Palliative Care; Prognosis; Quality of Life; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Female; Glioma; Humans; Male; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Temozolomide | 2013 |
Chemosensitized radiosurgery for recurrent brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Pilot Projects; Prognosis; Radiosurgery; Survival Rate; Temozolomide | 2012 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Grading; Temozolomide; Treatment Outcome; Vorinostat | 2012 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Radiotherapy, Conformal; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome; Victoria | 2012 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Temozolomide; Treatment Outcome | 2012 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Immunotherapy, Active; Male; Middle Aged; Nimustine; Temozolomide | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Radiation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Failure; Young Adult | 2014 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Neurosurgical Procedures; Prospective Studies; Radiotherapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Everolimus; Female; Humans; Induction Chemotherapy; Male; Melanoma; Middle Aged; Sirolimus; Skin Neoplasms; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Paclitaxel; Polyglutamic Acid; Survival Analysis; Temozolomide | 2014 |
Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Patient Selection; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Outcome | 2015 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide; Young Adult | 2013 |
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; DNA Methylation; DNA Mismatch Repair; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Temozolomide; Treatment Outcome | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Temozolomide; Young Adult | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2013 |
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Female; Histones; Humans; Hydroxamic Acids; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Neutropenia; Promoter Regions, Genetic; Recurrence; Spinal Cord Neoplasms; Temozolomide; Thrombocytopenia; Tumor Suppressor Proteins; Vorinostat | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Semustine; Temozolomide | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cefixime; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Pilot Projects; Sarcoma, Ewing; Temozolomide; Vincristine | 2013 |
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Pyridines; Supratentorial Neoplasms; Temozolomide | 2013 |
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiography; Temozolomide; Treatment Outcome | 2013 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Communication; Dacarbazine; Disease Progression; Fatigue; Female; Glioblastoma; Health Status; Humans; Karnofsky Performance Status; Male; Neuropsychological Tests; Prospective Studies; Quality of Life; Social Participation; Surveys and Questionnaires; Temozolomide | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Temozolomide | 2013 |
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Longitudinal Studies; Lymphoma; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Retrospective Studies; Temozolomide | 2013 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Everolimus; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Temozolomide | 2013 |
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Quality of Life; Radiotherapy, Intensity-Modulated; Temozolomide | 2013 |
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies; Sirolimus; Temozolomide; Treatment Outcome | 2013 |
Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Male; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Survival Rate; Temozolomide; Time Factors; Vincristine | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Imaging, Three-Dimensional; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Genotype; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Irinotecan; Male; Medulloblastoma; Temozolomide | 2013 |
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Recurrence; Temozolomide; Vincristine; Young Adult | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Tamoxifen; Temozolomide; Treatment Outcome | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors | 2013 |
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dacarbazine; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Temozolomide; Treatment Outcome | 2013 |
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Italy; Middle Aged; Prevalence; Prospective Studies; Risk Assessment; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Karnofsky Performance Status; Male; Quality of Life; Remission Induction; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2013 |
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Recurrence; Temozolomide; Topotecan; Young Adult | 2014 |
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Hematologic Diseases; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Proton Pump Inhibitors; Temozolomide; Tumor Suppressor Proteins | 2015 |
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Temozolomide; Treatment Outcome | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neuropsychological Tests; Proportional Hazards Models; Quality of Life; Temozolomide; Young Adult | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Magnetic Resonance Imaging; Oxygen; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; HIV Protease Inhibitors; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nelfinavir; Outcome Assessment, Health Care; Temozolomide; Time Factors | 2014 |
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Retrospective Studies; RNA, Small Interfering; Survival Rate; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2014 |
Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Borohydrides; Boron Compounds; Boron Neutron Capture Therapy; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Germany; Glioblastoma; Humans; Male; Middle Aged; Phenylalanine; Prevalence; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome | 2014 |
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Snake Venoms; Temozolomide; Treatment Outcome | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Temozolomide; Treatment Outcome | 2014 |
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Humans; Italy; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Temozolomide; Young Adult | 2014 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Neoplasm, Residual; Prospective Studies; Radiation Injuries; Radiotherapy, Intensity-Modulated; Temozolomide | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Double-Blind Method; Glioblastoma; Humans; Proportional Hazards Models; Survival Analysis; Temozolomide | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Glioblastoma; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Life; Temozolomide; Young Adult | 2014 |
Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2016 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Retreatment; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide | 2014 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Young Adult | 2014 |
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; DNA Repair; Humans; Kallikreins; Male; Middle Aged; Pilot Projects; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Temozolomide; Treatment Outcome | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Temozolomide; Treatment Outcome | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Leukopenia; Male; Middle Aged; Nimustine; Postoperative Complications; Temozolomide; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Prognosis; Temozolomide; Tissue Distribution; Young Adult | 2014 |
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Young Adult | 2014 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Uveal Neoplasms | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; DNA, Neoplasm; Female; Glioma; Humans; Isocitrate Dehydrogenase; Lomustine; Male; Predictive Value of Tests; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiography; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Failure; Treatment Outcome | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Temozolomide; Treatment Outcome | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Demography; Female; Glioblastoma; Humans; Hydroxychloroquine; Male; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Follow-Up Studies; Glioblastoma; Humans; Japan; Male; Middle Aged; Prospective Studies; Radiotherapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Radiography; Risk; Survival Analysis; Temozolomide | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Therapy; Glioblastoma; Guanine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Prospective Studies; Temozolomide; Tumor Suppressor Proteins | 2014 |
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiosurgery; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Neoplasm Staging; Prognosis; Quality of Life; Temozolomide | 2015 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2015 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin Neoplasms; Temozolomide; Tissue Distribution; Tumor Suppressor Proteins | 2015 |
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Reference Values; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Combinations; Female; Glioblastoma; Humans; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazoles; Sulfonamides; Temozolomide; Thalidomide; Young Adult | 2015 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Humans; Middle Aged; Prospective Studies; Temozolomide | 2015 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Disease-Free Survival; Feasibility Studies; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Temozolomide; Treatment Outcome | 2015 |
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dog Diseases; Dogs; Melanoma; Radiotherapy; Temozolomide | 2016 |
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2015 |
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblastoma; Humans; Positron-Emission Tomography; Prognosis; Survival Analysis; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Oligodendroglioma; Patient Outcome Assessment; Prognosis; Quality of Life; Survival Rate; Temozolomide; Young Adult | 2015 |
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Temozolomide | 2015 |
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2015 |
Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM.
Topics: Alleles; Anilides; Cell Division; Cell Line, Tumor; Dacarbazine; Exome; Female; Follow-Up Studies; G2 Phase; Gene Frequency; Glioblastoma; Hedgehog Proteins; Humans; Male; Neoplasm Proteins; Pyridines; Radiography; Spheroids, Cellular; Temozolomide | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Cortex; Contrast Media; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy, Conformal; Research Design; Risk Factors; Temozolomide; Young Adult | 2015 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2015 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; WT1 Proteins | 2015 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Radiotherapy, Conformal; Random Allocation; Survival Rate; Tamoxifen; Temozolomide; Thromboembolism; Treatment Outcome; Young Adult | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Metalloporphyrins; Multivariate Analysis; Supratentorial Neoplasms; Temozolomide | 2015 |
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Piperidines; Quinazolines; Temozolomide; Treatment Outcome | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide; Young Adult | 2015 |
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2015 |
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Neoplasm Staging; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Postoperative Period; Prognosis; Prospective Studies; Radiotherapy Dosage; Survival Rate; Temozolomide | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Double-Blind Method; Female; Glioblastoma; Humans; Male; Middle Aged; Placebos; Quality of Life; Surveys and Questionnaires; Survival Analysis; Temozolomide | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide; Treatment Outcome | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Feasibility Studies; Female; Follow-Up Studies; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2015 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2016 |
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Oligodendroglioma; Radiotherapy; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Temozolomide | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Time Factors; Valproic Acid | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate; Temozolomide; Young Adult | 2015 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Diffusion Tensor Imaging; Glioblastoma; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2015 |
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Taxoids; Temozolomide | 2016 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Treatment Outcome | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Temozolomide | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Molecular Imaging; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Prognosis; Proton Magnetic Resonance Spectroscopy; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome | 2015 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure | 2015 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2015 |
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; France; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome; Tumor Burden; Tumor Suppressor Proteins | 2016 |
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Phenylurea Compounds; Quinolines; Temozolomide; Young Adult | 2015 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2016 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Constipation; Dacarbazine; Diarrhea; Fatigue; Female; Glioblastoma; Humans; Hypertension; L-Lactate Dehydrogenase; Leukopenia; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Grading; Neurosurgical Procedures; Neutropenia; Pyridines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2016 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Electric Stimulation Therapy; Europe; Female; Glioblastoma; Humans; Israel; Maintenance Chemotherapy; Male; Middle Aged; Republic of Korea; Temozolomide; United States; Young Adult | 2015 |
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Prospective Studies; Quality of Life; Temozolomide; Treatment Outcome; Vincristine | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Prognosis; Promoter Regions, Genetic; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2015 |
Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Temozolomide; Thiotepa | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Female; Follow-Up Studies; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Vincristine | 2016 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2016 |
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Procarbazine; Snake Venoms; Temozolomide; Treatment Failure; Tumor Suppressor Proteins; Young Adult | 2016 |
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram; Dose-Response Relationship, Drug; Drug Repositioning; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Supratentorial Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Tumor-Treating Fields-A Fundamental Change in Locoregional Management for Glioblastoma.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Field Therapy; Male; Middle Aged; Temozolomide | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Lomustine; Male; Temozolomide; Young Adult | 2016 |
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Rituximab; Temozolomide; Whole-Body Irradiation; Young Adult | 2016 |
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide | 2016 |
Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cerebellum; Cytarabine; Dacarbazine; Eye Neoplasms; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Survival Analysis; Temozolomide; Vincristine | 2016 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Proportional Hazards Models; Sirolimus; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Psychometrics; Quality of Life; Temozolomide | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quality of Life; Quinuclidines; Surveys and Questionnaires; Temozolomide | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; NF-KappaB Inhibitor alpha; Proteasome Endopeptidase Complex; Temozolomide; Treatment Outcome | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarbazine; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Preoperative Care; Rectal Neoplasms; Temozolomide; Treatment Outcome; Vomiting | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2016 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Taxoids; Temozolomide | 2016 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Grading; Prognosis; Prospective Studies; Survival Rate; Temozolomide; Young Adult | 2017 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult | 2016 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life; Temozolomide | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Radiotherapy, Conformal; Temozolomide | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; Glioma; Humans; Immunotherapy; Male; Middle Aged; Temozolomide; Up-Regulation | 2016 |
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Republic of Korea; Temozolomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Clinical Protocols; Dacarbazine; Drug Monitoring; Female; Humans; Models, Statistical; Paclitaxel; Research Design; Sample Size; Temozolomide | 2017 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Complex; CD4 Antigens; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lipopolysaccharide Receptors; Lymphocyte Count; Lymphocytes; Male; Melanoma; Middle Aged; Monocytes; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome | 2017 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Dacarbazine; Female; Glioma; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Prognosis; Prospective Studies; Survival Rate; Temozolomide; Young Adult | 2017 |
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; Female; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Predictive Value of Tests; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide | 2017 |
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoadjuvant Therapy; Pancytopenia; Prospective Studies; Radiation Dose Hypofractionation; Reoperation; Temozolomide; Time Factors; Treatment Failure; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Immunoconjugates; Male; Maximum Tolerated Dose; Middle Aged; Temozolomide; Treatment Outcome | 2017 |
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Epidemiologic Methods; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Proteins; Prognosis; Receptor Protein-Tyrosine Kinases; Temozolomide; Tumor Suppressor Proteins | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Neuropsychological Tests; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients].
Topics: Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide | 2016 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2017 |
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; China; Cisplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Quality of Life; Radiotherapy; Survival Analysis; Temozolomide | 2017 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; Male; Mice; Middle Aged; Neoplasm Staging; Prognosis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; GTP Phosphohydrolases; Humans; Membrane Proteins; Middle Aged; Mutation; Nausea; Neoplasm Metastasis; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Retreatment; Survival Rate; Temozolomide; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2017 |
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Oligodendroglioma; Stem Cell Transplantation; Temozolomide; Transplantation, Autologous | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oxides; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Communication; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quality of Life; Radiation Dose Hypofractionation; Radiosurgery; Surveys and Questionnaires; Survivors; Temozolomide; Treatment Outcome | 2017 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Temozolomide | 2017 |
VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Rhabdomyoma; Survival Rate; Temozolomide; Vinculin | 2018 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2017 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Proportional Hazards Models; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome; Vaccines, Subunit; Young Adult | 2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therapy; Cross-Over Studies; Dacarbazine; Electric Stimulation Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Mental Status and Dementia Tests; Middle Aged; Quality of Life; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiation Dose Hypofractionation; Radiation Oncology; Societies, Medical; Temozolomide | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Re-Irradiation; Salvage Therapy; Temozolomide; Time Factors | 2018 |
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Everolimus; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide; Young Adult | 2018 |
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Prognosis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate; Temozolomide | 2017 |
Efficacy and safety of temozolomide plus whole-brain radiotherapy in the treatment of intracranial metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Quality of Life; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Electric Stimulation Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Maintenance Chemotherapy; Male; Middle Aged; Mitosis; Survival Analysis; Temozolomide | 2017 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Purines; Pyrazoles; Receptor, Adenosine A2A; Temozolomide | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Glioma; Humans; Prospective Studies; Quality Assurance, Health Care; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Quality of Life; Radiation Dose Hypofractionation; Surveys and Questionnaires; Temozolomide | 2018 |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth Processes; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2018 |
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Systems; Female; Glioma; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Nanoparticles; Pilot Projects; Polymers; Supratentorial Neoplasms; Temozolomide; Treatment Outcome; Tumor Burden | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Thrombocytopenia | 2018 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Endostatins; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Recombinant Proteins; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide | 2019 |
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Topics: Adolescent; Adult; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Humans; Lapatinib; Prospective Studies; Spinal Cord Neoplasms; Temozolomide | 2021 |
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bayes Theorem; Brain Neoplasms; Dacarbazine; Humans; Maximum Tolerated Dose; Temozolomide | 2021 |
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2021 |
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Prospective Studies; Temozolomide | 2022 |
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA-Binding Proteins; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2022 |
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DNA; DNA Methylation; DNA Repair Enzymes; Glioblastoma; Humans; Prospective Studies; Rectal Neoplasms; Temozolomide | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Prognosis; Temozolomide | 2023 |
Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Interferon-alpha; Male; Middle Aged; Temozolomide; Young Adult | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
2814 other study(ies) available for dacarbazine and temozolomide
| Article | Year |
|---|---|
Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Survival; Dacarbazine; DNA; DNA Primers; Heterocyclic Compounds; Mice; Models, Molecular; Molecular Probes; Molecular Sequence Data; Temozolomide; Tumor Cells, Cultured | 1995 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
New benzothieno[3,2-d]-1,2,3-triazines with antiproliferative activity: synthesis, spectroscopic studies, and biological activity.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Circular Dichroism; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Molecular Structure; Spectrophotometry, Ultraviolet; Structure-Activity Relationship; Thiophenes; Triazines; Viscosity | 2014 |
Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas.
Topics: Alkalies; Alkylation; Animals; Antineoplastic Agents; Cell Division; Dacarbazine; DNA Damage; DNA, Neoplasm; Drug Resistance; Drug Screening Assays, Antitumor; Guanine; Leukemia L1210; Methyltransferases; Mice; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1992 |
Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC.
Topics: Antineoplastic Agents; Crystallography; Dacarbazine; Models, Molecular; Nitrogen Mustard Compounds; Structure-Activity Relationship; Temozolomide | 1992 |
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dacarbazine; DNA Glycosylases; DNA Repair; DNA, Neoplasm; Drug Resistance; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mice; N-Glycosyl Hydrolases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfuric Acid Esters; Temozolomide | 1992 |
Antitumour imidazotetrazines--XXIV. Growth suppression by DNA from cells treated with imidazotetrazinones.
Topics: Animals; Antineoplastic Agents; Cell Division; Dacarbazine; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Temozolomide; Transfection; Tumor Cells, Cultured | 1991 |
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Topics: Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Dacarbazine; Lymphoma; Mice; Prodrugs; Temozolomide; Tumor Cells, Cultured | 1991 |
Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA.
Topics: Antineoplastic Agents; Dacarbazine; DNA; In Vitro Techniques; Models, Molecular; Nitrogen Mustard Compounds; Structure-Activity Relationship; Temozolomide | 1990 |
Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones.
Topics: Alkylation; Antineoplastic Agents; Cell Line; Dacarbazine; DNA; Imidazoles; Nitrogen Mustard Compounds; Proteins; RNA; Temozolomide | 1987 |
Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.
Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esterases; Female; Flow Cytometry; Mammary Neoplasms, Experimental; Mesylates; Mice; Nitrogen Mustard Compounds; Spectrometry, Fluorescence; Temozolomide; Thiepins; Tumor Cells, Cultured | 1989 |
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation.
Topics: Blotting, Northern; Cell Cycle; Cell Differentiation; Dacarbazine; DNA Damage; DNA, Neoplasm; Flow Cytometry; Genes, ras; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methylation; Proto-Oncogenes; Temozolomide; Tumor Cells, Cultured | 1989 |
Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones.
Topics: 5-Methylcytosine; Antineoplastic Agents; Cell Division; Cell Line; Cytosine; Dacarbazine; DNA; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Humans; Imidazoles; Lymphocytes; Methylation; Temozolomide | 1989 |
Prodrugs in cancer chemotherapy.
Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chemistry, Pharmaceutical; Cyclophosphamide; Dacarbazine; Drug Evaluation; Female; Galactosidases; Glucuronosyltransferase; Humans; Imidazoles; Liver; Male; Nausea; Neoplasms; Neoplasms, Experimental; Structure-Activity Relationship; Temozolomide; Vomiting | 1986 |
Antitumour imidazotetrazines and gene expression.
Topics: Alkylation; Antineoplastic Agents; Dacarbazine; DNA; Gene Expression Regulation; Imidazoles; Nitrogen Mustard Compounds; Temozolomide | 1988 |
Antitumour imidazotetrazines-X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045; M & B 39831; NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562.
Topics: 5-Methylcytosine; Antineoplastic Agents; Cell Differentiation; Cell Line; Cytosine; Dacarbazine; DNA Replication; DNA, Neoplasm; Gene Expression Regulation; Globins; Hemoglobins; Humans; Imidazoles; Leukemia, Erythroblastic, Acute; Methylation; Temozolomide; Templates, Genetic; Time Factors | 1986 |
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Chlorambucil; Colonic Neoplasms; Dacarbazine; DNA Repair; Dose-Response Relationship, Drug; Guanine; Humans; Imidazoles; Kinetics; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Methyltransferases; Mice; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide | 1987 |
Glyoxalase activity during differentiation of human leukaemia cells in vitro.
Topics: Cell Differentiation; Dacarbazine; Formamides; Humans; Imidazoles; In Vitro Techniques; Lactoylglutathione Lyase; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Lyases; Temozolomide; Thiolester Hydrolases; Tumor Cells, Cultured | 1987 |
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Flow Cytometry; Leukemia L1210; Methylation; Methyltransferases; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 1987 |
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Mice, Inbred DBA; Mice, Inbred Strains; Neoplasms, Experimental; Plasmacytoma; Sarcoma, Experimental; Species Specificity; Temozolomide | 1987 |
Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism.
Topics: Cell Division; Cell Line; Dacarbazine; Dose-Response Relationship, Drug; Humans; Imidazoles; Leukemia, Erythroblastic, Acute; Nucleoside Diphosphate Sugars; Poly Adenosine Diphosphate Ribose; Temozolomide | 1985 |
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Gene Expression; Humans; Leukemia; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; RNA, Messenger; Temozolomide; Tumor Cells, Cultured | 1995 |
Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer.
Topics: Animals; Antineoplastic Agents, Alkylating; Carbon Radioisotopes; Dacarbazine; Infusions, Intravenous; Injections, Intraperitoneal; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide | 1995 |
Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Survival; Dacarbazine; DNA Damage; Drug Synergism; Enzyme Inhibitors; Isoquinolines; Mice; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 1995 |
Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Dacarbazine; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Pilot Projects; Temozolomide | 1995 |
Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: role of alpha-6 integrin phosphorylation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Adhesion; Cell Membrane; Dacarbazine; Dose-Response Relationship, Drug; Integrin alpha6; Integrins; Male; Mice; Mice, Inbred C57BL; Naphthalenes; Phosphorylation; Protein Kinase C; Temozolomide; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1995 |
Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Stability; Humans; Hydrogen-Ion Concentration; Pilot Projects; Sensitivity and Specificity; Temozolomide | 1995 |
Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Topics: Antineoplastic Agents; Cisplatin; Dacarbazine; Drug Resistance; Drug Screening Assays, Antitumor; Germinoma; Humans; Male; Temozolomide; Testicular Neoplasms; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1995 |
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Topics: Animals; Carmustine; Central Nervous System Neoplasms; Dacarbazine; Female; Guanine; Humans; Male; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Temozolomide; Transplantation, Heterologous | 1995 |
O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Dacarbazine; Granulocytes; Guanine; Humans; Macrophages; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 1995 |
DCMCIT, an analogue of the antitumour drugs mitozolomide and temozolomide.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Dacarbazine; Models, Molecular; Molecular Conformation; Molecular Structure; Nitrogen Mustard Compounds; Structure-Activity Relationship; Temozolomide | 1994 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Methyltransferases; Mice; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1994 |
NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.
Topics: Antineoplastic Agents; Calorimetry; Dacarbazine; DNA; Drug Stability; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Molecular Conformation; Molecular Structure; Nucleic Acid Conformation; Temozolomide | 1994 |
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Dacarbazine; Humans; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1993 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine; Humans; Melanoma; Mice; Nitrogen Mustard Compounds; Prodrugs; Temozolomide | 1993 |
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Topics: Antineoplastic Agents; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Guanine; Humans; Lomustine; Methyltransferases; Neoplasms, Experimental; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1993 |
O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Dacarbazine; DNA Damage; DNA Primers; Humans; Leukemia L1210; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Molecular Sequence Data; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection; Triazines; Tumor Cells, Cultured | 1995 |
Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Guanine; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1996 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Guanine; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Melanoma; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous | 1996 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexanes; Dacarbazine; Factor VIII; Glioma; Microscopy, Confocal; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Rats; Sesquiterpenes; Temozolomide; Tumor Cells, Cultured | 1996 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Dacarbazine; Glioblastoma; Guanine; Humans; Kinetics; Methyltransferases; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Guanine; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured | 1996 |
In vitro inactivation of human O6-alkylguanine DNA alkyltransferase by antitumor triazene compounds.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; DNA; Drug Resistance; Guanine; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Spodoptera; Temozolomide; Triazenes; Tumor Cells, Cultured | 1996 |
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; DNA Adducts; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Methylation; Methyltransferases; Microsatellite Repeats; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Carmustine; Cell Division; Dacarbazine; Drug Synergism; Female; Guanine; Hematopoietic Stem Cells; Male; Mice; Temozolomide | 1997 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Adducts; DNA Repair; Glioblastoma; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1997 |
Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Guanine; Humans; Melanoma, Experimental; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1997 |
Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Fragmentation; DNA Methylation; DNA Repair; DNA, Neoplasm; Humans; Leukemia; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Cells, Cultured | 1997 |
Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair.
Topics: Animals; Antineoplastic Agents; Carcinogens; Cell Division; Dacarbazine; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Leukemia L1210; Methylnitronitrosoguanidine; Mice; NAD; Nicotinamide-Nucleotide Adenylyltransferase; Ribavirin; Temozolomide | 1997 |
High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Circadian Rhythm; Dacarbazine; Drug Stability; Freezing; Half-Life; Humans; Linear Models; Osmolar Concentration; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Temozolomide; Temperature; Time Factors | 1997 |
Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; Enzyme Inhibitors; Guanine; HL-60 Cells; Humans; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Suppressor Protein p53 | 1998 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Feasibility Studies; Female; Fluorouracil; Glioma; Humans; Middle Aged; Spectrum Analysis; Temozolomide; Tomography, Emission-Computed | 1998 |
Involvement of the mismatch repair system in temozolomide-induced apoptosis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA Repair; Etoposide; Humans; Nucleic Acid Heteroduplexes; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate.
Topics: Animals; Bone Marrow Cells; Cells, Cultured; Dacarbazine; DNA Glycosylases; Erythrocytes; Ethylnitrosourea; Female; Fibroblasts; Guanine; Hypoxanthine Phosphoribosyltransferase; Leukocyte Count; Liver; Male; Methyl Methanesulfonate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Mutagens; Mutation; N-Glycosyl Hydrolases; Temozolomide | 1998 |
Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro.
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Cell Line; Cell Survival; Dacarbazine; Gene Transfer Techniques; Genetic Vectors; Guanine; Hematopoietic Stem Cells; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Retroviridae; Temozolomide | 1998 |
Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Cell Survival; Dacarbazine; Gene Expression; Gene Transfer Techniques; Genetic Vectors; Male; Mice; Mice, Inbred Strains; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Retroviridae; Spleen; Stem Cells; Temozolomide | 1998 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Division; Dacarbazine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematologic Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urogenital Neoplasms | 1997 |
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Division; Cell Survival; Cisplatin; Dacarbazine; Densitometry; Doxorubicin; Humans; Jurkat Cells; Polymerase Chain Reaction; Sensitivity and Specificity; Telomerase; Temozolomide; Tumor Cells, Cultured; U937 Cells | 1997 |
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; Humans; Methyl Methanesulfonate; Methylation; Methylnitronitrosoguanidine; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin; Temozolomide; Tumor Cells, Cultured | 1996 |
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; DNA, Neoplasm; Drug Administration Schedule; Female; Glioblastoma; Humans; Imidazoles; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Temozolomide; Treatment Outcome | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, Antisense; Endothelial Growth Factors; Genetic Vectors; Glioma; Humans; Lymphokines; Male; Neoplasm Proteins; Neovascularization, Pathologic; Rats; Rats, Nude; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Combinations; Drug Resistance, Neoplasm; Guanine; Hematopoietic Stem Cells; Humans; Male; Mice; Mice, Inbred C3H; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic; Transfection; Tumor Cells, Cultured | 1999 |
Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
Topics: Androstadienes; Animals; Antineoplastic Agents; Cell Survival; CHO Cells; Cricetinae; Dacarbazine; DNA; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; DNA, Single-Stranded; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Quinazolines; Temozolomide; Wortmannin | 1999 |
Cytokinetics of a novel 1,2,3-triazene-containing heterocycle, 8-nitro-3-methyl-benzo-1,2,3,5-tetrazepin-4(3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3.
Topics: Alkylation; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Azepines; Base Sequence; Binding Sites; Cell Cycle; Cell Division; Cell Survival; Dacarbazine; DNA Damage; DNA, Neoplasm; Female; Guanine; Humans; Ovarian Neoplasms; Plasmids; RNA, Neoplasm; Structure-Activity Relationship; Temozolomide; Tumor Cells, Cultured | 1999 |
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine.
Topics: Animals; Apoptosis; Cells, Cultured; Cisplatin; Dacarbazine; DNA Repair; DNA-Binding Proteins; Guanine; Intestinal Mucosa; Intestine, Small; Methylnitronitrosoguanidine; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, Knockout; Mutagenesis; Mutagens; MutS Homolog 2 Protein; Proto-Oncogene Proteins; Stem Cells; Temozolomide | 1999 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Inhibitory Concentration 50; Lomustine; Oligodendroglioma; Temozolomide; Tumor Cells, Cultured | 1999 |
Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Burkitt Lymphoma; Combined Modality Therapy; Dacarbazine; Humans; Immunotoxins; Mice; Mice, SCID; N-Glycosyl Hydrolases; Plant Proteins; Ribosome Inactivating Proteins, Type 1; Temozolomide; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Treatment of neoplastic meningitis with intrathecal temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Screening Assays, Antitumor; Humans; Meningeal Neoplasms; Neoplasm Transplantation; Rats; Rats, Nude; Solubility; Subarachnoid Space; Temozolomide; Transplantation, Heterologous | 1999 |
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Dacarbazine; DNA Glycosylases; DNA Ligases; DNA Repair; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Jurkat Cells; Leukemia; N-Glycosyl Hydrolases; Poly(ADP-ribose) Polymerase Inhibitors; RNA, Messenger; Temozolomide; Transcription, Genetic; Triazenes | 1999 |
DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinogens; Carmustine; Dacarbazine; Genotype; Hematopoietic System; Liver; Methylnitronitrosoguanidine; Mice; Mice, Knockout; Mitomycin; Models, Biological; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin; Temozolomide | 1999 |
Antitumour imidazotetrazines. Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing the minor groove.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cattle; Circular Dichroism; Dacarbazine; DNA; DNA-Binding Proteins; Drug Carriers; Kinetics; Male; Molecular Sequence Data; Nitrogen Mustard Compounds; Nucleic Acid Conformation; Oligopeptides; Salmon; Spectrometry, Fluorescence; Substrate Specificity; Taq Polymerase; Temozolomide | 1999 |
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Colonic Neoplasms; Dacarbazine; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 1999 |
Oral temozolomide approved for refractory brain tumor.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Humans; Temozolomide | 1999 |
O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Alkylating; Cell Line; Dacarbazine; Enzyme Inhibitors; Guanine; Humans; Immunity, Cellular; Immunity, Innate; Immunosuppressive Agents; Interleukin-2; Monocytes; T-Lymphocytes, Regulatory; Temozolomide; Tumor Cells, Cultured | 1999 |
Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Temozolomide | 1999 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Guanine; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2000 |
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Guanine; Humans; Male; Melanoma, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous | 2000 |
An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
Topics: Animals; Antineoplastic Agents, Alkylating; Calibration; Chromatography, High Pressure Liquid; Dacarbazine; Dogs; Female; Male; Mass Spectrometry; Quality Control; Rats; Reproducibility of Results; Temozolomide | 1999 |
Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Cells; Cell Division; Cell Survival; Chemokine CCL3; Chemokine CCL4; Colony-Forming Units Assay; Dacarbazine; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Macrophage Inflammatory Proteins; Streptozocin; Temozolomide | 2000 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Carrier Proteins; Cell Division; Child; Dacarbazine; DNA Repair; DNA-Binding Proteins; Female; Humans; Mice; Mice, Inbred CBA; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Proto-Oncogene Proteins; Rhabdomyosarcoma; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Salvage Therapy; Temozolomide; Treatment Outcome | 2000 |
Understanding low-grade glioma: a decade of progress.
Topics: Antineoplastic Agents, Alkylating; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Glioma; Humans; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2000 |
In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biotransformation; Cisplatin; Cytochrome P-450 Enzyme System; Dacarbazine; DNA Damage; Enzyme Inhibitors; Guanine; Intestine, Small; Methylnitrosourea; Mice; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2000 |
Temozolomide (Temodal) for treatment of primary brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Monitoring; Glioblastoma; Humans; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Glioma; Humans; Temozolomide; United States | 2000 |
Human mesenchymal stem cells provide stromal support for efficient CD34+ transduction.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Cytokines; Dacarbazine; Drug Resistance, Multiple; Genetic Vectors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Mesoderm; Monocytes; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Retroviridae; Signal Transduction; Stem Cells; Stromal Cells; Temozolomide | 1999 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quality of Life; Skin Neoplasms; Survival Analysis; Temozolomide | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Cisplatin; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Gene Expression; Humans; Jurkat Cells; Kinetics; O(6)-Methylguanine-DNA Methyltransferase; RNA, Messenger; Temozolomide | 2000 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Pyrrolo[2,1-d][1,2,3,5]tetrazinones deaza analogues of temozolomide with potent antitumor activity.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Heterocyclic Compounds, 2-Ring; Temozolomide | 2000 |
Temozolomide for refractory anaplastic astrocytoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Replication; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Humans; Multicenter Studies as Topic; Temozolomide | 1999 |
Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; CHO Cells; Cricetinae; Cyclophosphamide; Dacarbazine; Drug Interactions; Enzyme Inhibitors; Guanine; Mutagenicity Tests; Mutagens; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indwelling; Dacarbazine; Drug Delivery Systems; Glioma; Humans; Male; Neoplasm Transplantation; Rats; Rats, Nude; Temozolomide; Time Factors; Tumor Cells, Cultured | 2000 |
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nervous System Neoplasms; Temozolomide; Time Factors; Tumor Cells, Cultured | 2000 |
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.
Topics: Antineoplastic Agents, Alkylating; Cell Extracts; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Guanine; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Structure-Activity Relationship; Temozolomide; Tumor Cells, Cultured | 2000 |
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents; Benzimidazoles; Crystallography, X-Ray; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Humans; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Temozolomide; Topotecan; Tumor Cells, Cultured | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Glioma; Humans; Quality of Life; Temozolomide | 2000 |
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Base Pair Mismatch; Carboplatin; Carrier Proteins; Cisplatin; Colonic Neoplasms; Dacarbazine; Decitabine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Blotting, Western; Carrier Proteins; Dacarbazine; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Software; Temozolomide; Tumor Cells, Cultured | 2000 |
Population pharmacokinetics of temozolomide in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Body Fluid Compartments; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Temozolomide; Thrombocytopenia | 2000 |
Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; B-Lymphocytes; Blood Platelets; Blotting, Southern; Cell Culture Techniques; Dacarbazine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythrocytes; Female; Flow Cytometry; Genetic Vectors; Granulocytes; Green Fluorescent Proteins; Guanine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobins; Luminescent Proteins; Mice; Mice, Inbred C57BL; Models, Genetic; Neutrophils; Plasmids; Retroviridae; T-Lymphocytes; Temozolomide; Time Factors | 2001 |
Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
Topics: Antineoplastic Agents; Cell Division; Dacarbazine; DNA; DNA Damage; ErbB Receptors; Humans; Protein-Tyrosine Kinases; Quinazolines; Temozolomide; Tumor Cells, Cultured | 2001 |
High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Humans; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temozolomide | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carmustine; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Guanine; Humans; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain; Dacarbazine; Deoxyguanosine; DNA Adducts; DNA Methylation; Immunoassay; Liver; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Wistar; Sensitivity and Specificity; Temozolomide; Thymus Gland | 2001 |
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; G2 Phase; Glioblastoma; Humans; Mitosis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms; Temozolomide | 2000 |
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
Topics: Antineoplastic Agents, Alkylating; Blotting, Northern; Cell Division; Cell Survival; Chromosome Aberrations; Dacarbazine; DNA; DNA Repair; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; Humans; Jurkat Cells; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbon-Sulfur Lyases; Carmustine; Choline; Dacarbazine; Diet; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Methionine; Mice; Mice, Inbred BALB C; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Temozolomide; Xenograft Model Antitumor Assays | 2001 |
Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line; Cell Survival; Colorectal Neoplasms, Hereditary Nonpolyposis; Dacarbazine; DNA Repair; DNA-Binding Proteins; Heterozygote; Humans; Lymphocytes; Mutation; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Temozolomide; Tumor Cells, Cultured | 2001 |
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Western; Bromodeoxyuridine; Cell Division; Dacarbazine; DNA Repair; DNA Replication; Enzyme Inhibitors; Fluorouracil; Gene Deletion; Genetic Vectors; Humans; Jurkat Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Transport; Quinazolines; Temozolomide; Thiophenes; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Gene Transfer Techniques; Glioma; Humans; Inhibitory Concentration 50; Sensitivity and Specificity; Temozolomide; Transcription Factors; Tumor Cells, Cultured | 2001 |
Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cyclohexanes; Dacarbazine; Dialysis Solutions; Drug Interactions; Humans; Male; Microdialysis; Neoplasms, Experimental; O-(Chloroacetylcarbamoyl)fumagillol; Rats; Rats, Nude; Sesquiterpenes; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Temozolomide chemotherapy in recurrent oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide; Time Factors | 2001 |
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Topics: Alkaloids; Antineoplastic Agents, Alkylating; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; Drug Synergism; Enzyme Inhibitors; G2 Phase; Glioblastoma; Humans; Mitosis; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2001 |
Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
Topics: Alkylating Agents; Alkylation; Animals; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Dacarbazine; DNA Damage; DNA, Complementary; Drug Resistance; Genetic Vectors; Hematopoietic Stem Cells; Humans; Lomustine; Mice; Moloney murine leukemia virus; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Fusion Proteins; Retroviridae; Sarcoma Viruses, Murine; Spleen Focus-Forming Viruses; Temozolomide; Terminal Repeat Sequences; Transfection | 2001 |
Late recurrence of a primitive neuro-ectodermal tumor.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cerebellar Neoplasms; Cervical Vertebrae; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dacarbazine; Dura Mater; Female; Humans; Isoenzymes; Lumbosacral Region; Meningeal Neoplasms; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Phosphopyruvate Hydratase; Pinealoma; Radiosurgery; Remission Induction; Sciatica; Spinal Neoplasms; Synaptophysin; Temozolomide; Time Factors; Vincristine | 2001 |
Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells.
Topics: Apoptosis; Blotting, Western; Colonic Neoplasms; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Humans; Hydroxylamines; In Situ Nick-End Labeling; Temozolomide; Tumor Cells, Cultured | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Interactions; Drug Synergism; Ganciclovir; Genetic Therapy; Glioma; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Simplexvirus; Temozolomide; Thymidine Kinase; Tumor Cells, Cultured | 2001 |
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Neuroepithelial; Temozolomide; Treatment Outcome | 2001 |
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
Topics: Antineoplastic Agents; Biotransformation; Carmustine; Cytochrome P-450 Enzyme System; Cytosol; Dacarbazine; DNA Repair; Guanine; Humans; Isoenzymes; Kinetics; Liver; Microsomes, Liver; Temozolomide | 2001 |
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Carboplatin; Carotid Arteries; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dacarbazine; Etoposide; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Physical Examination; Rupture, Spontaneous; Temozolomide; Temporal Lobe; Vertebral Artery | 2001 |
NICE verdict on Temozolomide: where next?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Approval; Evidence-Based Medicine; Glioblastoma; Humans; Survival Rate; Temozolomide; Treatment Outcome | 2002 |
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Survival Analysis; Survival Rate; Temozolomide | 2002 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Frontal Lobe; Humans; Melanoma; Remission Induction; Temozolomide; Thalidomide | 2001 |
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Caspase 3; Caspases; Combined Modality Therapy; Dacarbazine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases, Membrane-Associated; Metalloendopeptidases; Mice; Neoplasm Invasiveness; Protein-Tyrosine Kinases; Rats; Receptors, Vitronectin; Temozolomide; Tumor Cells, Cultured; Up-Regulation | 2002 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carrier Proteins; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA Repair Enzymes; DNA-Binding Proteins; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Glioma; Guanine; Humans; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Phenotype; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Synthesis and antibacterial activity of dual-action agents of a beta-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; beta-Lactams; Dacarbazine; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Nitrogen Mustard Compounds; Structure-Activity Relationship; Temozolomide | 2002 |
First-line therapy with temozolomide induces regression of primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Lymphoma; Male; Middle Aged; Temozolomide | 2002 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Temozolomide | 2002 |
Treatment of newly diagnosed glioblastoma multiforme.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Meta-Analysis as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Tenascin; Treatment Outcome | 2002 |
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2002 |
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Humans; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Time Factors | 2002 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Nucleus; Cytosol; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Glioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Temozolomide; Thioguanine; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosomes, Human, Pair 1; Combined Modality Therapy; Dacarbazine; DNA Fingerprinting; DNA, Neoplasm; Glioma; Glutathione Transferase; Humans; Immunohistochemistry; Intermediate Filament Proteins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Nerve Tissue Proteins; Nestin; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vimentin; Xenograft Model Antitumor Assays | 2002 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunophenotyping; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Melanoma; Microscopy, Electron; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Temozolomide; Time Factors; Tumor Cells, Cultured; Vindesine | 2002 |
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Camptothecin; Dacarbazine; Humans; Irinotecan; Longitudinal Studies; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide; Xenograft Model Antitumor Assays | 2002 |
Base excision repair as a therapeutic target in colon cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Bone Marrow Diseases; Chromosome Aberrations; Colonic Neoplasms; Dacarbazine; Deoxyguanosine; DNA Adducts; DNA Repair; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Humans; Hydroxylamines; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Sister Chromatid Exchange; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; Dacarbazine; DNA Adducts; DNA Damage; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Induction; Glioblastoma; Humans; Hypochlorous Acid; Methyl Methanesulfonate; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Dacarbazine; DNA Repair; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; G2 Phase; Glioblastoma; Glioma; Humans; Mitosis; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Proteins; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2002 |
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Radiography; Temozolomide | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors | 2002 |
Treatment of leptomeningeal relapse of medulloblastoma with temozolomide.
Topics: Brain; Child; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Recurrence; Temozolomide | 2002 |
Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cystitis; Dacarbazine; Female; Hemorrhage; Humans; Middle Aged; Temozolomide | 2002 |
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Dacarbazine; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Humans; Indoles; Isoquinolines; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Structure-Activity Relationship; Temozolomide; Topotecan; Tumor Cells, Cultured | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Brain Stem Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; Data Interpretation, Statistical; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Time Factors | 2002 |
Antitumor imidazotetrazines. 40. Radiosyntheses of [4-11C-carbonyl]- and [3-N-11C-methyl]-8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) for positron emission tomography (PET) studies.
Topics: Antineoplastic Agents; Brain Diseases; Carbon Radioisotopes; Cyclization; Dacarbazine; Gas Chromatography-Mass Spectrometry; Humans; Isotope Labeling; Magnetic Resonance Spectroscopy; Parietal Lobe; Prodrugs; Structure-Activity Relationship; Temozolomide; Tomography, Emission-Computed | 2002 |
Antitumor imidazotetrazines. 41. Conjugation of the antitumor agents mitozolomide and temozolomide to peptides and lexitropsins bearing DNA major and minor groove-binding structural motifs.
Topics: Amino Acids; Animals; Antineoplastic Agents; Cell Line; Dacarbazine; DNA; Drug Screening Assays, Antitumor; Humans; Hydrolysis; Mice; Models, Molecular; Netropsin; Nitrogen Mustard Compounds; Peptides; Temozolomide; Tumor Cells, Cultured | 2002 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Temozolomide; Temporal Lobe | 2002 |
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Clinical Trials, Phase I as Topic; Cytosine; Dacarbazine; Dioxolanes; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Paclitaxel; Retrospective Studies; Temozolomide; Uracil | 2002 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sulfones; Telomerase; Temozolomide; Transfection; Tumor Cells, Cultured | 2003 |
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Topics: Antineoplastic Agents; Benzimidazoles; Binding Sites; Cell Line; Crystallography, X-Ray; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Heterocyclic Compounds, 3-Ring; Humans; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Stereoisomerism; Structure-Activity Relationship; Temozolomide; Topotecan | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DNA Ligases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Melanoma; Temozolomide; Tumor Cells, Cultured | 2003 |
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Movement; Cellular Senescence; Dacarbazine; DNA Fragmentation; Drug Resistance, Neoplasm; Glioma; Humans; In Situ Nick-End Labeling; Neoplasm Invasiveness; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured | 2003 |
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Dacarbazine; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Temozolomide; Treatment Outcome | 2003 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Eye Neoplasms; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lymphocyte Activation; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; T-Lymphocyte Subsets; Temozolomide; Treatment Outcome | 2003 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; Drug Interactions; Glioma; Indoles; Neoplasm Transplantation; Neoplasms, Experimental; Pyrroles; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Tumor Cells, Cultured | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Dacarbazine; Ependymoma; Female; Glioblastoma; Glioma; Humans; Image Enhancement; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Oligodendroglioma; Paclitaxel; Procarbazine; Sensitivity and Specificity; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony-Forming Units Assay; Dacarbazine; G2 Phase; Glioma; Guanine; Humans; Mitosis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Tumor Cells, Cultured | 2003 |
Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
Topics: Animals; beta-Thalassemia; Crosses, Genetic; Dacarbazine; Drug Resistance; Female; Genetic Vectors; Globins; Guanine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Lentivirus; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Fusion Proteins; Selection, Genetic; Temozolomide; Transplantation Chimera; Transplantation Conditioning | 2003 |
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Leukocytes, Mononuclear; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2003 |
Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Blood-Brain Barrier; Dacarbazine; Half-Life; Infusions, Intravenous; Macaca mulatta; Male; Temozolomide | 2003 |
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; Data Interpretation, Statistical; Female; Humans; Loss of Heterozygosity; Male; Middle Aged; Oligodendroglioma; Retrospective Studies; Temozolomide; Treatment Outcome | 2003 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; CpG Islands; Dacarbazine; Disease Progression; DNA; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Hydroxamic Acids; Ribonucleotide Reductases; Temozolomide; Tumor Cells, Cultured | 2003 |
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Line; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Kinetics; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Time Factors | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Glioma; Humans; Male; Retrospective Studies; Survival Rate; Temozolomide | 2003 |
Repopulating defect of mismatch repair-deficient hematopoietic stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Cell Division; Cell Survival; Dacarbazine; DNA Repair; DNA-Binding Proteins; Graft Survival; Hematopoiesis; Hematopoietic Stem Cells; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Microsatellite Repeats; MutS Homolog 2 Protein; Proto-Oncogene Proteins; Telomere; Temozolomide | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; Carbon Radioisotopes; Dacarbazine; Glioma; Humans; Male; Middle Aged; Temozolomide; Tomography, Emission-Computed | 2003 |
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Infant; Male; Retrospective Studies; Temozolomide | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Leukemia, Erythroblastic, Acute; Leukocytes, Mononuclear; Lymphocytes; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2003 |
Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease Models, Animal; DNA Adducts; DNA Mutational Analysis; Dose-Response Relationship, Drug; Gene Expression Regulation; Gene Frequency; O(6)-Methylguanine-DNA Methyltransferase; Point Mutation; Rats; Severity of Illness Index; Statistics as Topic; Temozolomide; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Synergism; Irinotecan; Mice; Models, Biological; Models, Statistical; Neoplasms, Experimental; Research Design; Sample Size; Statistics, Nonparametric; Temozolomide | 2003 |
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Division; Cell Line, Tumor; Dacarbazine; DNA Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indoles; Kinetics; Models, Chemical; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Temperature; Time Factors; Tissue Distribution; Topotecan | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression; Glioma; Guanine; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Temozolomide; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2003 |
Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Animals; Apoptosis; Base Pair Mismatch; Bromodeoxyuridine; Carrier Proteins; Dacarbazine; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Intestine, Small; Male; Methylnitrosourea; Mice; Mice, Mutant Strains; Mismatch Repair Endonuclease PMS2; Mitotic Index; Mutation; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Proto-Oncogene Proteins; Temozolomide; Time Factors | 2003 |
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; Deoxyguanosine; DNA Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; O(6)-Methylguanine-DNA Methyltransferase; Pancreatic Neoplasms; Temozolomide; Time Factors | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as Topic; Cognition Disorders; Dacarbazine; Disease Progression; Glioma; Humans; Radiation Injuries; Reproducibility of Results; Temozolomide | 2003 |
A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Glioma; Hematopoiesis; Humans; Models, Biological; Neutrophils; Temozolomide | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carboplatin; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Ependymoma; Gadolinium; Headache; Humans; Isotretinoin; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cisplatin; Dacarbazine; DNA Damage; DNA Repair; Endodeoxyribonucleases; Fluorouracil; Intestinal Mucosa; Intestine, Small; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Temozolomide | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Survival Rate; Temozolomide | 2003 |
The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Base Sequence; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; G2 Phase; Humans; Imidazoles; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pyridines; Temozolomide | 2003 |
Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Leukemia, B-Cell; Magnetic Resonance Imaging; Neoplasms, Neuroepithelial; Neoplasms, Radiation-Induced; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide; Treatment Outcome | 2003 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Glioblastoma; Humans; Lymphoma; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Rate; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Neoplasm Staging; Prognosis; Temozolomide | 2003 |
Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neutrophils; Phagocytosis; Superoxides; Temozolomide | 2004 |
Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasms, Neuroepithelial; Temozolomide; Treatment Outcome | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Guanine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2003 |
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gamma Rays; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation-Sensitizing Agents; Temozolomide; Transplantation, Heterologous | 2004 |
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Topics: Adenine; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Macrolides; Microtubule-Associated Proteins; Organelles; Temozolomide | 2004 |
Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Division; Dacarbazine; DNA Damage; DNA Replication; fas Receptor; Gamma Rays; Gene Expression Regulation; Guanine; Humans; Lymphocytes; Methylnitronitrosoguanidine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Tumor Suppressor Protein p53 | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphopenia; Male; Melanoma; Middle Aged; Multivariate Analysis; Opportunistic Infections; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2004 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; Melanoma; Opportunistic Infections; Temozolomide | 2004 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; Quality of Life; Skin Neoplasms; Temozolomide | 2003 |
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Azulenes; Base Pair Mismatch; Benzodiazepines; Cell Division; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Genotype; Guanine; Humans; Models, Chemical; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2004 |
Dual repair modulation reverses Temozolomide resistance in vitro.
Topics: Adaptor Proteins, Signal Transducing; Base Pair Mismatch; Carrier Proteins; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance; Guanine; Humans; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2004 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial Nerves; Dacarbazine; Fatal Outcome; Headache; Humans; Lymph Nodes; Magnetic Resonance Imaging; Male; Melanoma; Neoplasm Metastasis; Ophthalmoplegia; Orbital Neoplasms; Risk Factors; Skin Neoplasms; Survival Rate; Temozolomide | 2004 |
Primary cultures of microglial cells for testing toxicity of anticancer drugs.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Culture Techniques; Cell Survival; Dacarbazine; Drug Screening Assays, Antitumor; Humans; Lipopolysaccharides; Methotrexate; Microglia; Nervous System Diseases; Rats; Rats, Wistar; Temozolomide; Toxicity Tests | 2004 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide | 2004 |
Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.
Topics: Amides; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dacarbazine; Drug Synergism; Humans; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Temozolomide | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Diagnosis, Differential; Frontal Lobe; Glioblastoma; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Radiography; Temozolomide | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome | 2004 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Epilepsies, Partial; Etoposide; Female; Follow-Up Studies; Humans; Life Tables; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Oligodendroglioma; Organophosphorus Compounds; Procarbazine; Prognosis; Proportional Hazards Models; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis; Technetium Tc 99m Sestamibi; Temozolomide; Treatment Outcome; Vincristine | 2004 |
[Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme].
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Temozolomide; Time Factors | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kinetics; Male; Middle Aged; Temozolomide; Treatment Outcome | 2004 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Keratinocytes; Melanoma; Necrosis; Poly(ADP-ribose) Polymerases; Resveratrol; S Phase; Stilbenes; Temozolomide; Time Factors | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistance, Neoplasm; G2 Phase; Glioma; Humans; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinases; Temozolomide; Tumor Cells, Cultured | 2004 |
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Synergism; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Temozolomide; Treatment Outcome | 2004 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarbazine; Glioblastoma; Humans; Ifosfamide; Loss of Heterozygosity; Mice; Mice, Nude; Mutation; Oligodendroglioma; Temozolomide; Xenograft Model Antitumor Assays | 2004 |
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Guideline Adherence; Humans; Multicenter Studies as Topic; Practice Guidelines as Topic; Quality Assurance, Health Care; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Temozolomide | 2004 |
Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death.
Topics: Antineoplastic Agents; Cell Death; Dacarbazine; Enzyme Inhibitors; Glucose; HeLa Cells; Humans; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide | 2004 |
Bibliography. Current world literature. Therapeutic modalities.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dacarbazine; Genetic Therapy; Heat-Shock Proteins; Humans; Immunotherapy; Interferons; Oxides; Radiotherapy; Sirolimus; Temozolomide; Vitamin D | 2003 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Astrocytoma; Brain; Brain Neoplasms; Cell Cycle Proteins; Dacarbazine; Disease Progression; Female; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Neuroepithelial; Nerve Tissue Proteins; Procarbazine; Temozolomide; Vincristine | 2004 |
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Loss of Heterozygosity; Magnetic Resonance Imaging; Male; Middle Aged; Oligodendroglioma; Temozolomide | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Methylation; DNA Repair; Female; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2004 |
Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells.
Topics: Adenoviridae; Alkylating Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Dacarbazine; DNA Glycosylases; DNA Repair; Dose-Response Relationship, Drug; Genetic Therapy; Genetic Vectors; Humans; Hydroxylamines; Immunohistochemistry; Methyl Methanesulfonate; Methylnitronitrosoguanidine; Methylnitrosourea; Oligonucleotides; Sensitivity and Specificity; Sulfuric Acid Esters; Temozolomide; Time Factors | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cisplatin; Dacarbazine; Doxorubicin; Drug Interactions; Glioma; Humans; Temozolomide; Topotecan; Tumor Cells, Cultured | 2004 |
Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide.
Topics: Antigens, CD34; Blotting, Western; Carmustine; Cell Line; Colony-Forming Units Assay; Dacarbazine; DNA Primers; Flow Cytometry; Gene Expression Regulation, Enzymologic; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lentivirus; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Temozolomide; Transduction, Genetic; Transgenes; Tumor Cells, Cultured | 2004 |
DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Base Pair Mismatch; Cell Cycle; Cell Cycle Proteins; Cell Division; Checkpoint Kinase 1; Checkpoint Kinase 2; Dacarbazine; DNA Damage; DNA Repair; DNA-Binding Proteins; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Serine; Temozolomide; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2004 |
Disposition and pharmacokinetics of temozolomide in rat.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Autoradiography; Brain; Carbon Radioisotopes; Dacarbazine; Female; Injections, Intravenous; Male; Radiopharmaceuticals; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Temozolomide; Tissue Distribution | 2004 |
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Mice; Mice, Nude; Temozolomide; Transcription, Genetic; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Europe; Female; Glioblastoma; Health Care Costs; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2004 |
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Male; Membrane Glycoproteins; Rats; Rats, Nude; Recombinant Proteins; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2004 |
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Repair; Dose-Response Relationship, Drug; Female; Humans; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotides; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Tetrazolium Salts; Thiazoles; Thionucleotides; Time Factors; Up-Regulation | 2004 |
Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; CD4 Antigens; Cloning, Molecular; Dacarbazine; DNA Primers; Dogs; Drug Resistance; Genetic Therapy; Leukocytes; Models, Animal; Platelet Count; Stem Cell Transplantation; Temozolomide | 2005 |
Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4.
Topics: Animals; Bone Marrow Cells; Cell Line; Colony-Forming Units Assay; Dacarbazine; Deoxyguanosine; Genetic Vectors; Green Fluorescent Proteins; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Mice; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Retroviridae; Temozolomide; Transcription Factors | 2004 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Likelihood Functions; Longitudinal Studies; Mice; Mice, SCID; Models, Biological; Models, Statistical; Neoplasms, Experimental; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2005 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Patient Selection; Selection Bias; Temozolomide; Treatment Outcome | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Esthesioneuroblastoma, Olfactory; Female; Humans; Middle Aged; Nasal Cavity; Nose Neoplasms; Quality of Life; Temozolomide | 2004 |
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Central Nervous System Neoplasms; Dacarbazine; Humans; Lymphoma; Rituximab; Temozolomide | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Extremities; Female; Infusions, Parenteral; Melanoma; Melphalan; Probability; Random Allocation; Rats; Rats, Nude; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Skin Neoplasms; Survival Rate; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2004 |
The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Cell Cycle; Cyclic N-Oxides; Dacarbazine; Drug Interactions; Glioblastoma; Humans; Spin Labels; Temozolomide; Tumor Cells, Cultured | 2004 |
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Immunohistochemistry; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Temozolomide | 2005 |
New (1-deaza)purine derivatives via efficient C-2 nitration of the (1-deaza)purine ring.
Topics: Acetic Anhydrides; Antiprotozoal Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Electrons; Fluoroacetates; Humans; Kinetics; Magnetic Resonance Spectroscopy; Models, Chemical; Nitrogen; Purines; Receptors, Purinergic P1; Temozolomide; Temperature; Trifluoroacetic Acid | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Retrospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vinblastine; Vulvar Neoplasms | 2004 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simulation; Cyclohexanes; Dacarbazine; Female; Humans; Male; Models, Biological; O-(Chloroacetylcarbamoyl)fumagillol; Ovarian Neoplasms; Predictive Value of Tests; Rats; Rats, Inbred F344; Rats, Nude; Sesquiterpenes; Temozolomide; Topotecan; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2004 |
Hierarchical models for tumor xenograft experiments in drug development.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Camptothecin; Dacarbazine; Humans; Likelihood Functions; Longitudinal Studies; Markov Chains; Mice; Models, Statistical; Monte Carlo Method; Neoplasm Transplantation; Neuroblastoma; Predictive Value of Tests; Temozolomide; Transplantation, Heterologous | 2004 |
Making inferences about projected completors in longitudinal studies.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Camptothecin; Dacarbazine; Humans; Likelihood Functions; Longitudinal Studies; Markov Chains; Mice; Models, Statistical; Monte Carlo Method; Neoplasm Transplantation; Neuroblastoma; Predictive Value of Tests; Temozolomide; Transplantation, Heterologous | 2004 |
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Calcium; Calpain; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; Dexamethasone; Glioblastoma; Humans; Proto-Oncogene Proteins c-bcl-2; Spectrin; Temozolomide | 2004 |
The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors.
Topics: Cell Line, Tumor; Dacarbazine; DNA Damage; Enzyme Inhibitors; Flap Endonucleases; Humans; Methyl Methanesulfonate; Structure-Activity Relationship; Temozolomide; Urea; Urinary Bladder Neoplasms; Xeroderma Pigmentosum | 2005 |
Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O(6)-benzylguanine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Diazomethane; DNA Methylation; Drug Resistance, Neoplasm; Guanine; Humans; Hydrolysis; Prodrugs; Temozolomide; Triazenes | 2004 |
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatography, Liquid; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Organic Chemicals; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Temozolomide; Time Factors | 2005 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hemangioma; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Radiation-Induced; Paresis; Seizures; Temozolomide; Tinea Capitis | 2005 |
Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Blotting, Western; Calpain; Cell Line, Tumor; Cell Survival; Dacarbazine; Dexamethasone; DNA Fragmentation; Enzyme Activation; Glioblastoma; Humans; In Situ Nick-End Labeling; Temozolomide; Trypan Blue | 2005 |
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; Female; Humans; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Neoadjuvant Therapy; Temozolomide | 2005 |
Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioma; Humans; Temozolomide; Up-Regulation | 2005 |
Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Chondrosarcoma, Mesenchymal; Dacarbazine; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2005 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Clinical Trials, Phase I as Topic; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Hematologic Diseases; Humans; Kidney; Lymphoma; Maximum Tolerated Dose; Meningeal Neoplasms; Neoplasm Recurrence, Local; Rituximab; Temozolomide; Treatment Outcome | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Temozolomide | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; Gene Silencing; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide | 2005 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child, Preschool; Dacarbazine; Gene Silencing; Glioblastoma; Humans; Medulloblastoma; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Drug Interactions; Glioma; Humans; Temozolomide; Thiazoles; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2005 |
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain; Carmustine; Cell Survival; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Guanine; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Tumor Cells, Cultured | 2005 |
Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Nucleus; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Guanine; Hematopoietic Stem Cells; Humans; K562 Cells; Methyl Methanesulfonate; Mitochondria; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2005 |
Treatment of brain metastases from melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Endpoint Determination; Humans; Reproducibility of Results; Temozolomide; Treatment Outcome | 2005 |
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Culture Media; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Hydrolysis; K562 Cells; Leukemia; Protein-Tyrosine Kinases; Temozolomide; Time Factors; Triazenes; U937 Cells | 2005 |
Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cimetidine; Dacarbazine; Female; Glioblastoma; Mice; Mice, Nude; Temozolomide; Transplantation, Heterologous | 2005 |
Temozolomide and radiation for aggressive pediatric central nervous system malignancies.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Temozolomide | 2005 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasm Recurrence, Local; Procarbazine; Temozolomide; Vincristine | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Dacarbazine; DNA Damage; Drug Interactions; Drug Resistance, Neoplasm; Glioma; Humans; Immunotherapy, Active; Intramolecular Oxidoreductases; T-Lymphocytes, Cytotoxic; Temozolomide; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 2; Dacarbazine; Enzyme Activation; G2 Phase; Glioblastoma; Humans; Methylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Temozolomide | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Gene Silencing; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Salvage Therapy; Survival Analysis; Temozolomide | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide | 2005 |
Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma.
Topics: Dacarbazine; DNA Repair; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase; Phenytoin; Temozolomide | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylcellulose Sodium; Combined Modality Therapy; Contrast Media; Dacarbazine; Dose Fractionation, Radiation; Female; Gadolinium DTPA; Glioma; Humans; Interferon Inducers; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Poly I-C; Polylysine; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Humans; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Phosphorus Isotopes; Temozolomide | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Temozolomide | 2005 |
Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Fertility; Humans; Infertility, Male; Male; Temozolomide; Treatment Outcome | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2005 |
Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Polyomavirus Transforming; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line; Cell Line, Transformed; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; DNA-Binding Proteins; Endothelial Cells; Flow Cytometry; Gene Expression; HT29 Cells; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms, Experimental; Plasmids; Platelet Endothelial Cell Adhesion Molecule-1; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Telomere; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor | 2005 |
The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Transformed; Dacarbazine; DNA Glycosylases; DNA Polymerase beta; DNA Repair; Drug Resistance, Neoplasm; Histones; Mice; Phosphorylation; RNA, Small Interfering; Temozolomide; Transfection | 2005 |
Cardiac metastasis of melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Heart Neoplasms; Heart Ventricles; Humans; Magnetic Resonance Imaging; Melanoma; Temozolomide | 2005 |
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Inhibitory Concentration 50; Melanoma; Mitomycin; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Transfection | 2006 |
Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Temozolomide | 2005 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Etoposide; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Modeling antitumor activity in xenograft tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Computer-Assisted; Irinotecan; Mice; Models, Biological; Models, Statistical; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Genetic Therapy; Guanine; Humans; Male; Mice; Mice, Inbred C57BL; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic; Xenograft Model Antitumor Assays | 2006 |
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Finland; Glioblastoma; Humans; Recurrence; Temozolomide | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase; G2 Phase; Glioma; Humans; Mice; Mice, Transgenic; Phosphorylcholine; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2005 |
Author comments on drug-dispensing change.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neoplasms; Patient Education as Topic; Temozolomide | 2005 |
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon-beta; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Protein p53 | 2005 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cerebellar Neoplasms; Cerebellopontine Angle; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Disease Progression; Humans; Magnetic Resonance Imaging; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Meninges; Neoplasm Recurrence, Local; Neoplasm Seeding; Pia Mater; Radiotherapy Dosage; Temozolomide; Time Factors | 2005 |
Current therapies for glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cranial Irradiation; Craniotomy; Dacarbazine; Drug Delivery Systems; Drug Design; Genetic Therapy; Glioblastoma; Humans; Neoplasm Proteins; Patient Acceptance of Health Care; Quality of Life; Research Design; RNA, Antisense; Survival Rate; Temozolomide; Vascular Endothelial Growth Factor A | 2004 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Glioma; Gliosarcoma; Humans; Male; Methionine; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Positron-Emission Tomography; Prospective Studies; Statistics, Nonparametric; Stereotaxic Techniques; Temozolomide; Tomography, Emission-Computed, Single-Photon | 2005 |
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Methionine; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Retinoblastoma Protein; Signal Transduction; Temozolomide; Transforming Growth Factor beta | 2005 |
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Indoles; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.
Topics: Antineoplastic Agents; Astrocytoma; Blotting, Western; Carmustine; Cell Cycle; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Gene Silencing; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2005 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer Graphics; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Necrosis; Oligonucleotide Array Sequence Analysis; Software; Temozolomide | 2006 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 9; Cytogenetics; Dacarbazine; Female; Gene Deletion; Genetic Markers; Glioblastoma; Glioma; Humans; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Models, Genetic; Multivariate Analysis; Nucleic Acid Hybridization; Paraffin; Prognosis; Proportional Hazards Models; Sex Factors; Temozolomide; Time Factors; Treatment Outcome | 2005 |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retrospective Studies; Temozolomide; Treatment Outcome; Vinblastine | 2005 |
Avoiding glucocorticoid administration in a neurooncological case.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Celecoxib; Cerebellum; Cyclooxygenase Inhibitors; Dacarbazine; Follow-Up Studies; Glioblastoma; Glucocorticoids; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pyrazoles; Sulfonamides; Temozolomide; Time Factors; Treatment Outcome | 2005 |
Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Humans; Temozolomide | 2005 |
Salvage temozolomide for prior temozolomide responders.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Oligodendroglioma; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Temozolomide | 2005 |
Efficiency, quality and bureaucracy: not always in the same bag!!
Topics: Antineoplastic Agents, Alkylating; Biomedical Research; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Temozolomide; Treatment Outcome | 2005 |
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Topics: Animals; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Guanine; Humans; Male; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Xenograft Model Antitumor Assays | 2005 |
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Time Factors; Tumor Burden | 2005 |
10 questions about temozolomide and the treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Temozolomide | 2005 |
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Genetic Vectors; HeLa Cells; Humans; Methyl Methanesulfonate; Ovarian Neoplasms; RNA Interference; RNA, Small Interfering; Temozolomide; Ultraviolet Rays; Uterine Cervical Neoplasms | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Interactions; Fluorenes; Glycoside Hydrolases; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Skin Neoplasms; Temozolomide | 2005 |
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Dacarbazine; Drug Overdose; Humans; Leukopenia; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Thrombocytopenia | 2006 |
Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cisplatin; Cyclophosphamide; Dacarbazine; DNA-Binding Proteins; Humans; Methylnitronitrosoguanidine; Mitomycin; Mutagens; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2006 |
A congenital brain tumor associated with assisted in vitro fertilization. Case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Fertilization in Vitro; Humans; Infant, Newborn; Magnetic Resonance Imaging; Male; Pregnancy; Temozolomide; Vincristine | 2005 |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Child; Dacarbazine; Female; Humans; Injections, Intravenous; Irinotecan; Male; Neoplasm Metastasis; Sarcoma, Ewing; Temozolomide | 2007 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Glioma; Humans; In Situ Nick-End Labeling; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Temozolomide; Thalidomide; Transplantation, Heterologous | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Dacarbazine; Glioma; Immunohistochemistry; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Temozolomide | 2006 |
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Profiling; Glioblastoma; Humans; Hyaluronan Receptors; Intracellular Signaling Peptides and Proteins; NF-kappa B; Nuclear Proteins; Proteins; Temozolomide; Tumor Necrosis Factor alpha-Induced Protein 3 | 2006 |
Evidence, economics, and emotions: the case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Female; Glioblastoma; Humans; Male; National Health Programs; New Zealand; Temozolomide | 2005 |
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Glioblastoma; Humans; National Health Programs; New Zealand; Social Values; Temozolomide; Terminal Care | 2005 |
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Guanine; Humans; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Oncolytic Viruses; Plasmids; Protein Phosphatase 1; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Small Interfering; Simplexvirus; Temozolomide; Transcription, Genetic; Transfection; Transplantation, Heterologous | 2006 |
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytotoxicity, Immunologic; Dacarbazine; Humans; Hyperthermia, Induced; Immunohistochemistry; Ki-67 Antigen; Melanoma, Experimental; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Models, Biological; Monte Carlo Method; Neural Networks, Computer; Pharmacokinetics; Pharmacology; Regression Analysis; Temozolomide | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2006 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; Cell Proliferation; Dacarbazine; Drug Delivery Systems; Esterases; Esters; Humans; Liver; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Rats; Skin; Skin Neoplasms; Swine; Temozolomide; Tumor Cells, Cultured | 2006 |
O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Synergism; Guanine; HL-60 Cells; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 2006 |
Chemotherapy for glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2006 |
Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
Topics: Alkylating Agents; Carmustine; Dacarbazine; Drug Resistance; Genetic Engineering; Guanine; Hematopoietic Stem Cells; Humans; K562 Cells; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Humans; Neoplasm Recurrence, Local; Temozolomide; Time Factors | 2006 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Signal Transduction; Temozolomide | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Infections; Lymphopenia; Male; Middle Aged; Temozolomide | 2006 |
Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carbon Isotopes; Contrast Media; Dacarbazine; Feasibility Studies; Female; Gadolinium DTPA; Imaging, Three-Dimensional; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Phantoms, Imaging; Temozolomide | 2006 |
Primary malignant melanoma of the lung: a case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide; Tomography, X-Ray Computed | 2006 |
More from PHARMAC on temozolomide: feedback needed.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Glioblastoma; Humans; National Health Programs; New Zealand; Temozolomide | 2006 |
Oral regimen for metastatic neuroendocrine tumours.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide; Thalidomide; Treatment Outcome | 2006 |
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease Progression; DNA Repair; Female; Humans; Immunohistochemistry; Loss of Heterozygosity; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Oligodendroglioma; Temozolomide | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Humans; Injections, Intra-Arterial; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Rats; Rats, Inbred Strains; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Mutagenic potential of temozolomide in bone marrow cells in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutagens; Temozolomide | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamazepine; Carmustine; Case Management; Cesarean Section; Chemotherapy, Adjuvant; Cranial Irradiation; Craniotomy; Dacarbazine; Female; Frontal Lobe; Glioblastoma; Humans; Infant, Newborn; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Paresis; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Radiotherapy, Adjuvant; Remission Induction; Supratentorial Neoplasms; Temozolomide; Temporal Lobe | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Synergism; Drug Therapy, Combination; Glioma; Male; Microcirculation; Radiosurgery; Rats; Rats, Sprague-Dawley; Temozolomide; Thalidomide | 2006 |
Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Dacarbazine; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Perilipin-3; Pregnancy Proteins; Proteomics; rhoA GTP-Binding Protein; Temozolomide; Vesicular Transport Proteins | 2006 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Gene Silencing; Glioblastoma; Humans; Kaplan-Meier Estimate; Neoplasm Proteins; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2007 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Glioma; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinases; Temozolomide | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosum; Dacarbazine; Frontal Lobe; Glioma; Humans; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Postoperative Care; Temozolomide | 2006 |
Complications of a temozolomide overdose: a case report.
Topics: Antineoplastic Agents, Alkylating; Bacterial Infections; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Pancytopenia; Temozolomide | 2006 |
Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: a case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Cerebral Ventricle Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Temozolomide | 2006 |
Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Glioblastoma; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Risk Factors; Temozolomide | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Male; Melanoma; Middle Aged; Patient Selection; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Vinblastine | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Down-Regulation; Drug Synergism; Glioblastoma; Growth Inhibitors; Humans; Male; Mice; Mice, Nude; Perylene; Tamoxifen; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2006 |
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Dacarbazine; Female; Humans; Lomustine; Male; Middle Aged; Procarbazine; Retrospective Studies; Survival Rate; Temozolomide; Vincristine | 2006 |
Autophagy: is it cancer's friend or foe?
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Survival; Chloroquine; Dacarbazine; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mice; Neoplasms; Oncogenes; Proteins; Sirolimus; Temozolomide | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neuronal; Dacarbazine; Disease Models, Animal; Glioma; Hippocampus; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Pyridines; Rats; Rats, Inbred F344; Rats, Wistar; Temozolomide; Tumor Cells, Cultured | 2006 |
Temozolomide: a novel treatment for pituitary carcinoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma; Combined Modality Therapy; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Temozolomide; Treatment Outcome | 2006 |
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Listeriosis; Male; Middle Aged; Neoadjuvant Therapy; Pneumocystis carinii; Pneumonia, Pneumocystis; Sarcoma, Kaposi; Temozolomide | 2006 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Diagnostic Errors; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Ifosfamide; Kidney Neoplasms; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Taxoids; Temozolomide; Thoracic Surgery, Video-Assisted; Uterine Neoplasms | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Temozolomide | 2006 |
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioma; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Temozolomide; Tissue Inhibitor of Metalloproteinase-2; Up-Regulation | 2006 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden | 2006 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cycle; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; DNA Damage; Fas Ligand Protein; Fas-Associated Death Domain Protein; Flow Cytometry; Glioma; Guanine; Humans; Methylnitronitrosoguanidine; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2007 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Dacarbazine; Gamma Rays; Glioma; Hematopoietic Stem Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Signal Transduction; Temozolomide; Transcription, Genetic; Transforming Growth Factor beta | 2006 |
In vivo selection of transduced hematopoietic stem cells and little evidence of their conversion into hepatocytes in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Differentiation; Cell Line; Dacarbazine; Drug Resistance; Genetic Vectors; Guanine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hepatocytes; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic; Transplantation, Heterologous | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Glioma; Glucose; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Temozolomide; Treatment Outcome | 2006 |
Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comorbidity; Dacarbazine; Drug Resistance; Epilepsy; Humans; Magnetic Resonance Imaging; Male; Oligodendroglioma; Temozolomide; Treatment Outcome | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma; Colonic Neoplasms; Dacarbazine; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Glioma; Humans; Lymphopenia; Temozolomide | 2006 |
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Guanine; Humans; Methylation; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aryl Hydrocarbon Receptor Nuclear Translocator; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Humans; Hypoxia; Indazoles; Mice; Mice, SCID; Phenylurea Compounds; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Oligodendroglioma; Prospective Studies; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Computer Simulation; Dacarbazine; Drug Therapy; Drug Therapy, Computer-Assisted; Glioblastoma; Humans; Models, Biological; Temozolomide; Treatment Outcome | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Lomustine; Magnetic Resonance Imaging; Male; Neoplasms, Neuroepithelial; Procarbazine; Survival Rate; Temozolomide | 2006 |
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Damage; Etoposide; Glioma; Humans; Membrane Proteins; Oxidation-Reduction; Phosphorylation; Temozolomide | 2007 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Up-Regulation | 2006 |
Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Humans; Liver Neoplasms; Male; Methotrexate; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Prednisone; Remission Induction; Supratentorial Neoplasms; Temozolomide; Treatment Outcome; Vincristine | 2007 |
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Topics: Antineoplastic Agents; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Lomustine; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2006 |
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Glioma; Humans; In Situ Hybridization, Fluorescence; Karyotyping; O(6)-Methylguanine-DNA Methyltransferase; RNA, Messenger; Temozolomide | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rats; Temozolomide | 2007 |
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Division; Cell Line, Tumor; Contrast Media; Dacarbazine; Drug Screening Assays, Antitumor; Female; Gadolinium DTPA; Immunohistochemistry; Luciferases; Luminescence; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Temozolomide | 2006 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance; Enzyme Inhibitors; Glioblastoma; Guanine; Humans; Infusions, Intralesional; Male; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2007 |
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Microscopy, Electron; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Treatment Outcome | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Dose Fractionation, Radiation; Female; Ganglioglioma; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neuroglia; Neurologic Examination; Radiotherapy, Adjuvant; Reoperation; Temozolomide; Temporal Lobe | 2007 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Medical Oncology; Neurology; Societies, Medical; Spain; Temozolomide; Treatment Outcome | 2006 |
Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Comet Assay; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide; Tumor Suppressor Protein p53 | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2007 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Glioma; Humans; Interferon-beta; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide | 2006 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Temozolomide; Thrombocytopenia; Treatment Outcome | 2007 |
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Quality of Life; Temozolomide; Treatment Outcome | 2006 |
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Topics: Alkylating Agents; Animals; Carmustine; Cell Line, Tumor; Cyclophosphamide; Dacarbazine; Guanine; Male; Mice; Mice, Transgenic; Mutagenicity Tests; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection | 2007 |
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
Topics: Acid Anhydride Hydrolases; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatin; Dacarbazine; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Fluorescent Antibody Technique; G2 Phase; Glioblastoma; Humans; Models, Biological; MRE11 Homologue Protein; MutL Protein Homolog 1; Nuclear Proteins; Signal Transduction; Temozolomide | 2006 |
Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Drug Screening Assays, Antitumor; Female; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Temozolomide; Tumor Cells, Cultured | 2007 |
Malignant transformation of conus medullaris ganglioglioma: case report.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Ganglioglioma; Glioblastoma; Humans; Lumbosacral Region; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Paraplegia; Radiotherapy; Spinal Cord Neoplasms; Temozolomide | 2007 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Male; Middle Aged; Nausea; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Remission Induction; Temozolomide; Young Adult | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Male; Radiotherapy Dosage; Survival Rate; Temozolomide | 2006 |
Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Sequence; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Glycosylases; DNA Repair; Dose-Response Relationship, Drug; Female; Humans; Hydroxylamines; Molecular Sequence Data; Ovarian Neoplasms; Temozolomide | 2007 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Repair; Dose-Response Relationship, Drug; Fever; Humans; Inhibitory Concentration 50; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide | 2007 |
New [1,2,4]triazolo[4,3-c]quinazoline enhances cisplatin- and temozolomide-induced growth inhibition and apoptosis in HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Cisplatin; Dacarbazine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Molecular Structure; Quinazolines; Temozolomide; Triazoles | 2007 |
Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents.
Topics: Alkylating Agents; Cell Survival; Cells, Cultured; Dacarbazine; Dendritic Cells; DNA Methylation; DNA Repair; Drug Hypersensitivity; Humans; Methyl Methanesulfonate; Methylnitronitrosoguanidine; Monocytes; Mutagens; Temozolomide | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Group F Protein; Fanconi Anemia Complementation Group Proteins; Glioma; Guanine; Humans; Protein Processing, Post-Translational; RNA Interference; RNA, Small Interfering; Temozolomide; Time Factors; Transfection; Tumor Suppressor Proteins; Ubiquitins | 2007 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Yttrium Radioisotopes | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Delayed-Action Preparations; Drug Implants; Drug Screening Assays, Antitumor; Glioma; Maximum Tolerated Dose; Polymers; Rats; Rats, Inbred F344; Temozolomide | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line; Cell Proliferation; Cell Survival; Dacarbazine; Drug Evaluation, Preclinical; Endothelial Cells; Glioma; Humans; Hydrogen-Ion Concentration; Hypoxia-Inducible Factor 1, alpha Subunit; Microdialysis; Neoplasm Transplantation; Rats; Rats, Nude; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2007 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide | 2007 |
Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cross-Priming; Dacarbazine; Dendritic Cells; Disease Models, Animal; Female; Inhibitor of Apoptosis Proteins; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Repressor Proteins; Survivin; Temozolomide; Transfection; Vaccination | 2007 |
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Topics: Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Dacarbazine; Hematologic Neoplasms; Hematology; Humans; Hydrazines; Leukemia, Myeloid; Multiple Myeloma; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-kit; Sulfonamides; Temozolomide | 2007 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Incidence; Lymphoma; Magnetic Resonance Imaging; Microarray Analysis; Neuronavigation; Patient Care Team; Prognosis; Prospective Studies; Quality of Life; Radiosurgery; Radiotherapy, Conformal; Temozolomide | 2006 |
[Temozolomide, an oral chemotherapeutic agent with potential severe toxicity].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Female; Fever; Glioblastoma; Humans; Male; Middle Aged; Neutropenia; Temozolomide | 2007 |
Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Bone Marrow Cells; Dacarbazine; DNA; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type II; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Drug Synergism; Fluorescent Antibody Technique; Humans; Hydroxylamines; Mice; Temozolomide; Tumor Cells, Cultured | 2007 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine; Diagnosis, Differential; Female; Glioma; Humans; Laryngeal Neoplasms; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Positron-Emission Tomography; Radiotherapy; Temozolomide | 2007 |
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Binding, Competitive; Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Inhibitory Concentration 50; O(6)-Methylguanine-DNA Methyltransferase; Receptors, Cell Surface; Temozolomide | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Drug Implants; Fatal Outcome; Female; Glioblastoma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Reoperation; Temozolomide; Temporal Lobe; Ventriculostomy | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Hybridization; Temozolomide | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured | 2007 |
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Repair; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Gamma Rays; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Structure-Activity Relationship; Temozolomide; Topoisomerase I Inhibitors; Topotecan | 2007 |
Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA, Viral; Glioblastoma; Hepatitis B; Humans; Immunocompromised Host; Immunosuppression Therapy; Lamivudine; Liver; Male; Middle Aged; Patient Selection; Reverse Transcriptase Inhibitors; Risk Factors; Spinal Neoplasms; Temozolomide; Treatment Outcome; Viral Load; Virus Activation | 2007 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genes, p53; Glioma; Humans; Mice; Mice, Nude; Oncolytic Virotherapy; Simplexvirus; Temozolomide; Tumor Suppressor Proteins | 2006 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins | 2007 |
Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Mutation; Temozolomide | 2007 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Irinotecan; Lung Neoplasms; Temozolomide | 2006 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Hepatitis B; Hepatitis B virus; Humans; Temozolomide; Temporal Lobe; Valproic Acid; Viral Load; Virus Activation | 2007 |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2007 |
A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Practice Guidelines as Topic; State Medicine; Temozolomide; United Kingdom | 2007 |
Multiple gangliogliomas of the optic pathway.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ganglioglioma; Humans; Magnetic Resonance Imaging; Male; Optic Nerve Neoplasms; Temozolomide; Treatment Outcome; Vision Disorders | 2006 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Temozolomide | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazine; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Genes, p53; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Biology; Temozolomide | 2007 |
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dacarbazine; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Temozolomide; Treatment Outcome | 2007 |
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Interactions; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Mice; Mice, Nude; Nelfinavir; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Radiation Tolerance; Temozolomide | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Infusions, Intravenous; Melanoma; Melphalan; Neoplasm Transplantation; Rats; Rats, Nude; Skin Neoplasms; Temozolomide | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Temozolomide | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line, Tumor; Cisplatin; Dacarbazine; Disease Models, Animal; Female; Galectin 1; Gene Expression Regulation, Neoplastic; HSP72 Heat-Shock Proteins; Melanoma; Mice; Mice, Knockout; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunotherapy; Interleukin-2; Leukemia; Mice; O(6)-Methylguanine-DNA Methyltransferase; Pilot Projects; Purines; Temozolomide; Tumor Suppressor Proteins | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic Resonance Imaging; Mice; Mice, Mutant Strains; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retroviridae; Temozolomide | 2007 |
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
Topics: Aged; Bronchial Neoplasms; Carcinoid Tumor; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Temozolomide; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Diffusion; Humans; Models, Statistical; Models, Theoretical; Radiation Oncology; Radiotherapy; Radiotherapy Dosage; Temozolomide; Time Factors | 2007 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Pancytopenia; Sepsis; Temozolomide | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Genotype; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL22; Chemokines; Chemotaxis, Leukocyte; Cytoplasm; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glioma; Humans; Receptors, CCR2; Receptors, CCR4; T-Lymphocytes, Regulatory; Temozolomide | 2008 |
Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2007 |
Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Combined Modality Therapy; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; O(6)-Methylguanine-DNA Methyltransferase; Reoperation; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Temozolomide | 2007 |
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cetuximab; Chemotherapy, Adjuvant; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Epidermal Growth Factor; Glioblastoma; Humans; Radiation Dosage; Temozolomide | 2007 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Mice; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Suppressor Proteins; Valproic Acid | 2007 |
Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prospective Studies; Singapore; Survival Analysis; Temozolomide | 2007 |
Salvage chemotherapy in progressive high-grade astrocytoma.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Singapore; Survival Analysis; Temozolomide | 2007 |
Temozolomide-associated organizing pneumonitis.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Male; Pneumocystis carinii; Pneumonia, Pneumocystis; Temozolomide | 2007 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; Glioma; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oncolytic Virotherapy; Sirolimus; Temozolomide | 2007 |
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Down-Regulation; Eye Neoplasms; Female; Genes, Reporter; Glioma; Humans; Interferon Type I; Luciferases; Mice; Mice, Inbred BALB C; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2008 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Survival; Dacarbazine; Flow Cytometry; Giant Cells; Glioma; Humans; Mutation; Protein Serine-Threonine Kinases; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Magnetic Resonance Imaging; Mice; Mice, SCID; Models, Biological; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Vascular Endothelial Growth Factor A | 2007 |
Temozolomide in pediatric low-grade glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Hematologic Diseases; Humans; Male; Nausea; Radiography; Retrospective Studies; Spinal Cord Neoplasms; Survival Rate; Temozolomide; Vincristine | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Mouth Neoplasms; Neoplasms, Unknown Primary; Rectal Neoplasms; Research Design; Temozolomide; Treatment Outcome | 2007 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Herpes Zoster; Humans; Incidence; Lymphopenia; Male; Middle Aged; Neuroendocrine Tumors; Opportunistic Infections; Pneumonia, Pneumocystis; Temozolomide | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of Health Care; Glioma; Humans; Temozolomide; United Kingdom | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Patient Care Team; Radiosurgery; Recombinant Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2007 |
Prophylactic radiotherapy for glioblastoma in the elderly.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2007 |
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Models, Animal; Rats; Temozolomide | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug Carriers; Drug Delivery Systems; Emulsions; Esters; In Vitro Techniques; Melanoma; Mice; Mice, Hairless; Myristates; Oleic Acid; Permeability; Pharmaceutical Vehicles; Polyethylene Glycols; Prodrugs; Rats; Skin Absorption; Skin Neoplasms; Solubility; Temozolomide; Vitamin E | 2007 |
Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Damage; Guanine; Humans; Luciferases; Microscopy, Fluorescence; NF-kappa B; Protein Binding; Subcellular Fractions; Temozolomide; Tetradecanoylphorbol Acetate; Time Factors; Transcription Factor RelA | 2007 |
Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; CD4 Lymphocyte Count; Dacarbazine; Glioma; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Risk Assessment; Risk Factors; Temozolomide | 2007 |
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Female; Glioma; Immunity, Cellular; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Neoplasm Proteins; Recombinant Fusion Proteins; Repressor Proteins; Spleen; Survival Analysis; Survivin; tat Gene Products, Human Immunodeficiency Virus; Temozolomide; Transduction, Genetic; Treatment Outcome | 2007 |
Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brain; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Lymphatic Irradiation; Lymphoma; Magnetic Resonance Imaging; Middle Aged; Radiography; Rituximab; Temozolomide | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Sensitivity and Specificity; Temozolomide | 2007 |
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Death; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; Humans; Irinotecan; Mice; Phthalimides; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Dosage; Gene Expression; Glioblastoma; Glioma; Humans; Immunohistochemistry; Molecular Sequence Data; Netherlands; Polymerase Chain Reaction; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Tumor Suppressor Proteins | 2007 |
Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Cisplatin; Dacarbazine; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Temozolomide | 2007 |
Metastatic medulloblastoma in an adult; treatment with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Medulloblastoma; Neoplasm Recurrence, Local; Spinal Cord Neoplasms; Temozolomide | 2007 |
Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Reoperation; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; G2 Phase; Gene Amplification; Genome, Viral; Humans; Melanoma; Oncolytic Virotherapy; Skin Neoplasms; Temozolomide; Treatment Outcome; Tumor Cells, Cultured | 2007 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Radiosurgery; Retrospective Studies; Temozolomide | 2008 |
Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth.
Topics: Antibodies; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cells, Cultured; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Estramustine; Humans; Paclitaxel; Temozolomide; Time Factors; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Radiotherapy Dosage; Relative Biological Effectiveness; Temozolomide; Therapeutic Equivalency; Tumor Burden | 2007 |
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Irinotecan; Mice; Mice, SCID; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neuroblastoma; Nuclear Proteins; Temozolomide; Tumor Suppressor Proteins | 2007 |
Temozolomide treatment of an adult with a relapsing medulloblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Radionuclide Imaging; Temozolomide; Treatment Outcome | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Glioblastoma; Luminescence; Luminescent Agents; Mice; Mice, Nude; Monitoring, Physiologic; Salvage Therapy; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Quality of Life; Taxoids; Temozolomide | 2007 |
Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Topics: Adenine Nucleotides; Animals; Apoptosis; Astrocytes; Autophagy; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Genetic Therapy; Glioma; Humans; Mice; Oligonucleotides, Antisense; Oligoribonucleotides; RNA; RNA, Long Noncoding; RNA, Untranslated; Telomerase; Temozolomide | 2007 |
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2008 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; White People | 2007 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Guanine; Humans; Luciferases; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
[The effect of oxygenation on the biological behaviour of tumours].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Deoxyglucose; Glioblastoma; Glycolysis; Humans; Hyperbaric Oxygenation; Kidney Neoplasms; Neoplasms; Oncogene Proteins; Oncolytic Virotherapy; Temozolomide; Transplantation, Heterologous | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA, Complementary; Female; Gene Transfer Techniques; Genetic Therapy; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2008 |
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dacarbazine; DNA Methylation; Dose Fractionation, Radiation; Genes, Tumor Suppressor; Glioblastoma; Humans; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Survival Analysis; Temozolomide | 2008 |
Temozolomide induces senescence but not apoptosis in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Dacarbazine; G2 Phase; Humans; Lymphoma; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2008 |
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred Strains; Neoplasms; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Temozolomide; Topotecan | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Temozolomide | 2007 |
Acquired hypopigmentation (leukoderma) as a presenting feature of metastatic amelanotic melanoma with brain involvement.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Dexamethasone; Humans; Hypopigmentation; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Melanoma, Amelanotic; Middle Aged; Neurologic Examination; Skin Neoplasms; Temozolomide | 2007 |
Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Survival Analysis; Temozolomide | 2007 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Flow Cytometry; Glioblastoma; Humans; Immunotherapy; Male; Middle Aged; Radiotherapy; T-Lymphocyte Subsets; T-Lymphocytes; Temozolomide; Vaccines, Subunit | 2008 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA Repair; Gene Silencing; Glioma; Humans; Immunohistochemistry; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Transplantation, Heterologous | 2007 |
An orthotopic skull base model of malignant meningioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Meningeal Neoplasms; Meningioma; Mice; Mice, Nude; Neoplasm Transplantation; Skull Base Neoplasms; Temozolomide; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Suppressor Proteins | 2008 |
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Central Nervous System Neoplasms; Child; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Temozolomide; Treatment Outcome | 2007 |
Temozolomide and resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; Piperidines; Quinazolines; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Glioma; Neoplasm Transplantation; Piperidines; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2008 |
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Selection Bias; Survival Analysis; Temozolomide | 2008 |
[Treatment of marignant brain tumor: today and tomorrow].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Dacarbazine; Genetic Therapy; Humans; Magnetic Resonance Imaging; Neurosurgical Procedures; Radiosurgery; Radiotherapy, Conformal; Temozolomide | 2008 |
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Replication; Glioblastoma; Humans; Mitosis; Radiation-Sensitizing Agents; Temozolomide; Tumor Stem Cell Assay | 2008 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Neurosurgical Procedures; Survival; Temozolomide | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Genetic Markers; Glioma; Humans; Lymphoma; Prognosis; Promoter Regions, Genetic; Temozolomide; Topotecan; Tumor Suppressor Proteins | 2008 |
Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Dacarbazine; Data Interpretation, Statistical; Drug Carriers; Heart Diseases; Injections, Intravenous; Kidney Diseases; Mice; Nanoparticles; Rabbits; Solubility; Temozolomide; Tissue Distribution | 2008 |
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3.
Topics: Animals; Antibodies; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Ceramides; Dacarbazine; Female; Glioblastoma; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Oxides; Paclitaxel; Phagosomes; Survival Rate; Temozolomide; Transplantation, Heterologous; Tubulin Modulators | 2008 |
Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up.
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cerebral Angiography; Chemotherapy, Adjuvant; Craniotomy; Dacarbazine; Glial Fibrillary Acidic Protein; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Neuroepithelial; Parietal Lobe; Radiotherapy, Adjuvant; Reoperation; Rhabdoid Tumor; Temozolomide; Time Factors; Treatment Outcome; Vimentin | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neurosurgical Procedures; Positron-Emission Tomography; Retrospective Studies; Survival; Temozolomide; Treatment Outcome | 2008 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Skin Neoplasms; Temozolomide | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Galectin 1; Glioma; Humans; Mice; RNA, Small Interfering; Temozolomide; Tumor Suppressor Protein p53 | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Collagen Type IV; Dacarbazine; Drug Combinations; Glioma; Immunoenzyme Techniques; Indoles; Laminin; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Dacarbazine; Disease Models, Animal; Eye Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Transgenic; Neurofibromin 1; Optic Nerve Glioma; Protein Kinases; Signal Transduction; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2008 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Temozolomide; Tomography, X-Ray Computed; Tumor Suppressor Proteins | 2008 |
[Temozolomide: Temodal].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Temozolomide | 2008 |
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Endothelial Cells; Integrins; Male; Melanoma; Mice; Mice, Inbred C57BL; Snake Venoms; Temozolomide | 2008 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Headache; Humans; International Normalized Ratio; Male; Neurosurgical Procedures; Pedigree; Temozolomide; Tomography, X-Ray Computed | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Implants; Glioblastoma; Humans; Kaplan-Meier Estimate; Radiotherapy; Retrospective Studies; Temozolomide | 2008 |
[The sodium pump could constitute a new target to combat glioblastomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Brain Neoplasms; Calotropis; Cardenolides; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Neovascularization, Pathologic; Signal Transduction; Sodium-Potassium-Exchanging ATPase; Temozolomide | 2008 |
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2008 |
Low grade astrocytoma presenting with visual loss.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; ErbB Receptors; Humans; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Optic Nerve; Optic Nerve Neoplasms; Papilledema; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Spinal Cord Neoplasms; Subarachnoid Space; Temozolomide; Thalamus; Vision, Low | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid; Cryptococcus neoformans; Dacarbazine; Dexamethasone; Fatal Outcome; Fluconazole; Flucytosine; Glioma; Humans; Immunosuppression Therapy; Lomustine; Male; Meningitis, Cryptococcal; Opportunistic Infections; Temozolomide; Treatment Outcome | 2008 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Clinical Trials as Topic; Dacarbazine; Forecasting; Glioblastoma; Humans; Prognosis; Sirolimus; Temozolomide; Transcription Factors | 2007 |
Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Antipyrine; Apoptosis; Artemisinins; Cell Survival; Cisplatin; Dacarbazine; Drug Synergism; Edaravone; Free Radical Scavengers; Glioma; Rats; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2008 |
Multifocal glioblastoma multiforme with synchronous spontaneous hemorrhage: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cerebral Hemorrhage; Cerebrum; Dacarbazine; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Male; Neoplasms, Multiple Primary; Paresis; Radiotherapy; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; B-Lymphocytes; Breast Neoplasms; Carcinoma; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; HCT116 Cells; Humans; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Temozolomide | 2008 |
Noninvasive imaging of apoptosis and its application in cancer therapeutics.
Topics: Animals; Apoptosis; Caspase 3; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Dacarbazine; Glioblastoma; Humans; Luminescent Measurements; Mice; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2008 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Humans; Lung Neoplasms; Melanoma; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Skin; Skin Neoplasms; Temozolomide; Treatment Outcome | 2008 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmium Chloride; Carmustine; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Mismatch Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Guanine; Humans; Hydroxylamines; Nimustine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2008 |
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoribonucleases; Female; Galectin 1; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Therapy; Glioblastoma; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Membrane Proteins; Mice; Molecular Chaperones; Neovascularization, Pathologic; Oxidative Stress; Protein Serine-Threonine Kinases; Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Temozolomide; Transplantation, Heterologous | 2008 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; Caspases; Cell Line, Tumor; Dacarbazine; Dexamethasone; Drug Interactions; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Inflammation; Mitochondria; Neoplasm Proteins; NF-kappa B; RNA, Messenger; RNA, Neoplasm; Temozolomide; Vascular Endothelial Growth Factor A | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2008 |
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.
Topics: Animals; Animals, Genetically Modified; Blood Vessels; Cell Proliferation; Cell Survival; Dacarbazine; Embryo, Nonmammalian; Embryonic Development; Feasibility Studies; Glioma; Green Fluorescent Proteins; Humans; Luminescent Proteins; Radiation-Sensitizing Agents; Red Fluorescent Protein; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2008 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Genes, myc; Glioma; Humans; In Situ Hybridization, Fluorescence; Medulloblastoma; Neoplasm Metastasis; Neoplasms, Multiple Primary; Neuroectodermal Tumors, Primitive; Prognosis; Proto-Oncogene Proteins; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brazil; Cell Line, Transformed; Cell Line, Tumor; Complex Mixtures; Dacarbazine; Glioma; Humans; Porifera; Temozolomide | 2009 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Administration Schedule; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Mice; Mice, Nude; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Glycosylases; DNA Polymerase beta; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Predictive Value of Tests; Temozolomide | 2008 |
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunotherapy; Melanoma; Melphalan; Models, Biological; Neoplasm Transplantation; Phenotype; Rats; Rats, Nude; Temozolomide | 2008 |
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Dacarbazine; DNA Damage; DNA-Binding Proteins; Genes, abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Molecular Chaperones; Oncogene Proteins; RNA-Binding Proteins; Temozolomide; Tumor Suppressor Protein p53 | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome | 2008 |
Polymorphs and polymorphic cocrystals of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Crystallization; Dacarbazine; Drug Stability; Hydrogen Bonding; Molecular Structure; Temozolomide | 2008 |
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cisplatin; Dacarbazine; Enzyme Inhibitors; Humans; Melanoma, Experimental; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2008 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Temozolomide; Treatment Outcome | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2008 |
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Methylation; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Burden | 2009 |
A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Female; Glioma; Health Status Indicators; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Temozolomide; Treatment Outcome | 2008 |
The role of temozolomide in newly-diagnosed glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2008 |
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; Female; Humans; Myelodysplastic Syndromes; Neoplasm Metastasis; Neuroblastoma; Recurrence; Temozolomide | 2008 |
Different initial steps of apoptosis induced by two types of antineoplastic drugs.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Dacarbazine; DNA Damage; DNA Repair; Fibroblasts; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; MutL Protein Homolog 1; Nimustine; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Phosphatidylserines; Structure-Activity Relationship; Temozolomide | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide | 2008 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; Glioblastoma; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Sirolimus; Temozolomide | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Etoposide; Female; Glioblastoma; Glioma; Hepatocytes; Humans; Lomustine; Male; Membrane Glycoproteins; Middle Aged; Procarbazine; Recombinant Fusion Proteins; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vincristine | 2008 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide | 2008 |
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cells, Cultured; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Temozolomide; Tumor Suppressor Proteins | 2008 |
Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Gliosarcoma; Injections, Intralesional; Male; Radiotherapy, High-Energy; Rats; Rats, Inbred F344; Survival Analysis; Survival Rate; Synchrotrons; Temozolomide; Treatment Outcome | 2008 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Convection; Cranial Irradiation; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Gliosarcoma; Injections, Intraperitoneal; Male; Nimustine; Rats; Rats, Inbred F344; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Clinical Trials as Topic; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Melanoma, Experimental; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Radiography; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Therapy, Combination; ErbB Receptors; Glioma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Nude; Mice, SCID; PTEN Phosphohydrolase; Radiation Tolerance; Stem Cells; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Frequency; Genotype; Glioblastoma; Humans; K562 Cells; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Quality of life in low-grade glioma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Oligodendroglioma; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Quality of Life; Sickness Impact Profile; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Disseminated salmonellosis in a patient treated with temozolomide.
Topics: Adult; Anti-Infective Agents; Antineoplastic Agents, Alkylating; Arthritis, Infectious; Astrocytoma; Aza Compounds; Bacteremia; Brain Neoplasms; Dacarbazine; Drainage; Fluoroquinolones; Focal Infection; Humans; Immunocompromised Host; Male; Moxifloxacin; Quinolines; Salmonella Infections; Temozolomide | 2008 |
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Convection; Dacarbazine; Female; Genetic Vectors; Genome, Viral; Glioblastoma; Green Fluorescent Proteins; Herpesvirus 1, Human; Humans; Immediate-Early Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Radiation Tolerance; Temozolomide; Ubiquitin-Protein Ligases | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioma; Male; Rats; Rats, Sprague-Dawley; Temozolomide; Tetrahydroisoquinolines; Tissue Culture Techniques; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Repair Enzymes; Fatal Outcome; Glioblastoma; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Remission Induction; Temozolomide | 2008 |
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Benzothiazoles; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epothilones; Female; Half-Life; Humans; Male; Mice; Mice, Nude; Paclitaxel; Rats; Rats, Wistar; Survival Rate; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Glioblastoma; Glioma; Humans; Temozolomide | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Lomustine; Neoplasm Recurrence, Local; Procarbazine; Prognosis; Radiotherapy; Radiotherapy Dosage; Temozolomide; Vincristine | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy Dosage; Temozolomide; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
TMZ-BioShuttle--a reformulated temozolomide.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Comet Assay; Dacarbazine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Carriers; Glioblastoma; Humans; Male; Nuclear Localization Signals; Peptide Fragments; Prostatic Neoplasms; Temozolomide; Tumor Cells, Cultured | 2008 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Lymphoma, Non-Hodgkin; Mice; Middle Aged; Neoplasms, Second Primary; Risk Assessment; Temozolomide | 2008 |
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Survival; Cycloheximide; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Stability; Gene Expression Regulation, Neoplastic; Glioma; Green Fluorescent Proteins; Guanine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Protein Synthesis Inhibitors; Recombinant Fusion Proteins; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2009 |
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lineage; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Intermediate Filament Proteins; Nerve Tissue Proteins; Nestin; Neurons; Phenotype; Prognosis; Research Design; Temozolomide; Treatment Outcome | 2008 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarbazine; Female; Glioma; Humans; Temozolomide | 2009 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; Enzyme Inhibitors; Female; Humans; Melanoma; Mice; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Temozolomide; Young Adult | 2009 |
Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs.
Topics: Animals; Apoptosis; BRCA2 Protein; Cell Death; CHO Cells; Chromosome Aberrations; Cricetinae; Cricetulus; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Down-Regulation; Fluorescent Antibody Technique; Guanine; Mice; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Recombination, Genetic; Sister Chromatid Exchange; Temozolomide; Transfection | 2009 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Survival; Temozolomide; Treatment Outcome | 2009 |
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Death; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide | 2008 |
Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Paclitaxel; RNA, Small Interfering; Telomerase; Temozolomide | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2008 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2009 |
[Alveolo-interstitial pneumonia due to Temozolamide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Bronchoalveolar Lavage; Dacarbazine; Female; Glioblastoma; Humans; Lung Diseases, Interstitial; Lymphocytosis; Middle Aged; Radiography, Thoracic; Temozolomide; Time Factors; Tomography, X-Ray Computed | 2008 |
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Humans; Mice; Mice, Nude; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Mice; Mice, Nude; Random Allocation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Antitumor efficacy testing in rodents.
Topics: Animals; Antineoplastic Agents; Biological Availability; Dacarbazine; Data Interpretation, Statistical; Drug Approval; Drug Design; Drug Screening Assays, Antitumor; Drugs, Investigational; Endpoint Determination; Humans; Kaplan-Meier Estimate; Mice; Neoplasms; Pharmaceutical Vehicles; Random Allocation; Rats; Research Design; Rodentia; Sample Size; Tamoxifen; Temozolomide; Topotecan; Transplantation, Heterologous; United States | 2008 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interactions; Glioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Imatinib Mesylate; Melanoma; Mice; Piperazines; Pyrimidines; Temozolomide; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2008 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Anticholesteremic Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Combined Modality Therapy; Cyclosporine; Dacarbazine; Dexamethasone; Female; Fluoxetine; Glioblastoma; Heptanoic Acids; Humans; Immunosuppressive Agents; Isoniazid; Middle Aged; Omeprazole; Phenobarbital; Prednisone; Pyrazinamide; Pyrroles; Radiotherapy; Red-Cell Aplasia, Pure; Rifampin; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2009 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intermediate Filament Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Nerve Tissue Proteins; Nestin; RNA-Binding Proteins; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Treatment of Nelson's syndrome with temozolomide.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged; Nelson Syndrome; Temozolomide | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nimustine; Temozolomide | 2009 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Fatal Outcome; Humans; Male; Myelodysplastic Syndromes; Temozolomide | 2008 |
Methylation status of MGMT gene promoter in meningiomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2008 |
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dependovirus; Genetic Therapy; Genetic Vectors; Glioma; Humans; Microscopy, Fluorescence; Signal Transduction; Stem Cell Transplantation; Stem Cells; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2008 |
Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.
Topics: Acridine Orange; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gamma Rays; Humans; Indazoles; Radiation-Sensitizing Agents; Radiotherapy; Temozolomide | 2008 |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Sequence Data; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Combined Modality Therapy; Dacarbazine; Erythropoietin; Glioma; Gliosarcoma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2008 |
[Orthogonal experiments for optimizing the formulation and preparation conditions of temozolomide solid lipid nanoparticles].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Carriers; Lipids; Nanoparticles; Particle Size; Stearic Acids; Temozolomide | 2008 |
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; KATP Channels; Mice; Minoxidil; Survival Rate; Temozolomide; Transplantation, Heterologous; Trastuzumab | 2009 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Glioblastoma; Humans; Reproducibility of Results; Survival Analysis; Survival Rate; Temozolomide; Time Factors | 2008 |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neurosurgical Procedures; Pancytopenia; Polymerase Chain Reaction; Radiotherapy; Temozolomide; Thrombocytopenia; Tumor Suppressor Proteins | 2009 |
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Retrospective Studies; Survival Rate; Temozolomide | 2009 |
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cyclic Nucleotide Phosphodiesterases, Type 4; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Phosphodiesterase Inhibitors; Rolipram; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Temozolomide | 2008 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukins; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Suppressor Protein p53 | 2008 |
IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Interferon-beta; Interleukins; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
Possible leukemogenic potential of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; DNA; Mice; Mice, Transgenic; Mutation; Neoplasms, Second Primary; Polymerase Chain Reaction; Temozolomide | 2009 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Survival Analysis; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
Topics: Adult; Cohort Studies; Dacarbazine; Gene Expression; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide | 2009 |
Pituitary carcinoma presenting with multiple metastases: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Papilledema; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2008 |
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Brain Neoplasms; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Mice; Poly(ADP-ribose) Polymerases; Temozolomide; Toluene; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2008 |
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; France; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome; Waiting Lists | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Reoperation; Survival Analysis; Survivors; Temozolomide; Time Factors | 2009 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Headache; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Nausea; Neuroectodermal Tumors, Primitive; Rhabdoid Tumor; Temozolomide; Teratoma; Treatment Outcome; Vomiting | 2009 |
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cytoskeleton; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Endothelial Cells; Focal Adhesion Kinase 1; Glioblastoma; Humans; Oncogene Protein v-akt; Phosphorylation; Promoter Regions, Genetic; Snake Venoms; src-Family Kinases; Swine; Temozolomide; Tight Junctions; Tumor Suppressor Proteins | 2008 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Senescence; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Dacarbazine; DNA Methylation; Glioma; Heterochromatin; Histones; Humans; Methyl-CpG-Binding Protein 2; Temozolomide | 2009 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Confusion; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Tolerance; Radiotherapy, Adjuvant; Reoperation; Temozolomide; Treatment Outcome | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Glioma; Humans; Isotope Labeling; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide; Tissue Distribution | 2009 |
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; O(6)-Methylguanine-DNA Methyltransferase; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2009 |
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 9; Combined Modality Therapy; Craniotomy; Dacarbazine; Gastric Bypass; Glioblastoma; Humans; Male; Middle Aged; Obesity, Morbid; Temozolomide | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Type XI; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Everolimus; Humans; Melanoma; Necrosis; Phosphorylation; Sirolimus; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2009 |
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; Exploratory Behavior; Flow Cytometry; Glioblastoma; Male; Peptide Fragments; Rats; Rats, Wistar; Receptors, Bombesin; Temozolomide | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Radiation; Glioma; Humans; Kaplan-Meier Estimate; Middle Aged; Radiation Dosage; Radiotherapy; Retrospective Studies; Temozolomide; Young Adult | 2009 |
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Carboplatin; Cyclophosphamide; Dacarbazine; Dogs; Enzyme Inhibitors; Female; Haplorhini; Humans; Magnetic Resonance Spectroscopy; Melanoma, Experimental; Mice; Mice, SCID; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide | 2009 |
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Inhibitory Concentration 50; Melanoma; Microsatellite Repeats; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Repair; Enzyme Inhibitors; Glioblastoma; Humans; In Vitro Techniques; Mice; Mitosis; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiotherapy; Temozolomide | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Diagnostic Errors; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Magnetic Resonance Imaging; Male; Mice; Microscopy, Fluorescence; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Temozolomide; Treatment Outcome | 2009 |
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Humans; Indoles; Mice; Neuroblastoma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2009 |
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Inverse-electron-demand Diels-Alder reaction as a highly efficient chemoselective ligation procedure: synthesis and function of a BioShuttle for temozolomide transport into prostate cancer cells.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Drug Carriers; Humans; Male; Molecular Structure; Peptides; Prostatic Neoplasms; Temozolomide | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioma; Glutathione S-Transferase pi; Humans; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Neoplasm Staging; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Risk Factors; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Temozolomide; Tumor Suppressor Proteins | 2009 |
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Temozolomide | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Glioma; Humans; PTEN Phosphohydrolase; Pyrimidines; Temozolomide; Thiazoles | 2009 |
Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance; Glioblastoma; Humans; Neoplasm Invasiveness; Neurosurgical Procedures; Patient Care Team; Sodium-Potassium-Exchanging ATPase; Temozolomide | 2009 |
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
Topics: Acridine Orange; Betulinic Acid; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, Tumor; Cell Survival; Cyclosporine; Cytostatic Agents; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioma; Humans; Indazoles; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pentacyclic Triterpenes; Polymerase Chain Reaction; Retinoids; Temozolomide; Triterpenes | 2009 |
Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Squamous Cell; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tonsillar Neoplasms | 2009 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DNA, Viral; Female; Glioma; Humans; Middle Aged; Opportunistic Infections; Temozolomide; Tomography, X-Ray Computed | 2009 |
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Melanoma; Methylation; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prodrugs; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; Drug Therapy, Combination; Gene Silencing; Glioma; Humans; Immunoblotting; In Vitro Techniques; Integrin alphaVbeta3; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Vitronectin; Snake Venoms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Flow Cytometry; Forkhead Transcription Factors; Glioma; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Rats; Rats, Inbred F344; Spleen; T-Lymphocytes, Regulatory; Temozolomide; Tumor Cells, Cultured | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Odds Ratio; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Treatment Outcome | 2009 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Cholestasis; Dacarbazine; Glioblastoma; Humans; Liver Failure; Male; Middle Aged; Temozolomide; Valproic Acid | 2008 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Primary malignant melanoma of the vagina.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lymphatic Metastasis; Melanoma; Middle Aged; Temozolomide; Vaginal Neoplasms | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Sodium-Potassium-Exchanging ATPase; Temozolomide | 2009 |
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoquinones; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; NAD(P)H Dehydrogenase (Quinone); RNA, Messenger; Temozolomide | 2009 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Mismatch Repair; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Silencing; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Temozolomide | 2008 |
[Evaluation of stability of temozolomide in solutions after opening the capsule].
Topics: Antineoplastic Agents, Alkylating; Buffers; Capsules; Dacarbazine; Drug Stability; Hydrogen-Ion Concentration; Solutions; Temozolomide; Time Factors; Water | 2009 |
Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Carboplatin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; DNA Methylation; Etoposide; Female; Glioma; Humans; Interferon-beta; Magnetic Resonance Imaging; Male; Nitrosourea Compounds; Retrospective Studies; Temozolomide; Treatment Outcome | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Dacarbazine; Glioma; Humans; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Temozolomide | 2009 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Cells, Cultured; Chromones; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Humans; Mice; Mice, Nude; Mitoxantrone; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Temozolomide | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Drug Administration Schedule; Drug Monitoring; Glioma; Humans; Lymphopenia; Nausea; Netherlands; Neutropenia; Nurse Practitioners; Nurse's Role; Nursing Evaluation Research; Oncology Nursing; Prospective Studies; Statistics, Nonparametric; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Melanoma; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
Topics: Animals; Brain Neoplasms; Cell Polarity; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Interleukin-4; Luminescent Measurements; Lymphoma; Macrophages; Mice; Mice, Nude; STAT6 Transcription Factor; Temozolomide; Tumor Suppressor Proteins | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Mitosis; Oncolytic Virotherapy; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Carbon; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; Heavy Ion Radiotherapy; Humans; Radiation Tolerance; Relative Biological Effectiveness; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell Line, Tumor; Corpus Striatum; Dacarbazine; Drug Evaluation, Preclinical; Glioma; Indomethacin; Injections, Intraperitoneal; Male; Nanocapsules; Neovascularization, Pathologic; Random Allocation; Rats; Rats, Wistar; Supratentorial Neoplasms; Temozolomide; Tumor Burden | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide; Time; Treatment Outcome | 2009 |
Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; beta-Galactosidase; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Damage; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Histones; Humans; Immunohistochemistry; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Temozolomide; Time Factors; Tumor Suppressor Protein p53 | 2009 |
Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Middle Aged; Nausea; Postoperative Complications; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Remission Induction; Sarcoma; Temozolomide; Tumor Burden; Vomiting | 2009 |
The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Recurrence; Temozolomide; Topotecan | 2009 |
Hypersensitivity pneumonitis associated with the use of temozolomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents, Alkylating; Biopsy; Bronchoscopy; Dacarbazine; Female; Glucocorticoids; Humans; Middle Aged; Prednisolone; Temozolomide; Tomography, X-Ray Computed | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Drug Implants; Glioma; Humans; Maximum Tolerated Dose; Mice; Polymers; Rats; Rats, Wistar; Temozolomide; Tissue Distribution; Tumor Cells, Cultured | 2009 |
BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Death; Cell Line; Cell Nucleus; Chromatin Immunoprecipitation; Dacarbazine; DNA Fragmentation; Electrophoresis, Gel, Pulsed-Field; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase 1; Histone Deacetylases; Humans; Membrane Proteins; Protein Binding; Proto-Oncogene Proteins; PTB-Associated Splicing Factor; RNA-Binding Proteins; Temozolomide; Transfection | 2009 |
Use of temozolomide in aggressive pituitary tumors: case report.
Topics: Adenoma; Adult; Antineoplastic Agents, Alkylating; Cushing Syndrome; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Temozolomide | 2009 |
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; Female; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Opportunistic Infections; Radiotherapy; Temozolomide | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Genetic Therapy; Genetic Vectors; Glioma; Humans; Interleukins; Mice; Mice, Nude; Oncolytic Virotherapy; Promoter Regions, Genetic; Recombinant Proteins; Temozolomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2009 |
Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression; Humans; Jurkat Cells; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Microtubules; Mitochondria; Phosphatidylserines; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Temozolomide; Tubulin; Tubulin Modulators | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Prognosis; Research; Temozolomide | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Temozolomide; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured | 2009 |
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Nimustine; Retrospective Studies; Salvage Therapy; Survival Analysis; Temozolomide | 2009 |
Primary diffuse leptomeningeal gliomatosis.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain; Dacarbazine; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meninges; Meningitis; Neoplasms, Neuroepithelial; Perfusion Imaging; Spinal Cord; Temozolomide; Treatment Outcome; Young Adult | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding Factors, Epidemiologic; Dacarbazine; Female; Glioma; Humans; Hypersensitivity; Immunoglobulin E; Immunotherapy; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; San Francisco; Surveys and Questionnaires; Temozolomide | 2009 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Glioma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Temozolomide | 2010 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Etoposide; Female; Glioblastoma; Gliosarcoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligodendroglioma; Prognosis; Temozolomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Dacarbazine; Dentate Gyrus; Electrophysiology; Excitatory Postsynaptic Potentials; Female; Hippocampus; Immunoenzyme Techniques; Long-Term Potentiation; Maze Learning; Mice; Mice, Inbred C57BL; Neurogenesis; Neurons; Psychomotor Performance; Space Perception; Temozolomide | 2009 |
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy.
Topics: Adenoviridae; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Folic Acid Antagonists; Glioma; Humans; Melanoma; Molecular Structure; Poly(ADP-ribose) Polymerases; Pyrimethamine; Temozolomide | 2009 |
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Glioblastoma; Humans; Mice; Radiation, Ionizing; Survival Analysis; Survivors; Temozolomide | 2009 |
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Becaplermin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dietary Supplements; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA Modification Methylases; DNA Repair Enzymes; Folic Acid; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Middle Aged; Neoplasm Invasiveness; Platelet-Derived Growth Factor; Protein Binding; Proto-Oncogene Proteins c-sis; Repetitive Sequences, Nucleic Acid; Sp1 Transcription Factor; Sp3 Transcription Factor; Survival Analysis; Survivin; Temozolomide; Tumor Suppressor Proteins | 2009 |
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Interferon-beta; Oligodendroglia; Signal Transduction; STAT3 Transcription Factor; Temozolomide | 2009 |
Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Neck; Radiotherapy; Scalp; Stevens-Johnson Syndrome; Temozolomide; Thorax | 2009 |
In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Dacarbazine; Genetic Therapy; Genetic Vectors; Guanine; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Lentivirus; Macaca mulatta; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon-beta; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide | 2009 |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Survival Rate; Temozolomide | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidase; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Survival; Cellular Senescence; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; G2 Phase; Glioma; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Digestive System Neoplasms; Disease Progression; Endocrine Gland Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome | 2009 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Glioblastoma; Humans; Models, Economic; Quality-Adjusted Life Years; Survival Analysis; Temozolomide; Treatment Outcome | 2009 |
Non-Hodgkin lymphoma following temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, Non-Hodgkin; Neoplasms, Second Primary; Temozolomide | 2009 |
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2009 |
Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged; Paraganglioma; Temozolomide | 2009 |
Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Hospitals, Community; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Survival; Temozolomide | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dacarbazine; Drug Therapy, Combination; Early Detection of Cancer; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphatic Metastasis; Male; Melanoma; Neoplasms, Multiple Primary; Skin Neoplasms; Splenic Neoplasms; Temozolomide | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; In Situ Nick-End Labeling; Membrane Proteins; Middle Aged; Prognosis; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2009 |
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Dacarbazine; Drug Administration Routes; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Myeloid Cells; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Temozolomide; Thalidomide; Time Factors | 2011 |
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Cycle Proteins; Dacarbazine; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Glioblastoma; Mice; Mice, SCID; Neuroblastoma; Polo-Like Kinase 1; Protein Phosphatase 2; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Temozolomide | 2009 |
Glioblastoma stem cells resistant to temozolomide-induced autophagy.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Blotting, Western; Caspase 3; Cells, Cultured; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Membrane Proteins; Microtubule-Associated Proteins; Peptides; Temozolomide | 2009 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Humans; Temozolomide; Thalidomide | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Ependymoma; Female; Ferrous Compounds; Humans; Male; Metallocenes; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Supratentorial Neoplasms; Temozolomide | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioma; Humans; Interferon-beta; Temozolomide | 2009 |
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Mutational Analysis; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Microsatellite Instability; Mutation; RNA Interference; Temozolomide; Tumor Cells, Cultured | 2009 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Diagnostic Imaging; Disease Models, Animal; Glioma; Humans; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Luciferases; Luminescent Agents; Male; Neoplasm Transplantation; Rats; Rats, Nude; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2010 |
High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Hydrocortisone; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed; Young Adult | 2009 |
FEN1 is overexpressed in testis, lung and brain tumors.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Brain Neoplasms; Cisplatin; Dacarbazine; Flap Endonucleases; Flow Cytometry; Humans; Lung Neoplasms; Male; Methyl Methanesulfonate; Nimustine; RNA, Messenger; RNA, Small Interfering; Temozolomide; Testicular Neoplasms | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Suppressor Proteins | 2009 |
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Topics: Aniline Compounds; Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; Indicator Dilution Techniques; Oligonucleotide Array Sequence Analysis; Phosphotransferases (Alcohol Group Acceptor); Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Thiazoles | 2009 |
DNA ligase IV as a new molecular target for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Ligase ATP; DNA Ligases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Temozolomide | 2009 |
Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dacarbazine; Female; Humans; Language; Male; Memory; Middle Aged; Neuropsychological Tests; Retrospective Studies; Space Perception; Temozolomide | 2010 |
Comment re: Temozolomide preferentially depletes cancer stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplastic Stem Cells; Temozolomide | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azacitidine; Brain Neoplasms; Cell Line, Tumor; CpG Islands; Dacarbazine; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Survival Rate; Temozolomide; Young Adult | 2009 |
The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Dacarbazine; DNA Damage; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Screening Assays, Antitumor; Flow Cytometry; Mice; Mice, Knockout; Microscopy, Fluorescence; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2009 |
Diagnosis and management of leptomeningeal disease.
Topics: Adult; Antineoplastic Agents, Alkylating; Benzenesulfonates; Dacarbazine; Female; Humans; Meningeal Carcinomatosis; Meningeal Neoplasms; Niacinamide; Phenylurea Compounds; Prevalence; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Temozolomide | 2009 |
Hypersensitivity pneumonitis associated with temozolomide.
Topics: Alveolitis, Extrinsic Allergic; Biopsy; Brain; Dacarbazine; Dyspnea; Humans; Lung; Lung Diseases, Interstitial; Lymphocytes; Middle Aged; Prednisone; Pulmonary Fibrosis; Temozolomide | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Reoperation; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2009 |
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Female; Hormones; Humans; Immunohistochemistry; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Paraffin Embedding; Pituitary Neoplasms; Positron-Emission Tomography; Prolactin; Prolactinoma; Temozolomide; Young Adult | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neoplasms; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fluorometry; Glioma; Glutathione; Humans; Medulloblastoma; Methionine; Methotrexate; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2009 |
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Neoplasms, Neuroepithelial; Neovascularization, Pathologic; Prognosis; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
A rare case of aplastic anemia caused by temozolomide.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Temozolomide | 2009 |
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2009 |
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Genes, erbB-1; Genes, p53; Glioblastoma; Humans; Methylation; Mice; O(6)-Methylguanine-DNA Methyltransferase; PTEN Phosphohydrolase; Radiation-Sensitizing Agents; Random Allocation; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Predictive Value of Tests; Prognosis; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Nitrosourea Compounds; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2009 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Memory; Mental Processes; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Radiotherapy, Adjuvant; Temozolomide; Verbal Learning | 2010 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2010 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Female; Flow Cytometry; Glioma; Humans; Immunoblotting; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Mice; Mice, Nude; Rats; Rats, Nude; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Temozolomide; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Methylation; Middle Aged; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2010 |
Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Repair; DNA, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; White People | 2009 |
Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Arachnoid; Brain; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Mutational Analysis; Gene Deletion; Genetic Predisposition to Disease; Genotype; Humans; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Meningeal Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Oligodendroglioma; Pia Mater; Radiotherapy; Spinal Cord; Subarachnoid Space; Temozolomide; Treatment Outcome | 2009 |
Rituximab maintenance therapy in central nervous system lymphoma?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Availability; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Humans; Lymphoma, Large B-Cell, Diffuse; Retrospective Studies; Rituximab; Salvage Therapy; Temozolomide | 2009 |
Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity.
Topics: Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Enzyme Activation; G2 Phase; Guanine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Radiation Dosage; Radiation Tolerance; Temozolomide | 2009 |
Glioblastoma masquerading as a hypertensive putaminal hemorrhage: a diagnostic pitfall.
Topics: Antihypertensive Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Diabetes Complications; Diagnosis, Differential; Diagnostic Errors; Fatal Outcome; Glioblastoma; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Putaminal Hemorrhage; Risk Factors; Temozolomide; Tomography, X-Ray Computed; Treatment Failure | 2009 |
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiazepines; Blood Vessels; Capillary Permeability; Dacarbazine; Drug Resistance, Neoplasm; Female; HT29 Cells; Humans; Indoles; Mice; Mice, Nude; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Cycle; Dacarbazine; DNA Breaks, Double-Stranded; DNA Damage; Mice; Neoplasms; Phosphorylation; Protein Phosphatase 2; Proteome; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Gliosarcoma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide | 2010 |
A novel use of temozolomide in a patient with malignant prolactinoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2009 |
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Conformal; Retrospective Studies; Temozolomide | 2010 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Temozolomide | 2010 |
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Histones; Humans; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Recombination, Genetic; RNA, Small Interfering; Sequence Homology; Temozolomide | 2009 |
Recurrent PNET with MGMT methylation responds to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Methylation; Neuroectodermal Tumors, Primitive; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Carcinoma; Choroid Plexus; Choroid Plexus Neoplasms; Craniotomy; Dacarbazine; Drug Administration Schedule; Female; Humans; Lateral Ventricles; Magnetic Resonance Imaging; Neurosurgical Procedures; Radiotherapy; Temozolomide; Temporal Lobe; Treatment Outcome | 2009 |
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2009 |
A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Radiation; Humans; Kaplan-Meier Estimate; Linear Models; Models, Biological; Radiation Tolerance; Randomized Controlled Trials as Topic; Temozolomide; Time Factors | 2010 |
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Geriatrics; Humans; Lymphoma; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2010 |
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.
Topics: Antineoplastic Agents, Alkylating; Colonic Neoplasms; Consensus Sequence; Dacarbazine; DNA Repair; Down-Regulation; Glioblastoma; HCT116 Cells; Humans; Lung Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Protein Binding; Sp1 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53 | 2009 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Databases, Factual; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Kinetics; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Oligodendroglioma; Retrospective Studies; Temozolomide; Young Adult | 2010 |
Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytoprotection; Dacarbazine; Doxorubicin; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Lentivirus; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Temozolomide | 2010 |
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Humans; Injections, Spinal; Liposomes; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Oligodendroglioma; Temozolomide | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Skin; Temozolomide | 2009 |
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzimidazoles; Biological Availability; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous | 2009 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; Dendritic Cells; Disease Models, Animal; Drug Therapy, Combination; Female; Glioma; Humans; Immunotherapy; Mice; Mice, Inbred C57BL; Survival Analysis; T-Lymphocytes, Regulatory; Temozolomide | 2010 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Models, Theoretical; Radiosurgery; Regression Analysis; Statistics as Topic; Temozolomide; Tumor Burden | 2009 |
Preparation and the influencing factors of timozolomide liposomes.
Topics: Administration, Intranasal; Alkylating Agents; Amides; Ammonium Sulfate; Dacarbazine; Drug Carriers; Drug Stability; Imidazoles; Liposomes; Nasal Mucosa; Particle Size; Temozolomide | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Lomustine; Procarbazine; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Temozolomide; Time Factors; Treatment Failure; Tumor Suppressor Proteins; Vincristine | 2009 |
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Survivors; Temozolomide; Treatment Outcome | 2009 |
Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytotoxicity, Immunologic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Neoplasms; Simian Immunodeficiency Virus; T-Lymphocytes; Temozolomide; Transduction, Genetic; Tumor Suppressor Proteins | 2010 |
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Combined Modality Therapy; Dacarbazine; DNA Repair; DNA-Binding Proteins; Drug Administration Schedule; G2 Phase; Glioblastoma; Humans; Morpholines; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Pyrones; Radiation Tolerance; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2009 |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
Topics: Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockdown Techniques; Humans; I-kappa B Proteins; Inhibitory Concentration 50; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Pentacyclic Triterpenes; Phosphorylation; Proteasome Endopeptidase Complex; Protein Transport; RNA, Small Interfering; Temozolomide; Triterpenes; Tumor Necrosis Factor-alpha; Ubiquitinated Proteins | 2009 |
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Temozolomide; Tumor Suppressor Proteins | 2009 |
High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.
Topics: Aneuploidy; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA, Neoplasm; Drug Delivery Systems; Drug Monitoring; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Prostatic Neoplasms; Temozolomide | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Radiography; Temozolomide; Treatment Outcome | 2011 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Cluster Analysis; Dacarbazine; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; RNA Interference; Temozolomide; Transplantation, Heterologous; Tumor Burden; Y-Box-Binding Protein 1 | 2009 |
A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Binding Sites; Cell Death; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dacarbazine; DNA Ligase ATP; DNA Ligases; DNA Mismatch Repair; DNA Polymerase beta; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Flap Endonucleases; Humans; Mice; Nucleotides; Protein Binding; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Diffusion; Disease Models, Animal; Glioblastoma; Hypoxia, Brain; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Neoplasm Transplantation; Oxygen; Radiation-Sensitizing Agents; Rats; Rats, Sprague-Dawley; Temozolomide; Vitamin A | 2010 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; CHO Cells; Cricetinae; Cricetulus; Dacarbazine; DNA Breaks, Double-Stranded; DNA Polymerase beta; DNA Repair; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Fluorescent Antibody Technique; Genes, BRCA2; Humans; Lithocholic Acid; Mice; Mutation; Temozolomide; Transfection | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Dacarbazine; Feasibility Studies; Female; Humans; Injections, Spinal; Liposomes; Meningeal Neoplasms; Temozolomide | 2009 |
The Diels-Alder-reaction with inverse-electron-demand, a very efficient versatile click-reaction concept for proper ligation of variable molecular partners.
Topics: Chloroform; Dacarbazine; Deuterium; Dimethyl Sulfoxide; Magnetic Resonance Spectroscopy; Molecular Structure; Organic Chemicals; Organic Chemistry Phenomena; Peptides; Solvents; Temozolomide | 2009 |
Therapeutic windows.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; History, 20th Century; Humans; Molecular Structure; Temozolomide | 2009 |
Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Gliosarcoma; Humans; Male; Middle Aged; Temozolomide | 2010 |
Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Dacarbazine; Esthesioneuroblastoma, Olfactory; Humans; Hydrocortisone; Immunohistochemistry; Ketoconazole; Magnetic Resonance Imaging; Male; Middle Aged; Nasal Cavity; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nose Neoplasms; Octreotide; Temozolomide | 2010 |
Up-front temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Geriatrics; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Recurrence; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Genomics; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligodendroglioma; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportunistic Infections; Temozolomide | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide | 2010 |
In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Female; Fluorescent Dyes; Lung Neoplasms; Melanoma, Experimental; Mice; Particle Size; Reproducibility of Results; Temozolomide | 2010 |
Medical oncology: treatment and management of malignant gliomas.
Topics: Angiogenesis Inhibitors; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Salvage Therapy; Temozolomide; Treatment Outcome | 2010 |
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Dideoxynucleosides; Fluorine Radioisotopes; Glioblastoma; Humans; Methionine; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Temozolomide | 2010 |
Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Leiomyosarcoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Recurrence; Retrospective Studies; Temozolomide; Uterine Neoplasms | 2010 |
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2010 |
Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Dacarbazine; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Genomic Imprinting; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide; Tumor Suppressor Proteins | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models, Animal; Drug Administration Routes; Drug Therapy, Combination; Female; Glioma; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Safety; Survival Rate; Temozolomide; Young Adult | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Extremities; Humans; In Vitro Techniques; Indoles; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Rats, Nude; Severity of Illness Index; Temozolomide; Treatment Outcome | 2010 |
Patent watch.
Topics: Antineoplastic Agents, Alkylating; Antiparkinson Agents; Benzothiazoles; Brain Neoplasms; Dacarbazine; Humans; Parkinson Disease; Patents as Topic; Pramipexole; Temozolomide; Time Factors | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retrospective Studies; Temozolomide; Time Factors | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Genetic Therapy; Glioma; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; RNA Interference; RNA, Messenger; RNA, Small Interfering; Temozolomide; Time Factors; Transfection | 2010 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2009 |
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2010 |
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Polymerase theta; DNA Repair; DNA-Directed DNA Polymerase; Gene Knockdown Techniques; HeLa Cells; Histones; Humans; Infrared Rays; Neoplasms; Radiation Tolerance; RNA, Small Interfering; Temozolomide; Transfection | 2010 |
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central Nervous System Neoplasms; Cerebrospinal Fluid; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival; Temozolomide | 2010 |
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Infant; Male; Mice; Mice, Nude; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Radiotherapy, Adjuvant; Recurrence; Temozolomide; Time Factors; Treatment Outcome | 2010 |
Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Blotting, Western; Cell Proliferation; Dacarbazine; Docetaxel; Drug Therapy, Combination; Extracellular Fluid; Female; Flow Cytometry; Immunoenzyme Techniques; Interleukin 1 Receptor Antagonist Protein; Macrophages; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes, Regulatory; Taxoids; Temozolomide; Tumor Cells, Cultured | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Doxorubicin; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Vincristine | 2010 |
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biological Availability; Blood-Brain Barrier; BRCA1 Protein; Carboplatin; Cell Line, Tumor; Crystallography, X-Ray; Dacarbazine; Drug Screening Assays, Antitumor; Female; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, SCID; Models, Molecular; Neoplasm Transplantation; Poly(ADP-ribose) Polymerase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous | 2010 |
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.
Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay | 2010 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasms; Carboxymethylcellulose Sodium; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Interferon Inducers; Male; Middle Aged; Poly I-C; Polylysine; Receptors, AMPA; Snake Venoms; Survival Rate; Temozolomide; Treatment Outcome; United States; Young Adult | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Oligonucleotide Array Sequence Analysis; Organophosphorus Compounds; Polymorphism, Single Nucleotide; Temozolomide; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Regression Analysis; Signal Transduction; Temozolomide; Transcription, Genetic | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Microsurgery; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Nimustine; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Reoperation; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Temozolomide; Treatment Outcome | 2010 |
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dacarbazine; Drug Interactions; Glioblastoma; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Sulfonamides; Temozolomide | 2010 |
Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid).
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Humans; Liposomes; Malates; Molecular Weight; Nanoparticles; Polymers; Temozolomide | 2010 |
Sensitivity to temozolomide in brain tumor initiating cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Chemokine CXCL12; Dacarbazine; Enzyme Activation; Estrenes; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioma; Humans; Pyrrolidinones; Receptors, CXCR; Temozolomide | 2010 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End Labeling; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Temozolomide | 2011 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult | 2011 |
Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.
Topics: Acromegaly; Adult; Dacarbazine; Human Growth Hormone; Humans; Male; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biocompatible Materials; Carmustine; Dacarbazine; Decanoic Acids; Drug Carriers; Humans; Polyesters; Temozolomide; Treatment Outcome | 2010 |
Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioma; Humans; Rats; Staining and Labeling; Temozolomide | 2010 |
Pseudoprogression after radiotherapy with concurrent temozolomide in a child with anaplastic astrocytoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Child, Preschool; Dacarbazine; Humans; Hypothalamic Neoplasms; Magnetic Resonance Imaging; Male; Radiography; Radiotherapy; Temozolomide | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Profiling; Glioma; Humans; Inhibitory Concentration 50; Oligonucleotide Array Sequence Analysis; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2010 |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Portugal; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
Malignant transformation of an optic pathway glioma without prior radiation therapy.
Topics: Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; Chemotherapy, Adjuvant; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Fatal Outcome; Humans; Hypothalamus; Magnetic Resonance Imaging; Male; Neoplasms, Radiation-Induced; Optic Chiasm; Optic Nerve; Optic Nerve Glioma; Radiotherapy, Adjuvant; Temozolomide | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Response Relationship, Drug; Fatal Outcome; Glioma; Humans; Male; Recurrence; Temozolomide; Thrombocytopenia | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; Dacarbazine; DNA Primers; DNA, Complementary; Exons; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2010 |
Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Paternalism in practice: informing patients about expensive unsubsidised drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Attitude of Health Personnel; Bevacizumab; Dacarbazine; Drug Costs; Female; Health Services Accessibility; Humans; Male; Medical Oncology; New Zealand; Paternalism; Patient Education as Topic; Rituximab; Temozolomide | 2010 |
Tonsillar pseudotumor: complications of chronically-administered temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Palatine Tonsil; Temozolomide | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Knockdown Techniques; Glioma; Histocompatibility Antigens Class II; Humans; Immunohistochemistry; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Female; France; Glioma; Humans; Male; Middle Aged; Polyesters; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2010 |
miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Primers; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Temozolomide | 2010 |
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorine Radioisotopes; Follow-Up Studies; Glioblastoma; Humans; Male; Methylation; Middle Aged; Positron-Emission Tomography; Pyrazoles; Retrospective Studies; Sulfonamides; Temozolomide; Tumor Suppressor Proteins; Tyrosine | 2010 |
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gamma Rays; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Maximum Tolerated Dose; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nitrosourea Compounds; Retrospective Studies; Temozolomide; Treatment Outcome | 2010 |
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; G2 Phase; HeLa Cells; Humans; Melanoma, Experimental; Methylation; Mice; Netropsin; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Models, Biological; Mutation; Octreotide; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Time Factors; Transfection | 2010 |
Temozolomide-induced inhibition of pituitary adenoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Enzyme-Linked Immunosorbent Assay; In Situ Nick-End Labeling; Mice; Prolactin; Prolactinoma; Rats; Temozolomide; Tumor Cells, Cultured | 2011 |
STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Neural Stem Cells; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Cells, Cultured | 2011 |
MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dacarbazine; Female; Humans; Middle Aged; Pituitary Neoplasms; Salvage Therapy; Somatostatin; Temozolomide; Treatment Outcome | 2010 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Prognosis; Radiotherapy; Temozolomide | 2010 |
Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dichloroacetic Acid; Doxorubicin; Drug Delivery Systems; Drug Interactions; Drug Stability; Glucose; HEK293 Cells; Humans; Membrane Potential, Mitochondrial; Neoplasms; Temozolomide | 2011 |
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Corpus Callosum; Dacarbazine; Female; Frontal Lobe; Functional Laterality; Humans; Motor Cortex; Neoadjuvant Therapy; Preoperative Period; Temozolomide; Treatment Outcome | 2010 |
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; CpG Islands; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Nucleic Acid Amplification Techniques; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2010 |
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Repair; Drug Delivery Systems; Glioblastoma; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Craniotomy; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Retreatment; Temozolomide; Treatment Outcome | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Embryonic Stem Cells; Enzyme-Linked Immunosorbent Assay; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Glioma; Humans; Immunoenzyme Techniques; Interleukins; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Transgenes; Tumor Stem Cell Assay | 2010 |
Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Drug Implants; Female; Glioblastoma; Humans; Independent Living; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Perioperative Period; Postoperative Period; Retrospective Studies; Risk Assessment; Supratentorial Neoplasms; Survival; Temozolomide; Treatment Outcome | 2011 |
Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.
Topics: Anticonvulsants; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Humans; Levetiracetam; Piracetam; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Damage; DNA Repair; Glioblastoma; Methylnitronitrosoguanidine; Mice; Mice, Transgenic; Poly(ADP-ribose) Polymerase Inhibitors; PTEN Phosphohydrolase; Recombination, Genetic; Temozolomide | 2010 |
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; International Cooperation; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Telomerase; Telomere; Temozolomide; Young Adult | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Analysis; Survivors; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Temozolomide (Temodar).
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Costs; Glioblastoma; Humans; Temozolomide | 2010 |
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Melanins; Melanoma; Mutation; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Protein Transport; Quercetin; RNA Interference; Temozolomide; Time Factors; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Follow-Up Studies; Genetic Markers; Glioma; Humans; Incidence; Loss of Heterozygosity; Neoplasm Staging; Prognosis; Radiotherapy; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Temozolomide; Treatment Outcome | 2010 |
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Male; Oligodendroglioma; Polymerase Chain Reaction; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
Topics: Adenoma; Clinical Trials as Topic; Dacarbazine; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Somatostatin; Temozolomide; Treatment Outcome | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
MGMT gene promoter methylation in pediatric glioblastomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoenzyme Techniques; Infant; Male; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.
Topics: Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Glioma; Gossypol; Humans; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Signal Transduction; Temozolomide; Transfection; Tumor Suppressor Proteins | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Glioma; Humans; Microsatellite Instability; Microsatellite Repeats; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Temozolomide | 2010 |
Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neuroblastoma; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioma; Humans; Mutation; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Boron Compounds; Boron Neutron Capture Therapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease-Free Survival; Fructose; Glioblastoma; Humans; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Randomized Controlled Trials as Topic; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Epilepsy; Exanthema; Female; Humans; Male; Middle Aged; Oxcarbazepine; Radiotherapy; Temozolomide | 2010 |
Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Brain Neoplasms; Cell Survival; Convection; Dacarbazine; Drug Delivery Systems; Glioblastoma; Humans; Longevity; Male; Micelles; Polymers; Rats; Rats, Inbred F344; Rats, Nude; Rats, Sprague-Dawley; Retinoids; Temozolomide; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2010 |
Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monitoring, Intraoperative; Neurosurgical Procedures; Prospective Studies; Retrospective Studies; Surgery, Computer-Assisted; Survival Rate; Temozolomide; Treatment Outcome | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Spectroscopy; Male; Middle Aged; Necrosis; Radiation Injuries; Radiotherapy; Retrospective Studies; Temozolomide; Young Adult | 2010 |
Analysis and stability study of temozolomide using capillary electrophoresis.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Chromatography, Micellar Electrokinetic Capillary; Dacarbazine; Drug Stability; Half-Life; Humans; Hydrogen-Ion Concentration; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Temperature; Water | 2010 |
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Rats; Survival Analysis; Temozolomide; Tumor Burden | 2010 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2011 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Division; Cell Line, Tumor; Dacarbazine; Flow Cytometry; Glioblastoma; Glioma; Humans; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Temozolomide | 2010 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Diagnostic Imaging; Mice; Microscopy, Electron, Transmission; Nanogels; Nanotechnology; Neoplasms; Phototherapy; Polyethylene Glycols; Polyethyleneimine; Temozolomide; Temperature | 2010 |
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Databases, Factual; Female; Glioblastoma; Humans; Italy; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neurosurgical Procedures; Patient Care; Radiotherapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Temozolomide; Tyrosine | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult | 2011 |
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Guanine; Humans; Hydrazines; Mice; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Temozolomide | 2010 |
Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line.
Topics: Apoptosis; Astrocytoma; Blotting, Western; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Fluorescent Antibody Technique, Indirect; Humans; Quercetin; Temozolomide | 2010 |
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Female; Frontal Lobe; Genes, p53; Germ-Line Mutation; Humans; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2010 |
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylation; Female; France; Humans; Male; Middle Aged; Neoplasm Invasiveness; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sequence Analysis, DNA; Temozolomide | 2010 |
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.
Topics: Antineoplastic Agents; Dacarbazine; DNA Methylation; Humans; Immunohistochemistry; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2010 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Infant; Male; Neoplasm Recurrence, Local; Radiosurgery; Radiotherapy, Adjuvant; Reoperation; Republic of Korea; Retrospective Studies; Survival Rate; Temozolomide | 2010 |
Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bordetella bronchiseptica; Bordetella Infections; Brain Neoplasms; Cats; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Immunocompromised Host; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Respiratory Tract Infections; Temozolomide; Zoonoses | 2011 |
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Nervous System Diseases; Pancytopenia; Radiotherapy, Adjuvant; Temozolomide | 2010 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Epigenomics; Female; Glioblastoma; Humans; Male; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nervous System Diseases; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Topics: Adult; Case-Control Studies; Dacarbazine; Dexamethasone; Female; Glioma; Humans; Hypersensitivity; Immune Tolerance; Immunity, Humoral; Immunity, Innate; Immunoglobulin E; Lipopolysaccharide Receptors; Male; Middle Aged; Receptors, IgE; Temozolomide; Young Adult | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Fibroblasts; Guanine; Homozygote; Humans; Melanoma; Methylnitronitrosoguanidine; Mutagens; Mutation; Necrosis; Nijmegen Breakage Syndrome; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Temozolomide; Uveal Neoplasms | 2010 |
Hepatic encephalopathy after treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Hepatic Encephalopathy; Humans; Temozolomide; Treatment Outcome | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Linear Models; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Reoperation; Retreatment; Salvage Therapy; Temozolomide; Time Factors; Young Adult | 2011 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dipeptides; Glioblastoma; Humans; Mice; Neoplasm Recurrence, Local; Receptors, Notch; RNA, Messenger; Signal Transduction; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Topics: Antineoplastic Agents; Base Sequence; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Interleukin-2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2010 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Death; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Frontal Lobe; Glioblastoma; Hemorrhagic Disorders; Humans; Magnetic Resonance Imaging; Middle Aged; Parietal Lobe; Temozolomide | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Predictive Value of Tests; Radiotherapy, Adjuvant; Severity of Illness Index; Statistics, Nonparametric; Temozolomide | 2010 |
Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Silencing; Humans; Neoplasm Recurrence, Local; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2010 |
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Phenothiazines; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Psychotropic Drugs; Pyrimidines; Selective Serotonin Reuptake Inhibitors; Temozolomide | 2010 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Glioma; Humans; Lactic Acid; Male; Neovascularization, Pathologic; Phthalazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyridines; Rats; Rats, Sprague-Dawley; Temozolomide; Treatment Outcome | 2010 |
Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Methylation; Female; Gene Expression Regulation, Enzymologic; Humans; Immunoenzyme Techniques; Lomustine; Male; Medulloblastoma; Multicenter Studies as Topic; Neuroectodermal Tumors, Primitive; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide | 2011 |
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glucose Transport Proteins, Facilitative; HT29 Cells; Humans; Mice; Mice, Nude; Temozolomide; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2011 |
Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Cervical Vertebrae; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Fatal Outcome; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Neurosurgical Procedures; Radiotherapy; Spinal Cord Neoplasms; Temozolomide | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2011 |
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Male; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Temozolomide | 2010 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Humans; In Vitro Techniques; Melanoma; Melphalan; Mice; Mice, Nude; Mice, SCID; Resveratrol; Skin Neoplasms; Stilbenes; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 2010 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioma; Humans; Kaplan-Meier Estimate; Loss of Heterozygosity; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins | 2011 |
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.
Topics: Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Glioma; Hedgehog Proteins; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Neoplastic Stem Cells; Radiation Tolerance; RNA, Small Interfering; Temozolomide; Transcription Factors; Transcription, Genetic; Up-Regulation; Zinc Finger Protein GLI1 | 2011 |
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Prospective Studies; Sequence Analysis; Stereotaxic Techniques; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Probability; Prospective Studies; Retrospective Studies; Temozolomide; Time Factors; Young Adult | 2011 |
Urticarial hypersensitivity reaction caused by temozolomide.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Eruptions; Eosinophils; Fluocinonide; Histamine H1 Antagonists; Humans; Male; Skin; Temozolomide; Urticaria | 2010 |
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Female; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Prospective Studies; Salvage Therapy; Temozolomide | 2010 |
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA, Mitochondrial; Drug Resistance, Neoplasm; Electron Transport Chain Complex Proteins; Glioma; Humans; Mice; Mitochondria; Neoplasm Proteins; Neoplasm Transplantation; Oxygen Consumption; Temozolomide; Transplantation, Heterologous | 2010 |
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Small Cell Lung Carcinoma; Temozolomide; Treatment Outcome | 2010 |
Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Guanine; Humans; Mechanistic Target of Rapamycin Complex 1; Methylnitronitrosoguanidine; Multiprotein Complexes; Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2010 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2010 |
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Female; Glioblastoma; Humans; Hypericum; Magnetic Resonance Imaging; Middle Aged; Optic Nerve; Optic Nerve Diseases; Radiation; Radiation Injuries; Radiotherapy; Temozolomide | 2010 |
A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to αvβ3 integrin for therapy.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Cell Size; Dacarbazine; Female; Flow Cytometry; HeLa Cells; Humans; Inhibitory Concentration 50; Integrin alphaVbeta3; Microscopy, Confocal; Peptides, Cyclic; Temozolomide; Uterine Cervical Neoplasms | 2010 |
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Guanine; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Cluster Analysis; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Inhibitory Concentration 50; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Temozolomide | 2010 |
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.
Topics: Adult; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dacarbazine; Female; Glioma; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Myeloproliferative Disorders; NAD(P)H Dehydrogenase (Quinone); Neoplasms, Neuroepithelial; O(6)-Methylguanine-DNA Methyltransferase; Patients; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Temozolomide | 2011 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 Phase; Gene Silencing; Humans; Melanoma; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; S Phase; Skin Neoplasms; Temozolomide | 2011 |
Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2010 |
High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Monitoring, Intraoperative; Neurosurgical Procedures; Retrospective Studies; Temozolomide | 2011 |
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Topics: ACTH-Secreting Pituitary Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Ophthalmoplegia; Pituitary Neoplasms; Temozolomide | 2011 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Female; Glioma; Humans; Isocitrate Dehydrogenase; Loss of Heterozygosity; Male; Middle Aged; Mutation; Pharmacogenetics; Predictive Value of Tests; Retrospective Studies; Statistics as Topic; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolomide | 2010 |
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Division; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Child; Dacarbazine; DNA Mismatch Repair; DNA Repair; Humans; Indoles; Medulloblastoma; Mice; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Temozolomide; Transplantation, Heterologous | 2010 |
Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Mismatch Repair; Fibroblasts; Guanine; Humans; In Situ Nick-End Labeling; Mice; O(6)-Methylguanine-DNA Methyltransferase; Pancreatic Neoplasms; Temozolomide; Tumor Suppressor Protein p53 | 2010 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retreatment; Retrospective Studies; Survival Analysis; Temozolomide; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
Topics: Adult; Antineoplastic Agents, Alkylating; Cryopreservation; Dacarbazine; Embryo, Mammalian; Female; Glioma; Humans; Infertility, Female; Oocytes; Pregnancy; Pregnancy Outcome; Reproductive Techniques, Assisted; Retrospective Studies; Temozolomide | 2010 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Perfusion; Radiotherapy, Adjuvant; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2011 |
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Neurosurgical Procedures; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stereotaxic Techniques; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiography; Retrospective Studies; Salvage Therapy; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2011 |
Clinical significance of molecular biomarkers in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; PTEN Phosphohydrolase; Regression Analysis; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Young Adult | 2010 |
Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Middle Aged; Nelson Syndrome; Temozolomide; Tumor Suppressor Proteins | 2010 |
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dacarbazine; Glioma; Humans; Meloxicam; Temozolomide; Thiazines; Thiazoles; Time Factors; Tumor Cells, Cultured; X-Rays | 2011 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2010 |
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Treatment Outcome | 2011 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylation; Female; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Neuro-oncology, a decade of temozolomide and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Quality of Life; Temozolomide; Treatment Outcome | 2010 |
In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dacarbazine; Enzyme Activation; Firefly Luciferin; Flow Cytometry; Glioblastoma; Humans; Luminescent Measurements; Luminescent Proteins; Mice; Mice, Nude; Oligopeptides; Staining and Labeling; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; NF-kappa B; Placenta Growth Factor; Pregnancy Proteins; RNA, Antisense; Temozolomide; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dacarbazine; Glioblastoma; Humans; Immunotherapy, Adoptive; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Glioblastoma; Humans; Radiotherapy Dosage; Radiotherapy, Conformal; Temozolomide; Translational Research, Biomedical | 2011 |
Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment.
Topics: Administration, Inhalation; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Compounding; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Humans; Lung Neoplasms; Microscopy, Electron, Scanning; Models, Theoretical; Particle Size; Powders; Solubility; Surface Properties; Temozolomide | 2011 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CCL2; Dacarbazine; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Glioma; Humans; Immunotherapy, Active; Macrophages; Mice; Mice, Inbred C57BL; Mice, SCID; Myeloid Cells; Neoplasm Transplantation; Poly I-C; Statistics, Nonparametric; Temozolomide | 2011 |
FDA accelerated approval benefits glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Dacarbazine; Drug Approval; Glioblastoma; Humans; Temozolomide; United States; United States Food and Drug Administration | 2010 |
Taming glioblastoma by targeting angiogenesis: 3 years later.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblastoma; Humans; Neovascularization, Pathologic; Temozolomide | 2011 |
The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; DNA Methylation; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Triazenes | 2011 |
Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma.
Topics: Aged; Antineoplastic Agents; Cisplatin; Dacarbazine; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Subarachnoid Space; Temozolomide | 2011 |
Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Excipients; Glioma; Humans; Microscopy, Electron, Scanning; Particle Size; Polypropylenes; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Non-stem cell origin for oligodendroglioma.
Topics: Animals; Antigens; Benzamides; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Diphenylamine; Humans; Mice; Mitogen-Activated Protein Kinases; Neural Stem Cells; Oligodendroglia; Oligodendroglioma; Oncogene Proteins v-erbB; Proteoglycans; Temozolomide; Tumor Suppressor Protein p53 | 2010 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Platelet Count; Prospective Studies; Sensitivity and Specificity; Temozolomide; Thrombocytopenia; Young Adult | 2011 |
Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Carriers; Humans; Lactic Acid; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Spectrophotometry, Infrared; Temozolomide; Transferrin | 2011 |
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2011 |
Synthesis and antitumor activity of 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d][1,2,3,5]tetrazine-8-carboxylates and -carboxamides.
Topics: Antineoplastic Agents; Dacarbazine; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 2-Ring; HL-60 Cells; Humans; Neoplasms; Solubility; Temozolomide; Water | 2010 |
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome; Trisomy; Tumor Suppressor Protein p53 | 2011 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chi-Square Distribution; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Radiotherapy, Intensity-Modulated; Regression Analysis; Reproducibility of Results; Retrospective Studies; Temozolomide | 2011 |
Case of atypical teratoid/rhabdoid tumor in an adult, with long survival.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosomal Proteins, Non-Histone; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Neurosurgical Procedures; Parietal Lobe; Rhabdoid Tumor; SMARCB1 Protein; Temozolomide; Teratoma; Time Factors; Transcription Factors; Tumor Suppressor Proteins | 2011 |
Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Oligodendroglioma; Spinal Cord Neoplasms; Temozolomide | 2011 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Glioma; Hemochromatosis Protein; Histocompatibility Antigens Class I; HSP72 Heat-Shock Proteins; Humans; Membrane Proteins; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Radiation Tolerance; Temozolomide; Tumor Suppressor Proteins | 2011 |
Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Neuroendocrine; Dacarbazine; Female; Humans; Liver Neoplasms; Salvage Therapy; Temozolomide | 2012 |
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Topics: Animals; Brain; Brain Neoplasms; Capsules; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Gliosarcoma; Immunohistochemistry; In Situ Nick-End Labeling; Kinetics; Rats; Rats, Inbred F344; Temozolomide | 2011 |
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dacarbazine; Dronabinol; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Mice; Mice, Nude; Random Allocation; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2011 |
Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Biopsy; Colectomy; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Female; Humans; Immunohistochemistry; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Precision Medicine; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Autoantibodies; Autoantigens; Blotting, Western; Cells, Cultured; Dacarbazine; Electrophoresis, Gel, Two-Dimensional; Electroretinography; Exudates and Transudates; Fluorescein Angiography; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Mass Spectrometry; Melanoma; Middle Aged; Neoplasms, Unknown Primary; Paraneoplastic Syndromes; Peroxiredoxin III; Peroxiredoxins; Retinal Pigment Epithelium; Temozolomide; Tomography, Optical Coherence; Vitelliform Macular Dystrophy | 2011 |
Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dura Mater; Female; Humans; Radiotherapy; Sinus Thrombosis, Intracranial; Temozolomide | 2011 |
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Humans; Methylprednisolone Hemisuccinate; Neuroectodermal Tumors, Primitive; Neuroprotective Agents; Radiotherapy; Spinal Neoplasms; Temozolomide; Thiotepa; Thoracic Vertebrae; Vincristine; Young Adult | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Seizures; Temozolomide; Treatment Outcome | 2011 |
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Primers; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Glycolysis; Hexokinase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Neovascularization, Pathologic; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Vascular Endothelial Growth Factor A | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Mice; Neoplasm Transplantation; Piperidines; Prenylation; Pyridines; Radiation, Ionizing; ras Proteins; Signal Transduction; Temozolomide; Time Factors | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Glioblastoma; Humans; Immunohistochemistry; Mice; Mice, Knockout; Temozolomide | 2011 |
MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; Diazonium Compounds; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infant; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2011 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; Drug Synergism; Glutathione Transferase; Humans; Inhibitory Concentration 50; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Temozolomide | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioma; Hospitals; Humans; Incidence; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Thrombocytopenia; Tumor Burden; Tumor Suppressor Proteins; Young Adult | 2012 |
Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasms, Neuroepithelial; Neurosurgical Procedures; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Young Adult | 2010 |
Treatment of glioblastoma multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation of randomised controlled trial evidence into routine clinical practice.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Temozolomide | 2011 |
DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Polymerase beta; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, SCID; Molecular Targeted Therapy; Organophosphates; Pyrimidinones; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Topics: Adenoma; Adolescent; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Promoter Regions, Genetic; Statistics as Topic; Temozolomide; Young Adult | 2011 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Glioblastoma; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Survival Rate; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
MGMT immunoexpression in adamantinomatous craniopharyngiomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Child; Child, Preschool; Craniopharyngioma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; PrPC Proteins; Receptors, Thrombin; RNA, Small Interfering; Temozolomide; Transfection | 2012 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell Line, Tumor; Cells, Cultured; Cytological Techniques; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Glioma; Heat-Shock Proteins; Humans; Immunohistochemistry; Mice; Rats; Temozolomide | 2011 |
O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Retrospective Studies; Temozolomide; Treatment Outcome | 2011 |
[Efficiency of radiation or chemoradiation therapy for diffusely growing brainstem tumors in children].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Dacarbazine; Disease Progression; Humans; Temozolomide; Treatment Outcome; Vincristine | 2008 |
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Female; Flow Cytometry; Glioblastoma; Humans; Lymphocyte Subsets; Male; Middle Aged; Prognosis; Radiotherapy Dosage; T-Lymphocytes, Regulatory; Temozolomide; Young Adult | 2011 |
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice; Neoplasm Metastasis; Pheochromocytoma; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Serine; Temozolomide; Threonine | 2011 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; Humans; Oxidation-Reduction; Temozolomide; Valproic Acid | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents, Alkylating; beta-Galactosidase; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Association Studies; Haplotypes; Humans; Linkage Disequilibrium; Luciferases; Lung Neoplasms; Male; Methylation; Middle Aged; Polymorphism, Single Nucleotide; Precancerous Conditions; Promoter Regions, Genetic; Smoking; Sputum; Temozolomide; Transcription, Genetic; Tumor Suppressor Proteins | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; Glioma; Glycoproteins; Humans; Immunoenzyme Techniques; Peptides; Rad51 Recombinase; Radiation Tolerance; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; X-Rays | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Radiotherapy, Adjuvant; RNA, Messenger; Temozolomide; Treatment Outcome | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; Drug Synergism; Glioma; Guanine; Humans; Hydroxylamines; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasing Hormone; Dacarbazine; Dexamethasone; Glioma; Humans; Male; Mice; Mice, Nude; Rats; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Transformation, Neoplastic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunohistochemistry; Middle Aged; Mutation; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2012 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Humans; Mice; Receptors, CXCR; Temozolomide | 2011 |
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Flow Cytometry; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Radiation, Ionizing; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins | 2011 |
Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
Topics: Acrylamides; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Glycosylases; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Hydroxylamines; Immunoblotting; Methyl Methanesulfonate; NAD; Piperidines; Poly(ADP-ribose) Polymerases; RNA Interference; Temozolomide | 2011 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepines; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Energy Metabolism; Enzyme Activation; Glioblastoma; Humans; Metformin; Olanzapine; Temozolomide | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, Regulator; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Xeroderma Pigmentosum Group D Protein; Young Adult | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Mismatch Repair; DNA Repair Enzymes; DNA-Binding Proteins; Female; Glioblastoma; Humans; Male; Middle Aged; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Recurrence, Local; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2011 |
Complete remission of recurrent and refractory uterine epithelioid leiomyosarcoma using weekly administration of bevacizumab and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Remission Induction; Temozolomide; Uterine Neoplasms | 2011 |
Radiation-induced astrocytoma with rapid malignant transformation: case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Basal Ganglia; Brain Neoplasms; Cell Transformation, Neoplastic; Cerebellar Neoplasms; Dacarbazine; Fatal Outcome; Gait Disorders, Neurologic; Humans; Hydrocephalus; Male; Neoplasms, Germ Cell and Embryonal; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Temozolomide; Time Factors; Young Adult | 2011 |
MGMT promoter methylation and temozolomide response in choroid plexus carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Choroid Plexus; Choroid Plexus Neoplasms; Dacarbazine; DNA Methylation; Humans; Hydrocephalus; Lateral Ventricles; Magnetic Resonance Imaging; Male; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2011 |
Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine; Microscopy, Electron, Transmission; Nanoparticles; Organ Specificity; Polysorbates; Rats; Rats, Wistar; Spectroscopy, Fourier Transform Infrared; Temozolomide | 2011 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Outcome | 2011 |
The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Separation; Dacarbazine; Flow Cytometry; Humans; Inhibitory Concentration 50; Medulloblastoma; Polymerase Chain Reaction; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Temozolomide | 2011 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Evaluation, Preclinical; Enzyme Activation; Glioma; Glutathione S-Transferase pi; Growth Inhibitors; Humans; Nitric Oxide Donors; para-Aminobenzoates; Rats; Rats, Nude; Temozolomide | 2012 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Gene Expression; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2011 |
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Vessels; Computer Simulation; Cytotoxins; Dacarbazine; Glioblastoma; Humans; Models, Biological; Neoplasms; Stilbenes; Temozolomide; Treatment Outcome | 2011 |
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; GATA4 Transcription Factor; Glioblastoma; Humans; Mice; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2011 |
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Interferon-beta; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide | 2011 |
Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Positron-Emission Tomography; Temozolomide | 2010 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2011 |
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Hemangiopericytoma; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Solitary Fibrous Tumors; Temozolomide; Treatment Outcome | 2011 |
Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Cell Line, Tumor; Cord Blood Stem Cell Transplantation; Dacarbazine; Dose-Response Relationship, Drug; Female; Glioblastoma; Guanine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Survival Analysis; Temozolomide; Transplantation Chimera; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Female; Glioma; Humans; Incidence; Logistic Models; Male; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Time Factors | 2011 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Radiosurgery; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Interferon-beta; Male; Melanoma; Mice; Temozolomide; Tumor Suppressor Proteins; Valproic Acid | 2011 |
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinosarcoma; Dacarbazine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Temozolomide | 2011 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast Media; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Fluorine Radioisotopes; Gadolinium DTPA; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Tumor Burden; Tyrosine | 2011 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Recurrence; Supratentorial Neoplasms; Temozolomide; Treatment Outcome | 2011 |
Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Dacarbazine; Disease Progression; ErbB Receptors; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Pons; Temozolomide | 2011 |
Considering temozolomide as a novel potential treatment for esophageal cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CXCL12; Dacarbazine; Esophageal Neoplasms; Female; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Temozolomide and pituitary adenoma.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Humans; Pituitary Neoplasms; Prolactin; Temozolomide | 2011 |
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Formaldehyde; Frontal Lobe; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Dacarbazine; ErbB Receptors; Glioma; Humans; Immunoblotting; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; X-Rays | 2011 |
Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Electroencephalography; Female; Humans; Seizures; Temozolomide | 2011 |
PARP inhibitors stumble in breast cancer.
Topics: Alleles; Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Damage; DNA Repair; Enzyme Inhibitors; Female; Genes, BRCA1; Genes, BRCA2; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2011 |
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
Topics: Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Glioblastoma; Humans; Temozolomide; Tumor Escape; Tumor Suppressor Proteins | 2011 |
Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Drug Synergism; Etoposide; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Microtubules; Pyridines; Temozolomide | 2011 |
FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.
Topics: Animals; BRCA2 Protein; Cell Line; Dacarbazine; DNA Damage; DNA Repair; Down-Regulation; Fanconi Anemia; Gene Silencing; Glioblastoma; Humans; Mice; Models, Biological; Nimustine; Rad51 Recombinase; Recombination, Genetic; RNA, Small Interfering; Temozolomide | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Child; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Glioma; Humans; Infusions, Intravenous; Male; Nausea; Neutropenia; Nimustine; Temozolomide; Teniposide; Thrombocytopenia; Young Adult | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; Male; Melanoma; Mutation; Proto-Oncogene Proteins p21(ras); Skin Neoplasms; Temozolomide | 2011 |
Another cause of pancytopenia in a patient receiving temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Pancytopenia; Risk Factors; Temozolomide; Vitamin B 12 Deficiency; Young Adult | 2011 |
Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies; Survival Rate; Temozolomide | 2011 |
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Isotopes; Cell Line, Tumor; Dacarbazine; Drug Monitoring; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Imaging; Male; Neoplasm Transplantation; Pyruvic Acid; Rats; Temozolomide; Treatment Outcome | 2011 |
Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Care Facilities; Combined Modality Therapy; Dacarbazine; Developing Countries; Female; Follow-Up Studies; Gliosarcoma; Humans; India; Intracranial Hypertension; Kaplan-Meier Estimate; Karnofsky Performance Status; Lost to Follow-Up; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Psychomotor Disorders; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Necrosis; Quercetin; Temozolomide | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prospective Studies; Protons; Temozolomide; Treatment Outcome | 2011 |
Hematologic adverse events associated with temozolomide.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Hematologic Diseases; Humans; Risk; Temozolomide; Time Factors; United States; United States Food and Drug Administration | 2012 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Glioma; Humans; PTEN Phosphohydrolase; Radiation Tolerance; Radiation, Ionizing; Temozolomide; Tumor Cells, Cultured | 2011 |
Effect of temozolomide on cell viability in gonadotroph adenoma cell lines.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Enzyme Activation; Follicle Stimulating Hormone; Gonadotrophs; Luteinizing Hormone; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Temozolomide | 2011 |
Successful desensitization with temozolomide.
Topics: Dacarbazine; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Middle Aged; Temozolomide | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinomatosis; Temozolomide | 2011 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; International Agencies; Lomustine; Male; Middle Aged; Oligodendroglioma; Procarbazine; Radiotherapy; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Vincristine; Young Adult | 2011 |
Rare phenomenon: liver metastases from glioblastoma multiforme.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Liver Neoplasms; Male; Radiotherapy; Temozolomide | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Tomography, X-Ray Computed | 2011 |
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiotherapy; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immunohistochemistry; Injections, Intralesional; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retinal Neoplasms; Risk Assessment; Skin Neoplasms; Temozolomide; Treatment Outcome; Visual Acuity; Visual Fields | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome | 2011 |
Immunotherapy for glioblastoma: the devil is in the details.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Dacarbazine; ErbB Receptors; Glioblastoma; Humans; Mutation; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, Western; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Daunorubicin; Genetic Therapy; Genetic Vectors; Glioma; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Oncolytic Virotherapy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Virus Replication; Y-Box-Binding Protein 1 | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Glioma; Humans; Imidazoles; O(6)-Methylguanine-DNA Methyltransferase; Pilot Projects; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Temozolomide | 2011 |
Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Middle Aged; Salvage Therapy; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2012 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Gamma Rays; Glioma; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Oligopeptides; Radiation-Sensitizing Agents; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Topics: Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Male; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Transforming Growth Factor beta2; Tumor Cells, Cultured | 2011 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Injections, Intravenous; Male; Temozolomide; Young Adult | 2012 |
Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography.
Topics: Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Chromatography, Micellar Electrokinetic Capillary; Dacarbazine; Humans; Temozolomide | 2011 |
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; Humans; Injections, Spinal; Liposomes; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Temozolomide | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Verrucous; Combined Modality Therapy; Dacarbazine; Dermatomycoses; Diagnosis, Differential; Ependymoma; Fatal Outcome; Folliculitis; Frontal Lobe; Hand Dermatoses; Humans; Immunocompromised Host; Keratosis; Male; Neutrophils; Pyrimidines; Skin Neoplasms; Staining and Labeling; Temozolomide; Triazoles; Voriconazole | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte Count; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Hospitalization; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Outcome Assessment, Health Care; Prospective Studies; Temozolomide; Time Factors | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide | 2011 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neuropsychological Tests; Neurosurgical Procedures; Quality of Life; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2012 |
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Infant; Kaplan-Meier Estimate; Male; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Tumor Suppressor Proteins | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Dacarbazine; Drug Administration Schedule; Etoposide; Female; Glioma; Humans; Ifosfamide; Male; Middle Aged; Recurrence; Retrospective Studies; Temozolomide; Treatment Failure | 2011 |
MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Nucleus; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Human Growth Hormone; Humans; Immunohistochemistry; Keratins; Ki-67 Antigen; Male; Middle Aged; Neoplasm Proteins; Pituitary Neoplasms; Protein Transport; Temozolomide; Tumor Suppressor Proteins | 2011 |
Poly(methyl malate) nanoparticles: formation, degradation, and encapsulation of anticancer drugs.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Compounding; Emulsions; Humans; Hydrogen-Ion Concentration; Hydrolysis; Magnetic Resonance Spectroscopy; Malates; Nanoparticles; Particle Size; Polyesters; Polymers; Powders; Sonication; Temozolomide; Time Factors | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Enzyme Induction; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon-beta; Male; Oligonucleotide Array Sequence Analysis; Temozolomide | 2011 |
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Dacarbazine; Dioxoles; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibronectins; Humans; Liposarcoma, Myxoid; Oncogene Proteins, Fusion; Promoter Regions, Genetic; RNA-Binding Protein FUS; Serum Amyloid P-Component; Signal Transduction; Temozolomide; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP; Tumor Suppressor Proteins; Ultraviolet Rays | 2012 |
Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.
Topics: Antineoplastic Agents, Alkylating; Antiviral Agents; Astrocytoma; Brain Neoplasms; Carrier State; Chemoradiotherapy; Dacarbazine; Female; Hepatitis B; Hepatitis B virus; Humans; Immunosuppression Therapy; Middle Aged; Temozolomide; Virus Activation | 2012 |
[Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Dose Fractionation, Radiation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Proton Therapy; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Planning, Computer-Assisted; Temozolomide; Treatment Failure; Tumor Burden | 2011 |
Method for novel anti-cancer drug development using tumor explants of surgical specimens.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Flow Cytometry; Glioblastoma; Humans; Injections, Intralesional; Temozolomide | 2011 |
Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Survival Rate; Temozolomide; Young Adult | 2011 |
New targeted therapies in pituitary carcinoma resistant to temozolomide.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Pituitary Neoplasms; Sirolimus; Temozolomide | 2012 |
Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Young Adult | 2012 |
MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Cytochromes c; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Mitochondria; Neoplastic Stem Cells; Temozolomide; Tumor Cells, Cultured | 2012 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Dacarbazine; Dendritic Cells; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Ipilimumab; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2011 |
Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; SEER Program; Temozolomide; Treatment Outcome; United States | 2012 |
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Retrospective Studies; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tyrphostins; Young Adult | 2011 |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2012 |
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Topics: Alkylating Agents; Animals; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Temozolomide; Time Factors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Posterior Leukoencephalopathy Syndrome; Temozolomide | 2011 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiotherapy, Adjuvant; Craniology; Dacarbazine; Female; Glioblastoma; Humans; Hydrocephalus; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Retrospective Studies; Temozolomide | 2011 |
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Isocitrate Dehydrogenase; Medical Oncology; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2011 |
Anti-VEGF therapy in pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Positron-Emission Tomography; Temozolomide; Vascular Endothelial Growth Factor A | 2012 |
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Endostatins; Gliosarcoma; Immunoglobulin Fc Fragments; Male; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide | 2011 |
Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Mice; Mice, Nude; Noscapine; Temozolomide; Xenograft Model Antitumor Assays | 2011 |
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA, Mitochondrial; Drug Resistance, Neoplasm; Electron Transport Complex IV; Glioma; Glutathione; Glutathione Disulfide; Humans; Reactive Oxygen Species; Temozolomide | 2011 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; Mice; Mice, Inbred C57BL; Skin Neoplasms; T-Lymphocytes; Temozolomide | 2011 |
MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Topics: Aminoacetonitrile; Animals; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imidazoles; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-mdm2; RNA Interference; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell Line, Tumor; Dacarbazine; Docosahexaenoic Acids; Down-Regulation; gamma-Linolenic Acid; Glioblastoma; Glioma; Humans; MicroRNAs; Neoplasm Proteins; Osmolar Concentration; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Up-Regulation | 2011 |
Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide.
Topics: Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; ErbB Receptors; Glioma; Humans; rho-Associated Kinases; RNA, Small Interfering; Temozolomide; Transfection | 2011 |
O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Salvage Therapy; Temozolomide; Treatment Outcome | 2012 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Factors; Temozolomide | 2011 |
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Temozolomide; Wound Healing | 2012 |
Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Knockdown Techniques; Humans; Melanoma; Microphthalmia-Associated Transcription Factor; Neoplasm Proteins; RNA-Binding Proteins; RNA, Small Interfering; Temozolomide; Vinblastine | 2012 |
The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Costs and Cost Analysis; Dacarbazine; Developing Countries; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Health Care; Radiotherapy, Adjuvant; Temozolomide; Young Adult | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Neoplasm Recurrence, Local; Retreatment; Temozolomide | 2011 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Temozolomide | 2012 |
Primary central nervous system lymphoma presenting as Parinaud syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Diagnosis, Differential; Diplopia; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Ocular Motility Disorders; Spinal Puncture; Temozolomide; Tomography, X-Ray Computed | 2011 |
American Society of Clinical Oncology 2011 CNS tumors update.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Risk; Temozolomide; Time Factors; Treatment Outcome | 2011 |
Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review.
Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Humans; Male; Meningeal Neoplasms; Middle Aged; Neoplasms, Neuroepithelial; Survival Rate; Temozolomide; Treatment Outcome | 2011 |
Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Glioblastoma; Hepatitis B; Hepatitis B virus; Humans; Male; Middle Aged; Temozolomide; Virus Activation | 2011 |
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasms; Dacarbazine; Drug Therapy, Combination; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Temozolomide | 2011 |
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Base Sequence; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Protein p53 | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Etoposide; Female; Glioblastoma; Glioma; Humans; Male; Neoplasm Recurrence, Local; Salvage Therapy; Supratentorial Neoplasms; Temozolomide | 2012 |
Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Young Adult | 2011 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gamma Rays; Glioma; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Valproic Acid | 2012 |
Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Female; Humans; Male; Medulloblastoma; Radiation Dosage; Retreatment; Temozolomide; Young Adult | 2011 |
Glioblastoma survival in the United States before and during the temozolomide era.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; United States; Young Adult | 2012 |
Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Methionine; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Salvage Therapy; Survival Rate; Temozolomide; Tissue Distribution; Young Adult | 2012 |
In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.
Topics: Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Glioblastoma; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pyridines; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Temozolomide; Transcription Factors; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cytochromes c; Dacarbazine; Down-Regulation; Gene Knockdown Techniques; Glioma; Humans; MicroRNAs; Mitochondria; Proto-Oncogene Proteins; RNA, Small Interfering; Signal Transduction; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Chromones; Dacarbazine; Down-Regulation; Drug Synergism; Glioma; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Reactive Oxygen Species; Resveratrol; Stilbenes; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Transformation, Neoplastic; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Molecular Sequence Data; Neoplastic Stem Cells; Octamer Transcription Factor-3; Polyethyleneimine; Polyurethanes; Radiation Tolerance; SOXB1 Transcription Factors; Temozolomide | 2012 |
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Dacarbazine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Glioblastoma; Humans; Male; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Temozolomide; Topoisomerase II Inhibitors | 2012 |
Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.
Topics: Abdominal Neoplasms; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Desmoplastic Small Round Cell Tumor; Erythrocyte Transfusion; Feasibility Studies; Humans; Hyperthermia, Induced; Interferons; Irinotecan; Liver Neoplasms; Male; Pelvic Neoplasms; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide; Thrombocytopenia; Vinblastine; Vinorelbine; Young Adult | 2012 |
Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diagnostic Imaging; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Cell death forms and HSP70 expression in U87 cells after ionizing radiation and/or chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chemoradiotherapy; Dacarbazine; Dose-Response Relationship, Radiation; Flow Cytometry; Gamma Rays; Glioblastoma; HSP70 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Temozolomide; Tumor Cells, Cultured | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Time Factors | 2011 |
Evolving drug targets in DNA base excision repair for cancer therapy.
Topics: Antineoplastic Agents, Alkylating; BRCA1 Protein; BRCA2 Protein; Dacarbazine; DNA Repair; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2012 |
Temozolomide: mechanisms of action, repair and resistance.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Suppressor Proteins | 2012 |
Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Hemoglobinometry; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Temozolomide; Tumor Suppressor Proteins | 2011 |
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cysteine; Dacarbazine; DNA Repair; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells.
Topics: Aged; Antigens, Surface; CD8-Positive T-Lymphocytes; Dacarbazine; Dendritic Cells; Female; Glioblastoma; Humans; Interleukin-2; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Monocytes; Phagocytosis; Phenotype; Temozolomide | 2012 |
Temozolomide induced liver injury.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Temozolomide | 2011 |
Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Glycosylases; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islands; Dacarbazine; DNA Methylation; Down-Regulation; Female; Gene Knockdown Techniques; Gene Silencing; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Oligodendroglia; Peroxiredoxins; Promoter Regions, Genetic; Radiation Tolerance; Temozolomide; Young Adult | 2012 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Temozolomide; Time Factors | 2012 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Temozolomide | 2011 |
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Genetic Vectors; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Methylation; Mice; Mice, Nude; Neoplastic Stem Cells; Oncolytic Virotherapy; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Simplexvirus; Temozolomide; Tumor Suppressor Proteins; Vero Cells; Virus Replication | 2012 |
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms; Bone Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Doublecortin Domain Proteins; Haplotypes; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Humans; Immunotherapy; Interleukin-2; Killer Cells, Natural; Male; Microtubule-Associated Proteins; Neoplasm, Residual; Neuroblastoma; Neuropeptides; Remission Induction; Temozolomide; Topotecan; Transcription Factors; Transplantation, Homologous; Tyrosine 3-Monooxygenase | 2012 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Dacarbazine; Electric Impedance; Female; Gene Knockout Techniques; Glioblastoma; Glioma; Humans; Immunohistochemistry; Male; Microtubule-Associated Proteins; Middle Aged; Neurofilament Proteins; Phosphopyruvate Hydratase; Real-Time Polymerase Chain Reaction; Temozolomide; Tubulin; Young Adult | 2011 |
Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Dacarbazine; Dexamethasone; Glioblastoma; Glucocorticoids; Humans; Male; Striae Distensae; Supratentorial Neoplasms; Temozolomide; Vascular Endothelial Growth Factor A | 2012 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozygosity; MAP Kinase Kinase Kinase 5; MAP Kinase Kinase Kinases; Melanoma; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured | 2011 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2012 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiotherapy; Retrospective Studies; Temozolomide; Time Factors | 2011 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Temozolomide | 2012 |
Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.
Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers; Carrier Proteins; Cell Death; Dacarbazine; Glial Fibrillary Acidic Protein; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Microtubule-Associated Proteins; Neuroglia; Neurons; Nimustine; Piperazines; Propidium; Pyrimidines; Rats; Temozolomide; Vincristine | 2012 |
Targeting protein-trafficking pathways alters melanoma treatment sensitivity.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Melanoma; Melanosomes; Microscopy, Electron; Microscopy, Fluorescence; Molecular Sequence Data; Mutation; Protein Transport; Receptor, Melanocortin, Type 1; RNA Interference; Temozolomide; Up-Regulation; Vesicular Transport Proteins | 2012 |
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Profiling; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Prospective Studies; Survival Analysis; Temozolomide; Tumor Burden; Tumor Suppressor Proteins | 2012 |
Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Temozolomide | 2012 |
Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Germany; Glioblastoma; Humans; Male; Prevalence; Prognosis; Radiotherapy, Conformal; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.
Topics: Animals; Antineoplastic Agents; Brain Stem Neoplasms; Caspase 3; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Luminescent Agents; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Pons; Pyridines; Retinoblastoma Protein; Temozolomide; Time Factors; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2012 |
Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Ceramides; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glucosyltransferases; Humans; Paclitaxel; Temozolomide | 2012 |
[Brain metastasis in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Karnofsky Performance Status; Lomustine; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine | 2011 |
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Patient Care; Temozolomide; United States; Young Adult | 2012 |
Expression of EGFRvIII in glioblastoma: prognostic significance revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; ErbB Receptors; Female; Gene Expression; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Recurrence; Spheroids, Cellular; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Young Adult | 2011 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Longitudinal Studies; Male; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2012 |
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Dacarbazine; DNA Methylation; ErbB Receptors; Female; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Responsive fluorescent Bi(2)O(3)@PVA hybrid nanogels for temperature-sensing, dual-modal imaging, and drug delivery.
Topics: Animals; Bismuth; Cell Line, Tumor; Cell Survival; Dacarbazine; Diagnostic Imaging; Drug Delivery Systems; Endocytosis; Mice; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Nanogels; Oxides; Phase Transition; Photoelectron Spectroscopy; Polyethylene Glycols; Polyethyleneimine; Polyvinyl Alcohol; Quantum Dots; Spectrophotometry, Infrared; Temozolomide; Temperature; X-Ray Diffraction | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
Prognostic significance of MRP5 immunohistochemical expression in glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Multivariate Analysis; Prognosis; Retrospective Studies; Sex Factors; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Postoperative Complications; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Carriers; Durapatite; Glioma; Humans; Integrin alphaVbeta3; Lactic Acid; Microspheres; Nanostructures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Temozolomide | 2012 |
CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Chemokine CXCL12; Dacarbazine; Glioma; Rats; Receptors, CXCR; Receptors, CXCR4; Temozolomide; Transcription, Genetic | 2012 |
Invasive Mycoleptodiscus fungal cellulitis and myositis.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Ascomycota; Cellulitis; Cluster Analysis; Dacarbazine; DNA, Fungal; DNA, Ribosomal; DNA, Ribosomal Spacer; Glioblastoma; Humans; Leg; Male; Molecular Sequence Data; Mycoses; Myositis; Phylogeny; Sequence Analysis, DNA; Temozolomide | 2012 |
[Protracted low-dose temozolomide combined with concomitant whole brain radiotherapy for brain metastases from non-small cell lung cancer].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Temozolomide; Vomiting | 2011 |
[Analysis of the relevant factors of mechanism for telozolomide chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzimidazoles; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Humans; Membrane Proteins; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Purines; Pyrimidines; Temozolomide; Tumor Suppressor Protein p53 | 2011 |
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Membrane Proteins; Microtubule-Associated Proteins; Radiation-Sensitizing Agents; RNA Interference; RNA, Small Interfering; Sirolimus; Temozolomide | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Glioblastoma; Humans; Induction Chemotherapy; Membrane Proteins; Mice; Mice, Nude; Neoplastic Stem Cells; Propylene Glycols; Proto-Oncogene Proteins; Receptors, Lysosphingolipid; Sphingosine; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide | 2012 |
Cotard's syndrome with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Corpus Callosum; Dacarbazine; Delusions; Depressive Disorder, Major; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Psychotic Disorders; Suicide, Attempted; Syndrome; Temozolomide | 2012 |
Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.
Topics: Astrocytes; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dacarbazine; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Glioblastoma; Histones; Humans; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Repressor Proteins; Temozolomide; Thioxanthenes; Tripartite Motif-Containing Protein 28; Tumor Suppressor Proteins | 2012 |
Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Prognosis; Reoperation; Survival; Temozolomide; Young Adult | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2012 |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Topics: Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Survival Analysis; Temozolomide; Temperature; Tumor Suppressor Proteins | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Feasibility Studies; Female; Glioblastoma; Infusions, Intraventricular; Microinjections; Rats; Rats, Inbred F344; Survival Rate; Temozolomide; Transplantation, Homologous; Treatment Outcome | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Glutamic Acid; Humans; Male; Mice; Mice, Nude; Oxaloacetic Acid; Rats; Rats, Sprague-Dawley; Temozolomide; Tumor Burden | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Coculture Techniques; Combined Modality Therapy; Cytotoxicity, Immunologic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; NK Cell Lectin-Like Receptor Subfamily K; Recombinant Proteins; Temozolomide; Tetrahydrofolate Dehydrogenase; Trimetrexate; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |
Cerebellar anaplastic pilocytic astrocytoma in a patient of neurofibromatosis type-1: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Cerebellar Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Gait Disorders, Neurologic; Humans; Magnetic Resonance Imaging; Middle Aged; Neurofibromatosis 1; Neurosurgical Procedures; Recovery of Function; Temozolomide | 2012 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide | 2012 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Epilepsy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Survival Rate; Temozolomide; Thrombocytopenia | 2012 |
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Promoter Regions, Genetic; Radiotherapy, Conformal; Reoperation; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2012 |
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Utilization; Female; France; Glioma; Guideline Adherence; Humans; Male; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Temozolomide | 2012 |
Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Glioblastoma; Humans; NF-kappa B; Resveratrol; Stilbenes; Temozolomide; Tumor Suppressor Proteins | 2012 |
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
Topics: Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Likelihood Functions; Molecular Probe Techniques; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Prospective Studies; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins | 2012 |
Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Dacarbazine; Diffusion Chambers, Culture; Glioblastoma; Humans; Ifosfamide; Liver; Microscopy, Electron, Scanning; Perfusion; Polyesters; Porosity; Precision Medicine; Temozolomide; Tissue Engineering; Tissue Scaffolds | 2012 |
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dacarbazine; Deoxycytidine; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Male; Paraganglioma; Retroperitoneal Neoplasms; Succinate Dehydrogenase; Temozolomide; Treatment Outcome | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Ions; Male; Meningioma; Middle Aged; Proton Therapy; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Temozolomide; Young Adult | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Cetuximab; Dacarbazine; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Male; Mannitol; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Treatment Outcome | 2012 |
Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Temozolomide | 2012 |
Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzothiazoles; Brain; Cell Extracts; Dacarbazine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Synergism; HeLa Cells; Humans; Injections, Intraperitoneal; Methyl Methanesulfonate; Mice; Small Molecule Libraries; Structure-Activity Relationship; Temozolomide; Thiophenes; Tissue Distribution | 2012 |
Expression of O⁶-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neurofilament Proteins; Pineal Gland; Pinealoma; Synaptophysin; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2012 |
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid.
Topics: Antineoplastic Agents, Alkylating; Cryptogenic Organizing Pneumonia; Dacarbazine; Dyspnea; Female; Glioblastoma; Glucocorticoids; Humans; Methylprednisolone; Middle Aged; Temozolomide; Tomography, X-Ray Computed | 2012 |
In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma.
Topics: Alpha Particles; Cell Division; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Glioblastoma; Humans; In Vitro Techniques; Linear Energy Transfer; Neoplasm Proteins; Particle Accelerators; Photons; Promoter Regions, Genetic; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; NF-kappa B; Nuclear Pore Complex Proteins; Oligopeptides; Prognosis; RNA-Binding Proteins; Temozolomide | 2013 |
SSBP2 variants are associated with survival in glioblastoma patients.
Topics: Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Genome-Wide Association Study; Glioblastoma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Temozolomide | 2012 |
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Temozolomide; Young Adult | 2012 |
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; Signal Transduction; Survival Analysis; Temozolomide; Young Adult | 2012 |
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Dacarbazine; Glioma; HSP27 Heat-Shock Proteins; Humans; Osteonectin; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Temozolomide | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Contrast Media; Dacarbazine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Glioma; Kinetics; Lactic Acid; Light; Magnetic Resonance Imaging; Magnetite Nanoparticles; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Nanomedicine; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polysorbates; Rats; Scattering, Radiation; Solubility; Spectrophotometry, Atomic; Technology, Pharmaceutical; Temozolomide | 2012 |
Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Dacarbazine; Doxorubicin; Drug Administration Schedule; Maximum Tolerated Dose; Neoplasms; Neutropenia; Pilot Projects; Retrospective Studies; Stomatitis; Temozolomide | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Brain Neoplasms; Calpain; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Selenium; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Mice; Mice, Inbred BALB C; Microvessels; Piperidines; Quinazolines; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; CD57 Antigens; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Chemokine CCL4; Cohort Studies; Combined Modality Therapy; Cytomegalovirus; Dacarbazine; Epitopes; Female; Flow Cytometry; Glioblastoma; HLA Antigens; Humans; Immunotherapy, Adoptive; Interferon-gamma; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; Peptides; Temozolomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Topics: Antineoplastic Agents, Alkylating; China; Cohort Studies; Cost-Benefit Analysis; Dacarbazine; Glioblastoma; Health Resources; Humans; Markov Chains; Middle Aged; Models, Economic; Prognosis; Quality-Adjusted Life Years; Survival Analysis; Temozolomide; Uncertainty | 2012 |
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nervous System; Temozolomide | 2012 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dopamine Agonists; Hormone Replacement Therapy; Humans; Hyperprolactinemia; Hypophysectomy; Hypopituitarism; Male; Multiple Endocrine Neoplasia Type 1; Mutation, Missense; Neoplasm Recurrence, Local; Ophthalmoplegia; Pancreatic Neoplasms; Parathyroid Neoplasms; Pituitary Apoplexy; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins; Radiotherapy, Adjuvant; Remission Induction; Spinal Neoplasms; Temozolomide | 2012 |
Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Labeling; Fatal Outcome; Female; Glioma; Haemophilus influenzae; Humans; Immunocompromised Host; Japan; Male; Middle Aged; Pneumocystis carinii; Pneumonia; Pneumothorax; Pseudomonas aeruginosa; Radiography; Staphylococcus aureus; Temozolomide | 2012 |
MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; MicroRNAs; Temozolomide | 2012 |
Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Calcium-Binding Proteins; Cell Line, Tumor; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Nude; Reactive Oxygen Species; Resveratrol; Signal Transduction; Stilbenes; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Proteins | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherapy; Dacarbazine; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Drug Screening Assays, Antitumor; Gemcitabine; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Neoplasms, Experimental; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome; Tumor Burden | 2012 |
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Etoposide; Europe; Feasibility Studies; Female; Fenofibrate; Humans; Infant; Isotretinoin; Male; Neoplasms; Pyrazoles; Registries; Sulfonamides; Temozolomide; Vitamin D; Young Adult | 2012 |
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oligodendroglioma; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Base Sequence; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Primers; DNA-Binding Proteins; Glioblastoma; Humans; Interferon-beta; Nuclear Proteins; Phosphoproteins; Promyelocytic Leukemia Protein; Real-Time Polymerase Chain Reaction; Temozolomide; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation; YAP-Signaling Proteins | 2012 |
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; Neoplastic Stem Cells; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
Drug-induced cholestatic hepatitis: how late can it occur even after the cessation of the culpable drug?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Cholestasis; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Temozolomide | 2012 |
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatin; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; DNA Replication; Drug Resistance, Neoplasm; Flow Cytometry; Gene Silencing; Genes, Reporter; Glioblastoma; Humans; p21-Activated Kinases; Polymerase Chain Reaction; RNA Interference; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoblotting; Luciferases; MicroRNAs; Oligonucleotide Array Sequence Analysis; Prognosis; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Treatment of elderly patients with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Temozolomide | 2012 |
Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Comorbidity; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Risk Factors; Temozolomide; Time Factors; Treatment Failure | 2012 |
2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Male; MAP Kinase Signaling System; Membrane Lipids; Mice; Mice, Nude; Microscopy, Confocal; Oleic Acids; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; ras Proteins; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2012 |
Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Equipment Design; Female; Gliosarcoma; Rats; Rats, Inbred F344; Temozolomide | 2012 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Integrin alpha5beta1; Mice; Piperazines; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; DNA Methylation; Epigenomics; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2012 |
Crystal engineering of stable temozolomide cocrystals.
Topics: Antineoplastic Agents, Alkylating; Crystallization; Crystallography, X-Ray; Dacarbazine; Drug Stability; Half-Life; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrolysis; Malates; Molecular Conformation; Oxalic Acid; Salicylic Acid; Succinic Acid; Tartrates; Temozolomide; Temperature | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Topics: Animals; Carmustine; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dogs; Genetic Therapy; Glioblastoma; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lentivirus; Temozolomide; Transplantation Conditioning; Tumor Suppressor Proteins | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Interactions; Extracellular Fluid; Glioma; Humans; Male; Metabolic Clearance Rate; Microdialysis; Rats; Rats, Nude; Temozolomide; Time Factors | 2012 |
Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Platelet Count; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; France; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Waiting Lists | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus Cinguli; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Regression Analysis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Follow-Up Studies; Gene Deletion; Humans; International Agencies; Male; Middle Aged; Oligodendroglioma; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioblastoma; Glioma; Hyperbaric Oxygenation; Rats; Rats, Wistar; Temozolomide | 2012 |
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Topics: Acetylation; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Methylation; Mice; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Vorinostat; Xenograft Model Antitumor Assays | 2012 |
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Arachnoid; Bevacizumab; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide; Young Adult | 2012 |
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Female; Geriatrics; Glioblastoma; Humans; Longitudinal Studies; Male; Retrospective Studies; Sex Factors; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Dacarbazine; Disease Progression; Fatal Outcome; Female; Gadolinium; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Temozolomide; Tumor Suppressor Proteins; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Topics: Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Dacarbazine; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Flow Cytometry; Glioma; Humans; Immunoblotting; rho GTP-Binding Proteins; Signal Transduction; Temozolomide | 2012 |
The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Delayed-Action Preparations; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Temozolomide; Treatment Outcome | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2012 |
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Subarachnoid Hemorrhage, Traumatic; Temozolomide; Tomography, X-Ray Computed; Ultrasonography, Doppler, Transcranial | 2012 |
Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dacarbazine; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Olea; Plant Extracts; Plant Leaves; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2012 |
Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Irinotecan; Male; Rhabdomyosarcoma, Alveolar; Temozolomide; Vincristine | 2013 |
Knockdown of CDK6 enhances glioma sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 6; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Membrane Proteins; Mice; Oligonucleotide Array Sequence Analysis; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; RNA Interference; Temozolomide; Transcription, Genetic | 2012 |
Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Dacarbazine; Drug Stability; Humans; Hydroxylamines; Linear Models; Liquid-Liquid Extraction; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Temozolomide | 2012 |
Quantitative proteomic analysis and functional studies reveal that nucleophosmin is involved in cell death in glioblastoma cell line transfected with siRNA.
Topics: Adult; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; Prognosis; Proteome; Proteomics; RNA Interference; RNA, Small Interfering; Temozolomide; Transfection | 2012 |
Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glioma; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Mitochondria; Reactive Oxygen Species; Temozolomide | 2012 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Mutation; Neoplasms, Multiple Primary; Oligodendroglioma; Radiotherapy; Retrospective Studies; Second-Look Surgery; Temozolomide | 2013 |
MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Glioblastoma; Humans; MicroRNAs; Oligonucleotides, Antisense; Temozolomide; Transfection | 2012 |
Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells.
Topics: Apoptosis; Bumetanide; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Size; Chlorides; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Minor Histocompatibility Antigens; Neoplastic Stem Cells; Potassium; Protein Serine-Threonine Kinases; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 2; Temozolomide; Time-Lapse Imaging; WNK Lysine-Deficient Protein Kinase 1 | 2012 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Synergism; Enzyme Inhibitors; Glutathione; Humans; Melanins; Melanoma; Molybdenum; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Temozolomide | 2009 |
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Hyperoxia; Mitogen-Activated Protein Kinase Kinases; Temozolomide | 2012 |
Action of db-cAMP on the bystander effect and chemosensitivity through connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Bucladesine; Bystander Effect; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Connexin 43; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Gap Junctions; Gossypol; Humans; Medulloblastoma; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Rats; Signal Transduction; Simplexvirus; Temozolomide; Teniposide; Thymidine Kinase | 2012 |
Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caspases; Cell Cycle Proteins; Cell Differentiation; Checkpoint Kinase 1; Checkpoint Kinase 2; Dacarbazine; Dendritic Cells; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Enzyme Activation; fas Receptor; Histones; Humans; Macrophages; Mitochondria; Monocytes; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Bevacizumab; Biopsy; Cerebral Angiography; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Hydrocephalus; Hypothalamic Neoplasms; Intracranial Arteriovenous Malformations; Middle Aged; Paresis; Radiosurgery; Subarachnoid Hemorrhage; Temozolomide; Tomography, X-Ray Computed | 2013 |
MGMT expression and pituitary tumours: relationship to tumour biology.
Topics: Adult; Aged; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2013 |
N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Survival; Comet Assay; Dacarbazine; DNA Breaks; DNA Glycosylases; DNA Repair; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; MCF-7 Cells; Methyl Methanesulfonate; Nuclear Proteins; Point Mutation; Protein Binding; Protein Interaction Mapping; Protein Structure, Tertiary; Substrate Specificity; Temozolomide; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Glioma; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Necrosis; Paclitaxel; Polyglutamic Acid; Temozolomide | 2012 |
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Neurosurgical Procedures; Physician-Patient Relations; Practice Patterns, Physicians'; Radiotherapy; Temozolomide | 2012 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dacarbazine; Fluorescent Antibody Technique; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; Humans; Immunoenzyme Techniques; Mice; Mice, SCID; Neoplastic Stem Cells; Peptides; Receptors, CXCR4; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dacarbazine; Delayed-Action Preparations; Female; Glioma; Humans; Mice; Mice, Nude; Microspheres; Random Allocation; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Age-dependent effects of hippocampal neurogenesis suppression on spatial learning.
Topics: Age Factors; Aging; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Dentate Gyrus; Female; Hippocampus; Male; Maze Learning; Memory Disorders; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Neurogenesis; Space Perception; Temozolomide | 2013 |
Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.
Topics: Alkylating Agents; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydroxylamines; Neuroglia; Temozolomide | 2013 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Inhibitory Concentration 50; Male; Microscopy, Confocal; Middle Aged; Neoplastic Stem Cells; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins | 2012 |
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Dendrimers; Drug Synergism; Genetic Therapy; Glioma; Humans; MicroRNAs; Nanoparticles; PTEN Phosphohydrolase; STAT3 Transcription Factor; Temozolomide | 2012 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Ganciclovir; Glioblastoma; Green Fluorescent Proteins; Male; Mice; Mice, Transgenic; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Transgenes | 2012 |
Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Conformal; Survival Rate; Temozolomide | 2012 |
Novel nonclassical antifolate, 2-[N-(2´-Hydroxyethyl)amino]methyl-3H-quinazolin-4-one, with a potent antineoplastic activity toward leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cisplatin; Dacarbazine; Female; Folic Acid Antagonists; Humans; Leukemia; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Mitogen-Activated Protein Kinases; Quinazolines; Temozolomide; U937 Cells | 2012 |
A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Norway; Prognosis; Prospective Studies; Radiotherapy Dosage; Registries; Survival Rate; Temozolomide | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Fibronectins; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Peptide Fragments; Temozolomide; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; Female; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Temozolomide | 2012 |
Glioblastoma therapy in the elderly: one age does not fit all.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Off-patent oral oncology drugs for kids (O3K FP7-project): from bedside to PUMA.
Topics: Administration, Oral; Antineoplastic Agents; Child; Cyclophosphamide; Dacarbazine; Drugs, Generic; European Union; Humans; Legislation, Drug; Pharmaceutical Preparations; Temozolomide | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosis; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Isoenzymes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Response Elements; Retinal Dehydrogenase; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Tretinoin | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide | 2012 |
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Middle Aged; Quality of Life; Temozolomide; Vinblastine; Vinorelbine | 2012 |
Chemotherapy-associated steatohepatitis with temozolomide and dexamethasone.
Topics: Antineoplastic Agents; Dacarbazine; Dexamethasone; Diabetes Mellitus, Type 2; Fatty Liver; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Time Factors | 2012 |
Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Lymphoma, Non-Hodgkin; Male; Temozolomide | 2012 |
Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Shape; Cell Survival; Chromatin Assembly and Disassembly; Dacarbazine; DNA Fragmentation; Glioblastoma; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Molecular Targeted Therapy; Mutant Proteins; Oxidoreductases; Ploidies; Recombinant Proteins; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; WW Domain-Containing Oxidoreductase | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Glioma; Humans; Hyperbaric Oxygenation; Temozolomide; Vascular Endothelial Growth Factor A | 2012 |
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Nuclear Proteins; Polycomb Repressive Complex 1; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; Repressor Proteins; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplastic Stem Cells; Skin Neoplasms; Temozolomide | 2012 |
Prognosis of patients with multifocal glioblastoma: a case-control study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Prognosis; Radiotherapy; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2012 |
Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Serum-Free; Dacarbazine; Glioblastoma; Humans; Intermediate Filament Proteins; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; RNA-Binding Proteins; SOXB1 Transcription Factors; Spheroids, Cellular; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2012 |
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dacarbazine; Eukaryotic Translation Initiation Factor 5A; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Lysine; Male; Mixed Function Oxygenases; Molecular Targeted Therapy; Neoplasm Grading; Oxidoreductases Acting on CH-NH Group Donors; Peptide Initiation Factors; RNA-Binding Proteins; Temozolomide | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glioma; Humans; Mice; Monoterpenes; Nelfinavir; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Bridged-Ring Compounds; Calorimetry; Cell Survival; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Imidazoles; Temozolomide; Thermodynamics; Tumor Cells, Cultured | 2012 |
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dacarbazine; Female; Glioma; Humans; Inflammation; Male; Middle Aged; Neovascularization, Pathologic; Temozolomide | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Curcuma; Curcumin; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Glioblastoma; Humans; Inhibitory Concentration 50; Medulloblastoma; Phytotherapy; Plant Extracts; Plants, Medicinal; Rhizome; Temozolomide | 2012 |
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Colonic Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Sarcosine; Temozolomide | 2013 |
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Disease Progression; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Temozolomide | 2012 |
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Genotype; Glioblastoma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Transfection; Tumor Suppressor Proteins; Young Adult | 2013 |
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Male; Medulloblastoma; MutL Protein Homolog 1; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Suppressor Proteins | 2012 |
FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
Topics: Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; Prognosis; Promoter Regions, Genetic; Protein Binding; Rad51 Recombinase; Recurrence; Temozolomide; Transcription, Genetic; Transcriptional Activation | 2012 |
Temozolomide for relapsed primary CNS lymphoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Recurrence; Salvage Therapy; Temozolomide; Treatment Outcome | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Decitabine; Down-Regulation; Epigenesis, Genetic; Gene Silencing; Glioma; Humans; Methylation; MicroRNAs; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Quality of Life; Survival Rate; Temozolomide | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Fasting; Glioblastoma; Glioma; Insulin-Like Growth Factor I; Luminescence; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Rats; Temozolomide | 2012 |
Decision making and management of gliomas: practical considerations.
Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Meta-Analysis as Topic; Oligodendroglioma; Temozolomide; Tumor Suppressor Proteins | 2012 |
Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Central Nervous System Neoplasms; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; MicroRNAs; Middle Aged; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Reproducibility of Results; Temozolomide; Transcriptome; Tumor Suppressor Proteins | 2013 |
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Humans; Recurrence; Temozolomide | 2012 |
A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Temozolomide | 2012 |
Radiation-induced spinal cord anaplastic astrocytoma subsequent to radiotherapy for testicular seminoma.
Topics: Antineoplastic Agents; Astrocytoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Fatal Outcome; Humans; Hydrocephalus; Laminectomy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Nimustine; Seminoma; Spinal Cord Compression; Spinal Cord Neoplasms; Syringomyelia; Temozolomide; Testicular Neoplasms; Thoracic Vertebrae; Time Factors | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Melanoma; Middle Aged; Temozolomide; Treatment Outcome | 2012 |
Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Celecoxib; Cyclooxygenase 2 Inhibitors; Dacarbazine; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Male; Pyrazoles; Sulfonamides; Temozolomide; Young Adult | 2012 |
F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carmustine; Cell Survival; Cloning, Molecular; Cytoprotection; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Genetic Vectors; Hematopoietic Stem Cells; HL-60 Cells; Humans; K562 Cells; Lentivirus; Nimustine; Paclitaxel; Peptides; Real-Time Polymerase Chain Reaction; Temozolomide; Transgenes; Tumor Suppressor Proteins | 2012 |
Alkylation sensitivity screens reveal a conserved cross-species functionome.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Bacterial Proteins; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Glycosylases; DNA Repair; Drug Resistance, Neoplasm; Escherichia coli; Glioblastoma; Humans; N-Glycosyl Hydrolases; Reactive Oxygen Species; Saccharomyces cerevisiae; Temozolomide; Ubiquitin-Protein Ligases; Uracil-DNA Glycosidase | 2012 |
Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Association Learning; Conditioning, Eyelid; Dacarbazine; Hippocampus; Male; Memory, Long-Term; Memory, Short-Term; Neurogenesis; Rats; Rats, Sprague-Dawley; Temozolomide; Theta Rhythm | 2012 |
Prime time for molecular marker diagnostics in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Prognosis; Promoter Regions, Genetic; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Prognosis; Promoter Regions, Genetic; Stem Cell Transplantation; Temozolomide; Transplantation, Autologous; Tumor Suppressor Proteins | 2013 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Resistance, Neoplasm; Glioblastoma; Humans; Immunoenzyme Techniques; Temozolomide | 2012 |
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genome, Human; Humans; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide; Tumor Suppressor Proteins | 2012 |
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; Cell Division; Cell Proliferation; Dacarbazine; DNA Damage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; G2 Phase; Glioblastoma; Humans; Immunoenzyme Techniques; Mice; Morpholines; Neurons; Protein Serine-Threonine Kinases; Pyrones; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2012 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Temozolomide; Treatment Failure | 2013 |
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mebendazole; Melanoma; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Transplantation, Heterologous; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2013 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Disease Management; Glioma; Humans; Male; Middle Aged; Steroids; Temozolomide; Treatment Outcome | 2012 |
Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gonadotrophs; Humans; Ki-67 Antigen; Luteinizing Hormone; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2012 |
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Morphogenetic Protein 2; Cell Differentiation; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Signal Transduction; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Glioblastoma; Humans; Kaplan-Meier Estimate; Mibefradil; Mice; Neoplasm Transplantation; Skin Neoplasms; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amino Acid Transport System y+; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Excitatory Amino Acid Transporter 2; Female; Glioblastoma; Glutamate Plasma Membrane Transport Proteins; Humans; Immunohistochemistry; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neuropsychological Tests; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2013 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Glioma; Humans; Hypersensitivity, Delayed; Immune Tolerance; Skin Tests; Temozolomide | 2012 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephalitis, Herpes Simplex; Glioma; Humans; Magnetic Resonance Imaging; Male; Recurrence; Temozolomide; Virus Activation | 2013 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; Disease Progression; Gliosarcoma; Humans; Isocitrate Dehydrogenase; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Oligodendroglioma; Temozolomide | 2012 |
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Regulation; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Indoles; Melanocytes; Melanoma; Sulfonamides; Temozolomide; Vemurafenib | 2012 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Dacarbazine; Electromagnetic Radiation; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Mutant Proteins; Mutation; Radiation Tolerance; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2013 |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Prognosis; PTEN Phosphohydrolase; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Brain Neoplasms; Dacarbazine; Fluorodeoxyglucose F18; Glioblastoma; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Nude; Survival Rate; Temozolomide; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Humans; Neovascularization, Pathologic; Psoriasis; Stomatitis; Temozolomide | 2012 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Nitric Oxide; O(6)-Methylguanine-DNA Methyltransferase; Scorpion Venoms; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarbazine; Down-Regulation; Flow Cytometry; Fluorescent Antibody Technique; Glioma; Humans; Microscopy, Electron, Transmission; NF-E2-Related Factor 2; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Disease-Free Survival; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiosurgery; Retrospective Studies; Temozolomide | 2013 |
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Retinal Dehydrogenase; Temozolomide; Transfection; Tumor Suppressor Proteins | 2012 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; Glioblastoma; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Hydrocarbons, Brominated; Hypoxia; Mice; Mice, SCID; Mitochondria; Neoplastic Stem Cells; Propionates; Temozolomide | 2013 |
Neuro-oncology: treatment decisions in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Middle Aged; Temozolomide | 2012 |
In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Biosensing Techniques; Dacarbazine; Diazonium Compounds; DNA; Electrochemical Techniques; Humans; Neoplasms; Oxidation-Reduction; Temozolomide | 2013 |
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Kaplan-Meier Estimate; Male; Melanoma; Temozolomide; Vincristine | 2013 |
An efficient and practical radiosynthesis of [11C]temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Molecular Structure; Radiopharmaceuticals; Temozolomide; Tissue Distribution | 2012 |
Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Cerebellar Neoplasms; Dacarbazine; Ependymoma; Female; Humans; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Temozolomide | 2013 |
Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cnidarian Venoms; Dacarbazine; Drug Synergism; Etoposide; Glioblastoma; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Temozolomide | 2012 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Transformation, Neoplastic; Child, Preschool; Dacarbazine; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Ganglioglioma; Humans; Magnetic Resonance Imaging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Temozolomide | 2013 |
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Neoplastic Stem Cells; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Receptors, Metabotropic Glutamate; RNA, Messenger; Signal Transduction; Survival Rate; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xanthenes | 2013 |
Immunohistochemical molecular gene expression profile of metastatic brain tumor as a potent personalized medicine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Precision Medicine; Receptor, ErbB-2; Temozolomide; Tumor Suppressor Proteins | 2013 |
The effect of temozolomide on the prevention of epidural fibrosis developing after lumbar laminectomy in rats.
Topics: Animals; Dacarbazine; Dura Mater; Epidural Space; Fibroblasts; Fibrosis; Laminectomy; Lumbar Vertebrae; Male; Mitomycin; Rats; Rats, Wistar; Temozolomide | 2012 |
Suppression of adult neurogenesis impairs population coding of similar contexts in hippocampal CA3 region.
Topics: Alkylating Agents; Animals; CA3 Region, Hippocampal; Conditioning, Psychological; Dacarbazine; Discrimination, Psychological; Ganciclovir; Hippocampus; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurogenesis; Temozolomide | 2012 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Implants; Feasibility Studies; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Postoperative Complications; Prospective Studies; Supratentorial Neoplasms; Survival Analysis; Survival Rate; Temozolomide | 2013 |
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, p53; Glioblastoma; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide; Up-Regulation | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Female; Gels; Glioma; Humans; Neoplasm Transplantation; Paclitaxel; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide | 2013 |
Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Glioblastoma; Health Services Accessibility; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2012 |
Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspirin; beta Catenin; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Synergism; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microspheres; Random Allocation; Temozolomide; Transcriptional Activation; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Magnetic Resonance Imaging; Male; Necrosis; Neoplasm Recurrence, Local; Nervous System Diseases; Temozolomide | 2013 |
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Female; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Mice; Mice, Knockout; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Peptides; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2012 |
Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Bystander Effect; Catalase; Cell Proliferation; Culture Media, Conditioned; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Glutathione; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Superoxide Dismutase; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Pons; Prognosis; Survival Rate; Temozolomide | 2013 |
DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Topics: Apoptosis; Brain Neoplasms; Dacarbazine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Messenger; STAT3 Transcription Factor; STAT5 Transcription Factor; Survivin; Temozolomide | 2013 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; Histone Deacetylase Inhibitors; Humans; Temozolomide; Valproic Acid | 2012 |
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Matched-Pair Analysis; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Dacarbazine; Dioxygenases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug.
Topics: Cell Nucleus; Cell Proliferation; Cellular Senescence; Cytoprotection; Dacarbazine; DNA Mismatch Repair; Drug Screening Assays, Antitumor; HCT116 Cells; HEK293 Cells; Humans; I-kappa B Proteins; MCF-7 Cells; NF-kappa B; NF-KappaB Inhibitor alpha; Peptides; Phosphorylation; Protein Transport; Proteolysis; Proto-Oncogene Proteins c-akt; RNA Interference; Temozolomide; Transcription Factor RelA; Transcription, Genetic | 2012 |
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Craniotomy; Cytoplasm; Dacarbazine; Diagnostic Imaging; Glioma; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Red Fluorescent Protein; Temozolomide | 2013 |
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Follow-Up Studies; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Neoplasm Staging; Prognosis; Retrospective Studies; ROC Curve; Survival Rate; Temozolomide | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Supratentorial Neoplasms; Survival Rate; Temozolomide | 2013 |
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Spectroscopy; Middle Aged; Radiometry; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Recurrence; Temozolomide; Tomography, X-Ray Computed | 2013 |
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Endothelium, Vascular; Female; Glioblastoma; Histiocytes; Humans; Male; Middle Aged; Predictive Value of Tests; Promoter Regions, Genetic; Staining and Labeling; Survival Rate; Taiwan; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2013 |
Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Prognosis; Referral and Consultation; Sweden; Temozolomide; Tertiary Care Centers; Thymus Gland; Thymus Neoplasms; Young Adult | 2013 |
[Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Humans; Reactive Oxygen Species; Signal Transduction; Sirtuin 1; Temozolomide | 2012 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neuroendocrine; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Necrolytic Migratory Erythema; Neoplasm Staging; Pancreatic Neoplasms; Paraneoplastic Syndromes; Risk Assessment; Temozolomide; Treatment Outcome | 2013 |
Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Dacarbazine; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Green Fluorescent Proteins; GTPase-Activating Proteins; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; RNA Interference; RNA, Messenger; RNA, Small Interfering; Temozolomide; Time Factors; Transfection | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Glioma; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Semen; Sperm Motility; Temozolomide; Time Factors | 2013 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Medulloblastoma; Recurrence; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thymus Neoplasms; Treatment Outcome | 2013 |
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Male; Masoprocol; Mitotic Index; Radiation-Sensitizing Agents; RNA Splicing; RNA, Messenger; Sp1 Transcription Factor; Survivin; Temozolomide; Transcription, Genetic | 2013 |
Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome | 2013 |
Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation; Genetic Vectors; Glioblastoma; Humans; Lentivirus; Mice; Mice, Nude; RNA, Small Interfering; Temozolomide; Transduction, Genetic; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytotoxicity, Immunologic; Dacarbazine; Diphosphonates; Drug Resistance, Neoplasm; Flow Cytometry; Genetic Engineering; Genetic Vectors; Glioblastoma; GPI-Linked Proteins; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Interleukin-2; Lentivirus; O(6)-Methylguanine-DNA Methyltransferase; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Temozolomide; Zoledronic Acid | 2013 |
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2013 |
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Retrospective Studies; Temozolomide | 2013 |
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Neoplasms; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Oncogene Protein v-akt; Signal Transduction; src-Family Kinases; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; MicroRNAs; O(6)-Methylguanine-DNA Methyltransferase; Polyadenylation; Promoter Regions, Genetic; Temozolomide | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2014 |
Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Proto-Oncogene Proteins c-myc; Temozolomide; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2013 |
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Data Collection; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Japan; Ki-67 Antigen; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Young Adult | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2013 |
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Cellular Senescence; Dacarbazine; DNA Damage; DNA Mismatch Repair; DNA Modification Methylases; DNA-Binding Proteins; Glioma; Guanine; Homologous Recombination; Humans; Protein Serine-Threonine Kinases; Temozolomide; Tumor Suppressor Proteins | 2013 |
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Failure; Young Adult | 2013 |
The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.
Topics: Aniline Compounds; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Interactions; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Microarray Analysis; Phosphorylation; Temozolomide | 2014 |
Breast metastasis of anaplastic oligodendroglioma: a case report.
Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Mammography; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide | 2012 |
A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Dacarbazine; Endothelial Cells; Humans; Maximum Tolerated Dose; Models, Theoretical; Temozolomide | 2013 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine; Diabetes Mellitus; Fatal Outcome; Glioblastoma; Humans; Hypernatremia; Hypertension; Liver Diseases; Male; Middle Aged; Neoplasms, Second Primary; Radiotherapy, Conformal; Sepsis; Temozolomide; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide | 2013 |
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Dacarbazine; Forkhead Transcription Factors; Glioblastoma; HEK293 Cells; Humans; Mice; Mitosis; Neoplastic Stem Cells; Neural Stem Cells; Peptides; Phosphorylation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Temozolomide; Up-Regulation | 2013 |
Reversing the Warburg effect as a treatment for glioblastoma.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Energy Metabolism; Female; Glioblastoma; Humans; Lactates; Methylene Blue; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxygen Consumption; Structure-Activity Relationship; Temozolomide; Tolonium Chloride | 2013 |
Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Forecasting; Ganciclovir; Humans; Mice; Molecular Targeted Therapy; Neoplasms; Neoplastic Stem Cells; Research Personnel; Temozolomide | 2013 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Radiometry; Radiotherapy; Temozolomide | 2013 |
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neurosurgical Procedures; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Prognosis; Retrospective Studies; Temozolomide | 2013 |
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Blepharoptosis; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Diplopia; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Neuroepithelial; Neurosurgical Procedures; Seizures; Temozolomide; Young Adult | 2013 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Radiosurgery; Radiotherapy; Retrospective Studies; Skin Neoplasms; Temozolomide; Young Adult | 2014 |
A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genetic Therapy; Genetic Vectors; Humans; Immunoenzyme Techniques; Interleukins; Ki-67 Antigen; Melanoma; Oncolytic Virotherapy; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Dacarbazine; Female; Least-Squares Analysis; Mice; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Temozolomide; Tissue Distribution | 2013 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Procollagen-Proline Dioxygenase; Protein Disulfide-Isomerases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Temozolomide | 2013 |
Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apitherapy; Biological Transport; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Glioblastoma; Humans; NF-kappa B; Propolis; Temozolomide | 2013 |
Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Data Interpretation, Statistical; Endpoint Determination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
Case of pleomorphic xanthoastrocytoma with anaplastic features in the pineal gland.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Humans; Interferon-beta; Male; Middle Aged; Pinealoma; Radiotherapy Dosage; Temozolomide; Treatment Outcome; Vincristine | 2013 |
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Grading; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Spain; Survival Rate; Temozolomide; Time Factors; Young Adult | 2013 |
Steroid management in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Glucocorticoids; Humans; Male; Middle Aged; Radiotherapy; Randomized Controlled Trials as Topic; Retrospective Studies; Temozolomide | 2013 |
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspartic Acid; Cell Survival; Cells, Cultured; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Stability; Drug Synergism; Flow Cytometry; Glioblastoma; Gold; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Neoplastic Stem Cells; Temozolomide | 2013 |
Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Human Growth Hormone; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neurosurgical Procedures; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Temozolomide; Tumor Burden; World Health Organization; Young Adult | 2013 |
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Glioblastoma; Humans; Immunoenzyme Techniques; Mice; Prognosis; Real-Time Polymerase Chain Reaction; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vulvar Neoplasms | 2013 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Meningeal Neoplasms; Middle Aged; Muscle Weakness; Prognosis; Reoperation; Spinal Cord Neoplasms; Temozolomide | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Dacarbazine; DNA Methylation; DNA, Neoplasm; Glioma; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Pyrroles; Sunitinib; Temozolomide; Tumor Cells, Cultured; Vascular Resistance | 2013 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Fatal Outcome; Frontal Lobe; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Topics: Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Enzyme Inhibitors; Fluorescent Antibody Technique; Glioblastoma; Humans; Poly(ADP-ribose) Polymerases; Temozolomide | 2013 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioma; Humans; Temozolomide; Tumor Suppressor Proteins | 2012 |
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Glioblastoma; Humans; Male; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide | 2013 |
Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Comet Assay; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Polymerase Chain Reaction; Promoter Regions, Genetic; Purines; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2013 |
Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cellular Senescence; Checkpoint Kinase 2; Cyclin B; Dacarbazine; DNA Damage; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Histones; Humans; Mitosis; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases; Resveratrol; Stilbenes; Temozolomide; Time Factors | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Seizures; Survival Analysis; Temozolomide; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioblastoma; Magnetic Resonance Imaging; Male; Rats; Sound; Temozolomide | 2013 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Immunotherapy; Interleukin-2; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Transgenic; Temozolomide; Vaccines, Subunit | 2013 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Microsatellite Instability; Neoplasms, Complex and Mixed; Neurosurgical Procedures; Oligodendroglioma; Phenotype; Temozolomide | 2013 |
Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Damage; DNA Methylation; DNA, Mitochondrial; fas Receptor; Gene Expression Profiling; Guanine; Histones; Humans; Membrane Potential, Mitochondrial; Myeloid Progenitor Cells; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Temozolomide | 2013 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Dacarbazine; Headache; Hemangioma, Capillary; Humans; Magnetic Resonance Imaging; Male; Nausea; Neoplasm Recurrence, Local; Neurosurgical Procedures; Temozolomide; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vomiting | 2013 |
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Topics: Adenosine Triphosphate; Adenoviridae; Adolescent; Adult; Aged; Animals; Antibodies, Neutralizing; Antineoplastic Agents; Autophagy; Calreticulin; Cell Death; Cell Line, Tumor; Child; Combined Modality Therapy; Cyclophosphamide; Cytokines; Dacarbazine; DNA, Viral; Dose-Response Relationship, Drug; Female; HMGB1 Protein; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Microscopy, Electron; Middle Aged; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; T-Lymphocytes, Regulatory; Temozolomide; Virus Replication; Xenograft Model Antitumor Assays; Young Adult | 2013 |
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Microglia; NAD; Oxidative Stress; Pentosyltransferases; Quinolinic Acid; Temozolomide; Tryptophan; Tryptophan Oxygenase | 2013 |
Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Prognosis; Radiosurgery; Retrospective Studies; Sex Factors; Survival Analysis; Temozolomide; Young Adult | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Humans; Immunohistochemistry; Luciferases; Mice; Mice, Nude; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Oligonucleotides; Paraffin Embedding; Plasmids; Real-Time Polymerase Chain Reaction; Temozolomide | 2013 |
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Mutation; NF-kappa B; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 7; Caspase 9; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Dacarbazine; DNA Damage; Drug Synergism; Female; Folic Acid Antagonists; Histones; Leucovorin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Pituitary Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrimethamine; Rats; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbon; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Organ Culture Techniques; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; X-Rays | 2013 |
Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter?
Topics: Carbon; Cell Cycle; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Photons; Radiation-Sensitizing Agents; Temozolomide | 2013 |
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Caspase 12; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Cytochromes c; Dacarbazine; Endoplasmic Reticulum Stress; Enzyme Activation; Glioblastoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Quercetin; Temozolomide | 2013 |
Posttransplant lymphoproliferative disorder in an 11-year-old immunosuppressed boy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Child; Dacarbazine; Heart Transplantation; Humans; Hypesthesia; Immunosuppression Therapy; Lymphoproliferative Disorders; Magnetic Resonance Imaging; Male; Methotrexate; Muscle Weakness; Rituximab; Temozolomide | 2013 |
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Female; Green Fluorescent Proteins; Humans; Luciferases, Firefly; Mice; Mice, Nude; Neoplasms, Experimental; Radiation-Sensitizing Agents; Temozolomide; Triple Negative Breast Neoplasms | 2013 |
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; Cancer Vaccines; Dacarbazine; Glioblastoma; Humans; Lymphocyte Depletion; Lymphopenia; Temozolomide | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Survival; Cluster Analysis; Dacarbazine; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Glioma; Humans; Interleukin-1 Receptor-Associated Kinases; NF-kappa B; Proteome; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Temozolomide; Toll-Like Receptors | 2013 |
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioblastoma; Humans; Lentivirus; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide | 2013 |
Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.
Topics: Amyloid Precursor Protein Secretases; Animals; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Receptors, Notch; Signal Transduction; Temozolomide; Thiadiazoles; Xenograft Model Antitumor Assays | 2013 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Reporter; Glioma; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; MicroRNAs; Mutant Proteins; Neoplasm Proteins; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Temozolomide; Transfection; Tumor Cells, Cultured | 2013 |
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-akt; Pyrazines; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Proliferation; Cesium Radioisotopes; Dacarbazine; Drug Synergism; Everolimus; Flow Cytometry; Gamma Rays; Glioblastoma; Humans; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Dacarbazine; Drug Synergism; Extracellular Fluid; Glioma; Humans; Male; Microdialysis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Effect of temozolomide on male gametes: an epigenetic risk to the offspring?
Topics: Adult; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Female; Germ Cells; Glioma; Humans; Male; Pregnancy; Proteins; RNA, Long Noncoding; Spermatogenesis; Spermatozoa; Temozolomide; Tumor Suppressor Proteins | 2013 |
An expanded role for Caveolin-1 in brain tumors.
Topics: Animals; Apoptosis; Caveolin 1; Dacarbazine; Humans; Temozolomide | 2013 |
Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.
Topics: Antineoplastic Agents; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Methylation; DNA Mismatch Repair; Enzyme Activation; Humans; Phosphorylation; Protein Kinases; Temozolomide; Time Factors | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ceramides; Clone Cells; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Glucosyltransferases; Humans; Meperidine; Radiation, Ionizing; Signal Transduction; Sphingomyelin Phosphodiesterase; Temozolomide; Treatment Outcome | 2013 |
Cerebellar anaplastic astrocytoma in an adult with neurofibromatosis type 1: case report and review of literature.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Cerebellar Neoplasms; Combined Modality Therapy; Dacarbazine; Dopamine Agents; Electrodiagnosis; Electroencephalography; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 1; Neurosurgical Procedures; Positron-Emission Tomography; Surgery, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Case-Control Studies; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Postoperative Period; Prognosis; Survival Rate; Temozolomide | 2013 |
Isotretinoin maintenance therapy for glioblastoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Isotretinoin; Male; Middle Aged; Retrospective Studies; Temozolomide | 2014 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Radiation Injuries; Retrospective Studies; Risk Factors; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Levetiracetam; Male; Middle Aged; Neoplasm Recurrence, Local; Piracetam; Prognosis; Retrospective Studies; Seizures; Survival Rate; Temozolomide; Valproic Acid; Young Adult | 2013 |
Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Brain Neoplasms; Caspase 3; Caspase 9; Caspases; Cell Survival; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mitochondrial Proteins; Temozolomide; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphoma; Male; Temozolomide | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connexin 43; Cytochromes c; Dacarbazine; Dose-Response Relationship, Drug; Fluoresceins; Glioma; Humans; Mitochondria; Mutation; Phosphorylation; RNA, Small Interfering; Signal Transduction; Temozolomide; Time Factors; Transfection | 2013 |
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Mutation; Receptor-Like Protein Tyrosine Phosphatases, Class 2; Signal Transduction; Temozolomide | 2013 |
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chickens; Dacarbazine; Drug Resistance, Neoplasm; Epilepsy; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; NF-kappa B; Proto-Oncogene Proteins c-akt; Receptors, Tumor Necrosis Factor; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Cyclobutanes; Dacarbazine; Feasibility Studies; Glioma; Magnetic Resonance Imaging; Male; Methionine; Permeability; Rats; Temozolomide; Treatment Outcome | 2013 |
Stability of sample solution as a crucial point during HPLC determination of chemical purity of temozolomide drug substance.
Topics: Chromatography, High Pressure Liquid; Dacarbazine; Drug Stability; Solutions; Temozolomide | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell Survival; Dacarbazine; Disease Progression; Extracellular Matrix; Fibronectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Glioma; Humans; Integrin alphaV; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Oligopeptides; Proteomics; Reproducibility of Results; RNA, Messenger; Spheroids, Cellular; Survival Analysis; Temozolomide | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase; Glioma; Humans; Plasma Gases; Temozolomide; Tumor Stem Cell Assay | 2013 |
Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Signal Transduction; Temozolomide | 2013 |
Primary undifferentiated spindle-cell sarcoma of sella turcica: successful treatment with adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Diagnosis, Differential; Humans; Male; Pituitary Neoplasms; Sarcoma; Sella Turcica; Temozolomide | 2013 |
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Topics: Adult; Aged; Cancer Vaccines; CTLA-4 Antigen; Dacarbazine; Dendritic Cells; Female; Forkhead Transcription Factors; Hemocyanins; Humans; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Male; Melanoma; Middle Aged; T-Lymphocytes, Regulatory; Temozolomide; Treatment Outcome | 2013 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Computational Biology; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Imatinib Mesylate; Microarray Analysis; Piperazines; Pyrimidines; rac1 GTP-Binding Protein; Receptors, Notch; RNA, Neoplasm; Signal Transduction; Temozolomide | 2013 |
Lycopene modulates growth and survival associated genes in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carotenoids; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Humans; Lycopene; Male; Necrosis; PPAR gamma; Prostatic Neoplasms; Temozolomide | 2013 |
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Flow Cytometry; Glioblastoma; Humans; Inhibitory Concentration 50; Male; Middle Aged; Promoter Regions, Genetic; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2013 |
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Female; Glioma; Humans; Spinal Neoplasms; Temozolomide; Treatment Outcome | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired Infections; Dacarbazine; Female; Glioma; Hematologic Diseases; Humans; Logistic Models; Male; Middle Aged; Neutropenia; Predictive Value of Tests; Temozolomide; Thrombocytopenia | 2013 |
Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta Catenin; Blood-Brain Barrier; Capillary Permeability; Cell Line, Tumor; Dacarbazine; DNA Methylation; Gene Expression Regulation; Humans; Promoter Regions, Genetic; Signal Transduction; Temozolomide; Wnt3 Protein | 2014 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Glioma; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy, Adoptive; Injections, Intralesional; Mice; Mice, Inbred C57BL; Temozolomide | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Female; Humans; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Radiosurgery; Temozolomide; Tomography, X-Ray Computed | 2013 |
microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; MicroRNAs; Radiation, Ionizing; Temozolomide; Ubiquitin-Activating Enzymes | 2013 |
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Dacarbazine; Glioblastoma; Humans; Practice Patterns, Physicians'; Spain; Surveys and Questionnaires; Temozolomide | 2014 |
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Small Cell; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Parotid Neoplasms; Temozolomide | 2013 |
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Topics: Aminooxyacetic Acid; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glutamine; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Mutation; Oxidative Stress; RNA, Small Interfering; Signal Transduction; Temozolomide | 2013 |
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Nerve Tissue Proteins; Proto-Oncogene Proteins c-myb; Receptors, Immunologic; Roundabout Proteins; Temozolomide; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; Zinc Finger E-box-Binding Homeobox 1 | 2013 |
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Space; Glioblastoma; Humans; Intracellular Space; Lysophospholipids; Models, Biological; Neoplastic Stem Cells; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Temozolomide | 2013 |
MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion.
Topics: Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Vitro Techniques; MicroRNAs; Neoplasm Invasiveness; Receptor, Notch1; Temozolomide | 2013 |
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Random Allocation; Temozolomide; Tomography, X-Ray Computed; Tumor Burden | 2013 |
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Temozolomide; Uveal Neoplasms | 2013 |
LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Topoisomerases, Type II; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Temozolomide | 2013 |
miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.
Topics: Animals; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; MicroRNAs; Molecular Chaperones; Neoplastic Stem Cells; Protein Inhibitors of Activated STAT; RNA, Small Interfering; Temozolomide | 2014 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazine; Early Diagnosis; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Injections, Intraventricular; Injections, Subcutaneous; Mice; Mice, Nude; Neoplasms, Experimental; Temozolomide; Tomography, Emission-Computed; Treatment Outcome; Tumor Burden | 2013 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Neurosurgical Procedures; Photosensitizing Agents; Retrospective Studies; Surgery, Computer-Assisted; Temozolomide; Treatment Outcome | 2014 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacarbazine; Disease Models, Animal; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasm Transplantation; Phenyl Ethers; Temozolomide; Thiazolidines; Tubulin Modulators; Tumor Cells, Cultured | 2013 |
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Temozolomide; Tumor Stem Cell Assay | 2013 |
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model.
Topics: Acridine Orange; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Culture Techniques; Cell Death; Cell Line, Tumor; Curcumin; Dacarbazine; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Magnetics; Nanoparticles; Propidium; Staining and Labeling; Temozolomide | 2013 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric Compounds; Glioma; Humans; Magnetic Resonance Imaging; Mice; Nanoparticles; Polymers; Radiography; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta Catenin; Brain Neoplasms; Dacarbazine; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3; Humans; Mice; Neoplastic Stem Cells; Temozolomide; Tumor Cells, Cultured; Wnt Signaling Pathway; Wnt3A Protein | 2013 |
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Recurrence; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; NF-kappa B; Prognosis; RNA Interference; Temozolomide; Tissue Array Analysis; TNF Receptor-Associated Death Domain Protein | 2013 |
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Nimustine; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2014 |
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Combined Modality Therapy; Dacarbazine; Gamma Rays; Genetic Vectors; Glioblastoma; Humans; Mice; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Survival Analysis; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Central diabetes insipidus: a previously unreported side effect of temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Diabetes Insipidus, Neurogenic; Humans; Male; Middle Aged; Pituitary Gland; Pituitary Gland, Posterior; Polydipsia; Polyuria; Temozolomide | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Glioma; Heavy Ion Radiotherapy; Humans; Infant; Neoplasm Grading; Photons; Retrospective Studies; Temozolomide | 2013 |
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Dacarbazine; Glioblastoma; Humans; Markov Chains; Temozolomide; Time Factors; United States | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Burden; United States | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; Comet Assay; Cyclin-Dependent Kinases; Dacarbazine; Drug Synergism; Female; Flavonoids; Fluorescent Antibody Technique; Glioma; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Clinical Laboratory Services; Dacarbazine; Female; Glioblastoma; Hematologic Diseases; Humans; Male; Medication Adherence; Middle Aged; Self Administration; Software; Temozolomide | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cryopreservation; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Dosage; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Temozolomide; Tumor Cells, Cultured; Vincristine | 2013 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dacarbazine; Epstein-Barr Virus Infections; Fatal Outcome; Glioblastoma; Headache; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Temozolomide; Tomography, X-Ray Computed | 2014 |
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Leupeptins; Neoplastic Stem Cells; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2014 |
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Methotrexate; Middle Aged; Survival Rate; Temozolomide; Young Adult | 2013 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Melanoma; Methylnitronitrosoguanidine; Phosphorylation; Protein Kinases; Signal Transduction; Temozolomide; Tumor Suppressor Proteins | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarbazine; Drug Synergism; Female; Flucytosine; Gene Expression; Gene Transfer Techniques; Genetic Vectors; Glioblastoma; Mice; Mice, Nude; Retroviridae; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Effect of temozolomide in patients with metastatic bronchial carcinoids.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bronchial Neoplasms; Carcinoid Tumor; Cohort Studies; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Temozolomide; Young Adult | 2013 |
HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
Topics: 2-Methoxyestradiol; Adult; Animals; Antineoplastic Agents, Alkylating; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Estradiol; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Pituitary Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2013 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; Meningeal Neoplasms; Neoplasm Seeding; Temozolomide | 2017 |
Glioblastoma management in the temozolomide era: have we improved outcome?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Management; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2013 |
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2013 |
Case of pediatric optic pathway oligodendroglioma presenting widespread invasion and dissemination in the cerebrospinal fluid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Child; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neurosurgical Procedures; Oligodendroglioma; Optic Nerve Neoplasms; Temozolomide; Treatment Outcome; Vincristine; Visual Pathways | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell Cycle; Cells, Cultured; Dacarbazine; Dietary Supplements; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Triacetin | 2014 |
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Reoperation; Risk Factors; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Craniopharyngioma; Dacarbazine; Glioblastoma; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2014 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
Topics: Absorbable Implants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Humans; Paclitaxel; Temozolomide | 2014 |
Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Lineage; Dacarbazine; Electrophoretic Mobility Shift Assay; Fluorescent Antibody Technique, Indirect; Humans; Methylnitronitrosoguanidine; Neoplasm Proteins; Neoplasms; Temozolomide | 2013 |
APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Fas Ligand Protein; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Recombinant Fusion Proteins; Temozolomide | 2013 |
Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quercetin; Signal Transduction; Temozolomide | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioma; Humans; Lipogenesis; Mice; Molecular Chaperones; Neoplasm Grading; Prognosis; RNA, Messenger; Signal Transduction; Temozolomide; Transcription Factors; Transcription, Genetic; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; Mice; Neoplastic Stem Cells; Oncolytic Viruses; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins; Virus Replication; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Clone Cells; Connexin 43; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; HEK293 Cells; Humans; Mice; Mice, Nude; MicroRNAs; Molecular Sequence Data; Protein Binding; Rats; RNA, Messenger; Temozolomide | 2013 |
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide; Time Factors | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Radiography; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; ATPases Associated with Diverse Cellular Activities; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Chemoradiotherapy; Dacarbazine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoenzyme Techniques; Male; Membrane Proteins; Middle Aged; Mitochondria; Mitochondrial Proteins; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Radiation Tolerance; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Temozolomide; Tumor Cells, Cultured | 2013 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Maintenance Chemotherapy; Male; Middle Aged; Temozolomide | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Glioma; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Subcutaneous Tissue; Temozolomide; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality Therapy; Dacarbazine; Ganciclovir; Genes, Transgenic, Suicide; Genes, Viral; Genetic Therapy; Genetic Vectors; Glioma; Herpesvirus 1, Human; Humans; Male; Neoplasms, Experimental; Rats; Temozolomide; Thymidine Kinase; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid | 2013 |
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioblastoma; Heme Oxygenase-1; Humans; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Radiation; RNA, Messenger; Temozolomide | 2014 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Epilepsy, Complex Partial; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Medulloblastoma; Temozolomide; Tomography, X-Ray Computed | 2013 |
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neurosurgical Procedures; Scotland; Survival Analysis; Temozolomide; Young Adult | 2014 |
Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Oxidation-Reduction; Oxidoreductases Acting on CH-CH Group Donors; Paclitaxel; Reactive Oxygen Species; Temozolomide | 2013 |
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Temozolomide; Vincristine; Wilms Tumor | 2014 |
Chemotherapy-induced secondary pneumothorax.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Combined Modality Therapy; Dacarbazine; Fatal Outcome; Humans; Humerus; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pneumothorax; Rupture, Spontaneous; Sarcoma, Synovial; Temozolomide; Tomography, X-Ray Computed | 2014 |
Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.
Topics: Adult; Brain Neoplasms; Cell Transformation, Neoplastic; Cerebrospinal Fluid; Chemotherapy, Adjuvant; Child, Preschool; Craniospinal Irradiation; Dacarbazine; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Neurocytoma; Radiotherapy, Adjuvant; Temozolomide; Young Adult | 2014 |
Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment.
Topics: Apoptosis; Astrocytoma; Autophagy; Caspase 12; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Dacarbazine; Endoplasmic Reticulum Stress; Gene Silencing; Glioblastoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Molecular Chaperones; Quercetin; Temozolomide | 2013 |
High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Receptors, Leptin; Signal Transduction; SOXB1 Transcription Factors; STAT3 Transcription Factor; Temozolomide | 2013 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2014 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Glioblastoma; Hematologic Diseases; Humans; Ifosfamide; Interferons; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2013 |
Treatment results of glioblastoma during the last 30 years in a single institute.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Hospitals, University; Humans; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neuronavigation; Nimustine; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; RNA Interference; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Glioma; Humans; Matrix Metalloproteinase 14; Mice; MicroRNAs; Radiation; RNA Interference; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Dacarbazine; Male; Rats; Rats, Sprague-Dawley; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.
Topics: Aged; Astrocytoma; Brain Neoplasms; Cognition Disorders; Cohort Studies; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Health Status; Humans; Male; Middle Aged; Neuropsychological Tests; Quality of Life; Radiotherapy; Statistics, Nonparametric; Survivors; Temozolomide; Tumor Suppressor Proteins | 2014 |
Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genomics; Humans; Lymphoma, Large B-Cell, Diffuse; Promoter Regions, Genetic; Temozolomide; Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anae
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow; Dacarbazine; Humans; Middle Aged; Temozolomide; Young Adult | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Follow-Up Studies; Glioma; Humans; Laminin; Male; Rats; Rats, Nude; Survival Analysis; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Radiosurgery; Regression Analysis; Statistics, Nonparametric; Temozolomide; Treatment Outcome | 2014 |
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Therapy, Combination; Ependymoma; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Radiography; Temozolomide; Treatment Outcome | 2013 |
Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta).
Topics: Animals; Brain Stem; Cerebral Cortex; Dacarbazine; Macaca mulatta; Magnetic Resonance Imaging; Male; Microdialysis; Models, Animal; Temozolomide | 2013 |
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Employment; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Radiotherapy, Intensity-Modulated; Severity of Illness Index; Survivors; Temozolomide; Young Adult | 2014 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary ACTH Hypersecretion; Temozolomide | 2014 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Glioblastoma; Guanosine; Humans; Methylation; Middle Aged; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2013 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cognition Disorders; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide; Transfection | 2013 |
Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.
Topics: Adaptation, Physiological; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Gene Expression; Glioblastoma; Glucose; Humans; Signal Transduction; Stem Cells; Stress, Physiological; Temozolomide; Up-Regulation | 2013 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Cortex; Cognition Disorders; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Leukoencephalopathies; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Temozolomide; Young Adult | 2014 |
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.
Topics: Adolescent; Adult; Aged; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Temozolomide; Young Adult | 2013 |
NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cellular Senescence; Dacarbazine; Dose-Response Relationship, Drug; Gene Expression; Gene Silencing; Glioblastoma; Humans; Integrin beta4; Nerve Growth Factors; Netrins; Phosphorylation; Proto-Oncogene Proteins c-akt; Temozolomide | 2013 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromosomes, Human, 1-3; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Deletion; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2013 |
Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Neuroblastoma; Renal Dialysis; Renal Insufficiency; Temozolomide; Treatment Outcome | 2014 |
Quantitative assessment of the dose-response of alkylating agents in DNA repair proficient and deficient ames tester strains.
Topics: Alkylating Agents; Dacarbazine; DNA Helicases; DNA Repair; Dose-Response Relationship, Drug; Ethyl Methanesulfonate; Methyl Methanesulfonate; Methylnitrosourea; Methyltransferases; Mutagenicity Tests; Mutagens; Salmonella typhimurium; Species Specificity; Temozolomide | 2014 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Retrospective Studies; Temozolomide | 2014 |
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; Fatal Outcome; Female; Glioblastoma; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide; Translocation, Genetic | 2014 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Elongation Factor 2 Kinase; Glioma; Humans; Male; Mice; Protein Kinase Inhibitors; RNA Interference; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Mutation; Temozolomide; Treatment Outcome | 2014 |
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Chemoradiotherapy; Dacarbazine; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Phenotype; Temozolomide; Tumor Cells, Cultured | 2014 |
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Topics: Anthracenes; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Kinase 4; Neoplastic Stem Cells; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2014 |
Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.
Topics: Antineoplastic Agents; Base Sequence; Benzofurans; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Damage; DNA Primers; DNA Repair; Drug Synergism; Glioblastoma; Humans; Hydroxybenzoates; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2013 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Temozolomide | 2014 |
Identification and physicochemical characteristics of temozolomide process-related impurities.
Topics: Antineoplastic Agents, Alkylating; Crystallography, X-Ray; Dacarbazine; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Spectrum Analysis, Raman; Temozolomide; Thermodynamics | 2013 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutational Analysis; Glioma; Humans; Mutagenesis; Neoplasm Grading; Neoplasm Recurrence, Local; Nuclear Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Protein p53; X-linked Nuclear Protein | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Disease Models, Animal; Glioma; Male; Pertussis Toxin; Rats; Rats, Wistar; Survival Rate; Temozolomide | 2014 |
[Results of postoperative radiochemotherapy of glioblastoma multiforme].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Hungary; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Sex Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
[Our experience with targeted therapy in glioblastoma multiforme].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neurosurgical Procedures; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Topics: Adenosine Triphosphate; Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorescence Polarization; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Methyl Methanesulfonate; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Stereoisomerism; Temozolomide | 2014 |
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Female; Gliosarcoma; Minocycline; Neoplasm Transplantation; Polymers; Rats; Rats, Inbred F344; Temozolomide | 2014 |
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Temozolomide | 2015 |
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Blood-Brain Barrier; Catalytic Domain; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; Glioblastoma; Humans; Imidazoles; Mice; Mice, Transgenic; Phosphoinositide-3 Kinase Inhibitors; Protein Interaction Domains and Motifs; Quinolines; Radiation-Sensitizing Agents; Temozolomide; TOR Serine-Threonine Kinases | 2014 |
Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Purines; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Glioma; Humans; Immunotherapy; Magnetic Resonance Imaging; Neoplasm Grading; Neoplasms; Precision Medicine; Remission Induction; Temozolomide; Translational Research, Biomedical | 2013 |
Extraneural metastases of anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide | 2014 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Cancer Vaccines; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Doxorubicin; Drug Evaluation; Fatal Outcome; Ganglioglioma; Humans; Immunotherapy; Indoles; Infant; Irinotecan; Male; Mutation, Missense; Neoplasm Proteins; Point Mutation; Polyethylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Salvage Therapy; Sulfonamides; Temozolomide; Thalamus; Treatment Outcome; Vemurafenib | 2014 |
Concomitant viral and bacterial encephalitis after temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Encephalitis, Viral; Glioblastoma; Humans; Infectious Encephalitis; Male; Middle Aged; Temozolomide | 2014 |
A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Gas Analysis; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Dacarbazine; Electrocardiography; Fatal Outcome; Female; Glioblastoma; Humans; Lung; Lung Diseases, Interstitial; Physical Examination; Pneumocystis carinii; Pneumonia, Pneumocystis; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; Glioblastoma; Hippocampus; Humans; Magnetic Resonance Imaging; Organs at Risk; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Temozolomide; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chemoradiotherapy; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Radiation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; ErbB Receptors; Glioma; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Neoplasm Grading; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; RNA Interference; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Transfection; Tumor Suppressor Proteins | 2014 |
Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Female; Glioma; Humans; Male; Pons; Retrospective Studies; Survival Analysis; Temozolomide | 2014 |
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Notification; Disease-Free Survival; DNA Methylation; DNA-Cytosine Methylases; Female; Glioblastoma; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; ROC Curve; Sequence Analysis, DNA; Survival Analysis; Temozolomide; Treatment Outcome | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Endothelial Cells; Enediynes; Glioma; Heterografts; Humans; Male; Mice, Nude; Neovascularization, Pathologic; Rats; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; Glioma; Humans; Male; MAP Kinase Signaling System; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Middle Aged; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Dacarbazine; Diploidy; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycolysis; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Spheroids, Cellular; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Temozolomide-induced liver damage. A case report.
Topics: Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Dacarbazine; Diagnosis, Differential; Female; Humans; Middle Aged; Temozolomide; Treatment Outcome | 2014 |
Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Flow Cytometry; Glioblastoma; HEK293 Cells; Humans; Male; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Binding; Proto-Oncogene Proteins c-cbl; Rho Guanine Nucleotide Exchange Factors; RNA Interference; Signal Transduction; Spheroids, Cellular; Temozolomide; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Conformal; Retreatment; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Failure; Treatment Outcome | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Reoperation; Retrospective Studies; Survival Analysis; Temozolomide; Time Factors; Young Adult | 2014 |
Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Probability; Prognosis; Retrospective Studies; Temozolomide; Time Factors; Young Adult | 2014 |
Case of primary diffuse leptomeningeal gliomatosis.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Methylation; Middle Aged; Neoplasms, Neuroepithelial; Promoter Regions, Genetic; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2014 |
The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Topics: Adherens Junctions; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Caspase 7; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; HEK293 Cells; Histone Deacetylases; Humans; In Situ Nick-End Labeling; Melanoma-Specific Antigens; Neoplasm Proteins; Temozolomide; Transcription, Genetic; Tumor Suppressor Protein p53 | 2014 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Immunosuppressive Agents; Ipilimumab; Kidney Transplantation; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mycophenolic Acid; Platinum Compounds; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Skin Neoplasms; Tacrolimus; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Gene Expression; Glioblastoma; Humans; Mice; Receptors, Notch; Signal Transduction; Temozolomide; Transfection | 2014 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Glioblastoma; Immunotherapy; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Temozolomide; Thymidine Kinase | 2014 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia Ligase; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Glutamine; Humans; Male; Medulloblastoma; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Inhibitory Concentration 50; Necrosis; Temozolomide | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Cervical Vertebrae; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Quadriplegia; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins | 2014 |
Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Interferon-beta; K562 Cells; MCF-7 Cells; Molecular Sequence Data; Neoplastic Stem Cells; Receptor, Interferon alpha-beta; Signal Transduction; Temozolomide | 2014 |
Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; Drug Resistance, Neoplasm; Ependymoma; Glioblastoma; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Stem Cells; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Gene Expression; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mice; Mice, Nude; Mutation; Temozolomide | 2014 |
Bevacizumab in glioblastoma--still much to learn.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2014 |
Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Temozolomide; Treatment Outcome | 2013 |
The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation; Glioblastoma; Heterografts; Humans; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; NF-kappa B; Peptides; Temozolomide; Tumor Cells, Cultured | 2014 |
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Muscle, Skeletal; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; CpG Islands; Cytosine; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Quantitative Trait Loci; Temozolomide; Tumor Suppressor Proteins | 2014 |
miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
Topics: Actins; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeleton; Dacarbazine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; Molecular Sequence Data; rap GTP-Binding Proteins; Temozolomide; Up-Regulation | 2014 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Management; Female; France; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Palliative Care; Temozolomide; Treatment Outcome | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Survival Rate; Temozolomide | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Metabolome; Mutation; Temozolomide | 2014 |
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; CpG Islands; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Temozolomide | 2014 |
Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line.
Topics: Animals; Antineoplastic Agents; Bees; Biological Products; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioblastoma; Honey; Humans; Neoplasm Metastasis; Temozolomide | 2014 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Olfaction Disorders; Oxidative Stress; Radiotherapy; Saliva; Salivary Proteins and Peptides; Taste Disorders; Temozolomide | 2015 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Platinum Compounds; Practice Patterns, Physicians'; Retrospective Studies; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neutropenia; Remission Induction; Temozolomide; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; Glioblastoma; Humans; Male; Mice, Nude; Neoplastic Stem Cells; Phenotype; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Proportional Hazards Models; Temozolomide; Treatment Outcome; United States | 2014 |
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blotting, Western; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Young Adult | 2014 |
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Mice; Mice, SCID; Prognosis; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2014 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Combinations; Drug Resistance, Neoplasm; Humans; Mice; Monoterpenes; Temozolomide; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Mutational Analysis; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Receptor, ErbB-2; Temozolomide; Transcriptome | 2014 |
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Topics: Apoptosis; Azepines; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Protein Kinase Inhibitors; Pyrimidines; Radiation, Ionizing; Temozolomide | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; MCF-7 Cells; Mice; Mice, Nude; RNA Interference; Temozolomide; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Male; Radiotherapy, Conformal; Survival Rate; Temozolomide; Treatment Outcome | 2014 |
Downregulation of ROCK2 through nanocomplex sensitizes the cytotoxic effect of temozolomide in U251 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Nanoconjugates; Neurons; Polyethylene Glycols; Polyethyleneimine; Proto-Oncogene Proteins c-bcl-2; rho-Associated Kinases; RNA, Small Interfering; Signal Transduction; Temozolomide | 2014 |
miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; Neoplastic Stem Cells; Temozolomide | 2014 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeability; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Melanoma; Melphalan; Neoplasm Transplantation; Oligopeptides; Peptides, Cyclic; Phosphatidylinositol 3-Kinases; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide | 2015 |
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain; Cell Line, Tumor; Dacarbazine; Dogs; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Metabolic Clearance Rate; Mice, Knockout; Mice, Nude; PTEN Phosphohydrolase; Swine; Temozolomide; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chickens; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2014 |
Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Lateral Ventricles; Male; Middle Aged; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Female; Fibrin Tissue Adhesive; Glioma; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm Transplantation; Temozolomide | 2014 |
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coloring Agents; Connexin 43; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Knockdown Techniques; Glioblastoma; Humans; JNK Mitogen-Activated Protein Kinases; Protein Binding; Signal Transduction; Temozolomide; Transcription Factor AP-1 | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarbazine; Dose Fractionation, Radiation; G2 Phase; Glioblastoma; HMGB1 Protein; HSP70 Heat-Shock Proteins; Humans; Mutation; Necrosis; Temozolomide; Tumor Suppressor Protein p53; Valproic Acid | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide | 2014 |
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Methylmalonic Acid; Positron-Emission Tomography; Temozolomide; Treatment Outcome | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; CTLA-4 Antigen; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Knockout; T-Lymphocytes, Regulatory; Temozolomide | 2014 |
Base excision repair of chemotherapeutically-induced alkylated DNA damage predominantly causes contractions of expanded GAA repeats associated with Friedreich's ataxia.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Replication; Friedreich Ataxia; Genomic Instability; Humans; Introns; Nucleic Acid Conformation; Sequence Deletion; Temozolomide; Trinucleotide Repeat Expansion | 2014 |
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplastic Stem Cells; Survival Rate; Temozolomide; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cells; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Silencing; Glioblastoma; Humans; Radiation Tolerance; Radiation, Ionizing; RNA, Small Interfering; Sirolimus; Temozolomide; Transfection; Ubiquitin-Activating Enzymes | 2014 |
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Iron; Mice; Nanoparticles; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Scorpion Venoms; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Modeling sustained treatment effects in tumor xenograft experiments.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Interactions; Humans; Irinotecan; Mice; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide | 2015 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; Disease Models, Animal; Diterpenes; Drug Synergism; Epoxy Compounds; Glioma; Humans; Mice; Neoplasm Transplantation; NF-kappa B; Phenanthrenes; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stimulation, Chemical; Temozolomide; Transcription, Genetic; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.
Topics: Acylation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chitosan; Dacarbazine; Drug Synergism; ErbB Receptors; Gene Silencing; Glioblastoma; Humans; Lipids; Nanocapsules; Particle Size; RNA, Small Interfering; Temozolomide; Treatment Outcome | 2014 |
Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H⁺ extrusion, cell migration and survival.
Topics: Acid-Base Equilibrium; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Biological Transport; Cation Transport Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Signaling System; Mice; Neural Stem Cells; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Temozolomide; Up-Regulation | 2014 |
Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evidence-Based Medicine; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Temozolomide | 2014 |
Glioblastoma treatment in the elderly in the temozolomide therapy era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Heme Oxygenase-1; Humans; MAP Kinase Signaling System; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Withanolides | 2014 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; Female; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Myo-Inositol-1-Phosphate Synthase; Neoplasm Proteins; Prospective Studies; Proteomics; S100 Proteins; Skin Neoplasms; Tandem Mass Spectrometry; Temozolomide; Young Adult | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relationship, Drug; Fatal Outcome; Glioma; Humans; Male; Neoplasm Recurrence, Local; Temozolomide | 2014 |
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Retrospective Studies; Switzerland; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Autophagy; Autophagy-Related Protein-1 Homolog; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Microtubule-Associated Proteins; Morpholines; Protein Serine-Threonine Kinases; Pyrones; Signal Transduction; Temozolomide | 2014 |
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Betulinic Acid; Cathepsin B; Cell Death; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Dipeptides; Glioma; Humans; Macrolides; Neoplasm Proteins; Pentacyclic Triterpenes; Temozolomide; Triterpenes | 2014 |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Prognosis; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2014 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Paraganglioma; Pheochromocytoma; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Succinate Dehydrogenase; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2014 |
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Grading; Temozolomide; Transcriptome; Tumor Suppressor Proteins | 2014 |
Experimental study of combined therapy for malignant glioma.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indoles; Neoplasm Transplantation; Nitrosourea Compounds; Oligodendroglioma; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Rats, Wistar; Temozolomide | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioma; Humans; Temozolomide | 2014 |
Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Movement; Cell Proliferation; Curcumin; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Progranulins; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; RNA Interference; RNA, Small Interfering; Temozolomide; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured | 2015 |
Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Prognosis; Spain; Survival Analysis; Temozolomide | 2014 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Protein Array Analysis; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proteomics; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Small Molecule Libraries; Staurosporine; Temozolomide; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Mice; Microscopy, Atomic Force; Nanomedicine; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Nude; Protein-Tyrosine Kinases; Radiation Tolerance; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms, Experimental; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; Magnetite Nanoparticles; Membrane Potential, Mitochondrial; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Technology, Pharmaceutical; Temozolomide | 2015 |
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Humans; Male; Middle Aged; Temozolomide | 2014 |
Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Treatment Outcome | 2014 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Humans; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Blotting, Western; Cell Differentiation; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Glycoproteins; Heterografts; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Peptides; Sesquiterpenes; Temozolomide | 2014 |
YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Topics: Adipokines; Animals; Antigens, Neoplasm; Biomarkers, Tumor; Cell Line, Tumor; Chitinase-3-Like Protein 1; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Lectins; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Experimental; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enediynes; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Rats; Signal Transduction; Temozolomide | 2014 |
Prospective identification of functionally distinct stem cells and neurosphere-initiating cells in adult mouse forebrain.
Topics: Aging; Animals; Antimitotic Agents; Cell Proliferation; Cell Separation; Dacarbazine; Glial Fibrillary Acidic Protein; Integrases; Mice, Inbred C57BL; Neural Stem Cells; Neurogenesis; Neuroglia; Phenotype; Polycomb Repressive Complex 1; Prosencephalon; Proto-Oncogene Proteins; Spheroids, Cellular; Temozolomide | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Magnetic Resonance Imaging; Neoplasm Transplantation; Rats; Rats, Wistar; Temozolomide | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes, ras; Glioma; Humans; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neovascularization, Pathologic; ras Proteins; Signal Transduction; Temozolomide | 2014 |
β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal‑regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Flavonoids; Glia Maturation Factor; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Sesquiterpenes; Survivin; Temozolomide | 2014 |
Irinotecan and temozolomide brain distribution: a focus on ABCB1.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Blood-Brain Barrier; Brain; Camptothecin; Dacarbazine; Female; Half-Life; Injections, Intraperitoneal; Irinotecan; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Nerve Tissue Proteins; Neurons; Prodrugs; Temozolomide; Tissue Distribution; Topoisomerase I Inhibitors | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy; Temozolomide | 2014 |
Overcoming multiple drug resistance mechanisms in medulloblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cells, Cultured; Cerebellar Neoplasms; Child; Child, Preschool; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Medulloblastoma; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2014 |
Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide | 2014 |
miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; MicroRNAs; Nuclear Proteins; ras Proteins; RNA, Neoplasm; Temozolomide; Tumor Necrosis Factor alpha-Induced Protein 3 | 2014 |
Nanoparticles of esterified polymalic acid for controlled anticancer drug release.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Delayed-Action Preparations; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Malates; Nanocapsules; Polymers; Temozolomide | 2014 |
Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; Glioblastoma; HSP27 Heat-Shock Proteins; Humans; Quercetin; Temozolomide | 2014 |
Longitudinal quality of life data: a comparison of continuous and ordinal approaches.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appetite; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Health Status; Humans; Longitudinal Studies; Middle Aged; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Sleep Stages; Surveys and Questionnaires; Temozolomide; Vincristine | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Temozolomide; Treatment Failure; Young Adult | 2014 |
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Genetic Vectors; Glioblastoma; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Neoplastic Stem Cells; Neural Cell Adhesion Molecule L1; Repressor Proteins; RNA, Messenger; RNA, Small Interfering; Telomeric Repeat Binding Protein 2; Temozolomide; Tubulin | 2014 |
mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cycloheximide; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA, Neoplasm; Gene Expression; Humans; Morpholines; Mutation; Neuroglia; Protein Biosynthesis; Pyrimidines; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2014 |
NMR as evaluation strategy for cellular uptake of nanoparticles.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glioblastoma; Gold; Humans; Magnetic Resonance Spectroscopy; Nanoparticles; Rhamnose; Temozolomide | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Irinotecan; Middle Aged; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.
Topics: Carrier Proteins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Regulatory Networks; Glioblastoma; Humans; MicroRNAs; Repressor Proteins; RNA, Messenger; Temozolomide; Up-Regulation | 2014 |
Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Glioblastoma; Humans; Hyperoxia; Procollagen-Proline Dioxygenase; Protein Disulfide-Isomerases; Temozolomide; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Telomerase; Temozolomide | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzyme Inhibitors; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide | 2014 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineoplastic Agents; Dacarbazine; Dexamethasone; Drug Combinations; Erythema; gamma-Globulins; Glioblastoma; Humans; Immunologic Factors; Levetiracetam; Male; Methylprednisolone; Middle Aged; Omeprazole; Oxycodone; Piperidines; Piracetam; Proton Pump Inhibitors; Quinazolines; Stevens-Johnson Syndrome; Temozolomide; Wound Healing | 2014 |
Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; BRCA2 Protein; Cell Cycle; Cell Line, Tumor; Child; Cyclin A2; Dacarbazine; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Haploinsufficiency; Histones; Homologous Recombination; Humans; Mutagens; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Reproducibility of Results; Single-Cell Analysis; Temozolomide | 2014 |
Radiation recall after a transarterial hepatic chemoembolization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Chemoembolization, Therapeutic; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Fluoroscopy; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Radiodermatitis; Radiography, Interventional; Risk Factors; Temozolomide; Time Factors | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Genes, ras; Genes, Tumor Suppressor; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Signal Transduction; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2014 |
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Melanoma; Mice; Mice, Transgenic; Temozolomide; Tumor Microenvironment | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Carcinogenesis; Cell Line, Tumor; Cell Movement; Child; Dacarbazine; Epithelial-Mesenchymal Transition; Female; Glioma; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Transforming Growth Factor beta; Young Adult | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Choline; Contrast Media; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Temozolomide; Time Factors | 2014 |
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Fatal Outcome; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Pineal Gland; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2014 |
Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds.
Topics: Antineoplastic Agents; Bradykinin; Cell Line, Tumor; Cell Survival; Dacarbazine; HEK293 Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proto-Oncogene Proteins c-akt; Temozolomide; Thiazolidines; Tyrosine | 2014 |
miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeleton; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; rap GTP-Binding Proteins; Temozolomide; Up-Regulation | 2014 |
Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.
Topics: Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Dogs; Drug Carriers; Drug Delivery Systems; Glioma; Half-Life; Humans; Lactic Acid; Madin Darby Canine Kidney Cells; Male; Nanoparticles; Polyesters; Polyethylene Glycols; Polymers; Polysorbates; Rats; Rats, Wistar; Temozolomide; Tissue Distribution | 2016 |
Analyzing temozolomide medication errors: potentially fatal.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, Factual; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Medication Errors; Middle Aged; Pharmaceutical Preparations; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; United States | 2014 |
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.
Topics: Adenoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Blotting, Western; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Pituitary Neoplasms; Receptors, Dopamine D2; Temozolomide; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A | 2014 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Middle Aged; Temozolomide | 2014 |
MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.
Topics: Adult; Aged; Biomarkers, Tumor; Central Nervous System Neoplasms; Dacarbazine; DNA Methylation; Female; Humans; Immunohistochemistry; Lymphoma; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2014 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Glioma; Homologous Recombination; Humans; Isocitrate Dehydrogenase; Mutation; Rad51 Recombinase; Temozolomide | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide; Young Adult | 2014 |
Exo1 independent DNA mismatch repair involves multiple compensatory nucleases.
Topics: Animals; Cell Line; Dacarbazine; DNA Mismatch Repair; DNA Repair Enzymes; DNA-Binding Proteins; Endodeoxyribonucleases; Endonucleases; Exodeoxyribonucleases; Fibroblasts; Guanine; Mice; Mice, Inbred C57BL; MRE11 Homologue Protein; Multifunctional Enzymes; Nuclear Proteins; Temozolomide; Up-Regulation | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neurosurgical Procedures; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Tumor Burden | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Hematologic Diseases; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Republic of Korea; Retrospective Studies; Severity of Illness Index; Sex Factors; Temozolomide; Vomiting; Young Adult | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hydrocarbons, Brominated; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred BALB C; MicroRNAs; Sesquiterpenes; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Mice; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Dacarbazine; ErbB Receptors; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Signal Transduction; Temozolomide; Transfection; Xenograft Model Antitumor Assays | 2014 |
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Dichloroacetic Acid; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Glioblastoma; Glycolysis; Humans; Kaplan-Meier Estimate; Polymers; Pyruvates; Rats; Rats, Inbred F344; Temozolomide | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Endpoint Determination; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Seizures; Survival Analysis; Temozolomide | 2015 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Glioma; Humans; Neoplasm Grading; Temozolomide | 2014 |
Survival in granular cell astrocytomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Fatal Outcome; Female; Humans; Male; Middle Aged; Neurosurgical Procedures; Occipital Lobe; Radiotherapy, Adjuvant; Temozolomide | 2015 |
Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2014 |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Genotype; Glioblastoma; Humans; Male; Mice; Middle Aged; Mutation; Oligodendroglioma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding Sites; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioma; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MicroRNAs; Response Elements; RNA Interference; RNA-Binding Proteins; Temozolomide; Transcription, Genetic; Transcriptional Activation | 2014 |
Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Topics: Adenocarcinoma; Adenoma; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Neoplasms, Hereditary Nonpolyposis; Dacarbazine; Disease Models, Animal; DNA Mismatch Repair; Female; Intestinal Mucosa; Intestines; Male; Mice, Knockout; MutS Homolog 2 Protein; Neoplastic Stem Cells; Risk Factors; Temozolomide; Time Factors | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Glioma; Humans; Insulin-Like Growth Factor Binding Protein 2; Integrin beta1; MAP Kinase Signaling System; Neoplasm Invasiveness; Temozolomide; Tissue Array Analysis | 2014 |
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Approval; Drug Repositioning; Etidronic Acid; Female; High-Throughput Screening Assays; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasms; Risedronic Acid; Temozolomide; Tetrazoles; Xenograft Model Antitumor Assays | 2014 |
Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; HMGB1 Protein; HSP70 Heat-Shock Proteins; Humans; Temozolomide; Tumor Microenvironment | 2014 |
ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cluster Analysis; Dacarbazine; Disease Models, Animal; DNA Copy Number Variations; DNA Glycosylases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Models, Biological; Phosphorylation; RNA Interference; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Flow Cytometry; Genetic Therapy; Humans; Immunoenzyme Techniques; Interleukins; Ki-67 Antigen; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide | 2014 |
Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Combined Modality Therapy; Connexin 43; Dacarbazine; Drug Administration Schedule; Female; Gamma Rays; Glioblastoma; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Protein Structure, Tertiary; Rats; Rats, Wistar; Stereotaxic Techniques; Survival Analysis; Temozolomide; Tumor Burden | 2014 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Imidazoles; Mice; O(6)-Methylguanine-DNA Methyltransferase; ras Proteins; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.
Topics: Animals; Cell Proliferation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Glioma; Mice; Neoplasm Transplantation; Peptides; Temozolomide; Trans-Activators | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy.
Topics: Chitosan; Dacarbazine; Doxorubicin; Drug Delivery Systems; Humans; Lactic Acid; Male; Molecular Structure; Nanoparticles; Particle Size; Polyesters; Polymers; Surface Properties; Surface-Active Agents; Temozolomide; Temperature | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; HEK293 Cells; Humans; Introns; Male; Middle Aged; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-met; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, RNA; Temozolomide; Translocation, Genetic; Young Adult | 2014 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality Therapy; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioma; Humans; Isocitrate Dehydrogenase; Middle Aged; Optic Nerve Glioma; Radiosurgery; Temozolomide; Vision Disorders; Visual Fields | 2015 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Heat-Shock Proteins; HSC70 Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Molecular Chaperones; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2015 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Snake Venoms; Temozolomide; Tumor Suppressor Proteins | 2014 |
Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Chemoradiotherapy; Cohort Studies; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Female; Follow-Up Studies; France; Glioblastoma; Health Care Costs; Hospital Costs; Hospitals, University; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome | 2014 |
Primary brain tumors: introduction.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Humans; Molecular Diagnostic Techniques; Neurosurgical Procedures; Temozolomide | 2014 |
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Glioma; Humans; Isoenzymes; Neoplastic Stem Cells; Rats; Retinal Dehydrogenase; RNA, Messenger; Temozolomide | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizures; Temozolomide | 2015 |
Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Abscess; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Neuroepithelial; Nocardia Infections; Temozolomide | 2015 |
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide; Tertiary Care Centers; Treatment Outcome | 2014 |
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Small Cell Lung Carcinoma; Temozolomide; Treatment Outcome | 2014 |
Reinvestigating nanoprecipitation via Box-Behnken design: a systematic approach.
Topics: Dacarbazine; Models, Chemical; Polyesters; Surface-Active Agents; Temozolomide | 2015 |
Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Metabolome; Mice; Mice, Inbred C57BL; Mitosis; Pattern Recognition, Automated; Temozolomide; Tumor Burden | 2014 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Oncogene Proteins; R-SNARE Proteins; Temozolomide | 2015 |
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Lysosomes; Mice; Mice, Nude; Nanostructures; Phosphatidylserines; Random Allocation; Saposins; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auranofin; Brain Neoplasms; Captopril; Celecoxib; Dacarbazine; Disulfiram; Glioblastoma; Humans; Itraconazole; Molecular Targeted Therapy; Morpholines; Neoplasm Recurrence, Local; Pyrazoles; Ritonavir; Sertraline; Signal Transduction; Sulfonamides; Temozolomide; Treatment Outcome | 2014 |
Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemical Fractionation; Dacarbazine; Ficus; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Situ Nick-End Labeling; Latex; MicroRNAs; Models, Biological; Neoplasm Invasiveness; Neovascularization, Physiologic; Phytotherapy; Plant Extracts; Temozolomide | 2015 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lateral Ventricles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Young Adult | 2014 |
DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Cohort Studies; Dacarbazine; Diacylglycerol Kinase; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Nomograms; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2014 |
Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Forkhead Box Protein O3; Forkhead Transcription Factors; Genetic Therapy; Humans; Male; Melanoma; Mice; Mice, Inbred BALB C; Temozolomide; Transcription Factors; Xenograft Model Antitumor Assays | 2014 |
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Transfer Techniques; Glioblastoma; Humans; Mice; Nanoparticles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Double-salting out assisted liquid-liquid extraction (SALLE) HPLC method for estimation of temozolomide from biological samples.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Dacarbazine; Humans; Linear Models; Liquid-Liquid Extraction; Reproducibility of Results; Sensitivity and Specificity; Sodium Chloride; Sulfates; Temozolomide | 2014 |
Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Glioblastoma; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins c-akt; Snail Family Transcription Factors; Temozolomide; Transcription Factors; Twist-Related Protein 1 | 2014 |
Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; Pentacyclic Triterpenes; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Characterization of a novel anti-cancer compound for astrocytomas.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Profiling; Humans; Mice; Promoter Regions, Genetic; Temozolomide; Toxicity Tests, Acute; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramides; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Glioblastoma; Humans; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Temozolomide | 2014 |
Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Ouabain; Sodium; Sodium-Potassium-Exchanging ATPase; Temozolomide; Valinomycin | 2014 |
The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines.
Topics: Adult; Animals; Astrocytes; Astrocytoma; Bees; Cell Line, Tumor; Dacarbazine; Fatty Acids; Glioblastoma; Honey; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Propolis; Specimen Handling; Temozolomide | 2014 |
Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Maintenance Chemotherapy; Male; Middle Aged; Radiotherapy Planning, Computer-Assisted; Temozolomide; Treatment Outcome; Young Adult | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Photochemotherapy; Photosensitizing Agents; Porphyrins; Temozolomide; Treatment Outcome | 2014 |
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Membrane Proteins; MicroRNAs; Real-Time Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; RNA, Small Interfering; Temozolomide; Transfection | 2014 |
Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation.
Topics: Antineoplastic Agents, Alkylating; bcl-Associated Death Protein; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; JNK Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Temozolomide | 2014 |
N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Histones; Humans; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
Topics: Astrocytes; Brain Neoplasms; Cell Compartmentation; Cell Count; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Glioblastoma; Humans; Luminescence; Models, Biological; Reproducibility of Results; Spheroids, Cellular; Stromal Cells; Temozolomide | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Follow-Up Studies; Glioma; Humans; Image Interpretation, Computer-Assisted; Middle Aged; Multivariate Analysis; Neoplasm Grading; Principal Component Analysis; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2014 |
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Topics: Cell Proliferation; Cisplatin; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Reactive Oxygen Species; Temozolomide | 2015 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide; Time Factors | 2014 |
Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Glioblastoma; Humans; Longitudinal Studies; Male; Middle Aged; Pneumonia, Pneumocystis; Retrospective Studies; T-Lymphocytes; Temozolomide; Young Adult | 2014 |
Pine (Pinus morrisonicola Hayata) needle extracts sensitize GBM8901 human glioblastoma cells to temozolomide by downregulating autophagy and O(6)-methylguanine-DNA methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Synergism; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pinus; Plant Extracts; Plant Leaves; Temozolomide | 2014 |
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Topics: Animals; Apoptosis; Arsenites; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Humans; Mice; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Sodium Compounds; Telomere; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Temozolomide | 2015 |
RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Prognosis; Protein Stability; Protein Transport; ras Proteins; Spheroids, Cellular; STAT3 Transcription Factor; Temozolomide; Tumor Cells, Cultured | 2014 |
Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enzyme Activation; Flavones; Glioblastoma; Humans; Reactive Oxygen Species; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Mutation; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
Topics: Apoptosis; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Damage; DNA Repair; Gene Expression; Glioblastoma; Humans; L-Lactate Dehydrogenase; Magnetic Resonance Imaging; Membrane Proteins; Methyltransferases; NAD; Protein Kinases; Pyruvic Acid; Temozolomide; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Temozolomide: fatal hepatic failure.
Topics: Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Dacarbazine; Humans; Liver Failure; Liver Function Tests; Risk Assessment; Risk Factors; Temozolomide; Time Factors | 2014 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome | 2015 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dacarbazine; Deubiquitinating Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoenzyme Techniques; Membrane Proteins; Neoplasm Grading; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2014 |
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capsules; Caspase 3; Dacarbazine; Doxorubicin; Female; Humans; Mammary Neoplasms, Experimental; Neoplasm Metastasis; Neoplasm Proteins; Rats; Rats, Inbred F344; Temozolomide | 2014 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Estrogen Receptor beta; Flavanones; Glioma; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 2-Ring; Humans; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Case-Control Studies; Caspase 3; Cell Proliferation; Dacarbazine; Flow Cytometry; Glioma; Humans; Inhibitor of Apoptosis Proteins; Proteolysis; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Mice, Nude; Temozolomide; Tumor Suppressor Protein p53 | 2014 |
Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Hypoxia; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Protein Binding; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Radiation; Everolimus; Gamma Rays; Glioblastoma; Histones; Humans; Linear Energy Transfer; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Disease Progression; Down-Regulation; Female; Glioma; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Prognosis; Repressor Proteins; RNA, Small Interfering; Temozolomide; Transcription Factors; Treatment Outcome; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2014 |
Primary glioblastoma of the trigeminal nerve root entry zone: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modality Therapy; Cranial Nerve Neoplasms; Dacarbazine; Disease Progression; Glioblastoma; Humans; Male; Temozolomide; Trigeminal Nerve Diseases | 2015 |
Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Flavonoids; Glioblastoma; Humans; Neoplasm Invasiveness; NF-kappa B; Signal Transduction; Temozolomide | 2015 |
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autoantibodies; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Temozolomide | 2015 |
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drugs, Investigational; Half-Life; Humans; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Receptor, trkB; Survival Analysis; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
MGMT methylation in glioblastoma: tale of the tail.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide | 2015 |
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Neoplasm Proteins; Polycomb Repressive Complex 2; RNA Interference; RNA, Messenger; Temozolomide; Time Factors; Transfection | 2014 |
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioma; Humans; NF-kappa B; Osteopontin; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Temozolomide | 2015 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2014 |
SPOT14-positive neural stem/progenitor cells in the hippocampus respond dynamically to neurogenic regulators.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Biomarkers; Cell Proliferation; Dacarbazine; Green Fluorescent Proteins; Hippocampus; Immunohistochemistry; Mice, Transgenic; Microscopy, Fluorescence; Neural Stem Cells; Neurogenesis; Nuclear Proteins; Temozolomide; Transcription Factors | 2014 |
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Contrast Media; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Radiography; Temozolomide; Young Adult | 2014 |
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Topics: Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Shape; Cell Survival; Dacarbazine; Glioblastoma; Humans; Ligands; Neoplastic Stem Cells; Receptor, Adenosine A1; Receptor, Adenosine A2B; Temozolomide | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Diphosphonates; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Male; Mice; Mice, Inbred Strains; Nanoparticles; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Transferrin; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Cholestyramine Resin; Common Bile Duct Diseases; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Immunohistochemistry; Jaundice; Liver Function Tests; Middle Aged; Syndrome; Temozolomide; Treatment Outcome; Ursodeoxycholic Acid | 2014 |
Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transfection | 2015 |
Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antirheumatic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Death; Cell Line, Tumor; Chloroquine; Dacarbazine; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Glioblastoma; Heat-Shock Proteins; Humans; Membrane Proteins; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Temozolomide; Transcription Factor CHOP; Transfection; Xenograft Model Antitumor Assays | 2014 |
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Ki-67 Antigen; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Sulfites; Temozolomide; Time Factors; Tumor Suppressor Proteins | 2014 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; O(6)-Methylguanine-DNA Methyltransferase; Propensity Score; Radiotherapy Dosage; Regression Analysis; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome | 2015 |
Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
Topics: Adenocarcinoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Pituitary Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Therapy, Combination; Glioma; Hematoporphyrins; Male; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Wistar; Temozolomide; Treatment Outcome | 2014 |
LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.
Topics: Adult; Aged; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Membrane Glycoproteins; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Superoxide Dismutase; Temozolomide; Young Adult | 2015 |
Antineoplastic effect of decoy oligonucleotide derived from MGMT enhancer.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Death; Cell Line, Tumor; Dacarbazine; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Injections, Intralesional; Mice, Nude; NF-kappa B; Nucleotide Motifs; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotides; Protein Binding; RNA, Messenger; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Neoplasm Grading; Retrospective Studies; Supratentorial Neoplasms; Temozolomide; Treatment Outcome | 2015 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioma; Hospitals, Religious; Hospitals, University; Humans; Male; Neoplasm Grading; Neurons; Prognosis; Prospective Studies; Rome; Survival Analysis; Temozolomide | 2015 |
Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Capillaries; Capillary Permeability; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Glioma; Humans; Male; Mice; Microbubbles; Survival Analysis; Temozolomide; Tight Junctions; Tumor Burden; Ultrasonics; Xenograft Model Antitumor Assays | 2014 |
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Topics: Aged; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Databases, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Grading; Prognosis; Regression Analysis; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Immunoblotting; Mice; Mice, SCID; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Topics: Adenoviridae; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytopathogenic Effect, Viral; Dacarbazine; Gene Expression; Genes, Transgenic, Suicide; Genetic Vectors; Glioma; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Spheroids, Cellular; Temozolomide; Transduction, Genetic; Tumor Cells, Cultured; Virus Replication; Y-Box-Binding Protein 1 | 2015 |
MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; E2F3 Transcription Factor; Gene Knockdown Techniques; Glioma; Humans; MicroRNAs; Molecular Sequence Data; RNA Interference; Temozolomide | 2015 |
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Melanoma; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Topics: Antineoplastic Agents, Alkylating; Antipsychotic Agents; Apoptosis; Benzodiazepines; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Olanzapine; Phosphoproteins; Protein Array Analysis; Temozolomide; Tumor Cells, Cultured | 2015 |
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Chloroquine; Dacarbazine; Drug Synergism; Glioma; Humans; Mitochondria; Rats; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2015 |
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Time Factors | 2015 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose F18; Humans; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Myelitis; Paraplegia; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2014 |
Glioblastoma multiforme and hepatitis B: do the right thing(s).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hepatitis B; Hepatitis B virus; Humans; Male; Middle Aged; Temozolomide; Virus Activation | 2014 |
Fatal lymphomatoid granulomatosis with primary CNS-involvement in an immunocompetent 80-year-old woman.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System; Central Nervous System Neoplasms; Dacarbazine; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Lymphomatoid Granulomatosis; Rituximab; Temozolomide | 2014 |
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene Knockdown Techniques; Glioblastoma; Humans; In Vitro Techniques; MicroRNAs; Mitogen-Activated Protein Kinase 13; Mitogen-Activated Protein Kinase 14; Oxidative Stress; Temozolomide | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electron Transport Complex I; Glioma; Humans; Male; Methylation; Mitochondria; Promoter Regions, Genetic; Rats, Sprague-Dawley; Tamoxifen; Temozolomide; Tumor Suppressor Proteins | 2015 |
Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Curcumin; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Glioblastoma; Humans; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Rats; Temozolomide | 2015 |
Anticancer potential and mechanism of action of mango ginger (Curcuma amada Roxb.) supercritical CO₂ extract in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carbon Dioxide; Cell Line, Tumor; Cell Survival; Curcuma; Dacarbazine; Etoposide; Glioblastoma; Humans; Mice; Plant Extracts; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cellular Senescence; Chemoradiotherapy; Cyclin B1; Dacarbazine; Glioma; Humans; Immunohistochemistry; Male; Mice, Nude; Mitosis; Polyploidy; Receptors, Erythropoietin; RNA Interference; RNAi Therapeutics; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Glioblastoma; Histones; Humans; Indoles; Male; Middle Aged; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Quinazolines; Temozolomide | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Phosphorylation; Protein Kinase C; Tamoxifen; Temozolomide | 2015 |
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pituitary Neoplasms; Prognosis; Retrospective Studies; Somatostatin; Survival Rate; Temozolomide; Tertiary Care Centers | 2015 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Humans; Indoles; Melanoma; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Single-Cell Analysis; Temozolomide | 2015 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2015 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cystathionine gamma-Lyase; Cysteine; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Glioblastoma; Glutathione; Humans; NF-E2-Related Factor 2; Piperazines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Sulfasalazine; Temozolomide | 2015 |
Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Biphenyl Compounds; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Models, Molecular; Muscle Proteins; Nitrophenols; Peptide Fragments; Piperazines; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Temozolomide; Tumor Cells, Cultured | 2015 |
Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Humans; Immunohistochemistry; Male; Matrix Metalloproteinases; Middle Aged; Neoplasm Invasiveness; STAT3 Transcription Factor; Temozolomide; Tumor Stem Cell Assay | 2016 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiotherapy; Retrospective Studies; Temozolomide | 2015 |
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Hedgehog Proteins; HEK293 Cells; Humans; MicroRNAs; Neoplasm Proteins; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Temozolomide | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiosurgery; Reoperation; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2015 |
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; HEK293 Cells; Humans; Kruppel-Like Factor 4; MicroRNAs; Neoplastic Stem Cells; Neurofilament Proteins; Proteomics; RNA Interference; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Temozolomide; Time Factors; Transfection; Two-Dimensional Difference Gel Electrophoresis | 2015 |
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Cell Cycle Proteins; Dacarbazine; Disease Models, Animal; DNA Damage; Glioblastoma; Humans; Mice; Nuclear Proteins; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Longitudinal Studies; Male; Microsurgery; Middle Aged; Neurosurgical Procedures; Positron-Emission Tomography; Prospective Studies; Temozolomide; Treatment Outcome; Tumor Burden; Tyrosine | 2015 |
Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Pituitary ACTH Hypersecretion; Remission Induction; Temozolomide; Treatment Outcome; Tumor Burden | 2015 |
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Retreatment; Temozolomide; Treatment Outcome | 2016 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Dacarbazine; Electric Stimulation Therapy; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Thioguanine; Treatment Failure | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Expression; Glioblastoma; Glycoproteins; Humans; Immunophenotyping; Mice; Neoplastic Stem Cells; Peptides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Transcription, Genetic; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Coculture Techniques; Connexin 43; Dacarbazine; Drug Resistance, Neoplasm; Gap Junctions; Gene Knockdown Techniques; Glioma; Humans; Temozolomide; Tumor Microenvironment; Vincristine | 2015 |
Fever-range hyperthermia vs. hypothermia effect on cancer cell viability, proliferation and HSP90 expression.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cold Temperature; Cold-Shock Response; Dacarbazine; Drug Screening Assays, Antitumor; Heat-Shock Response; Hot Temperature; HSP90 Heat-Shock Proteins; Humans; Temozolomide | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Gene Deletion; Genetic Predisposition to Disease; Glioma; Humans; Male; Middle Aged; Missouri; Prevalence; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Galectin 1; Gene Silencing; Glioblastoma; Humans; Lipids; Mice, Nude; Nanocapsules; RNA, Small Interfering; Temozolomide; Tumor Burden | 2015 |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; MutL Protein Homolog 1; Nuclear Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrones; RNA Interference; RNA, Small Interfering; Temozolomide | 2015 |
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Cells, Cultured; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Gene Expression Profiling; Glioblastoma; Humans; Mice, Inbred NOD; Mice, SCID; Microarray Analysis; Neoplasm Transplantation; Promoter Regions, Genetic; Radiation-Sensitizing Agents; Temozolomide; Tumor Suppressor Proteins; Valproic Acid | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Peduncle; Child; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infratentorial Neoplasms; Irinotecan; Laser Therapy; Male; Neoplasms, Multiple Primary; Neurofibromatosis 1; Neuroimaging; Optic Nerve Glioma; Supratentorial Neoplasms; Temozolomide | 2015 |
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Multivariate Analysis; Promoter Regions, Genetic; Radiotherapy; Retrospective Studies; Survival Analysis; Temozolomide | 2015 |
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Temozolomide; Vinblastine | 2015 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cannabidiol; Cannabinoids; Cannabinol; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dronabinol; Drug Combinations; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Plant Extracts; Proto-Oncogene Proteins B-raf; ras Proteins; Skin Neoplasms; Temozolomide | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Glioma; Humans; Neoplasm Grading; RNA Interference; Temozolomide; Tetraspanins; Up-Regulation | 2015 |
The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Growth Processes; Cell Line, Tumor; Chloroquine; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Protein p53 | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Kaplan-Meier Estimate; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; PTEN Phosphohydrolase; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Glioma; Heme Oxygenase-1; Humans; Imidazoles; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Temozolomide | 2015 |
Synthesis of [3-N-(11) C-methyl]temozolomide via in situ activation of 3-N-hydroxymethyl temozolomide and alkylation with [(11) C]methyl iodide.
Topics: Alkylation; Carbon Radioisotopes; Chemistry Techniques, Synthetic; Dacarbazine; Hydrocarbons, Iodinated; Radiochemistry; Temozolomide | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Dacarbazine; DNA Damage; Enzyme Activation; Glioma; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phenotype; Protein Serine-Threonine Kinases; Single-Cell Analysis; Sirolimus; Temozolomide; Time Factors; TOR Serine-Threonine Kinases | 2015 |
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Epithelial-Mesenchymal Transition; Female; Glioblastoma; Humans; Insulin-Like Growth Factor II; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy, Needle; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neuronavigation; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA Repair-Deficiency Disorders; Female; Glioma; Humans; Male; Mutation; Receptors, Immunologic; Statistics, Nonparametric; Temozolomide; Tumor Suppressor Proteins | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
[Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line].
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioma; Rats; Temozolomide; Up-Regulation | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Regulation, Neoplastic; Genome, Human; Glioma; Humans; Isoenzymes; Mice; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Signal Transduction; Temozolomide; Transcription, Genetic | 2015 |
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Topics: Administration, Metronomic; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; ErbB Receptors; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Odds Ratio; Proportional Hazards Models; Temozolomide; Up-Regulation | 2015 |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Topics: AC133 Antigen; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Glioblastoma; Glycoproteins; Humans; Hyaluronan Receptors; Mesoderm; Neoplastic Stem Cells; Neural Stem Cells; Peptides; Predictive Value of Tests; Temozolomide | 2015 |
Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Craniospinal Irradiation; Dacarbazine; Disease-Free Survival; Etoposide; Female; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Neurosurgical Procedures; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine; Young Adult | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Genes, p53; Glioma; Humans; Inhibitor of Apoptosis Proteins; Mutation; PTEN Phosphohydrolase; Silybin; Silymarin; Survivin; Temozolomide | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompatible Materials; Boron Compounds; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Lactic Acid; Magnetic Resonance Spectroscopy; Methacrylates; Methylmethacrylates; Micelles; Nanoconjugates; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectrometry, Fluorescence; Temozolomide | 2015 |
Temozolomide nanoparticles for targeted glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Delivery Systems; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Nanoparticles; Temozolomide | 2015 |
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression; Glioblastoma; Homeodomain Proteins; Humans; Mice; Oncogenes; Prognosis; Temozolomide; Tissue Array Analysis; Transcriptome; Transfection; Xenograft Model Antitumor Assays | 2015 |
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Glioblastoma; Homeodomain Proteins; Humans; Lignans; Neoplastic Stem Cells; Receptor, Notch3; Receptors, Notch; Temozolomide; Transcription Factor HES-1; Tumor Cells, Cultured | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm Recurrence, Local; Neurosurgical Procedures; Nuclear Proteins; Prognosis; Temozolomide; Tumor Suppressor Protein p53; X-linked Nuclear Protein | 2015 |
Step-wise and punctuated genome evolution drive phenotype changes of tumor cells.
Topics: Antineoplastic Agents, Alkylating; Chromosomal Instability; Dacarbazine; DNA Damage; Evolution, Molecular; Gene Regulatory Networks; Genetic Vectors; Genome, Human; HEK293 Cells; HeLa Cells; Humans; Temozolomide; Transfection | 2015 |
Downregulation of Id2 increases chemosensitivity of glioma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Differentiation Protein 2; RNA Interference; Temozolomide | 2015 |
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Temozolomide | 2015 |
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Suppressor Proteins | 2015 |
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Topics: Amino Acid Motifs; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA Damage; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Protein c-fli-1; Real-Time Polymerase Chain Reaction; RNA-Binding Protein EWS; Sarcoma, Ewing; Sequence Analysis, DNA; Temozolomide | 2015 |
Focused ultrasound with microbubbles increases temozolomide delivery in U87 transfected mice.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Mice; Microbubbles; Neoplasms, Experimental; Temozolomide; Transfection; Ultrasonics | 2015 |
Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth.
Topics: beta Catenin; Blotting, Western; Cell Dedifferentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Reprogramming; Cellular Reprogramming Techniques; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Induced Pluripotent Stem Cells; Mitogens; Neoplastic Stem Cells; Neural Stem Cells; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Spheroids, Cellular; Temozolomide | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2015 |
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Membrane Glycoproteins; Methylation; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins; Up-Regulation | 2015 |
Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Glioma; GPI-Linked Proteins; Humans; Male; Mice, Nude; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins; Receptors, Tumor Necrosis Factor, Member 10c; Temozolomide; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor Decoy Receptors; Xenograft Model Antitumor Assays | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor; Dacarbazine; Drug Evaluation, Preclinical; Female; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Luminescent Proteins; Mice; Mice, Nude; Optical Imaging; Temozolomide | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide | 2015 |
Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Movement; Dacarbazine; Dopamine; Gene Expression; Glioma; Macrophages; Male; Rats; Rats, Wistar; Receptors, Dopamine D2; Temozolomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Topics: ADAM Proteins; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Fluorescence Resonance Energy Transfer; Glioblastoma; Humans; Immunoblotting; Membrane Proteins; Neoplasm Invasiveness; Real-Time Polymerase Chain Reaction; Temozolomide; Transcriptome | 2015 |
[Radiation and temozolomide therapy].
Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Glioblastoma; Humans; Risk Factors; Temozolomide | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Progression; Female; Frontal Lobe; Glioma; Hippocampus; Humans; Neoplasm Recurrence, Local; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Supratentorial Neoplasms; Temozolomide; Tumor Burden; Young Adult | 2015 |
Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neuroblastoma; Temozolomide | 2015 |
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Multivariate Analysis; Propensity Score; Retrospective Studies; Selection Bias; Temozolomide | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.
Topics: Alkylating Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Down-Regulation; Exonucleases; Female; Histones; Humans; Temozolomide | 2015 |
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carboplatin; Child; Child, Preschool; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Induction Chemotherapy; Infant; Kaplan-Meier Estimate; Male; Pilot Projects; Temozolomide; Treatment Outcome; Vincristine | 2015 |
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine CXCL12; Chemoradiotherapy; Child; Child, Preschool; Cyclams; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Gene Expression Profiling; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Retrospective Studies; Signal Transduction; Temozolomide; Time Factors; Tissue Culture Techniques; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Proportional Hazards Models; Radiation Tolerance; Radiotherapy; Rats; RNA, Small Interfering; Temozolomide; Thrombospondins; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioblastoma; Glycolysis; Humans; Metformin; Mice; Mice, Nude; Mitochondria; Temozolomide; Transcription Factors; Xenograft Model Antitumor Assays | 2015 |
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Brain Neoplasms; China; Cluster Analysis; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Temozolomide; Treatment Outcome | 2015 |
Pharmacological reduction of adult hippocampal neurogenesis modifies functional brain circuits in mice exposed to a cocaine conditioned place preference paradigm.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Brain; Choice Behavior; Cocaine; Conditioning, Psychological; Dacarbazine; Dentate Gyrus; Dopamine Uptake Inhibitors; Extinction, Psychological; Hippocampus; Male; Mice; Multivariate Analysis; Neural Pathways; Neurogenesis; Nucleus Accumbens; Paraventricular Hypothalamic Nucleus; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Temozolomide | 2016 |
Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells.
Topics: Apoptosis; Caspase 3; Cell Proliferation; Curcumin; Dacarbazine; Diarylheptanoids; Glioblastoma; Humans; Neoplastic Stem Cells; Primary Cell Culture; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplastic Stem Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Mutation; Sirolimus; Temozolomide | 2015 |
miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Models, Biological; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2015 |
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Glioblastoma; Humans; Paclitaxel; Temozolomide | 2015 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Interferon-beta; Male; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Inbred F344; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Tissue Distribution; Treatment Outcome | 2015 |
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Genotype; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk Factors; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Female; Glioblastoma; Humans; Male; Middle Aged; Nervous System Neoplasms; Neurosurgery; Prospective Studies; Retrospective Studies; Survival Analysis; Temozolomide; Young Adult | 2015 |
Transport of treosulfan and temozolomide across an in-vitro blood-brain barrier model.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Busulfan; Capillaries; Cells, Cultured; Dacarbazine; Endothelial Cells; Gray Matter; Swine; Temozolomide | 2015 |
NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.
Topics: Apoptosis; Benzothiazoles; Cell Cycle; Cell Cycle Checkpoints; Cellular Senescence; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; DNA Damage; DNA Polymerase beta; DNA Repair; Enzyme Inhibitors; HCT116 Cells; Humans; Small Molecule Libraries; Sulfhydryl Compounds; Sulfonamides; Temozolomide; Toluene; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Bortezomib; Cell Survival; Dacarbazine; Disulfiram; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nestin; Peptides; Pituitary Neoplasms; Primary Cell Culture; Proteasome Inhibitors; Proteolysis; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitination; Xenograft Model Antitumor Assays | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Karnofsky Performance Status; Logistic Models; Male; Middle Aged; Motor Disorders; Multivariate Analysis; Neurosurgical Procedures; Odds Ratio; Postoperative Complications; Postoperative Hemorrhage; Prognosis; Psychotic Disorders; Retrospective Studies; Risk Factors; Seizures; Surgical Wound Infection; Temozolomide | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Doxorubicin; Genotype; Glioblastoma; Humans; Kaplan-Meier Estimate; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proteins; Temozolomide; Valproic Acid | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Evidence-Based Medicine; Glioma; Humans; Lomustine; Neoplasm Grading; Neoplasm Staging; Oligodendroglioma; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Evidence-Based Medicine; Glioma; Humans; Lomustine; Neoplasm Grading; Neoplasm Staging; Oligodendroglioma; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Glioblastoma; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rats; Rats, Wistar; Survival Rate; Temozolomide; Transplantation, Homologous | 2015 |
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Exosomes; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunomagnetic Separation; Mice, Nude; Microfluidics; RNA, Messenger; Temozolomide; Treatment Outcome | 2015 |
miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Membrane Glycoproteins; Mice, Nude; MicroRNAs; Temozolomide | 2015 |
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Temozolomide | 2015 |
Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Health Care Surveys; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Levetiracetam; Male; Middle Aged; Piracetam; Proportional Hazards Models; Retrospective Studies; Temozolomide; Young Adult | 2015 |
Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
Topics: Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase Inhibitors; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Ligands; Neoplastic Stem Cells; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic; Receptors, Purinergic P1; Receptors, Purinergic P2X7; Temozolomide | 2015 |
Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Female; Glioblastoma; Humans; Hydrogels; Light; Methacrylates; Mice, Nude; Microglia; Polyethylene Glycols; Temozolomide; Tumor Burden | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investigational; Tissue Distribution | 2015 |
Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Isothiocyanates; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Models, Biological; Neoplasm Proteins; Phytotherapy; Random Allocation; RNA, Neoplasm; Sulfoxides; Temozolomide; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Colorectal Neoplasms; Cysteine; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glutathione; Guanine; HCT116 Cells; Humans; Male; Mice, Inbred BALB C; Molecular Targeted Therapy; Temozolomide; Thioctic Acid; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Male; Middle Aged; Nitrosourea Compounds; Prospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Brain Neoplasms; Dacarbazine; Dexamethasone; Female; Glioblastoma; Humans; Hyperglycemia; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Temozolomide | 2015 |
Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; DNA; Drug Carriers; Drug Delivery Systems; Humans; Lipids; Mice; Nanomedicine; Nanostructures; Neoplasms, Neuroepithelial; Temozolomide; Transfection | 2016 |
A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Models, Biological; Promoter Regions, Genetic; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2017 |
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagonists; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Mutation; Nitriles; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Pyridones; Survival Analysis; Temozolomide | 2015 |
Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Germany; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Radiotherapy, Adjuvant; Retrospective Studies; Temozolomide | 2015 |
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, p53; Glioblastoma; Humans; Mice, Inbred C57BL; MutS Homolog 2 Protein; Radiation, Ionizing; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Dacarbazine; Female; Glioma; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Odds Ratio; Radiotherapy Dosage; Regression Analysis; Sex Factors; Temozolomide; Young Adult | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Carmustine; Dacarbazine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioma; Inhibitory Concentration 50; Oxidative Stress; Rats; Temozolomide | 2015 |
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition; Glioma; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Snails; Temozolomide; Twist-Related Protein 1 | 2015 |
Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro.
Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Inhibitors; HCT116 Cells; HT29 Cells; Humans; In Vitro Techniques; Lactones; Leukocytes, Mononuclear; Neoplasms; Orlistat; Purines; Temozolomide; Tumor Suppressor Proteins | 2015 |
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; CD11b Antigen; Cell Line, Tumor; Cell Nucleus; Cytosol; Dacarbazine; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Microscopy, Fluorescence; Nuclear Proteins; RNA Interference; Temozolomide; Transcription Factors; Twist-Related Protein 1; von Willebrand Factor | 2015 |
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Complex and Mixed; Neurosurgical Procedures; Oligodendroglioma; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Glioblastoma; Glioma; Histones; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Mice; Potassium Channel Blockers; Pyrazoles; Radiation-Sensitizing Agents; RNA, Messenger; Signal Transduction; Temozolomide | 2015 |
Resveratrol Inhibits the Invasion of Glioblastoma-Initiating Cells via Down-Regulation of the PI3K/Akt/NF-κB Signaling Pathway.
Topics: Animals; Cell Adhesion; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Glioblastoma; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduction; Stilbenes; Temozolomide | 2015 |
TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Temozolomide; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Up-Regulation | 2015 |
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioma; Humans; Protein Kinase Inhibitors; src-Family Kinases; Temozolomide | 2016 |
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Chemoradiotherapy; Comorbidity; Cyclooxygenase 2 Inhibitors; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2015 |
Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hypertension; Male; Middle Aged; Outcome Assessment, Health Care; Supratentorial Neoplasms; Temozolomide | 2015 |
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Damage; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gene Knockout Techniques; Glioblastoma; Heterografts; Humans; Mice; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Small Interfering; Temozolomide | 2015 |
β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Repair; Drug Synergism; Glioblastoma; Humans; Radiation-Sensitizing Agents; Rats; Sesquiterpenes; Temozolomide | 2015 |
[A pleural transudate with a 0 g/L protein level].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Catheters, Indwelling; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diuretics; Drainage; Dyspnea; Exudates and Transudates; Fluid Therapy; Glioblastoma; Humans; Male; Methylene Blue; Middle Aged; Pleural Cavity; Pleural Effusion; Pneumothorax; Proteins; Radiography; Temozolomide | 2015 |
Photodynamic therapy in the treatment of brain tumours. A feasibility study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dihematoporphyrin Ether; Feasibility Studies; Female; Humans; Male; Mesoporphyrins; Middle Aged; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing Agents; Survival Analysis; Temozolomide; Young Adult | 2015 |
Photochemical internalization of bleomycin and temozolomide--in vitro studies on the glioma cell line F98.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Light; Molecular Structure; Photochemical Processes; Photosensitizing Agents; Porphyrins; Rats; Temozolomide; Tumor Stem Cell Assay | 2015 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Temozolomide | 2015 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Temozolomide; Tumor Burden; Young Adult | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells; Endothelin Receptor Antagonists; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; NIH 3T3 Cells; Pyrimidines; Sulfonamides; Temozolomide | 2015 |
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Phosphoinositide-3 Kinase Inhibitors; Progesterone; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DNA; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Management of glioblastoma in Victoria, Australia (2006-2008).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neurosurgical Procedures; Retrospective Studies; Temozolomide; Victoria | 2015 |
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Furans; Glioblastoma; Humans; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase III as Topic; Dacarbazine; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Temozolomide; Treatment Outcome | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Phenotype; Prognosis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells; Proto-Oncogene Proteins c-cbl; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2015 |
Use of temozolomide instead of cyclophosphamide in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Dacarbazine; Drug Hypersensitivity; Drug Substitution; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Immunophenotyping; Lymphoma, Large B-Cell, Diffuse; Positron Emission Tomography Computed Tomography; Recurrence; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brain Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dacarbazine; Dogs; Female; Glioblastoma; Madin Darby Canine Kidney Cells; Male; Mice; Piperazines; Protein Kinase Inhibitors; Pyridines; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Embryonic Stem Cell-Related Protein L1TD1 Is Required for Cell Viability, Neurosphere Formation, and Chemoresistance in Medulloblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Glycoproteins; Humans; Medulloblastoma; Nestin; Neural Stem Cells; Peptides; Proteins; Temozolomide | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Glioblastoma; Mice, SCID; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Spheroids, Cellular; Temozolomide | 2015 |
IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; eIF-2 Kinase; Glioma; Humans; Interleukins; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Temozolomide; Transfection; Up-Regulation | 2014 |
PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Cell Movement; Cell Survival; Chromones; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Morpholines; Neoplasm Invasiveness; Neoplastic Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Temozolomide; Tumor Cells, Cultured; Wnt Proteins; Wnt Signaling Pathway | 2015 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Male; Soft Tissue Neoplasms; Temozolomide | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioma; Mice; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2015 |
In vitro and in vivo effect of human lactoferrin on glioblastoma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Lactoferrin; Male; Mice; Mice, Nude; Temozolomide; Tumor Cells, Cultured | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glioma; Humans; Imidazoles; Inhibitory Concentration 50; Male; Mice, SCID; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioma; Humans; Male; MAP Kinase Kinase 2; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Grading; Prognosis; Temozolomide; Treatment Outcome; Up-Regulation | 2016 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; Male; Mice; Rabbits; Solubility; Temozolomide; Tissue Distribution | 2015 |
New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Cell Proliferation; Chemistry, Pharmaceutical; Dacarbazine; Dry Powder Inhalers; Folic Acid; Humans; Lung Neoplasms; Mice; Nanoparticles; Particle Size; Temozolomide | 2015 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastoma; Glioma; Lipids; Mice; Nanostructures; Phosphatidylethanolamines; Polyethylene Glycols; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; Glioma; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanostructures; Particle Size; Temozolomide; Vincristine | 2016 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, Competitive; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cricetinae; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluoresceins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Temozolomide; Transcription, Genetic; Transcriptional Activation; Transfection; Up-Regulation | 2015 |
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms | 2015 |
Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
Topics: Adult; Aged; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Postoperative Care; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Topics: Brain Neoplasms; Chondroitin Sulfate Proteoglycans; Dacarbazine; Decorin; Glioblastoma; Humans; Keratan Sulfate; Lumican; Neoplastic Stem Cells; Neuroblastoma; Temozolomide; Tumor Microenvironment | 2015 |
Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; NF-kappa B; Signal Transduction; Temozolomide | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Japan; Karnofsky Performance Status; Male; Middle Aged; Polyesters; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Mice; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Radiation-Sensitizing Agents; Survival Analysis; Temozolomide | 2015 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden | 2015 |
Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability.
Topics: Animals; Biological Assay; Cell Count; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Formazans; Humans; Inhibitory Concentration 50; Rats; Rats, Wistar; Sirolimus; Temozolomide; Tetrazolium Salts | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contrast Media; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; ROC Curve; Temozolomide; Time Factors; Treatment Outcome | 2015 |
Temozolomide for central nervous system involvement in mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Dacarbazine; Dexamethasone; Female; Humans; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Retreatment; Skin Neoplasms; Temozolomide; Treatment Outcome | 2016 |
Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.
Topics: Animals; Carcinoma; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Proteins; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Cell Size; Clone Cells; Dacarbazine; Glioma; Humans; Models, Biological; Molecular Targeted Therapy; Neoplastic Stem Cells; Temozolomide | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Ependyma; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Sensitivity and Specificity; Temozolomide; Young Adult | 2015 |
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child, Preschool; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Ependymoma; Female; Humans; Immunohistochemistry; Infant; Male; Temozolomide; Tumor Suppressor Proteins | 2016 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; DNA Methylation; Epigenesis, Genetic; Glioma; HeLa Cells; Humans; Oxidative Stress; Rats; Temozolomide | 2015 |
Diagnosis and Management of Spinal Metastasis of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Spinal Neoplasms; Temozolomide | 2015 |
Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; Neoplasm Proteins; RNA, Neoplasm; STAT3 Transcription Factor; Temozolomide | 2015 |
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Metabolomics; Purines; Temozolomide; Tritium; Tumor Suppressor Proteins | 2015 |
HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
Topics: Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; HMGN Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Invasiveness; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Temozolomide; Trans-Activators; Transfection | 2015 |
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Young Adult | 2016 |
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Glioblastoma; Humans; Mice, Nude; Nanocapsules; Temozolomide; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents; Autophagy; Brain Neoplasms; Carbazoles; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase; Glioblastoma; Humans; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Diabetes Complications; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hyperglycemia; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Retrospective Studies; Temozolomide; Young Adult | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Interferon Type I; Male; Mice; Neoplastic Stem Cells; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice, Nude; RNA Interference; RNAi Therapeutics; Temozolomide; Time Factors; Transfection; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice, Inbred C57BL; MicroRNAs; Promoter Regions, Genetic; Temozolomide | 2015 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Nausea; Prospective Studies; Temozolomide; Vomiting; Young Adult | 2015 |
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Oligodendroglioma; Spinal Cord Neoplasms; Temozolomide | 2016 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2015 |
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP-Binding Cassette Transporters; Blotting, Western; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorescent Antibody Technique; Glucose; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2015 |
Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death.
Topics: Apoptosis; Caspases; Cell Death; Dacarbazine; Glioblastoma; Humans; Interferon-beta; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Combinations; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Nanoparticles; Peptide Nucleic Acids; Peptides; Porosity; Rats; Silicon Dioxide; Temozolomide | 2015 |
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Immunocompromised Host; Inhibitory Concentration 50; Isotretinoin; MAP Kinase Signaling System; Mice; Neoplasm Proteins; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2015 |
Dual loading miR-218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted anti-tumor drug delivery system with sequential release functions.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chitosan; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Fatty Acids; Female; Glioblastoma; Gold Compounds; Humans; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanogels; Polyethylene Glycols; Polyethyleneimine; Sulfhydryl Compounds; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Nucleus; Comet Assay; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Kinase 4; MAP Kinase Signaling System; Membrane Proteins; Nimustine; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; RNA, Small Interfering; Signal Transduction; Temozolomide; Up-Regulation | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2015 |
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Italy; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Radiotherapy Dosage; Retrospective Studies; Temozolomide | 2015 |
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Peptides, Cyclic; Polyethylene Glycols; Proto-Oncogene Proteins c-mdm2; Temozolomide; Tumor Burden; Tumor Suppressor Protein p53 | 2015 |
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Male; Metformin; Mice; Mice, SCID; Neoplastic Stem Cells; Random Allocation; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Central Nervous System; Dacarbazine; Dogs; Glioblastoma; Humans; Indoles; Madin Darby Canine Kidney Cells; Mice; Mice, Knockout; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Dactinomycin; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Ifosfamide; Metabolic Networks and Pathways; Mitochondria; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Temozolomide; Vincristine | 2015 |
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Gliosarcoma; Humans; Male; Retrospective Studies; Survival Analysis; Survival Rate; Temozolomide; Young Adult | 2015 |
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neurosurgical Procedures; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycoproteins; Guanine; Humans; Inhibitory Concentration 50; Peptides; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; MicroRNAs; Proto-Oncogene Proteins c-myc; Signal Transduction; Temozolomide | 2015 |
The radiosensitivity index predicts for overall survival in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Radiation Tolerance; Temozolomide; Transcriptome; Treatment Outcome | 2015 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide | 2016 |
Electrochemical monitoring of the interaction between Temozolamide and nucleic acids by using disposable pencil graphite electrodes.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Dacarbazine; Disposable Equipment; DNA; Electrochemistry; Electrodes; Graphite; Limit of Detection; Temozolomide | 2015 |
Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Curcumin; Dacarbazine; Diarylheptanoids; Drug Synergism; G1 Phase; Glioblastoma; Humans; Janus Kinases; Mice; Mice, Nude; Neoplasm Proteins; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Glucose; Humans; Paclitaxel; Temozolomide | 2015 |
Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Humans; Hypnotics and Sedatives; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Midazolam; Neuroblastoma; Temozolomide; Time Factors | 2015 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Reoperation; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrazines; Receptor, IGF Type 1; Survival Analysis; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplastic Stem Cells; Phosphorylation; Resveratrol; Signal Transduction; Stilbenes; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Immunoenzyme Techniques; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Prospective Studies; Registries; Survival Rate; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2015 |
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; Homologous Recombination; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MicroRNAs; Nanotechnology; Temozolomide | 2015 |
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Blotting, Western; Carboplatin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Repair; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Isoquinolines; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Neoplasms; Neoplasms, Experimental; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Reverse Transcriptase Polymerase Chain Reaction; Tankyrases; Temozolomide; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Secondary non-Hodgkin lymphoma of the ethmoid sinus after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Ethmoid Sinus; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paranasal Sinus Neoplasms; Temozolomide | 2015 |
Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Culture Media, Conditioned; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Ontology; Genomic Instability; Glioblastoma; Humans; Microscopy, Fluorescence; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Transcriptome | 2015 |
APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Humans; RNA, Small Interfering; Temozolomide | 2015 |
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dexamethasone; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Compounding; Glioblastoma; Humans; Irinotecan; Liposomes; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioma; Humans; Rats; Survival Analysis; Temozolomide | 2016 |
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Humans; Middle Aged; Temozolomide | 2016 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Comorbidity; Dacarbazine; Female; Glioblastoma; Hematologic Diseases; Humans; Longitudinal Studies; Male; Middle Aged; Prevalence; Radiotherapy, Conformal; Republic of Korea; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Middle Aged; Nucleolin; Peptides; Phosphoproteins; RNA-Binding Proteins; Temozolomide; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Brain Neoplasms; Cell Line, Tumor; Connexin 43; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Peptides; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Bone Morphogenetic Protein 7; Cell Proliferation; Cell Survival; Dacarbazine; DNA Modification Methylases; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Neoplastic Stem Cells; Temozolomide; Tumor Cells, Cultured | 2015 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Seizures; Temozolomide; Treatment Outcome | 2016 |
The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Child; Cisplatin; Dacarbazine; DNA Repair; Humans; Hydroxylamines; Medulloblastoma; Radiation-Sensitizing Agents; Radiation, Ionizing; Temozolomide; Thiotepa; Tumor Stem Cell Assay | 2015 |
MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation.
Topics: Adult; Aged; alpha Karyopherins; Animals; Autophagy; Cadherins; Cell Line, Tumor; Cell Movement; Dacarbazine; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; MicroRNAs; Middle Aged; Nuclear Proteins; Phenotype; Temozolomide; Tumor Suppressor Protein p53 | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MicroRNAs; Nanoparticles; PTEN Phosphohydrolase; Temozolomide | 2015 |
Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
Topics: Adenoviridae; Adenoviridae Infections; Adenovirus E1B Proteins; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; HEK293 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Temozolomide; Tumor Suppressor Proteins; Virus Replication; Xenograft Model Antitumor Assays | 2016 |
Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits.
Topics: Animals; Antineoplastic Agents; Blood Chemical Analysis; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Dacarbazine; Irinotecan; Male; Microbubbles; Rabbits; Reproducibility of Results; Temozolomide; Ultrasonography | 2016 |
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Shape; Dacarbazine; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genotype; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Neoplastic Stem Cells; Phenotype; Retinoblastoma-Binding Protein 2; RNA Interference; Temozolomide; Time Factors; Transfection | 2015 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; G1 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sarcoma, Ewing; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53; Vorinostat | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Caspase 8; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Female; Glioblastoma; Humans; Luteolin; Mice; Mice, Nude; MicroRNAs; Signal Transduction; Silybin; Silymarin; Sirolimus; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Positron-Emission Tomography; ROC Curve; Seizures; Sensitivity and Specificity; Temozolomide; Young Adult | 2016 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioma; Humans; Protein Interaction Maps; Signal Transduction; Survival Analysis; Temozolomide | 2015 |
Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Humans; Hydrocortisone; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Temozolomide; Treatment Failure | 2016 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Physicians; Surveys and Questionnaires; Temozolomide | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Proliferation; Dacarbazine; Glioblastoma; HIV Protease Inhibitors; Humans; Immunoenzyme Techniques; Morpholines; Ritonavir; Temozolomide; Tumor Cells, Cultured | 2016 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; DNA Methylation; Female; Glioblastoma; Guanine; Humans; Isocitrate Dehydrogenase; Japan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Temozolomide | 2016 |
Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2016 |
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pituitary Neoplasms; Prognosis; Survival Rate; Temozolomide | 2016 |
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Polymerase Chain Reaction; Random Allocation; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Therapeutic effect of TMZ-POH on human nasopharyngeal carcinoma depends on reactive oxygen species accumulation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Enzyme Activation; Female; G2 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Monoterpenes; Nasopharyngeal Neoplasms; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Dacarbazine; Drug Delivery Systems; Female; Purines; Pyrazoles; Rats; Rats, Inbred F344; Tandem Mass Spectrometry; Temozolomide; Tissue Distribution | 2016 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Young Adult | 2016 |
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Prognosis; Repressor Proteins; Temozolomide | 2016 |
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Gene Knockdown Techniques; Glioma; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; RNA, Messenger; Survival Analysis; Temozolomide; Treatment Outcome; Tryptophan; Tumor Burden | 2016 |
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calmodulin-Binding Proteins; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glycoproteins; Humans; Neoplastic Stem Cells; Peptides; Temozolomide | 2015 |
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Nerve Tissue Proteins; Prognosis; RNA Interference; Temozolomide | 2016 |
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Topics: Adenoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Hypoxia-Inducible Factor 1, alpha Subunit; Lysosomes; Pituitary Neoplasms; Presenilin-1; Rats; Temozolomide | 2016 |
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Glioblastoma; Humans; Isothiocyanates; Mice; Mice, Nude; NF-kappa B; Signal Transduction; Sulfoxides; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2016 |
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Caspase 8; Cell Line, Tumor; Cell Survival; Dacarbazine; Dipeptides; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; In Vitro Techniques; Indoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Phase-Contrast; Neoplasm Transplantation; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Movement; Cell Proliferation; Chromosomal Proteins, Non-Histone; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Immunoprecipitation; Male; Middle Aged; Neoplasm Grading; Nuclear Proteins; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Trans-Activators; Tumor Cells, Cultured | 2016 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neurosurgical Procedures; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Temozolomide | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Glioma; Green Fluorescent Proteins; Humans; Mice, Transgenic; Microglia; Microscopy, Confocal; Microscopy, Fluorescence; Neovascularization, Pathologic; Organ Culture Techniques; Rats, Wistar; Reproducibility of Results; Temozolomide; Tumor Microenvironment | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lomustine; Male; Neurosurgical Procedures; Procarbazine; Prognosis; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Survival Rate; Temozolomide; Vincristine | 2016 |
Polymer Nanocomposites Based Thermo-Sensitive Gel for Paclitaxel and Temozolomide Co-Delivery to Glioblastoma Cells.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Nanocomposites; Paclitaxel; Polyesters; Polyethylene Glycols; Rats; Temozolomide | 2015 |
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Gene Expression; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mesenchymal Stem Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Dacarbazine; Early Diagnosis; Female; Follow-Up Studies; Glioma; Humans; Leukoencephalopathies; Male; Prospective Studies; Radiotherapy; Temozolomide | 2015 |
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Humans; Injections, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Rats; Rats, Nude; Small Cell Lung Carcinoma; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Peptide Nucleic Acids; Phenotype; Surface Plasmon Resonance; Temozolomide | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chloride Channels; Comet Assay; Dacarbazine; Flow Cytometry; Glioma; Humans; Nitrobenzoates; Patch-Clamp Techniques; Temozolomide | 2016 |
Downregulation of TRAP1 sensitizes glioblastoma cells to temozolomide chemotherapy through regulating metabolic reprogramming.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Neoplastic Stem Cells; Neural Stem Cells; Temozolomide | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regulation; Gene Transfer Techniques; Genetic Therapy; Glioma; Green Fluorescent Proteins; Magnetic Resonance Imaging; Male; Nanoparticles; Open Reading Frames; Plasmids; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Survival Rate; Temozolomide; Transferrin | 2016 |
In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dacarbazine; Electric Stimulation Therapy; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; RNA Interference; RNAi Therapeutics; Temozolomide; Transfection; Tumor Cells, Cultured | 2016 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Temozolomide; Transfection | 2015 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphopenia; Male; Neoplasm Grading; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Costs; Female; Follow-Up Studies; France; Glioblastoma; Health Care Costs; Hospitalization; Hospitals, University; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide | 2016 |
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
Topics: Antibodies; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; B-Lymphocytes, Regulatory; Cancer Vaccines; Dacarbazine; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Interleukin-10; Lymphocyte Activation; Lymphocyte Count; Temozolomide; Vaccines, Subunit | 2016 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysfunction; Cranial Irradiation; Dacarbazine; Delirium; Dexamethasone; Diagnosis, Differential; Encephalitis, Herpes Simplex; Female; Glioma; Herpesvirus 1, Human; Humans; Leukocytosis; Magnetic Resonance Imaging; Seizures; Temozolomide; Young Adult | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokine TWEAK; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Guanine Nucleotide Exchange Factors; Humans; NF-kappa B; Receptors, Tumor Necrosis Factor; Signal Transduction; Temozolomide; Tumor Necrosis Factors; TWEAK Receptor; Up-Regulation | 2016 |
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Cerebellar Neoplasms; Dacarbazine; Female; Humans; Irinotecan; Medulloblastoma; Temozolomide; Young Adult | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Mutation; Signal Transduction; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2016 |
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioma; Humans; Liposomes; Phosphatidylethanolamines; Polyethylene Glycols; Quercetin; Random Allocation; Rats; Rats, Sprague-Dawley; Temozolomide | 2016 |
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Gene Library; Genome; Glioblastoma; HEK293 Cells; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins; RNA, Small Interfering; Temozolomide; Up-Regulation | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials as Topic; Dacarbazine; Epilepsy; Female; Glioblastoma; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Prognosis; Survival Analysis; Temozolomide; Valproic Acid | 2016 |
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Humans; Indazoles; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Mice, Transgenic; Mutation; Neoplastic Stem Cells; Signal Transduction; Temozolomide | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioma; Immunotherapy; Inflammation; Lipids; Mice, Inbred C57BL; Nanotubes, Carbon; Neoplasm Invasiveness; Oligodeoxyribonucleotides; Polyethylene Glycols; Spleen; Temozolomide; Treatment Outcome | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Valproic Acid; Young Adult | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Craniospinal Irradiation; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphopenia; Male; Neoplasm Staging; Neuroectodermal Tumors, Primitive; Neutropenia; Prognosis; Survival Rate; Temozolomide; Thrombocytopenia; Young Adult | 2016 |
Temozolomide-induced biliary ductopenia: a case report.
Topics: Antineoplastic Agents, Alkylating; Bile Duct Diseases; Bile Ducts, Intrahepatic; Chemoradiotherapy; Cholestasis; Dacarbazine; Female; Glioblastoma; Humans; Hyperbilirubinemia; Middle Aged; Temozolomide | 2016 |
Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients.
Topics: Area Under Curve; Astrocytoma; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; ROC Curve; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Nude; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Sirolimus; SOX9 Transcription Factor; SOXB1 Transcription Factors; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Reproducibility of Results; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; HeLa Cells; Humans; Plasma Gases; Reactive Oxygen Species; Temozolomide | 2016 |
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Genetic Association Studies; Genotype; Glioblastoma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Radiotherapy; STAT3 Transcription Factor; Survival Analysis; Temozolomide; Ubiquitin-Protein Ligases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Nuclear Proteins; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Temozolomide; Transcription Factors | 2016 |
Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation.
Topics: Biophysical Phenomena; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Delivery Systems; Glioblastoma; Humans; Lactic Acid; Microscopy, Confocal; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Temozolomide; Time Factors | 2016 |
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Perfusion Imaging; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Uveal Neoplasms; Vascular Endothelial Growth Factor A | 2016 |
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Agonism; Drug Design; Female; G2 Phase; Humans; Mice, Nude; Organosilicon Compounds; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Recombinant Proteins; Temozolomide; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
p28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cell-Penetrating Peptides; Dacarbazine; DNA Damage; Female; G2 Phase; Heterografts; Male; Mice, Nude; Temozolomide; Tumor Suppressor Protein p53 | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Proteoglycans; Temozolomide | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Chromosomal Proteins, Non-Histone; Dacarbazine; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Kinesins; Male; MicroRNAs; Neoplasm Grading; Oncogene Proteins; Temozolomide | 2016 |
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Multivariate Analysis; Mutation, Missense; Neoplasm Grading; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Temozolomide | 2016 |
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
Topics: Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Engineering; Glioblastoma; Humans; Magnetic Resonance Imaging; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2016 |
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Gene Expression Profiling; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histones; Humans; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2016 |
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Promoter Regions, Genetic; Prospective Studies; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2016 |
Temozolomide-perillyl alcohol conjugate induced reactive oxygen species accumulation contributes to its cytotoxicity against non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Monoterpenes; Reactive Oxygen Species; Temozolomide | 2016 |
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Glycosylases; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Endoplasmic Reticulum Stress; Glioblastoma; Humans; Mice; Pyrans; Rad51 Recombinase; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2016 |
Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Cinnamates; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Glioblastoma; Humans; Neuropilin-1; Promoter Regions, Genetic; RNA, Small Interfering; Temozolomide; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols; Rats; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Glioblastoma; Heterografts; Humans; Mice; Signal Transduction; Temozolomide | 2016 |
Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Alkylating; Case-Control Studies; Cyclophosphamide; Dacarbazine; Dog Diseases; Dogs; Lymphocyte Count; Neoplasms; T-Lymphocytes, Regulatory; Temozolomide; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2017 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinases; Phosphorylation; Skin Neoplasms; Temozolomide | 2016 |
Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; E1A-Associated p300 Protein; Glioblastoma; Histones; Humans; Microscopy, Fluorescence; Phosphorylation; Promoter Regions, Genetic; Rad51 Recombinase; Real-Time Polymerase Chain Reaction; Retinoblastoma-Binding Protein 4; RNA Interference; RNA, Small Interfering; Temozolomide | 2016 |
Breakable mesoporous silica nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disulfides; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Nanoparticles; Oxidation-Reduction; Particle Size; Porosity; Reducing Agents; Silicon Dioxide; Temozolomide | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cancer Vaccines; Cell Line, Tumor; Dacarbazine; Glioblastoma; Mice; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Valproic Acid; Xenograft Model Antitumor Assays | 2016 |
Suppressing H19 Modulates Tumorigenicity and Stemness in U251 and U87MG Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; RNA, Long Noncoding; RNA, Neoplasm; Temozolomide; Up-Regulation | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Seizures; Temozolomide; Valproic Acid | 2016 |
Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Shape; Cell Survival; Cell Transformation, Neoplastic; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide; Valproic Acid | 2016 |
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Glioblastoma; Humans; Mice, Nude; Micelles; Phosphatidylethanolamines; Protons; Receptors, Platelet-Derived Growth Factor; Temozolomide | 2016 |
MGMT in colorectal cancer: a promising component of personalized treatment.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Precision Medicine; Prognosis; Proportional Hazards Models; Temozolomide; Tumor Suppressor Proteins | 2016 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Models, Animal; Disulfiram; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Profiling; Glioblastoma; High-Throughput Screening Assays; Humans; Mice; Neoplastic Stem Cells; Proteasome Endopeptidase Complex; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Opportunistic Infections; Pneumonia, Pneumocystis; Pulmonary Embolism; Temozolomide; Tomography, X-Ray Computed | 2016 |
Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Topics: Biomarkers, Tumor; Dacarbazine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Matrix Metalloproteinase 9; Neoplasm Grading; Prognosis; Proportional Hazards Models; RNA, Messenger; Survival Analysis; Temozolomide; Treatment Outcome | 2016 |
Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gliosarcoma; Humans; Isocitrate Dehydrogenase; Male; Microsurgery; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Proportional Hazards Models; Retrospective Studies; Telomerase; Temozolomide; Tumor Suppressor Proteins | 2016 |
Tautomeric transformation of temozolomide, their proton affinities and chemical reactivities: A theoretical approach.
Topics: Dacarbazine; Gases; Isomerism; Models, Theoretical; Protons; Quantum Theory; Temozolomide; Thermodynamics | 2016 |
c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.
Topics: Animals; Cell Hypoxia; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Endothelial Cells; Female; Glioblastoma; Humans; Male; Matrix Metalloproteinase 14; Mice; Mice, Knockout; Neovascularization, Pathologic; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-met; Temozolomide | 2016 |
A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; India; Radium; Retrospective Studies; Temozolomide | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Molecular Imaging; Reproducibility of Results; Sensitivity and Specificity; Temozolomide; Treatment Outcome | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Brain Edema; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Magnetic Resonance Imaging; Rats, Wistar; Sulfasalazine; Temozolomide; Tumor Microenvironment | 2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Creatine; Dacarbazine; Electric Stimulation Therapy; Electromagnetic Fields; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Outcome Assessment, Health Care; Temozolomide; Thalamus | 2016 |
Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Calcium Chloride; Dacarbazine; Dose-Response Relationship, Drug; Edema; Female; Humans; Male; Membrane Potential, Mitochondrial; Microscopy, Electron, Transmission; Mitochondria; Reactive Oxygen Species; Retrospective Studies; Temozolomide; Tumor Cells, Cultured | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Kruppel-Like Transcription Factors; Mice; Real-Time Polymerase Chain Reaction; Repressor Proteins; RNA Interference; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; Neoplasm Proteins; RNA, Small Interfering; Signal Transduction; Temozolomide; Transfection | 2016 |
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Glioblastoma; Glycoproteins; Humans; Mice, SCID; Temozolomide; Uracil; Uridine | 2016 |
Temozolomide-Associated Liver Fibrosis.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Liver Cirrhosis; Male; Middle Aged; Temozolomide | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Drug Therapy, Combination; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Microglia; Neoplasms, Experimental; Neoplastic Stem Cells; Phosphorylation; Primary Cell Culture; Pyrazoles; Temozolomide | 2016 |
miR-487b-5p Regulates Temozolomide Resistance of Lung Cancer Cells Through LAMP2-Medicated Autophagy.
Topics: A549 Cells; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lysosomal-Associated Membrane Protein 2; MicroRNAs; Microtubule-Associated Proteins; Oligonucleotides; Plasmids; Signal Transduction; Temozolomide; Transfection | 2016 |
Pseudo progression identification of glioblastoma with dictionary learning.
Topics: Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Machine Learning; Male; Temozolomide | 2016 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Humans; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neuroendocrine Tumors; Pituitary Neoplasms; Positron-Emission Tomography; Temozolomide | 2016 |
Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Chemistry, Pharmaceutical; Curcumin; Dacarbazine; Doxorubicin; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; MCF-7 Cells; Oligopeptides; Peptides, Cyclic; Spheroids, Cellular; Temozolomide | 2016 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Epirubicin; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Procarbazine; Temozolomide; Treatment Outcome; Vincristine | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbazine; Drug Combinations; Drug Synergism; Epithelial-Mesenchymal Transition; fas Receptor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunoglobulin G; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Primary Cell Culture; Prognosis; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Spheroids, Cellular; Survival Analysis; Temozolomide | 2016 |
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Repair; Estrogen Receptor beta; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarbazine; Fatal Outcome; Filgrastim; Glioblastoma; Hemoglobinuria, Paroxysmal; Humans; Male; Receptors, Fc; Recombinant Fusion Proteins; Temozolomide; Thrombopoietin; Treatment Failure | 2016 |
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Administration, Metronomic; Animals; Carcinoma, Neuroendocrine; Cell Differentiation; Dacarbazine; Female; Humans; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Temozolomide; Tomography, X-Ray Computed | 2016 |
Protein Markers Predict Survival in Glioma Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Prognosis; Proportional Hazards Models; Proteomics; Survival Analysis; Temozolomide; Young Adult | 2016 |
Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-Fluorouracil and Temozolomide.
Topics: Alginates; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chitosan; Dacarbazine; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Drug Stability; Fluorouracil; Glucuronic Acid; Hexuronic Acids; Nanoparticles; Pectins; Prodrugs; Temozolomide | 2016 |
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.
Topics: Alkylating Agents; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Damage; Glioma; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Ionomycin; Large-Conductance Calcium-Activated Potassium Channels; Membrane Potentials; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Temozolomide | 2016 |
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Humans; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Gliosarcoma; Humans; Male; Middle Aged; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Histones; Humans; Infant; Male; Radiotherapy; Risk Factors; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2016 |
Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carriers; Drug Delivery Systems; Glioblastoma; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanostructures; Particle Size; Polymers; Temozolomide | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neoplasms, Neuroepithelial; Temozolomide | 2016 |
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; Mice; Mice, Nude; Receptors, Notch; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Glioma; Humans; MAP Kinase Signaling System; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Temozolomide | 2016 |
Accelerated hyperfractionation plus temozolomide in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Young Adult | 2016 |
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Databases, Factual; Female; Glioblastoma; Humans; Male; Radiotherapy; Temozolomide; Treatment Outcome | 2016 |
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Brain; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Metalloporphyrins; Mice, Inbred C57BL; Mice, Nude; Motor Activity; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Temozolomide; X-Ray Therapy | 2016 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Temozolomide | 2016 |
Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Forecasting; Humans; Pituitary Neoplasms; Temozolomide | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioma; Humans; Immunohistochemistry; Male; NIMA-Related Kinase 1; Temozolomide; Tumor Stem Cell Assay; Up-Regulation | 2016 |
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Oligodendroglioma; Temozolomide | 2016 |
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Protein Stability; Signal Transduction; Temozolomide; Time Factors; Transfection; Up-Regulation | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Evolution; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Genomics; Glioblastoma; Humans; Isocitrate Dehydrogenase; Latent TGF-beta Binding Proteins; Longitudinal Studies; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Transcriptome; Transforming Growth Factor beta; Tumor Suppressor Proteins | 2016 |
Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy; Temozolomide | 2017 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Endoplasmic Reticulum Stress; Fluoxetine; Glioma; Membrane Potential, Mitochondrial; Rats; Signal Transduction; Temozolomide; Transcription Factor CHOP | 2016 |
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Endoplasmic Reticulum Stress; Glioblastoma; Humans; Hydroxyquinolines; Male; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; Gastrins; Glioma; Humans; Intracellular Signaling Peptides and Proteins; Lutetium; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Purines; Radioisotopes; Signal Transduction; Temozolomide | 2016 |
Adult-onset atypical teratoid/rhabdoid tumor featuring long spindle cells with nuclear palisading and perivascular pseudorosettes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Occipital Lobe; Rhabdoid Tumor; Temozolomide; Teratoma; Treatment Outcome; Young Adult | 2017 |
Connection between Proliferation Rate and Temozolomide Sensitivity of Primary Glioblastoma Cell Culture and Expression of YB-1 and LRP/MVP.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Y-Box-Binding Protein 1 | 2016 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cranial Irradiation; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Multiple Primary; Neurosurgical Procedures; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Telomerase; Temozolomide; Temporal Lobe | 2017 |
Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; bcl-2-Associated X Protein; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Dacarbazine; Deoxyglucose; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gene Expression; Glioblastoma; Humans; Morpholines; Oxygen; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2016 |
Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Cranial Irradiation; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Radiation Dose Hypofractionation; Survival Analysis; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy, Adjuvant; Re-Irradiation; Retrospective Studies; Temozolomide | 2016 |
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.
Topics: Animals; Bacterial Proteins; CRISPR-Associated Protein 9; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Endonucleases; Gene Expression Regulation, Leukemic; Genetic Techniques; Leukemia, Experimental; Mice; Sequence Analysis, RNA; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2016 |
Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytotoxins; Dacarbazine; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Sulfasalazine; Temozolomide | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; NF-E2-Related Factor 2; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Topics: Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; DNA Repair; Etoposide; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation, Ionizing; Recombinational DNA Repair; Sarcoma, Synovial; Temozolomide; Topoisomerase II Inhibitors | 2016 |
Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.
Topics: A549 Cells; Amides; Antineoplastic Agents; Benzimidazoles; Binding Sites; Cell Survival; Dacarbazine; Drug Design; Enzyme Inhibitors; HCT116 Cells; Humans; Molecular Docking Simulation; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship; Temozolomide | 2016 |
Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.
Topics: Animals; Antineoplastic Agents, Alkylating; Arginine; Dacarbazine; DNA Methylation; Histones; Humans; Lysine; Mass Spectrometry; Methylation; Temozolomide; Xenopus | 2016 |
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplasm Transplantation; Recombinational DNA Repair; Temozolomide; Tumor Suppressor Proteins | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Large-Conductance Calcium-Activated Potassium Channels; Microfilament Proteins; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide | 2016 |
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Proliferation; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Glioblastoma; High Mobility Group Proteins; Humans; Mice; Mice, Nude; Temozolomide; Transcriptional Elongation Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytoplasmic Dyneins; Dacarbazine; Disease Models, Animal; Drug Resistance; Fluorescent Antibody Technique; Gene Expression Profiling; Glioblastoma; Heterografts; Humans; Immunohistochemistry; Kinesins; Mice, Nude; Neoplasm Transplantation; Neuroglia; Proteome; Real-Time Polymerase Chain Reaction; Temozolomide | 2016 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Treatment Outcome; Young Adult | 2017 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Mice; MicroRNAs; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Sp1 Transcription Factor; Temozolomide; Treatment Outcome | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Irinotecan; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glioma; Hippocampus; Humans; Image Processing, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; S100 Proteins; Statistics, Nonparametric; Temozolomide; Young Adult | 2016 |
Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Gene Transfer Techniques; Genetic Therapy; Glioblastoma; Rats; Temozolomide; Thymidine Kinase | 2017 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Regression Analysis; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioma; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Wnt Proteins | 2016 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrovascular Circulation; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Organometallic Compounds; Polymerase Chain Reaction; Retrospective Studies; Temozolomide; Treatment Outcome | 2017 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Mice; Mice, Nude; Oxidative Stress; Physical Conditioning, Animal; Reactive Oxygen Species; Temozolomide | 2016 |
Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism?
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Cyclin D1; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2016 |
Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.
Topics: A549 Cells; Alkylating Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Dacarbazine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Lung Neoplasms; Methylnitrosourea; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Temozolomide | 2016 |
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Phenotype; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Enzyme Activation; Gene Knockdown Techniques; Glioma; GTPase-Activating Proteins; Humans; Lysosomes; Membrane Fusion; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Temozolomide | 2017 |
Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cricetinae; Cytarabine; Dacarbazine; DNA Breaks; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Homologous Recombination; Humans; Platinum; Poly (ADP-Ribose) Polymerase-1; Temozolomide; Tumor Suppressor Protein p53 | 2016 |
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Methylation; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2016 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neoplasms; Cognition Disorders; Cross-Sectional Studies; Dacarbazine; Frail Elderly; Geriatric Assessment; Glioblastoma; Humans; Neurologists; Oncologists; Patient Care Team; Patient Selection; Practice Patterns, Physicians'; Referral and Consultation; Temozolomide | 2016 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; Depression; Drug Interactions; Fluoxetine; Glioblastoma; Humans; Imipramine; Temozolomide; Tranylcypromine; Tumor Hypoxia | 2017 |
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Neurosurgical Procedures; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide; Tumor Suppressor Protein p53 | 2016 |
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Gene Silencing; Glioblastoma; HMGA1a Protein; Humans; Neoplastic Stem Cells; RNA, Small Interfering; Temozolomide | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA-Activated Protein Kinase; Drug Synergism; Female; Glioma; Humans; Mice; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Breaks, Double-Stranded; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Knockdown Techniques; Glioblastoma; Humans; Integrin alphaVbeta3; Integrin beta3; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; NF-KappaB Inhibitor alpha; Peptides, Cyclic; Phosphorylation; Proto-Oncogene Proteins c-akt; Rad51 Recombinase; Receptor-Interacting Protein Serine-Threonine Kinases; Receptors, Vitronectin; Recombinational DNA Repair; RNA Interference; RNA, Small Interfering; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Models, Theoretical; Nitrophenols; Piperazines; Signal Transduction; Sulfonamides; Systems Biology; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome | 2016 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Japan; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Survival Analysis; Telomerase; Temozolomide; Tumor Suppressor Proteins | 2016 |
Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Lactic Acid; MicroRNAs; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Real-Time Polymerase Chain Reaction; Temozolomide | 2016 |
Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
Topics: Animals; Annexin A5; Apoptosis; Benzoic Acid; Cell Line, Tumor; Cell Movement; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; para-Aminobenzoates; Platelet Endothelial Cell Adhesion Molecule-1; Radiation; Radiation-Sensitizing Agents; STAT3 Transcription Factor; Sulfonamides; Temozolomide; Tumor Suppressor Proteins; Wound Healing | 2016 |
Interactions of Nucleic Acid Bases with Temozolomide. Stacked, Perpendicular, and Coplanar Heterodimers.
Topics: Adenine; Cytosine; Dacarbazine; Dimerization; Guanine; Quantum Theory; Temozolomide; Thymine; Uracil | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Glioma; Humans; Imidazoles; Pyrimidinones; Signal Transduction; Temozolomide; Tetraspanins; TOR Serine-Threonine Kinases | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Choline; Creatine; Dacarbazine; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Proton Therapy; Statistics, Nonparametric; Temozolomide; Young Adult | 2016 |
Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Nimustine; Proton Therapy; Retrospective Studies; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Prospective Studies; Reproducibility of Results; Sequence Analysis, DNA; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
A Potential Nanofiber Membrane Device for Filling Surgical Residual Cavity to Prevent Glioma Recurrence and Improve Local Neural Tissue Reconstruction.
Topics: Alginates; Animals; Antineoplastic Agents, Alkylating; Biological Availability; Cell Line, Tumor; Dacarbazine; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Glucuronic Acid; Hexuronic Acids; Hydrogels; Kinetics; Microscopy, Electron, Scanning; Nanofibers; Nerve Growth Factor; Neuroglia; Neurons; Polyesters; Rats; Temozolomide | 2016 |
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Discovery; Genes, BRCA1; Humans; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co-Repressor Proteins; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Molecular Chaperones; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Telomere; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; X-linked Nuclear Protein | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Systems, Clinical; DNA Repair; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioblastoma; Glioma; High-Throughput Nucleotide Sequencing; Histone Deacetylase Inhibitors; Histones; Humans; RNA; RNA, Small Interfering; Temozolomide; Transcription, Genetic; Treatment Outcome; Valproic Acid | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Drug Synergism; Glioblastoma; Humans; Ki-67 Antigen; Mice; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays; Zinc | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotaxis; Cyclic GMP-Dependent Protein Kinase Type I; Dacarbazine; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neoplastic Stem Cells; Neurons; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Stem Cells; Temozolomide | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Hepatocyte Growth Factor; Humans; Male; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-met; Radiotherapy; RNA, Messenger; Survival Analysis; Temozolomide | 2016 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choline; Cohort Studies; Combined Modality Therapy; Creatine; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Grading; Prognosis; Radiotherapy, Conformal; Survival Rate; Temozolomide; Tumor Burden | 2017 |
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Guanidines; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Pyrrolidines; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Dacarbazine; DNA Damage; Glioblastoma; HEK293 Cells; Hexokinase; Humans; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; RNA Interference; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; China; Combined Modality Therapy; Contraindications; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Young Adult | 2016 |
Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Progression; Embryonic Stem Cells; Glioma; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Octamer Transcription Factor-3; Prognosis; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured | 2016 |
Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mitotane; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Young Adult | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Glioma; Humans; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Pyramidal Cells; Rats; Sorafenib; Temozolomide | 2016 |
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Brain; Cell Line, Tumor; Chromatography, Liquid; Dacarbazine; Humans; Rats; Tandem Mass Spectrometry; Temozolomide | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Dacarbazine; Everolimus; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Pituitary Neoplasms; Protein Serine-Threonine Kinases; Temozolomide | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; Cell Death; Cellular Senescence; Dacarbazine; Glioma; Homologous Recombination; Humans; Mice; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Survival Analysis; Temozolomide | 2016 |
Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.
Topics: Acetylation; Active Transport, Cell Nucleus; Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Central Nervous System Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; NF-kappa B; Signal Transduction; Temozolomide; Transcription Factor RelA; Transcription, Genetic; Transcriptional Activation; Tumor Suppressor Proteins | 2016 |
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Combined Modality Therapy; Dacarbazine; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Therapy; Glioma; Humans; Lentivirus; Neoplasm Proteins; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Protein Phosphatase 2C; Temozolomide | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Methionine; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Highlights in Central Nervous System Tumors.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Temozolomide | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Glioblastoma; Glutathione; Humans; Mice; Neoplasm Transplantation; Reactive Oxygen Species; Sulfasalazine; Temozolomide | 2016 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Glioma; Humans; Temozolomide | 2017 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2016 |
The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines.
Topics: Animals; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Kinetics; Mice; Temozolomide | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptides; Drug Synergism; Glioma; Humans; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Perfusion Imaging; Prognosis; Radiotherapy; Retrospective Studies; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Cells, Cultured; Dacarbazine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Glioblastoma; Humans; Interferon-Stimulated Gene Factor 3, gamma Subunit; Mice; Mice, Nude; Survival Analysis; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2016 |
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Topics: Acetazolamide; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Caspase 3; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Micelles; Spheroids, Cellular; Temozolomide; Time Factors; Tumor Cells, Cultured | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Grading; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Temozolomide; Vimentin | 2016 |
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Choline; Choline Kinase; Dacarbazine; Energy Metabolism; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; Phenotype; SOXB1 Transcription Factors; Temozolomide; Vimentin; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Interferons; Male; Mice, Inbred NOD; MicroRNAs; Neoplasm Invasiveness; RNA Interference; Signal Transduction; STAT1 Transcription Factor; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Neurosurgical Procedures; Pituitary Neoplasms; Postoperative Complications; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Temozolomide | 2017 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Fibrinogen; Gelatin; Glioma; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogels; Models, Biological; Neoplastic Stem Cells; Porosity; Printing, Three-Dimensional; Temozolomide; Tissue Scaffolds; Vascular Endothelial Growth Factor A | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mice; Neoplasm Invasiveness; Phosphotransferases (Alcohol Group Acceptor); Rats; Spheroids, Cellular; Temozolomide; Time-Lapse Imaging; Tumor Cells, Cultured | 2016 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Deferiprone; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Inhibitory Concentration 50; Iron Chelating Agents; Pyridones; Temozolomide | 2016 |
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2017 |
[RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Furans; Glioblastoma; Humans; Temozolomide | 2016 |
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; Inhibitory Concentration 50; Metformin; Mice, SCID; Neoplasm Invasiveness; SOXB1 Transcription Factors; Temozolomide; Time Factors; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Promoter Regions, Genetic; RNA Interference; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Suppressor Proteins | 2016 |
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Models, Theoretical; ROC Curve; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Pulsed Electromagnetic Field with Temozolomide Can Elicit an Epigenetic Pro-apoptotic Effect on Glioblastoma T98G Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Bioreactors; Cell Proliferation; Dacarbazine; Electromagnetic Fields; Epigenesis, Genetic; Glioblastoma; Humans; MicroRNAs; Temozolomide | 2016 |
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Chitinase-3-Like Protein 1; Cyclophilin C; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Kaplan-Meier Estimate; Male; Membrane Glycoproteins; Microarray Analysis; Middle Aged; Neoplasm Grading; Prognosis; Temozolomide | 2016 |
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Proportional Hazards Models; Spain; Survival Analysis; Temozolomide; Treatment Outcome | 2017 |
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cytarabine; Dacarbazine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Iodobenzenes; Leukemia, Myeloid, Acute; Male; Paraganglioma; Radiation Tolerance; Temozolomide | 2017 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Topics: Aged; Antineoplastic Agents; Brain; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Temozolomide; Treatment Outcome | 2016 |
Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; Female; Humans; Pituitary Neoplasms; Prognosis; Prolactin; Prolactinoma; Temozolomide | 2016 |
Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Dacarbazine; Humans; Male; Middle Aged; Pituitary ACTH Hypersecretion; Temozolomide; Treatment Outcome | 2016 |
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Glioblastoma; Histone Deacetylase 2; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; RNA, Small Interfering; Temozolomide | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Temozolomide; Young Adult | 2016 |
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Salmonella typhimurium; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Dynamin III; Exosomes; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Temozolomide; Transcription Factor RelA | 2017 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Gene Expression; Glioma; Homeodomain Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Hedyotis; Humans; Lobelia; Melanoma; Phytotherapy; Plant Extracts; Plants, Medicinal; Reactive Oxygen Species; Scutellaria; Skin Neoplasms; Solanum nigrum; Solvents; Tandem Mass Spectrometry; Temozolomide; Water | 2016 |
Refractory pituitary adenoma: a novel classification for pituitary tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pituitary Neoplasms; Salvage Therapy; Temozolomide; Terminology as Topic; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Electromagnetic Fields; Glioblastoma; Humans; Neoplastic Stem Cells; Neurons; Temozolomide; Tumor Suppressor Proteins | 2017 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene Expression; Glioma; Humans; MAP Kinase Signaling System; Phenotype; Phosphorylation; Rats; Temozolomide; Vascular Endothelial Growth Factor C | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioma; Humans; Kaplan-Meier Estimate; MicroRNAs; NF-kappa B; Phenotype; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Radiation Tolerance; RNA Interference; Temozolomide; Time Factors; Transcription, Genetic; Transfection | 2016 |
Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Aged; Aspergillosis; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Skin; Temozolomide | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioma; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Temozolomide; Valproic Acid; Young Adult | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Metal Nanoparticles; Silver Compounds; Temozolomide | 2017 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin-Like Growth Factor I; Membrane Potential, Mitochondrial; MicroRNAs; Reactive Oxygen Species; Signal Transduction; Survival Rate; Temozolomide; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Glioma; Humans; Nuclear Proteins; Pyridines; Pyrimidines; Receptor, Notch1; Signal Transduction; Temozolomide; Tumor Suppressor Proteins; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2016 |
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Longitudinal Studies; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Prospective Studies; Salvage Therapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2017 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Temozolomide; Young Adult | 2017 |
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Haplorhini; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Evaluation of the mutagenicity of alkylating agents, methylnitrosourea and temozolomide, using the rat Pig-a assay with total red blood cells or reticulocytes.
Topics: Alkylating Agents; Animals; Body Weight; Dacarbazine; Erythrocytes; Male; Membrane Proteins; Methylnitrosourea; Mutagenicity Tests; Mutagens; Rats; Rats, Sprague-Dawley; Reticulocytes; Temozolomide | 2016 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Longitudinal Studies; Male; Models, Theoretical; Procarbazine; Temozolomide; Vincristine | 2017 |
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Guanosine; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Transmission; O(6)-Methylguanine-DNA Methyltransferase; Polymers; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Temozolomide | 2017 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Chromones; Dacarbazine; Drug Synergism; Humans; Melanoma; Morpholines; Skin Neoplasms; Temozolomide | 2017 |
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Repositioning; Female; Glioblastoma; Humans; Mice; Mice, Nude; Rats; Rats, Inbred F344; Ribavirin; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cytokines; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunotherapy; Leukocytes, Mononuclear; Male; Middle Aged; T-Lymphocytes, Regulatory; Temozolomide; Vascular Endothelial Growth Factor A | 2017 |
Microtubule actin cross-linking factor 1, a novel target in glioblastoma.
Topics: Animals; Axin Protein; beta Catenin; Dacarbazine; Drug Resistance, Neoplasm; Genetic Heterogeneity; Glioblastoma; Humans; Mice; Microfilament Proteins; Temozolomide; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Drug Synergism; Female; Glioma; Humans; Mice; Neoplasm Transplantation; Protein Binding; Receptor, TIE-2; Ribonuclease, Pancreatic; Temozolomide; Treatment Outcome; Tumor Microenvironment | 2016 |
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Female; Frontal Lobe; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oligodendroglioma; Temozolomide | 2016 |
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Dacarbazine; gamma-Glutamylcyclotransferase; Gene Expression Regulation, Neoplastic; Glioma; Humans; Intracellular Space; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 8; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Receptor, Notch3; RNA, Messenger; Signal Transduction; Temozolomide | 2017 |
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Autoimmunity; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Neoplasm Staging; Nivolumab; Programmed Cell Death 1 Receptor; Temozolomide; Tumor Suppressor Proteins | 2016 |
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2016 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glutathione; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Rats; Sulfasalazine; Temozolomide | 2017 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; Dacarbazine; Dexamethasone; Glioblastoma; Humans; Levetiracetam; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Regression, Spontaneous; Neoplasms, Second Primary; Piracetam; Temozolomide | 2016 |
The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis.
Topics: Animals; Antidepressive Agents; Antimitotic Agents; Avoidance Learning; beta Catenin; Dacarbazine; Depressive Disorder; Disease Models, Animal; Doublecortin Protein; Glycogen Synthase Kinase 3; Hippocampus; Male; Maze Learning; Mice, Inbred C57BL; Mitosis; Motor Activity; Neural Stem Cells; Neurogenesis; Neurons; Random Allocation; Stress, Psychological; Temozolomide | 2017 |
CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; Doxorubicin; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Polycomb Repressive Complex 1; Polycomb-Group Proteins; Temozolomide | 2016 |
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiosurgery; Re-Irradiation; Survival Analysis; Temozolomide | 2017 |
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Exome; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Male; Oxadiazoles; Protein Kinase Inhibitors; Quinolines; Signal Transduction; STAT3 Transcription Factor; Temozolomide; TOR Serine-Threonine Kinases | 2017 |
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
Acute liver injury induced by levetiracetam and temozolomide co-treatment.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; Dacarbazine; Drug Therapy, Combination; Female; Humans; Israel; Levetiracetam; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Piracetam; Regression Analysis; Retrospective Studies; Temozolomide | 2017 |
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Topics: 3' Untranslated Regions; Antagomirs; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; MicroRNAs; PAX6 Transcription Factor; RNA Interference; RNA, Small Interfering; Sequence Alignment; Signal Transduction; Temozolomide | 2017 |
Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dendrimers; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Magnetic Resonance Spectroscopy; Melanoma; Microscopy, Electron, Transmission; Nanoparticles; Peptides; Spectroscopy, Fourier Transform Infrared; Temozolomide | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Dacarbazine; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurocognitive Disorders; Prognosis; Quality of Life; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Activated Protein Kinase; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hyaluronan Receptors; Ku Autoantigen; Male; Middle Aged; Nuclear Proteins; Oligodendrocyte Transcription Factor 2; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide; Tissue Array Analysis | 2017 |
Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Topics: Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Chondroitin ABC Lyase; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression; Genetic Vectors; Glioblastoma; Herpesvirus 1, Human; Humans; Mice; Mutation; Oncolytic Virotherapy; Temozolomide; Transduction, Genetic; Treatment Outcome; Tumor Burden; Tumor Cells, Cultured; Vero Cells; Xenograft Model Antitumor Assays | 2017 |
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Topics: Acrylamides; Anthracenes; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Cytokines; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 8; Nicotinamide Phosphoribosyltransferase; Piperidines; Reactive Oxygen Species; Signal Transduction; Temozolomide; Tocopherols | 2016 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Indoles; Insurance Claim Review; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib; Young Adult | 2017 |
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Aurintricarboxylic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cytokine TWEAK; Dacarbazine; Drug Synergism; Glioblastoma; HEK293 Cells; Humans; Kaplan-Meier Estimate; Mice, Nude; Molecular Structure; Receptors, Tumor Necrosis Factor; RNA Interference; Signal Transduction; Small Molecule Libraries; Temozolomide; Tumor Necrosis Factors; TWEAK Receptor; Xenograft Model Antitumor Assays | 2017 |
A novel biocompatible drug delivery system of chitosan/temozolomide nanoparticles loaded PCL-PU nanofibers for sustained delivery of temozolomide.
Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitosan; Dacarbazine; Drug Carriers; Drug Liberation; Humans; Kinetics; Nanofibers; Nanoparticles; Polyesters; Polyurethanes; Temozolomide | 2017 |
An unusual pituitary stalk lesion: What is the place of surgery?
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes Insipidus; Endoscopy; Fatal Outcome; Female; Hemianopsia; Humans; Hypopituitarism; Indoles; Melanoma; Pituitary Neoplasms; Sulfonamides; Temozolomide; Tomography, X-Ray Computed; Vemurafenib | 2016 |
LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Topics: Adult; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Glioma; Humans; In Vitro Techniques; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Binding; PTEN Phosphohydrolase; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; Temozolomide; Tumor Suppressor Proteins | 2017 |
A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells.
Topics: Autophagy; Dacarbazine; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Temozolomide; Transfection; Ubiquitination | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression; Glioma; Humans; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Temozolomide | 2017 |
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Glioblastoma; Humans; Indazoles; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Radiation-Sensitizing Agents; Signal Transduction; Sulfonamides; Temozolomide | 2017 |
Gold coated poly (ε-caprolactonediol) based polyurethane nanofibers for controlled release of temozolomide.
Topics: Caproates; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Delayed-Action Preparations; Drug Liberation; Gold; Humans; Kinetics; Lactones; Nanofibers; Particle Size; Polyesters; Polyurethanes; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Temozolomide | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Radiation; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Survival Analysis; Temozolomide; Tumor Suppressor Proteins | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Guanine; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2017 |
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Topics: Cell Cycle Proteins; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Temozolomide | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Replication Protein C; Temozolomide; Thiostrepton | 2017 |
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; MicroRNAs; Neoplasm Staging; Prognosis; RNA, Long Noncoding; Survival Rate; Temozolomide; Thymidylate Synthase; Tumor Cells, Cultured | 2017 |
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Contrast Media; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Medication Adherence; Middle Aged; Neural Stem Cells; Radiotherapy Dosage; Survival Rate; Temozolomide; Tomography, X-Ray Computed; Tumor Suppressor Proteins | 2017 |
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Dacarbazine; DNA Damage; Drug Synergism; Etoposide; Glioblastoma; Humans; Temozolomide | 2018 |
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Temozolomide | 2017 |
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; Middle Aged; Models, Biological; Neoplasm Grading; Temozolomide | 2017 |
Antitumor activity of intratracheal inhalation of temozolomide (TMZ) loaded into gold nanoparticles and/or liposomes against urethane-induced lung cancer in BALB/c mice.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Drug Compounding; Drug Stability; Gold; Lipids; Liposomes; Lung Neoplasms; Male; Metal Nanoparticles; Mice, Inbred BALB C; Nanomedicine; Particle Size; Temozolomide; Tumor Burden; Urethane | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Glioblastoma; Glioma; Glycogen Synthase Kinase 3; Humans; In Situ Nick-End Labeling; Phosphorylation; Phytotherapy; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Sesquiterpenes; Temozolomide; TOR Serine-Threonine Kinases | 2017 |
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Glioblastoma; Heat Shock Transcription Factors; Humans; Matrix Metalloproteinase 2; Neoplastic Stem Cells; Protein Transport; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; SOXB1 Transcription Factors; Temozolomide; Transcription Factors; Transcription, Genetic | 2017 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Base Sequence; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Nucleic Acid; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Temozolomide; Up-Regulation | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Glioma; Humans; Nanofibers; Neoplasm Recurrence, Local; Rats, Wistar; Survival Analysis; Temozolomide; Theranostic Nanomedicine | 2017 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance Imaging; Models, Theoretical; Neoplasm Grading; Temozolomide | 2016 |
BMI-1 Promotes Self-Renewal of Radio- and Temozolomide (TMZ)-Resistant Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, SCID; Polycomb Repressive Complex 1; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Role of
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Benzodiazepines; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dacarbazine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Protein Stability; RNA, Messenger; S-Phase Kinase-Associated Proteins; Temozolomide; Transcription Factors; Transcriptional Activation; Ubiquitin-Protein Ligases; Ubiquitination; Up-Regulation | 2017 |
A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Humans; Leukemia, Myeloid, Acute; Male; Temozolomide | 2017 |
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Blood-Brain Barrier; Dacarbazine; Disease Models, Animal; Macaca mulatta; Male; Nasal Absorption; Phosphorylcholine; Temozolomide; Valproic Acid | 2017 |
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Chemoradiotherapy; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide | 2017 |
Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Mice; Mice, Nude; Rutin; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Sex Factors; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2017 |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
Answer to the comment of Hai Lu et al. regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Synergism; Female; Glioma; Glucose; Glucose Transport Proteins, Facilitative; Humans; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Spheroids, Cellular; Temozolomide | 2017 |
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; France; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Polymerase Chain Reaction; Precision Medicine; Predictive Value of Tests; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; MicroRNAs; Neoplastic Stem Cells; PAX6 Transcription Factor; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Neoplasm; Signal Transduction; Temozolomide | 2017 |
Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma.
Topics: Adipocytes; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastoma; Humans; Lactic Acid; Magnetite Nanoparticles; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Oleic Acid; Paclitaxel; Particle Size; Permeability; Polyglutamic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stem Cells; Surface Properties; Temozolomide; Tissue Distribution | 2017 |
Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line; Crystallography, X-Ray; Dacarbazine; Drug Design; Drug Synergism; Enzyme Inhibitors; Heterografts; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Structure-Activity Relationship; Temozolomide | 2017 |
Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cytochromes c; Dacarbazine; Drug Synergism; Glioblastoma; Glutathione; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Nitric Oxide; Reactive Oxygen Species; Staining and Labeling; Temozolomide | 2017 |
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Topics: Aged; Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Fas Ligand Protein; Female; Gene Knockdown Techniques; Glioblastoma; Glycogen Synthase Kinase 3; Humans; Lithium; Male; Mice; Middle Aged; Neoplasm Transplantation; NFATC Transcription Factors; Primary Cell Culture; Protein Transport; Signal Transduction; Survival Rate; Temozolomide; Tumor Suppressor Protein p53 | 2017 |
Adult neurogenesis reduction by a cytostatic treatment improves spatial reversal learning in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Avoidance Learning; Dacarbazine; Dentate Gyrus; Male; Neurogenesis; Neurons; Rats; Rats, Long-Evans; Reversal Learning; Spatial Learning; Temozolomide | 2017 |
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Temozolomide | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Disease Management; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Neuroepithelial; Neurosurgical Procedures; Oligodendroglioma; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Rate; Temozolomide | 2017 |
Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Hydrazones; Membrane Potential, Mitochondrial; Neoplastic Stem Cells; Pyrazoles; Temozolomide | 2018 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Remission Induction; Retrospective Studies; Rituximab; Stem Cell Transplantation; Temozolomide; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Tumor Suppressor Proteins | 2017 |
Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorescence; Glioblastoma; Humans; Mice; Mice, SCID; Nanoconjugates; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Karnofsky Performance Status; Laminectomy; Male; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Cattle; Cell Line, Tumor; Coumaric Acids; Dacarbazine; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Mice; Models, Molecular; Mustard Plant; Nanoparticles; Phosphorylcholine; Polymethacrylic Acids; Rats; Serum Albumin, Bovine; Temozolomide; Tissue Distribution | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Rats; RNA, Messenger; Temozolomide | 2017 |
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lateral Ventricles; Male; Middle Aged; Prognosis; Radiation Dosage; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Humans; Naphthoquinones; Temozolomide | 2017 |
Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Genes, MHC Class I; Glioma; Humans; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Signal Transduction; Stem Cells; Temozolomide | 2017 |
Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Movement; Dacarbazine; Glioblastoma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Temozolomide; Transcription, Genetic | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Glioma; Humans; Reactive Oxygen Species; Temozolomide; Thiazolidines | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; Drug Resistance, Neoplasm; Female; Genotype; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Prognosis; Temozolomide; Vomiting | 2017 |
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glioblastoma; Glycolysis; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Models, Molecular; Molecular Conformation; Permeability; Phosphorylation; Protein Binding; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma.
Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; RNA, Small Nucleolar; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The sustained delivery of temozolomide from electrospun PCL-Diol-b-PU/gold nanocompsite nanofibers to treat glioblastoma tumors.
Topics: Cell Line, Tumor; Dacarbazine; Drug Implants; Glioblastoma; Humans; Nanocomposites; Nanofibers; Temozolomide | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Repositioning; Drug Synergism; Glioma; Humans; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Neoplastic Stem Cells; Oligodendroglia; Quetiapine Fumarate; Temozolomide; Tumor Burden | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Mice, Nude; Temozolomide | 2017 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Early Growth Response Protein 1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lentivirus; Melanoma; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Signal Transduction; Sirolimus; Skin; Skin Neoplasms; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Vemurafenib | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; GTP-Binding Proteins; Humans; Mesenchymal Stem Cells; Neoplastic Stem Cells; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Stem Cells; Temozolomide; Transglutaminases; Tretinoin; Up-Regulation | 2017 |
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Transplantation; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplasm Invasiveness; Temozolomide; Tumor Suppressor Proteins | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Multidrug Resistance-Associated Proteins; Mutation; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2017 |
A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery.
Topics: Adult; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Dacarbazine; Humans; Intracranial Thrombosis; Male; Oligodendroglioma; Radiotherapy; Temozolomide; Treatment Outcome; Venous Thrombosis | 2017 |
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiotherapy; Cohort Studies; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; France; Humans; Male; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pituitary Neoplasms; Practice Patterns, Physicians'; Prolactinoma; Retrospective Studies; Survival Analysis; Temozolomide; Tumor Burden | 2017 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Demethylases; Humans; Hydrazones; Mice; Phosphorylation; Proto-Oncogene Proteins c-akt; Retinoblastoma-Binding Protein 2; Small Molecule Libraries; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Expression and function of ABCG2 and XIAP in glioblastomas.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Brain Neoplasms; Cells, Cultured; Dacarbazine; Diketopiperazines; Female; Follow-Up Studies; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Temozolomide; X-Linked Inhibitor of Apoptosis Protein | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Retrospective Studies; Survival Rate; Temozolomide | 2017 |
EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytokines; Dacarbazine; G2 Phase; Glioblastoma; Humans; Mitosis; Neoplasm Proteins; Neoplastic Stem Cells; RNA-Binding Proteins; Signal Transduction; Temozolomide | 2017 |
Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Biochemical Phenomena; Brain; Brain Neoplasms; Corticosterone; Dacarbazine; Dentate Gyrus; Depressive Disorder; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Prevalence; Stress Disorders, Traumatic, Acute; Temozolomide | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplasm Invasiveness; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Temozolomide | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Synergism; Epithelial-Mesenchymal Transition; Glioma; Hedgehog Proteins; Humans; Signal Transduction; Temozolomide; Translocation, Genetic; Zinc Finger Protein GLI1 | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line, Tumor; Cell Proliferation; Chlorpromazine; Dacarbazine; Dopamine Antagonists; Drug Repositioning; Drug Resistance, Neoplasm; Electron Transport Complex IV; Glioma; Humans; Mice, Nude; Mitochondria, Heart; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Population Surveillance; Registries; SEER Program; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ARNTL Transcription Factors; Cell Line, Tumor; Cell Proliferation; Circadian Rhythm; Dacarbazine; DNA Repair; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Period Circadian Proteins; Temozolomide | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Temozolomide | 2017 |
Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Temozolomide | 2018 |
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Micelles; Signal Transduction; Temozolomide; Tumor Stem Cell Assay; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2017 |
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Phytotherapy; Plant Preparations; Plants, Medicinal; Temozolomide; Treatment Outcome | 2016 |
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Glioblastoma; Humans; Phosphotransferases (Alcohol Group Acceptor); Radiation Tolerance; Radiation-Sensitizing Agents; Temozolomide | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Glioma; Humans; Hypoxia; Mitochondria; Neoplastic Stem Cells; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Neoplasm Transplantation; Random Allocation; Temozolomide | 2017 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cyclohexenes; Dacarbazine; DNA Damage; Doxorubicin; Fibroblasts; Glioma; Humans; Oxidation-Reduction; Sesquiterpenes; Temozolomide | 2018 |
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Exosomes; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Oncogene Proteins, Fusion; Phenotype; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Temozolomide | 2017 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Survival; Chromogranin A; Dacarbazine; Humans; Male; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Nestin; Neuroendocrine Tumors; Primary Cell Culture; SOXB1 Transcription Factors; Spheroids, Cellular; Synaptophysin; Temozolomide; Tumor Cells, Cultured | 2017 |
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; CpG Islands; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; ROC Curve; Temozolomide; Tumor Suppressor Proteins | 2017 |
Telodendrimers for Physical Encapsulation and Covalent Linking of Individual or Combined Therapeutics.
Topics: Acetazolamide; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Survival; Dacarbazine; Dendrimers; Drug Delivery Systems; Glioblastoma; Humans; Lactates; Micelles; Polyesters; Polyethylene Glycols; Quercetin; Spheroids, Cellular; Temozolomide | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Postoperative Complications; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Serbia; Survival Analysis; Temozolomide | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heterografts; Humans; Neoplastic Stem Cells; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Guanosine; Humans; Membrane Potential, Mitochondrial; Receptors, Purinergic P1; Temozolomide | 2017 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Proportional Hazards Models; Temozolomide | 2017 |
Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Cytotoxins; Dacarbazine; Electromagnetic Fields; Glioblastoma; Humans; Magnetic Field Therapy; Temozolomide | 2017 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornithine; Glioblastoma; HL-60 Cells; Humans; Melarsoprol; Temozolomide; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Glioblastoma; Humans; Mice; Neoplasms, Experimental; ras Proteins; Signal Transduction; Temozolomide; Tumor Cells, Cultured | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; HEK293 Cells; Humans; Mice; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oncolytic Virotherapy; Simplexvirus; Temozolomide; TNF-Related Apoptosis-Inducing Ligand | 2017 |
Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Topics: Aquaporin 4; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Temozolomide | 2017 |
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Computer Simulation; Dacarbazine; Databases, Factual; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioblastoma; Glycolysis; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Isocitrate Dehydrogenase; Mutation; Neoplasm Invasiveness; Neoplastic Stem Cells; Prognosis; RNA, Messenger; Temozolomide; Tumor Hypoxia; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Ethnicity; Female; Glioma; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2017 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Germany; Glioma; Hematologic Neoplasms; Humans; Incidence; Infant; Kaplan-Meier Estimate; Male; Switzerland; Temozolomide | 2017 |
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Temozolomide | 2017 |
Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioma; Hydrogels; Male; Nanocomposites; Nanoparticles; Paclitaxel; Rats; Rats, Wistar; Temozolomide; Temperature | 2017 |
Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glutaminase; Glutamine; Humans; Melanoma; MicroRNAs; Temozolomide | 2017 |
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Kaplan-Meier Estimate; Methylation; Multivariate Analysis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Temozolomide; Time Factors; Tumor Suppressor Proteins | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Glypicans; Humans; Isocitrate Dehydrogenase; Karnofsky Performance Status; Ki-67 Antigen; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2017 |
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Child; Dacarbazine; Databases, Factual; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Pharmacogenetics; Promoter Regions, Genetic; Sequence Analysis, DNA; Temozolomide; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Connexin 43; Dacarbazine; Glioma; Green Fluorescent Proteins; Humans; Neoplasm Proteins; Temozolomide; Transfection | 2017 |
Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connective Tissue Growth Factor; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioblastoma; Humans; Hyaluronan Receptors; Male; Mice; Mice, Nude; Neoplasm Transplantation; Signal Transduction; Smad Proteins; Temozolomide; Transforming Growth Factor beta1 | 2017 |
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Glycolysis; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasms; Organometallic Compounds; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Signal Transduction; Temozolomide; Thioredoxin Reductase 1; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Topics: Acrylamides; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Enzyme Inhibitors; Female; Glioma; Humans; Isocitrate Dehydrogenase; Mice; Mice, SCID; Mutation; NAD; Nicotinamide Phosphoribosyltransferase; Piperidines; Random Allocation; Stress, Physiological; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Nanoparticles; Polymers; Temozolomide | 2017 |
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Carcinoma, Hepatocellular; Dacarbazine; Glucagon; Glucagonoma; Humans; Jaundice; Liver; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Temozolomide; Treatment Outcome | 2017 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dog Diseases; Dogs; Female; Glioma; Male; Radiosurgery; Survival Analysis; Temozolomide | 2018 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Ferric Compounds; Flow Cytometry; Gene Expression; Glioblastoma; Humans; Magnetic Resonance Imaging; Mass Spectrometry; Matrix Metalloproteinase 14; Mice; Nanoparticles; Temozolomide; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2017 |
Liposomal temozolomide drug delivery using convection enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Convection; Dacarbazine; Drug Delivery Systems; Gadolinium DTPA; Glioblastoma; Liposomes; Male; Nanoparticles; Particle Size; Polyethylene Glycols; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Survival Rate; Temozolomide; Tumor Burden | 2017 |
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Heterografts; Humans; Indazoles; Melanoma; Mice; Mice, Nude; Temozolomide; Transplantation, Heterologous | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Dacarbazine; Female; Glioma; Humans; Immunotherapy, Adoptive; Lymphopenia; Male; Middle Aged; Prospective Studies; T-Lymphocyte Subsets; Temozolomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; RNA, Long Noncoding; Temozolomide; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Glioma; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Mice; Neoplastic Stem Cells; Protein Transport; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Signal Transduction; Survival Rate; Temozolomide; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2017 |
A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation.
Topics: Antineoplastic Agents; Astrocytes; Bone Morphogenetic Protein 2; Cell Differentiation; Dacarbazine; Glioblastoma; Humans; Mesenchymal Stem Cells; Molecular Mimicry; Neoplastic Stem Cells; Osteogenesis; Peptide Fragments; Temozolomide | 2017 |
[Combination Therapy with Radiation, Temozolomide, and Bevacizumab after Partial Tumor Removal in Glioblastoma Patients with Low Performance Status].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide; Treatment Outcome | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Dacarbazine; Furans; Glioblastoma; Humans; Lactic Acid; Phosphorylcholine; Proton Magnetic Resonance Spectroscopy; Pyridines; Pyrimidines; Temozolomide; Treatment Outcome | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Glioma; Humans; Inflammation; Macrophages; Mice; Receptors, Purinergic; Temozolomide; Tumor Microenvironment | 2017 |
Glioblastoma entities express subtle differences in molecular composition and response to treatment.
Topics: Apoptosis; Astrocytoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Glioblastoma; Humans; Neoplasm Grading; Protein Kinase C; Signal Transduction; Tamoxifen; Temozolomide | 2017 |
Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; Oligonucleotide Array Sequence Analysis; RNA, Long Noncoding; RNA, Messenger; Temozolomide | 2017 |
The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; HLA-A2 Antigen; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Knockout; Mice, Nude; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; Cohort Studies; Dacarbazine; Databases, Factual; Delivery of Health Care; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Young Adult | 2017 |
Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide.
Topics: Cell Line, Tumor; Cellular Senescence; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Leiomyosarcoma; O(6)-Methylguanine-DNA Methyltransferase; Sarcoma; Temozolomide; Tumor Suppressor Protein p53 | 2017 |
Acyclic cucurbit[n]uril conjugated dextran for drug encapsulation and bioimaging.
Topics: Bridged-Ring Compounds; Dacarbazine; Dextrans; Drug Carriers; Ethylenediamines; Fluorouracil; HeLa Cells; Humans; Imidazoles; Luminescent Agents; Microscopy, Confocal; Nanoparticles; Particle Size; Polyethyleneimine; Temozolomide | 2017 |
A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glioblastoma; Heterografts; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Nanocomposites; Nanoparticles; Nestin; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Perfusion; Spin Labels; Temozolomide | 2017 |
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mitochondria; Sodium-Hydrogen Exchangers; Temozolomide; Ultrasonic Waves | 2017 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Sex Factors; Supratentorial Neoplasms; Survival Analysis; Temozolomide; Time Factors; Treatment Outcome | 2017 |
Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Glycolysis; Humans; Lactate Dehydrogenases; Structure-Activity Relationship; Temozolomide | 2017 |
Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Databases, Factual; Dog Diseases; Dogs; Doxorubicin; Kaplan-Meier Estimate; Lymphoma; Recurrence; Retrospective Studies; Survival; Temozolomide; Treatment Outcome; United Kingdom | 2018 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Shape; Dacarbazine; Glioma; Humans; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2018 |
FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Integrins; Male; Membrane Proteins; Middle Aged; Neoplasm Proteins; Temozolomide; Wnt Signaling Pathway | 2017 |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Glioma; Humans; Male; Temozolomide | 2017 |
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Horses; Humans; Middle Aged; Myocarditis; Nivolumab; Temozolomide | 2017 |
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Hong Kong; Humans; Male; Middle Aged; Registries; Retrospective Studies; Temozolomide | 2017 |
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cricetulus; Dacarbazine; DNA Repair; DNA, Neoplasm; Guanine; Humans; Mutation; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2017 |
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Topics: Animals; Brain Neoplasms; Cells, Cultured; CRISPR-Cas Systems; Dacarbazine; Dependovirus; DNA Mutational Analysis; Female; Gene Knock-In Techniques; Gene Knockout Techniques; Glioblastoma; Humans; Male; Mice; Mutation; Suppression, Genetic; Temozolomide; Transcriptome | 2017 |
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Histoplasmosis; Humans; Lung Diseases, Fungal; Male; Middle Aged; Opportunistic Infections; Radiotherapy, Adjuvant; Temozolomide | 2016 |
Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Reactive Oxygen Species; Sp1 Transcription Factor; Superoxide Dismutase; Temozolomide; Tumor Suppressor Proteins | 2017 |
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lomustine; Temozolomide | 2018 |
Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child, Preschool; Cyclophosphamide; Dacarbazine; Dactinomycin; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Humans; Irinotecan; Male; MicroRNAs; Neoplasm Metastasis; Promoter Regions, Genetic; Rhabdomyosarcoma, Alveolar; RNA, Neoplasm; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2018 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Ventricles; Dacarbazine; Disease Models, Animal; Doublecortin Domain Proteins; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hyaluronan Receptors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microtubule-Associated Proteins; Mutation; Nestin; Neurofibromin 1; Neuropeptides; Proto-Oncogene Proteins c-sis; PTEN Phosphohydrolase; RNA, Small Interfering; Temozolomide | 2017 |
Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Doxycycline; Drug Synergism; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Oxidative Stress; Random Allocation; Reactive Oxygen Species; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Female; Humans; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Mutation; Neurosurgical Procedures; Radiotherapy; Spinal Cord Neoplasms; Temozolomide | 2017 |
Hospitalizations in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Costs and Cost Analysis; Dacarbazine; Emergency Service, Hospital; Glioblastoma; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Temozolomide | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Glioma; Humans; Hydrogels; Mice; Neoplasm Recurrence, Local; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Combined Modality Therapy; Dacarbazine; Female; Fluorescent Antibody Technique; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neoplastic Stem Cells; Oncolytic Virotherapy; Temozolomide; Vero Cells; Zika Virus | 2017 |
[Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Temozolomide; Young Adult | 2017 |
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isocitrate Dehydrogenase; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome | 2018 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Gene Expression Regulation, Neoplastic; Glioma; GPI-Linked Proteins; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplastic Stem Cells; Signal Transduction; Temozolomide; Time Factors; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.
Topics: Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Glioma; Humans; MicroRNAs; Neoplasm Invasiveness; Nuclear Proteins; Phenotype; Protein-Tyrosine Kinases; Temozolomide | 2017 |
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Pituitary Neoplasms; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2017 |
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Membrane Proteins; MicroRNAs; Neoplastic Stem Cells; Phenotype; RNA Interference; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2017 |
Identification of WISP1 as a novel oncogene in glioblastoma.
Topics: Brain Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Temozolomide; Up-Regulation | 2017 |
Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.
Topics: Brain Neoplasms; Cell Death; Cell Differentiation; Cell Self Renewal; Dacarbazine; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Recombination, Genetic; Temozolomide; Vaccinia virus; Vesicular Stomatitis; Virus Replication | 2017 |
Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, SCID; Neoplastic Stem Cells; Oxidative Stress; Sp1 Transcription Factor; Temozolomide; Treatment Outcome | 2017 |
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Proteome; Temozolomide | 2017 |
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Heparin-binding EGF-like Growth Factor; Histones; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Proteolysis; RNA, Messenger; RNA, Neoplasm; Temozolomide; Ubiquitin Thiolesterase | 2017 |
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dihydroorotase; DNA Damage; Doxorubicin; Enzyme Activation; Humans; Irinotecan; Mutagenesis; Mutation; Neoplasms; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Vincristine | 2017 |
Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Temozolomide; Vincristine | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Cohort Studies; Dacarbazine; Etoposide; Female; Glioma; Humans; Ifosfamide; Leukopenia; Male; Neoplasm Grading; Prospective Studies; Temozolomide; Treatment Outcome; Vincristine | 2018 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioma; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Phenotype; Proto-Oncogene Proteins c-sis; Temozolomide; Vascular Endothelial Growth Factor A | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; ErbB Receptors; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Hyperthermia, Induced; Rats, Wistar; Reference Standards; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Temperature | 2017 |
PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Topics: Animals; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Lentivirus; Mice; N-Acetylglucosaminyltransferases; Neoplasm Recurrence, Local; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; MicroRNAs; Neoplasm Recurrence, Local; Signal Transduction; Temozolomide; TNF Receptor-Associated Factor 6; Xenograft Model Antitumor Assays | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Disease-Free Survival; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Proton Therapy; Retrospective Studies; Temozolomide; Young Adult | 2017 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Databases, Factual; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Radiotherapy; Retrospective Studies; Temozolomide; Treatment Outcome | 2018 |
Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient.
Topics: Aged, 80 and over; Anaplasia; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Optic Chiasm; Optic Nerve Neoplasms; Sensation Disorders; Temozolomide; Visual Acuity | 2017 |
Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Furans; Glioblastoma; Humans; In Vitro Techniques; Phenanthrenes; Quinones; Temozolomide; Tumor Cells, Cultured | 2017 |
Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Propyl Gallate; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Reproducibility of Results; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Temozolomide | 2017 |
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Dacarbazine; Female; Humans; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Temozolomide | 2018 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Female; Germany; Glioblastoma; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Regression Analysis; Retrospective Studies; Temozolomide | 2017 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Temozolomide | 2018 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Ganglioglioma; Glioblastoma; Glioma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2017 |
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioblastoma; Glutathione; Glutathione Reductase; Homeostasis; Humans; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Oxidants; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; RNA, Small Interfering; Temozolomide; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2018 |
Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication.
Topics: Analgesics, Opioid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cell Line, Tumor; Connexin 43; Dacarbazine; Drug Interactions; Gap Junctions; Glioblastoma; Humans; Temozolomide; Tramadol; Transfection | 2018 |
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Melanoma; MicroRNAs; Prohibitins; Repressor Proteins; Sulfonamides; Temozolomide; Transfection; Vemurafenib | 2017 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Gene Knockdown Techniques; Glioblastoma; Heme Oxygenase-1; Humans; NF-E2-Related Factor 2; RNA, Messenger; RNA, Small Interfering; Temozolomide | 2017 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation | 2018 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Dose-Response Relationship, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide | 2017 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Hydrogels; Injections; Iodine Radioisotopes; Male; Mice; Mice, Nude; Prognosis; Temozolomide | 2018 |
Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 8; Cell Line, Tumor; Cholesterol; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Intracellular Fluid; Membrane Microdomains; Receptors, TNF-Related Apoptosis-Inducing Ligand; Temozolomide | 2018 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Proliferation; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Dacarbazine; Disease Models, Animal; Endothelial Cells; Glioblastoma; Humans; Mice, Inbred C57BL; Neoplastic Stem Cells; Neural Stem Cells; Organ Specificity; Stem Cell Niche; Temozolomide; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells.
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Green Chemistry Technology; Humans; Metal Nanoparticles; Plant Extracts; Plant Leaves; Temozolomide; Zinc Oxide | 2018 |
MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Dacarbazine; Databases, Genetic; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Magnetic Resonance Imaging; Neural Networks, Computer; Regulatory Sequences, Nucleic Acid; Temozolomide; Tumor Suppressor Proteins | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Dacarbazine; Female; Glioma; Humans; Male; Neoplasm Grading; Radiotherapy; Randomized Controlled Trials as Topic; Temozolomide | 2018 |
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Coordination Complexes; Dacarbazine; Female; Glioblastoma; HeLa Cells; Humans; Kaplan-Meier Estimate; Mice, Nude; Neoplastic Stem Cells; Osmium; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; Male; Middle Aged; Skull; Skull Neoplasms; Temozolomide | 2018 |
Integrative analysis of rewired central metabolism in temozolomide resistant cells.
Topics: Amino Acids; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Glucose; Humans; Metabolic Flux Analysis; Pyruvic Acid; Systems Integration; Temozolomide | 2018 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Cell Survival; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Janus Kinase 2; Male; Mice; Mice, SCID; Microsomes, Liver; Permeability; Pyrimidines; STAT3 Transcription Factor; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Meningeal Neoplasms; Pituitary Neoplasms; Prolactinoma; Spinal Cord Neoplasms; Temozolomide | 2017 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Temozolomide; Tumor Burden | 2018 |
Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.
Topics: Administration, Intravenous; Animals; Brain; Dacarbazine; Drug Liberation; Glioblastoma; Liposomes; Polyethylene Glycols; Rats; Temozolomide | 2018 |
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Dacarbazine; Dendrimers; Drug Liberation; Drug Stability; Glioma; Half-Life; Humans; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Particle Size; Rats; Rats, Wistar; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Temozolomide; Tissue Distribution | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Monocytes; Temozolomide; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2018 |
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mutation; Protein Binding; Sequestosome-1 Protein; Temozolomide | 2018 |
Relationship between Hedgehog Signaling Pathway and Drug Resistance of Poorly Differentiated Gliomas.
Topics: Antineoplastic Agents; Astrocytes; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Cisplatin; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neuroglia; Peptides; Signal Transduction; Temozolomide; Veratrum Alkaloids | 2018 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult | 2018 |
Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxycycline; Drug Resistance, Neoplasm; Fucosyltransferases; Glioblastoma; Humans; Lewis X Antigen; Mitochondria; Neoplastic Stem Cells; Nestin; Temozolomide; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Female; Glioma; Humans; Ligands; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Temozolomide; Tumor Cells, Cultured | 2018 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; Humans; Immunohistochemistry; Melanoma; Melanoma, Experimental; Mice; Molecular Structure; Nanoparticles; Neoplastic Stem Cells; Temozolomide | 2018 |
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2018 |
Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cerebrovascular Circulation; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Photons; Proton Therapy; Temozolomide; White Matter; Young Adult | 2018 |
Primary extraskeletal myxoid chondrosarcoma in cerebellum: A case report with literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Cerebellum; Chemoradiotherapy, Adjuvant; Chondrosarcoma; Dacarbazine; Female; Humans; Intracranial Hypertension; Neoplasms, Connective and Soft Tissue; Neurosurgical Procedures; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Salvage Therapy; Temozolomide | 2017 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazine; Temozolomide | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Oligodendroglioma; Temozolomide | 2018 |
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Databases, Factual; Glioblastoma; Humans; Ki-67 Antigen; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Proteasome Endopeptidase Complex; RNA Interference; Temozolomide | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Down-Regulation; F-Box-WD Repeat-Containing Protein 7; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Prognosis; Receptor, Notch1; RNA, Small Interfering; Temozolomide; Ubiquitin-Protein Ligases | 2018 |
A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Chemotherapy, Adjuvant; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Neuroectodermal Tumors, Primitive; Temozolomide; Treatment Outcome | 2018 |
Additional increased effects of mannitol-temozolomide combined treatment on blood-brain barrier permeability.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Capillary Permeability; Cell Line; Dacarbazine; Drug Synergism; Humans; Male; Mannitol; Rats; Rats, Sprague-Dawley; Temozolomide; Tight Junction Proteins | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cysts; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Implants; Drug Synergism; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Postoperative Hemorrhage; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Microenvironment | 2018 |
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Topics: AC133 Antigen; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; RNA, Messenger; Temozolomide; Tumor Hypoxia; Vascular Endothelial Growth Factors | 2018 |
Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nimustine; Proportional Hazards Models; Quality of Life; Radiotherapy; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.
Topics: Aged; CpG Islands; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Tumor Burden | 2018 |
Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; Protein Array Analysis; Protein Interaction Maps; src-Family Kinases; Temozolomide | 2018 |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isocitrate Dehydrogenase; MicroRNAs; Mutation; Oncogenes; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Signal Transduction; Temozolomide; Up-Regulation | 2018 |
Temozolomide-induced inflammation of disseminated superficial actinic porokeratosis.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Humans; Inflammation; Male; Middle Aged; Porokeratosis; Skin; Temozolomide | 2018 |
Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Humans; Temozolomide | 2018 |
Ghee Butter as a Therapeutic Delivery System.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Carriers; Ghee; Human Umbilical Vein Endothelial Cells; Humans; Nanoparticles; Temozolomide | 2017 |
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; Female; Glioblastoma; Humans; Lateral Ventricles; Male; Methyltransferases; Middle Aged; Temozolomide; Tumor Suppressor Proteins | 2018 |
Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neoplasm Proteins; Proteomics; Ribosomal Protein L3; Signal Transduction; Temozolomide; Up-Regulation | 2018 |
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mitosis; Molecular Structure; Molecular Targeted Therapy; Necrosis; Neoplasm Proteins; Reactive Oxygen Species; Tacrine; Temozolomide | 2018 |
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Liberation; Glioblastoma; Humans; Kinetics; Lactic Acid; Nanoparticles; Nanotechnology; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Receptors, Transferrin; Technology, Pharmaceutical; Temozolomide | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy, Adjuvant; Dacarbazine; Datasets as Topic; Disease-Free Survival; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Prognosis; Temozolomide; TWEAK Receptor | 2018 |
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Replication; DNA-Binding Proteins; DNA, Mitochondrial; Gene Expression Regulation, Neoplastic; Glioma; Humans; Melatonin; Membrane Potential, Mitochondrial; Mitochondrial Proteins; Molecular Targeted Therapy; Neoplasm Proteins; Reactive Oxygen Species; RNA, Messenger; Temozolomide; Transcription Factors; Transcription, Genetic | 2018 |
Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Topics: Antigens, Neoplasm; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Signal Transduction; SOX9 Transcription Factor; Temozolomide | 2018 |
GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Glycogen Synthase Kinase 3 beta; Humans; Models, Molecular; Muscle Proteins; Phosphorylation; Protein Domains; Protein Interaction Maps; Proto-Oncogene Proteins c-bcl-2; Temozolomide | 2018 |
Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Topics: Animals; Apoptosis; Autophagy; Caspase 7; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melanoma; Mice; Proto-Oncogene Proteins B-raf; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Ferritins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxidoreductases; Temozolomide; Transcription Factor CHOP; Young Adult | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Disease Models, Animal; Glioma; Humans; Male; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Temozolomide; Tumor Burden | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Neoplasm Recurrence, Local; Radiosurgery; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2018 |
Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study.
Topics: Administration, Intranasal; Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Goats; Hydrogels; Nasal Absorption; Nasal Mucosa; Rats; Rats, Wistar; Temozolomide | 2018 |
Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydrogen Peroxide; Mitochondria; Oxidative Stress; Oxygen Consumption; Radiation Tolerance; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured; Ubiquinone | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Blood-Brain Barrier; Brain Neoplasms; Cerebral Angiography; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Craniotomy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Mannitol; Middle Aged; Temozolomide; Treatment Outcome | 2018 |
Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Memory; Middle Aged; Temozolomide; Treatment Outcome | 2018 |
Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Topics: Adenine Phosphoribosyltransferase; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Female; Genes, Neoplasm; Genetic Markers; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mismatch Repair Endonuclease PMS2; Poly(ADP-ribose) Polymerases; Prospective Studies; RNA Polymerase II; RNA, Messenger; Temozolomide | 2018 |
Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Drug Administration Schedule; Drug Synergism; Glioblastoma; Gossypol; Humans; Hydroxychloroquine; Temozolomide | 2018 |
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Lactoferrin; Lipids; Mice, Inbred BALB C; Nanostructures; Neoplasms, Neuroepithelial; Oligopeptides; Temozolomide; Tissue Distribution; Vincristine; Xenograft Model Antitumor Assays | 2018 |
Improved survival of Swedish glioblastoma patients treated according to Stupp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Survival Rate; Sweden; Temozolomide | 2018 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioma; Heterografts; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2018 |
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice, Nude; MicroRNAs; RNA Interference; Temozolomide; Wnt Proteins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Delivery Systems; Folic Acid; Gene Silencing; Genes, bcl-2; Glioma; Humans; Micelles; Nanoparticles; Particle Size; Polyethylene Glycols; Polyethyleneimine; Polymers; Proton Magnetic Resonance Spectroscopy; Rats; RNA, Messenger; RNA, Small Interfering; Static Electricity; Temozolomide | 2018 |
Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Radiosurgery; Remission Induction; Temozolomide | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Genotype; Glioma; Humans; Infant; Kaplan-Meier Estimate; Life Style; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Temozolomide; Young Adult | 2018 |
Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Temozolomide; Verapamil | 2018 |
[IV. How Do We Think about Generics of Anti-Cancer Agent - Focusing on Temozolomide Oral Preparation].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Dosage Forms; Drugs, Generic; Glioma; Humans; Occupational Exposure; Temozolomide | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution | 2018 |
Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caffeine; Cell Line, Tumor; Central Nervous System Stimulants; Dacarbazine; G2 Phase Cell Cycle Checkpoints; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Brainstem Glioblastoma Multiforme in a Patient with NF1.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Stem; Brain Stem Neoplasms; Chemoradiotherapy; Codon, Nonsense; Dacarbazine; Glioblastoma; Humans; Male; Neurofibromin 1; Temozolomide; Young Adult | 2018 |
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Databases, Factual; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Myosin Light Chains; Phosphorylation; Pyrazoles; Temozolomide; Transplantation, Heterologous; TRPC Cation Channels | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Electron Transport Complex III; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Mice, Nude; Middle Aged; Mitochondrial Proteins; Prognosis; RNA Interference; RNA, Small Interfering; Temozolomide | 2018 |
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Dacarbazine; Databases, Genetic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Protein Interaction Maps; Temozolomide | 2018 |
MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Temozolomide; Thiazoles | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Neoplasm Transplantation; Neoplastic Stem Cells; Nerve Tissue Proteins; Radiotherapy; Rats; Rats, Sprague-Dawley; Receptors, Nerve Growth Factor; Temozolomide; Up-Regulation | 2018 |
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Dacarbazine; DNA Fragmentation; Drugs, Chinese Herbal; Fas Ligand Protein; Glioma; Humans; Lignans; Membrane Potential, Mitochondrial; Mice; Mitochondria; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2018 |
Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Glioblastoma; Humans; Juniperus; Mice; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Proliferating Cell Nuclear Antigen; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma.
Topics: Animals; Apoptosis; Aurora Kinase B; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Lactoferrin; Mice; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Death; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; MCF-7 Cells; Molecular Structure; Phenylurea Compounds; RNA, Messenger; Structure-Activity Relationship; Sulfonamides; Temozolomide; Tumor Cells, Cultured | 2019 |
Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Topics: Antineoplastic Agents, Alkylating; Cholesterol; Dacarbazine; Dimyristoylphosphatidylcholine; Drug Interactions; Glioblastoma; Humans; Membranes, Artificial; Temozolomide | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide | 2019 |
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Neoplastic Stem Cells; Silicon Dioxide; Temozolomide | 2019 |
[Lomustine and temozolomide in combination with radiotherapy : New treatment option for patients with MGMT promoter methylated Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Lomustine; Temozolomide; Tumor Suppressor Proteins | 2019 |
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ
Topics: Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Outcome Assessment, Health Care; Pancreatic Neoplasms; Progression-Free Survival; Temozolomide; Withholding Treatment | 2020 |
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide | 2020 |
Management of glioblastoma: an Australian perspective.
Topics: Australia; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; MicroRNAs; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2020 |
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Risk Factors; Salvage Therapy; Temozolomide; Treatment Outcome | 2021 |
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Temozolomide | 2020 |
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Hydrogels; Temozolomide | 2020 |
Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Gas Chromatography-Mass Spectrometry; Glioma; Humans; Mice; Mice, Inbred C57BL; O(6)-Methylguanine-DNA Methyltransferase; Radiation-Sensitizing Agents; Temozolomide; Xenograft Model Antitumor Assays | 2020 |
Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?"
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2020 |
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2021 |
Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Prognosis; Temozolomide | 2020 |
Desquamative skin rash associated with temozolomide in a patient with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Exanthema; Glioblastoma; Humans; Temozolomide | 2021 |
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Guanine; Humans; Mice; Poly ADP Ribosylation; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Suppressor Proteins | 2021 |
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
Topics: Brain Neoplasms; Dacarbazine; Humans; Oligodendroglioma; Temozolomide | 2021 |
Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy.
Topics: Central Nervous System Neoplasms; Dacarbazine; Humans; Lymphoma, T-Cell; Temozolomide | 2021 |
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Temozolomide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2021 |
Sheep, Meet Stupp.
Topics: Animals; Dacarbazine; Sheep; Temozolomide | 2021 |
Stupp the Wolf.
Topics: Animals; Dacarbazine; Temozolomide; Wolves | 2021 |
UV spectroscopic method for estimation of temozolomide: Application in stability studies in simulated plasma pH, degradation rate kinetics, formulation design, and selection of dissolution media.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Hydrogen-Ion Concentration; Kinetics; Reproducibility of Results; Solubility; Temozolomide | 2021 |
In Vitro Effects of Selective COX and LOX Inhibitors and Their Combinations with Antineoplastic Drugs in the Mouse Melanoma Cell Line B16F10.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase Inhibitors; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Lipoxygenase Inhibitors; Melanoma, Experimental; Mice; Molecular Structure; Temozolomide | 2021 |
Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!
Topics: Dacarbazine; Glioblastoma; Humans; Standard of Care; Temozolomide | 2021 |
Silencing glioblastoma networks to make temozolomide more effective.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dog Diseases; Dogs; Glioma; Humans; Temozolomide; Tumor Suppressor Proteins | 2021 |
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Quality of Life; Retrospective Studies; Temozolomide | 2021 |
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Immunotherapy; Isocitrate Dehydrogenase; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2022 |
Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Quality Indicators, Health Care; Retrospective Studies; Temozolomide; Tertiary Healthcare | 2022 |
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma, Ewing; Temozolomide | 2022 |
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Republic of Korea; Surveys and Questionnaires; Temozolomide | 2022 |
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gliosarcoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2022 |
KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response.
Topics: Alkylating Agents; Dacarbazine; DNA; DNA Repair; Epigenesis, Genetic; Guanine; O(6)-Methylguanine-DNA Methyltransferase; Parthanatos; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2022 |
MGMT in glial carcinogenesis. Roles from prevention to treatment.
Topics: Brain Neoplasms; Carcinogenesis; Carcinogens; Dacarbazine; DNA; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Humans; O(6)-Methylguanine-DNA Methyltransferase; Polycyclic Aromatic Hydrocarbons; Solvents; Temozolomide; Tumor Suppressor Proteins | 2022 |
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Levetiracetam; Male; Middle Aged; Prognosis; Retrospective Studies; Seizures; Temozolomide; Tumor Suppressor Proteins | 2022 |
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Dacarbazine; Flavones; Glioma; Humans; Temozolomide | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free Survival; DNA; Glioblastoma; Humans; Isocitrate Dehydrogenase; Methyltransferases; Temozolomide | 2022 |
Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Dacarbazine; Humans; Irinotecan; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Mechanism-based design of agents that selectively target drug-resistant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Design; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cathelicidins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Mitochondria; Neoplasm Recurrence, Local; Nerve Growth Factor; Temozolomide | 2022 |
Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System; Central Nervous System Neoplasms; Dacarbazine; Humans; Leukemia, Plasma Cell; Temozolomide | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Diseases; Lymphopenia; Methylhydrazines; Neutropenia; Temozolomide; Thrombocytopenia | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; MutS Homolog 2 Protein; Neoplasm Recurrence, Local; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins | 2022 |
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Isocitrate Dehydrogenase; Mutation; Retrospective Studies; Temozolomide; World Health Organization | 2022 |
Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Guanine; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Purines; Signal Transduction; Temozolomide | 2023 |
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2023 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retrospective Studies; Temozolomide | 2022 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Phosphatidylinositol 3-Kinases; Recombinational DNA Repair; Temozolomide; Triterpenes; Zebrafish | 2023 |
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transcription Factors | 2022 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; O(6)-Methylguanine-DNA Methyltransferase; RNA, Small Interfering; Temozolomide | 2023 |
Is there a future for maintenance temozolomide chemotherapy in PCNSL?
Topics: Brain; Dacarbazine; Humans; Lymphoma; Methotrexate; Temozolomide | 2023 |
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Temozolomide | 2023 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide | 2023 |
Letter to the editor regarding "The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies".
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Radiotherapy, Adjuvant; Temozolomide | 2023 |
Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question.
Topics: Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Temozolomide | 2023 |
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase; Progression-Free Survival; Temozolomide; Tumor Suppressor Proteins | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolomide | 2023 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Prognosis; Temozolomide | 2023 |
Combination of SIX4-siRNA and temozolomide inhibits the growth and migration of A-172 glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Homeodomain Proteins; Humans; RNA, Small Interfering; Temozolomide; Trans-Activators | 2023 |
GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; GTP-Binding Proteins; Humans; Temozolomide | 2023 |
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Prognosis; Temozolomide | 2023 |
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide; Thiazoles | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
The Impact of O6-Methylguanine-DNA Methyltransferase (
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Humans; Leiomyosarcoma; Methyltransferases; Middle Aged; Retrospective Studies; Temozolomide; Tumor Suppressor Proteins | 2023 |
The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide; Tumor Suppressor Proteins | 2023 |
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Precision Medicine; Temozolomide | 2023 |
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Lipids; Temozolomide; Tumor Suppressor Proteins | 2023 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Nitric Oxide; Stem Cells; Temozolomide | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolomide; Tumor Microenvironment | 2023 |
Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Temozolomide; Treatment Outcome | 2023 |
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide.
Topics: Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Dacarbazine; Humans; Lung Neoplasms; Neuroendocrine Tumors; Temozolomide; Treatment Outcome | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Temozolomide | 2023 |
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Genetic; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Suppressor Proteins | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Temozolomide; TOR Serine-Threonine Kinases | 2023 |
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genomics; Glioblastoma; Humans; Phenotype; Temozolomide | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Treatment of glioblastoma in Greenlandic patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Proteomics; Tandem Mass Spectrometry; Temozolomide | 2023 |